Summary Tables by Market Group, Health Area, Country and Product
## CYPs, Cases, and Deaths by Market Group

### 1/2020 - 2/2020

<table>
<thead>
<tr>
<th>Market Group</th>
<th>New HIV Infections</th>
<th>STI Deaths</th>
<th>PWID Deaths</th>
<th>TB Deaths</th>
<th>CYP*</th>
<th>Maternal Deaths</th>
<th>Unintended Pregnancies</th>
<th>Malaria Deaths</th>
<th>Diarrhea Deaths</th>
<th>Pneumonia Deaths</th>
<th>Cervical Cancer Death</th>
<th>Sum of All Deaths</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acceleration Market Group</td>
<td>6,510</td>
<td>-</td>
<td>-</td>
<td>347</td>
<td>589,260</td>
<td>694</td>
<td>276,303</td>
<td>41</td>
<td>27</td>
<td>24</td>
<td>-</td>
<td>3,608</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>11,094</td>
<td>4</td>
<td>-</td>
<td>1</td>
<td>278,035</td>
<td>315</td>
<td>111,986</td>
<td>7</td>
<td>36</td>
<td>-</td>
<td>1</td>
<td>2,495</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Gro</td>
<td>874</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>410,141</td>
<td>666</td>
<td>169,944</td>
<td>86</td>
<td>219</td>
<td>-</td>
<td>-</td>
<td>5,099</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>668</td>
<td>-</td>
<td>13</td>
<td>304</td>
<td>541,591</td>
<td>275</td>
<td>201,923</td>
<td>-</td>
<td>8</td>
<td>-</td>
<td>-</td>
<td>1,898</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>415</td>
<td>-</td>
<td>-</td>
<td>156</td>
<td>264,083</td>
<td>299</td>
<td>103,822</td>
<td>7,143</td>
<td>10</td>
<td>105</td>
<td>-</td>
<td>9,866</td>
</tr>
<tr>
<td>Social Enterprise</td>
<td>4,449</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>110,354</td>
<td>144</td>
<td>34,049</td>
<td>-</td>
<td>85</td>
<td>-</td>
<td>-</td>
<td>419</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>24,010</strong></td>
<td><strong>5</strong></td>
<td><strong>13</strong></td>
<td><strong>808</strong></td>
<td><strong>2,193,464</strong></td>
<td><strong>2,392</strong></td>
<td><strong>898,028</strong></td>
<td><strong>7,278</strong></td>
<td><strong>384</strong></td>
<td><strong>128</strong></td>
<td><strong>2</strong></td>
<td><strong>23,386</strong></td>
</tr>
</tbody>
</table>

* Using USAID CYP conversion factors
### Monthly DALY Report by Market Group

**Period:** 2  
**Year:** 2020

<table>
<thead>
<tr>
<th>GRAND TOTAL</th>
<th>1,163,958</th>
<th>2,717,278</th>
<th>2,862,173</th>
<th>5%</th>
<th>25,180,634</th>
<th>11%</th>
</tr>
</thead>
</table>
| **Accelera**
| **Modern Contraception** | 123,175 | 226,781 | 226,376 | 0% | 1,778,590 | 13% |
| **HIV & STIs** | 152,483 | 222,596 | 269,626 | 21% | 1,484,172 | 18% |
| **Malaria** | 320 | 10,197 | 3,535 | (65)% | 59,224 | 6% |
| **Maternal, Newborn, and Child H** | 4,309 | 5,690 | 8,655 | 52% | 54,704 | 16% |
| **Non-communicable diseases** | 2 | 11 | 10 | (17)% | 83 | 11% |
| **Safe Abortion** | 8,546 | 12,376 | 17,701 | 43% | 97,978 | 18% |
| **Tuberculosis** | 4,756 | 12,479 | 10,654 | (15)% | 80,537 | 13% |
| **WASH** | 343 | 2,116 | 779 | (63)% | 8,841 | 9% |
| **Acceleration Market Group** | 293,333 | 492,248 | 537,336 | 9% | 3,564,129 | 15% |

| Anglophone Africa Market Group | 389,807 | 1,004,090 | 648,574 | (35)% | 5,843,838 | 11% |
| **Modern Contraception** | 130,168 | 392,368 | 196,397 | (50)% | 1,722,188 | 11% |
| **HIV & STIs** | 256,815 | 607,157 | 447,669 | (26)% | 4,084,113 | 11% |
| **Malaria** | 490 | 917 | 490 | (47)% | 3,758 | 13% |
| **Maternal, Newborn, and Child H** | 110 | 122 | 165 | 36% | 3,398 | 5% |
| **Non-communicable diseases** | 15 | 39 | 38 | (3)% | 177 | 22% |
| **Safe Abortion** | 1,173 | 2,332 | 2,047 | (12)% | 18,149 | 11% |
| **Tuberculosis** | 16 | 33 | 49 | 50% | 293 | 17% |
| **WASH** | 1,019 | 1,123 | 1,719 | 53% | 11,763 | 15% |

| Franco/Lusophone Africa Market Group | 117,053 | 281,806 | 448,457 | 59% | 2,182,456 | 21% |
| **Modern Contraception** | 88,494 | 160,310 | 373,358 | 133% | 1,149,343 | 32% |
| **HIV & STIs** | 18,550 | 74,483 | 37,059 | (50)% | 408,786 | 9% |
| **Malaria** | 1,080 | 41,860 | 6,399 | (85)% | 567,509 | 1% |
| **Maternal, Newborn, and Child H** | 1,065 | 1,798 | 14,486 | 706% | 20,960 | 69% |
| **Non-communicable diseases** | - | - | - | (100)% | - | - |
| **Nutrition** | - | - | - | 0% | - | - |
| **Safe Abortion** | 6,376 | 2,132 | 14,090 | 561% | 17,789 | 79% |
| **WASH** | 1,489 | 1,222 | 3,065 | 151% | 18,068 | 17% |

| Latin America & Asia Market Group | 95,053 | 210,328 | 174,837 | (17)% | 1,204,959 | 15% |
| **Modern Contraception** | 66,696 | 144,884 | 117,852 | (19)% | 964,897 | 12% |
| **HIV & STIs** | 14,951 | 35,389 | 31,942 | (10)% | 197,848 | 10% |
| **Malaria** | 7 | 50 | 26 | (49)% | 581 | 4% |
| **Maternal, Newborn, and Child H** | 506 | 1,107 | 747 | (32)% | 3,691 | 20% |
| **Non-communicable diseases** | - | - | - | 0% | - | - |
| **Nutrition** | 1 | 1 | 0 | 0% | - | - |
| **Safe Abortion** | 4,576 | 10,347 | 8,134 | (21)% | 37,681 | 21% |
| **Tuberculosis** | 8,317 | 18,534 | 16,133 | (13)% | 90 | 20,152% |
| **WASH** | - | 17 | - | (98)% | 1 | 40%

| Foundation Market Group | 145,002 | 553,078 | 851,737 | 54% | 11,202,350 | 8% |
| **Modern Contraception** | 98,177 | 86,746 | 177,957 | 105% | 460,183 | 39% |
| **HIV & STIs** | 9,814 | 5,140 | 22,782 | 343% | 158,082 | 14% |
| **Malaria** | 321 | 427,822 | 610,743 | 43% | 10,271,807 | 6% |
| **Maternal, Newborn, and Child H** | 10,366 | 9,794 | 13,514 | 38% | 134,346 | 10% |
| **Non-communicable diseases** | 10 | 2 | 10 | 402% | 123 | 8% |
| **Nutrition** | 16,335 | 8,585 | 16,335 | 90% | 95,835 | 17% |
| **Safe Abortion** | 1,173 | 1,023 | 1,585 | 55% | 16,308 | 10% |
| **Tuberculosis** | 8,790 | 13,352 | 8,790 | (34)% | 61,049 | 14% |
| **WASH** | 16 | 614 | 22 | (96)% | 4,616 | 0% |

<p>| Social Enterprise | 123,110 | 175,728 | 201,233 | 15% | 1,182,902 | 17% |</p>
<table>
<thead>
<tr>
<th>Service</th>
<th>DALY 2/2020</th>
<th>YTD DALY 2019</th>
<th>YTD DALY 2020</th>
<th>Percentage Change</th>
<th>Percentage of Category</th>
<th>Annual DALY Target</th>
<th>Percentage of Target Achieved</th>
</tr>
</thead>
<tbody>
<tr>
<td>Modern Contraception</td>
<td>9,779</td>
<td>26,142</td>
<td>17,556</td>
<td>(33)%</td>
<td>9%</td>
<td>228,403</td>
<td>8%</td>
</tr>
<tr>
<td>HIV &amp; STIs</td>
<td>101,355</td>
<td>133,834</td>
<td>169,368</td>
<td>27%</td>
<td>84%</td>
<td>746,210</td>
<td>23%</td>
</tr>
<tr>
<td>Maternal, Newborn, and Child H</td>
<td>6,373</td>
<td>7,511</td>
<td>7,324</td>
<td>(2)%</td>
<td>4%</td>
<td>77,506</td>
<td>9%</td>
</tr>
<tr>
<td>Nutrition</td>
<td>28</td>
<td>37</td>
<td>53</td>
<td>43%</td>
<td>0%</td>
<td>361</td>
<td>15%</td>
</tr>
<tr>
<td>Safe Abortion</td>
<td>5,575</td>
<td>8,203</td>
<td>6,931</td>
<td>(16)%</td>
<td>3%</td>
<td>130,422</td>
<td>5%</td>
</tr>
<tr>
<td>Other</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>0%</td>
<td>-</td>
<td>0%</td>
</tr>
<tr>
<td>Category</td>
<td>DALY 2020</td>
<td>YTD DALY 2019</td>
<td>YTD DALY 2020</td>
<td>Percentage Change</td>
<td>Percentage of Category</td>
<td>Annual DALY Target</td>
<td>Percentage of Target Achieved</td>
</tr>
<tr>
<td>----------------------------------</td>
<td>-----------</td>
<td>----------------</td>
<td>----------------</td>
<td>--------------------</td>
<td>------------------------</td>
<td>-------------------</td>
<td>-------------------------------</td>
</tr>
<tr>
<td>GRAND TOTAL</td>
<td>1,163,958</td>
<td>2,717,278</td>
<td>2,862,173</td>
<td>5%</td>
<td>100%</td>
<td>25,180,634</td>
<td>11%</td>
</tr>
<tr>
<td>Modern Contraception</td>
<td>516,490</td>
<td>1,037,230</td>
<td>1,109,496</td>
<td>7%</td>
<td>100%</td>
<td>6,303,605</td>
<td>18%</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>123,175</td>
<td>226,781</td>
<td>226,376</td>
<td>0%</td>
<td>20%</td>
<td>1,778,590</td>
<td>13%</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>130,168</td>
<td>392,368</td>
<td>196,397</td>
<td>(50)%</td>
<td>18%</td>
<td>1,722,188</td>
<td>11%</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>88,494</td>
<td>160,310</td>
<td>373,358</td>
<td>133%</td>
<td>34%</td>
<td>1,149,343</td>
<td>32%</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>66,696</td>
<td>144,884</td>
<td>117,852</td>
<td>(19)%</td>
<td>11%</td>
<td>964,897</td>
<td>12%</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>98,177</td>
<td>86,746</td>
<td>177,957</td>
<td>105%</td>
<td>16%</td>
<td>460,183</td>
<td>39%</td>
</tr>
<tr>
<td>Social Enterprise</td>
<td>9,779</td>
<td>26,142</td>
<td>17,556</td>
<td>(33)%</td>
<td>2%</td>
<td>228,403</td>
<td>8%</td>
</tr>
<tr>
<td>HIV &amp; STIs</td>
<td>553,968</td>
<td>1,078,600</td>
<td>978,447</td>
<td>(9)%</td>
<td>100%</td>
<td>7,079,211</td>
<td>14%</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>152,483</td>
<td>222,596</td>
<td>269,626</td>
<td>21%</td>
<td>28%</td>
<td>1,484,172</td>
<td>18%</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>256,815</td>
<td>607,157</td>
<td>447,669</td>
<td>(26)%</td>
<td>46%</td>
<td>4,084,113</td>
<td>11%</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>18,550</td>
<td>74,483</td>
<td>37,059</td>
<td>(50)%</td>
<td>4%</td>
<td>408,786</td>
<td>9%</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>14,951</td>
<td>35,389</td>
<td>31,942</td>
<td>(10)%</td>
<td>3%</td>
<td>197,848</td>
<td>16%</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>9,814</td>
<td>5,140</td>
<td>22,782</td>
<td>343%</td>
<td>2%</td>
<td>158,082</td>
<td>14%</td>
</tr>
<tr>
<td>Social Enterprise</td>
<td>101,355</td>
<td>133,834</td>
<td>169,368</td>
<td>27%</td>
<td>17%</td>
<td>746,210</td>
<td>23%</td>
</tr>
<tr>
<td>Malaria</td>
<td>2,217</td>
<td>480,847</td>
<td>621,194</td>
<td>29%</td>
<td>100%</td>
<td>10,902,879</td>
<td>6%</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>320</td>
<td>10,197</td>
<td>3,535</td>
<td>(65)%</td>
<td>1%</td>
<td>59,224</td>
<td>6%</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>490</td>
<td>917</td>
<td>490</td>
<td>(47)%</td>
<td>0%</td>
<td>3,758</td>
<td>13%</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>1,080</td>
<td>41,860</td>
<td>6,399</td>
<td>(85)%</td>
<td>1%</td>
<td>567,509</td>
<td>1%</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>7</td>
<td>50</td>
<td>26</td>
<td>(49)%</td>
<td>0%</td>
<td>581</td>
<td>4%</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>321</td>
<td>427,822</td>
<td>610,743</td>
<td>43%</td>
<td>98%</td>
<td>10,271,807</td>
<td>6%</td>
</tr>
<tr>
<td>Maternal, Newborn, and Child Health</td>
<td>22,728</td>
<td>26,021</td>
<td>44,892</td>
<td>73%</td>
<td>100%</td>
<td>294,605</td>
<td>15%</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>4,309</td>
<td>5,690</td>
<td>8,655</td>
<td>52%</td>
<td>19%</td>
<td>54,704</td>
<td>16%</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>110</td>
<td>122</td>
<td>165</td>
<td>36%</td>
<td>0%</td>
<td>3,398</td>
<td>5%</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>1,065</td>
<td>1,798</td>
<td>14,486</td>
<td>706%</td>
<td>32%</td>
<td>20,960</td>
<td>69%</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>506</td>
<td>1,107</td>
<td>747</td>
<td>(32)%</td>
<td>2%</td>
<td>3,691</td>
<td>20%</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>10,366</td>
<td>9,794</td>
<td>13,514</td>
<td>38%</td>
<td>30%</td>
<td>134,346</td>
<td>10%</td>
</tr>
<tr>
<td>Social Enterprise</td>
<td>6,373</td>
<td>7,511</td>
<td>7,324</td>
<td>(2)%</td>
<td>16%</td>
<td>77,506</td>
<td>9%</td>
</tr>
<tr>
<td>Non-communicable diseases</td>
<td>28</td>
<td>53</td>
<td>58</td>
<td>9%</td>
<td>100%</td>
<td>384</td>
<td>15%</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>2</td>
<td>11</td>
<td>10</td>
<td>(17)%</td>
<td>16%</td>
<td>83</td>
<td>11%</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>15</td>
<td>39</td>
<td>38</td>
<td>(3)%</td>
<td>66%</td>
<td>177</td>
<td>22%</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>(100)%</td>
<td>0%</td>
<td>-</td>
<td>0%</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>0%</td>
<td>-</td>
<td>0%</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>10</td>
<td>2</td>
<td>10</td>
<td>402%</td>
<td>18%</td>
<td>123</td>
<td>8%</td>
</tr>
<tr>
<td>Nutrition</td>
<td>16,363</td>
<td>8,622</td>
<td>16,388</td>
<td>90%</td>
<td>100%</td>
<td>96,196</td>
<td>17%</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>0%</td>
<td>-</td>
<td>0%</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>1</td>
<td>-</td>
<td>1</td>
<td>0%</td>
<td>0%</td>
<td>-</td>
<td>0%</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>16,335</td>
<td>8,585</td>
<td>16,335</td>
<td>90%</td>
<td>100%</td>
<td>95,835</td>
<td>17%</td>
</tr>
<tr>
<td>Social Enterprise</td>
<td>28</td>
<td>37</td>
<td>53</td>
<td>43%</td>
<td>0%</td>
<td>361</td>
<td>15%</td>
</tr>
<tr>
<td>Safe Abortion</td>
<td>27,420</td>
<td>36,414</td>
<td>50,488</td>
<td>39%</td>
<td>100%</td>
<td>318,507</td>
<td>16%</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>8,546</td>
<td>12,376</td>
<td>17,701</td>
<td>43%</td>
<td>35%</td>
<td>97,978</td>
<td>18%</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>1,173</td>
<td>2,332</td>
<td>2,047</td>
<td>(12)%</td>
<td>4%</td>
<td>18,149</td>
<td>11%</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>6,376</td>
<td>2,132</td>
<td>14,090</td>
<td>561%</td>
<td>28%</td>
<td>17,789</td>
<td>79%</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>4,576</td>
<td>10,347</td>
<td>8,134</td>
<td>(21)%</td>
<td>16%</td>
<td>37,861</td>
<td>21%</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>1,173</td>
<td>1,023</td>
<td>1,585</td>
<td>55%</td>
<td>3%</td>
<td>16,308</td>
<td>10%</td>
</tr>
<tr>
<td>Social Enterprise</td>
<td>5,575</td>
<td>8,203</td>
<td>6,931</td>
<td>(16)%</td>
<td>14%</td>
<td>130,422</td>
<td>5%</td>
</tr>
<tr>
<td>Tuberculosis</td>
<td>21,879</td>
<td>44,398</td>
<td>35,626</td>
<td>(20)%</td>
<td>100%</td>
<td>141,959</td>
<td>25%</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>4,756</td>
<td>12,479</td>
<td>10,654</td>
<td>(15)%</td>
<td>30%</td>
<td>80,537</td>
<td>13%</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>16</td>
<td>33</td>
<td>49</td>
<td>50%</td>
<td>0%</td>
<td>293</td>
<td>17%</td>
</tr>
</tbody>
</table>
## Monthly DALY Report by Health Area

### Period: 2  
### Year: 2020

<table>
<thead>
<tr>
<th></th>
<th>DALY 2/2020</th>
<th>YTD DALY 2019</th>
<th>YTD DALY 2020</th>
<th>Percentage Change</th>
<th>Percentage of Category</th>
<th>Annual DALY Target</th>
<th>Percentage of Target Achieved</th>
</tr>
</thead>
<tbody>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>8,317</td>
<td>18,534</td>
<td>16,133</td>
<td>(13)%</td>
<td>45 %</td>
<td>80</td>
<td>20,152%</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>8,790</td>
<td>13,352</td>
<td>8,790</td>
<td>(34)%</td>
<td>25 %</td>
<td>61,049</td>
<td>14%</td>
</tr>
<tr>
<td>WASH</td>
<td>2,866</td>
<td>5,092</td>
<td>5,584</td>
<td>10%</td>
<td>100%</td>
<td>43,289</td>
<td>13%</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>343</td>
<td>2,116</td>
<td>779</td>
<td>(63)%</td>
<td>14 %</td>
<td>8,841</td>
<td>9%</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>1,019</td>
<td>1,123</td>
<td>1,719</td>
<td>53%</td>
<td>31 %</td>
<td>11,763</td>
<td>15%</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>1,489</td>
<td>1,222</td>
<td>3,065</td>
<td>151%</td>
<td>55 %</td>
<td>18,068</td>
<td>17%</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>-</td>
<td>17</td>
<td>-</td>
<td>(98)%</td>
<td>0 %</td>
<td>1</td>
<td>40%</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>16</td>
<td>614</td>
<td>22</td>
<td>(96)%</td>
<td>0 %</td>
<td>4,616</td>
<td>0%</td>
</tr>
<tr>
<td>Other</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>0%</td>
<td>-</td>
<td>0%</td>
</tr>
<tr>
<td>Social Enterprise</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>0%</td>
<td>-</td>
<td>0%</td>
</tr>
</tbody>
</table>
### Monthly DALY Report by Country

**Period:** 2  
**Year:** 2020

<table>
<thead>
<tr>
<th>Country</th>
<th>DALY 2/2020</th>
<th>YTD DALY 2019</th>
<th>YTD DALY 2020</th>
<th>Percentage Change</th>
<th>Percentage of Category</th>
<th>Annual DALY Target</th>
<th>Percentage of Target Achieved</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>GRAND TOTAL</strong></td>
<td>1,163,958</td>
<td>2,717,278</td>
<td>2,862,173</td>
<td>5%</td>
<td></td>
<td>25,180,634</td>
<td>11%</td>
</tr>
<tr>
<td><strong>Acceleration Market Group</strong></td>
<td>293,333</td>
<td>492,248</td>
<td>537,336</td>
<td>9%</td>
<td>100%</td>
<td>3,564,129</td>
<td>15%</td>
</tr>
<tr>
<td><strong>India</strong></td>
<td>44,558</td>
<td>42,610</td>
<td>77,044</td>
<td>81%</td>
<td>14%</td>
<td>199,217</td>
<td>39%</td>
</tr>
<tr>
<td>Modern Contraception</td>
<td>44,558</td>
<td>41,243</td>
<td>77,044</td>
<td>87%</td>
<td>14%</td>
<td>192,947</td>
<td>40%</td>
</tr>
<tr>
<td>Tuberculosis</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>0%</td>
<td>1,092</td>
<td>0%</td>
</tr>
<tr>
<td>WASH</td>
<td>-</td>
<td>1,366</td>
<td>-</td>
<td>(100)%</td>
<td>0%</td>
<td>5,179</td>
<td>0%</td>
</tr>
<tr>
<td><strong>Kenya</strong></td>
<td>185,938</td>
<td>252,412</td>
<td>266,784</td>
<td>6%</td>
<td>50%</td>
<td>1,375,513</td>
<td>19%</td>
</tr>
<tr>
<td>Modern Contraception</td>
<td>49,551</td>
<td>84,166</td>
<td>94,774</td>
<td>13%</td>
<td>18%</td>
<td>555,460</td>
<td>17%</td>
</tr>
<tr>
<td>HIV &amp; STIs</td>
<td>132,760</td>
<td>157,741</td>
<td>160,770</td>
<td>2%</td>
<td>30%</td>
<td>766,687</td>
<td>21%</td>
</tr>
<tr>
<td>Malaria</td>
<td>75</td>
<td>5,251</td>
<td>3,190</td>
<td>(39)%</td>
<td>1%</td>
<td>19,786</td>
<td>16%</td>
</tr>
<tr>
<td>Maternal, Newborn, and Child Health</td>
<td>3,209</td>
<td>4,496</td>
<td>7,267</td>
<td>62%</td>
<td>1%</td>
<td>29,849</td>
<td>24%</td>
</tr>
<tr>
<td>Non-communicable diseases</td>
<td>-</td>
<td>8</td>
<td>4</td>
<td>(49)%</td>
<td>0%</td>
<td>69</td>
<td>6%</td>
</tr>
<tr>
<td>Tuberculosis</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>0%</td>
<td>-</td>
<td>0%</td>
</tr>
<tr>
<td>WASH</td>
<td>343</td>
<td>750</td>
<td>779</td>
<td>4%</td>
<td>0%</td>
<td>3,663</td>
<td>21%</td>
</tr>
<tr>
<td><strong>Myanmar</strong></td>
<td>17,816</td>
<td>38,018</td>
<td>33,242</td>
<td>(13)%</td>
<td>6%</td>
<td>273,552</td>
<td>12%</td>
</tr>
<tr>
<td>Modern Contraception</td>
<td>6,311</td>
<td>9,425</td>
<td>9,846</td>
<td>4%</td>
<td>2%</td>
<td>64,796</td>
<td>15%</td>
</tr>
<tr>
<td>HIV &amp; STIs</td>
<td>5,402</td>
<td>9,970</td>
<td>11,003</td>
<td>10%</td>
<td>2%</td>
<td>65,003</td>
<td>17%</td>
</tr>
<tr>
<td>Malaria</td>
<td>245</td>
<td>4,946</td>
<td>345</td>
<td>(93)%</td>
<td>0%</td>
<td>39,438</td>
<td>1%</td>
</tr>
<tr>
<td>Maternal, Newborn, and Child Health</td>
<td>1,100</td>
<td>1,194</td>
<td>1,388</td>
<td>16%</td>
<td>0%</td>
<td>24,854</td>
<td>6%</td>
</tr>
<tr>
<td>Non-communicable diseases</td>
<td>2</td>
<td>3</td>
<td>5</td>
<td>57%</td>
<td>0%</td>
<td>15</td>
<td>37%</td>
</tr>
<tr>
<td>Tuberculosis</td>
<td>4,756</td>
<td>12,479</td>
<td>10,654</td>
<td>(15)%</td>
<td>2%</td>
<td>79,446</td>
<td>13%</td>
</tr>
<tr>
<td><strong>Nigeria</strong></td>
<td>11,204</td>
<td>14,367</td>
<td>20,841</td>
<td>45%</td>
<td>4%</td>
<td>43,299</td>
<td>48%</td>
</tr>
<tr>
<td>Modern Contraception</td>
<td>11,204</td>
<td>14,367</td>
<td>20,841</td>
<td>45%</td>
<td>4%</td>
<td>43,299</td>
<td>48%</td>
</tr>
<tr>
<td>PSI Nigeria</td>
<td>20,097</td>
<td>89,956</td>
<td>41,572</td>
<td>(54)%</td>
<td>8%</td>
<td>1,021,259</td>
<td>4%</td>
</tr>
<tr>
<td>Modern Contraception</td>
<td>11,551</td>
<td>77,580</td>
<td>23,871</td>
<td>(69)%</td>
<td>4%</td>
<td>922,089</td>
<td>3%</td>
</tr>
<tr>
<td>HIV &amp; STIs</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>0%</td>
<td>1,193</td>
<td>0%</td>
</tr>
<tr>
<td>Safe Abortion</td>
<td>8,546</td>
<td>12,376</td>
<td>17,701</td>
<td>43%</td>
<td>3%</td>
<td>97,978</td>
<td>18%</td>
</tr>
<tr>
<td><strong>South Africa</strong></td>
<td>14,320</td>
<td>54,886</td>
<td>97,852</td>
<td>78%</td>
<td>18%</td>
<td>651,289</td>
<td>15%</td>
</tr>
<tr>
<td>HIV &amp; STIs</td>
<td>14,320</td>
<td>54,886</td>
<td>97,852</td>
<td>78%</td>
<td>18%</td>
<td>651,289</td>
<td>15%</td>
</tr>
<tr>
<td><strong>Anglophone Africa Market Group</strong></td>
<td>389,807</td>
<td>1,004,090</td>
<td>648,574</td>
<td>(35)%</td>
<td>100%</td>
<td>5,843,838</td>
<td>11%</td>
</tr>
<tr>
<td>Eswatini</td>
<td>60,591</td>
<td>116,219</td>
<td>117,229</td>
<td>1 %</td>
<td>18%</td>
<td>590,342</td>
<td>20%</td>
</tr>
<tr>
<td>Modern Contraception</td>
<td>3,978</td>
<td>7,498</td>
<td>7,680</td>
<td>2%</td>
<td>1%</td>
<td>37,556</td>
<td>20%</td>
</tr>
<tr>
<td>HIV &amp; STIs</td>
<td>56,613</td>
<td>108,721</td>
<td>109,548</td>
<td>1%</td>
<td>17%</td>
<td>552,786</td>
<td>20%</td>
</tr>
<tr>
<td>Non-communicable diseases</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>0%</td>
<td>-</td>
<td>0%</td>
</tr>
<tr>
<td>Tuberculosis</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>0%</td>
<td>-</td>
<td>0%</td>
</tr>
<tr>
<td><strong>Ethiopia</strong></td>
<td>7,910</td>
<td>38,405</td>
<td>9,179</td>
<td>(76)%</td>
<td>1%</td>
<td>146,885</td>
<td>6%</td>
</tr>
<tr>
<td>Modern Contraception</td>
<td>2,257</td>
<td>12,676</td>
<td>2,644</td>
<td>(79)%</td>
<td>0%</td>
<td>42,806</td>
<td>6%</td>
</tr>
<tr>
<td>HIV &amp; STIs</td>
<td>4,697</td>
<td>25,116</td>
<td>4,955</td>
<td>(80)%</td>
<td>1%</td>
<td>94,112</td>
<td>5%</td>
</tr>
<tr>
<td>Non-communicable diseases</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>0%</td>
<td>-</td>
<td>0%</td>
</tr>
<tr>
<td>Tuberculosis</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>0%</td>
<td>-</td>
<td>0%</td>
</tr>
<tr>
<td>WASH</td>
<td>957</td>
<td>613</td>
<td>1,581</td>
<td>158%</td>
<td>0%</td>
<td>9,966</td>
<td>16%</td>
</tr>
<tr>
<td><strong>Ghana</strong></td>
<td>15</td>
<td>6,963</td>
<td>46</td>
<td>(99)%</td>
<td>-%</td>
<td>100,519</td>
<td>-%</td>
</tr>
<tr>
<td>Modern Contraception</td>
<td>-</td>
<td>6,953</td>
<td>-</td>
<td>(100)%</td>
<td>0%</td>
<td>95,979</td>
<td>0%</td>
</tr>
<tr>
<td>HIV &amp; STIs</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>0%</td>
<td>4,347</td>
<td>0%</td>
</tr>
<tr>
<td>WASH</td>
<td>15</td>
<td>10</td>
<td>46</td>
<td>361%</td>
<td>0%</td>
<td>193</td>
<td>24%</td>
</tr>
<tr>
<td><strong>Lesotho</strong></td>
<td>3,258</td>
<td>7,558</td>
<td>7,387</td>
<td>(2)%</td>
<td>1%</td>
<td>62,691</td>
<td>12%</td>
</tr>
</tbody>
</table>
### Monthly DALY Report by Country

**Period:** 2  
**Year:** 2020

<table>
<thead>
<tr>
<th>Category</th>
<th>DALY 2/2020</th>
<th>YTD DALY 2019</th>
<th>YTD DALY 2020</th>
<th>Percentage Change</th>
<th>Percentage of Category</th>
<th>Annual DALY Target</th>
<th>Percentage of Target Achieved</th>
</tr>
</thead>
<tbody>
<tr>
<td>Modern Contraception</td>
<td>314</td>
<td>896</td>
<td>722</td>
<td>(19)%</td>
<td>0%</td>
<td>6,840</td>
<td>11%</td>
</tr>
<tr>
<td>HIV &amp; STIs</td>
<td>2,928</td>
<td>6,630</td>
<td>6,616</td>
<td>0%</td>
<td>1%</td>
<td>55,559</td>
<td>12%</td>
</tr>
<tr>
<td>Non-communicable diseases</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>0%</td>
<td>-</td>
<td>0%</td>
</tr>
<tr>
<td>Tuberculosis</td>
<td>16</td>
<td>33</td>
<td>49</td>
<td>50%</td>
<td>0%</td>
<td>293</td>
<td>17%</td>
</tr>
<tr>
<td><strong>Malawi</strong></td>
<td><strong>61,847</strong></td>
<td><strong>153,099</strong></td>
<td><strong>95,625</strong></td>
<td><strong>(38)%</strong></td>
<td><strong>15%</strong></td>
<td><strong>934,320</strong></td>
<td><strong>10%</strong></td>
</tr>
<tr>
<td>Modern Contraception</td>
<td>28,875</td>
<td>61,460</td>
<td>52,279</td>
<td>(15)%</td>
<td>8%</td>
<td>340,789</td>
<td>15%</td>
</tr>
<tr>
<td>HIV &amp; STIs</td>
<td>32,464</td>
<td>91,228</td>
<td>42,837</td>
<td>(53)%</td>
<td>7%</td>
<td>589,659</td>
<td>7%</td>
</tr>
<tr>
<td>Malaria</td>
<td>490</td>
<td>339</td>
<td>490</td>
<td>44%</td>
<td>0%</td>
<td>3,758</td>
<td>13%</td>
</tr>
<tr>
<td>Non-communicable diseases</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>0%</td>
<td>-</td>
<td>0%</td>
</tr>
<tr>
<td><strong>WASH</strong></td>
<td><strong>17</strong></td>
<td><strong>71</strong></td>
<td><strong>17</strong></td>
<td><strong>(75)%</strong></td>
<td><strong>0%</strong></td>
<td><strong>113</strong></td>
<td><strong>15%</strong></td>
</tr>
<tr>
<td><strong>PSI Uganda</strong></td>
<td><strong>32,214</strong></td>
<td><strong>186,806</strong></td>
<td><strong>41,153</strong></td>
<td><strong>(78)%</strong></td>
<td><strong>6%</strong></td>
<td><strong>797,959</strong></td>
<td><strong>5%</strong></td>
</tr>
<tr>
<td>Modern Contraception</td>
<td>21,897</td>
<td>181,010</td>
<td>24,967</td>
<td>(86)%</td>
<td>4%</td>
<td>727,280</td>
<td>3%</td>
</tr>
<tr>
<td>HIV &amp; STIs</td>
<td>9,035</td>
<td>3,709</td>
<td>13,973</td>
<td>277%</td>
<td>2%</td>
<td>50,244</td>
<td>28%</td>
</tr>
<tr>
<td>Maternal, Newborn, and Child Health</td>
<td>110</td>
<td>122</td>
<td>165</td>
<td>36%</td>
<td>0%</td>
<td>3,398</td>
<td>5%</td>
</tr>
<tr>
<td>Non-communicable diseases</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>0%</td>
<td>-</td>
<td>0%</td>
</tr>
<tr>
<td>Safe Abortion</td>
<td>1,173</td>
<td>1,929</td>
<td>2,047</td>
<td>6%</td>
<td>0%</td>
<td>16,888</td>
<td>12%</td>
</tr>
<tr>
<td><strong>WASH</strong></td>
<td><strong>-</strong></td>
<td><strong>35</strong></td>
<td><strong>1</strong></td>
<td><strong>(98)%</strong></td>
<td><strong>0%</strong></td>
<td><strong>149</strong></td>
<td><strong>1%</strong></td>
</tr>
<tr>
<td><strong>Rwanda</strong></td>
<td><strong>30,179</strong></td>
<td><strong>59,605</strong></td>
<td><strong>39,270</strong></td>
<td><strong>(34)%</strong></td>
<td><strong>6%</strong></td>
<td>-</td>
<td>-%</td>
</tr>
<tr>
<td>Modern Contraception</td>
<td>7,616</td>
<td>16,573</td>
<td>11,266</td>
<td>(32)%</td>
<td>2%</td>
<td>-</td>
<td>0%</td>
</tr>
<tr>
<td>HIV &amp; STIs</td>
<td>22,553</td>
<td>42,987</td>
<td>27,951</td>
<td>(35)%</td>
<td>4%</td>
<td>-</td>
<td>0%</td>
</tr>
<tr>
<td><strong>WASH</strong></td>
<td><strong>10</strong></td>
<td><strong>44</strong></td>
<td><strong>53</strong></td>
<td><strong>20%</strong></td>
<td><strong>0%</strong></td>
<td>-</td>
<td>-%</td>
</tr>
<tr>
<td><strong>Tanzania</strong></td>
<td><strong>53,400</strong></td>
<td><strong>64,923</strong></td>
<td><strong>60,060</strong></td>
<td><strong>(7)%</strong></td>
<td><strong>9%</strong></td>
<td><strong>731,561</strong></td>
<td><strong>8%</strong></td>
</tr>
<tr>
<td>Modern Contraception</td>
<td>53,379</td>
<td>63,842</td>
<td>60,404</td>
<td>(6)%</td>
<td>9%</td>
<td>307,245</td>
<td>20%</td>
</tr>
<tr>
<td>HIV &amp; STIs</td>
<td>-</td>
<td>46</td>
<td>-</td>
<td>(100)%</td>
<td>0%</td>
<td>421,714</td>
<td>0%</td>
</tr>
<tr>
<td>Malaria</td>
<td>-</td>
<td>577</td>
<td>-</td>
<td>(100)%</td>
<td>0%</td>
<td>-</td>
<td>0%</td>
</tr>
<tr>
<td>Safe Abortion</td>
<td>-</td>
<td>403</td>
<td>-</td>
<td>(100)%</td>
<td>0%</td>
<td>1,261</td>
<td>0%</td>
</tr>
<tr>
<td><strong>WASH</strong></td>
<td><strong>20</strong></td>
<td><strong>55</strong></td>
<td><strong>20</strong></td>
<td><strong>(63)%</strong></td>
<td><strong>0%</strong></td>
<td><strong>1,341</strong></td>
<td><strong>2%</strong></td>
</tr>
<tr>
<td><strong>Uganda</strong></td>
<td><strong>13,339</strong></td>
<td><strong>5,063</strong></td>
<td><strong>32,193</strong></td>
<td><strong>475 %</strong></td>
<td><strong>5%</strong></td>
<td><strong>443,775</strong></td>
<td><strong>7%</strong></td>
</tr>
<tr>
<td>Modern Contraception</td>
<td>-</td>
<td>45</td>
<td>1,955</td>
<td>4,232%</td>
<td>0%</td>
<td>80,990</td>
<td>2%</td>
</tr>
<tr>
<td>HIV &amp; STIs</td>
<td>13,339</td>
<td>5,558</td>
<td>30,238</td>
<td>444%</td>
<td>5%</td>
<td>362,785</td>
<td>8%</td>
</tr>
<tr>
<td>Malaria</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>0%</td>
<td>-</td>
<td>0%</td>
</tr>
<tr>
<td>Safe Abortion</td>
<td>-</td>
<td>87,767</td>
<td>37,461</td>
<td>(57)%</td>
<td>6%</td>
<td>223,787</td>
<td>17%</td>
</tr>
<tr>
<td><strong>Zambia</strong></td>
<td><strong>-</strong></td>
<td><strong>28,362</strong></td>
<td><strong>16,582</strong></td>
<td><strong>(42)%</strong></td>
<td><strong>3%</strong></td>
<td><strong>0%</strong></td>
<td><strong>0%</strong></td>
</tr>
<tr>
<td>Modern Contraception</td>
<td>-</td>
<td>28,362</td>
<td>16,582</td>
<td>(42)%</td>
<td>3%</td>
<td>-</td>
<td>0%</td>
</tr>
<tr>
<td>HIV &amp; STIs</td>
<td>-</td>
<td>59,110</td>
<td>20,879</td>
<td>(65)%</td>
<td>3%</td>
<td>223,787</td>
<td>9%</td>
</tr>
<tr>
<td><strong>WASH</strong></td>
<td><strong>-</strong></td>
<td><strong>295</strong></td>
<td><strong>-</strong></td>
<td><strong>(100)%</strong></td>
<td><strong>0%</strong></td>
<td><strong>-</strong></td>
<td><strong>0%</strong></td>
</tr>
<tr>
<td><strong>Zimbabwe</strong></td>
<td><strong>127,054</strong></td>
<td><strong>277,142</strong></td>
<td><strong>208,971</strong></td>
<td><strong>(25)%</strong></td>
<td><strong>32%</strong></td>
<td><strong>1,812,000</strong></td>
<td><strong>12%</strong></td>
</tr>
<tr>
<td>Modern Contraception</td>
<td>11,852</td>
<td>13,053</td>
<td>18,261</td>
<td>40%</td>
<td>3%</td>
<td>82,702</td>
<td>22%</td>
</tr>
<tr>
<td>HIV &amp; STIs</td>
<td>115,186</td>
<td>264,051</td>
<td>190,671</td>
<td>(28)%</td>
<td>29%</td>
<td>1,729,120</td>
<td>11%</td>
</tr>
<tr>
<td>Non-communicable diseases</td>
<td>15</td>
<td>38</td>
<td>38</td>
<td>1%</td>
<td>0%</td>
<td>177</td>
<td>22%</td>
</tr>
<tr>
<td>Tuberculosis</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>0%</td>
<td>-</td>
<td>0%</td>
</tr>
</tbody>
</table>

| Franco/Lusophone Africa Market Group  | 117,053     | 281,806        | 448,457        | 59%               | 100%                   | 2,182,456          | 21%                         |

| **Angola**                            | **1,637**   | **45,755**     | **4,013**      | **(91)%**         | **1%**                 | **349,295**        | **1%**                      |
| Modern Contraception                  | 737         | 11,932         | 1,145          | (90)%             | 0%                     | 64,097             | 2%                          |
| HIV & STIs                            | 196         | 1,963          | 431            | (78)%             | 0%                     | 15,167             | 3%                          |
| Malaria                               | 575         | 31,475         | 2,052          | (93)%             | 0%                     | 265,665            | 1%                          |
| Safe Abortion                         | 101         | 150            | 323            | 116%              | 0%                     | 3,067              | 11%                         |
| **WASH**                              | **28**      | **235**        | **62**         | **(74)%**         | **0%**                 | **1,300**          | **5%**                      |
### Monthly DALY Report by Country

**Period:** 2  
**Year:** 2020

<table>
<thead>
<tr>
<th></th>
<th>DALY 2/2020</th>
<th>YTD DALY 2019</th>
<th>YTD DALY 2020</th>
<th>Percentage Change</th>
<th>Percentage of Category</th>
<th>Annual DALY Target</th>
<th>Percentage of Target Achieved</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Benin</strong></td>
<td>19,965</td>
<td>10,800</td>
<td>35,657</td>
<td>230 %</td>
<td>8%</td>
<td>234,593</td>
<td>15%</td>
</tr>
<tr>
<td>Modern Contraception</td>
<td>16,714</td>
<td>7,222</td>
<td>18,336</td>
<td>154%</td>
<td>4%</td>
<td>181,647</td>
<td>10%</td>
</tr>
<tr>
<td>HIV &amp; STIs</td>
<td>1,510</td>
<td>1,815</td>
<td>1,646</td>
<td>(9)%</td>
<td>0%</td>
<td>24,736</td>
<td>7%</td>
</tr>
<tr>
<td>Maternal, Newborn, and Child Health</td>
<td>940</td>
<td>1,251</td>
<td>14,352</td>
<td>1,047%</td>
<td>3%</td>
<td>18,400</td>
<td>78%</td>
</tr>
<tr>
<td>Non-communicable diseases</td>
<td>76</td>
<td>144</td>
<td>178</td>
<td>23%</td>
<td>0%</td>
<td>630</td>
<td>28%</td>
</tr>
<tr>
<td>Safe Abortion</td>
<td>726</td>
<td>367</td>
<td>1,146</td>
<td>212%</td>
<td>0%</td>
<td>9,180</td>
<td>12%</td>
</tr>
<tr>
<td><strong>Burundi</strong></td>
<td>2,152</td>
<td>30,318</td>
<td>7,208</td>
<td>(76)%</td>
<td>2%</td>
<td>179,536</td>
<td>4%</td>
</tr>
<tr>
<td>Modern Contraception</td>
<td>1,261</td>
<td>9,326</td>
<td>2,079</td>
<td>(78)%</td>
<td>0%</td>
<td>50,190</td>
<td>4%</td>
</tr>
<tr>
<td>HIV &amp; STIs</td>
<td>550</td>
<td>10,866</td>
<td>1,101</td>
<td>(90)%</td>
<td>0%</td>
<td>49,867</td>
<td>2%</td>
</tr>
<tr>
<td>Malaria</td>
<td>319</td>
<td>10,069</td>
<td>3,964</td>
<td>(61)%</td>
<td>1%</td>
<td>79,063</td>
<td>5%</td>
</tr>
<tr>
<td>Safe Abortion</td>
<td>23</td>
<td>57</td>
<td>64</td>
<td>14%</td>
<td>0%</td>
<td>417</td>
<td>15%</td>
</tr>
<tr>
<td><strong>Cameroon</strong></td>
<td>33,000</td>
<td>92,739</td>
<td>68,739</td>
<td>(26)%</td>
<td>15%</td>
<td>639,529</td>
<td>11%</td>
</tr>
<tr>
<td>Modern Contraception</td>
<td>13,463</td>
<td>59,660</td>
<td>27,006</td>
<td>(55)%</td>
<td>6%</td>
<td>355,312</td>
<td>8%</td>
</tr>
<tr>
<td>HIV &amp; STIs</td>
<td>14,276</td>
<td>31,397</td>
<td>29,149</td>
<td>(7)%</td>
<td>6%</td>
<td>173,620</td>
<td>17%</td>
</tr>
<tr>
<td>Malaria</td>
<td>108</td>
<td>260</td>
<td>212</td>
<td>(19)%</td>
<td>0%</td>
<td>101,036</td>
<td>0%</td>
</tr>
<tr>
<td>Maternal, Newborn, and Child Health</td>
<td>125</td>
<td>547</td>
<td>134</td>
<td>(75)%</td>
<td>0%</td>
<td>2,560</td>
<td>5%</td>
</tr>
<tr>
<td>Nutrition</td>
<td>78</td>
<td>28</td>
<td>78</td>
<td>177%</td>
<td>0%</td>
<td>-</td>
<td>0%</td>
</tr>
<tr>
<td>Safe Abortion</td>
<td>86</td>
<td>148</td>
<td>182</td>
<td>23%</td>
<td>0%</td>
<td>1,023</td>
<td>18%</td>
</tr>
<tr>
<td><strong>Cote d'Ivoire</strong></td>
<td>7,066</td>
<td>10,582</td>
<td>12,259</td>
<td>16%</td>
<td>3%</td>
<td>92,522</td>
<td>13%</td>
</tr>
<tr>
<td>Modern Contraception</td>
<td>6,398</td>
<td>10,406</td>
<td>10,990</td>
<td>6%</td>
<td>2%</td>
<td>90,049</td>
<td>12%</td>
</tr>
<tr>
<td>HIV &amp; STIs</td>
<td>504</td>
<td>-</td>
<td>1,009</td>
<td>0%</td>
<td>0%</td>
<td>1,450</td>
<td>70%</td>
</tr>
<tr>
<td>Safe Abortion</td>
<td>78</td>
<td>28</td>
<td>78</td>
<td>177%</td>
<td>0%</td>
<td>-</td>
<td>0%</td>
</tr>
<tr>
<td>WASH</td>
<td>86</td>
<td>148</td>
<td>182</td>
<td>23%</td>
<td>0%</td>
<td>1,023</td>
<td>18%</td>
</tr>
<tr>
<td><strong>Mozambique</strong></td>
<td>34,970</td>
<td>71,637</td>
<td>287,424</td>
<td>301 %</td>
<td>64%</td>
<td>397,940</td>
<td>72%</td>
</tr>
<tr>
<td>Modern Contraception</td>
<td>34,382</td>
<td>45,320</td>
<td>285,854</td>
<td>531%</td>
<td>64%</td>
<td>270,930</td>
<td>106%</td>
</tr>
<tr>
<td>HIV &amp; STIs</td>
<td>-</td>
<td>25,968</td>
<td>-</td>
<td>(100)%</td>
<td>0%</td>
<td>121,004</td>
<td>0%</td>
</tr>
<tr>
<td>WASH</td>
<td>588</td>
<td>349</td>
<td>1,570</td>
<td>350%</td>
<td>0%</td>
<td>6,006</td>
<td>26%</td>
</tr>
<tr>
<td><strong>Niger</strong></td>
<td>8,757</td>
<td>10,078</td>
<td>17,583</td>
<td>74 %</td>
<td>4%</td>
<td>177,491</td>
<td>10%</td>
</tr>
<tr>
<td>Modern Contraception</td>
<td>8,653</td>
<td>9,729</td>
<td>17,342</td>
<td>78%</td>
<td>4%</td>
<td>59,529</td>
<td>29%</td>
</tr>
<tr>
<td>HIV &amp; STIs</td>
<td>-</td>
<td>245</td>
<td>-</td>
<td>(100)%</td>
<td>0%</td>
<td>-</td>
<td>0%</td>
</tr>
<tr>
<td>Malaria</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>0%</td>
<td>117,753</td>
<td>0%</td>
</tr>
<tr>
<td>Safe Abortion</td>
<td>104</td>
<td>103</td>
<td>241</td>
<td>134%</td>
<td>0%</td>
<td>208</td>
<td>116%</td>
</tr>
<tr>
<td><strong>PSI Benin</strong></td>
<td>4,130</td>
<td>3,200</td>
<td>4,130</td>
<td>29 %</td>
<td>1%</td>
<td>57,045</td>
<td>7%</td>
</tr>
<tr>
<td>Modern Contraception</td>
<td>3,164</td>
<td>2,403</td>
<td>3,164</td>
<td>32%</td>
<td>1%</td>
<td>50,558</td>
<td>6%</td>
</tr>
<tr>
<td>Safe Abortion</td>
<td>966</td>
<td>798</td>
<td>966</td>
<td>21%</td>
<td>0%</td>
<td>6,487</td>
<td>15%</td>
</tr>
<tr>
<td><strong>Senegal</strong></td>
<td>5,375</td>
<td>6,697</td>
<td>11,442</td>
<td>71 %</td>
<td>3%</td>
<td>54,505</td>
<td>21%</td>
</tr>
<tr>
<td>Modern Contraception</td>
<td>3,722</td>
<td>4,310</td>
<td>7,442</td>
<td>73%</td>
<td>2%</td>
<td>27,032</td>
<td>28%</td>
</tr>
<tr>
<td>HIV &amp; STIs</td>
<td>1,514</td>
<td>2,229</td>
<td>3,723</td>
<td>67%</td>
<td>1%</td>
<td>22,942</td>
<td>16%</td>
</tr>
<tr>
<td>Malaria</td>
<td>78</td>
<td>57</td>
<td>172</td>
<td>204%</td>
<td>0%</td>
<td>3,991</td>
<td>4%</td>
</tr>
<tr>
<td>WASH</td>
<td>60</td>
<td>101</td>
<td>105</td>
<td>4%</td>
<td>0%</td>
<td>539</td>
<td>19%</td>
</tr>
</tbody>
</table>

**Latin America & Asia Market Group**  
DALY 2/2020: 95,053  
YTD DALY 2019: 210,328  
YTD DALY 2020: 174,837  
Percentage Change: (17)%  
Percentage of Category: 100%  
Annual DALY Target: 1,204,959  
Percentage of Target Achieved: 15%

<table>
<thead>
<tr>
<th></th>
<th>DALY 2/2020</th>
<th>YTD DALY 2019</th>
<th>YTD DALY 2020</th>
<th>Percentage Change</th>
<th>Percentage of Category</th>
<th>Annual DALY Target</th>
<th>Percentage of Target Achieved</th>
</tr>
</thead>
<tbody>
<tr>
<td>Modern Contraception</td>
<td>9,620</td>
<td>17,765</td>
<td>18,233</td>
<td>3%</td>
<td>10%</td>
<td>123,175</td>
<td>15%</td>
</tr>
<tr>
<td>HIV &amp; STIs</td>
<td>5,571</td>
<td>15,319</td>
<td>10,861</td>
<td>(29)%</td>
<td>6%</td>
<td>68,638</td>
<td>16%</td>
</tr>
<tr>
<td>Malaria</td>
<td>-</td>
<td>2</td>
<td>1</td>
<td>(69)%</td>
<td>0%</td>
<td>392</td>
<td>0%</td>
</tr>
</tbody>
</table>
## Monthly DALY Report by Country

### Period: 2
### Year: 2020

<table>
<thead>
<tr>
<th>Category</th>
<th>DALY 2/2020</th>
<th>YTD DALY 2019</th>
<th>YTD DALY 2020</th>
<th>Percentage Change</th>
<th>Percentage of Category</th>
<th>Annual DALY Target</th>
<th>Percentage of Target Achieved</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maternal, Newborn, and Child Health</td>
<td>506</td>
<td>1,107</td>
<td>747</td>
<td>(32)%</td>
<td>0%</td>
<td>3,691</td>
<td>20%</td>
</tr>
<tr>
<td>Safe Abortion</td>
<td>1,971</td>
<td>5,230</td>
<td>4,003</td>
<td>(23)%</td>
<td>2%</td>
<td>25,024</td>
<td>16%</td>
</tr>
<tr>
<td>Caribbean</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-%</td>
</tr>
<tr>
<td>Non-communicable diseases</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-%</td>
</tr>
<tr>
<td>Costa Rica</td>
<td>195</td>
<td>377</td>
<td>369</td>
<td>(2)%</td>
<td>-%</td>
<td>2,573</td>
<td>14%</td>
</tr>
<tr>
<td>Modern Contraception</td>
<td>25</td>
<td>48</td>
<td>47</td>
<td>(2)%</td>
<td>0%</td>
<td>326</td>
<td>14%</td>
</tr>
<tr>
<td>HIV &amp; STIs</td>
<td>170</td>
<td>329</td>
<td>322</td>
<td>(2)%</td>
<td>0%</td>
<td>2,247</td>
<td>14%</td>
</tr>
<tr>
<td>Dominican Republic</td>
<td>1,926</td>
<td>4,200</td>
<td>3,322</td>
<td>(21)%</td>
<td>2%</td>
<td>10,901</td>
<td>30%</td>
</tr>
<tr>
<td>Modern Contraception</td>
<td>420</td>
<td>1,257</td>
<td>708</td>
<td>(44)%</td>
<td>0%</td>
<td>3,105</td>
<td>23%</td>
</tr>
<tr>
<td>HIV &amp; STIs</td>
<td>1,505</td>
<td>2,944</td>
<td>2,614</td>
<td>(11)%</td>
<td>1%</td>
<td>7,796</td>
<td>34%</td>
</tr>
<tr>
<td>El Salvador</td>
<td>9</td>
<td>925</td>
<td>18</td>
<td>(98)%</td>
<td>-%</td>
<td>7,203</td>
<td>-%</td>
</tr>
<tr>
<td>Modern Contraception</td>
<td>2</td>
<td>228</td>
<td>6</td>
<td>(97)%</td>
<td>0%</td>
<td>1,771</td>
<td>0%</td>
</tr>
<tr>
<td>HIV &amp; STIs</td>
<td>7</td>
<td>697</td>
<td>13</td>
<td>(98)%</td>
<td>0%</td>
<td>5,432</td>
<td>0%</td>
</tr>
<tr>
<td>Non-communicable diseases</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>0%</td>
<td>-</td>
<td>0%</td>
</tr>
<tr>
<td>El Salvador SA</td>
<td>813</td>
<td>303</td>
<td>1,671</td>
<td>451%</td>
<td>1%</td>
<td>3,844</td>
<td>43%</td>
</tr>
<tr>
<td>Modern Contraception</td>
<td>302</td>
<td>292</td>
<td>562</td>
<td>93%</td>
<td>0%</td>
<td>3,823</td>
<td>15%</td>
</tr>
<tr>
<td>HIV &amp; STIs</td>
<td>511</td>
<td>8</td>
<td>1,107</td>
<td>12,971%</td>
<td>1%</td>
<td>-</td>
<td>0%</td>
</tr>
<tr>
<td>Non-communicable diseases</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
<td>-</td>
<td>0%</td>
</tr>
<tr>
<td>Safe Abortion</td>
<td>-</td>
<td>3</td>
<td>2</td>
<td>(20)%</td>
<td>0%</td>
<td>21</td>
<td>11%</td>
</tr>
<tr>
<td>Guatemala</td>
<td>8</td>
<td>4,227</td>
<td>16</td>
<td>(100)%</td>
<td>-%</td>
<td>27,058</td>
<td>-%</td>
</tr>
<tr>
<td>Modern Contraception</td>
<td>3</td>
<td>1,839</td>
<td>5</td>
<td>(100)%</td>
<td>0%</td>
<td>11,992</td>
<td>0%</td>
</tr>
<tr>
<td>HIV &amp; STIs</td>
<td>5</td>
<td>2,388</td>
<td>12</td>
<td>(100)%</td>
<td>0%</td>
<td>15,065</td>
<td>0%</td>
</tr>
<tr>
<td>Guatemala SA</td>
<td>2,946</td>
<td>3,529</td>
<td>3,783</td>
<td>7%</td>
<td>2%</td>
<td>6,500</td>
<td>58%</td>
</tr>
<tr>
<td>Modern Contraception</td>
<td>1,359</td>
<td>3,456</td>
<td>1,810</td>
<td>(48)%</td>
<td>1%</td>
<td>6,331</td>
<td>29%</td>
</tr>
<tr>
<td>HIV &amp; STIs</td>
<td>1,586</td>
<td>7</td>
<td>1,940</td>
<td>27,955%</td>
<td>1%</td>
<td>-</td>
<td>0%</td>
</tr>
<tr>
<td>Non-communicable diseases</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
<td>-</td>
<td>0%</td>
</tr>
<tr>
<td>Safe Abortion</td>
<td>-</td>
<td>3</td>
<td>2</td>
<td>(20)%</td>
<td>0%</td>
<td>21</td>
<td>11%</td>
</tr>
<tr>
<td>Honduras</td>
<td>96</td>
<td>4,096</td>
<td>123</td>
<td>(97)%</td>
<td>-%</td>
<td>19,921</td>
<td>1%</td>
</tr>
<tr>
<td>Modern Contraception</td>
<td>86</td>
<td>634</td>
<td>109</td>
<td>(83)%</td>
<td>0%</td>
<td>2,733</td>
<td>4%</td>
</tr>
<tr>
<td>HIV &amp; STIs</td>
<td>10</td>
<td>3,463</td>
<td>14</td>
<td>(100)%</td>
<td>0%</td>
<td>17,188</td>
<td>0%</td>
</tr>
<tr>
<td>Honduras SA</td>
<td>1,541</td>
<td>-</td>
<td>3,423</td>
<td>-%</td>
<td>2%</td>
<td>-</td>
<td>-%</td>
</tr>
<tr>
<td>Modern Contraception</td>
<td>207</td>
<td>-</td>
<td>459</td>
<td>0%</td>
<td>0%</td>
<td>-</td>
<td>0%</td>
</tr>
<tr>
<td>HIV &amp; STIs</td>
<td>1,334</td>
<td>-</td>
<td>2,963</td>
<td>0%</td>
<td>2%</td>
<td>-</td>
<td>0%</td>
</tr>
<tr>
<td>Kazakhstan</td>
<td>71</td>
<td>109</td>
<td>136</td>
<td>25%</td>
<td>-%</td>
<td>186</td>
<td>73%</td>
</tr>
<tr>
<td>Modern Contraception</td>
<td>1</td>
<td>-</td>
<td>1</td>
<td>0%</td>
<td>0%</td>
<td>-</td>
<td>0%</td>
</tr>
<tr>
<td>HIV &amp; STIs</td>
<td>70</td>
<td>109</td>
<td>135</td>
<td>24%</td>
<td>0%</td>
<td>186</td>
<td>73%</td>
</tr>
<tr>
<td>Tuberculosis</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
<td>-</td>
<td>0%</td>
</tr>
<tr>
<td>Kyrgyzstan</td>
<td>67</td>
<td>91</td>
<td>130</td>
<td>43%</td>
<td>-%</td>
<td>324</td>
<td>40%</td>
</tr>
<tr>
<td>Modern Contraception</td>
<td>2</td>
<td>-</td>
<td>4</td>
<td>0%</td>
<td>0%</td>
<td>-</td>
<td>0%</td>
</tr>
<tr>
<td>HIV &amp; STIs</td>
<td>64</td>
<td>91</td>
<td>126</td>
<td>39%</td>
<td>0%</td>
<td>324</td>
<td>39%</td>
</tr>
<tr>
<td>Tuberculosis</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
<td>-</td>
<td>0%</td>
</tr>
<tr>
<td>Laos</td>
<td>1,036</td>
<td>5,012</td>
<td>2,483</td>
<td>(50)%</td>
<td>1%</td>
<td>28,594</td>
<td>9%</td>
</tr>
<tr>
<td>Modern Contraception</td>
<td>1,016</td>
<td>3,895</td>
<td>1,901</td>
<td>(51)%</td>
<td>1%</td>
<td>23,686</td>
<td>8%</td>
</tr>
<tr>
<td>HIV &amp; STIs</td>
<td>-</td>
<td>793</td>
<td>352</td>
<td>(56)%</td>
<td>0%</td>
<td>3,767</td>
<td>9%</td>
</tr>
<tr>
<td>Malaria</td>
<td>-</td>
<td>48</td>
<td>12</td>
<td>(75)%</td>
<td>0%</td>
<td>186</td>
<td>73%</td>
</tr>
<tr>
<td>Safe Abortion</td>
<td>-</td>
<td>263</td>
<td>199</td>
<td>(25)%</td>
<td>0%</td>
<td>994</td>
<td>20%</td>
</tr>
<tr>
<td>Tuberculosis</td>
<td>20</td>
<td>13</td>
<td>20</td>
<td>48%</td>
<td>0%</td>
<td>80</td>
<td>24%</td>
</tr>
<tr>
<td>Country</td>
<td>DALY 2/2020</td>
<td>YTD DALY 2019</td>
<td>YTD DALY 2020</td>
<td>Percentage Change</td>
<td>YTD DALY 2020 Percentage of Category</td>
<td>Annual DALY Target</td>
<td>Percentage of Target Achieved</td>
</tr>
<tr>
<td>------------------</td>
<td>-------------</td>
<td>---------------</td>
<td>---------------</td>
<td>-------------------</td>
<td>---------------------------------------</td>
<td>-------------------</td>
<td>-------------------------------</td>
</tr>
<tr>
<td>Nepal</td>
<td>1,243</td>
<td>1,687</td>
<td>2,479</td>
<td>47 %</td>
<td>1%</td>
<td>24,098</td>
<td>10%</td>
</tr>
<tr>
<td>Modern Contraception</td>
<td>117</td>
<td>172</td>
<td>1,354</td>
<td>687%</td>
<td>1%</td>
<td>13,421</td>
<td>10%</td>
</tr>
<tr>
<td>Safe Abortion</td>
<td>1,125</td>
<td>1,514</td>
<td>1,125</td>
<td>(26)%</td>
<td>1%</td>
<td>10,678</td>
<td>11%</td>
</tr>
<tr>
<td>Nicaragua</td>
<td>1,384</td>
<td>2,531</td>
<td>2,397</td>
<td>(5)%</td>
<td>1%</td>
<td>18,043</td>
<td>13%</td>
</tr>
<tr>
<td>Modern Contraception</td>
<td>697</td>
<td>1,360</td>
<td>1,140</td>
<td>(16)%</td>
<td>1%</td>
<td>11,144</td>
<td>10%</td>
</tr>
<tr>
<td>HIV &amp; STIs</td>
<td>676</td>
<td>1,155</td>
<td>1,218</td>
<td>6%</td>
<td>1%</td>
<td>6,766</td>
<td>18%</td>
</tr>
<tr>
<td>Safe Abortion</td>
<td>11</td>
<td>16</td>
<td>39</td>
<td>147%</td>
<td>0%</td>
<td>133</td>
<td>29%</td>
</tr>
<tr>
<td>Pakistan</td>
<td>46,372</td>
<td>100,137</td>
<td>62,941</td>
<td>(37)%</td>
<td>36%</td>
<td>472,656</td>
<td>13%</td>
</tr>
<tr>
<td>Modern Contraception</td>
<td>33,956</td>
<td>75,131</td>
<td>40,418</td>
<td>(46)%</td>
<td>23%</td>
<td>429,532</td>
<td>9%</td>
</tr>
<tr>
<td>HIV &amp; STIs</td>
<td>2,649</td>
<td>3,229</td>
<td>3,676</td>
<td>14%</td>
<td>2%</td>
<td>42,281</td>
<td>9%</td>
</tr>
<tr>
<td>Nutrition</td>
<td>1</td>
<td>-</td>
<td>1</td>
<td>0%</td>
<td>0%</td>
<td>-</td>
<td>0%</td>
</tr>
<tr>
<td>Safe Abortion</td>
<td>1,468</td>
<td>3,256</td>
<td>2,732</td>
<td>(16)%</td>
<td>2%</td>
<td>844</td>
<td>324%</td>
</tr>
<tr>
<td>Tuberculosis</td>
<td>8,297</td>
<td>18,521</td>
<td>16,114</td>
<td>(13)%</td>
<td>9%</td>
<td>-</td>
<td>0%</td>
</tr>
<tr>
<td>Panama</td>
<td>570</td>
<td>1,184</td>
<td>1,118</td>
<td>(6)%</td>
<td>1%</td>
<td>5,210</td>
<td>21%</td>
</tr>
<tr>
<td>Modern Contraception</td>
<td>133</td>
<td>277</td>
<td>261</td>
<td>(6)%</td>
<td>0%</td>
<td>1,197</td>
<td>22%</td>
</tr>
<tr>
<td>HIV &amp; STIs</td>
<td>436</td>
<td>906</td>
<td>857</td>
<td>(5)%</td>
<td>0%</td>
<td>4,014</td>
<td>21%</td>
</tr>
<tr>
<td>Papua New Guinea</td>
<td>41</td>
<td>2</td>
<td>298</td>
<td>12,405%</td>
<td>%</td>
<td>3,669</td>
<td>8%</td>
</tr>
<tr>
<td>Modern Contraception</td>
<td>22</td>
<td>-</td>
<td>155</td>
<td>0%</td>
<td>0%</td>
<td>1,917</td>
<td>8%</td>
</tr>
<tr>
<td>HIV &amp; STIs</td>
<td>20</td>
<td>-</td>
<td>142</td>
<td>0%</td>
<td>0%</td>
<td>1,751</td>
<td>8%</td>
</tr>
<tr>
<td>Maternal, Newborn, and Child Health</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>(100)%</td>
<td>0%</td>
<td>-</td>
<td>0%</td>
</tr>
<tr>
<td>WASH</td>
<td>-</td>
<td>2</td>
<td>-</td>
<td>(88)%</td>
<td>0%</td>
<td>1</td>
<td>40%</td>
</tr>
<tr>
<td>PSI Pakistan</td>
<td>18,958</td>
<td>40,632</td>
<td>52,179</td>
<td>28 %</td>
<td>30%</td>
<td>344,157</td>
<td>15%</td>
</tr>
<tr>
<td>Modern Contraception</td>
<td>18,705</td>
<td>38,500</td>
<td>50,574</td>
<td>31%</td>
<td>29%</td>
<td>330,568</td>
<td>15%</td>
</tr>
<tr>
<td>HIV &amp; STIs</td>
<td>253</td>
<td>2,132</td>
<td>1,605</td>
<td>(25)%</td>
<td>1%</td>
<td>13,590</td>
<td>12%</td>
</tr>
<tr>
<td>Tajikistan</td>
<td>83</td>
<td>243</td>
<td>4,033</td>
<td>1,560 %</td>
<td>2%</td>
<td>8,969</td>
<td>45%</td>
</tr>
<tr>
<td>Modern Contraception</td>
<td>1</td>
<td>9</td>
<td>49</td>
<td>458%</td>
<td>0%</td>
<td>167</td>
<td>29%</td>
</tr>
<tr>
<td>HIV &amp; STIs</td>
<td>82</td>
<td>234</td>
<td>3,984</td>
<td>1,601%</td>
<td>2%</td>
<td>8,802</td>
<td>45%</td>
</tr>
<tr>
<td>Tuberculosis</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>0%</td>
<td>-</td>
<td>0%</td>
</tr>
<tr>
<td>Viet Nam</td>
<td>29</td>
<td>1,621</td>
<td>71</td>
<td>(96)%</td>
<td>%</td>
<td>132</td>
<td>54%</td>
</tr>
<tr>
<td>Modern Contraception</td>
<td>23</td>
<td>22</td>
<td>58</td>
<td>161%</td>
<td>0%</td>
<td>9</td>
<td>613%</td>
</tr>
<tr>
<td>HIV &amp; STIs</td>
<td>-</td>
<td>1,584</td>
<td>-</td>
<td>(100)%</td>
<td>0%</td>
<td>-</td>
<td>0%</td>
</tr>
<tr>
<td>Malaria</td>
<td>7</td>
<td>-</td>
<td>13</td>
<td>4,531%</td>
<td>0%</td>
<td>123</td>
<td>11%</td>
</tr>
<tr>
<td>Non-communicable diseases</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>0%</td>
<td>-</td>
<td>0%</td>
</tr>
<tr>
<td>WASH</td>
<td>-</td>
<td>14</td>
<td>-</td>
<td>(100)%</td>
<td>0%</td>
<td>-</td>
<td>0%</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>145,002</td>
<td>553,078</td>
<td>851,737</td>
<td>54%</td>
<td>100%</td>
<td>11,202,350</td>
<td>8%</td>
</tr>
<tr>
<td>Haiti</td>
<td>15,100</td>
<td>18,275</td>
<td>22,039</td>
<td>21 %</td>
<td>3%</td>
<td>138,665</td>
<td>16%</td>
</tr>
<tr>
<td>Modern Contraception</td>
<td>74</td>
<td>2,294</td>
<td>613</td>
<td>(73)%</td>
<td>0%</td>
<td>-</td>
<td>0%</td>
</tr>
<tr>
<td>HIV &amp; STIs</td>
<td>6,236</td>
<td>2,615</td>
<td>12,636</td>
<td>383%</td>
<td>1%</td>
<td>27,495</td>
<td>46%</td>
</tr>
<tr>
<td>Malaria</td>
<td>-</td>
<td>3</td>
<td>-</td>
<td>(100)%</td>
<td>0%</td>
<td>50,121</td>
<td>0%</td>
</tr>
<tr>
<td>Maternal, Newborn, and Child Health</td>
<td>-</td>
<td>11</td>
<td>-</td>
<td>(100)%</td>
<td>0%</td>
<td>-</td>
<td>0%</td>
</tr>
<tr>
<td>Non-communicable diseases</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>0%</td>
<td>-</td>
<td>0%</td>
</tr>
<tr>
<td>Tuberculosis</td>
<td>8,790</td>
<td>13,352</td>
<td>8,790</td>
<td>(34)%</td>
<td>1%</td>
<td>61,049</td>
<td>14%</td>
</tr>
<tr>
<td>Liberia</td>
<td>-</td>
<td>1,081</td>
<td>-</td>
<td>(100)%</td>
<td>%</td>
<td>23,881</td>
<td>%</td>
</tr>
<tr>
<td>Modern Contraception</td>
<td>-</td>
<td>491</td>
<td>-</td>
<td>(100)%</td>
<td>0%</td>
<td>11,061</td>
<td>0%</td>
</tr>
<tr>
<td>HIV &amp; STIs</td>
<td>-</td>
<td>563</td>
<td>-</td>
<td>(100)%</td>
<td>0%</td>
<td>12,806</td>
<td>0%</td>
</tr>
<tr>
<td>WASH</td>
<td>-</td>
<td>27</td>
<td>-</td>
<td>(100)%</td>
<td>0%</td>
<td>14</td>
<td>0%</td>
</tr>
</tbody>
</table>
## Monthly DALY Report by Country

**Period:** 2  
**Year:** 2020

<table>
<thead>
<tr>
<th>Country</th>
<th>DALY 2/2020</th>
<th>YTD DALY 2019</th>
<th>YTD DALY 2020</th>
<th>Percentage Change</th>
<th>Percentage of Category</th>
<th>Annual DALY Target</th>
<th>Percentage of Target Achieved</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Madagascar</strong></td>
<td>57,589</td>
<td>148,692</td>
<td>126,193</td>
<td>(15)%</td>
<td>15%</td>
<td>1,727,997</td>
<td>7%</td>
</tr>
<tr>
<td>Modern Contraception</td>
<td>49,040</td>
<td>39,602</td>
<td>79,252</td>
<td>100%</td>
<td>9%</td>
<td>335,949</td>
<td>24%</td>
</tr>
<tr>
<td>HIV &amp; STIs</td>
<td>3,519</td>
<td>1,937</td>
<td>9,973</td>
<td>415%</td>
<td>1%</td>
<td>117,618</td>
<td>8%</td>
</tr>
<tr>
<td>Malaria</td>
<td>119</td>
<td>106,050</td>
<td>28,811</td>
<td>(73)%</td>
<td>3%</td>
<td>1,174,591</td>
<td>2%</td>
</tr>
<tr>
<td>Maternal, Newborn, and Child Health</td>
<td>4,248</td>
<td>38</td>
<td>7,396</td>
<td>19,530%</td>
<td>1%</td>
<td>84,736</td>
<td>9%</td>
</tr>
<tr>
<td>Non-communicable diseases</td>
<td>-</td>
<td>2</td>
<td>-</td>
<td>(100)%</td>
<td>0%</td>
<td>-</td>
<td>0%</td>
</tr>
<tr>
<td>Safe Abortion</td>
<td>657</td>
<td>676</td>
<td>750</td>
<td>11%</td>
<td>0%</td>
<td>10,995</td>
<td>7%</td>
</tr>
<tr>
<td>WASH</td>
<td>7</td>
<td>388</td>
<td>11</td>
<td>(97)%</td>
<td>0%</td>
<td>4,107</td>
<td>0%</td>
</tr>
<tr>
<td><strong>Mali</strong></td>
<td>49,237</td>
<td>319,515</td>
<td>678,823</td>
<td>112%</td>
<td>80%</td>
<td>5,745,163</td>
<td>12%</td>
</tr>
<tr>
<td>Modern Contraception</td>
<td>48,668</td>
<td>43,923</td>
<td>97,695</td>
<td>122%</td>
<td>11%</td>
<td>107,910</td>
<td>91%</td>
</tr>
<tr>
<td>HIV &amp; STIs</td>
<td>34</td>
<td>149</td>
<td>0</td>
<td>0%</td>
<td>0%</td>
<td>-</td>
<td>0%</td>
</tr>
<tr>
<td>Malaria</td>
<td>-</td>
<td>275,244</td>
<td>580,122</td>
<td>111%</td>
<td>68%</td>
<td>5,631,606</td>
<td>10%</td>
</tr>
<tr>
<td>Non-communicable diseases</td>
<td>10</td>
<td>10</td>
<td>0</td>
<td>0%</td>
<td>0%</td>
<td>123</td>
<td>8%</td>
</tr>
<tr>
<td>Safe Abortion</td>
<td>517</td>
<td>347</td>
<td>835</td>
<td>141%</td>
<td>0%</td>
<td>5,313</td>
<td>16%</td>
</tr>
<tr>
<td>WASH</td>
<td>9</td>
<td>1</td>
<td>11</td>
<td>718%</td>
<td>0%</td>
<td>211</td>
<td>5%</td>
</tr>
<tr>
<td><strong>Somaliland</strong></td>
<td>23,075</td>
<td>19,140</td>
<td>23,075</td>
<td>21%</td>
<td>3%</td>
<td>152,239</td>
<td>15%</td>
</tr>
<tr>
<td>Modern Contraception</td>
<td>396</td>
<td>437</td>
<td>396</td>
<td>(9)%</td>
<td>0%</td>
<td>5,263</td>
<td>8%</td>
</tr>
<tr>
<td>HIV &amp; STIs</td>
<td>25</td>
<td>25</td>
<td>25</td>
<td>(1)%</td>
<td>0%</td>
<td>162</td>
<td>15%</td>
</tr>
<tr>
<td>Malaria</td>
<td>202</td>
<td>150</td>
<td>202</td>
<td>34%</td>
<td>0%</td>
<td>1,085</td>
<td>19%</td>
</tr>
<tr>
<td>Maternal, Newborn, and Child Health</td>
<td>6,118</td>
<td>9,745</td>
<td>6,118</td>
<td>(37)%</td>
<td>1%</td>
<td>49,610</td>
<td>12%</td>
</tr>
<tr>
<td>Nutrition</td>
<td>16,335</td>
<td>8,585</td>
<td>16,335</td>
<td>90%</td>
<td>2%</td>
<td>95,835</td>
<td>17%</td>
</tr>
<tr>
<td>WASH</td>
<td>-</td>
<td>198</td>
<td>-</td>
<td>(100)%</td>
<td>0%</td>
<td>284</td>
<td>0%</td>
</tr>
<tr>
<td><strong>South Sudan</strong></td>
<td>-</td>
<td>46,375</td>
<td>1,608</td>
<td>(97)%</td>
<td>-%</td>
<td>3,414,404</td>
<td>-%</td>
</tr>
<tr>
<td>Malaria</td>
<td>-</td>
<td>46,375</td>
<td>1,608</td>
<td>(97)%</td>
<td>0%</td>
<td>3,414,404</td>
<td>0%</td>
</tr>
<tr>
<td><strong>Social Enterprise</strong></td>
<td>123,110</td>
<td>175,728</td>
<td>201,233</td>
<td>15%</td>
<td>100%</td>
<td>1,182,902</td>
<td>17%</td>
</tr>
<tr>
<td><strong>India LLC</strong></td>
<td>14,190</td>
<td>44,189</td>
<td>21,544</td>
<td>(51)%</td>
<td>11%</td>
<td>496,725</td>
<td>4%</td>
</tr>
<tr>
<td>Modern Contraception</td>
<td>2,303</td>
<td>17,163</td>
<td>5,202</td>
<td>(70)%</td>
<td>3%</td>
<td>178,127</td>
<td>3%</td>
</tr>
<tr>
<td>HIV &amp; STIs</td>
<td>(62)</td>
<td>11,312</td>
<td>2,086</td>
<td>(82)%</td>
<td>1%</td>
<td>110,671</td>
<td>2%</td>
</tr>
<tr>
<td>Maternal, Newborn, and Child Health</td>
<td>6,373</td>
<td>7,511</td>
<td>7,324</td>
<td>(2)%</td>
<td>4%</td>
<td>77,506</td>
<td>9%</td>
</tr>
<tr>
<td>Safe Abortion</td>
<td>5,575</td>
<td>8,203</td>
<td>6,931</td>
<td>(16)%</td>
<td>3%</td>
<td>130,422</td>
<td>5%</td>
</tr>
<tr>
<td>Other</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>0%</td>
<td>-</td>
<td>0%</td>
</tr>
<tr>
<td><strong>Paraguay</strong></td>
<td>2,201</td>
<td>3,678</td>
<td>4,843</td>
<td>32%</td>
<td>2%</td>
<td>24,633</td>
<td>20%</td>
</tr>
<tr>
<td>Modern Contraception</td>
<td>651</td>
<td>1,179</td>
<td>1,255</td>
<td>7%</td>
<td>1%</td>
<td>7,042</td>
<td>18%</td>
</tr>
<tr>
<td>HIV &amp; STIs</td>
<td>1,521</td>
<td>2,463</td>
<td>3,534</td>
<td>44%</td>
<td>2%</td>
<td>17,230</td>
<td>21%</td>
</tr>
<tr>
<td>Nutrition</td>
<td>28</td>
<td>37</td>
<td>53</td>
<td>43%</td>
<td>0%</td>
<td>361</td>
<td>15%</td>
</tr>
<tr>
<td><strong>PSI South Africa</strong></td>
<td>106,720</td>
<td>127,861</td>
<td>174,846</td>
<td>37%</td>
<td>87%</td>
<td>661,544</td>
<td>26%</td>
</tr>
<tr>
<td>Modern Contraception</td>
<td>6,824</td>
<td>7,801</td>
<td>11,098</td>
<td>42%</td>
<td>6%</td>
<td>43,235</td>
<td>26%</td>
</tr>
<tr>
<td>HIV &amp; STIs</td>
<td>99,896</td>
<td>120,060</td>
<td>163,748</td>
<td>36%</td>
<td>81%</td>
<td>618,309</td>
<td>26%</td>
</tr>
<tr>
<td>Product</td>
<td>YTD Users Reached 2020</td>
<td>YTD CYP 2020</td>
<td>YTD DALY 2020</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------------------------------------------</td>
<td>------------------------</td>
<td>--------------</td>
<td>---------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acute Malnutrition Screening_CUS</td>
<td>410</td>
<td>621,360</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antiretroviral Treatment</td>
<td>18,119</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antiretroviral Treatment (Currently Enrolled)</td>
<td>151,421</td>
<td>25,993</td>
<td>11,610</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>19,554</td>
<td>65,810</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>6,259</td>
<td>2,650</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>100%</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>459,287</td>
<td>174,024</td>
<td>434,310</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>3,744</td>
<td>27,179</td>
<td>153%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antiretroviral Treatment (Newly Enrolled)</td>
<td>13,833</td>
<td>1,702,464</td>
<td>25,993</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>15,054</td>
<td>19,554</td>
<td>65,810</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>2,216</td>
<td>15,479</td>
<td>6,259</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>599</td>
<td>456,100</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>6,742</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>1,276</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antiretroviral Treatment (Tablet)</td>
<td>97,980</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>1,064,698</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ARV Prophylaxis 28 wks (Mother and Baby)</td>
<td>382</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>382</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ARV Prophylaxis 28 wks (Mother Only)</td>
<td>359</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>359</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Basic Care Package</td>
<td>418,325</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>418,325</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>174,969,459</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>41,325</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(a)
## Monthly Distribution by Product

### Period: 2
### Year: 2020

|---------------------|---------------------------|-----------------------|---------------------------|-----------------------|----------------|-------------------------|-------------------------|--------------------------|----------------|----------------|

### CD4 Tests Provided to HIV+ Clients

<table>
<thead>
<tr>
<th>Group</th>
<th>2020</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acceleration Market Group</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Cervical Cancer-HPV DNA and Conization

<table>
<thead>
<tr>
<th>Group</th>
<th>2020</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acceleration Market Group</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Cervical Cancer-HPV DNA and Cryotherapy

<table>
<thead>
<tr>
<th>Group</th>
<th>2020</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acceleration Market Group</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Cervical Cancer-HPV DNA and Refer to any Treatment

<table>
<thead>
<tr>
<th>Group</th>
<th>2020</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acceleration Market Group</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Cervical Cancer-HPV DNA and Refer to Conization

<table>
<thead>
<tr>
<th>Group</th>
<th>2020</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acceleration Market Group</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Cervical Cancer-Pap and Conization

<table>
<thead>
<tr>
<th>Group</th>
<th>2020</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acceleration Market Group</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Cervical Cancer-Pap and Cryotherapy

<table>
<thead>
<tr>
<th>Group</th>
<th>2020</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acceleration Market Group</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Cervical Cancer-Pap and Refer to any Treatment

<table>
<thead>
<tr>
<th>Group</th>
<th>2020</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acceleration Market Group</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Cervical Cancer-Pap and Refer to Conization

<table>
<thead>
<tr>
<th>Group</th>
<th>2020</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acceleration Market Group</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Cervical Cancer-Pap and Refer to Cryotherapy

<table>
<thead>
<tr>
<th>Group</th>
<th>2020</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acceleration Market Group</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Cervical Cancer-Pap Screening

<table>
<thead>
<tr>
<th>Group</th>
<th>2020</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anglophone Africa Market Group</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Cervical Cancer-Pap and Conization

<table>
<thead>
<tr>
<th>Group</th>
<th>2020</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anglophone Africa Market Group</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Cervical Cancer-Pap and Cryotherapy

<table>
<thead>
<tr>
<th>Group</th>
<th>2020</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anglophone Africa Market Group</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Cervical Cancer-Pap and Refer to any Treatment

<table>
<thead>
<tr>
<th>Group</th>
<th>2020</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anglophone Africa Market Group</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Cervical Cancer-Pap and Refer to Conization

<table>
<thead>
<tr>
<th>Group</th>
<th>2020</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anglophone Africa Market Group</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Cervical Cancer-Pap and Refer to Cryotherapy

<table>
<thead>
<tr>
<th>Group</th>
<th>2020</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anglophone Africa Market Group</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

*aThe grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.*
### POPULATION SERVICES INTERNATIONAL
### Monthly Distribution by Product
### Period: 2
### Year: 2020

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Cervical Cancer-Pap and Refer to Conization</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Cervical Cancer-Pap Smear Screening</td>
<td>22</td>
<td>41</td>
<td>86</td>
<td>525</td>
<td>106</td>
<td>(20)%</td>
<td>436</td>
<td>7,880</td>
<td>85</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>-</td>
<td>10</td>
<td>31</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>6,528</td>
<td>31</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>291</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>22</td>
<td>31</td>
<td>54</td>
<td>525</td>
<td>106</td>
<td>(49)%</td>
<td>436</td>
<td>972</td>
<td>54</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Inactive</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>89</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Cervical Cancer-VIA and Conization</td>
<td>17</td>
<td>18</td>
<td>41</td>
<td>150</td>
<td>30</td>
<td>37%</td>
<td>245</td>
<td>590</td>
<td>41</td>
<td>-</td>
<td>15</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>17</td>
<td>18</td>
<td>41</td>
<td>150</td>
<td>30</td>
<td>37%</td>
<td>245</td>
<td>590</td>
<td>41</td>
<td>-</td>
<td>15</td>
</tr>
<tr>
<td>Cervical Cancer-VIA and Cryotherapy</td>
<td>61</td>
<td>40</td>
<td>100</td>
<td>872</td>
<td>130</td>
<td>(23)%</td>
<td>2,077</td>
<td>23,616</td>
<td>100</td>
<td>-</td>
<td>30</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>8</td>
<td>15</td>
<td>28</td>
<td>360</td>
<td>49</td>
<td>(43)%</td>
<td>307</td>
<td>11,581</td>
<td>28</td>
<td>-</td>
<td>7</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>19</td>
<td>15</td>
<td>36</td>
<td>352</td>
<td>74</td>
<td>(49)%</td>
<td>1,598</td>
<td>10,085</td>
<td>38</td>
<td>-</td>
<td>13</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>-</td>
<td>2</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>(100)%</td>
<td>16</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>8</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>34</td>
<td>9</td>
<td>34</td>
<td>160</td>
<td>8</td>
<td>467%</td>
<td>156</td>
<td>1,532</td>
<td>34</td>
<td>-</td>
<td>10</td>
</tr>
<tr>
<td>Inactive</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>20</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Cervical Cancer-VIA and Refer to any Treatment</td>
<td>3</td>
<td>3</td>
<td>5</td>
<td>9</td>
<td>(44)%</td>
<td>85</td>
<td>526</td>
<td>5</td>
<td>-</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>127</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>3</td>
<td>3</td>
<td>5</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>9</td>
<td>(100)%</td>
<td>85</td>
<td>-</td>
<td>1</td>
</tr>
<tr>
<td>Cervical Cancer-VIA and Refer to Conization</td>
<td>2</td>
<td>1</td>
<td>3</td>
<td>8</td>
<td>(50)%</td>
<td>23</td>
<td>2,086</td>
<td>3</td>
<td>-</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>4</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>2</td>
<td>1</td>
<td>3</td>
<td>-</td>
<td>6</td>
<td>(50)%</td>
<td>23</td>
<td>2,082</td>
<td>3</td>
<td>-</td>
<td>1</td>
</tr>
<tr>
<td>Cervical Cancer-VIA and Refer to Cryotherapy</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>2,084</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>913</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>625</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>10</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>536</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

---

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.
### Monthly Distribution by Product

**Period:** 2  
**Year:** 2020

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Cervical Cancer-VIA and Thermal Ablation</td>
<td>250</td>
<td></td>
<td></td>
<td></td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>-</td>
<td></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cervical Cancer-VIA/VILI Screening</td>
<td>9,165</td>
<td>8,673</td>
<td>12,492</td>
<td>32,860</td>
<td>(19)%</td>
<td>15,468</td>
<td>137,560</td>
<td>1,190,756</td>
<td>12,492</td>
<td>-</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>366</td>
<td>280</td>
<td>600</td>
<td>3,000</td>
<td>(90)%</td>
<td>6,039</td>
<td>37,955</td>
<td>502,987</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>2,071</td>
<td>2,516</td>
<td>3,308</td>
<td>23,800</td>
<td>(51)%</td>
<td>6,798</td>
<td>45,450</td>
<td>389,844</td>
<td>3,308</td>
<td>-</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>1,773</td>
<td>2,870</td>
<td>2,741</td>
<td>-</td>
<td>8%</td>
<td>2,528</td>
<td>192,246</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>4,955</td>
<td>3,006</td>
<td>5,843</td>
<td>6,000</td>
<td>5,573%</td>
<td>103</td>
<td>25,479</td>
<td>105,022</td>
<td>5,843</td>
<td>-</td>
</tr>
<tr>
<td>Inactive</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Chlorhexidine</td>
<td>1,055</td>
<td>1,358</td>
<td>2,156</td>
<td>41,604</td>
<td>179%</td>
<td>773</td>
<td>38,321</td>
<td>658,391</td>
<td>1,940</td>
<td>138</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>148,406</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>615</td>
<td>379</td>
<td>1,115</td>
<td>11,000</td>
<td>44%</td>
<td>773</td>
<td>6,590</td>
<td>44,370</td>
<td>1,004</td>
<td>77</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>440</td>
<td>979</td>
<td>1,040</td>
<td>30,604</td>
<td>-</td>
<td>31,731</td>
<td>465,615</td>
<td>936</td>
<td>-</td>
<td>61</td>
</tr>
<tr>
<td>Clean Delivery Kit</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1,708,471</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>346,994</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>470,003</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>710,114</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>180,586</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Inactive</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>774</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Condom</td>
<td>30,949,923</td>
<td>32,164,088</td>
<td>52,947,217</td>
<td>498,276,353</td>
<td>15%</td>
<td>62,509,869</td>
<td>417,754,403</td>
<td>21,917,711,688</td>
<td>397,104</td>
<td>578,247</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>5,791,331</td>
<td>3,069,555</td>
<td>7,665,355</td>
<td>39,310,200</td>
<td>21%</td>
<td>6,351,757</td>
<td>45,303,579</td>
<td>9,806,767,285</td>
<td>57,490</td>
<td>185,089</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>3,430,784</td>
<td>2,594,078</td>
<td>5,264,155</td>
<td>88,770,000</td>
<td>(40)%</td>
<td>8,805,352</td>
<td>46,499,698</td>
<td>3,198,672,536</td>
<td>39,481</td>
<td>99,078</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>2,886,139</td>
<td>4,134,915</td>
<td>5,461,699</td>
<td>51,814,542</td>
<td>(35)%</td>
<td>8,418,546</td>
<td>41,173,232</td>
<td>1,675,903,593</td>
<td>40,963</td>
<td>55,625</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>13,460,562</td>
<td>13,769,674</td>
<td>24,469,250</td>
<td>222,769,749</td>
<td>(7)%</td>
<td>26,441,144</td>
<td>184,767,633</td>
<td>4,063,344,284</td>
<td>183,519</td>
<td>55,373</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>163,632</td>
<td>91,856</td>
<td>204,768</td>
<td>2,495,736</td>
<td>(22)%</td>
<td>263,016</td>
<td>1,828,764</td>
<td>954,530,765</td>
<td>1,536</td>
<td>1,536</td>
</tr>
<tr>
<td>Social Enterprise</td>
<td>5,217,475</td>
<td>8,504,010</td>
<td>9,881,990</td>
<td>91,116,126</td>
<td>(19)%</td>
<td>12,232,054</td>
<td>98,181,497</td>
<td>820,582,362</td>
<td>74,115</td>
<td>181,224</td>
</tr>
<tr>
<td>USA</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>289,819</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

*The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.*
## Distribution by Product

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Inactive</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1,397,621,044</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Condom Provided</td>
<td>1,962</td>
<td>1,962</td>
<td>1,962</td>
<td>1,962</td>
<td>46%</td>
<td>19,252</td>
<td>197,597</td>
<td>2,858</td>
<td>9,524</td>
<td></td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>50,644</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>673,774</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>651,148</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>27,681</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1,095,308</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Counseling &amp; Tx for Moderate Acute Malnutrition</td>
<td>2,858</td>
<td>1,297</td>
<td>2,858</td>
<td>16,059</td>
<td>46%</td>
<td>19,252</td>
<td>197,597</td>
<td>2,858</td>
<td>9,524</td>
<td></td>
</tr>
<tr>
<td>Deworming Tablets</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1,095,308</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Diarrhea Treatment Kit</td>
<td>32,167</td>
<td>95,193</td>
<td>291,238</td>
<td>583,459</td>
<td>233%</td>
<td>432,701</td>
<td>20,461,412</td>
<td>282,114</td>
<td>14,797</td>
<td></td>
</tr>
<tr>
<td>Diarrhea Treatment Kit Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1,095,308</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Early Infant Male Circumcision</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>6,500</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

### Notes

- Users reached can be summed within product categories or as key interventions across health areas to represent scale.
- The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Anglophone Africa Market Group</td>
<td>16,597</td>
<td>21,783</td>
<td>37,631</td>
<td>46,500</td>
<td>8,305</td>
<td>353%</td>
<td>123,300</td>
<td>1,808,688</td>
<td>1,693</td>
<td>1,693</td>
<td>541</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>3,221</td>
<td>6,245</td>
<td>6,425</td>
<td>89,000</td>
<td>14,615</td>
<td>(56)%</td>
<td>51,168</td>
<td>733,899</td>
<td>289</td>
<td>289</td>
<td>167</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>263,297</td>
<td>205,850</td>
<td>477,551</td>
<td>4,598,531</td>
<td>436,526</td>
<td>9%</td>
<td>2,547,734</td>
<td>24,087,071</td>
<td>21,490</td>
<td>21,490</td>
<td>3,733</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>(9)</td>
<td>(5)</td>
<td>(13)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1,650,337</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Social Enterprise</td>
<td>95,355</td>
<td>43,792</td>
<td>164,653</td>
<td>484,873</td>
<td>63,798</td>
<td>158%</td>
<td>418,892</td>
<td>3,649,648</td>
<td>7,409</td>
<td>7,409</td>
<td>919</td>
</tr>
<tr>
<td>Emergency Contraception Provided</td>
<td>20,799</td>
<td>18,634</td>
<td>34,325</td>
<td>55,782</td>
<td>8,638</td>
<td>297%</td>
<td>201,747</td>
<td>301,021</td>
<td>1,716</td>
<td>1,716</td>
<td>313</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>15,533</td>
<td>12,764</td>
<td>23,908</td>
<td>48,170</td>
<td>1,823</td>
<td>1,211%</td>
<td>75,323</td>
<td>104,832</td>
<td>1,195</td>
<td>1,195</td>
<td>183</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>844</td>
<td>1,534</td>
<td>1,695</td>
<td>239</td>
<td>656</td>
<td>158%</td>
<td>91,980</td>
<td>101,781</td>
<td>85</td>
<td>85</td>
<td>44</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>207</td>
<td>296</td>
<td>504</td>
<td>3,000</td>
<td>739</td>
<td>(32)%</td>
<td>4,060</td>
<td>9,051</td>
<td>25</td>
<td>25</td>
<td>16</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>4,203</td>
<td>4,036</td>
<td>8,202</td>
<td>4,373</td>
<td>5,387</td>
<td>52%</td>
<td>30,261</td>
<td>83,236</td>
<td>410</td>
<td>410</td>
<td>70</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>12</td>
<td>5</td>
<td>16</td>
<td>-</td>
<td>33</td>
<td>(52)%</td>
<td>123</td>
<td>2,120</td>
<td>1</td>
<td>1</td>
<td>-</td>
</tr>
<tr>
<td>Inactive</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Expanded Clean Delivery Kit</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>25,000</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>25,000</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Expanded Clean Delivery Kit (+CHX)</td>
<td>457</td>
<td>276</td>
<td>601</td>
<td>18,000</td>
<td>464</td>
<td>30%</td>
<td>11,709</td>
<td>27,458</td>
<td>541</td>
<td>-</td>
<td>86</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>457</td>
<td>276</td>
<td>601</td>
<td>18,000</td>
<td>464</td>
<td>30%</td>
<td>11,709</td>
<td>27,458</td>
<td>541</td>
<td>-</td>
<td>86</td>
</tr>
<tr>
<td>Family Planning Counseling</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>42,190</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>15,882</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>21,833</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>3,787</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>688</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Fecal Sludge Management (Households)</td>
<td>-</td>
<td>2,723</td>
<td>-</td>
<td>36,037</td>
<td>274</td>
<td>(100)%</td>
<td>25,375</td>
<td>29,028</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>573</td>
<td>210</td>
<td>(100)%</td>
<td>489</td>
<td>2,768</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>-</td>
<td>2,723</td>
<td>-</td>
<td>35,464</td>
<td>64</td>
<td>(100)%</td>
<td>24,868</td>
<td>26,260</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Fecal Sludge Management (Liters)</td>
<td>-</td>
<td>4,009,667</td>
<td>-</td>
<td>49,506,489</td>
<td>2,282,000</td>
<td>(100)%</td>
<td>45,326,000</td>
<td>61,593,200</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1,719,000</td>
<td>1,050,000</td>
<td>(100)%</td>
<td>1,914,000</td>
<td>13,071,200</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.
### Female Condom

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>-</td>
<td>4,009,667</td>
<td>47,787,489</td>
<td>1,232,000</td>
<td>(100)%</td>
<td>43,412,000</td>
<td>48,522,000</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Female Condom</td>
<td>64,830</td>
<td>122,541</td>
<td>81,910</td>
<td>183,202</td>
<td>662,626</td>
<td>(88)%</td>
<td>1,721,664</td>
<td>87,966,438</td>
<td>614</td>
<td>614</td>
<td>1,841</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>23,460</td>
<td>(100)%</td>
<td>85,553</td>
<td>10,481,146</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>22,100</td>
<td>8,758</td>
<td>30,140</td>
<td>178,000</td>
<td>44,376</td>
<td>(32)%</td>
<td>174,851</td>
<td>48,774,818</td>
<td>226</td>
<td>226</td>
<td>1,292</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>42,710</td>
<td>113,783</td>
<td>51,750</td>
<td>5,202</td>
<td>594,790</td>
<td>(91)%</td>
<td>1,461,260</td>
<td>13,265,655</td>
<td>388</td>
<td>388</td>
<td>549</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>-</td>
<td>20</td>
<td>20</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>660,949</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>9,300,709</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Social Enterprise</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>985,104</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Inactive</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>4,498,057</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Female Condom Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>4,498,057</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

### Fever Cases Attended

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Acceleration Market Group</td>
<td>58,138</td>
<td>40,915</td>
<td>63,290</td>
<td>463,726</td>
<td>54,654</td>
<td>16%</td>
<td>520,128</td>
<td>3,041,565</td>
<td>63,290</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>-</td>
<td>22,518</td>
<td>-</td>
<td>340,000</td>
<td>-</td>
<td>-</td>
<td>238,868</td>
<td>238,868</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>26,907</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>-</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>3,027</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Fever Cases Attended</td>
<td>91,104</td>
<td>97,629</td>
<td>133,641</td>
<td>4,788,079</td>
<td>88,133</td>
<td>52%</td>
<td>1,051,956</td>
<td>7,331,832</td>
<td>133,641</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

### Fever Cases Tested with Microscopy

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Acceleration Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>7,474</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>-</td>
<td>4,026</td>
<td>9,823</td>
<td>47,274</td>
<td>4,361</td>
<td>124%</td>
<td>44,156</td>
<td>493,467</td>
<td>9,823</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>6,737</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Fever Cases Tested with Microscopy</td>
<td>5,049</td>
<td>4,026</td>
<td>9,823</td>
<td>47,274</td>
<td>4,361</td>
<td>124%</td>
<td>44,156</td>
<td>493,467</td>
<td>9,823</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

### Fever Cases Tested with RDTs

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Acceleration Market Group</td>
<td>58,138</td>
<td>40,915</td>
<td>63,290</td>
<td>463,726</td>
<td>54,654</td>
<td>16%</td>
<td>520,128</td>
<td>3,041,565</td>
<td>63,290</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>-</td>
<td>21,511</td>
<td>-</td>
<td>323,000</td>
<td>-</td>
<td>-</td>
<td>227,984</td>
<td>227,984</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

**Note:** The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.
### Monthly Distribution by Product

**Period:** 2  
**Year:** 2020

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Franco/Lusophone Africa Market Group</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>3,089</td>
<td>10,281</td>
<td>10,922</td>
<td>113,372</td>
<td>13,496</td>
<td>(19)%</td>
<td>116,202</td>
<td>422,811</td>
<td>10,922</td>
<td>-</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>47,203</td>
<td>34,943</td>
<td>92,009</td>
<td>3,895,899</td>
<td>42,060</td>
<td>119%</td>
<td>297,762</td>
<td>4,147,620</td>
<td>92,009</td>
<td>-</td>
</tr>
<tr>
<td><strong>Free Condom</strong></td>
<td>3,266,103</td>
<td>6,892,815</td>
<td>6,347,958</td>
<td>79,071,657</td>
<td>11,201,139</td>
<td>(43)%</td>
<td>105,689,754</td>
<td>2,735,125,550</td>
<td>47,610</td>
<td>47,610</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>17,310</td>
<td>1,049,760</td>
<td>(100)%</td>
<td>1,049,760</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>2,829,548</td>
<td>4,433,295</td>
<td>4,576,628</td>
<td>54,202,856</td>
<td>8,599,417</td>
<td>(47)%</td>
<td>61,742,141</td>
<td>796,265,420</td>
<td>34,325</td>
<td>34,325</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>7,500</td>
<td>318,759</td>
<td>10,232</td>
<td>4,956,000</td>
<td>31,100</td>
<td>(72)%</td>
<td>3,741,906</td>
<td>84,956,710</td>
<td>77</td>
<td>77</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>23,719</td>
<td>105,242</td>
<td>158,282</td>
<td>677,327</td>
<td>564,000</td>
<td>(119)%</td>
<td>1,187,067</td>
<td>61,901,553</td>
<td>1,187</td>
<td>1,187</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>405,336</td>
<td>2,035,363</td>
<td>1,602,816</td>
<td>19,218,164</td>
<td>95,862</td>
<td>68%</td>
<td>23,328,462</td>
<td>185,482,530</td>
<td>12,021</td>
<td>12,021</td>
</tr>
<tr>
<td>Inactive</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>118,640,479</td>
<td>-</td>
</tr>
<tr>
<td><strong>Free Female Condom</strong></td>
<td>39,313</td>
<td>54,174</td>
<td>86,358</td>
<td>451,719</td>
<td>16,160</td>
<td>434%</td>
<td>1,563,995</td>
<td>19,302,537</td>
<td>648</td>
<td>648</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>12,263</td>
<td>11,987</td>
<td>24,206</td>
<td>121,000</td>
<td>-</td>
<td>-%</td>
<td>49,875</td>
<td>6,641,844</td>
<td>182</td>
<td>182</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>26,950</td>
<td>35,589</td>
<td>56,750</td>
<td>188,719</td>
<td>16,160</td>
<td>251%</td>
<td>1,398,332</td>
<td>7,543,945</td>
<td>426</td>
<td>426</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>100</td>
<td>3,495</td>
<td>2,400</td>
<td>132,000</td>
<td>-</td>
<td>-%</td>
<td>99,284</td>
<td>1,156,378</td>
<td>18</td>
<td>18</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>-</td>
<td>3,103</td>
<td>3,000</td>
<td>10,000</td>
<td>-</td>
<td>-%</td>
<td>16,504</td>
<td>373,278</td>
<td>22</td>
<td>22</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Inactive</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>HAART (Mother and Baby)</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>256</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>HAART (Mother Only)</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>239</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>HIV Self-Testing Kit</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>39,192</td>
<td>101,878</td>
<td>74,200</td>
<td>755,106</td>
<td>108,580</td>
<td>(32)%</td>
<td>1,408,482</td>
<td>4,206,605</td>
<td>66,780</td>
<td>-</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>8,385</td>
<td>6,052</td>
<td>17,465</td>
<td>425,201</td>
<td>23,486</td>
<td>(26)%</td>
<td>647,230</td>
<td>2,022,117</td>
<td>15,719</td>
<td>-</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>20,115</td>
<td>95,318</td>
<td>54,044</td>
<td>319,994</td>
<td>85,094</td>
<td>(36)%</td>
<td>759,756</td>
<td>2,180,301</td>
<td>48,640</td>
<td>-</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>1,692</td>
<td>509</td>
<td>2,691</td>
<td>8,062</td>
<td>-</td>
<td>-%</td>
<td>1,496</td>
<td>4,187</td>
<td>2,422</td>
<td>-</td>
</tr>
<tr>
<td><strong>HIV Testing Services</strong></td>
<td>83,994</td>
<td>102,163</td>
<td>168,129</td>
<td>873,361</td>
<td>159,782</td>
<td>5%</td>
<td>1,375,018</td>
<td>24,862,685</td>
<td>168,129</td>
<td>-</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Acceleration Market Group</strong></td>
<td>13,895</td>
<td>14,530</td>
<td>27,597</td>
<td>85,856</td>
<td>64,509</td>
<td>(57)%</td>
<td>318,640</td>
<td>7,372,273</td>
<td>27,597</td>
</tr>
<tr>
<td><strong>Anglophone Africa Market Group</strong></td>
<td>37,517</td>
<td>21,398</td>
<td>58,210</td>
<td>464,226</td>
<td>49,969</td>
<td>16%</td>
<td>315,263</td>
<td>10,821,571</td>
<td>58,210</td>
</tr>
<tr>
<td><strong>Franco/Lusophone Africa Market Group</strong></td>
<td>7,133</td>
<td>5,171</td>
<td>10,148</td>
<td>45,316</td>
<td>15,243</td>
<td>(33)%</td>
<td>87,835</td>
<td>3,098,555</td>
<td>10,148</td>
</tr>
<tr>
<td><strong>Latin America &amp; Asia Market Group</strong></td>
<td>6,304</td>
<td>5,788</td>
<td>15,304</td>
<td>55,999</td>
<td>10,254</td>
<td>49%</td>
<td>69,479</td>
<td>456,564</td>
<td>15,304</td>
</tr>
<tr>
<td><strong>Foundation Market Group</strong></td>
<td>19,145</td>
<td>55,275</td>
<td>56,870</td>
<td>221,964</td>
<td>19,807</td>
<td>187%</td>
<td>583,801</td>
<td>2,339,272</td>
<td>56,870</td>
</tr>
<tr>
<td><strong>Inactive</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>774,450</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Hypertension Diagnosis</strong></td>
<td>1,529</td>
<td>9,120</td>
<td>3,887</td>
<td>266</td>
<td>6,807</td>
<td>(43)%</td>
<td>80,787</td>
<td>285,330</td>
<td>3,887</td>
</tr>
<tr>
<td><strong>Anglophone Africa Market Group</strong></td>
<td>-</td>
<td>7,191</td>
<td>615</td>
<td>-</td>
<td>1,417</td>
<td>(57)%</td>
<td>51,351</td>
<td>162,969</td>
<td>615</td>
</tr>
<tr>
<td><strong>Franco/Lusophone Africa Market Group</strong></td>
<td>1,529</td>
<td>1,908</td>
<td>3,269</td>
<td>266</td>
<td>2,448</td>
<td>34%</td>
<td>21,416</td>
<td>61,901</td>
<td>3,269</td>
</tr>
<tr>
<td><strong>Latin America &amp; Asia Market Group</strong></td>
<td>-</td>
<td>1</td>
<td>3</td>
<td>-</td>
<td>2,942</td>
<td>(100)%</td>
<td>7,961</td>
<td>60,401</td>
<td>3</td>
</tr>
<tr>
<td><strong>Foundation Market Group</strong></td>
<td>-</td>
<td>20</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>59</td>
<td>59</td>
<td>-</td>
</tr>
<tr>
<td><strong>Hypertension Screening</strong></td>
<td>72,678</td>
<td>89,829</td>
<td>144,169</td>
<td>144,169</td>
<td>202,633</td>
<td>(28)%</td>
<td>1,218,119</td>
<td>4,030,644</td>
<td>146,157</td>
</tr>
<tr>
<td><strong>Anglophone Africa Market Group</strong></td>
<td>-</td>
<td>10,354</td>
<td>1,381</td>
<td>-</td>
<td>16,839</td>
<td>(92)%</td>
<td>108,524</td>
<td>508,144</td>
<td>1,381</td>
</tr>
<tr>
<td><strong>Franco/Lusophone Africa Market Group</strong></td>
<td>72,678</td>
<td>79,473</td>
<td>144,773</td>
<td>144,169</td>
<td>121,060</td>
<td>20%</td>
<td>917,675</td>
<td>2,714,883</td>
<td>144,773</td>
</tr>
<tr>
<td><strong>Latin America &amp; Asia Market Group</strong></td>
<td>-</td>
<td>1</td>
<td>3</td>
<td>-</td>
<td>64,734</td>
<td>(100)%</td>
<td>191,920</td>
<td>807,617</td>
<td>3</td>
</tr>
<tr>
<td><strong>Hypertension Controlled Condition</strong></td>
<td>23</td>
<td>6,024</td>
<td>530</td>
<td>77</td>
<td>5,150</td>
<td>(90)%</td>
<td>51,877</td>
<td>168,263</td>
<td>212</td>
</tr>
<tr>
<td><strong>Anglophone Africa Market Group</strong></td>
<td>-</td>
<td>6,017</td>
<td>494</td>
<td>-</td>
<td>883</td>
<td>(44)%</td>
<td>39,737</td>
<td>125,377</td>
<td>198</td>
</tr>
<tr>
<td><strong>Franco/Lusophone Africa Market Group</strong></td>
<td>20</td>
<td>6</td>
<td>30</td>
<td>77</td>
<td>12</td>
<td>150%</td>
<td>105</td>
<td>292</td>
<td>12</td>
</tr>
<tr>
<td><strong>Latin America &amp; Asia Market Group</strong></td>
<td>3</td>
<td>1</td>
<td>6</td>
<td>-</td>
<td>4,255</td>
<td>(100)%</td>
<td>12,035</td>
<td>62,594</td>
<td>2</td>
</tr>
<tr>
<td><strong>Implant 3</strong></td>
<td>(3,320)</td>
<td>11,191</td>
<td>(5,081)</td>
<td>109,242</td>
<td>16,229</td>
<td>(131)%</td>
<td>110,512</td>
<td>1,132,804</td>
<td>(4,573)</td>
</tr>
<tr>
<td><strong>Anglophone Africa Market Group</strong></td>
<td>90</td>
<td>232</td>
<td>(155)</td>
<td>3,296</td>
<td>1,402</td>
<td>(111)%</td>
<td>10,355</td>
<td>828,746</td>
<td>(140)</td>
</tr>
<tr>
<td><strong>Franco/Lusophone Africa Market Group</strong></td>
<td>(4,169)</td>
<td>8,264</td>
<td>(5,093)</td>
<td>77,707</td>
<td>7,347</td>
<td>(169)%</td>
<td>74,741</td>
<td>221,718</td>
<td>(4,584)</td>
</tr>
<tr>
<td><strong>Latin America &amp; Asia Market Group</strong></td>
<td>8</td>
<td>377</td>
<td>(1,372)</td>
<td>20,373</td>
<td>1,081</td>
<td>(227)%</td>
<td>7,086</td>
<td>29,220</td>
<td>(1,235)</td>
</tr>
<tr>
<td><strong>Foundation Market Group</strong></td>
<td>573</td>
<td>316</td>
<td>1,037</td>
<td>6,506</td>
<td>944</td>
<td>10%</td>
<td>2,894</td>
<td>27,775</td>
<td>933</td>
</tr>
<tr>
<td><strong>Inactive</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>(2,265)</td>
<td>-</td>
</tr>
<tr>
<td><strong>Implant 3 Insertion</strong></td>
<td>24,082</td>
<td>29,397</td>
<td>40,946</td>
<td>191,494</td>
<td>51,880</td>
<td>(21)%</td>
<td>408,136</td>
<td>1,392,806</td>
<td>40,946</td>
</tr>
</tbody>
</table>

*a*The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.
### Monthly Distribution by Product

**Period:** 2  
**Year:** 2020

#### DISTRIBUTION 2/2020

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Acceleration Market Group</td>
<td>6,885</td>
<td>7,497</td>
<td>12,441</td>
<td>86,738</td>
<td>2,310</td>
<td>439%</td>
<td>51,603</td>
<td>76,539</td>
<td>12,441</td>
<td>31,103</td>
<td>23,496</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>8,913</td>
<td>12,321</td>
<td>13,246</td>
<td>69,961</td>
<td>35,396</td>
<td>(63)%</td>
<td>217,237</td>
<td>940,992</td>
<td>13,246</td>
<td>33,120</td>
<td>31,351</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>3,963</td>
<td>4,535</td>
<td>7,768</td>
<td>15,870</td>
<td>6,927</td>
<td>12%</td>
<td>69,284</td>
<td>123,755</td>
<td>7,768</td>
<td>19,420</td>
<td>18,934</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>983</td>
<td>742</td>
<td>1,569</td>
<td>12,428</td>
<td>2,114</td>
<td>(26)%</td>
<td>12,010</td>
<td>47,831</td>
<td>1,569</td>
<td>3,923</td>
<td>836</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>3,338</td>
<td>4,302</td>
<td>5,920</td>
<td>6,497</td>
<td>5,133</td>
<td>15%</td>
<td>58,002</td>
<td>198,962</td>
<td>5,920</td>
<td>14,800</td>
<td>11,394</td>
</tr>
<tr>
<td>Inactive</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Implant 4</td>
<td>1,045</td>
<td>719</td>
<td>2,970</td>
<td>6,168%</td>
<td>11,032</td>
<td>-</td>
<td>57,348</td>
<td>1,943</td>
<td>6,218</td>
<td>5,582</td>
<td></td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>1,045</td>
<td>720</td>
<td>2,971</td>
<td>-</td>
<td>18,459</td>
<td>-</td>
<td>29,243</td>
<td>2,674</td>
<td>8,556</td>
<td>7,665</td>
<td></td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>-</td>
<td>(1)</td>
<td>(1)</td>
<td>-</td>
<td>(97)</td>
<td>-</td>
<td>7,436</td>
<td>(1)</td>
<td>(3)</td>
<td>(2)</td>
<td></td>
</tr>
<tr>
<td>Implant 4 Insertion</td>
<td>1,060</td>
<td>883</td>
<td>1,943</td>
<td>31%</td>
<td>11,032</td>
<td>-</td>
<td>57,348</td>
<td>1,943</td>
<td>6,218</td>
<td>5,582</td>
<td></td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>1,060</td>
<td>882</td>
<td>1,942</td>
<td>28%</td>
<td>10,829</td>
<td>-</td>
<td>48,255</td>
<td>1,942</td>
<td>6,214</td>
<td>5,580</td>
<td></td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>3</td>
<td>(100)%</td>
<td>21</td>
<td>752</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>-</td>
<td>1</td>
<td>1</td>
<td>-</td>
<td>182</td>
<td>-</td>
<td>2,711</td>
<td>3</td>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Implant 5</td>
<td>6,544</td>
<td>5,495</td>
<td>6,539</td>
<td>113,355</td>
<td>7,787</td>
<td>(16)%</td>
<td>117,007</td>
<td>884,009</td>
<td>5,885</td>
<td>22,363</td>
<td>22,225</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>(2,250)</td>
<td>(2,437)</td>
<td>(4,760)</td>
<td>29,670</td>
<td>5</td>
<td>(95,300)%</td>
<td>(4,707)</td>
<td>(265,531)</td>
<td>(4,284)</td>
<td>(16,279)</td>
<td>(11,645)</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>(948)</td>
<td>2,522</td>
<td>(1,499)</td>
<td>16,628</td>
<td>4,458</td>
<td>(134)%</td>
<td>54,899</td>
<td>249,934</td>
<td>(1,349)</td>
<td>(5,127)</td>
<td>(9,142)</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>5,035</td>
<td>3,429</td>
<td>4,937</td>
<td>38,273</td>
<td>(326)</td>
<td>-</td>
<td>31,813</td>
<td>158,475</td>
<td>4,443</td>
<td>16,885</td>
<td>15,394</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>516</td>
<td>1,067</td>
<td>921</td>
<td>27,284</td>
<td>(840)</td>
<td>-</td>
<td>14,568</td>
<td>101,042</td>
<td>829</td>
<td>3,150</td>
<td>701</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>4,191</td>
<td>914</td>
<td>6,940</td>
<td>1,500</td>
<td>4,492</td>
<td>54%</td>
<td>20,434</td>
<td>97,392</td>
<td>6,246</td>
<td>23,735</td>
<td>26,917</td>
</tr>
<tr>
<td>Inactive</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Implant 5 Insertion</td>
<td>26,134</td>
<td>42,856</td>
<td>77,027</td>
<td>162,814</td>
<td>57,307</td>
<td>34%</td>
<td>449,186</td>
<td>2,513,174</td>
<td>77,027</td>
<td>292,703</td>
<td>293,924</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>4,696</td>
<td>8,703</td>
<td>11,402</td>
<td>30,953</td>
<td>16,734</td>
<td>(32)%</td>
<td>117,879</td>
<td>563,917</td>
<td>11,402</td>
<td>43,328</td>
<td>37,882</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>9,993</td>
<td>9,929</td>
<td>16,796</td>
<td>55,410</td>
<td>27,794</td>
<td>(40)%</td>
<td>175,768</td>
<td>965,300</td>
<td>16,798</td>
<td>63,832</td>
<td>54,538</td>
</tr>
</tbody>
</table>

*aThe grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.*

3004 - 4/15/2020 10:11:33AM Page 10 of 34
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Franco/Lusophone Africa Market Group</strong></td>
<td>6,337</td>
<td>17,708</td>
<td>38,842</td>
<td>65,065</td>
<td>9,115</td>
<td>326%</td>
<td>89,663</td>
<td>430,777</td>
<td>38,842</td>
<td>147,600</td>
<td>158,658</td>
<td></td>
</tr>
<tr>
<td><strong>Latin America &amp; Asia Market Group</strong></td>
<td>20</td>
<td>537</td>
<td>36</td>
<td>3,886</td>
<td>1,977</td>
<td>(98)%</td>
<td>20,152</td>
<td>107,968</td>
<td>36</td>
<td>137</td>
<td>21</td>
<td></td>
</tr>
<tr>
<td><strong>Foundation Market Group</strong></td>
<td>5,088</td>
<td>5,980</td>
<td>9,949</td>
<td>7,500</td>
<td>1,687</td>
<td>490%</td>
<td>45,724</td>
<td>381,614</td>
<td>9,949</td>
<td>37,806</td>
<td>42,824</td>
<td></td>
</tr>
<tr>
<td><strong>Inactive</strong></td>
<td></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Infant Fortified Food</strong></td>
<td></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Latin America &amp; Asia Market Group</strong></td>
<td></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Injectable 1</strong></td>
<td>(357)</td>
<td>14,450</td>
<td>5,003</td>
<td>152,498</td>
<td>30,430</td>
<td>(84)%</td>
<td>203,675</td>
<td>3,868,136</td>
<td>346</td>
<td>346</td>
<td>74</td>
<td></td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td></td>
<td>-</td>
<td>-</td>
<td>15,000</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Latin America &amp; Asia Market Group</strong></td>
<td>(357)</td>
<td>14,450</td>
<td>5,003</td>
<td>137,498</td>
<td>30,430</td>
<td>(84)%</td>
<td>203,675</td>
<td>2,321,963</td>
<td>346</td>
<td>346</td>
<td>74</td>
<td></td>
</tr>
<tr>
<td><strong>Inactive</strong></td>
<td></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Injectable 1 Provided</strong></td>
<td>1,318</td>
<td>6,142</td>
<td>2,038</td>
<td>29</td>
<td>10,337</td>
<td>(80)%</td>
<td>103,353</td>
<td>333,018</td>
<td>157</td>
<td>157</td>
<td>39</td>
<td></td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td></td>
<td>1</td>
<td>4</td>
<td>3</td>
<td>9</td>
<td>(50)%</td>
<td>44</td>
<td>84</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td></td>
<td>-</td>
<td>-</td>
<td>20</td>
<td>10</td>
<td>(100)%</td>
<td>42</td>
<td>1,809</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Latin America &amp; Asia Market Group</strong></td>
<td>1,315</td>
<td>6,138</td>
<td>2,035</td>
<td>-</td>
<td>10,321</td>
<td>(80)%</td>
<td>102,997</td>
<td>330,855</td>
<td>157</td>
<td>157</td>
<td>39</td>
<td></td>
</tr>
<tr>
<td><strong>Foundation Market Group</strong></td>
<td></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Injectable 2</strong></td>
<td>(827)</td>
<td>(458)</td>
<td>(1,224)</td>
<td>314,687</td>
<td>24,987</td>
<td>(105)%</td>
<td>146,097</td>
<td>23,432,829</td>
<td>(184)</td>
<td>(184)</td>
<td>(98)</td>
<td></td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td></td>
<td>-</td>
<td>-</td>
<td>20,000</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td></td>
<td>-</td>
<td>-</td>
<td>1,200</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Franco/Lusophone Africa Market Group</strong></td>
<td>(827)</td>
<td>(423)</td>
<td>(1,224)</td>
<td>65,016</td>
<td>195</td>
<td>(728)%</td>
<td>21,203</td>
<td>314,323</td>
<td>(184)</td>
<td>(184)</td>
<td>(98)</td>
<td></td>
</tr>
<tr>
<td><strong>Latin America &amp; Asia Market Group</strong></td>
<td></td>
<td>-</td>
<td>-</td>
<td>228,471</td>
<td>24,792</td>
<td>(100)%</td>
<td>124,894</td>
<td>7,211,502</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Inactive</strong></td>
<td></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Injectable 2 Provided</strong></td>
<td>3,736</td>
<td>6,682</td>
<td>9,348</td>
<td>60,003</td>
<td>11,238</td>
<td>(17)%</td>
<td>86,435</td>
<td>322,683</td>
<td>1,558</td>
<td>1,558</td>
<td>997</td>
<td></td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td></td>
<td>1,241</td>
<td>1,147</td>
<td>2,519</td>
<td>5,858</td>
<td>40%</td>
<td>13,459</td>
<td>21,853</td>
<td>420</td>
<td>420</td>
<td>353</td>
<td></td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td></td>
<td>1,331</td>
<td>2,937</td>
<td>5,107</td>
<td>770</td>
<td>42%</td>
<td>21,725</td>
<td>61,179</td>
<td>851</td>
<td>851</td>
<td>489</td>
<td></td>
</tr>
<tr>
<td><strong>Franco/Lusophone Africa Market Group</strong></td>
<td>1,164</td>
<td>977</td>
<td>1,722</td>
<td>-</td>
<td>2,356</td>
<td>(27)%</td>
<td>12,209</td>
<td>52,681</td>
<td>287</td>
<td>287</td>
<td>154</td>
<td></td>
</tr>
<tr>
<td><strong>Latin America &amp; Asia Market Group</strong></td>
<td>-</td>
<td>1,621</td>
<td>53,375</td>
<td>3,502</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note: The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Injectable 3-IM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>386,314</td>
<td>268,805</td>
<td>621,437</td>
<td>4,005,488</td>
<td>406,934</td>
<td>53%</td>
<td>3,929,254</td>
<td>96,494,876</td>
<td>139,823</td>
<td>139,823</td>
<td>57,446</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>40,060</td>
<td>42,896</td>
<td>47,285</td>
<td>468,000</td>
<td>82,022</td>
<td>(42)%</td>
<td>514,301</td>
<td>32,603,547</td>
<td>10,639</td>
<td>10,639</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>(318)</td>
<td>13,626</td>
<td>18,249</td>
<td>629,600</td>
<td>46,281</td>
<td>(61)%</td>
<td>721,284</td>
<td>14,824,531</td>
<td>4,106</td>
<td>4,106</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>1,095</td>
<td>9,203</td>
<td>1,076</td>
<td>137,085</td>
<td>17,149</td>
<td>(94)%</td>
<td>180,120</td>
<td>1,425,836</td>
<td>242</td>
<td>242</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>23,624</td>
<td>14,401</td>
<td>43,661</td>
<td>733,115</td>
<td>59,629</td>
<td>(27)%</td>
<td>323,866</td>
<td>12,115,886</td>
<td>9,824</td>
<td>9,824</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>318,445</td>
<td>187,396</td>
<td>509,229</td>
<td>1,868,316</td>
<td>194,563</td>
<td>162%</td>
<td>2,150,139</td>
<td>31,805,904</td>
<td>114,577</td>
<td>114,577</td>
</tr>
<tr>
<td>Social Enterprise</td>
<td>3,408</td>
<td>1,284</td>
<td>1,937</td>
<td>169,372</td>
<td>7,285</td>
<td>(73)%</td>
<td>39,544</td>
<td>240,291</td>
<td>436</td>
<td>436</td>
</tr>
<tr>
<td>Injectable 3-IM Provided</td>
<td>126,273</td>
<td>246,323</td>
<td>501,701</td>
<td>1,630,389</td>
<td>230,074</td>
<td>118%</td>
<td>1,716,865</td>
<td>5,356,957</td>
<td>125,425</td>
<td>125,425</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>41,933</td>
<td>43,833</td>
<td>78,164</td>
<td>449,871</td>
<td>34,405</td>
<td>127%</td>
<td>385,457</td>
<td>834,675</td>
<td>19,541</td>
<td>19,541</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>10,957</td>
<td>25,597</td>
<td>34,813</td>
<td>164,097</td>
<td>68,615</td>
<td>(49)%</td>
<td>416,171</td>
<td>1,159,732</td>
<td>8,703</td>
<td>8,703</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>29,752</td>
<td>113,533</td>
<td>309,985</td>
<td>157,287</td>
<td>41,689</td>
<td>644%</td>
<td>317,069</td>
<td>1,255,286</td>
<td>77,496</td>
<td>77,496</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>36,102</td>
<td>54,980</td>
<td>65,701</td>
<td>853,545</td>
<td>78,699</td>
<td>(17)%</td>
<td>517,607</td>
<td>1,741,315</td>
<td>16,425</td>
<td>16,425</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>7,529</td>
<td>8,381</td>
<td>13,038</td>
<td>5,589</td>
<td>6,668</td>
<td>96%</td>
<td>80,561</td>
<td>365,947</td>
<td>3,260</td>
<td>3,260</td>
</tr>
<tr>
<td>Injectable 3-SC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19,555</td>
<td>18,462</td>
<td>37,764</td>
<td>800,484</td>
<td>47,310</td>
<td>(20)%</td>
<td>843,570</td>
<td>2,551,896</td>
<td>8,497</td>
<td>8,497</td>
<td>4,111</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>3,146</td>
<td>2,568</td>
<td>5,213</td>
<td>240,000</td>
<td>3,334</td>
<td>56%</td>
<td>31,405</td>
<td>36,618</td>
<td>1,713</td>
<td>1,713</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>(2,175)</td>
<td>3,304</td>
<td>(2,131)</td>
<td>50,000</td>
<td>12,630</td>
<td>(117)%</td>
<td>91,046</td>
<td>144,815</td>
<td>(479)</td>
<td>(479)</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>18,597</td>
<td>12,171</td>
<td>34,729</td>
<td>30,000</td>
<td>10,055</td>
<td>245%</td>
<td>211,263</td>
<td>274,935</td>
<td>7,814</td>
<td>7,814</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>(13)</td>
<td>(45)</td>
<td>(47)</td>
<td>200</td>
<td>- -</td>
<td>%</td>
<td>(102)</td>
<td>(149)</td>
<td>(11)</td>
<td>(11)</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>-</td>
<td>465</td>
<td>-</td>
<td>480,284</td>
<td>21,291</td>
<td>(100)%</td>
<td>509,956</td>
<td>2,095,679</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Injectable 3-SC Provided</td>
<td>11,381</td>
<td>15,124</td>
<td>24,896</td>
<td>47,757</td>
<td>9,880</td>
<td>152%</td>
<td>108,959</td>
<td>139,759</td>
<td>6,224</td>
<td>6,224</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>1,323</td>
<td>995</td>
<td>2,512</td>
<td>3,580</td>
<td>1,987</td>
<td>26%</td>
<td>9,727</td>
<td>12,239</td>
<td>628</td>
<td>628</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>4,471</td>
<td>8,662</td>
<td>11,639</td>
<td>- -</td>
<td>- -</td>
<td>-%</td>
<td>33,304</td>
<td>44,943</td>
<td>2,910</td>
<td>2,910</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>5,068</td>
<td>4,965</td>
<td>9,961</td>
<td>41,377</td>
<td>7,830</td>
<td>27%</td>
<td>63,385</td>
<td>79,075</td>
<td>2,490</td>
<td>2,490</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>13</td>
<td>261</td>
<td>47</td>
<td>800</td>
<td>- -</td>
<td>-%</td>
<td>769</td>
<td>816</td>
<td>12</td>
<td>12</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>506</td>
<td>242</td>
<td>737</td>
<td>2,000</td>
<td>63</td>
<td>1,070%</td>
<td>1,774</td>
<td>2,686</td>
<td>184</td>
<td>184</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.
## Monthly Distribution by Product

**Period:** 2  
**Year:** 2020

### IPTp2

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Acceleration Market Group</strong></td>
<td>1,810</td>
<td>1,267</td>
<td>2,605</td>
<td>275,251</td>
<td>1,691</td>
<td>54%</td>
<td>12,028</td>
<td>359,084</td>
<td>2,605</td>
<td>-</td>
<td>179</td>
</tr>
<tr>
<td><strong>Iron Folic Acid Tablet</strong></td>
<td>719</td>
<td>885</td>
<td>1,514</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>13,755</td>
<td>-</td>
<td>-</td>
<td>48,263,018</td>
<td>-</td>
</tr>
<tr>
<td><strong>INN</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>420,232</td>
<td>-</td>
<td>-</td>
<td>1,265,503</td>
<td>20,663,108</td>
</tr>
<tr>
<td><strong>IUD 10</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>19,488</td>
<td>19,580</td>
<td>24,766</td>
<td>296,557</td>
<td>6,630</td>
</tr>
<tr>
<td><strong>IUD 10 Insertion</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>21,129</td>
<td>43,602</td>
<td>57,408</td>
<td>51,062</td>
<td>24,062</td>
</tr>
</tbody>
</table>

**Notes:**
- The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

**Accompanying Note:**
- The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.
<table>
<thead>
<tr>
<th>Period</th>
<th>Year</th>
<th>MONTHLY DISTRIBUTION 2020</th>
<th>YTD DISTRIBUTION 2020</th>
<th>DISTRIBUTION TARGET 2020</th>
<th>YTD DISTRIBUTION 2019</th>
<th>YTD % CHANGE</th>
<th>CUMULATIVE DISTRIBUTION</th>
<th>TOTAL DISTRIBUTION 2019</th>
<th>YTD USERS REACHED 2020</th>
<th>YTD CYP</th>
<th>YTD DALY</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>DISTRIBUTION</td>
<td>AVG PREV 3 MONTHS</td>
<td>DISTRIBUTION</td>
<td>%</td>
<td>YTD % CHANGE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inactive</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IUD 3</td>
<td></td>
<td>(45)</td>
<td>(28)</td>
<td>(5)</td>
<td>165,715</td>
<td>(250)</td>
<td>-%</td>
<td>(57)</td>
<td>6,891</td>
<td>(5)</td>
<td>(11)</td>
</tr>
<tr>
<td>Social Enterprise</td>
<td></td>
<td>(45)</td>
<td>(28)</td>
<td>(5)</td>
<td>165,715</td>
<td>(250)</td>
<td>-%</td>
<td>(57)</td>
<td>6,891</td>
<td>(5)</td>
<td>(11)</td>
</tr>
<tr>
<td>IUD 5</td>
<td></td>
<td>(5,170)</td>
<td>(303)</td>
<td>404</td>
<td>219,582</td>
<td>(1,470)</td>
<td>(99) %</td>
<td>171,635</td>
<td>4,557,898</td>
<td>364</td>
<td>1,200</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td></td>
<td>(6)</td>
<td>10</td>
<td>(76)</td>
<td>(1,133)</td>
<td>102</td>
<td>(175) %</td>
<td>362</td>
<td>1,136,807</td>
<td>(68)</td>
<td>(226)</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td></td>
<td>4,506</td>
<td>(682)</td>
<td>(1,180)</td>
<td>219,980</td>
<td>25,281</td>
<td>(105) %</td>
<td>40,646</td>
<td>3,090,186</td>
<td>(1,062)</td>
<td>(3,505)</td>
</tr>
<tr>
<td>Social Enterprise</td>
<td></td>
<td>670</td>
<td>368</td>
<td>1,660</td>
<td>735</td>
<td>16,112</td>
<td>(90) %</td>
<td>130,659</td>
<td>312,654</td>
<td>4,930</td>
<td>1,111</td>
</tr>
<tr>
<td>Inactive</td>
<td></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IUD 5 Insertion</td>
<td></td>
<td>27,265</td>
<td>31,118</td>
<td>52,324</td>
<td>101,766</td>
<td>49,978</td>
<td>5%</td>
<td>325,380</td>
<td>1,533,990</td>
<td>52,324</td>
<td>172,669</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td></td>
<td>14,090</td>
<td>19,325</td>
<td>27,329</td>
<td>90,233</td>
<td>11,374</td>
<td>140%</td>
<td>162,738</td>
<td>370,917</td>
<td>27,329</td>
<td>90,186</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>(100) %</td>
<td>162</td>
<td>28,984</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td></td>
<td>13,130</td>
<td>11,772</td>
<td>24,949</td>
<td>11,229</td>
<td>38,466</td>
<td>(35) %</td>
<td>162,215</td>
<td>24,949</td>
<td>82,332</td>
<td>25,621</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td></td>
<td>45</td>
<td>21</td>
<td>46</td>
<td>304</td>
<td>56</td>
<td>(18) %</td>
<td>265</td>
<td>610</td>
<td>46</td>
<td>152</td>
</tr>
<tr>
<td>IUS 3</td>
<td></td>
<td>(16)</td>
<td>(71)</td>
<td>(161)</td>
<td>-</td>
<td>24</td>
<td>(771) %</td>
<td>(326)</td>
<td>(391)</td>
<td>(145)</td>
<td>(362)</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td></td>
<td>-</td>
<td>(80)</td>
<td>(81)</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>(379)</td>
<td>(460)</td>
<td>(73)</td>
<td>(182)</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td></td>
<td>(16)</td>
<td>9</td>
<td>(80)</td>
<td>-</td>
<td>24</td>
<td>(433) %</td>
<td>51</td>
<td>69</td>
<td>(72)</td>
<td>(180)</td>
</tr>
<tr>
<td>IUS 3 Insertion</td>
<td></td>
<td>86</td>
<td>183</td>
<td>263</td>
<td>1,500</td>
<td>58</td>
<td>353%</td>
<td>1,510</td>
<td>1,908</td>
<td>263</td>
<td>658</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td></td>
<td>-</td>
<td>80</td>
<td>81</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>379</td>
<td>460</td>
<td>81</td>
<td>203</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td></td>
<td>86</td>
<td>103</td>
<td>182</td>
<td>1,500</td>
<td>58</td>
<td>214%</td>
<td>1,131</td>
<td>1,448</td>
<td>182</td>
<td>455</td>
</tr>
<tr>
<td>IUS 5</td>
<td></td>
<td>164</td>
<td>(2)</td>
<td>166</td>
<td>863</td>
<td>236</td>
<td>(30) %</td>
<td>803</td>
<td>2,049</td>
<td>493</td>
<td>197</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td></td>
<td>109</td>
<td>(12)</td>
<td>91</td>
<td>-</td>
<td>(28)</td>
<td>-%</td>
<td>395</td>
<td>1,566</td>
<td>82</td>
<td>279</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td></td>
<td>-</td>
<td>3</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>(11)</td>
<td>(11)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Social Enterprise</td>
<td></td>
<td>55</td>
<td>7</td>
<td>75</td>
<td>863</td>
<td>264</td>
<td>(72) %</td>
<td>419</td>
<td>494</td>
<td>68</td>
<td>223</td>
</tr>
<tr>
<td>IUS 5 Insertion</td>
<td></td>
<td>111</td>
<td>88</td>
<td>181</td>
<td>-</td>
<td>402</td>
<td>(55) %</td>
<td>1,744</td>
<td>4,434</td>
<td>181</td>
<td>597</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td></td>
<td>100</td>
<td>74</td>
<td>152</td>
<td>-</td>
<td>232</td>
<td>(34) %</td>
<td>1,102</td>
<td>2,655</td>
<td>152</td>
<td>502</td>
</tr>
</tbody>
</table>

a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.
<table>
<thead>
<tr>
<th>Period:</th>
<th>Year: 2020</th>
</tr>
</thead>
</table>

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Product**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Anglophone Africa Market Group</strong></td>
<td>11</td>
<td>12</td>
<td>29</td>
<td>-</td>
<td>167</td>
<td>(83)%</td>
<td>550</td>
<td>1,684</td>
<td>29</td>
<td>96</td>
</tr>
<tr>
<td><strong>Latin America &amp; Asia Market Group</strong></td>
<td>-</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>3</td>
<td>(100)%</td>
<td>10</td>
<td>13</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Foundation Market Group</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>82</td>
<td>82</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>LifeStraw</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>15,965</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Anglophone Africa Market Group</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>15,320</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Franco/Lusophone Africa Market Group</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>LLIN</strong></td>
<td>19,290</td>
<td>1,372,030</td>
<td>140,751</td>
<td>18,005,995</td>
<td>1,580,504</td>
<td>(91)%</td>
<td>9,265,240</td>
<td>368,041,390</td>
<td>228,017</td>
<td>-</td>
</tr>
<tr>
<td><strong>Acceleration Market Group</strong></td>
<td>1,452</td>
<td>4,419</td>
<td>2,964</td>
<td>188,475</td>
<td>39,765</td>
<td>(93)%</td>
<td>1,093,373</td>
<td>56,905,382</td>
<td>12,683</td>
<td>-</td>
</tr>
<tr>
<td><strong>Anglophone Africa Market Group</strong></td>
<td>7,824</td>
<td>118</td>
<td>7,829</td>
<td>60,000</td>
<td>16,912</td>
<td>(54)%</td>
<td>213,151</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Franco/Lusophone Africa Market Group</strong></td>
<td>6,994</td>
<td>204,400</td>
<td>47,388</td>
<td>948,043</td>
<td>248,932</td>
<td>(81)%</td>
<td>1,581,302</td>
<td>54,105,191</td>
<td>76,769</td>
<td>-</td>
</tr>
<tr>
<td><strong>Foundation Market Group</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>5,197,868</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Latin America &amp; Asia Market Group</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>LLIN (Hammock net)</strong></td>
<td>3,020</td>
<td>1,163,093</td>
<td>82,570</td>
<td>16,809,477</td>
<td>1,274,895</td>
<td>(94)%</td>
<td>6,377,414</td>
<td>182,724,057</td>
<td>133,763</td>
<td>-</td>
</tr>
<tr>
<td><strong>Inactive</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>4,061,119</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Lubricant</strong></td>
<td>670,588</td>
<td>970,008</td>
<td>1,700,417</td>
<td>8,463,767</td>
<td>1,874,339</td>
<td>(9)%</td>
<td>11,793,096</td>
<td>91,275,386</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Acceleration Market Group</strong></td>
<td>220,170</td>
<td>262,167</td>
<td>442,670</td>
<td>1,200,000</td>
<td>15,975</td>
<td>2,671%</td>
<td>2,318,836</td>
<td>16,313,795</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Anglophone Africa Market Group</strong></td>
<td>300,831</td>
<td>335,130</td>
<td>399,831</td>
<td>2,387,723</td>
<td>436,586</td>
<td>(8)%</td>
<td>2,926,726</td>
<td>12,069,739</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Franco/Lusophone Africa Market Group</strong></td>
<td>-</td>
<td>745</td>
<td>50</td>
<td>7,200</td>
<td>855</td>
<td>(94)%</td>
<td>11,039</td>
<td>1,533,108</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Latin America &amp; Asia Market Group</strong></td>
<td>101,961</td>
<td>99,357</td>
<td>236,700</td>
<td>1,392,857</td>
<td>306,471</td>
<td>(23)%</td>
<td>2,810,451</td>
<td>39,745,641</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Foundation Market Group</strong></td>
<td>23,900</td>
<td>259,831</td>
<td>580,400</td>
<td>1,392,857</td>
<td>306,471</td>
<td>(23)%</td>
<td>2,810,451</td>
<td>39,745,641</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Social Enterprise</strong></td>
<td>23,726</td>
<td>259,183</td>
<td>580,400</td>
<td>1,392,857</td>
<td>306,471</td>
<td>(23)%</td>
<td>2,810,451</td>
<td>39,745,641</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Inactive</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>14,433,610</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Malaria PPT (ACT)</strong></td>
<td>3,145</td>
<td>1,685,021</td>
<td>508,818</td>
<td>3,145,536</td>
<td>508,818</td>
<td>(15)%</td>
<td>6,513,485</td>
<td>142,943,602</td>
<td>1,167,773</td>
<td>-</td>
</tr>
<tr>
<td><strong>Acceleration Market Group</strong></td>
<td>1,233</td>
<td>636</td>
<td>1,807</td>
<td>254,408</td>
<td>34,896</td>
<td>(9)%</td>
<td>174,362</td>
<td>63,894,455</td>
<td>1,626</td>
<td>-</td>
</tr>
<tr>
<td><strong>Anglophone Africa Market Group</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Franco/Lusophone Africa Market Group</strong></td>
<td>1,912</td>
<td>2,141</td>
<td>7,173</td>
<td>954,610</td>
<td>43,412</td>
<td>(8)%</td>
<td>409,310</td>
<td>2,119,291</td>
<td>6,456</td>
<td>-</td>
</tr>
</tbody>
</table>

*a*The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>-</td>
<td>(18)</td>
<td>2,954</td>
<td>2,839,481</td>
<td>(227)</td>
<td>-3%</td>
<td>2,839,481</td>
<td>63,703,118</td>
<td>-607,275</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>-</td>
<td>1,682,262</td>
<td>1,288,567</td>
<td>12,248,518</td>
<td>430,578</td>
<td>199%</td>
<td>5,930,040</td>
<td>63,703,118</td>
<td>-1,159,710</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Malaria PPT (Non-ACT)</td>
<td>307</td>
<td>1,041</td>
<td>393</td>
<td>16,706</td>
<td>(195)</td>
<td>-3%</td>
<td>13,919,715</td>
<td>63,703,118</td>
<td>-55</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>307</td>
<td>141</td>
<td>393</td>
<td>16,706</td>
<td>(195)</td>
<td>-3%</td>
<td>13,919,715</td>
<td>63,703,118</td>
<td>-55</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>-</td>
<td>900</td>
<td>15,000</td>
<td>12,248,518</td>
<td>430,578</td>
<td>199%</td>
<td>5,930,040</td>
<td>63,703,118</td>
<td>-1,159,710</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Malaria RDK</td>
<td>203,535</td>
<td>901,115</td>
<td>372,235</td>
<td>13,997,664</td>
<td>152,165</td>
<td>145%</td>
<td>3,857,675</td>
<td>63,677,873</td>
<td>335,012</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>-</td>
<td>-</td>
<td>522,320</td>
<td>522,320</td>
<td>522,320</td>
<td>0%</td>
<td>522,320</td>
<td>63,703,118</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>-</td>
<td>37,972</td>
<td>8,100</td>
<td>366,400</td>
<td>24,575</td>
<td>67%</td>
<td>147,125</td>
<td>2,152,784</td>
<td>7,290</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>1,010</td>
<td>3,960</td>
<td>2,160</td>
<td>31,500</td>
<td>5,340</td>
<td>60%</td>
<td>35,300</td>
<td>7,092,356</td>
<td>1,944</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>202,525</td>
<td>859,358</td>
<td>361,975</td>
<td>13,077,644</td>
<td>122,250</td>
<td>196%</td>
<td>3,675,250</td>
<td>42,233,006</td>
<td>325,778</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male Circumcision (HIV-Positive)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Franolo/Lusophone Africa Market Group</td>
<td>-</td>
<td>37,972</td>
<td>8,100</td>
<td>366,400</td>
<td>24,575</td>
<td>67%</td>
<td>147,125</td>
<td>2,152,784</td>
<td>7,290</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>1,010</td>
<td>3,960</td>
<td>2,160</td>
<td>31,500</td>
<td>5,340</td>
<td>60%</td>
<td>35,300</td>
<td>7,092,356</td>
<td>1,944</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>202,525</td>
<td>859,358</td>
<td>361,975</td>
<td>13,077,644</td>
<td>122,250</td>
<td>196%</td>
<td>3,675,250</td>
<td>42,233,006</td>
<td>325,778</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male Vasodilator</td>
<td>106,960</td>
<td>48,000</td>
<td>150,960</td>
<td>786,000</td>
<td>174,900</td>
<td>14%</td>
<td>1,766,180</td>
<td>1,917,140</td>
<td>1,132</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Social Enterprise</td>
<td>106,960</td>
<td>48,000</td>
<td>150,960</td>
<td>786,000</td>
<td>174,900</td>
<td>14%</td>
<td>1,766,180</td>
<td>1,917,140</td>
<td>1,132</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Manual Vacuum Aspiration for PAC</td>
<td>6,571</td>
<td>6,651</td>
<td>12,040</td>
<td>23,436</td>
<td>23,261</td>
<td>48%</td>
<td>121,121</td>
<td>292,387</td>
<td>12,040</td>
<td>1,367</td>
<td></td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>228</td>
<td>410</td>
<td>228</td>
<td>6,236</td>
<td>1,576</td>
<td>(86)%</td>
<td>7,879</td>
<td>32,579</td>
<td>228</td>
<td></td>
<td>180</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>81</td>
<td>259</td>
<td>110</td>
<td>8,718</td>
<td>1,104</td>
<td>(90)%</td>
<td>6,339</td>
<td>16,970</td>
<td>110</td>
<td></td>
<td>31</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>270</td>
<td>1,031</td>
<td>481</td>
<td>2,479</td>
<td>456</td>
<td>5%</td>
<td>13,991</td>
<td>18,855</td>
<td>481</td>
<td></td>
<td>243</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>5,535</td>
<td>4,277</td>
<td>10,366</td>
<td>19,711</td>
<td>456</td>
<td>(47)%</td>
<td>85,407</td>
<td>201,737</td>
<td>10,366</td>
<td></td>
<td>531</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>457</td>
<td>674</td>
<td>855</td>
<td>6,003</td>
<td>414</td>
<td>107%</td>
<td>7,505</td>
<td>22,246</td>
<td>855</td>
<td></td>
<td>381</td>
</tr>
<tr>
<td>Manual Vacuum Aspiration for SA</td>
<td>174</td>
<td>308</td>
<td>451</td>
<td>1,026</td>
<td>237</td>
<td>90%</td>
<td>2,907</td>
<td>4,582</td>
<td>451</td>
<td></td>
<td>172</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>86</td>
<td>73</td>
<td>190</td>
<td>742</td>
<td>143</td>
<td>33%</td>
<td>805</td>
<td>1,406</td>
<td>190</td>
<td></td>
<td>69</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>88</td>
<td>208</td>
<td>261</td>
<td>283</td>
<td>86</td>
<td>203%</td>
<td>1,406</td>
<td>2,229</td>
<td>261</td>
<td></td>
<td>102</td>
</tr>
</tbody>
</table>

The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.
### Monthly Distribution by Product

**Period:** 2  
**Year:** 2020

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Medical Abortion</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>-</td>
<td>27</td>
<td>-</td>
<td>-</td>
<td>8</td>
<td>(100)%</td>
<td>696</td>
<td>947</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>107,363</td>
<td>61,066</td>
<td>167,323</td>
<td>1,827,066</td>
<td>-</td>
<td>-</td>
<td>948,334</td>
<td>6,543,197</td>
<td>150,591</td>
<td>2,430,565</td>
</tr>
<tr>
<td><strong>YTD USERS REACHED</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Latin America &amp; Asia Market Group</strong></td>
<td>948,334</td>
<td>6,543,197</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Foundation Market Group</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>948,334</td>
<td>6,543,197</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Medical Abortion Provided**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Anglophone Africa Market Group</td>
<td>84</td>
<td>49</td>
<td>146</td>
<td>742</td>
<td>225</td>
<td>(35)%</td>
<td>988</td>
<td>1,665</td>
<td>146</td>
<td></td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>19</td>
<td>142</td>
<td>44</td>
<td>341</td>
<td>111</td>
<td>(60)%</td>
<td>967</td>
<td>1,320</td>
<td>44</td>
<td></td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>103</td>
<td>192</td>
<td>190</td>
<td>1,083</td>
<td>336</td>
<td>(43)%</td>
<td>1,955</td>
<td>2,985</td>
<td>190</td>
<td></td>
</tr>
</tbody>
</table>

**Medical Abortion Provided**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Anglophone Africa Market Group</td>
<td>71</td>
<td>47</td>
<td>114</td>
<td>494</td>
<td>140</td>
<td>(19)%</td>
<td>775</td>
<td>2,257</td>
<td>114</td>
<td></td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>37</td>
<td>26</td>
<td>58</td>
<td>990</td>
<td>91</td>
<td>-</td>
<td>166</td>
<td>465</td>
<td>58</td>
<td></td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>108</td>
<td>1,117</td>
<td>172</td>
<td>4,864</td>
<td>1,364</td>
<td>(87)%</td>
<td>13,815</td>
<td>35,670</td>
<td>172</td>
<td></td>
</tr>
</tbody>
</table>

**Micronutrient Powder**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Anglophone Africa Market Group</td>
<td>300</td>
<td>34,143</td>
<td>900</td>
<td>78,120</td>
<td>(99)%</td>
<td>326,950</td>
<td>48,870,882</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>300</td>
<td>34,143</td>
<td>900</td>
<td>78,120</td>
<td>(99)%</td>
<td>326,950</td>
<td>48,870,882</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Misoprostol for PAC Provided**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Anglophone Africa Market Group</td>
<td>208</td>
<td>316</td>
<td>208</td>
<td>6,179</td>
<td>1,578</td>
<td>(87)%</td>
<td>7,331</td>
<td>22,394</td>
<td>208</td>
<td></td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>55</td>
<td>118</td>
<td>83</td>
<td>3,877</td>
<td>701</td>
<td>(88)%</td>
<td>3,078</td>
<td>7,997</td>
<td>83</td>
<td></td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>263</td>
<td>434</td>
<td>291</td>
<td>10,056</td>
<td>1,979</td>
<td>-</td>
<td>10,450</td>
<td>20,391</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.**

3004 - 4/15/2020 10:11:33AM Page 17 of 34
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Misoprostol for PPH</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>167</td>
<td>4,500</td>
<td>2,500</td>
<td>(100)%</td>
<td>15,500</td>
<td></td>
<td>6,332,438</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>167</td>
<td>4,500</td>
<td>2,500</td>
<td>(100)%</td>
<td>15,500</td>
<td></td>
<td>210,208</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Misoprostol for Safe Abortion</td>
<td>509,678</td>
<td>409,581</td>
<td>975,394</td>
<td>4,274,542</td>
<td>839,441</td>
<td>16%</td>
<td>5,680,307</td>
<td>24,085,155</td>
<td>51,208</td>
<td>22,603</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>185,300</td>
<td>82,603</td>
<td>393,000</td>
<td>1,977,921</td>
<td>218,558</td>
<td>80%</td>
<td>1,774,246</td>
<td>6,473,296</td>
<td>20,632</td>
<td>17,324</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>50,873</td>
<td>95,116</td>
<td>84,017</td>
<td>694,896</td>
<td>113,556</td>
<td>(26)%</td>
<td>1,553,194</td>
<td>10,677,187</td>
<td>4,411</td>
<td>1,381</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>73,680</td>
<td>62,717</td>
<td>89,828</td>
<td>517,149</td>
<td>76,943</td>
<td>17%</td>
<td>556,877</td>
<td>2,617,597</td>
<td>4,716</td>
<td>1,758</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>169,848</td>
<td>163,669</td>
<td>379,360</td>
<td>599,276</td>
<td>414,184</td>
<td>(6)%</td>
<td>1,689,170</td>
<td>4,117,257</td>
<td>19,916</td>
<td>1,486</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>29,975</td>
<td>5,477</td>
<td>29,191</td>
<td>485,300</td>
<td>16,200</td>
<td>80%</td>
<td>106,820</td>
<td>199,818</td>
<td>1,533</td>
<td>652</td>
</tr>
<tr>
<td>Multivitamin</td>
<td>163,571</td>
<td>131,137</td>
<td>309,011</td>
<td>2,120,171</td>
<td>215,610</td>
<td>43%</td>
<td>1,436,450</td>
<td>100,100,380</td>
<td>1,545</td>
<td>54</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>1,001</td>
<td>2,467</td>
<td>1,001</td>
<td></td>
<td></td>
<td></td>
<td>26,420</td>
<td>11,511,726</td>
<td>5</td>
<td>1</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Social Enterprise</td>
<td>162,570</td>
<td>128,670</td>
<td>308,010</td>
<td>2,106,000</td>
<td>215,610</td>
<td>43%</td>
<td>1,410,030</td>
<td>38,727,600</td>
<td>1,540</td>
<td>53</td>
</tr>
<tr>
<td>Inactive</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Naloxone</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inactive</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Needle &amp; Syringe</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inactive</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neonates Receiving Essential Care</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.


### Population Services International

**Monthly Distribution by Product**

**Period:** 2

**Year:** 2020

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>174</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>235</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>11,057</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>150</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>OCs</td>
<td>2,029,511</td>
<td>1,731,752</td>
<td>3,618,155</td>
<td>25,194,790</td>
<td>3,322,654</td>
<td>9%</td>
<td>23,088,670</td>
<td>662,363,362</td>
<td>217,089</td>
<td>-</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>729,543</td>
<td>784,205</td>
<td>1,448,307</td>
<td>8,420,270</td>
<td>1,340,477</td>
<td>8%</td>
<td>9,114,680</td>
<td>323,076,263</td>
<td>86,898</td>
<td>86,898</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>30,430</td>
<td>17,179</td>
<td>32,806</td>
<td>2,109,186</td>
<td>317,797</td>
<td>(90)%</td>
<td>1,545,840</td>
<td>81,533,699</td>
<td>1,968</td>
<td>1,968</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>52,897</td>
<td>116,322</td>
<td>111,769</td>
<td>994,174</td>
<td>350,780</td>
<td>(68)%</td>
<td>1,647,001</td>
<td>26,579,663</td>
<td>6,706</td>
<td>6,706</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>606,955</td>
<td>483,173</td>
<td>1,087,525</td>
<td>7,843,988</td>
<td>1,103,648</td>
<td>(1)%</td>
<td>7,120,821</td>
<td>107,661,017</td>
<td>65,252</td>
<td>65,252</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>376,273</td>
<td>190,280</td>
<td>550,207</td>
<td>1,789,552</td>
<td>73,238</td>
<td>651%</td>
<td>2,317,388</td>
<td>73,606,245</td>
<td>33,012</td>
<td>33,012</td>
</tr>
<tr>
<td>Social Enterprise</td>
<td>233,413</td>
<td>138,593</td>
<td>387,541</td>
<td>4,037,620</td>
<td>136,716</td>
<td>183%</td>
<td>1,342,940</td>
<td>17,813,881</td>
<td>23,252</td>
<td>23,252</td>
</tr>
<tr>
<td>Inactive</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>OCs Provided</td>
<td>335,848</td>
<td>486,354</td>
<td>899,004</td>
<td>2,676,598</td>
<td>357,975</td>
<td>151%</td>
<td>3,194,849</td>
<td>8,463,167</td>
<td>59,934</td>
<td>59,934</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>84,298</td>
<td>101,361</td>
<td>152,205</td>
<td>451,935</td>
<td>23,540</td>
<td>54%</td>
<td>756,782</td>
<td>1,154,096</td>
<td>10,147</td>
<td>10,147</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>30,444</td>
<td>35,251</td>
<td>69,021</td>
<td>218,906</td>
<td>64,927</td>
<td>6%</td>
<td>535,112</td>
<td>1,988,879</td>
<td>4,601</td>
<td>4,601</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>44,726</td>
<td>147,214</td>
<td>401,459</td>
<td>288,917</td>
<td>59,499</td>
<td>575%</td>
<td>1,890,798</td>
<td>26,764</td>
<td>26,764</td>
<td>23,455</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>175,012</td>
<td>201,074</td>
<td>273,878</td>
<td>1,709,652</td>
<td>208,574</td>
<td>31%</td>
<td>1,359,110</td>
<td>3,265,047</td>
<td>18,259</td>
<td>18,259</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>1,368</td>
<td>1,454</td>
<td>2,441</td>
<td>7,187</td>
<td>1,435</td>
<td>70%</td>
<td>12,988</td>
<td>164,343</td>
<td>163</td>
<td>163</td>
</tr>
<tr>
<td>Inactive</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>ORS</td>
<td>423,349</td>
<td>111,009</td>
<td>507,961</td>
<td>5,320,073</td>
<td>519,211</td>
<td>(2)%</td>
<td>3,143,681</td>
<td>444,087,201</td>
<td>228,582</td>
<td>-</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>37,907</td>
<td>48,337</td>
<td>47,854</td>
<td>856,600</td>
<td>41,145</td>
<td>16%</td>
<td>847,044</td>
<td>326,858,499</td>
<td>21,534</td>
<td>-</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>47,825</td>
<td>19,924</td>
<td>72,000</td>
<td>356,316</td>
<td>79,477</td>
<td>(9)%</td>
<td>648,134</td>
<td>4,997,115</td>
<td>32,400</td>
<td>-</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>-</td>
<td>27,448</td>
<td>-</td>
<td>-</td>
<td>570</td>
<td>(100)%</td>
<td>299,226</td>
<td>16,326,907</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Social Enterprise</td>
<td>337,707</td>
<td>15,300</td>
<td>388,107</td>
<td>2,410,157</td>
<td>398,019</td>
<td>(2)%</td>
<td>1,349,277</td>
<td>3,208,318</td>
<td>174,648</td>
<td>-</td>
</tr>
</tbody>
</table>

*The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.*

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

---

**Notes:**

1. The data reflects the distribution of products and services provided by Population Services International across various market groups and regions. The numbers indicate the quantity of users reached, with the percentage change and cumulative distribution also provided.
2. The grand total of users reached may not accurately reflect the true number of individuals impacted due to potential double counting.
3. Users can be categorized and summed within product groups to represent scale.

**Sources:**

- **Population Services International**
- **Monthly Distribution by Product Report**
- **Period:** 2
- **Year:** 2020

---

**3004 - 4/15/2020 10:11:33AM Page 19 of 34**
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Inactive</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DRS Provided</td>
<td>3,342</td>
<td>2,369</td>
<td>3,342</td>
<td>26,613</td>
<td>5,203</td>
<td>(36)%</td>
<td>31,138</td>
<td>115,442</td>
<td>3,342</td>
<td>-</td>
<td>134</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>758</td>
<td>(100)%</td>
<td>2,043</td>
<td>9,430</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>3,342</td>
<td>2,369</td>
<td>3,342</td>
<td>26,613</td>
<td>4,445</td>
<td>(25)%</td>
<td>29,095</td>
<td>106,012</td>
<td>3,342</td>
<td>-</td>
<td>134</td>
</tr>
<tr>
<td>Pneumonia PPT</td>
<td>10,246</td>
<td>9,755</td>
<td>18,352</td>
<td>221,280</td>
<td>-</td>
<td>-</td>
<td>152,526</td>
<td>7,295,535</td>
<td>16,517</td>
<td>-</td>
<td>6,735</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>10,246</td>
<td>9,755</td>
<td>18,352</td>
<td>221,280</td>
<td>-</td>
<td>-</td>
<td>152,526</td>
<td>4,298,998</td>
<td>16,517</td>
<td>-</td>
<td>6,735</td>
</tr>
<tr>
<td>Pneumonia PPT Provided</td>
<td>4,136</td>
<td>4,000</td>
<td>6,157</td>
<td>31,609</td>
<td>5,654</td>
<td>9%</td>
<td>38,483</td>
<td>200,312</td>
<td>6,157</td>
<td>-</td>
<td>4,242</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>2,237</td>
<td>2,158</td>
<td>4,256</td>
<td>17,650</td>
<td>2,965</td>
<td>44%</td>
<td>21,771</td>
<td>84,102</td>
<td>4,258</td>
<td>-</td>
<td>2,048</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>1,899</td>
<td>1,842</td>
<td>1,899</td>
<td>13,959</td>
<td>2,689</td>
<td>(20)%</td>
<td>16,712</td>
<td>113,710</td>
<td>1,899</td>
<td>-</td>
<td>2,194</td>
</tr>
<tr>
<td>Positive RDTs</td>
<td>11,136</td>
<td>20,144</td>
<td>19,007</td>
<td>593,946</td>
<td>4,390</td>
<td>333%</td>
<td>190,515</td>
<td>2,515,862</td>
<td>19,007</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>228</td>
<td>224</td>
<td>251</td>
<td>4,585</td>
<td>525</td>
<td>(52)%</td>
<td>4,386</td>
<td>43,874</td>
<td>251</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>-</td>
<td>14,222</td>
<td>-</td>
<td>209,952</td>
<td>-</td>
<td>-</td>
<td>155,419</td>
<td>155,419</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>68</td>
<td>122</td>
<td>166</td>
<td>4,000</td>
<td>611</td>
<td>(73)%</td>
<td>1,967</td>
<td>40,706</td>
<td>166</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>10,840</td>
<td>5,578</td>
<td>18,590</td>
<td>375,409</td>
<td>3,254</td>
<td>471%</td>
<td>28,743</td>
<td>2,235,505</td>
<td>18,590</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Positive RDTs Given First Line Treatment</td>
<td>285</td>
<td>13,744</td>
<td>396</td>
<td>197,356</td>
<td>1,023</td>
<td>(61)%</td>
<td>150,437</td>
<td>2,295,888</td>
<td>396</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>228</td>
<td>221</td>
<td>251</td>
<td>4,585</td>
<td>500</td>
<td>(50)%</td>
<td>4,242</td>
<td>39,095</td>
<td>251</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>-</td>
<td>13,425</td>
<td>-</td>
<td>188,956</td>
<td>-</td>
<td>-</td>
<td>144,641</td>
<td>144,641</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>57</td>
<td>97</td>
<td>145</td>
<td>3,815</td>
<td>523</td>
<td>(72)%</td>
<td>1,554</td>
<td>37,247</td>
<td>145</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Pregnancy Test</td>
<td>66,750</td>
<td>22,013</td>
<td>92,090</td>
<td>1,127,372</td>
<td>58,716</td>
<td>57%</td>
<td>313,592</td>
<td>1,911,806</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Acceleration Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>10,900</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>222,334</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>981,357</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>-</td>
<td>-</td>
<td>100,752</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>222,334</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Social Enterprise</td>
<td>66,750</td>
<td>22,013</td>
<td>92,090</td>
<td>1,015,720</td>
<td>58,718</td>
<td>57%</td>
<td>313,592</td>
<td>981,357</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Inactive</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PrEP</td>
<td>3,885</td>
<td>4,062</td>
<td>8,179</td>
<td>66,130</td>
<td>7,097</td>
<td>15%</td>
<td>46,921</td>
<td>92,653</td>
<td>682</td>
<td>-</td>
<td>254</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>55</td>
<td>67</td>
<td>110</td>
<td>823</td>
<td>-</td>
<td>-</td>
<td>547</td>
<td>657</td>
<td>9</td>
<td>-</td>
<td>5</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>3,830</td>
<td>3,995</td>
<td>8,069</td>
<td>64,162</td>
<td>7,097</td>
<td>14%</td>
<td>46,374</td>
<td>91,996</td>
<td>672</td>
<td>-</td>
<td>249</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PUR</td>
<td>7,714,120</td>
<td>5,490,468</td>
<td>17,915,140</td>
<td>48,073,067</td>
<td>9,928,130</td>
<td>80%</td>
<td>62,788,252</td>
<td>712,232,719</td>
<td>147,248</td>
<td>-</td>
<td>436</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>3,337,000</td>
<td>1,829,173</td>
<td>8,264,695</td>
<td>16,073,067</td>
<td>3,865,000</td>
<td>114%</td>
<td>30,213,032</td>
<td>364,360,269</td>
<td>67,929</td>
<td>-</td>
<td>241</td>
</tr>
<tr>
<td>Inactive</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>QAACTs Provided after Confirmatory Diagnosis</td>
<td>425</td>
<td>17,464</td>
<td>18,980</td>
<td>97,722</td>
<td>24,574</td>
<td>(23)%</td>
<td>60,929</td>
<td>2,286,402</td>
<td>18,980</td>
<td>-</td>
<td>3,146</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>37</td>
<td>17,253</td>
<td>18,509</td>
<td>92,151</td>
<td>23,955</td>
<td>(23)%</td>
<td>58,000</td>
<td>197,054</td>
<td>18,509</td>
<td>-</td>
<td>3,046</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>34</td>
<td>82</td>
<td>117</td>
<td>3,514</td>
<td>324</td>
<td>(64)%</td>
<td>1,181</td>
<td>36,748</td>
<td>117</td>
<td>-</td>
<td>21</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>354</td>
<td>129</td>
<td>354</td>
<td>2,057</td>
<td>295</td>
<td>20%</td>
<td>1,748</td>
<td>2,038,953</td>
<td>354</td>
<td>-</td>
<td>80</td>
</tr>
<tr>
<td>Referral to Advanced Cervical Cancer Treatment</td>
<td>-</td>
<td>1</td>
<td>0</td>
<td>10</td>
<td>(100)%</td>
<td>62</td>
<td>479</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to CD4/Clinical Staging</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.
## Monthly Distribution by Product

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>18</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>143</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to Clinical Staging</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>18,909</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>3,364</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>15,545</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to Diabetes Management (gestational)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>67</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>67</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to Diabetes Management (non-gestational)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to Early Infant Male Circumcision</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>94</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>94</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to Emergency Contraception</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>2%</td>
<td>2</td>
<td>253</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>1</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>2</td>
<td>110</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to HIV Testing Services</td>
<td>5,941</td>
<td>1,871</td>
<td>8,999</td>
<td>50,096</td>
<td>5,352</td>
<td>68%</td>
<td>55,718</td>
<td>375,175</td>
<td>8,999</td>
<td>279</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>21,265</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>5,941</td>
<td>1,871</td>
<td>8,996</td>
<td>50,096</td>
<td>5,352</td>
<td>68%</td>
<td>34,434</td>
<td>241,693</td>
<td>8,998</td>
<td>279</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>17,256</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>3</td>
<td>(67)%</td>
<td>17</td>
<td>35,720</td>
<td>1</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>33,366</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to Hypertension Management</td>
<td>49</td>
<td>30</td>
<td>97</td>
<td>-</td>
<td>43</td>
<td>126%</td>
<td>336</td>
<td>1,563</td>
<td>97</td>
<td>-</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>49</td>
<td>30</td>
<td>97</td>
<td>-</td>
<td>43</td>
<td>126%</td>
<td>336</td>
<td>1,563</td>
<td>97</td>
<td>-</td>
</tr>
<tr>
<td>Referral to Implant 3 Insertion</td>
<td>155</td>
<td>213</td>
<td>471</td>
<td>114</td>
<td>311</td>
<td>51%</td>
<td>2,357</td>
<td>20,399</td>
<td>471</td>
<td>589</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>996</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>86</td>
<td>258</td>
<td>114</td>
<td>-</td>
<td>293</td>
<td>8,506</td>
<td>258</td>
<td>323</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>155</td>
<td>127</td>
<td>213</td>
<td>-</td>
<td>311</td>
<td>(32)%</td>
<td>2,064</td>
<td>6,044</td>
<td>213</td>
<td>266</td>
</tr>
</tbody>
</table>

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.
### Monthly Distribution by Product

**Period:** 2  
**Year:** 2020

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Foundation Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1,674</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Inactive</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>3,178</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Referral to Implant 5 Insertion</strong></td>
<td><strong>5</strong></td>
<td>31</td>
<td>24</td>
<td>77 (69%)</td>
<td>579</td>
<td>20,332</td>
<td>24</td>
<td>46</td>
<td>27</td>
<td>-</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>584</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>-</td>
<td>5</td>
<td>16</td>
<td>-</td>
<td>-</td>
<td>11</td>
<td>3,623</td>
<td>16</td>
<td>30</td>
<td>25</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>4,681</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>5</td>
<td>26</td>
<td>8</td>
<td>77 (90%)</td>
<td>568</td>
<td>1,835</td>
<td>8</td>
<td>15</td>
<td>2</td>
<td>-</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>9,606</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Referral to Implant Insertion (duration unknown)</strong></td>
<td><strong>4</strong></td>
<td>3</td>
<td>6</td>
<td>20 (100%)</td>
<td>114</td>
<td>5</td>
<td>6</td>
<td>1</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>89</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>4</td>
<td>3</td>
<td>5</td>
<td>20 (100%)</td>
<td>25</td>
<td>5</td>
<td>6</td>
<td>1</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Referral to Injectable (duration unknown)</strong></td>
<td><strong>1</strong></td>
<td>4</td>
<td>1</td>
<td>1 (100%)</td>
<td>773</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>110</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>663</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Referral to Injectable 1</strong></td>
<td><strong>3</strong></td>
<td>390</td>
<td>997</td>
<td>851</td>
<td>105</td>
<td>850%</td>
<td>1,952</td>
<td>26,422</td>
<td>249</td>
<td>125</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>-</td>
<td>330</td>
<td>989</td>
<td>851</td>
<td>-</td>
<td>887</td>
<td>8,823</td>
<td>247</td>
<td>124</td>
<td>76</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>8,596</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>3</td>
<td>60</td>
<td>8</td>
<td>105 (92%)</td>
<td>1,065</td>
<td>9,003</td>
<td>2</td>
<td>1</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Referral to Injectable 2</strong></td>
<td><strong>2</strong></td>
<td>2</td>
<td>4</td>
<td>56 (100%)</td>
<td>56</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>56</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Referral to Injectable 3</strong></td>
<td><strong>3</strong></td>
<td>390</td>
<td>997</td>
<td>851</td>
<td>105</td>
<td>850%</td>
<td>1,952</td>
<td>26,422</td>
<td>249</td>
<td>125</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>-</td>
<td>330</td>
<td>989</td>
<td>851</td>
<td>-</td>
<td>887</td>
<td>8,823</td>
<td>247</td>
<td>124</td>
<td>76</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>8,596</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>3</td>
<td>60</td>
<td>8</td>
<td>105 (92%)</td>
<td>1,065</td>
<td>9,003</td>
<td>2</td>
<td>1</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Referral to IUD 10 Insertion</strong></td>
<td><strong>180</strong></td>
<td>169</td>
<td>228</td>
<td>297 (24%)</td>
<td>2,354</td>
<td>135,842</td>
<td>225</td>
<td>517</td>
<td>76</td>
<td>-</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>8,256</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>-</td>
<td>2</td>
<td>7</td>
<td>2 (100%)</td>
<td>4</td>
<td>24,183</td>
<td>7</td>
<td>16</td>
<td>13</td>
<td>-</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>6,239</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

*(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.*
# POPULATION SERVICES INTERNATIONAL

## Monthly Distribution by Product

**Period:** 2  
**Year:** 2020

<table>
<thead>
<tr>
<th>Product Description</th>
<th>YTD Users Reached 2020</th>
<th>YTD CYP 2020</th>
<th>YTD DALY 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>180</td>
<td>12,702</td>
<td>31,155</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Inactive</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Referral to IUD 5 Insertion</strong></td>
<td>8</td>
<td>3</td>
<td>12</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>8</td>
<td>3</td>
<td>12</td>
</tr>
<tr>
<td><strong>Referral to IUS 3 Insertion</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Referral to Linkage to HIV Care</strong></td>
<td>16,409</td>
<td>31,155</td>
<td>218,997</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>16,158</td>
<td>30,651</td>
<td>1,660</td>
</tr>
<tr>
<td><strong>Referral to Manual Vacuum Aspiration - PAC</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>251</td>
<td>504</td>
<td>83</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Inactive</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Referral to Medication Abortion</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Referral to OCs</strong></td>
<td>-</td>
<td>90</td>
<td>55</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>-</td>
<td>46</td>
<td>55</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>-</td>
<td>44</td>
<td>83</td>
</tr>
<tr>
<td><strong>Referral to Opioid Treatment</strong></td>
<td>2</td>
<td>4</td>
<td>10</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>2</td>
<td>4</td>
<td>3</td>
<td>10</td>
<td>(70)%</td>
<td>84</td>
<td>559</td>
<td>3</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to PAC Service (unknown)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to Pre-Exposure Prophylaxis (PrEP)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>3</td>
<td>253</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to STI Diagnosis (lab confirmed)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>332</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to STI Screening (syndromic)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>14,419</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to STI Treatment (unknown)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>9,012</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to TB Diagnosis</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>3,963</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>3,898</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>4,864</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to TB DOTS (completion confirmed)</td>
<td>79</td>
<td>63</td>
<td>129</td>
<td>1,832</td>
<td>165</td>
<td>(22)%</td>
<td>1,101</td>
<td>4,756</td>
<td>129</td>
<td>-</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>45</td>
<td>54</td>
<td>95</td>
<td>1,600</td>
<td>130</td>
<td>(27)%</td>
<td>1,020</td>
<td>3,961</td>
<td>95</td>
<td>-</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>34</td>
<td>9</td>
<td>34</td>
<td>232</td>
<td>35</td>
<td>(3)%</td>
<td>81</td>
<td>776</td>
<td>34</td>
<td>-</td>
</tr>
<tr>
<td>Referral to TB DOTS (completion unknown)</td>
<td>72</td>
<td>63</td>
<td>126</td>
<td>1,600</td>
<td>137</td>
<td>(9)%</td>
<td>1,293</td>
<td>11,106</td>
<td>125</td>
<td>-</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>45</td>
<td>63</td>
<td>98</td>
<td>1,600</td>
<td>133</td>
<td>(26)%</td>
<td>1,289</td>
<td>6,443</td>
<td>98</td>
<td>-</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>27</td>
<td>-</td>
<td>27</td>
<td>4</td>
<td>575%</td>
<td>4</td>
<td>275</td>
<td>27</td>
<td>-</td>
<td>8</td>
</tr>
<tr>
<td>Referral to TB Screening</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>59,060</td>
<td>-</td>
<td>-</td>
<td>115,621</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

\(\text{a}\)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.
<table>
<thead>
<tr>
<th>Referral to Treatment</th>
<th>Acceleration Market Group</th>
<th>Anglophone Africa Market Group</th>
<th>Latin America &amp; Asia Market Group</th>
<th>Anglophone Africa Market Group</th>
<th>Anglophone Africa Market Group</th>
<th>Anglophone Africa Market Group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cervicitis</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Genital Herpes</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Inguinal Bubo</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Lower Abdominal Pain</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Urethral Discharge (Men)</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Vaginitis</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Tubal Ligation</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Nonherpetic Genital Ulcer</td>
<td>1</td>
<td>(100)</td>
<td>1</td>
<td>(100)</td>
<td>1</td>
<td>(100)</td>
</tr>
<tr>
<td>Urethral Discharge (Women)</td>
<td>4</td>
<td>(100)</td>
<td>10</td>
<td>2,480</td>
<td>10</td>
<td>2,480</td>
</tr>
<tr>
<td>Vasectomy</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Voluntary Medical Male Circumcision</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

(1) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.
### Monthly Distribution by Product

**Period:** 2  
**Year:** 2020

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Anglophone Africa Market Group</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Retreatment</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Acceleration Market Group</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Anglophone Africa Market Group</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Franco/Lusophone Africa Market Group</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Latin America &amp; Asia Market Group</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Foundation Market Group</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Inactive</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Retreatment IconMaxx</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Anglophone Africa Market Group</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Latin America &amp; Asia Market Group</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Retreatment KO123</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Acceleration Market Group</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Anglophone Africa Market Group</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Franco/Lusophone Africa Market Group</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Retreatment KO123 net</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Anglophone Africa Market Group</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Safe Injection Kit</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Latin America &amp; Asia Market Group</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Acceleration Market Group</strong></td>
<td>125,136</td>
<td>98,620</td>
<td>286,224</td>
<td>1,500,000</td>
<td>297,324</td>
<td>(4)%</td>
<td>1,418,258</td>
<td>34,694,126</td>
<td>235,253</td>
<td>-</td>
</tr>
<tr>
<td><strong>Anglophone Africa Market Group</strong></td>
<td>46,872</td>
<td>64,713</td>
<td>91,824</td>
<td>1,485,515</td>
<td>287,578</td>
<td>(6)%</td>
<td>1,052,196</td>
<td>83,496,492</td>
<td>75,472</td>
<td>-</td>
</tr>
<tr>
<td><strong>Franco/Lusophone Africa Market Group</strong></td>
<td>137,103</td>
<td>145,356</td>
<td>365,967</td>
<td>1,400,000</td>
<td>81,360</td>
<td>350%</td>
<td>1,581,666</td>
<td>14,676,754</td>
<td>300,795</td>
<td>-</td>
</tr>
<tr>
<td><strong>Latin America &amp; Asia Market Group</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Foundation Market Group</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Inactive</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

3004 - 4/15/2020 10:11:33AM Page 27 of 34
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>SD NVP w/o Baby ARV Prophylaxis</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>SD NVP with Baby ARV Prophylaxis</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>SDM (Cycle Beads)</td>
<td>3</td>
<td>(12)</td>
<td>(2)</td>
<td>22,600</td>
<td>(30)</td>
<td>-</td>
<td>1,264</td>
<td>628,867</td>
<td>(2)</td>
<td>(3)</td>
<td>(1)</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>6</td>
<td>(4)</td>
<td>6</td>
<td>2,600</td>
<td>9 (33%)</td>
<td>-</td>
<td>1,449</td>
<td>49,484</td>
<td>5</td>
<td>8</td>
<td>6</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>2,494</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>(3)</td>
<td>(8)</td>
<td>(8)</td>
<td>-</td>
<td>(39)</td>
<td>-</td>
<td>(185)</td>
<td>351,093</td>
<td>(7)</td>
<td>(11)</td>
<td>(7)</td>
</tr>
<tr>
<td>Inactive</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>15,756</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>SDM (Cycle Beads) Provided</td>
<td>739</td>
<td>1,119</td>
<td>1,666</td>
<td>152</td>
<td>73</td>
<td>2,182%</td>
<td>6,967</td>
<td>21,298</td>
<td>1,666</td>
<td>2,499</td>
<td>1,955</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>686</td>
<td>1,097</td>
<td>1,600</td>
<td>-</td>
<td>20</td>
<td>7,900%</td>
<td>6,606</td>
<td>8,209</td>
<td>1,600</td>
<td>2,400</td>
<td>1,851</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>10</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>14</td>
<td>4</td>
<td>14</td>
<td>-</td>
<td>11</td>
<td>27%</td>
<td>110</td>
<td>521</td>
<td>14</td>
<td>21</td>
<td>16</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>2,494</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>39</td>
<td>19</td>
<td>52</td>
<td>152</td>
<td>41</td>
<td>27%</td>
<td>247</td>
<td>12,426</td>
<td>52</td>
<td>78</td>
<td>88</td>
</tr>
<tr>
<td>Seasonal Malaria Chemoprevention</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>4,420,982</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>344,748</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>4,076,234</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Seasonal Malaria Chemoprevention_children reached</td>
<td>-</td>
<td>1,590,938</td>
<td>-</td>
<td>5,288,964</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>4,772,814</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>-</td>
<td>926,912</td>
<td>-</td>
<td>2,791,734</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>2,780,737</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>-</td>
<td>664,026</td>
<td>-</td>
<td>2,497,230</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1,992,077</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Skilled Birth Attendance</td>
<td>5,155</td>
<td>5,330</td>
<td>8,888</td>
<td>40,731</td>
<td>6,035</td>
<td>47%</td>
<td>45,944</td>
<td>210,598</td>
<td>8,888</td>
<td>-</td>
<td>8,922</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>2,552</td>
<td>3,528</td>
<td>6,244</td>
<td>25,000</td>
<td>3,541</td>
<td>76%</td>
<td>25,406</td>
<td>93,816</td>
<td>6,244</td>
<td>-</td>
<td>5,190</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>50,567</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>183</td>
<td>76</td>
<td>224</td>
<td>-</td>
<td>255</td>
<td>(12)%</td>
<td>1,560</td>
<td>28,119</td>
<td>224</td>
<td>-</td>
<td>284</td>
</tr>
</tbody>
</table>

The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>STI Kit</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>2,420</td>
<td>1,727</td>
<td>2,420</td>
<td>15,731</td>
<td>2,239</td>
<td>18,979</td>
<td>38,094</td>
<td>2,420</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Inactive</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>STI Kit (Non-Ulcerative)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>1,560</td>
<td>372</td>
<td>1,560</td>
<td>2,066</td>
<td>2,067</td>
<td>(25)%</td>
<td>4,732</td>
<td>4,024,460</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>1,560</td>
<td>372</td>
<td>1,560</td>
<td>2,066</td>
<td>2,067</td>
<td>(25)%</td>
<td>4,732</td>
<td>872,293</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>STI Kit (Ulcerative)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>65</td>
<td>86</td>
<td>65</td>
<td>248</td>
<td>1,115</td>
<td>(94)%</td>
<td>1,588</td>
<td>1,855,807</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>65</td>
<td>86</td>
<td>65</td>
<td>248</td>
<td>1,115</td>
<td>(94)%</td>
<td>1,588</td>
<td>74,345</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>STI Screening</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>11,580</td>
<td>11,045</td>
<td>22,940</td>
<td>158,838</td>
<td>33,809</td>
<td>(32)%</td>
<td>153,919</td>
<td>1,463,247</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>-</td>
<td>897</td>
<td>798</td>
<td>16,000</td>
<td>3,926</td>
<td>(80)%</td>
<td>16,593</td>
<td>91,307</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>9,903</td>
<td>8,796</td>
<td>19,514</td>
<td>141,848</td>
<td>26,777</td>
<td>(27)%</td>
<td>118,274</td>
<td>700,704</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>843</td>
<td>619</td>
<td>1,459</td>
<td>-</td>
<td>1,726</td>
<td>(15)%</td>
<td>9,457</td>
<td>41,902</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>22</td>
<td>22</td>
<td>49</td>
<td>-</td>
<td>19</td>
<td>158%</td>
<td>265</td>
<td>4,304</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>812</td>
<td>710</td>
<td>1,120</td>
<td>990</td>
<td>1,361</td>
<td>(18)%</td>
<td>9,330</td>
<td>624,532</td>
</tr>
<tr>
<td>Inactive</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>TB Diagnosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>6,818</td>
<td>3,552</td>
<td>9,857</td>
<td>33,252</td>
<td>8,598</td>
<td>12%</td>
<td>52,626</td>
<td>286,140</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>950</td>
<td>1,067</td>
<td>1,264</td>
<td>14,326</td>
<td>1,275</td>
<td>(1)%</td>
<td>13,610</td>
<td>102,269</td>
</tr>
</tbody>
</table>

**Note:** The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.
### Monthly Distribution by Product

#### Period: 2
#### Year: 2020

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Anglophone Africa Market Group</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>25</td>
<td>40</td>
<td>240</td>
<td>35</td>
<td>14%</td>
<td>231</td>
<td>1,748</td>
<td>40</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Latin America &amp; Asia Market Group</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2,947</td>
<td>2,461</td>
<td>5,448</td>
<td>850</td>
<td>4,116</td>
<td>32%</td>
<td>28,670</td>
<td>119,754</td>
<td>5,448</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Foundation Market Group</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2,905</td>
<td>-</td>
<td>2,905</td>
<td>17,836</td>
<td>3,172</td>
<td>(8)%</td>
<td>10,115</td>
<td>52,150</td>
<td>2,905</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Inactive</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>10,219</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>TB DOTS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5,197</td>
<td>2,938</td>
<td>7,721</td>
<td>29,486</td>
<td>9,839</td>
<td>(22)%</td>
<td>49,491</td>
<td>441,778</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Acceleration Market Group</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>724</td>
<td>946</td>
<td>1,626</td>
<td>11,614</td>
<td>1,887</td>
<td>(14)%</td>
<td>12,584</td>
<td>236,071</td>
<td>1,626</td>
<td>-</td>
<td>10,086</td>
</tr>
<tr>
<td><strong>Anglophone Africa Market Group</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>3</td>
<td>6</td>
<td>36</td>
<td>4</td>
<td>50%</td>
<td>35</td>
<td>142</td>
<td>6</td>
<td>-</td>
<td>49</td>
</tr>
<tr>
<td><strong>Latin America &amp; Asia Market Group</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1,813</td>
<td>1,989</td>
<td>3,521</td>
<td>-</td>
<td>4,047</td>
<td>(13)%</td>
<td>25,764</td>
<td>143,092</td>
<td>3,521</td>
<td>-</td>
<td>16,114</td>
</tr>
<tr>
<td><strong>Foundation Market Group</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2,568</td>
<td>-</td>
<td>2,568</td>
<td>17,836</td>
<td>3,901</td>
<td>(34)%</td>
<td>11,108</td>
<td>56,710</td>
<td>2,568</td>
<td>-</td>
<td>8,790</td>
</tr>
<tr>
<td><strong>Inactive</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>5,763</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>TB Screening</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>44,836</td>
<td>31,863</td>
<td>72,342</td>
<td>621,979</td>
<td>86,258</td>
<td>(16)%</td>
<td>464,241</td>
<td>2,716,863</td>
<td>72,342</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Acceleration Market Group</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7,434</td>
<td>5,892</td>
<td>9,796</td>
<td>298,198</td>
<td>21,553</td>
<td>(55)%</td>
<td>118,645</td>
<td>608,840</td>
<td>9,796</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Anglophone Africa Market Group</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20,234</td>
<td>18,950</td>
<td>39,742</td>
<td>243,349</td>
<td>40,423</td>
<td>(2)%</td>
<td>241,495</td>
<td>1,732,262</td>
<td>39,742</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Latin America &amp; Asia Market Group</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6,596</td>
<td>7,022</td>
<td>12,232</td>
<td>3,764</td>
<td>9,349</td>
<td>31%</td>
<td>65,241</td>
<td>218,989</td>
<td>12,232</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Foundation Market Group</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10,572</td>
<td>-</td>
<td>10,572</td>
<td>76,668</td>
<td>14,933</td>
<td>(29)%</td>
<td>38,660</td>
<td>149,633</td>
<td>10,572</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Inactive</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>7,139</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Toilets Constructed</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>16,479</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Acceleration Market Group</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>12,802</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Franco/Lusophone Africa Market Group</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>5</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Foundation Market Group</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>3,672</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Toilets Sold</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7,945</td>
<td>6,897</td>
<td>11,493</td>
<td>90,011</td>
<td>14,341</td>
<td>(20)%</td>
<td>105,669</td>
<td>385,673</td>
<td>56,873</td>
<td>-</td>
<td>2,171</td>
</tr>
<tr>
<td><strong>Acceleration Market Group</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-</td>
<td>2,812</td>
<td>-</td>
<td>44,280</td>
<td>11,363</td>
<td>(100)%</td>
<td>68,647</td>
<td>314,891</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Anglophone Africa Market Group</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4,382</td>
<td>2,211</td>
<td>7,071</td>
<td>31,656</td>
<td>1,468</td>
<td>382%</td>
<td>20,460</td>
<td>33,181</td>
<td>32,048</td>
<td>-</td>
<td>1,228</td>
</tr>
<tr>
<td><strong>Franco/Lusophone Africa Market Group</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3,553</td>
<td>1,868</td>
<td>4,404</td>
<td>14,075</td>
<td>1,094</td>
<td>302%</td>
<td>15,356</td>
<td>23,777</td>
<td>24,725</td>
<td>-</td>
<td>939</td>
</tr>
<tr>
<td><strong>Latin America &amp; Asia Market Group</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>410</td>
<td>(100)%</td>
<td>1,113</td>
<td>7,416</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Foundation Market Group</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>6</td>
<td>16</td>
<td>-</td>
<td>6</td>
<td>199%</td>
<td>93</td>
<td>6,406</td>
<td>101</td>
<td>-</td>
<td>4</td>
</tr>
<tr>
<td><strong>Toilets Sold - All</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15,728</td>
<td>11,748</td>
<td>26,326</td>
<td>-</td>
<td>15,521</td>
<td>70%</td>
<td>127,071</td>
<td>222,426</td>
<td>124,989</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Acceleration Market Group</td>
<td>6,006</td>
<td>6,437</td>
<td>10,720</td>
<td>-</td>
<td>11,363</td>
<td>(6)%</td>
<td>74,806</td>
<td>135,891</td>
<td>51,456</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>5,336</td>
<td>2,947</td>
<td>10,055</td>
<td>-</td>
<td>2,031</td>
<td>395%</td>
<td>27,092</td>
<td>44,413</td>
<td>42,791</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>4,182</td>
<td>2,236</td>
<td>5,198</td>
<td>-</td>
<td>1,599</td>
<td>225%</td>
<td>22,150</td>
<td>33,074</td>
<td>28,730</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>410</td>
<td>(100)%</td>
<td>1,113</td>
<td>5,272</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>202</td>
<td>127</td>
<td>353</td>
<td>-</td>
<td>118</td>
<td>199%</td>
<td>1,908</td>
<td>3,776</td>
<td>2,012</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Cervicitis</td>
<td>13</td>
<td>18</td>
<td>28</td>
<td>132</td>
<td>42</td>
<td>(33)%</td>
<td>316</td>
<td>763</td>
<td>28</td>
<td>-</td>
<td>2</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>9</td>
<td>12</td>
<td>20</td>
<td>132</td>
<td>16</td>
<td>25%</td>
<td>193</td>
<td>576</td>
<td>20</td>
<td>-</td>
<td>2</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>-</td>
<td>2</td>
<td>-</td>
<td>-</td>
<td>6</td>
<td>(100)%</td>
<td>29</td>
<td>42</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>4</td>
<td>4</td>
<td>8</td>
<td>-</td>
<td>20</td>
<td>(60)%</td>
<td>94</td>
<td>145</td>
<td>8</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Genital Herpes</td>
<td>83</td>
<td>39</td>
<td>106</td>
<td>48</td>
<td>131</td>
<td>(20)%</td>
<td>612</td>
<td>888</td>
<td>105</td>
<td>-</td>
<td>1</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>21</td>
<td>20</td>
<td>39</td>
<td>48</td>
<td>655%</td>
<td>135</td>
<td>273</td>
<td>39</td>
<td>-</td>
<td>1</td>
<td>-</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>62</td>
<td>19</td>
<td>66</td>
<td>-</td>
<td>124</td>
<td>(47)%</td>
<td>476</td>
<td>606</td>
<td>66</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>(100)%</td>
<td>1</td>
<td>9</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Inguinal Bubo</td>
<td>11</td>
<td>7</td>
<td>18</td>
<td>16</td>
<td>12</td>
<td>50%</td>
<td>99</td>
<td>337</td>
<td>18</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>16</td>
<td>-</td>
<td>18</td>
<td>35</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>8</td>
<td>4</td>
<td>12</td>
<td>-</td>
<td>6</td>
<td>100%</td>
<td>55</td>
<td>134</td>
<td>12</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>3</td>
<td>2</td>
<td>6</td>
<td>-</td>
<td>6</td>
<td>-</td>
<td>26</td>
<td>168</td>
<td>6</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Lower Abdominal Pain</td>
<td>151</td>
<td>132</td>
<td>252</td>
<td>119</td>
<td>263</td>
<td>(4)%</td>
<td>1,963</td>
<td>5,592</td>
<td>252</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>30</td>
<td>43</td>
<td>56</td>
<td>119</td>
<td>22</td>
<td>155%</td>
<td>465</td>
<td>734</td>
<td>56</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>84</td>
<td>56</td>
<td>137</td>
<td>-</td>
<td>174</td>
<td>(21)%</td>
<td>997</td>
<td>2,201</td>
<td>137</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>(100)%</td>
<td>7</td>
<td>7</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>37</td>
<td>32</td>
<td>59</td>
<td>-</td>
<td>66</td>
<td>(11)%</td>
<td>494</td>
<td>2,650</td>
<td>59</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Nonherpetic Genital Ulcer</td>
<td>206</td>
<td>188</td>
<td>392</td>
<td>513</td>
<td>374</td>
<td>5%</td>
<td>2,444</td>
<td>19,363</td>
<td>392</td>
<td>-</td>
<td>74</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>57</td>
<td>42</td>
<td>98</td>
<td>513</td>
<td>95</td>
<td>3%</td>
<td>663</td>
<td>1,907</td>
<td>98</td>
<td>-</td>
<td>35</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>100</td>
<td>104</td>
<td>220</td>
<td>-</td>
<td>167</td>
<td>32%</td>
<td>1,093</td>
<td>3,102</td>
<td>220</td>
<td>-</td>
<td>32</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>2</td>
<td>1</td>
<td>5</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>2</td>
<td>9</td>
<td>5</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>47</td>
<td>41</td>
<td>69</td>
<td>-</td>
<td>112</td>
<td>(38)%</td>
<td>686</td>
<td>14,345</td>
<td>69</td>
<td>-</td>
<td>8</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.
### Monthly Distribution by Product

**Period:** 2  
**Year:** 2020

<table>
<thead>
<tr>
<th>Product Description</th>
<th>AVG DISTRIBUTION 2020</th>
<th>AVG DISTRIBUTION 2019</th>
<th>AVG DISTRIBUTION CHANGE</th>
<th>CUMULATIVE DISTRIBUTION</th>
<th>USERS REACHED 2020</th>
<th>USERS REACHED 2019</th>
<th>CYP 2020</th>
<th>DALY 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment for Pre-Eclampsia (with MgSO4)</td>
<td>92</td>
<td>63</td>
<td>111</td>
<td>313</td>
<td>43</td>
<td>158%</td>
<td>453</td>
<td>1,077</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>13</td>
<td>13</td>
<td>32</td>
<td>-</td>
<td>5</td>
<td>540%</td>
<td>43</td>
<td>245</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>79</td>
<td>50</td>
<td>79</td>
<td>313</td>
<td>38</td>
<td>108%</td>
<td>410</td>
<td>832</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>1,294</strong></td>
<td><strong>548</strong></td>
<td><strong>1,294</strong></td>
<td><strong>6,773</strong></td>
<td><strong>389</strong></td>
<td><strong>233%</strong></td>
<td><strong>6,999</strong></td>
<td><strong>62,836</strong></td>
</tr>
<tr>
<td>Treatment for Severe Acute Malnutrition</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>4</td>
<td>-</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>1,294</strong></td>
<td><strong>548</strong></td>
<td><strong>1,294</strong></td>
<td><strong>6,773</strong></td>
<td><strong>389</strong></td>
<td><strong>233%</strong></td>
<td><strong>6,999</strong></td>
<td><strong>62,836</strong></td>
</tr>
<tr>
<td>Treatment for Urethral Discharge (Men)</td>
<td>572</td>
<td>517</td>
<td>976</td>
<td>487</td>
<td>1,073</td>
<td>(9)%</td>
<td>6,451</td>
<td>24,504</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>97</td>
<td>71</td>
<td>170</td>
<td>487</td>
<td>77</td>
<td>121%</td>
<td>741</td>
<td>1,813</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>182</td>
<td>167</td>
<td>369</td>
<td>-</td>
<td>433</td>
<td>(15)%</td>
<td>2,005</td>
<td>5,330</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>293</td>
<td>279</td>
<td>439</td>
<td>-</td>
<td>563</td>
<td>(22)%</td>
<td>3,705</td>
<td>17,361</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>358</strong></td>
<td><strong>452</strong></td>
<td><strong>860</strong></td>
<td><strong>676</strong></td>
<td><strong>824</strong></td>
<td><strong>4%</strong></td>
<td><strong>4,783</strong></td>
<td><strong>10,714</strong></td>
</tr>
<tr>
<td>Treatment for Urethral Discharge (Women)</td>
<td>538</td>
<td>452</td>
<td>860</td>
<td>676</td>
<td>824</td>
<td>4%</td>
<td>4,783</td>
<td>10,714</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>138</td>
<td>104</td>
<td>226</td>
<td>676</td>
<td>90</td>
<td>151%</td>
<td>1,141</td>
<td>2,890</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>400</td>
<td>254</td>
<td>634</td>
<td>-</td>
<td>734</td>
<td>(14)%</td>
<td>3,359</td>
<td>7,516</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>9</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>-</td>
<td>94</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>282</td>
<td>297</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>538</strong></td>
<td><strong>452</strong></td>
<td><strong>860</strong></td>
<td><strong>676</strong></td>
<td><strong>824</strong></td>
<td><strong>4%</strong></td>
<td><strong>4,783</strong></td>
<td><strong>10,714</strong></td>
</tr>
<tr>
<td>Treatment for Vaginitis</td>
<td>259</td>
<td>238</td>
<td>406</td>
<td>336</td>
<td>653</td>
<td>(38)%</td>
<td>3,931</td>
<td>18,617</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>23</td>
<td>16</td>
<td>35</td>
<td>336</td>
<td>131</td>
<td>(73)%</td>
<td>351</td>
<td>2,598</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>150</td>
<td>159</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>16</td>
<td>17</td>
<td>36</td>
<td>-</td>
<td>54</td>
<td>(33)%</td>
<td>217</td>
<td>281</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>219</td>
<td>201</td>
<td>333</td>
<td>-</td>
<td>468</td>
<td>(29)%</td>
<td>3,213</td>
<td>15,579</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>259</strong></td>
<td><strong>238</strong></td>
<td><strong>406</strong></td>
<td><strong>336</strong></td>
<td><strong>653</strong></td>
<td><strong>38%</strong></td>
<td><strong>3,931</strong></td>
<td><strong>18,617</strong></td>
</tr>
<tr>
<td>Tubal Ligation</td>
<td>10,298</td>
<td>7,557</td>
<td>16,866</td>
<td>40,731</td>
<td>10,707</td>
<td>58%</td>
<td>63,831</td>
<td>452,253</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>9,637</td>
<td>6,600</td>
<td>15,915</td>
<td>33,550</td>
<td>9,344</td>
<td>70%</td>
<td>44,513</td>
<td>142,643</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>661</td>
<td>727</td>
<td>951</td>
<td>7,158</td>
<td>1,018</td>
<td>(7)%</td>
<td>10,713</td>
<td>47,478</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>-</td>
<td>229</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>8,574</td>
<td>261,781</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>-</td>
<td>1</td>
<td>23</td>
<td>1</td>
<td>(100)%</td>
<td>-</td>
<td>31</td>
<td>147</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>0</td>
<td>9</td>
<td>1</td>
<td>27</td>
<td>1,463</td>
<td>-</td>
<td>1</td>
<td>-</td>
</tr>
</tbody>
</table>

*The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.*
<table>
<thead>
<tr>
<th>Product</th>
<th>2019</th>
<th>2020</th>
<th>Change %</th>
<th>YTD CYP 2020</th>
<th>YTD DALY 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type 2 Diabetes Screening</td>
<td></td>
<td></td>
<td>(94)%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Type 2 Diabetes Controlled Condition</td>
<td></td>
<td></td>
<td>100%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vaginal Wash</td>
<td></td>
<td></td>
<td>(99)%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vasectomy</td>
<td></td>
<td></td>
<td>100%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vivax Treatment after Confirmatory Diagnosis</td>
<td></td>
<td></td>
<td>(16)%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Voluntary Medical Male Circumcision</td>
<td></td>
<td></td>
<td>(7)%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Water Treatment Tablets</td>
<td></td>
<td></td>
<td>(31)%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>5,000</td>
<td>2,583</td>
<td>6,000</td>
<td>15,000</td>
<td>50,500</td>
<td>(88)%</td>
<td>74,110</td>
<td>10,833,093</td>
<td>99</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>172,000</td>
<td>232,267</td>
<td>252,000</td>
<td>6,079,936</td>
<td>1,123,360</td>
<td>(78)%</td>
<td>4,854,942</td>
<td>284,771,498</td>
<td>4,142</td>
<td>-</td>
<td>18</td>
</tr>
<tr>
<td>Woman Condom</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>480</td>
<td>(100)%</td>
<td>1,920</td>
<td>141,480</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>480</td>
<td>(100)%</td>
<td>1,920</td>
<td>141,480</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Zika Prevention Kit</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>8,022</td>
<td>873</td>
<td>8,022</td>
<td>32,134</td>
<td>42</td>
<td>19,000%</td>
<td>2,822</td>
<td>7,220,243</td>
<td>7,220</td>
<td>-</td>
<td>32</td>
</tr>
<tr>
<td>Acceleration Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>953,402</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Anglophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>1,034,758</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Franco/Lusophone Africa Market Group</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>669,429</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>6,910</td>
<td>23</td>
<td>6,910</td>
<td>32,134</td>
<td>2</td>
<td>345,400%</td>
<td>132</td>
<td>488,291</td>
<td>6,219</td>
<td>-</td>
<td>27</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>1,112</td>
<td>850</td>
<td>1,112</td>
<td>-</td>
<td>40</td>
<td>2,680%</td>
<td>2,690</td>
<td>4,074,363</td>
<td>1,001</td>
<td>-</td>
<td>5</td>
</tr>
<tr>
<td>Zinc Provided</td>
<td>3,333</td>
<td>2,408</td>
<td>3,333</td>
<td>26,010</td>
<td>4,376</td>
<td>(24)%</td>
<td>28,688</td>
<td>76,930</td>
<td>3,333</td>
<td>-</td>
<td>67</td>
</tr>
<tr>
<td>Foundation Market Group</td>
<td>3,333</td>
<td>2,408</td>
<td>3,333</td>
<td>26,010</td>
<td>4,376</td>
<td>(24)%</td>
<td>28,688</td>
<td>76,930</td>
<td>3,333</td>
<td>-</td>
<td>67</td>
</tr>
</tbody>
</table>

The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.
Acceleration Market Group
<table>
<thead>
<tr>
<th></th>
<th>New HIV Infections</th>
<th>STI Deaths</th>
<th>PWID Deaths</th>
<th>TB Deaths</th>
<th>CYP*</th>
<th>Maternal Deaths</th>
<th>Unintended Pregnancies</th>
<th>Malaria Deaths</th>
<th>Diarrhea Deaths</th>
<th>Pneumonia Deaths</th>
<th>Cervical Cancer Death</th>
<th>Sum of All Deaths</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Acceleration Market Group</strong></td>
<td>6,510</td>
<td>-</td>
<td>-</td>
<td>347</td>
<td>589,260</td>
<td>694</td>
<td>276,303</td>
<td>41</td>
<td>27</td>
<td>24</td>
<td>-</td>
<td>3,608</td>
</tr>
<tr>
<td><strong>India</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>307,432</td>
<td>78</td>
<td>167,900</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>933</td>
</tr>
<tr>
<td><strong>Kenya</strong></td>
<td>3,679</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>163,027</td>
<td>189</td>
<td>62,083</td>
<td>37</td>
<td>12</td>
<td>24</td>
<td>-</td>
<td>1,313</td>
</tr>
<tr>
<td><strong>Myanmar</strong></td>
<td>249</td>
<td>-</td>
<td>-</td>
<td>347</td>
<td>77,833</td>
<td>18</td>
<td>27,663</td>
<td>4</td>
<td>15</td>
<td>-</td>
<td>-</td>
<td>489</td>
</tr>
<tr>
<td><strong>Nigeria</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>19,233</td>
<td>44</td>
<td>8,688</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>260</td>
</tr>
<tr>
<td><strong>PSI Nigeria</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>21,735</td>
<td>365</td>
<td>9,969</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>613</td>
</tr>
<tr>
<td><strong>South Africa</strong></td>
<td>2,582</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

* Using USAID CYP conversion factors
### Monthly Distribution by Market Group and Product

**Period:** 2  
**Year:** 2020

|---------------------------|----------------------|---------------------------|-----------------------|--------------------------|-----------------------|--------------|-------------------------|------------------|-------------------|-------------------|  |  |  |  |
| Antiretroviral Treatment (Currently Enrolled) | 15,821 | 15,582 | 31,802 | 115,209 | 27,179 | 17% | 174,024 | 434,310 | 2,650 | - | 589,260 | 537,336 |
| Antiretroviral Treatment (Newly Enrolled) | 309 | 244 | 503 | 2,916 | 599 | (16)% | 3,744 | 13,833 | 503 | - | - |
| Cervical Cancer-Pap and Cryotherapy | - | 3 | 9 | - | - | -% | - | 9 | 9 | - | - |
| Cervical Cancer-Pap Smear Screening | - | 10 | 31 | - | - | -% | - | 31 | 31 | - | - |
| Cervical Cancer-VIA and Cryotherapy | 8 | 15 | 28 | 360 | 49 | (43)% | 307 | 4,608 | 28 | - | 7 |
| Cervical Cancer-VIA/VILI Screening | 366 | 280 | 600 | 3,000 | 6,039 | (90)% | 37,955 | 326,284 | 600 | - | - |
| Condom | 5,791,331 | 3,069,555 | 7,665,355 | 39,310,200 | 6,351,757 | 21% | 45,303,579 | 1,028,472,982 | 57,490 | 57,490 | 185,089 |
| Diarrhea Treatment Kit Provided | - | - | - | 20,000 | 3,853 | (100)% | 15,147 | 69,404 | - | - | - |
| Emergency Contraception | - | 22 | - | 6,500 | - | -% | - | 1,000 | 1,000 | - | - |
| Emergency Contraception Provided | 15,533 | 12,764 | 23,908 | 48,170 | 1,823 | 1,211% | 75,323 | 103,278 | 1,195 | 1,195 | 183 |
| Fecal Sludge Management (Households) | - | - | - | 573 | 210 | (100)% | 489 | 2,768 | - | - | - |
| Fecal Sludge Management (Litters) | - | - | - | 1,719,000 | 1,050,000 | (100)% | 1,914,000 | 13,071,200 | - | - | - |
| Female Condom | - | - | - | - | 23,460 | (100)% | 85,553 | 1,556,019 | - | - | - |
| Fever Cases Attended | 58,138 | 40,915 | 63,290 | 463,728 | 54,654 | 16% | 520,128 | 3,014,586 | 63,290 | - | - |
| Fever Cases Tested with RDTs | 58,138 | 40,915 | 63,290 | 463,728 | 54,654 | 16% | 520,128 | 3,014,586 | 63,290 | - | - |
| Free Condom | - | 156 | - | 17,310 | 1,049,760 | (100)% | 1,920,960 | 92,418,397 | - | - | - |
| Free Female Condom | 12,263 | 11,987 | 24,208 | 121,000 | - | -% | 49,875 | 74,083 | 182 | 182 | 130 |
| HIV Self-Testing Kit | 8,385 | 6,052 | 17,465 | 425,201 | 23,486 | (26)% | 647,230 | 2,021,117 | 15,719 | - | - |
| HIV Testing Services | 13,895 | 14,530 | 27,597 | 85,856 | 64,509 | (57)% | 318,640 | 3,918,594 | 27,597 | - | 752 |
| Hypertension Diagnosis | - | 7,191 | 615 | - | 1,417 | (57)% | 51,351 | 125,775 | 615 | - | - |
| Hypertension Screening | - | 10,354 | 1,381 | - | 16,839 | (92)% | 108,524 | 321,059 | 1,381 | - | - |

---

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypertension_Controlled Condition</td>
<td>-</td>
<td>6,017</td>
<td>494</td>
<td>-</td>
<td>883</td>
<td>(44)%</td>
<td>39,737</td>
<td>96,040</td>
<td>198</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Implant 3</td>
<td>90</td>
<td>232</td>
<td>(155)</td>
<td>3,296</td>
<td>1,402</td>
<td>(111)%</td>
<td>10,355</td>
<td>828,876</td>
<td>(140)</td>
<td>(349)</td>
<td>(59)</td>
</tr>
<tr>
<td>Implant 3 Insertion</td>
<td>6,885</td>
<td>7,497</td>
<td>12,441</td>
<td>86,738</td>
<td>2,310</td>
<td>439%</td>
<td>51,603</td>
<td>76,409</td>
<td>12,441</td>
<td>31,103</td>
<td>23,496</td>
</tr>
<tr>
<td>Implant 5</td>
<td>(2,250)</td>
<td>(2,437)</td>
<td>(4,760)</td>
<td>29,670</td>
<td>5</td>
<td>(95,300)%</td>
<td>(4,707)</td>
<td>44,523</td>
<td>(4,284)</td>
<td>(16,279)</td>
<td>(11,645)</td>
</tr>
<tr>
<td>Implant 5 Insertion</td>
<td>(2,250)</td>
<td>(2,437)</td>
<td>(4,760)</td>
<td>29,670</td>
<td>5</td>
<td>(95,300)%</td>
<td>(4,707)</td>
<td>44,523</td>
<td>(4,284)</td>
<td>(16,279)</td>
<td>(11,645)</td>
</tr>
<tr>
<td>Injectable 1 Provided</td>
<td>1</td>
<td>4</td>
<td>3</td>
<td>9</td>
<td>6</td>
<td>(50)%</td>
<td>44</td>
<td>84</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Injectable 2</td>
<td>-</td>
<td>-</td>
<td>20,000</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Injectable 2 Provided</td>
<td>1,241</td>
<td>1,147</td>
<td>2,519</td>
<td>5,858</td>
<td>1,793</td>
<td>40%</td>
<td>13,459</td>
<td>21,853</td>
<td>420</td>
<td>420</td>
<td>353</td>
</tr>
<tr>
<td>Injectable 3-IM</td>
<td>40,060</td>
<td>42,896</td>
<td>47,285</td>
<td>468,000</td>
<td>82,022</td>
<td>(42)%</td>
<td>514,301</td>
<td>16,325,231</td>
<td>10,639</td>
<td>10,639</td>
<td>1,887</td>
</tr>
<tr>
<td>Injectable 3-IM Provided</td>
<td>41,933</td>
<td>43,833</td>
<td>78,164</td>
<td>449,871</td>
<td>34,405</td>
<td>127%</td>
<td>385,457</td>
<td>523,591</td>
<td>19,541</td>
<td>19,541</td>
<td>9,673</td>
</tr>
<tr>
<td>Injectable 3-SC</td>
<td>3,146</td>
<td>2,568</td>
<td>5,213</td>
<td>240,000</td>
<td>3,334</td>
<td>56%</td>
<td>31,405</td>
<td>36,618</td>
<td>1,173</td>
<td>1,173</td>
<td>146</td>
</tr>
<tr>
<td>Injectable 3-SC Provided</td>
<td>1,323</td>
<td>995</td>
<td>2,512</td>
<td>3,580</td>
<td>1,987</td>
<td>26%</td>
<td>9,727</td>
<td>12,239</td>
<td>628</td>
<td>628</td>
<td>528</td>
</tr>
<tr>
<td>IPTp2</td>
<td>719</td>
<td>885</td>
<td>1,514</td>
<td>-</td>
<td>938</td>
<td>61%</td>
<td>6,109</td>
<td>21,920</td>
<td>1,514</td>
<td>-</td>
<td>57</td>
</tr>
<tr>
<td>IUD 10</td>
<td>(10)</td>
<td>(66)</td>
<td>(10)</td>
<td>81,455</td>
<td>35</td>
<td>(129)%</td>
<td>(331)</td>
<td>13,005</td>
<td>(9)</td>
<td>(41)</td>
<td>(50)</td>
</tr>
<tr>
<td>IUD 10 Insertion</td>
<td>4,463</td>
<td>7,611</td>
<td>8,923</td>
<td>99,944</td>
<td>14,439</td>
<td>(38)%</td>
<td>101,968</td>
<td>637,893</td>
<td>8,923</td>
<td>41,046</td>
<td>33,884</td>
</tr>
<tr>
<td>IUD 5</td>
<td>(6)</td>
<td>10</td>
<td>(76)</td>
<td>(1,133)</td>
<td>102</td>
<td>(175)%</td>
<td>362</td>
<td>(57,145)</td>
<td>(68)</td>
<td>(226)</td>
<td>(38)</td>
</tr>
<tr>
<td>IUD 5 Insertion</td>
<td>14,090</td>
<td>19,325</td>
<td>27,329</td>
<td>90,233</td>
<td>11,374</td>
<td>140%</td>
<td>162,738</td>
<td>364,053</td>
<td>27,329</td>
<td>90,166</td>
<td>20,289</td>
</tr>
<tr>
<td>IUS 5 Insertion</td>
<td>100</td>
<td>74</td>
<td>152</td>
<td>-</td>
<td>232</td>
<td>(34)%</td>
<td>1,102</td>
<td>2,596</td>
<td>152</td>
<td>502</td>
<td>576</td>
</tr>
<tr>
<td>LLIN</td>
<td>1,452</td>
<td>4,419</td>
<td>2,964</td>
<td>188,475</td>
<td>39,765</td>
<td>(93)%</td>
<td>1,093,373</td>
<td>24,779,064</td>
<td>4,802</td>
<td>-</td>
<td>100</td>
</tr>
<tr>
<td>Lubricant</td>
<td>220,170</td>
<td>262,167</td>
<td>442,670</td>
<td>1,200,000</td>
<td>15,975</td>
<td>2,671%</td>
<td>2,318,836</td>
<td>7,994,192</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Malaria PPT (ACT)</td>
<td>1,233</td>
<td>636</td>
<td>1,807</td>
<td>254,408</td>
<td>34,896</td>
<td>(95)%</td>
<td>174,362</td>
<td>3,365,065</td>
<td>1,626</td>
<td>-</td>
<td>254</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.
**Monthly Distribution by Market Group and Product**

**Period:** 2  
**Year:** 2020

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Malaria PPT (Non-ACT)</td>
<td>307</td>
<td>141</td>
<td>393</td>
<td>3,706</td>
<td>(195)</td>
<td>-%</td>
<td>2,954</td>
<td>107,673</td>
<td>354</td>
<td>-</td>
</tr>
<tr>
<td>Malaria RDK</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>522,320</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>4,731,974</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Manual Vacuum Aspiration for PAC</td>
<td>228</td>
<td>410</td>
<td>228</td>
<td>6,236</td>
<td>1,576</td>
<td>(86)%</td>
<td>7,879</td>
<td>27,283</td>
<td>228</td>
<td>-</td>
</tr>
<tr>
<td>Medical Abortion</td>
<td>-</td>
<td>333</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>2,000</td>
<td>2,000</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Misoprostol for PAC Provided</td>
<td>208</td>
<td>316</td>
<td>208</td>
<td>6,179</td>
<td>1,578</td>
<td>(87)%</td>
<td>7,331</td>
<td>22,394</td>
<td>208</td>
<td>-</td>
</tr>
<tr>
<td>Misoprostol for Safe Abortion</td>
<td>185,300</td>
<td>82,603</td>
<td>393,000</td>
<td>1,977,921</td>
<td>218,558</td>
<td>80%</td>
<td>1,774,246</td>
<td>4,488,446</td>
<td>20,632</td>
<td>-</td>
</tr>
<tr>
<td>Needle &amp; Syringe</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>10,100</td>
<td>1,956,069</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>OCs</td>
<td>729,543</td>
<td>784,205</td>
<td>1,448,307</td>
<td>8,420,270</td>
<td>1,340,477</td>
<td>8%</td>
<td>9,114,680</td>
<td>76,435,885</td>
<td>86,898</td>
<td>86,898</td>
</tr>
<tr>
<td>OCs Provided</td>
<td>84,298</td>
<td>101,361</td>
<td>152,205</td>
<td>451,935</td>
<td>23,540</td>
<td>547%</td>
<td>756,782</td>
<td>1,081,553</td>
<td>10,147</td>
<td>10,147</td>
</tr>
<tr>
<td>ORS</td>
<td>37,907</td>
<td>48,337</td>
<td>47,854</td>
<td>856,600</td>
<td>41,145</td>
<td>16%</td>
<td>847,044</td>
<td>2,125,752</td>
<td>21,534</td>
<td>-</td>
</tr>
<tr>
<td>ORS Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>758</td>
<td>(100)%</td>
<td>2,043</td>
<td>9,430</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Pneumonia PPT Provided</td>
<td>2,237</td>
<td>2,158</td>
<td>4,258</td>
<td>17,650</td>
<td>2,965</td>
<td>44%</td>
<td>21,771</td>
<td>84,102</td>
<td>4,258</td>
<td>-</td>
</tr>
<tr>
<td>Positive RDTs</td>
<td>228</td>
<td>224</td>
<td>251</td>
<td>4,585</td>
<td>525</td>
<td>(52)%</td>
<td>4,386</td>
<td>40,108</td>
<td>251</td>
<td>-</td>
</tr>
<tr>
<td>Positive RDTs Given First Line Treatment</td>
<td>228</td>
<td>221</td>
<td>251</td>
<td>4,585</td>
<td>500</td>
<td>(50)%</td>
<td>4,242</td>
<td>35,496</td>
<td>251</td>
<td>-</td>
</tr>
<tr>
<td>PrEP</td>
<td>55</td>
<td>67</td>
<td>110</td>
<td>823</td>
<td>-</td>
<td>-%</td>
<td>547</td>
<td>657</td>
<td>9</td>
<td>-</td>
</tr>
<tr>
<td>PUR</td>
<td>4,377,120</td>
<td>3,661,295</td>
<td>9,650,445</td>
<td>30,000,000</td>
<td>6,063,130</td>
<td>59%</td>
<td>32,575,220</td>
<td>207,147,801</td>
<td>79,319</td>
<td>-</td>
</tr>
<tr>
<td>QAACTs Provided after Confirmatory Diagnosis</td>
<td>37</td>
<td>17,253</td>
<td>18,509</td>
<td>92,151</td>
<td>23,955</td>
<td>(23)%</td>
<td>58,000</td>
<td>197,054</td>
<td>18,509</td>
<td>-</td>
</tr>
<tr>
<td>Referral to HIV Testing Services</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>21,265</td>
<td>21,265</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to Linkage to HIV Care</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>301</td>
<td>-</td>
<td>-%</td>
<td>5,843</td>
<td>5,843</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to TB DOTS (completion confirmed)</td>
<td>45</td>
<td>54</td>
<td>95</td>
<td>1,600</td>
<td>130</td>
<td>(27)%</td>
<td>1,020</td>
<td>2,622</td>
<td>95</td>
<td>-</td>
</tr>
<tr>
<td>Referral to TB DOTS (completion unknown)</td>
<td>45</td>
<td>63</td>
<td>98</td>
<td>1,600</td>
<td>133</td>
<td>(26)%</td>
<td>1,289</td>
<td>2,962</td>
<td>98</td>
<td>-</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.
### Monthly Distribution by Market Group and Product

**Period:** 2  
**Year:** 2020

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Safe Water Solution</strong></td>
<td>125,136</td>
<td>98,620</td>
<td>286,224</td>
<td>1,500,000</td>
<td>297,324</td>
<td>(4)%</td>
<td>1,418,258</td>
<td>23,178,382</td>
<td>235,253</td>
<td></td>
<td>580</td>
</tr>
<tr>
<td><strong>SDM (Cycle Beads)</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td>-</td>
</tr>
<tr>
<td><strong>SDM (Cycle Beads) Provided</strong></td>
<td>686</td>
<td>1,097</td>
<td>1,600</td>
<td>-</td>
<td>20</td>
<td>7,900%</td>
<td>6,606</td>
<td>8,206</td>
<td>1,600</td>
<td>2,400</td>
<td>1,851</td>
</tr>
<tr>
<td><strong>Skilled Birth Attendance</strong></td>
<td>2,552</td>
<td>3,528</td>
<td>6,244</td>
<td>25,000</td>
<td>3,541</td>
<td>76%</td>
<td>25,405</td>
<td>93,818</td>
<td>6,244</td>
<td></td>
<td>5,190</td>
</tr>
<tr>
<td><strong>STI Screening</strong></td>
<td>-</td>
<td>897</td>
<td>798</td>
<td>16,000</td>
<td>3,926</td>
<td>(80)%</td>
<td>16,593</td>
<td>77,900</td>
<td>798</td>
<td></td>
<td>-</td>
</tr>
<tr>
<td><strong>TB Diagnosis</strong></td>
<td>950</td>
<td>1,067</td>
<td>1,264</td>
<td>14,326</td>
<td>1,275</td>
<td>(1)%</td>
<td>13,610</td>
<td>74,478</td>
<td>1,264</td>
<td></td>
<td>-</td>
</tr>
<tr>
<td><strong>TB DOTS</strong></td>
<td>724</td>
<td>946</td>
<td>1,626</td>
<td>11,614</td>
<td>1,887</td>
<td>(14)%</td>
<td>12,584</td>
<td>231,661</td>
<td>1,626</td>
<td>-</td>
<td>10,086</td>
</tr>
<tr>
<td><strong>TB Screening</strong></td>
<td>7,434</td>
<td>5,892</td>
<td>9,796</td>
<td>298,198</td>
<td>21,553</td>
<td>(55)%</td>
<td>118,645</td>
<td>500,648</td>
<td>9,796</td>
<td></td>
<td>-</td>
</tr>
<tr>
<td><strong>Toilets Sold</strong></td>
<td>-</td>
<td>2,812</td>
<td>-</td>
<td>44,280</td>
<td>11,363</td>
<td>(100)%</td>
<td>68,647</td>
<td>119,010</td>
<td>-</td>
<td></td>
<td>-</td>
</tr>
<tr>
<td><strong>Toilets Sold - All</strong></td>
<td>6,006</td>
<td>6,437</td>
<td>10,720</td>
<td>-</td>
<td>11,363</td>
<td>(6)%</td>
<td>74,808</td>
<td>135,891</td>
<td>51,456</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Treatment for Pre-Eclampsia (with MgSO4)</strong></td>
<td>13</td>
<td>13</td>
<td>32</td>
<td>-</td>
<td>5</td>
<td>540%</td>
<td>43</td>
<td>245</td>
<td>32</td>
<td>-</td>
<td>29</td>
</tr>
<tr>
<td><strong>Tubal Ligation</strong></td>
<td>9,637</td>
<td>6,600</td>
<td>15,915</td>
<td>33,550</td>
<td>9,344</td>
<td>70%</td>
<td>44,513</td>
<td>142,631</td>
<td>15,915</td>
<td>206,214</td>
<td>55,625</td>
</tr>
<tr>
<td><strong>Vasectomy</strong></td>
<td>84</td>
<td>233</td>
<td>238</td>
<td>1,265</td>
<td>36</td>
<td>561%</td>
<td>1,717</td>
<td>5,910</td>
<td>238</td>
<td>3,064</td>
<td>859</td>
</tr>
<tr>
<td><strong>Vivax Treatment after Confirmatory Diagnosis</strong></td>
<td>120</td>
<td>93</td>
<td>134</td>
<td>2,434</td>
<td>204</td>
<td>(34)%</td>
<td>1,993</td>
<td>11,333</td>
<td>134</td>
<td>-</td>
<td>25</td>
</tr>
<tr>
<td><strong>Voluntary Medical Male Circumcision</strong></td>
<td>2,033</td>
<td>12,288</td>
<td>13,892</td>
<td>92,463</td>
<td>7,740</td>
<td>79%</td>
<td>103,723</td>
<td>269,842</td>
<td>13,892</td>
<td>-</td>
<td>97,852</td>
</tr>
<tr>
<td><strong>Water Treatment Tablets</strong></td>
<td>-</td>
<td>23,760</td>
<td>60,480</td>
<td>300,000</td>
<td>594,000</td>
<td>(90)%</td>
<td>708,480</td>
<td>6,706,160</td>
<td>994</td>
<td>-</td>
<td>2</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.
## Acceleration Market Group

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>India</td>
<td>14,308</td>
<td>11,805</td>
<td>21,734</td>
<td>39,600</td>
<td>1,387</td>
<td>1467%</td>
<td>69,642</td>
<td>93,950</td>
<td>1,087</td>
<td>1,087</td>
<td>138</td>
<td>307,432</td>
</tr>
<tr>
<td>Emergency Contraception Provided</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-PSI Emergency Contraception</td>
<td>14,308</td>
<td>11,805</td>
<td>21,734</td>
<td>39,600</td>
<td>1,387</td>
<td>1467%</td>
<td>69,642</td>
<td>93,950</td>
<td>1,087</td>
<td>1,087</td>
<td>138</td>
<td>307,432</td>
</tr>
<tr>
<td>Fecal Sludge Management (Households)</td>
<td>-</td>
<td>-</td>
<td>573</td>
<td>210</td>
<td>(100)</td>
<td>489</td>
<td>2,768</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fecal Sludge Management (Households)</td>
<td>-</td>
<td>-</td>
<td>573</td>
<td>210</td>
<td>(100)</td>
<td>489</td>
<td>2,768</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fecal Sludge Management (Liters)</td>
<td>-</td>
<td>-</td>
<td>1,719,000</td>
<td>1,050,000</td>
<td>(100)</td>
<td>1,914,000</td>
<td>13,071,200</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension Diagnosis</td>
<td>-</td>
<td>6,415</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>19,246</td>
<td>19,246</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension Screening</td>
<td>-</td>
<td>8,782</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>26,346</td>
<td>26,346</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension Controlled Condition</td>
<td>-</td>
<td>5,431</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>16,293</td>
<td>16,293</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Injectable 3-IM Provided</td>
<td>5,754</td>
<td>9,202</td>
<td>10,713</td>
<td>42,350</td>
<td>8,038</td>
<td>33%</td>
<td>98,086</td>
<td>160,228</td>
<td>2,678</td>
<td>2,678</td>
<td>445</td>
<td></td>
</tr>
<tr>
<td>Non-PSI Injectable 3 IM Provided</td>
<td>5,754</td>
<td>9,202</td>
<td>10,713</td>
<td>42,350</td>
<td>8,038</td>
<td>33%</td>
<td>98,086</td>
<td>160,228</td>
<td>2,678</td>
<td>2,678</td>
<td>445</td>
<td></td>
</tr>
<tr>
<td>IUD 5 Insertion</td>
<td>13,959</td>
<td>19,240</td>
<td>27,128</td>
<td>89,100</td>
<td>11,153</td>
<td>143%</td>
<td>161,532</td>
<td>304,447</td>
<td>27,128</td>
<td>89,522</td>
<td>20,177</td>
<td></td>
</tr>
<tr>
<td>Non-PSI IUD 5 Inserted</td>
<td>13,959</td>
<td>19,240</td>
<td>27,128</td>
<td>89,100</td>
<td>11,153</td>
<td>143%</td>
<td>161,532</td>
<td>304,447</td>
<td>27,128</td>
<td>89,522</td>
<td>20,177</td>
<td></td>
</tr>
<tr>
<td>OCs Provided</td>
<td>49,501</td>
<td>92,140</td>
<td>108,543</td>
<td>367,400</td>
<td>15,937</td>
<td>581%</td>
<td>680,972</td>
<td>954,172</td>
<td>7,236</td>
<td>7,236</td>
<td>1,270</td>
<td></td>
</tr>
<tr>
<td>Non-PSI OCs Provided</td>
<td>49,501</td>
<td>92,140</td>
<td>108,543</td>
<td>367,400</td>
<td>15,937</td>
<td>581%</td>
<td>680,972</td>
<td>954,172</td>
<td>7,236</td>
<td>7,236</td>
<td>1,270</td>
<td></td>
</tr>
<tr>
<td>TB Diagnosis</td>
<td>-</td>
<td>-</td>
<td>326</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TB Diagnosis</td>
<td>-</td>
<td>-</td>
<td>326</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TB DOTS</td>
<td>-</td>
<td>-</td>
<td>326</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TB DOTS</td>
<td>-</td>
<td>-</td>
<td>326</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TB Screening</td>
<td>-</td>
<td>-</td>
<td>210,000</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>TB Screening</td>
<td>-</td>
<td>-</td>
<td>210,000</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Toilets Sold</td>
<td>-</td>
<td>2,812</td>
<td>-</td>
<td>44,280</td>
<td>11,363</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Toilets Sold - All</td>
<td>6,006</td>
<td>6,437</td>
<td>10,720</td>
<td>-</td>
<td>11,363</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Tubal Ligation</td>
<td>9,547</td>
<td>6,494</td>
<td>15,688</td>
<td>33,550</td>
<td>9,344</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Vasectomy</td>
<td>78</td>
<td>230</td>
<td>228</td>
<td>1,265</td>
<td>36</td>
<td>1,711</td>
<td>5,894</td>
<td>228</td>
</tr>
<tr>
<td>Kenya</td>
<td>163,027</td>
<td>266,784</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antiretroviral Treatment (Currently Enrolled)</td>
<td>8,389</td>
<td>8,309</td>
<td>17,063</td>
<td>31,950</td>
<td>15,329</td>
<td>11%</td>
<td>94,314</td>
<td>225,829</td>
</tr>
<tr>
<td>Antiretroviral Treatment (Currently Enrolled)</td>
<td>8,389</td>
<td>8,309</td>
<td>17,063</td>
<td>31,950</td>
<td>15,329</td>
<td>11%</td>
<td>94,314</td>
<td>225,829</td>
</tr>
<tr>
<td>Antiretroviral Treatment (Newly Enrolled)</td>
<td>111</td>
<td>122</td>
<td>215</td>
<td>565</td>
<td>215</td>
<td>0%</td>
<td>1,427</td>
<td>5,062</td>
</tr>
<tr>
<td>Cervical Cancer-Pap and Cryotherapy</td>
<td>-</td>
<td>3</td>
<td>9</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Cervical Cancer-Pap Smear Screening</td>
<td>-</td>
<td>10</td>
<td>31</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Cervical Cancer-VIA and Cryotherapy</td>
<td>-</td>
<td>2</td>
<td>6</td>
<td>300</td>
<td>35</td>
<td>(83)%</td>
<td>174</td>
<td>3,496</td>
</tr>
<tr>
<td>Cervical Cancer-VIA and Cryotherapy</td>
<td>-</td>
<td>2</td>
<td>6</td>
<td>300</td>
<td>35</td>
<td>(83)%</td>
<td>174</td>
<td>3,496</td>
</tr>
<tr>
<td>Cervical Cancer-VIA/VILI Screening</td>
<td>-</td>
<td>6</td>
<td>18</td>
<td>-</td>
<td>5,591</td>
<td>(100)%</td>
<td>34,361</td>
<td>314,753</td>
</tr>
<tr>
<td>Cervical Cancer-VIA/VILI Screening</td>
<td>-</td>
<td>6</td>
<td>18</td>
<td>-</td>
<td>5,591</td>
<td>(100)%</td>
<td>34,361</td>
<td>314,753</td>
</tr>
<tr>
<td>Condom</td>
<td>4,937,760</td>
<td>2,175,528</td>
<td>5,911,127</td>
<td>28,700,000</td>
<td>4,708,080</td>
<td>26%</td>
<td>31,033,515</td>
<td>599,747,959</td>
</tr>
<tr>
<td>Trust</td>
<td>4,434,912</td>
<td>1,709,904</td>
<td>4,792,679</td>
<td>23,000,000</td>
<td>3,777,264</td>
<td>27%</td>
<td>25,288,945</td>
<td>532,309,872</td>
</tr>
<tr>
<td>Trust Ribbed</td>
<td>63,072</td>
<td>56,232</td>
<td>139,104</td>
<td>700,000</td>
<td>29,448</td>
<td>37%</td>
<td>706,873</td>
<td>4,538,840</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.
(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Trust Scented</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>216</td>
<td>5/14</td>
<td>(100)%</td>
<td>216</td>
<td>3,301,903</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Trust Studded</td>
<td>439,776</td>
<td>409,392</td>
<td>979,344</td>
<td>5,000,000</td>
<td>901,152</td>
<td>1/08</td>
<td>9%</td>
<td>5,037,481</td>
<td>59,597,344</td>
<td>7,345</td>
<td>7,345</td>
</tr>
<tr>
<td>Diarrhea Treatment Kit Provided</td>
<td>-</td>
<td>-</td>
<td>20,000</td>
<td>3,853</td>
<td>(100)%</td>
<td>15,147</td>
<td>69,404</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Non-PSI Diarrhea Treatment Kit Provided</td>
<td>-</td>
<td>-</td>
<td>20,000</td>
<td>3,853</td>
<td>(100)%</td>
<td>15,147</td>
<td>69,404</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Emergency Contraception Provided</td>
<td>1,165</td>
<td>950</td>
<td>2,110</td>
<td>8,562</td>
<td>431</td>
<td>390%</td>
<td>5,618</td>
<td>9,141</td>
<td>106</td>
<td>106</td>
<td>43</td>
</tr>
<tr>
<td>Non-PSI Emergency Contraception Provided</td>
<td>1,165</td>
<td>950</td>
<td>2,110</td>
<td>8,562</td>
<td>431</td>
<td>390%</td>
<td>5,618</td>
<td>9,141</td>
<td>106</td>
<td>106</td>
<td>43</td>
</tr>
<tr>
<td>Free Condom</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1,049,760</td>
<td>5/11</td>
<td>(100)%</td>
<td>1,913,760</td>
<td>92,411,197</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Free Male Condom - NASCOP</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1,049,760</td>
<td>5/11</td>
<td>(100)%</td>
<td>1,913,760</td>
<td>92,411,197</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>HIV Self-Testing Kit</td>
<td>8,385</td>
<td>6,052</td>
<td>17,465</td>
<td>59,385</td>
<td>11,038</td>
<td>58%</td>
<td>48,552</td>
<td>134,188</td>
<td>15,719</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>INSTI HIVST (Blood based)</td>
<td>4,591</td>
<td>2,925</td>
<td>9,266</td>
<td>14,835</td>
<td>-</td>
<td>-</td>
<td>6,698</td>
<td>55,964</td>
<td>8,339</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>ORAQUICK HIV Self-Testing Kit (Saliva based)</td>
<td>3,794</td>
<td>3,127</td>
<td>8,199</td>
<td>44,550</td>
<td>11,038</td>
<td>(26)%</td>
<td>41,854</td>
<td>78,224</td>
<td>7,379</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>HIV Testing Services</td>
<td>8,591</td>
<td>9,151</td>
<td>17,711</td>
<td>18,892</td>
<td>48,427</td>
<td>(63)%</td>
<td>209,881</td>
<td>1,415,154</td>
<td>17,711</td>
<td>-</td>
<td>740</td>
</tr>
<tr>
<td>VCT Individual (HIV-Negative)</td>
<td>8,427</td>
<td>8,973</td>
<td>17,381</td>
<td>18,315</td>
<td>47,666</td>
<td>(64)%</td>
<td>206,369</td>
<td>1,376,970</td>
<td>17,381</td>
<td>-</td>
<td>726</td>
</tr>
<tr>
<td>VCT Individual (HIV-Positive)</td>
<td>164</td>
<td>178</td>
<td>330</td>
<td>577</td>
<td>761</td>
<td>9/11</td>
<td>(57)%</td>
<td>3,512</td>
<td>38,184</td>
<td>330</td>
<td>-</td>
</tr>
<tr>
<td>Implant 3</td>
<td>-</td>
<td>167</td>
<td>-</td>
<td>1,500</td>
<td>3/14</td>
<td>(100)%</td>
<td>9,150</td>
<td>816,143</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Implanon</td>
<td>-</td>
<td>167</td>
<td>-</td>
<td>1,500</td>
<td>3/14</td>
<td>(100)%</td>
<td>9,150</td>
<td>816,143</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Implant 3 Insertion</td>
<td>5,524</td>
<td>5,646</td>
<td>9,167</td>
<td>77,200</td>
<td>-</td>
<td>0%</td>
<td>32,827</td>
<td>41,994</td>
<td>9,167</td>
<td>22,918</td>
<td>16,707</td>
</tr>
<tr>
<td>Non-PSI Implant 3 Inserted</td>
<td>5,524</td>
<td>5,646</td>
<td>9,167</td>
<td>77,200</td>
<td>-</td>
<td>-</td>
<td>32,827</td>
<td>41,994</td>
<td>9,167</td>
<td>22,918</td>
<td>16,707</td>
</tr>
<tr>
<td>Implant 5</td>
<td>(2,250)</td>
<td>(2,437)</td>
<td>(4,760)</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>(4,800)</td>
<td>44,323</td>
<td>(4,284)</td>
<td>(16,279)</td>
<td>(11,645)</td>
</tr>
<tr>
<td>Jadelle</td>
<td>-</td>
<td>750</td>
<td>2,250</td>
<td>2,400</td>
<td>1/09</td>
<td>-</td>
<td>18,820</td>
<td>205,998</td>
<td>2,025</td>
<td>7,695</td>
<td>5,504</td>
</tr>
<tr>
<td>(b)PSI Implant 5 Distributed Inserted</td>
<td>(2,250)</td>
<td>(3,187)</td>
<td>(7,010)</td>
<td>(2,400)</td>
<td>-</td>
<td>-</td>
<td>(23,620)</td>
<td>(161,675)</td>
<td>(6,309)</td>
<td>(23,974)</td>
<td>(17,149)</td>
</tr>
<tr>
<td>Implant 5 Insertion</td>
<td>2,250</td>
<td>5,292</td>
<td>7,010</td>
<td>10,043</td>
<td>-</td>
<td>(30)%</td>
<td>71,230</td>
<td>370,039</td>
<td>7,010</td>
<td>26,638</td>
<td>19,054</td>
</tr>
<tr>
<td>Non-PSI Implant 5 Inserted</td>
<td>-</td>
<td>2,105</td>
<td>-</td>
<td>10,043</td>
<td>(100)%</td>
<td>47,610</td>
<td>208,364</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PSI Implant 5 Inserted</td>
<td>2,250</td>
<td>3,187</td>
<td>7,010</td>
<td>2,400</td>
<td>-</td>
<td>-</td>
<td>23,620</td>
<td>161,675</td>
<td>7,010</td>
<td>26,638</td>
<td>19,054</td>
</tr>
<tr>
<td>Injectable 3-IM</td>
<td>-</td>
<td>13,824</td>
<td>6,048</td>
<td>60,000</td>
<td>38,016</td>
<td>(84)%</td>
<td>115,590</td>
<td>6,149,916</td>
<td>1,361</td>
<td>1,361</td>
<td>731</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
<table>
<thead>
<tr>
<th>Product Description</th>
<th>DISTRIBUTION 2020</th>
<th>MONTHLY AVG PREV 3 MONTHS</th>
<th>YTD DISTRIBUTION 2020</th>
<th>DISTRIBUTION TARGET 2020</th>
<th>YTD DISTRIBUTION 2019</th>
<th>LAUNCH DATE</th>
<th>YTD % CHANGE</th>
<th>TOTAL DISTRIBUTION 2020</th>
<th>CUMULATIVE DISTRIBUTION (a)</th>
<th>YTD USERS REACHED 2020</th>
<th>YTD CYP 2020</th>
<th>YTD DALY 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Femiplan Injectable</td>
<td>-</td>
<td>13,824</td>
<td>6,048</td>
<td>60,000</td>
<td>38,016</td>
<td>3/00</td>
<td>(84)%</td>
<td>115,590</td>
<td>6,149,916</td>
<td>1,361</td>
<td>1,361</td>
<td>731</td>
</tr>
<tr>
<td>Injectable 3-IM Provided</td>
<td>35,073</td>
<td>33,143</td>
<td>65,183</td>
<td>400,000</td>
<td>24,644</td>
<td>164%</td>
<td>268,996</td>
<td>334,179</td>
<td>16,296</td>
<td>16,296</td>
<td>8,750</td>
<td></td>
</tr>
<tr>
<td>Non-PSI Injectable 3 IM Provided</td>
<td>35,073</td>
<td>33,143</td>
<td>65,183</td>
<td>400,000</td>
<td>24,644</td>
<td>164%</td>
<td>268,996</td>
<td>334,179</td>
<td>16,296</td>
<td>16,296</td>
<td>8,750</td>
<td></td>
</tr>
<tr>
<td>IPTp2</td>
<td>719</td>
<td>885</td>
<td>1,514</td>
<td>-</td>
<td>938</td>
<td>61%</td>
<td>6,109</td>
<td>21,920</td>
<td>1,514</td>
<td>-</td>
<td>-</td>
<td>57</td>
</tr>
<tr>
<td>IPTp2</td>
<td>719</td>
<td>885</td>
<td>1,514</td>
<td>-</td>
<td>938</td>
<td>61%</td>
<td>6,109</td>
<td>21,920</td>
<td>1,514</td>
<td>-</td>
<td>-</td>
<td>57</td>
</tr>
<tr>
<td>IUD 10</td>
<td>(20)</td>
<td>(76)</td>
<td>(20)</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>(588)</td>
<td>9,419</td>
<td>(18)</td>
<td>(83)</td>
<td>(57)</td>
<td></td>
</tr>
<tr>
<td>CU 380A (Copper T)</td>
<td>-</td>
<td>-</td>
<td>2,400</td>
<td>-</td>
<td>3/09</td>
<td>%</td>
<td>190</td>
<td>99,414</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>(b)PSI IUD 10 Distributed Inserted</td>
<td>(20)</td>
<td>(76)</td>
<td>(20)</td>
<td>(2,400)</td>
<td>-</td>
<td>%</td>
<td>(778)</td>
<td>(89,995)</td>
<td>(18)</td>
<td>(83)</td>
<td>(57)</td>
<td></td>
</tr>
<tr>
<td>IUD 10 Insertion</td>
<td>2,965</td>
<td>3,524</td>
<td>5,717</td>
<td>43,052</td>
<td>2,994</td>
<td>91%</td>
<td>31,353</td>
<td>216,324</td>
<td>5,717</td>
<td>26,298</td>
<td>17,949</td>
<td></td>
</tr>
<tr>
<td>Non-PSI IUD 10 Inserted</td>
<td>2,945</td>
<td>3,448</td>
<td>5,697</td>
<td>40,652</td>
<td>2,994</td>
<td>90%</td>
<td>30,575</td>
<td>126,329</td>
<td>5,697</td>
<td>26,206</td>
<td>17,887</td>
<td></td>
</tr>
<tr>
<td>PSI IUD 10 Inserted</td>
<td>20</td>
<td>76</td>
<td>20</td>
<td>2,400</td>
<td>-</td>
<td>%</td>
<td>778</td>
<td>89,995</td>
<td>20</td>
<td>92</td>
<td>63</td>
<td></td>
</tr>
<tr>
<td>LLIN</td>
<td>1,452</td>
<td>971</td>
<td>2,904</td>
<td>151,000</td>
<td>39,765</td>
<td>(93)%</td>
<td>907,433</td>
<td>24,554,984</td>
<td>4,704</td>
<td>-</td>
<td>96</td>
<td></td>
</tr>
<tr>
<td>ANC LLIN</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>125,000</td>
<td>-</td>
<td>7/08</td>
<td>%</td>
<td>-</td>
<td>19,189,925</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Supanet Conical</td>
<td>852</td>
<td>445</td>
<td>1,604</td>
<td>9,000</td>
<td>1,790</td>
<td>10/16</td>
<td>(10)%</td>
<td>8,212</td>
<td>25,444</td>
<td>2,598</td>
<td>-</td>
<td>53</td>
</tr>
<tr>
<td>Supanet Rectangular</td>
<td>600</td>
<td>527</td>
<td>1,300</td>
<td>17,000</td>
<td>1,673</td>
<td>10/16</td>
<td>(22)%</td>
<td>7,390</td>
<td>27,313</td>
<td>2,106</td>
<td>-</td>
<td>43</td>
</tr>
<tr>
<td>Supanet XtraPower BL PNET USAID</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>36,302</td>
<td>3/14</td>
<td>(100)%</td>
<td>891,831</td>
<td>5,312,302</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>OCs</td>
<td>212,040</td>
<td>289,920</td>
<td>594,000</td>
<td>3,410,000</td>
<td>535,824</td>
<td>11%</td>
<td>3,139,760</td>
<td>42,453,076</td>
<td>35,640</td>
<td>35,640</td>
<td>20,188</td>
<td></td>
</tr>
<tr>
<td>Famipill</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>8,064</td>
<td>5/18</td>
<td>(100)%</td>
<td>9,000</td>
<td>149,628</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Femipill Oral Pills</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>10,000</td>
<td>11/16</td>
<td>%</td>
<td>4,792</td>
<td>176,728</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Non-PSI OCs Provided</td>
<td>7,886</td>
<td>7,894</td>
<td>15,607</td>
<td>80,856</td>
<td>6,047</td>
<td>158%</td>
<td>60,847</td>
<td>77,401</td>
<td>1,040</td>
<td>1,040</td>
<td>589</td>
<td></td>
</tr>
<tr>
<td>ORS Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>758</td>
<td>(100)%</td>
<td>2,043</td>
<td>9,430</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Non-PSI ORS Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>758</td>
<td>(100)%</td>
<td>2,043</td>
<td>9,430</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
<table>
<thead>
<tr>
<th>Service</th>
<th>DISTRIBUTION 2/2020</th>
<th>MONTHLY AVG PREV 3 MONTHS</th>
<th>YTD DISTRIBUTION 2020</th>
<th>DISTRIBUTION TARGET 2020</th>
<th>YTD DISTRIBUTION 2019</th>
<th>LAUNCH DATE</th>
<th>YTD % CHANGE</th>
<th>TOTAL DISTRIBUTION 2019</th>
<th>CUMULATIVE DISTRIBUTION (a)</th>
<th>%YTD USERS REACHED 2020</th>
<th>YTD CYP 2020</th>
<th>YTD DALY 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pneumonia PPT Provided</td>
<td>2,237</td>
<td>2,158</td>
<td>4,258</td>
<td>17,650</td>
<td>2,965</td>
<td></td>
<td>44%</td>
<td>21,771</td>
<td>84,102</td>
<td>4,258</td>
<td>-</td>
<td>2,048</td>
</tr>
<tr>
<td>Non-PSI Pneumonia PPT Provided</td>
<td>2,237</td>
<td>2,158</td>
<td>4,258</td>
<td>17,650</td>
<td>2,965</td>
<td></td>
<td>44%</td>
<td>21,771</td>
<td>84,102</td>
<td>4,258</td>
<td>-</td>
<td>2,048</td>
</tr>
<tr>
<td>PrEP</td>
<td>55</td>
<td>67</td>
<td>110</td>
<td>88</td>
<td>-</td>
<td></td>
<td>0%</td>
<td>547</td>
<td>657</td>
<td>9</td>
<td>-</td>
<td>5</td>
</tr>
<tr>
<td>PrEP</td>
<td>55</td>
<td>67</td>
<td>110</td>
<td>88</td>
<td>-</td>
<td>(22)%</td>
<td>56,824</td>
<td>176,193</td>
<td>18,463</td>
<td>-</td>
<td>3,037</td>
<td></td>
</tr>
<tr>
<td>PUR</td>
<td>4,377,120</td>
<td>3,661,295</td>
<td>9,650,445</td>
<td>30,000,000</td>
<td>6,063,130</td>
<td>2,006</td>
<td>59%</td>
<td>32,575,220</td>
<td>207,147,801</td>
<td>79,319</td>
<td>-</td>
<td>196</td>
</tr>
<tr>
<td>PurR</td>
<td>4,377,120</td>
<td>3,661,295</td>
<td>9,650,445</td>
<td>30,000,000</td>
<td>6,063,130</td>
<td>(22)%</td>
<td>56,824</td>
<td>176,193</td>
<td>18,463</td>
<td>-</td>
<td>3,037</td>
<td></td>
</tr>
<tr>
<td>Safe Water Solution</td>
<td>125,136</td>
<td>98,620</td>
<td>286,224</td>
<td>1,500,000</td>
<td>297,324</td>
<td></td>
<td>(4)%</td>
<td>1,418,258</td>
<td>23,178,382</td>
<td>-</td>
<td>580</td>
<td></td>
</tr>
<tr>
<td>WaterGuard</td>
<td>125,136</td>
<td>98,620</td>
<td>286,224</td>
<td>1,500,000</td>
<td>297,324</td>
<td></td>
<td>(4)%</td>
<td>1,418,258</td>
<td>23,178,382</td>
<td>-</td>
<td>580</td>
<td></td>
</tr>
<tr>
<td>SDM (Cycle Beads) Provided</td>
<td>682</td>
<td>1,090</td>
<td>1,593</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>6,494</td>
<td>8,087</td>
<td>1,593</td>
<td>2,390</td>
<td>1,838</td>
<td></td>
</tr>
<tr>
<td>Non-PSI SDM (Cycle Beads) Provided</td>
<td>682</td>
<td>1,090</td>
<td>1,593</td>
<td>-</td>
<td>-</td>
<td>(22)%</td>
<td>6,494</td>
<td>8,087</td>
<td>1,593</td>
<td>2,390</td>
<td>1,838</td>
<td></td>
</tr>
<tr>
<td>Skilled Birth Attendance</td>
<td>2,552</td>
<td>3,528</td>
<td>6,244</td>
<td>25,000</td>
<td>3,541</td>
<td></td>
<td>76%</td>
<td>25,405</td>
<td>93,818</td>
<td>6,244</td>
<td>-</td>
<td>5,190</td>
</tr>
<tr>
<td>Skilled Birth Attendance</td>
<td>2,552</td>
<td>3,528</td>
<td>6,244</td>
<td>25,000</td>
<td>3,541</td>
<td></td>
<td>76%</td>
<td>25,405</td>
<td>93,818</td>
<td>6,244</td>
<td>-</td>
<td>5,190</td>
</tr>
<tr>
<td>TB Diagnosis</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>110</td>
<td>-</td>
<td>(100)%</td>
<td>349</td>
<td>1,020</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>TB Diagnosis</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>110</td>
<td>-</td>
<td>(100)%</td>
<td>349</td>
<td>1,020</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>TB Screening</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>42,198</td>
<td>13,303</td>
<td>(100)%</td>
<td>40,435</td>
<td>120,813</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>TB Screening</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>42,198</td>
<td>13,303</td>
<td>(100)%</td>
<td>40,435</td>
<td>120,813</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Treatment for Pre-Eclampsia (with MgSO4)</td>
<td>13</td>
<td>13</td>
<td>32</td>
<td>-</td>
<td>5</td>
<td>540%</td>
<td>43</td>
<td>245</td>
<td>32</td>
<td>-</td>
<td>29</td>
<td></td>
</tr>
<tr>
<td>Treatment for Pre-Eclampsia (with MgSO4)</td>
<td>13</td>
<td>13</td>
<td>32</td>
<td>-</td>
<td>5</td>
<td>540%</td>
<td>43</td>
<td>245</td>
<td>32</td>
<td>-</td>
<td>29</td>
<td></td>
</tr>
<tr>
<td>Tubal Ligation</td>
<td>90</td>
<td>106</td>
<td>227</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>617</td>
<td>844</td>
<td>227</td>
<td>2,270</td>
<td>1,407</td>
<td></td>
</tr>
<tr>
<td>Tubal Ligation</td>
<td>90</td>
<td>106</td>
<td>227</td>
<td>-</td>
<td>-</td>
<td>(22)%</td>
<td>617</td>
<td>844</td>
<td>227</td>
<td>2,270</td>
<td>1,407</td>
<td></td>
</tr>
<tr>
<td>Vasectomy</td>
<td>6</td>
<td>3</td>
<td>10</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>6</td>
<td>16</td>
<td>10</td>
<td>100</td>
<td>63</td>
<td></td>
</tr>
<tr>
<td>Vasectomy</td>
<td>6</td>
<td>3</td>
<td>10</td>
<td>-</td>
<td>-</td>
<td>(22)%</td>
<td>6</td>
<td>16</td>
<td>10</td>
<td>100</td>
<td>63</td>
<td></td>
</tr>
<tr>
<td>Voluntary Medical Male Circumcision</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>22</td>
<td>(100)%</td>
<td>31</td>
<td>31</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Voluntary Medical Male Circumcision</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>22</td>
<td></td>
<td>(100)%</td>
<td>31</td>
<td>31</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Water Treatment Tablets</td>
<td>-</td>
<td>23,760</td>
<td>60,480</td>
<td>300,000</td>
<td>594,000</td>
<td>(90)%</td>
<td>708,480</td>
<td>6,706,160</td>
<td>994</td>
<td>2</td>
</tr>
<tr>
<td>Aquatab</td>
<td>-</td>
<td>23,760</td>
<td>60,480</td>
<td>300,000</td>
<td>594,000</td>
<td>(90)%</td>
<td>708,480</td>
<td>6,706,160</td>
<td>994</td>
<td>2</td>
</tr>
<tr>
<td>Myanmar</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>77,833</td>
</tr>
<tr>
<td>Antiretroviral Treatment (Currently Enrolled)</td>
<td>7,432</td>
<td>7,273</td>
<td>14,739</td>
<td>83,259</td>
<td>11,850</td>
<td>24%</td>
<td>79,710</td>
<td>208,481</td>
<td>1,228</td>
<td>-</td>
</tr>
<tr>
<td>Antiretroviral Treatment (Currently Enrolled)</td>
<td>7,432</td>
<td>7,273</td>
<td>14,739</td>
<td>83,259</td>
<td>11,850</td>
<td>24%</td>
<td>79,710</td>
<td>208,481</td>
<td>1,228</td>
<td>-</td>
</tr>
<tr>
<td>Antiretroviral Treatment (Newly Enrolled)</td>
<td>198</td>
<td>122</td>
<td>288</td>
<td>2,351</td>
<td>384</td>
<td>(25)%</td>
<td>2,317</td>
<td>8,771</td>
<td>288</td>
<td>-</td>
</tr>
<tr>
<td>Antiretroviral Treatment (Newly Enrolled)</td>
<td>198</td>
<td>122</td>
<td>288</td>
<td>2,351</td>
<td>384</td>
<td>(25)%</td>
<td>2,317</td>
<td>8,771</td>
<td>288</td>
<td>-</td>
</tr>
<tr>
<td>Cervical Cancer-VIA and Cryotherapy</td>
<td>8</td>
<td>13</td>
<td>22</td>
<td>60</td>
<td>14</td>
<td>57%</td>
<td>133</td>
<td>1,112</td>
<td>22</td>
<td>-</td>
</tr>
<tr>
<td>Cervical Cancer-VIA and Cryotherapy</td>
<td>8</td>
<td>13</td>
<td>22</td>
<td>60</td>
<td>14</td>
<td>57%</td>
<td>133</td>
<td>1,112</td>
<td>22</td>
<td>-</td>
</tr>
<tr>
<td>Cervical Cancer-VIA/VILI Screening</td>
<td>366</td>
<td>274</td>
<td>582</td>
<td>3,000</td>
<td>448</td>
<td>30%</td>
<td>3,594</td>
<td>11,531</td>
<td>582</td>
<td>-</td>
</tr>
<tr>
<td>Cervical Cancer-VIA/VILI Screening</td>
<td>366</td>
<td>274</td>
<td>582</td>
<td>3,000</td>
<td>448</td>
<td>30%</td>
<td>3,594</td>
<td>11,531</td>
<td>582</td>
<td>-</td>
</tr>
<tr>
<td>Condom</td>
<td>853,571</td>
<td>894,027</td>
<td>1,754,228</td>
<td>10,610,200</td>
<td>1,643,677</td>
<td>7%</td>
<td>14,270,064</td>
<td>428,725,023</td>
<td>13,157</td>
<td>13,157</td>
</tr>
<tr>
<td>Aphaw</td>
<td>182,700</td>
<td>215,580</td>
<td>365,040</td>
<td>-</td>
<td>34,700</td>
<td>7/96</td>
<td>952%</td>
<td>3,945,874</td>
<td>195,576,593</td>
<td>2,738</td>
</tr>
<tr>
<td>Aphaw - Natural Touch</td>
<td>20,289</td>
<td>104,578</td>
<td>124,248</td>
<td>750,000</td>
<td>2,646</td>
<td>8/12</td>
<td>4,596%</td>
<td>1,169,451</td>
<td>16,071,372</td>
<td>932</td>
</tr>
<tr>
<td>Aphaw Deluxe GL (3x1)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1,231,300</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Aphaw Flavors</td>
<td>362,305</td>
<td>562,405</td>
<td>960,253</td>
<td>3,936,600</td>
<td>607,080</td>
<td>10/01</td>
<td>58%</td>
<td>4,985,368</td>
<td>182,766,312</td>
<td>7,202</td>
</tr>
<tr>
<td>Aphaw Studded</td>
<td>242,889</td>
<td>5,797</td>
<td>247,299</td>
<td>1,567,300</td>
<td>362,211</td>
<td>7/12</td>
<td>(32%)</td>
<td>1,620,297</td>
<td>20,316,141</td>
<td>1,855</td>
</tr>
<tr>
<td>Generic Male Condom</td>
<td>45,388</td>
<td>5,667</td>
<td>57,388</td>
<td>3,125,000</td>
<td>635,600</td>
<td>1/08</td>
<td>(91%)</td>
<td>2,543,500</td>
<td>8,759,817</td>
<td>430</td>
</tr>
<tr>
<td>OK Condom</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1,440</td>
<td>-</td>
<td>5/03</td>
<td>(100)%</td>
<td>5,574</td>
<td>5,234,788</td>
<td>-</td>
</tr>
<tr>
<td>Emergency Contraception</td>
<td>-</td>
<td>22</td>
<td>-</td>
<td>6,500</td>
<td>-</td>
<td>0%</td>
<td>1,000</td>
<td>1,000</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Emergency Contraception</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>6,500</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Levonorgestrel 1.5 mg Tablet</td>
<td>-</td>
<td>22</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Female Condom</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>23,460</td>
<td>(100)%</td>
<td>85,553</td>
<td>1,556,019</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
### Monthly Distribution by Country

**Period:** 2  
**Year:** 2020

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Generic Female Condom</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>23,460</td>
<td>5/08</td>
<td>(100)%</td>
<td>85,553</td>
<td>1,556,019</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Fever Cases Attended</td>
<td>58,138</td>
<td>40,915</td>
<td>63,290</td>
<td>463,728</td>
<td>54,654</td>
<td>16%</td>
<td>520,128</td>
<td>3,014,586</td>
<td>63,290</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Fever Cases Attended</td>
<td>58,138</td>
<td>40,915</td>
<td>63,290</td>
<td>463,728</td>
<td>54,654</td>
<td>16%</td>
<td>520,128</td>
<td>3,014,586</td>
<td>63,290</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Fever Cases Tested with RDTs</td>
<td>58,138</td>
<td>40,915</td>
<td>63,290</td>
<td>463,728</td>
<td>54,654</td>
<td>16%</td>
<td>520,128</td>
<td>3,014,586</td>
<td>63,290</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Fever Cases Tested with RDTs</td>
<td>58,138</td>
<td>40,915</td>
<td>63,290</td>
<td>463,728</td>
<td>54,654</td>
<td>16%</td>
<td>520,128</td>
<td>3,014,586</td>
<td>63,290</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Free Condom</td>
<td>-</td>
<td>156</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>7,200</td>
<td>7,200</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Free Male Condom</td>
<td>-</td>
<td>156</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>7,200</td>
<td>7,200</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Free Female Condom</td>
<td>12,263</td>
<td>11,987</td>
<td>24,208</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>49,875</td>
<td>74,083</td>
<td>182</td>
<td>182</td>
<td>130</td>
</tr>
<tr>
<td>FC2 Female Condom</td>
<td>12,263</td>
<td>11,987</td>
<td>24,208</td>
<td>-</td>
<td>11/16</td>
<td>-</td>
<td>49,875</td>
<td>74,083</td>
<td>182</td>
<td>182</td>
<td>130</td>
</tr>
<tr>
<td>HIV Testing Services</td>
<td>5,304</td>
<td>5,380</td>
<td>9,886</td>
<td>66,964</td>
<td>8,721</td>
<td>13%</td>
<td>61,315</td>
<td>465,995</td>
<td>9,886</td>
<td>-</td>
<td>12</td>
</tr>
<tr>
<td>VCT Individual (HIV-Negative)</td>
<td>5,082</td>
<td>5,173</td>
<td>9,478</td>
<td>63,260</td>
<td>8,273</td>
<td>15%</td>
<td>58,510</td>
<td>434,945</td>
<td>9,478</td>
<td>-</td>
<td>11</td>
</tr>
<tr>
<td>VCT Individual (HIV-Positive)</td>
<td>222</td>
<td>206</td>
<td>408</td>
<td>3,704</td>
<td>448</td>
<td>(9)%</td>
<td>2,805</td>
<td>31,050</td>
<td>408</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Hypertension Diagnosis</td>
<td>-</td>
<td>776</td>
<td>615</td>
<td>-</td>
<td>1,417</td>
<td>(57)%</td>
<td>32,105</td>
<td>106,529</td>
<td>615</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Hypertension Diagnosis</td>
<td>-</td>
<td>776</td>
<td>615</td>
<td>-</td>
<td>1,417</td>
<td>(57)%</td>
<td>32,105</td>
<td>106,529</td>
<td>615</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Hypertension Screening</td>
<td>-</td>
<td>1,572</td>
<td>1,381</td>
<td>-</td>
<td>16,839</td>
<td>(92)%</td>
<td>82,178</td>
<td>294,713</td>
<td>1,381</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Hypertension Screening</td>
<td>-</td>
<td>1,572</td>
<td>1,381</td>
<td>-</td>
<td>16,839</td>
<td>(92)%</td>
<td>82,178</td>
<td>294,713</td>
<td>1,381</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Hypertension_Controlled Condition</td>
<td>-</td>
<td>586</td>
<td>494</td>
<td>-</td>
<td>883</td>
<td>(44)%</td>
<td>23,444</td>
<td>79,747</td>
<td>198</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Hypertension_Controlled Condition</td>
<td>-</td>
<td>586</td>
<td>494</td>
<td>-</td>
<td>883</td>
<td>(44)%</td>
<td>23,444</td>
<td>79,747</td>
<td>198</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Implant 3</td>
<td>90</td>
<td>65</td>
<td>(155)</td>
<td>3,296</td>
<td>(98)</td>
<td>0%</td>
<td>1,205</td>
<td>12,733</td>
<td>(140)</td>
<td>(349)</td>
<td>(59)</td>
</tr>
<tr>
<td>Implanon NXT</td>
<td>698</td>
<td>562</td>
<td>907</td>
<td>8,240</td>
<td>698</td>
<td>12/15</td>
<td>7,374</td>
<td>28,196</td>
<td>816</td>
<td>2,041</td>
<td>346</td>
</tr>
<tr>
<td>(b)PSI Implant 3 Distributed Inserted</td>
<td>(608)</td>
<td>(497)</td>
<td>(1,062)</td>
<td>(4,944)</td>
<td>(796)</td>
<td>-</td>
<td>(6,169)</td>
<td>(15,463)</td>
<td>(956)</td>
<td>(2,390)</td>
<td>(405)</td>
</tr>
<tr>
<td>Implant 3 Insertion</td>
<td>608</td>
<td>497</td>
<td>1,062</td>
<td>4,944</td>
<td>796</td>
<td>33%</td>
<td>6,169</td>
<td>15,463</td>
<td>1,062</td>
<td>2,655</td>
<td>450</td>
</tr>
<tr>
<td>PSI Implant 3 Inserted</td>
<td>608</td>
<td>497</td>
<td>1,062</td>
<td>4,944</td>
<td>796</td>
<td>33%</td>
<td>6,169</td>
<td>15,463</td>
<td>1,062</td>
<td>2,655</td>
<td>450</td>
</tr>
<tr>
<td>Implant 5</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>5</td>
<td>-</td>
<td>(100)%</td>
<td>93</td>
<td>200</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Jadelle</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>5</td>
<td>5/16</td>
<td>(100)%</td>
<td>93</td>
<td>200</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
### Monthly Distribution by Country

**Period:** 2  
**Year:** 2020

<table>
<thead>
<tr>
<th>Product/Category</th>
<th>DISTRIBUTION 2020</th>
<th>MONTHLY AVG PREV 3 MONTHS</th>
<th>DISTRIBUTION TARGET 2020</th>
<th>YTD DISTRIBUTION 2020</th>
<th>LAUNCH DATE</th>
<th>YTD % CHANGE</th>
<th>TOTAL DISTRIBUTION 2019</th>
<th>CUMULATIVE DISTRIBUTION (a)</th>
<th>YTD USERS REACHED 2020</th>
<th>YTD DALY 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Injectable 3-IM</td>
<td>40,060</td>
<td>29,072</td>
<td>41,237</td>
<td>368,000</td>
<td>44,006</td>
<td>(6)%</td>
<td>398,711</td>
<td>10,175,315</td>
<td>9,278</td>
<td>9,278</td>
</tr>
<tr>
<td>OK-3 Injection</td>
<td>40,060</td>
<td>29,072</td>
<td>41,237</td>
<td>368,000</td>
<td>44,006</td>
<td>9/01</td>
<td>(6)%</td>
<td>398,711</td>
<td>10,175,315</td>
<td>9,278</td>
</tr>
<tr>
<td>Injectable 3-SC</td>
<td>3,146</td>
<td>2,568</td>
<td>5,213</td>
<td>80,000</td>
<td>3,334</td>
<td>56%</td>
<td>31,405</td>
<td>36,618</td>
<td>1,173</td>
<td>1,173</td>
</tr>
<tr>
<td>Sayana Press</td>
<td>3,146</td>
<td>2,568</td>
<td>5,213</td>
<td>80,000</td>
<td>3,334</td>
<td>56%</td>
<td>31,405</td>
<td>36,618</td>
<td>1,173</td>
<td>1,173</td>
</tr>
<tr>
<td>IUD 10</td>
<td>10</td>
<td>10</td>
<td>10</td>
<td>2,060</td>
<td>35</td>
<td>(71)%</td>
<td>257</td>
<td>3,586</td>
<td>9</td>
<td>41</td>
</tr>
<tr>
<td>OK IUD (Copper T Cu 380A)</td>
<td>10</td>
<td>10</td>
<td>10</td>
<td>2,060</td>
<td>35</td>
<td>(71)%</td>
<td>257</td>
<td>3,586</td>
<td>9</td>
<td>41</td>
</tr>
<tr>
<td>IUD 5</td>
<td>6 (6)</td>
<td>10</td>
<td>76</td>
<td>1,133</td>
<td>102</td>
<td>(175)%</td>
<td>362</td>
<td>(57,145)</td>
<td>(68)</td>
<td>(226)</td>
</tr>
<tr>
<td>OK IUD (Inara Cu 375 Sleek)</td>
<td>125</td>
<td>95</td>
<td>125</td>
<td>-</td>
<td>323</td>
<td>(61)%</td>
<td>1,568</td>
<td>2,461</td>
<td>113</td>
<td>371</td>
</tr>
<tr>
<td>(b) PSI IUD 5 Distributed Inserted</td>
<td>131 (131)</td>
<td>(85)</td>
<td>(201)</td>
<td>(1,133)</td>
<td>(221)</td>
<td>-%</td>
<td>(1,206)</td>
<td>(59,606)</td>
<td>(181)</td>
<td>(597)</td>
</tr>
<tr>
<td>IUD 5 Insertion</td>
<td>131</td>
<td>85</td>
<td>201</td>
<td>1,133</td>
<td>221</td>
<td>(9)%</td>
<td>1,206</td>
<td>59,606</td>
<td>201</td>
<td>663</td>
</tr>
<tr>
<td>PSI IUD 5 Inserted</td>
<td>131</td>
<td>85</td>
<td>201</td>
<td>1,133</td>
<td>221</td>
<td>(9)%</td>
<td>1,206</td>
<td>59,606</td>
<td>201</td>
<td>663</td>
</tr>
<tr>
<td>LLIN</td>
<td>-</td>
<td>3,447</td>
<td>60</td>
<td>37,475</td>
<td>-</td>
<td>0%</td>
<td>185,940</td>
<td>224,080</td>
<td>97</td>
<td>-</td>
</tr>
<tr>
<td>LLIN</td>
<td>-</td>
<td>3,447</td>
<td>60</td>
<td>37,475</td>
<td>-</td>
<td>-%</td>
<td>185,940</td>
<td>224,080</td>
<td>97</td>
<td>-</td>
</tr>
<tr>
<td>Lubricant</td>
<td>220,170</td>
<td>262,167</td>
<td>442,670</td>
<td>1,200,000</td>
<td>15,975</td>
<td>2671%</td>
<td>2,318,836</td>
<td>7,994,192</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Aphaw Gel - Sachet</td>
<td>220,146</td>
<td>262,167</td>
<td>442,646</td>
<td>1,200,000</td>
<td>-</td>
<td>10/06</td>
<td>-%</td>
<td>2,286,002</td>
<td>7,156,956</td>
<td>-</td>
</tr>
<tr>
<td>Aphaw Gel - Tube 20 cc</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>8,765</td>
<td>10/06</td>
<td>(100)%</td>
<td>12,378</td>
<td>694,058</td>
<td>-</td>
</tr>
<tr>
<td>Aphaw Gel - Tube 20 cc - Flavors</td>
<td>24</td>
<td>-</td>
<td>24</td>
<td>-</td>
<td>7,210</td>
<td>10/14</td>
<td>(100)%</td>
<td>20,456</td>
<td>143,178</td>
<td>-</td>
</tr>
<tr>
<td>Malaria PPT (ACT)</td>
<td>1,233</td>
<td>636</td>
<td>1,807</td>
<td>254,408</td>
<td>34,896</td>
<td>(95)%</td>
<td>174,362</td>
<td>3,365,065</td>
<td>1,626</td>
<td>-</td>
</tr>
<tr>
<td>AL 1</td>
<td>367</td>
<td>151</td>
<td>525</td>
<td>1,035</td>
<td>402</td>
<td>7/12</td>
<td>31%</td>
<td>2,847</td>
<td>20,374</td>
<td>473</td>
</tr>
<tr>
<td>AL 2</td>
<td>371</td>
<td>151</td>
<td>529</td>
<td>1,035</td>
<td>389</td>
<td>7/12</td>
<td>36%</td>
<td>2,906</td>
<td>21,188</td>
<td>476</td>
</tr>
<tr>
<td>AL 3</td>
<td>109</td>
<td>151</td>
<td>251</td>
<td>1,670</td>
<td>433</td>
<td>1/11</td>
<td>(42)%</td>
<td>3,251</td>
<td>55,896</td>
<td>226</td>
</tr>
<tr>
<td>AL 4</td>
<td>139</td>
<td>126</td>
<td>226</td>
<td>9,460</td>
<td>773</td>
<td>1/11</td>
<td>(71)%</td>
<td>5,324</td>
<td>281,972</td>
<td>203</td>
</tr>
<tr>
<td>Arte+1</td>
<td>65</td>
<td>27</td>
<td>68</td>
<td>-</td>
<td>3</td>
<td>8/14</td>
<td>2,167%</td>
<td>815</td>
<td>23,162</td>
<td>61</td>
</tr>
<tr>
<td>Arte+2</td>
<td>66</td>
<td>28</td>
<td>69</td>
<td>-</td>
<td>3</td>
<td>8/14</td>
<td>2,200%</td>
<td>818</td>
<td>24,065</td>
<td>62</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

---

3002 - 4/15/2020 10:09:35AM
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Arte+3</td>
<td>64</td>
<td>27</td>
<td>67</td>
<td>-</td>
<td>3</td>
<td>8/14</td>
<td>2,133%</td>
<td>2,016</td>
<td>28,625</td>
<td>60</td>
<td></td>
<td>9</td>
</tr>
<tr>
<td>Arte+4</td>
<td>89</td>
<td>43</td>
<td>118</td>
<td>-</td>
<td>21,600</td>
<td>8/14</td>
<td>(99)%</td>
<td>74,629</td>
<td>656,115</td>
<td>106</td>
<td></td>
<td>17</td>
</tr>
<tr>
<td>(b) PSI QAACTs Distributed Provided after Diagnosis</td>
<td>(37)</td>
<td>(68)</td>
<td>(46)</td>
<td>(2,151)</td>
<td>(222)</td>
<td>-</td>
<td>-</td>
<td>(1,176)</td>
<td>(20,861)</td>
<td>(41)</td>
<td></td>
<td>(6)</td>
</tr>
<tr>
<td>Supa Arte 1</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>17,969</td>
<td>503</td>
<td>9/12</td>
<td>(100)%</td>
<td>1,503</td>
<td>122,214</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Supa Arte 2</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>22,686</td>
<td>503</td>
<td>9/12</td>
<td>(100)%</td>
<td>1,503</td>
<td>118,055</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Supa Arte 3</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>22,407</td>
<td>503</td>
<td>9/12</td>
<td>(100)%</td>
<td>1,503</td>
<td>197,962</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Supa Arte 4</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>180,297</td>
<td>10,003</td>
<td>9/12</td>
<td>(100)%</td>
<td>78,423</td>
<td>1,836,298</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Malaria PPT (Non-ACT)</td>
<td>307</td>
<td>141</td>
<td>393</td>
<td>3,706</td>
<td>(195)</td>
<td>0%</td>
<td>-</td>
<td>2,954</td>
<td>107,673</td>
<td>354</td>
<td></td>
<td>55</td>
</tr>
<tr>
<td>Chloroquine 10's</td>
<td>427</td>
<td>235</td>
<td>527</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>4,938</td>
<td>5,465</td>
<td>474</td>
<td></td>
<td>74</td>
</tr>
<tr>
<td>(b) PSI Vivax Tx Distributed Provided after Diagnosis</td>
<td>(120)</td>
<td>(93)</td>
<td>(134)</td>
<td>(2,434)</td>
<td>(204)</td>
<td>-</td>
<td>-</td>
<td>(1,993)</td>
<td>(11,333)</td>
<td>(121)</td>
<td></td>
<td>(19)</td>
</tr>
<tr>
<td>Vivax Treatment Kit</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>6,140</td>
<td>9</td>
<td>6/11</td>
<td>(100)%</td>
<td>9</td>
<td>113,541</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Malaria RDK</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>522,320</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>-</td>
<td>4,731,974</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Malaria RDT (Diagnosis)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>522,320</td>
<td>-</td>
<td>3/11</td>
<td>-%</td>
<td>-</td>
<td>4,731,974</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Needle &amp; Syringe</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>10,100</td>
<td>1,956,069</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Needle &amp; Syringe (LDS)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>10/15</td>
<td>-%</td>
<td>10,100</td>
<td>1,956,069</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OCs</td>
<td>517,503</td>
<td>494,285</td>
<td>854,307</td>
<td>5,003,310</td>
<td>804,653</td>
<td>6%</td>
<td>5,974,920</td>
<td>33,982,809</td>
<td>51,258</td>
<td>51,258</td>
<td>6,738</td>
<td></td>
</tr>
<tr>
<td>OK Pills</td>
<td>516,009</td>
<td>494,216</td>
<td>852,813</td>
<td>5,003,310</td>
<td>802,260</td>
<td>9/01</td>
<td>6%</td>
<td>5,961,595</td>
<td>33,931,368</td>
<td>51,169</td>
<td>51,169</td>
<td>6,726</td>
</tr>
<tr>
<td>OK Pills (Zinnia F)</td>
<td>1,494</td>
<td>69</td>
<td>1,494</td>
<td>2,393</td>
<td>11/16</td>
<td>(38)%</td>
<td>13,325</td>
<td>51,441</td>
<td>90</td>
<td>90</td>
<td>12</td>
<td></td>
</tr>
<tr>
<td>ORS</td>
<td>37,907</td>
<td>48,337</td>
<td>47,854</td>
<td>856,600</td>
<td>41,145</td>
<td>16%</td>
<td>847,044</td>
<td>2,125,752</td>
<td>21,534</td>
<td>-</td>
<td>1,388</td>
<td></td>
</tr>
<tr>
<td>Orasel (Lemon) - Oral Rehydration Salt</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>800,000</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ORS</td>
<td>37,907</td>
<td>48,337</td>
<td>47,854</td>
<td>56,600</td>
<td>41,145</td>
<td>1/08</td>
<td>16%</td>
<td>847,044</td>
<td>2,125,752</td>
<td>21,534</td>
<td>-</td>
<td>1,388</td>
</tr>
<tr>
<td>Positive RDTs</td>
<td>228</td>
<td>224</td>
<td>251</td>
<td>4,585</td>
<td>525</td>
<td>(52)%</td>
<td>4,386</td>
<td>40,108</td>
<td>251</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive RDTs</td>
<td>228</td>
<td>224</td>
<td>251</td>
<td>4,585</td>
<td>525</td>
<td>(52)%</td>
<td>4,386</td>
<td>40,108</td>
<td>251</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive RDTs Given First Line Treatment</td>
<td>228</td>
<td>222</td>
<td>251</td>
<td>4,585</td>
<td>500</td>
<td>(50)%</td>
<td>4,242</td>
<td>35,496</td>
<td>251</td>
<td>-</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
### Monthly Distribution by Country

**Period:** 2

**Year:** 2020

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Positive RDTs Given First Line Treatment</td>
<td>228</td>
<td>221</td>
<td>251</td>
<td>4,585</td>
<td>500</td>
<td>(50)%</td>
<td>4,242</td>
<td>35,496</td>
<td>251</td>
<td>-</td>
</tr>
<tr>
<td>PreP</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>735</td>
<td>-</td>
<td>0%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PreP</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>735</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>QAACTs Provided after Confirmatory Diagnosis</td>
<td>37</td>
<td>68</td>
<td>46</td>
<td>2,151</td>
<td>222</td>
<td>(79)%</td>
<td>1,176</td>
<td>20,861</td>
<td>46</td>
<td>-</td>
</tr>
<tr>
<td>PSI QAACTs Provided after Confirmed Diagnosis</td>
<td>37</td>
<td>68</td>
<td>46</td>
<td>2,151</td>
<td>222</td>
<td>(79)%</td>
<td>1,176</td>
<td>20,861</td>
<td>46</td>
<td>-</td>
</tr>
<tr>
<td>Referral to Linkage to HIV Care</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>301</td>
<td>-</td>
<td>0%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to Linkage to HIV Care</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>301</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to TB DOTS (completion confirmed)</td>
<td>45</td>
<td>54</td>
<td>95</td>
<td>1,600</td>
<td>130</td>
<td>(27)%</td>
<td>1,020</td>
<td>2,622</td>
<td>95</td>
<td>-</td>
</tr>
<tr>
<td>Referral to TB DOTS (completion confirmed)</td>
<td>45</td>
<td>54</td>
<td>95</td>
<td>1,600</td>
<td>130</td>
<td>(27)%</td>
<td>1,020</td>
<td>2,622</td>
<td>95</td>
<td>-</td>
</tr>
<tr>
<td>Referral to TB DOTS (completion unknown)</td>
<td>45</td>
<td>63</td>
<td>98</td>
<td>1,600</td>
<td>133</td>
<td>(26)%</td>
<td>1,289</td>
<td>2,962</td>
<td>98</td>
<td>-</td>
</tr>
<tr>
<td>Referral to TB DOTS (completion unknown)</td>
<td>45</td>
<td>63</td>
<td>98</td>
<td>1,600</td>
<td>133</td>
<td>(26)%</td>
<td>1,289</td>
<td>2,962</td>
<td>98</td>
<td>-</td>
</tr>
<tr>
<td>STI Screening</td>
<td>-</td>
<td>897</td>
<td>798</td>
<td>16,000</td>
<td>3,926</td>
<td>(80)%</td>
<td>16,593</td>
<td>77,900</td>
<td>798</td>
<td>-</td>
</tr>
<tr>
<td>STI Screening</td>
<td>-</td>
<td>897</td>
<td>798</td>
<td>16,000</td>
<td>3,926</td>
<td>(80)%</td>
<td>16,593</td>
<td>77,900</td>
<td>798</td>
<td>-</td>
</tr>
<tr>
<td>TB Diagnosis</td>
<td>950</td>
<td>1,067</td>
<td>1,264</td>
<td>14,000</td>
<td>1,165</td>
<td>8%</td>
<td>13,261</td>
<td>73,458</td>
<td>1,264</td>
<td>-</td>
</tr>
<tr>
<td>TB Diagnosis</td>
<td>950</td>
<td>1,067</td>
<td>1,264</td>
<td>14,000</td>
<td>1,165</td>
<td>8%</td>
<td>13,261</td>
<td>73,458</td>
<td>1,264</td>
<td>-</td>
</tr>
<tr>
<td>TB DOTS</td>
<td>724</td>
<td>946</td>
<td>1,626</td>
<td>11,288</td>
<td>1,887</td>
<td>(14)%</td>
<td>12,584</td>
<td>231,661</td>
<td>1,626</td>
<td>-</td>
</tr>
<tr>
<td>TB DOTS</td>
<td>724</td>
<td>946</td>
<td>1,626</td>
<td>11,288</td>
<td>1,887</td>
<td>(14)%</td>
<td>12,584</td>
<td>231,661</td>
<td>1,626</td>
<td>-</td>
</tr>
<tr>
<td>TB Screening</td>
<td>7,434</td>
<td>5,892</td>
<td>9,796</td>
<td>46,000</td>
<td>8,250</td>
<td>19%</td>
<td>78,210</td>
<td>379,835</td>
<td>9,796</td>
<td>-</td>
</tr>
<tr>
<td>TB Screening</td>
<td>7,434</td>
<td>5,892</td>
<td>9,796</td>
<td>46,000</td>
<td>8,250</td>
<td>19%</td>
<td>78,210</td>
<td>379,835</td>
<td>9,796</td>
<td>-</td>
</tr>
<tr>
<td>Vivax Treatment after Confirmatory Diagnosis</td>
<td>120</td>
<td>93</td>
<td>134</td>
<td>2,434</td>
<td>204</td>
<td>(34)%</td>
<td>1,993</td>
<td>11,333</td>
<td>134</td>
<td>-</td>
</tr>
<tr>
<td>PSI Vivax Treatment after Confirmed Diagnosis</td>
<td>120</td>
<td>93</td>
<td>134</td>
<td>2,434</td>
<td>204</td>
<td>(34)%</td>
<td>1,993</td>
<td>11,333</td>
<td>134</td>
<td>-</td>
</tr>
<tr>
<td>Nigeria</td>
<td>19,233</td>
<td>20,841</td>
<td>19,233</td>
<td>20,841</td>
<td>19,233</td>
<td>20,841</td>
<td>19,233</td>
<td>20,841</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Emergency Contraception Provided</td>
<td>60</td>
<td>-</td>
<td>60</td>
<td>8</td>
<td>5</td>
<td>1100%</td>
<td>10</td>
<td>130</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Non-PSI Emergency Contraception Provided</td>
<td>60</td>
<td>-</td>
<td>60</td>
<td>8</td>
<td>5</td>
<td>1100%</td>
<td>10</td>
<td>130</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Implant 3 Insertion</td>
<td>753</td>
<td>1,354</td>
<td>2,212</td>
<td>4,594</td>
<td>1,514</td>
<td>46%</td>
<td>12,607</td>
<td>18,952</td>
<td>2,212</td>
<td>5,530</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
### Monthly Distribution by Country

**Period:** 2  
**Year:** 2020

<table>
<thead>
<tr>
<th>Product Type</th>
<th>DISTRIBUTION 2/2020</th>
<th>MONTHLY AVG PREV 3 MONTHS</th>
<th>YTD DISTRIBUTION 2020</th>
<th>DISTRIBUTION TARGET 2020</th>
<th>YTD DISTRIBUTION 2019</th>
<th>LAUNCH DATE</th>
<th>YTD % CHANGE</th>
<th>TOTAL DISTRIBUTION 2019</th>
<th>CUMULATIVE DISTRIBUTION (a)</th>
<th>YTD USERS REACHED 2020</th>
<th>YTD CYP 2020</th>
<th>YTD DALY 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-PSI Implant 3 Inserted</td>
<td>753</td>
<td>1,354</td>
<td>2,212</td>
<td>4,594</td>
<td>1,514</td>
<td></td>
<td>46%</td>
<td>12,607</td>
<td>18,952</td>
<td>2,212</td>
<td>5,530</td>
<td>6,339</td>
</tr>
<tr>
<td>Implant 5 Insertion</td>
<td>1,346</td>
<td>1,039</td>
<td>2,211</td>
<td>4,751</td>
<td>1,525</td>
<td></td>
<td>45%</td>
<td>12,195</td>
<td>108,108</td>
<td>2,211</td>
<td>8,402</td>
<td>9,478</td>
</tr>
<tr>
<td>Non-PSI Implant 5 Inserted</td>
<td>1,346</td>
<td>1,039</td>
<td>2,211</td>
<td>4,751</td>
<td>1,525</td>
<td>3/16</td>
<td>45%</td>
<td>12,195</td>
<td>108,108</td>
<td>2,211</td>
<td>8,402</td>
<td>9,478</td>
</tr>
<tr>
<td>Injectable 1 Provided</td>
<td>1</td>
<td>4</td>
<td>3</td>
<td>9</td>
<td>6</td>
<td></td>
<td>(50)%</td>
<td>44</td>
<td>84</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Non-PSI Injectable 1 Provided</td>
<td>1</td>
<td>4</td>
<td>3</td>
<td>9</td>
<td>6</td>
<td></td>
<td>(50)%</td>
<td>44</td>
<td>84</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Injectable 2 Provided</td>
<td>1,241</td>
<td>1,147</td>
<td>2,519</td>
<td>5,858</td>
<td>1,793</td>
<td></td>
<td>40%</td>
<td>13,459</td>
<td>21,853</td>
<td>420</td>
<td>420</td>
<td>353</td>
</tr>
<tr>
<td>Non-PSI Injectable 2 Provided</td>
<td>1,241</td>
<td>1,147</td>
<td>2,519</td>
<td>5,858</td>
<td>1,793</td>
<td></td>
<td>40%</td>
<td>13,459</td>
<td>21,853</td>
<td>420</td>
<td>420</td>
<td>353</td>
</tr>
<tr>
<td>Injectable 3-IM Provided</td>
<td>1,084</td>
<td>1,473</td>
<td>2,218</td>
<td>7,521</td>
<td>1,696</td>
<td></td>
<td>31%</td>
<td>18,189</td>
<td>26,525</td>
<td>555</td>
<td>555</td>
<td>467</td>
</tr>
<tr>
<td>Non-PSI Injectable 3 IM Provided</td>
<td>1,084</td>
<td>1,473</td>
<td>2,218</td>
<td>7,521</td>
<td>1,696</td>
<td></td>
<td>31%</td>
<td>18,189</td>
<td>26,525</td>
<td>555</td>
<td>555</td>
<td>467</td>
</tr>
<tr>
<td>Injectable 3-SC Provided</td>
<td>1,323</td>
<td>995</td>
<td>2,512</td>
<td>3,580</td>
<td>1,987</td>
<td></td>
<td>26%</td>
<td>9,727</td>
<td>12,239</td>
<td>628</td>
<td>628</td>
<td>528</td>
</tr>
<tr>
<td>Non-PSI Injectable 3 SC Provided</td>
<td>1,323</td>
<td>995</td>
<td>2,512</td>
<td>3,580</td>
<td>1,987</td>
<td></td>
<td>26%</td>
<td>9,727</td>
<td>12,239</td>
<td>628</td>
<td>628</td>
<td>528</td>
</tr>
<tr>
<td>IUD 10 Insertion</td>
<td>128</td>
<td>156</td>
<td>295</td>
<td>1,286</td>
<td>306</td>
<td></td>
<td>(4)%</td>
<td>2,325</td>
<td>277,672</td>
<td>295</td>
<td>1,357</td>
<td>1,466</td>
</tr>
<tr>
<td>Non-PSI IUD 10 Inserted</td>
<td>128</td>
<td>156</td>
<td>295</td>
<td>1,286</td>
<td>306</td>
<td>3/16</td>
<td>(4)%</td>
<td>2,325</td>
<td>277,672</td>
<td>295</td>
<td>1,357</td>
<td>1,466</td>
</tr>
<tr>
<td>IUS 5 Insertion</td>
<td>100</td>
<td>74</td>
<td>152</td>
<td>-</td>
<td>232</td>
<td></td>
<td>(34)%</td>
<td>1,102</td>
<td>2,596</td>
<td>152</td>
<td>502</td>
<td>576</td>
</tr>
<tr>
<td>Non-PSI IUS 5 Inserted</td>
<td>100</td>
<td>74</td>
<td>152</td>
<td>-</td>
<td>232</td>
<td></td>
<td>(34)%</td>
<td>1,102</td>
<td>2,596</td>
<td>152</td>
<td>502</td>
<td>576</td>
</tr>
<tr>
<td>OCs Provided</td>
<td>26,670</td>
<td>898</td>
<td>27,554</td>
<td>3,679</td>
<td>1,081</td>
<td></td>
<td>2449%</td>
<td>9,451</td>
<td>42,591</td>
<td>1,837</td>
<td>1,837</td>
<td>1,631</td>
</tr>
<tr>
<td>Non-PSI OCs Provided</td>
<td>26,670</td>
<td>898</td>
<td>27,554</td>
<td>3,679</td>
<td>1,081</td>
<td></td>
<td>2449%</td>
<td>9,451</td>
<td>42,591</td>
<td>1,837</td>
<td>1,837</td>
<td>1,631</td>
</tr>
</tbody>
</table>

| Product Type | PSI Nigeria | | | | | | | | | | |
|--------------|-------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|
| Emergency Contraception Provided | - | 9 | 4 | - | - | - | 0% | 53 | 57 | - | - | - | - |
| Non-PSI Emergency Contraception Provided | - | 9 | 4 | - | - | - | -% | 53 | 57 | - | - | - | - |
| Free Condom | - | - | - | 17,310 | - | - | 0% | - | - | - | - | - | - |
| Generic Male Condom | - | - | - | 17,310 | - | - | -% | - | - | - | - | - | - |
| Free Female Condom | - | - | - | 121,000 | - | - | 0% | - | - | - | - | - | - |
| Generic Female Condom | - | - | - | 121,000 | - | - | -% | - | - | - | - | - | - |
| Implant 5 | - | - | - | 29,670 | - | - | 0% | - | - | - | - | - | - |

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.
(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Jadelle</td>
<td>-</td>
<td>-</td>
<td>29,670</td>
<td>-</td>
<td>2/18</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Implant 5 Insertion</td>
<td>1,100</td>
<td>2,372</td>
<td>2,181</td>
<td>23,802</td>
<td>5,166</td>
<td>(58)%</td>
<td>34,454</td>
<td>65,835</td>
<td>2,181</td>
<td>8,288</td>
<td>9,350</td>
<td>-</td>
</tr>
<tr>
<td>Non-PSI Implant 5 Inserted</td>
<td>1,100</td>
<td>2,372</td>
<td>2,181</td>
<td>23,802</td>
<td>5,166</td>
<td>(58)%</td>
<td>34,454</td>
<td>65,835</td>
<td>2,181</td>
<td>8,288</td>
<td>9,350</td>
<td>-</td>
</tr>
<tr>
<td>Injectable 2</td>
<td>-</td>
<td>-</td>
<td>20,000</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Noristerat</td>
<td>-</td>
<td>-</td>
<td>20,000</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Injectable 3-IM</td>
<td>-</td>
<td>-</td>
<td>40,000</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Depo-Provera</td>
<td>-</td>
<td>-</td>
<td>40,000</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Injectable 3-IM Provided</td>
<td>22</td>
<td>14</td>
<td>50</td>
<td>-</td>
<td>27</td>
<td>85%</td>
<td>186</td>
<td>2,659</td>
<td>13</td>
<td>13</td>
<td>11</td>
<td>-</td>
</tr>
<tr>
<td>Non-PSI Injectable 3 IM Provided</td>
<td>22</td>
<td>14</td>
<td>50</td>
<td>-</td>
<td>27</td>
<td>85%</td>
<td>186</td>
<td>2,659</td>
<td>13</td>
<td>13</td>
<td>11</td>
<td>-</td>
</tr>
<tr>
<td>Injectable 3-SC</td>
<td>-</td>
<td>-</td>
<td>160,000</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Sayana Press</td>
<td>-</td>
<td>-</td>
<td>160,000</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>IUD 10</td>
<td>-</td>
<td>-</td>
<td>79,395</td>
<td>-</td>
<td>2/18</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>IUD Copper T 380A</td>
<td>-</td>
<td>-</td>
<td>79,395</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>IUD 10 Insertion</td>
<td>1,370</td>
<td>3,931</td>
<td>2,911</td>
<td>55,606</td>
<td>11,139</td>
<td>(74)%</td>
<td>68,290</td>
<td>143,897</td>
<td>2,911</td>
<td>13,391</td>
<td>14,468</td>
<td>-</td>
</tr>
<tr>
<td>Non-PSI IUD 10 Inserted</td>
<td>1,370</td>
<td>3,931</td>
<td>2,911</td>
<td>55,606</td>
<td>11,139</td>
<td>(74)%</td>
<td>68,290</td>
<td>143,897</td>
<td>2,911</td>
<td>13,391</td>
<td>14,468</td>
<td>-</td>
</tr>
<tr>
<td>Manual Vacuum Aspiration for PAC</td>
<td>228</td>
<td>410</td>
<td>228</td>
<td>6,236</td>
<td>1,576</td>
<td>(86)%</td>
<td>7,879</td>
<td>27,283</td>
<td>228</td>
<td>-</td>
<td>180</td>
<td>-</td>
</tr>
<tr>
<td>MVA for PAC</td>
<td>228</td>
<td>410</td>
<td>228</td>
<td>6,236</td>
<td>1,576</td>
<td>(86)%</td>
<td>7,879</td>
<td>27,283</td>
<td>228</td>
<td>-</td>
<td>180</td>
<td>-</td>
</tr>
<tr>
<td>Medical Abortion</td>
<td>-</td>
<td>333</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>2,000</td>
<td>2,000</td>
<td>0%</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Mariprist</td>
<td>-</td>
<td>333</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>2,000</td>
<td>2,000</td>
<td>0%</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Misoprostol for PAC Provided</td>
<td>208</td>
<td>316</td>
<td>208</td>
<td>6,179</td>
<td>1,578</td>
<td>(87)%</td>
<td>7,331</td>
<td>22,394</td>
<td>208</td>
<td>-</td>
<td>197</td>
<td>-</td>
</tr>
<tr>
<td>Non-PSI Misoprostol for PAC Provided</td>
<td>208</td>
<td>-</td>
<td>208</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>208</td>
<td>208</td>
<td>-</td>
<td>197</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PSI Misoprostol for PAC Provided</td>
<td>-</td>
<td>316</td>
<td>-</td>
<td>6,179</td>
<td>1,578</td>
<td>(100)%</td>
<td>7,331</td>
<td>22,331</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Misoprostol for Safe Abortion</td>
<td>185,300</td>
<td>82,603</td>
<td>393,000</td>
<td>1,977,921</td>
<td>218,558</td>
<td>80%</td>
<td>1,774,246</td>
<td>4,488,446</td>
<td>20,632</td>
<td>-</td>
<td>17,324</td>
<td>-</td>
</tr>
<tr>
<td>Misoclear</td>
<td>185,300</td>
<td>83,867</td>
<td>393,000</td>
<td>2,002,637</td>
<td>224,870</td>
<td>75%</td>
<td>1,803,570</td>
<td>4,577,190</td>
<td>20,632</td>
<td>-</td>
<td>17,324</td>
<td>-</td>
</tr>
<tr>
<td>(b)PSI Misoprostol for Safe Abortion Dist Provided</td>
<td>- (1,264)</td>
<td>(24,716)</td>
<td>(6,312)</td>
<td>-</td>
<td>(29,324)</td>
<td>(88,744)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
## Monthly Distribution by Country

**Period:** 2  
**Year:** 2020

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>OCs</td>
<td></td>
<td>-</td>
<td>6,960</td>
<td>0%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Microlut</td>
<td></td>
<td>-</td>
<td>6,960</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>OCs Provided</td>
<td>241</td>
<td>429</td>
<td>501</td>
<td>-</td>
<td>475</td>
<td>5%</td>
<td>5,512</td>
<td>7,389</td>
<td>33</td>
</tr>
<tr>
<td>Non-PSI OCs Provided</td>
<td>241</td>
<td>429</td>
<td>501</td>
<td>-</td>
<td>475</td>
<td>5%</td>
<td>5,512</td>
<td>7,389</td>
<td>33</td>
</tr>
<tr>
<td>SDM (Cycle Beads)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>20,000</td>
<td>-</td>
<td>0%</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Cycle Beads</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>20,000</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>SDM (Cycle Beads) Provided</td>
<td>4</td>
<td>7</td>
<td>7</td>
<td>-</td>
<td>20</td>
<td>(65)%</td>
<td>112</td>
<td>119</td>
<td>7</td>
</tr>
<tr>
<td>Non-PSI SDM (Cycle Beads) Provided</td>
<td>4</td>
<td>7</td>
<td>7</td>
<td>-</td>
<td>20</td>
<td>(65)%</td>
<td>112</td>
<td>119</td>
<td>7</td>
</tr>
</tbody>
</table>

### South Africa

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV Self-Testing Kit</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>365,816</td>
<td>12,448</td>
<td>(100)%</td>
<td>1,886,929</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>ORAQUICK HIV Self-Testing Kit (Pouch)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>365,816</td>
<td>12,448</td>
<td>(100)%</td>
<td>1,886,929</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>HIV Testing Services</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>7,361</td>
<td>-</td>
<td>(100)%</td>
<td>2,037,445</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>VCT Individual (HIV-Negative)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>6,301</td>
<td>12/09</td>
<td>100%</td>
<td>1,869,831</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>VCT Individual (HIV-Positive)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1,060</td>
<td>12/09</td>
<td>100%</td>
<td>167,614</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to HIV Testing Services</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>21,265</td>
<td>21,265</td>
<td>-</td>
</tr>
<tr>
<td>Referral to HIV Testing Services</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>21,265</td>
<td>21,265</td>
<td>-</td>
</tr>
<tr>
<td>Referral to Linkage to HIV Care</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>5,843</td>
<td>5,843</td>
<td>-</td>
</tr>
<tr>
<td>Referral to Linkage to HIV Care</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>5,843</td>
<td>5,843</td>
<td>-</td>
</tr>
<tr>
<td>Voluntary Medical Male Circumcision</td>
<td>2,033</td>
<td>12,288</td>
<td>13,892</td>
<td>92,463</td>
<td>7,718</td>
<td>80%</td>
<td>103,692</td>
<td>269,811</td>
<td>13,892</td>
</tr>
</tbody>
</table>

### Notes

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

---

**3002 - 4/15/2020 10:09:35AM**
Anglophone Africa Market Group
### POPULATION SERVICES INTERNATIONAL

**CYPs, Cases, and Deaths by Country**

1/2020 - 2/2020

<table>
<thead>
<tr>
<th>Country</th>
<th>New HIV Infections</th>
<th>STI Deaths</th>
<th>PWID Deaths</th>
<th>TB Deaths</th>
<th>CYP*</th>
<th>Maternal Deaths</th>
<th>Unintended Pregnancies</th>
<th>Malaria Deaths</th>
<th>Diarrhea Deaths</th>
<th>Pneumonia Deaths</th>
<th>Cervical Cancer Death</th>
<th>Sum of All Deaths</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anglophone Africa Market Group</td>
<td>11,094</td>
<td>4</td>
<td>-</td>
<td>1</td>
<td>278,035</td>
<td>315</td>
<td>111,986</td>
<td>7</td>
<td>36</td>
<td>-</td>
<td>1</td>
<td>2,495</td>
</tr>
<tr>
<td>Eswatini</td>
<td>2,695</td>
<td>-</td>
<td>-</td>
<td>19,507</td>
<td>12</td>
<td>5,486</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>94</td>
</tr>
<tr>
<td>Ethiopia</td>
<td>120</td>
<td>2</td>
<td>-</td>
<td>5,035</td>
<td>2</td>
<td>1,498</td>
<td>-</td>
<td>33</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>67</td>
</tr>
<tr>
<td>Ghana</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1</td>
</tr>
<tr>
<td>Lesotho</td>
<td>159</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>1,815</td>
<td>1</td>
<td>562</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>10</td>
</tr>
<tr>
<td>Malawi</td>
<td>1,080</td>
<td>-</td>
<td>-</td>
<td>65,612</td>
<td>122</td>
<td>27,480</td>
<td>7</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>644</td>
</tr>
<tr>
<td>PSI Uganda</td>
<td>333</td>
<td>-</td>
<td>-</td>
<td>28,744</td>
<td>55</td>
<td>11,834</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>337</td>
</tr>
<tr>
<td>Rwanda</td>
<td>731</td>
<td>-</td>
<td>-</td>
<td>20,892</td>
<td>9</td>
<td>6,151</td>
<td>-</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>137</td>
</tr>
<tr>
<td>Tanzania</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>74,797</td>
<td>54</td>
<td>34,056</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>727</td>
</tr>
<tr>
<td>Uganda</td>
<td>599</td>
<td>-</td>
<td>-</td>
<td>3,296</td>
<td>2</td>
<td>922</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>24</td>
</tr>
<tr>
<td>Zambia</td>
<td>503</td>
<td>-</td>
<td>-</td>
<td>18,116</td>
<td>10</td>
<td>7,863</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>199</td>
</tr>
<tr>
<td>Zimbabwe</td>
<td>4,874</td>
<td>2</td>
<td>-</td>
<td>40,221</td>
<td>50</td>
<td>16,134</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>235</td>
</tr>
</tbody>
</table>

* Using USAID CYP conversion factors
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Antiretroviral Treatment (Currently Enrolled)</td>
<td>14,605</td>
<td>14,479</td>
<td>28,751</td>
<td>168,553</td>
<td>25,661</td>
<td>12%</td>
<td>163,277</td>
<td>459,287</td>
<td>2,396</td>
<td>-</td>
<td>5,146</td>
</tr>
<tr>
<td>Antiretroviral Treatment (Newly Enrolled)</td>
<td>850</td>
<td>703</td>
<td>1,514</td>
<td>6,266</td>
<td>824</td>
<td>84%</td>
<td>7,255</td>
<td>31,634</td>
<td>1,514</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Cervical Cancer-HPV DNA and Conization</td>
<td>3</td>
<td>5</td>
<td>11</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>10</td>
<td>21</td>
<td>11</td>
<td>-</td>
<td>5</td>
</tr>
<tr>
<td>Cervical Cancer-HPV DNA and Cryotherapy</td>
<td>-</td>
<td>4</td>
<td>8</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>8</td>
<td>19</td>
<td>8</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Cervical Cancer-HPV DNA and Refer to any Treatment</td>
<td>-</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>2</td>
<td>13</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Cervical Cancer-HPV DNA and Refer to Cryothera</td>
<td>2</td>
<td>-</td>
<td>2</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Cervical Cancer-HPV DNA Screening</td>
<td>162</td>
<td>502</td>
<td>719</td>
<td>17,000</td>
<td>-</td>
<td>-%</td>
<td>3,346</td>
<td>4,065</td>
<td>719</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Cervical Cancer-Pap and Conization</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>1,753</td>
<td>1,753</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Cervical Cancer-Pap and Refer to any Treatment</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>9</td>
<td>10</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Cervical Cancer-VIA and Conization</td>
<td>17</td>
<td>18</td>
<td>41</td>
<td>150</td>
<td>30</td>
<td>37%</td>
<td>245</td>
<td>590</td>
<td>41</td>
<td>-</td>
<td>15</td>
</tr>
<tr>
<td>Cervical Cancer-VIA and Cryotherapy</td>
<td>19</td>
<td>15</td>
<td>38</td>
<td>352</td>
<td>74</td>
<td>(49)%</td>
<td>1,598</td>
<td>5,756</td>
<td>38</td>
<td>-</td>
<td>13</td>
</tr>
<tr>
<td>Cervical Cancer-VIA and Refer to any Treatment</td>
<td>3</td>
<td>3</td>
<td>5</td>
<td>-</td>
<td>9</td>
<td>(44)%</td>
<td>85</td>
<td>401</td>
<td>5</td>
<td>-</td>
<td>1</td>
</tr>
<tr>
<td>Cervical Cancer-VIA and Refer to Conization</td>
<td>2</td>
<td>1</td>
<td>3</td>
<td>-</td>
<td>6</td>
<td>(50)%</td>
<td>23</td>
<td>2,060</td>
<td>3</td>
<td>-</td>
<td>1</td>
</tr>
<tr>
<td>Cervical Cancer-VIA/VILI Screening</td>
<td>2,071</td>
<td>2,516</td>
<td>3,308</td>
<td>23,800</td>
<td>6,798</td>
<td>(51)%</td>
<td>45,450</td>
<td>193,074</td>
<td>3,308</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Chlorhexidine</td>
<td>615</td>
<td>379</td>
<td>1,115</td>
<td>11,000</td>
<td>773</td>
<td>44%</td>
<td>6,590</td>
<td>30,916</td>
<td>1,004</td>
<td>-</td>
<td>77</td>
</tr>
<tr>
<td>Condom</td>
<td>3,430,784</td>
<td>2,594,078</td>
<td>5,264,155</td>
<td>88,770,000</td>
<td>8,805,352</td>
<td>(40)%</td>
<td>46,499,698</td>
<td>1,296,124,565</td>
<td>39,481</td>
<td>39,481</td>
<td>99,078</td>
</tr>
<tr>
<td>Emergency Contraception</td>
<td>16,597</td>
<td>21,783</td>
<td>37,631</td>
<td>46,500</td>
<td>8,473</td>
<td>344%</td>
<td>123,784</td>
<td>1,225,413</td>
<td>1,693</td>
<td>1,693</td>
<td>541</td>
</tr>
<tr>
<td>Emergency Contraception Provided</td>
<td>844</td>
<td>1,534</td>
<td>1,695</td>
<td>239</td>
<td>656</td>
<td>158%</td>
<td>91,980</td>
<td>101,727</td>
<td>85</td>
<td>85</td>
<td>44</td>
</tr>
<tr>
<td>Expanded Clean Delivery Kit (+CHX)</td>
<td>457</td>
<td>276</td>
<td>601</td>
<td>18,000</td>
<td>464</td>
<td>30%</td>
<td>11,709</td>
<td>26,147</td>
<td>541</td>
<td>-</td>
<td>88</td>
</tr>
<tr>
<td>Female Condom</td>
<td>22,100</td>
<td>8,758</td>
<td>30,140</td>
<td>178,000</td>
<td>44,376</td>
<td>(32)%</td>
<td>174,851</td>
<td>28,589,317</td>
<td>226</td>
<td>226</td>
<td>1,292</td>
</tr>
<tr>
<td>Fever Cases Attended</td>
<td>-</td>
<td>22,518</td>
<td>-</td>
<td>340,000</td>
<td>-</td>
<td>-%</td>
<td>238,868</td>
<td>238,868</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

\(a\) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.
### Monthly Distribution by Market Group and Product

**Period:** 2  
**Year:** 2020

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Fever Cases Tested with RDTs</td>
<td>-</td>
<td>-</td>
<td>21,511</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>227,984</td>
<td>227,984</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Free Condom</td>
<td>2,829,548</td>
<td>4,433,295</td>
<td>4,576,628</td>
<td>54,202,856</td>
<td>8,599,417</td>
<td>(47)%</td>
<td>61,742,141</td>
<td>450,564,020</td>
<td>34,325</td>
<td>34,325</td>
<td>146,829</td>
</tr>
<tr>
<td>Free Female Condom</td>
<td>26,950</td>
<td>35,589</td>
<td>56,750</td>
<td>188,719</td>
<td>16,160</td>
<td>251%</td>
<td>1,398,332</td>
<td>6,044,773</td>
<td>426</td>
<td>426</td>
<td>1,170</td>
</tr>
<tr>
<td>HIV Self-Testing Kit</td>
<td>29,115</td>
<td>95,318</td>
<td>54,044</td>
<td>319,994</td>
<td>85,094</td>
<td>(36)%</td>
<td>759,756</td>
<td>2,180,301</td>
<td>48,640</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>HIV Testing Services</td>
<td>37,517</td>
<td>21,398</td>
<td>58,210</td>
<td>464,226</td>
<td>49,969</td>
<td>16%</td>
<td>315,263</td>
<td>6,194,489</td>
<td>58,210</td>
<td>-</td>
<td>4,131</td>
</tr>
<tr>
<td>Hypertension Diagnosis</td>
<td>1,529</td>
<td>1,908</td>
<td>3,269</td>
<td>266</td>
<td>2,448</td>
<td>34%</td>
<td>21,416</td>
<td>60,090</td>
<td>3,269</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Hypertension Screening</td>
<td>72,678</td>
<td>79,473</td>
<td>144,773</td>
<td>144,169</td>
<td>121,060</td>
<td>20%</td>
<td>917,675</td>
<td>2,714,883</td>
<td>144,169</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Hypertension_Controlled Condition</td>
<td>20</td>
<td>6</td>
<td>30</td>
<td>77</td>
<td>12</td>
<td>150%</td>
<td>105</td>
<td>292</td>
<td>12</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Implant 3</td>
<td>(4,169)</td>
<td>8,265</td>
<td>(5,093)</td>
<td>77,707</td>
<td>7,574</td>
<td>(167)%</td>
<td>75,182</td>
<td>111,039</td>
<td>(4,584)</td>
<td>(11,459)</td>
<td>(11,289)</td>
</tr>
<tr>
<td>Implant 3 Insertion</td>
<td>8,913</td>
<td>12,321</td>
<td>13,248</td>
<td>69,961</td>
<td>35,396</td>
<td>(63)%</td>
<td>217,237</td>
<td>590,901</td>
<td>13,248</td>
<td>33,120</td>
<td>31,351</td>
</tr>
<tr>
<td>Implant 4</td>
<td>1,045</td>
<td>720</td>
<td>2,971</td>
<td>-</td>
<td>(28)</td>
<td>-%</td>
<td>18,459</td>
<td>17,547</td>
<td>2,674</td>
<td>8,556</td>
<td>7,665</td>
</tr>
<tr>
<td>Implant 4 Insertion</td>
<td>1,060</td>
<td>882</td>
<td>1,942</td>
<td>-</td>
<td>28</td>
<td>6,836%</td>
<td>10,829</td>
<td>46,654</td>
<td>1,942</td>
<td>6,214</td>
<td>5,580</td>
</tr>
<tr>
<td>Implant 5</td>
<td>(948)</td>
<td>2,522</td>
<td>(1,499)</td>
<td>16,628</td>
<td>4,458</td>
<td>(134)%</td>
<td>54,899</td>
<td>267,916</td>
<td>(1,349)</td>
<td>(5,127)</td>
<td>(9,142)</td>
</tr>
<tr>
<td>Implant 5 Insertion</td>
<td>9,993</td>
<td>9,929</td>
<td>16,798</td>
<td>55,410</td>
<td>27,794</td>
<td>(40)%</td>
<td>175,768</td>
<td>580,424</td>
<td>16,798</td>
<td>63,832</td>
<td>54,538</td>
</tr>
<tr>
<td>Injectable 1</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>15,000</td>
<td>-</td>
<td>-%</td>
<td>21,725</td>
<td>61,175</td>
<td>851</td>
<td>851</td>
<td>489</td>
</tr>
<tr>
<td>Injectable 1 Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>20</td>
<td>10</td>
<td>(100)%</td>
<td>42</td>
<td>1,809</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Injectable 2</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1,200</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Injectable 2 Provided</td>
<td>1,331</td>
<td>2,937</td>
<td>5,107</td>
<td>770</td>
<td>3,587</td>
<td>42%</td>
<td>21,725</td>
<td>61,175</td>
<td>851</td>
<td>851</td>
<td>489</td>
</tr>
<tr>
<td>Injectable 3-IM</td>
<td>(318)</td>
<td>13,626</td>
<td>18,249</td>
<td>629,600</td>
<td>46,529</td>
<td>(61)%</td>
<td>721,934</td>
<td>5,797,763</td>
<td>4,106</td>
<td>4,106</td>
<td>2,654</td>
</tr>
<tr>
<td>Injectable 3-IM Provided</td>
<td>10,957</td>
<td>25,597</td>
<td>34,813</td>
<td>164,097</td>
<td>68,615</td>
<td>(49)%</td>
<td>416,171</td>
<td>1,142,807</td>
<td>8,703</td>
<td>8,703</td>
<td>5,410</td>
</tr>
<tr>
<td>Injectable 3-SC</td>
<td>(2,175)</td>
<td>3,304</td>
<td>(2,131)</td>
<td>50,000</td>
<td>12,630</td>
<td>(117)%</td>
<td>91,046</td>
<td>144,815</td>
<td>(479)</td>
<td>(479)</td>
<td>(329)</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.
### Monthly Distribution by Market Group and Product

**Period:** 2

**Year:** 2020

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Injectable 3-SC Provided</td>
<td>4,471</td>
<td>8,662</td>
<td>11,639</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>33,304</td>
<td>44,943</td>
<td>2,910</td>
<td>2,910</td>
<td>2,062</td>
</tr>
<tr>
<td>ITN</td>
<td>-</td>
<td>420,232</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>1,265,503</td>
<td>1,265,503</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>IUD 10</td>
<td>13,739</td>
<td>14,437</td>
<td>13,652</td>
<td>74,158</td>
<td>2,755</td>
<td>396%</td>
<td>121,202</td>
<td>514,649</td>
<td>12,287</td>
<td>56,519</td>
<td>44,916</td>
</tr>
<tr>
<td>IUD 10 Insertion</td>
<td>2,195</td>
<td>5,372</td>
<td>3,715</td>
<td>31,494</td>
<td>16,649</td>
<td>(78)%</td>
<td>107,088</td>
<td>805,930</td>
<td>3,715</td>
<td>17,089</td>
<td>15,002</td>
</tr>
<tr>
<td>IUD 5 Insertion</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>80</td>
<td>(100)%</td>
<td>162</td>
<td>377</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>IUS 3</td>
<td>-</td>
<td>(80)</td>
<td>(81)</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>(379)</td>
<td>(460)</td>
<td>(73)</td>
<td>(182)</td>
<td>(172)</td>
</tr>
<tr>
<td>IUS 3 Insertion</td>
<td>-</td>
<td>80</td>
<td>81</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>379</td>
<td>460</td>
<td>81</td>
<td>203</td>
<td>192</td>
</tr>
<tr>
<td>IUS 5</td>
<td>109</td>
<td>(12)</td>
<td>91</td>
<td>(28)</td>
<td>-</td>
<td>-%</td>
<td>395</td>
<td>1,566</td>
<td>82</td>
<td>270</td>
<td>146</td>
</tr>
<tr>
<td>IUS 5 Insertion</td>
<td>11</td>
<td>12</td>
<td>29</td>
<td>-</td>
<td>167</td>
<td>(83)%</td>
<td>550</td>
<td>1,684</td>
<td>29</td>
<td>96</td>
<td>52</td>
</tr>
<tr>
<td>LLIN</td>
<td>7,824</td>
<td>118</td>
<td>7,829</td>
<td>60,000</td>
<td>16,912</td>
<td>(54)%</td>
<td>213,151</td>
<td>4,393,153</td>
<td>12,683</td>
<td>-</td>
<td>490</td>
</tr>
<tr>
<td>Lubricant</td>
<td>300,831</td>
<td>335,130</td>
<td>399,831</td>
<td>2,387,723</td>
<td>436,586</td>
<td>(8)%</td>
<td>2,926,726</td>
<td>9,034,852</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Manual Vacuum Aspiration for PAC</td>
<td>81</td>
<td>259</td>
<td>110</td>
<td>8,718</td>
<td>1,104</td>
<td>(90)%</td>
<td>6,339</td>
<td>14,666</td>
<td>110</td>
<td>-</td>
<td>31</td>
</tr>
<tr>
<td>Manual Vacuum Aspiration for SA</td>
<td>86</td>
<td>73</td>
<td>190</td>
<td>742</td>
<td>143</td>
<td>33%</td>
<td>805</td>
<td>1,256</td>
<td>190</td>
<td>-</td>
<td>69</td>
</tr>
<tr>
<td>Medical Abortion</td>
<td>675</td>
<td>657</td>
<td>1,431</td>
<td>12,328</td>
<td>854</td>
<td>68%</td>
<td>10,999</td>
<td>28,965</td>
<td>1,288</td>
<td>-</td>
<td>451</td>
</tr>
<tr>
<td>Medical Abortion (Misoprostol) Provided</td>
<td>84</td>
<td>49</td>
<td>146</td>
<td>742</td>
<td>225</td>
<td>(35)%</td>
<td>988</td>
<td>1,478</td>
<td>146</td>
<td>-</td>
<td>46</td>
</tr>
<tr>
<td>Medical Abortion Provided</td>
<td>71</td>
<td>47</td>
<td>114</td>
<td>494</td>
<td>140</td>
<td>(19)%</td>
<td>775</td>
<td>1,158</td>
<td>114</td>
<td>-</td>
<td>40</td>
</tr>
<tr>
<td>Misoprostol for PAC Provided</td>
<td>55</td>
<td>118</td>
<td>83</td>
<td>3,877</td>
<td>701</td>
<td>(88)%</td>
<td>3,078</td>
<td>6,345</td>
<td>83</td>
<td>-</td>
<td>29</td>
</tr>
<tr>
<td>Misoprostol for Safe Abortion</td>
<td>50,873</td>
<td>95,499</td>
<td>84,017</td>
<td>694,896</td>
<td>115,308</td>
<td>(27)%</td>
<td>1,562,074</td>
<td>2,874,915</td>
<td>4,411</td>
<td>-</td>
<td>1,381</td>
</tr>
<tr>
<td>OCs</td>
<td>30,430</td>
<td>17,179</td>
<td>32,806</td>
<td>2,109,186</td>
<td>318,427</td>
<td>(90)%</td>
<td>1,546,809</td>
<td>6,836,240</td>
<td>1,968</td>
<td>1,968</td>
<td>1,470</td>
</tr>
<tr>
<td>OCs Provided</td>
<td>30,444</td>
<td>35,251</td>
<td>69,021</td>
<td>218,906</td>
<td>64,927</td>
<td>6%</td>
<td>535,112</td>
<td>1,948,301</td>
<td>4,601</td>
<td>4,601</td>
<td>2,527</td>
</tr>
<tr>
<td>Positive RDTs</td>
<td>-</td>
<td>14,222</td>
<td>-</td>
<td>209,952</td>
<td>-</td>
<td>-%</td>
<td>155,419</td>
<td>155,419</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.
<table>
<thead>
<tr>
<th>Product Description</th>
<th>DISTRIBUTION 2/2020</th>
<th>MONTHLY AVG PREV 3 MONTHS</th>
<th>YTD DISTRIBUTION 2020</th>
<th>DISTRIBUTION TARGET 2020</th>
<th>YTD DISTRIBUTION 2019</th>
<th>YTD % CHANGE</th>
<th>TOTAL DISTRIBUTION 2019</th>
<th>CUMULATIVE SALES</th>
<th>YTD USERS REACHED (%)</th>
<th>YTD CYP 2020</th>
<th>YTD DALY 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Positive RDTs Given First Line Treatment</td>
<td>-</td>
<td>13,425</td>
<td>-</td>
<td>188,956</td>
<td>-</td>
<td>-%</td>
<td>144,641</td>
<td>144,641</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Pregnancy Test</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>10,900</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PrEP</td>
<td>3,830</td>
<td>3,995</td>
<td>8,069</td>
<td>64,162</td>
<td>7,097</td>
<td>14%</td>
<td>46,374</td>
<td>91,996</td>
<td>672</td>
<td>-</td>
<td>249</td>
</tr>
<tr>
<td>PUR</td>
<td>3,337,000</td>
<td>1,829,173</td>
<td>8,264,695</td>
<td>16,073,087</td>
<td>3,865,000</td>
<td>114%</td>
<td>30,213,032</td>
<td>196,001,494</td>
<td>67,929</td>
<td>-</td>
<td>241</td>
</tr>
<tr>
<td>Referral to Advanced Cervical Cancer Treatment</td>
<td>-</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>10</td>
<td>(100)%</td>
<td>34,434</td>
<td>55,135</td>
<td>8,998</td>
<td>-</td>
<td>279</td>
</tr>
<tr>
<td>Referral to HIV Testing Services</td>
<td>5,941</td>
<td>1,871</td>
<td>8,998</td>
<td>50,096</td>
<td>5,352</td>
<td>68%</td>
<td>34,434</td>
<td>55,135</td>
<td>8,998</td>
<td>-</td>
<td>279</td>
</tr>
<tr>
<td>Referral to Hypertension Management</td>
<td>49</td>
<td>30</td>
<td>97</td>
<td>43</td>
<td>126%</td>
<td>336</td>
<td>1,563</td>
<td>97</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to Implant 3 Insertion</td>
<td>-</td>
<td>86</td>
<td>258</td>
<td>114</td>
<td>-</td>
<td>-%</td>
<td>293</td>
<td>1,688</td>
<td>258</td>
<td>323</td>
<td>270</td>
</tr>
<tr>
<td>Referral to Implant 5 Insertion</td>
<td>-</td>
<td>5</td>
<td>16</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>11</td>
<td>331</td>
<td>16</td>
<td>30</td>
<td>25</td>
</tr>
<tr>
<td>Referral to Injectable 3</td>
<td>-</td>
<td>330</td>
<td>989</td>
<td>851</td>
<td>-</td>
<td>-%</td>
<td>887</td>
<td>4,290</td>
<td>247</td>
<td>124</td>
<td>76</td>
</tr>
<tr>
<td>Referral to IUD 10 Insertation</td>
<td>-</td>
<td>2</td>
<td>7</td>
<td>2</td>
<td>-</td>
<td>-%</td>
<td>4</td>
<td>150</td>
<td>7</td>
<td>16</td>
<td>13</td>
</tr>
<tr>
<td>Referral to Linkage to HIV Care</td>
<td>16,158</td>
<td>12,431</td>
<td>30,651</td>
<td>178,997</td>
<td>8,934</td>
<td>243%</td>
<td>112,751</td>
<td>185,432</td>
<td>30,651</td>
<td>-</td>
<td>25,288</td>
</tr>
<tr>
<td>Referral to OCs</td>
<td>-</td>
<td>46</td>
<td>138</td>
<td>55</td>
<td>-</td>
<td>-%</td>
<td>84</td>
<td>1,112</td>
<td>9</td>
<td>5</td>
<td>3</td>
</tr>
<tr>
<td>Referral to Pre-Exposure Prophylaxis (PrEP)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>3</td>
<td>253</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to TB Screening</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>59,060</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to Treatment for Urethral Discharge (Men)</td>
<td>2</td>
<td>-</td>
<td>2</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>115</td>
<td>2</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to Treatment for Vaginitis</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>1</td>
<td>9</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to Tx for Nonherpetic Genital Ulcer</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>(100)%</td>
<td>1</td>
<td>73</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to Tx for Urethral Discharge (Women)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>4</td>
<td>(100)%</td>
<td>10</td>
<td>557</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to Voluntary Medical Male Circumcision</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>3</td>
<td>10,818</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Safe Water Solution</td>
<td>46,872</td>
<td>64,713</td>
<td>91,824</td>
<td>1,485,515</td>
<td>287,578</td>
<td>(68)%</td>
<td>1,052,196</td>
<td>71,119,911</td>
<td>75,472</td>
<td>-</td>
<td>229</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>STI Kit (Non-Ulcerative)</td>
<td>1,560</td>
<td>372</td>
<td>1,560</td>
<td>2,006</td>
<td>2,067</td>
<td>(25)%</td>
<td>4,732</td>
<td>837,823</td>
<td>1,404</td>
<td>-</td>
<td>100</td>
</tr>
<tr>
<td>STI Kit (Ulcerative)</td>
<td>65</td>
<td>86</td>
<td>65</td>
<td>248</td>
<td>1,115</td>
<td>(94)%</td>
<td>1,588</td>
<td>73,881</td>
<td>59</td>
<td>-</td>
<td>12</td>
</tr>
<tr>
<td>STI Screening</td>
<td>9,903</td>
<td>8,796</td>
<td>19,514</td>
<td>141,848</td>
<td>26,777</td>
<td>(27)%</td>
<td>118,274</td>
<td>700,704</td>
<td>19,514</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>TB Diagnosis</td>
<td>14</td>
<td>25</td>
<td>40</td>
<td>240</td>
<td>35</td>
<td>14%</td>
<td>231</td>
<td>1,748</td>
<td>40</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>TB DOTS</td>
<td>2</td>
<td>3</td>
<td>6</td>
<td>36</td>
<td>4</td>
<td>50%</td>
<td>35</td>
<td>88</td>
<td>6</td>
<td>-</td>
<td>49</td>
</tr>
<tr>
<td>TB Screening</td>
<td>20,234</td>
<td>18,950</td>
<td>39,742</td>
<td>243,349</td>
<td>40,423</td>
<td>(2)%</td>
<td>241,495</td>
<td>1,732,262</td>
<td>39,742</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Toilets Sold</td>
<td>4,382</td>
<td>2,211</td>
<td>7,071</td>
<td>31,656</td>
<td>1,468</td>
<td>382%</td>
<td>20,460</td>
<td>33,181</td>
<td>32,048</td>
<td>-</td>
<td>1,228</td>
</tr>
<tr>
<td>Toilets Sold - All</td>
<td>5,336</td>
<td>2,947</td>
<td>10,055</td>
<td>-</td>
<td>2,031</td>
<td>395%</td>
<td>27,092</td>
<td>44,413</td>
<td>42,791</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Cervicitis</td>
<td>9</td>
<td>12</td>
<td>20</td>
<td>132</td>
<td>16</td>
<td>25%</td>
<td>193</td>
<td>576</td>
<td>20</td>
<td>-</td>
<td>2</td>
</tr>
<tr>
<td>Treatment for Genital Herpes</td>
<td>21</td>
<td>20</td>
<td>39</td>
<td>48</td>
<td>6</td>
<td>550%</td>
<td>135</td>
<td>254</td>
<td>39</td>
<td>-</td>
<td>1</td>
</tr>
<tr>
<td>Treatment for Inguinal Bubo</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>16</td>
<td>-</td>
<td>-%</td>
<td>18</td>
<td>30</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Lower Abdominal Pain</td>
<td>30</td>
<td>43</td>
<td>56</td>
<td>119</td>
<td>22</td>
<td>155%</td>
<td>465</td>
<td>734</td>
<td>56</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Nonherpetic Genital Ulcer</td>
<td>57</td>
<td>42</td>
<td>98</td>
<td>513</td>
<td>95</td>
<td>3%</td>
<td>663</td>
<td>1,907</td>
<td>98</td>
<td>-</td>
<td>35</td>
</tr>
<tr>
<td>Treatment for Urethral Discharge (Men)</td>
<td>97</td>
<td>71</td>
<td>170</td>
<td>487</td>
<td>77</td>
<td>121%</td>
<td>741</td>
<td>1,813</td>
<td>170</td>
<td>-</td>
<td>18</td>
</tr>
<tr>
<td>Treatment for Urethral Discharge (Women)</td>
<td>138</td>
<td>104</td>
<td>226</td>
<td>676</td>
<td>90</td>
<td>151%</td>
<td>1,141</td>
<td>2,814</td>
<td>226</td>
<td>-</td>
<td>35</td>
</tr>
<tr>
<td>Treatment for Vaginitis</td>
<td>23</td>
<td>16</td>
<td>35</td>
<td>336</td>
<td>131</td>
<td>(73)%</td>
<td>351</td>
<td>2,598</td>
<td>35</td>
<td>-</td>
<td>1</td>
</tr>
<tr>
<td>Tubal Ligation</td>
<td>661</td>
<td>727</td>
<td>951</td>
<td>7,158</td>
<td>1,018</td>
<td>(7)%</td>
<td>10,713</td>
<td>47,355</td>
<td>951</td>
<td>9,510</td>
<td>7,479</td>
</tr>
<tr>
<td>Type 2 Diabetes Screening</td>
<td>172</td>
<td>367</td>
<td>332</td>
<td>691</td>
<td>5,797</td>
<td>(94)%</td>
<td>22,647</td>
<td>39,569</td>
<td>332</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Vasectomy</td>
<td>-</td>
<td>2</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>17</td>
<td>17</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Voluntary Medical Male Circumcision</td>
<td>18,369</td>
<td>12,803</td>
<td>31,373</td>
<td>284,293</td>
<td>41,071</td>
<td>(24)%</td>
<td>270,203</td>
<td>1,015,598</td>
<td>31,373</td>
<td>-</td>
<td>198,828</td>
</tr>
<tr>
<td>Water Treatment Tablets</td>
<td>300,001</td>
<td>869,433</td>
<td>300,001</td>
<td>20,804,000</td>
<td>919,400</td>
<td>(67)%</td>
<td>6,229,910</td>
<td>126,874,262</td>
<td>4,934</td>
<td>-</td>
<td>20</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.
<table>
<thead>
<tr>
<th>Woman Condom</th>
<th>DISTRIBUTION 2/2020</th>
<th>MONTHLY AVG PREV 3 MONTHS</th>
<th>YTD DISTRIBUTION 2020</th>
<th>DISTRIBUTION TARGET 2020</th>
<th>YTD DISTRIBUTION 2019</th>
<th>YTD % CHANGE</th>
<th>TOTAL DISTRIBUTION 2019</th>
<th>CUMULATIVE SALES</th>
<th>YTD USERS REACHED(a) 2020</th>
<th>YTD CYP 2020</th>
<th>YTD DALY 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>480</td>
<td>(100)%</td>
<td>1,920</td>
<td>141,480</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.
### Anglophone Africa Market Group

#### Eswatini

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Antiretroviral Treatment (Currently Enrolled)</td>
<td>1,884</td>
<td>1,746</td>
<td>3,692</td>
<td>6,692</td>
<td>1,981</td>
<td>86%</td>
<td>15,930</td>
<td>30,532</td>
<td>308</td>
<td>-</td>
<td>759</td>
</tr>
<tr>
<td>Antiretroviral Treatment (Currently Enrolled)</td>
<td>1,884</td>
<td>1,746</td>
<td>3,692</td>
<td>6,692</td>
<td>1,981</td>
<td>86%</td>
<td>15,930</td>
<td>30,532</td>
<td>308</td>
<td>-</td>
<td>759</td>
</tr>
<tr>
<td>Antiretroviral Treatment (Newly Enrolled)</td>
<td>71</td>
<td>42</td>
<td>125</td>
<td>752</td>
<td>69</td>
<td>81%</td>
<td>728</td>
<td>2,015</td>
<td>125</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Antiretroviral Treatment (Newly Enrolled)</td>
<td>71</td>
<td>42</td>
<td>125</td>
<td>752</td>
<td>69</td>
<td>81%</td>
<td>728</td>
<td>2,015</td>
<td>125</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Cervical Cancer-VIA/VILI Screening</td>
<td>44</td>
<td>34</td>
<td>101</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>85</td>
<td>187</td>
<td>101</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Cervical Cancer-VIA/VILI Screening</td>
<td>44</td>
<td>34</td>
<td>101</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>85</td>
<td>187</td>
<td>101</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Emergency Contraception Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>3</td>
<td>10</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Non-PSI Emergency Contraception Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>3</td>
<td>10</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Female Condom</td>
<td>22,000</td>
<td>8,333</td>
<td>30,000</td>
<td>60,000</td>
<td>17,000</td>
<td>76%</td>
<td>94,000</td>
<td>1,156,727</td>
<td>225</td>
<td>225</td>
<td>1,289</td>
</tr>
<tr>
<td>Female Condom</td>
<td>22,000</td>
<td>8,333</td>
<td>30,000</td>
<td>60,000</td>
<td>17,000</td>
<td>76%</td>
<td>94,000</td>
<td>1,156,727</td>
<td>225</td>
<td>225</td>
<td>1,289</td>
</tr>
<tr>
<td>Free Condom</td>
<td>1,326,000</td>
<td>953,000</td>
<td>2,571,000</td>
<td>12,640,000</td>
<td>2,517,000</td>
<td>2%</td>
<td>11,877,000</td>
<td>77,297,544</td>
<td>19,282</td>
<td>19,282</td>
<td>111,468</td>
</tr>
<tr>
<td>Generic</td>
<td>846,000</td>
<td>672,000</td>
<td>1,707,000</td>
<td>8,640,000</td>
<td>1,200,000</td>
<td>42%</td>
<td>8,589,000</td>
<td>72,434,544</td>
<td>12,802</td>
<td>12,802</td>
<td>74,009</td>
</tr>
<tr>
<td>Vanilla &amp; Strawberry</td>
<td>480,000</td>
<td>281,000</td>
<td>864,000</td>
<td>4,000,000</td>
<td>1,317,000</td>
<td>(34)%</td>
<td>3,288,000</td>
<td>4,863,000</td>
<td>6,480</td>
<td>6,480</td>
<td>37,460</td>
</tr>
<tr>
<td>HIV Self-Testing Kit</td>
<td>2,388</td>
<td>3,797</td>
<td>5,387</td>
<td>27,000</td>
<td>-</td>
<td>0%</td>
<td>27,687</td>
<td>69,649</td>
<td>4,848</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>ORAQUICK HIV Self-Testing Kit (Pouch)</td>
<td>2,388</td>
<td>3,797</td>
<td>5,387</td>
<td>27,000</td>
<td>-</td>
<td>-%</td>
<td>27,687</td>
<td>69,649</td>
<td>4,848</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>HIV Testing Services</td>
<td>1,999</td>
<td>1,800</td>
<td>4,791</td>
<td>32,788</td>
<td>7,785</td>
<td>(38)%</td>
<td>33,375</td>
<td>658,137</td>
<td>4,791</td>
<td>-</td>
<td>651</td>
</tr>
<tr>
<td>VCT Individual (HIV-Negative)</td>
<td>1,717</td>
<td>1,572</td>
<td>4,249</td>
<td>25,752</td>
<td>7,016</td>
<td>(39)%</td>
<td>28,812</td>
<td>600,858</td>
<td>4,249</td>
<td>-</td>
<td>578</td>
</tr>
<tr>
<td>VCT Individual (HIV-Positive)</td>
<td>282</td>
<td>229</td>
<td>542</td>
<td>7,036</td>
<td>769</td>
<td>(30)%</td>
<td>4,563</td>
<td>57,279</td>
<td>542</td>
<td>-</td>
<td>74</td>
</tr>
<tr>
<td>Hypertension Screening</td>
<td>207</td>
<td>391</td>
<td>395</td>
<td>2,000</td>
<td>917</td>
<td>(57)%</td>
<td>6,115</td>
<td>15,014</td>
<td>395</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Hypertension Screening</td>
<td>207</td>
<td>391</td>
<td>395</td>
<td>2,000</td>
<td>917</td>
<td>(57)%</td>
<td>6,115</td>
<td>15,014</td>
<td>395</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Implant 3 Insertion</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>8</td>
<td>3</td>
<td>(100)%</td>
<td>25</td>
<td>197</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Non-PSI Implant 3 Inserted</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>8</td>
<td>3</td>
<td>(100)%</td>
<td>25</td>
<td>197</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Injectable 1 Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>20</td>
<td>10</td>
<td>(100)%</td>
<td>41</td>
<td>1,800</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
### Monthly Distribution by Country

**Period:** 2020  
**Year:** 2020

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-PSI Injectable 1 Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>20</td>
<td>10</td>
<td>(100)%</td>
<td>41</td>
<td>1,800</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Injectable 2 Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>20</td>
<td>-</td>
<td>0%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Non-PSI Injectable 2 Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>20</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Injectable 3-IM Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>40</td>
<td>39</td>
<td>(100)%</td>
<td>121</td>
<td>2,954</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Non-PSI Injectable 3 IM Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>40</td>
<td>39</td>
<td>(100)%</td>
<td>121</td>
<td>2,954</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Lubricant</td>
<td>108,000</td>
<td>84,667</td>
<td>194,000</td>
<td>600,000</td>
<td>113,000</td>
<td>72%</td>
<td>795,000</td>
<td>3,004,000</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Lifestyles Liquid Personal Lubricant (4.5 g)</td>
<td>108,000</td>
<td>84,667</td>
<td>194,000</td>
<td>600,000</td>
<td>113,000</td>
<td>8/11</td>
<td>72%</td>
<td>795,000</td>
<td>3,004,000</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>OCs Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>40</td>
<td>17</td>
<td>(100)%</td>
<td>97</td>
<td>2,308</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Non-PSI OCs Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>40</td>
<td>17</td>
<td>(100)%</td>
<td>97</td>
<td>2,308</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PrEP</td>
<td>11</td>
<td>13</td>
<td>26</td>
<td>-</td>
<td>19</td>
<td>37%</td>
<td>177</td>
<td>281</td>
<td>2</td>
<td>1</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PrEP</td>
<td>11</td>
<td>13</td>
<td>26</td>
<td>-</td>
<td>19</td>
<td>37%</td>
<td>177</td>
<td>281</td>
<td>2</td>
<td>1</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to Hypertension Management</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>(100)%</td>
<td>1</td>
<td>46</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to Hypertension Management</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>(100)%</td>
<td>1</td>
<td>46</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to Linkage to HIV Care</td>
<td>190</td>
<td>107</td>
<td>312</td>
<td>5,628</td>
<td>539</td>
<td>(42)%</td>
<td>2,374</td>
<td>9,289</td>
<td>312</td>
<td>-</td>
<td>204</td>
<td>-</td>
</tr>
<tr>
<td>Referral to Linkage to HIV Care</td>
<td>190</td>
<td>107</td>
<td>312</td>
<td>5,628</td>
<td>539</td>
<td>(42)%</td>
<td>2,374</td>
<td>9,289</td>
<td>312</td>
<td>-</td>
<td>204</td>
<td>-</td>
</tr>
<tr>
<td>STI Screening</td>
<td>2,327</td>
<td>1,836</td>
<td>5,182</td>
<td>32,788</td>
<td>7,858</td>
<td>(34)%</td>
<td>33,799</td>
<td>148,429</td>
<td>5,182</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>STI Screening</td>
<td>2,327</td>
<td>1,836</td>
<td>5,182</td>
<td>32,788</td>
<td>7,858</td>
<td>(34)%</td>
<td>33,799</td>
<td>148,429</td>
<td>5,182</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>TB Screening</td>
<td>2,243</td>
<td>1,997</td>
<td>5,044</td>
<td>34,528</td>
<td>7,785</td>
<td>(35)%</td>
<td>33,964</td>
<td>139,305</td>
<td>5,044</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>TB Screening</td>
<td>2,243</td>
<td>1,997</td>
<td>5,044</td>
<td>34,528</td>
<td>7,785</td>
<td>(35)%</td>
<td>33,964</td>
<td>139,305</td>
<td>5,044</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Genital Herpes</td>
<td>-</td>
<td>2</td>
<td>-</td>
<td>20</td>
<td>6</td>
<td>(100)%</td>
<td>24</td>
<td>68</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Genital Herpes</td>
<td>-</td>
<td>2</td>
<td>-</td>
<td>20</td>
<td>6</td>
<td>(100)%</td>
<td>24</td>
<td>68</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Lower Abdominal Pain</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>20</td>
<td>20</td>
<td>(100)%</td>
<td>64</td>
<td>173</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Lower Abdominal Pain</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>40</td>
<td>20</td>
<td>(100)%</td>
<td>64</td>
<td>173</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Nonherpetic Genital Ulcer</td>
<td>2</td>
<td>2</td>
<td>8</td>
<td>40</td>
<td>20</td>
<td>(58)%</td>
<td>80</td>
<td>327</td>
<td>19</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Nonherpetic Genital Ulcer</td>
<td>2</td>
<td>2</td>
<td>8</td>
<td>40</td>
<td>20</td>
<td>(58)%</td>
<td>80</td>
<td>327</td>
<td>19</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
### Monthly Distribution by Country

**Period:** 2  
**Year:** 2020

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment for Urethral Discharge (Men)</td>
<td>13</td>
<td>8</td>
<td>23</td>
<td>60</td>
<td>51</td>
<td>(55)%</td>
<td>270</td>
<td>707</td>
<td>23</td>
<td>-</td>
<td>3</td>
</tr>
<tr>
<td>Treatment for Urethral Discharge (Men)</td>
<td>13</td>
<td>8</td>
<td>23</td>
<td>60</td>
<td>51</td>
<td>(55)%</td>
<td>270</td>
<td>707</td>
<td>23</td>
<td>-</td>
<td>3</td>
</tr>
<tr>
<td>Treatment for Urethral Discharge (Women)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>3</td>
<td>(100)%</td>
<td>3</td>
<td>7</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Urethral Discharge (Women)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>3</td>
<td>(100)%</td>
<td>3</td>
<td>7</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Vaginitis</td>
<td>-</td>
<td>-</td>
<td>80</td>
<td>72</td>
<td>(100)%</td>
<td>216</td>
<td>1,182</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Treatment for Vaginitis</td>
<td>-</td>
<td>-</td>
<td>80</td>
<td>72</td>
<td>(100)%</td>
<td>216</td>
<td>1,182</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Type 2 Diabetes Screening</td>
<td>116</td>
<td>323</td>
<td>228</td>
<td>400</td>
<td>5,709</td>
<td>(96)%</td>
<td>22,275</td>
<td>23,420</td>
<td>228</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Type 2 Diabetes Screening</td>
<td>116</td>
<td>323</td>
<td>228</td>
<td>400</td>
<td>5,709</td>
<td>(96)%</td>
<td>22,275</td>
<td>23,420</td>
<td>228</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Voluntary Medical Male Circumcision</td>
<td>98</td>
<td>96</td>
<td>204</td>
<td>2,160</td>
<td>322</td>
<td>(37)%</td>
<td>2,580</td>
<td>9,651</td>
<td>204</td>
<td>-</td>
<td>2,849</td>
</tr>
<tr>
<td>Voluntary Medical Male Circumcision</td>
<td>98</td>
<td>96</td>
<td>204</td>
<td>2,160</td>
<td>322</td>
<td>(37)%</td>
<td>2,580</td>
<td>9,651</td>
<td>204</td>
<td>-</td>
<td>2,849</td>
</tr>
<tr>
<td><strong>Ethiopia</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5,035</td>
<td>9,179</td>
</tr>
<tr>
<td>Antiretroviral Treatment (Currently Enrolled)</td>
<td>793</td>
<td>857</td>
<td>1,611</td>
<td>63,600</td>
<td>2,227</td>
<td>(28)%</td>
<td>13,267</td>
<td>42,128</td>
<td>134</td>
<td>-</td>
<td>258</td>
</tr>
<tr>
<td>Antiretroviral Treatment (Currently Enrolled)</td>
<td>793</td>
<td>857</td>
<td>1,611</td>
<td>63,600</td>
<td>2,227</td>
<td>(28)%</td>
<td>13,267</td>
<td>42,128</td>
<td>134</td>
<td>-</td>
<td>258</td>
</tr>
<tr>
<td>Antiretroviral Treatment (Newly Enrolled)</td>
<td>39</td>
<td>40</td>
<td>69</td>
<td>670</td>
<td>53</td>
<td>30%</td>
<td>521</td>
<td>3,160</td>
<td>69</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Antiretroviral Treatment (Newly Enrolled)</td>
<td>39</td>
<td>40</td>
<td>69</td>
<td>670</td>
<td>53</td>
<td>30%</td>
<td>521</td>
<td>3,160</td>
<td>69</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Free Condom</td>
<td>605,000</td>
<td>1,129,360</td>
<td>605,000</td>
<td>11,362,320</td>
<td>3,398,500</td>
<td>(82)%</td>
<td>14,086,380</td>
<td>179,254,825</td>
<td>4,537</td>
<td>4,537</td>
<td>6,595</td>
</tr>
<tr>
<td>No Logo Condom</td>
<td>605,000</td>
<td>1,129,360</td>
<td>605,000</td>
<td>11,362,320</td>
<td>2,298,000</td>
<td>8/09</td>
<td>(74)%</td>
<td>12,807,680</td>
<td>23,397,680</td>
<td>4,537</td>
<td>4,537</td>
</tr>
<tr>
<td>Protector Plus</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1,100,500</td>
<td>12/12</td>
<td>(100)%</td>
<td>1,278,700</td>
<td>155,857,145</td>
<td>-</td>
</tr>
<tr>
<td>Free Female Condom</td>
<td>-</td>
<td>5,167</td>
<td>72,719</td>
<td>-</td>
<td>0%</td>
<td>89,231</td>
<td>988,320</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Free Female Condoms</td>
<td>-</td>
<td>5,167</td>
<td>72,719</td>
<td>-</td>
<td>0%</td>
<td>89,231</td>
<td>988,320</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>HIV Self-Testing Kit</td>
<td>-</td>
<td>1,036</td>
<td>5,070</td>
<td>-</td>
<td>0%</td>
<td>4,067</td>
<td>19,025</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>ORAQUICK HIV Self-Testing Kit (Pouch)</td>
<td>-</td>
<td>1,036</td>
<td>5,070</td>
<td>-</td>
<td>0%</td>
<td>4,067</td>
<td>19,025</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>HIV Testing Services</td>
<td>3,448</td>
<td>2,520</td>
<td>5,388</td>
<td>32,203</td>
<td>6,759</td>
<td>(20)%</td>
<td>38,841</td>
<td>1,233,443</td>
<td>5,388</td>
<td>-</td>
<td>29</td>
</tr>
<tr>
<td>VCT Individual (HIV-Negative)</td>
<td>3,226</td>
<td>2,336</td>
<td>5,011</td>
<td>29,136</td>
<td>6,582</td>
<td>(24)%</td>
<td>36,820</td>
<td>1,202,917</td>
<td>5,011</td>
<td>-</td>
<td>27</td>
</tr>
<tr>
<td>VCT Individual (HIV-Positive)</td>
<td>222</td>
<td>184</td>
<td>377</td>
<td>3,067</td>
<td>177</td>
<td>3/13</td>
<td>113%</td>
<td>2,021</td>
<td>30,526</td>
<td>377</td>
<td>-</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
### Monthly Distribution by Country

#### Period: 2  
#### Year: 2020

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hypertension Diagnosis</strong></td>
<td>1,494</td>
<td>1,882</td>
<td>3,204</td>
<td>-</td>
<td>2,392</td>
<td>34%</td>
<td>21,145</td>
<td>59,196</td>
<td>3,204</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Hypertension Diagnosis</strong></td>
<td>1,494</td>
<td>1,882</td>
<td>3,204</td>
<td>-</td>
<td>2,392</td>
<td>34%</td>
<td>21,145</td>
<td>59,196</td>
<td>3,204</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Hypertension Screening</strong></td>
<td>63,116</td>
<td>71,243</td>
<td>126,254</td>
<td>-</td>
<td>94,967</td>
<td>33%</td>
<td>783,040</td>
<td>2,063,276</td>
<td>126,254</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Hypertension Screening</strong></td>
<td>63,116</td>
<td>71,243</td>
<td>126,254</td>
<td>-</td>
<td>94,967</td>
<td>33%</td>
<td>783,040</td>
<td>2,063,276</td>
<td>126,254</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>LLIN</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>-</td>
<td>14</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>PermaNet NGO Bag</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>9/04</td>
<td>-%</td>
<td>14</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Lubricant</strong></td>
<td>8,750</td>
<td>3,188</td>
<td>8,750</td>
<td>47,343</td>
<td>-</td>
<td>0%</td>
<td>-</td>
<td>20,309</td>
<td>91,706</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Lubricant gel 4.5 g</strong></td>
<td>8,750</td>
<td>3,188</td>
<td>8,750</td>
<td>47,343</td>
<td>-</td>
<td>-%</td>
<td>20,309</td>
<td>91,706</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>PrEP</strong></td>
<td>358</td>
<td>273</td>
<td>675</td>
<td>17,862</td>
<td>-</td>
<td>0%</td>
<td>2,464</td>
<td>3,139</td>
<td>56</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>PrEP</strong></td>
<td>358</td>
<td>273</td>
<td>675</td>
<td>17,862</td>
<td>-</td>
<td>-%</td>
<td>2,464</td>
<td>3,139</td>
<td>56</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>P&amp;G Purifier of Water</strong></td>
<td>2,637,000</td>
<td>1,725,005</td>
<td>7,540,455</td>
<td>6,991,487</td>
<td>-</td>
<td>0%</td>
<td>18,892,846</td>
<td>111,145,706</td>
<td>61,976</td>
<td>622</td>
<td>-</td>
</tr>
<tr>
<td><strong>Referral to Implant 3 Insertion</strong></td>
<td>-</td>
<td>86</td>
<td>258</td>
<td>114</td>
<td>-</td>
<td>0%</td>
<td>293</td>
<td>1,688</td>
<td>258</td>
<td>323</td>
<td>270</td>
</tr>
<tr>
<td><strong>Referral to Implant 3 Insertion</strong></td>
<td>-</td>
<td>86</td>
<td>258</td>
<td>114</td>
<td>-</td>
<td>0%</td>
<td>293</td>
<td>1,688</td>
<td>258</td>
<td>323</td>
<td>270</td>
</tr>
<tr>
<td><strong>Referral to Implant 5 Insertion</strong></td>
<td>-</td>
<td>5</td>
<td>16</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>11</td>
<td>331</td>
<td>16</td>
<td>30</td>
<td>25</td>
</tr>
<tr>
<td><strong>Referral to Implant 5 Insertion</strong></td>
<td>-</td>
<td>5</td>
<td>16</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>11</td>
<td>331</td>
<td>16</td>
<td>30</td>
<td>25</td>
</tr>
<tr>
<td><strong>Referral to Injectable 3</strong></td>
<td>-</td>
<td>330</td>
<td>989</td>
<td>851</td>
<td>-</td>
<td>0%</td>
<td>887</td>
<td>4,290</td>
<td>247</td>
<td>124</td>
<td>76</td>
</tr>
<tr>
<td><strong>Referral to Injectable 3</strong></td>
<td>-</td>
<td>330</td>
<td>989</td>
<td>851</td>
<td>-</td>
<td>1/15</td>
<td>0%</td>
<td>887</td>
<td>4,290</td>
<td>247</td>
<td>124</td>
</tr>
<tr>
<td><strong>Referral to IUD 10 Insertion</strong></td>
<td>-</td>
<td>2</td>
<td>7</td>
<td>2</td>
<td>-</td>
<td>0%</td>
<td>4</td>
<td>150</td>
<td>16</td>
<td>13</td>
<td>-</td>
</tr>
<tr>
<td><strong>Referral to IUD 10 Insertion</strong></td>
<td>-</td>
<td>2</td>
<td>7</td>
<td>2</td>
<td>-</td>
<td>12/14</td>
<td>0%</td>
<td>4</td>
<td>150</td>
<td>16</td>
<td>13</td>
</tr>
<tr>
<td><strong>Referral to Linkage to HIV Care</strong></td>
<td>195</td>
<td>192</td>
<td>424</td>
<td>3,067</td>
<td>-</td>
<td>0%</td>
<td>1,780</td>
<td>5,037</td>
<td>424</td>
<td>-</td>
<td>215</td>
</tr>
<tr>
<td><strong>Referral to Linkage to HIV Care</strong></td>
<td>195</td>
<td>192</td>
<td>424</td>
<td>3,067</td>
<td>-</td>
<td>-%</td>
<td>1,780</td>
<td>5,037</td>
<td>424</td>
<td>-</td>
<td>215</td>
</tr>
<tr>
<td><strong>Referral to OCs</strong></td>
<td>-</td>
<td>46</td>
<td>138</td>
<td>55</td>
<td>-</td>
<td>0%</td>
<td>84</td>
<td>1,112</td>
<td>9</td>
<td>5</td>
<td>3</td>
</tr>
<tr>
<td><strong>Referral to OCs</strong></td>
<td>-</td>
<td>46</td>
<td>138</td>
<td>55</td>
<td>-</td>
<td>1/15</td>
<td>0%</td>
<td>84</td>
<td>1,112</td>
<td>9</td>
<td>5</td>
</tr>
<tr>
<td><strong>Referral to TB Screening</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>59,060</td>
<td>-</td>
<td>0%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
### Monthly Distribution by Country

**Period:** 2  
**Year:** 2020

<table>
<thead>
<tr>
<th>Product Type</th>
<th>Referrals to TB Screening</th>
<th>Safe Water Solution</th>
<th>Wuha Agar</th>
<th>STI Kit (Non-Ulcerative)</th>
<th>STI kit for Urethral Discharge</th>
<th>STI Kit for Vaginal Discharge</th>
<th>STI Kit (Ulcerative)</th>
<th>STI Kit for Genital Ulcer</th>
<th>STI Screening</th>
<th>TB Screening</th>
<th>Toilets Sold</th>
<th>Toilets Sold - All</th>
<th>Treatment for Inguinal Bubo</th>
<th>Treatment for Lower Abdominal Pain</th>
<th>Treatment for Nonherpetic Genital Ulcer</th>
<th>Treatment for Urethral Discharge (Men)</th>
<th>Treatment for Vaginitis</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DISTRIBUTION</strong></td>
<td>59,060</td>
<td>1,485,515</td>
<td>1,015</td>
<td>59,060</td>
<td>59,060</td>
<td>59,060</td>
<td>59,060</td>
<td>59,060</td>
<td>59,060</td>
<td>59,060</td>
<td>59,060</td>
<td>59,060</td>
<td>59,060</td>
<td>59,060</td>
<td>59,060</td>
<td>59,060</td>
<td>59,060</td>
</tr>
<tr>
<td><strong>AVG PREV 3 MONTHS</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>MONTHLY DISTRIBUTION 2020</strong></td>
<td>59,060</td>
<td>1,485,515</td>
<td>1,015</td>
<td>59,060</td>
<td>59,060</td>
<td>59,060</td>
<td>59,060</td>
<td>59,060</td>
<td>59,060</td>
<td>59,060</td>
<td>59,060</td>
<td>59,060</td>
<td>59,060</td>
<td>59,060</td>
<td>59,060</td>
<td>59,060</td>
<td>59,060</td>
</tr>
<tr>
<td><strong>TARGET DISTRIBUTION 2020</strong></td>
<td>122,314</td>
<td>122,314</td>
<td>2/06</td>
<td>122,314</td>
<td>122,314</td>
<td>122,314</td>
<td>122,314</td>
<td>122,314</td>
<td>122,314</td>
<td>122,314</td>
<td>122,314</td>
<td>122,314</td>
<td>122,314</td>
<td>122,314</td>
<td>122,314</td>
<td>122,314</td>
<td>122,314</td>
</tr>
<tr>
<td><strong>YTD % CHANGE</strong></td>
<td>(51)%</td>
<td>659,666</td>
<td>(18)%</td>
<td>659,666</td>
<td>659,666</td>
<td>59,760</td>
<td>384,352</td>
<td>659,666</td>
<td>59,760</td>
<td>453,471</td>
<td>384,352</td>
<td>1,485,515</td>
<td>659,666</td>
<td>659,666</td>
<td>659,666</td>
<td>659,666</td>
<td>659,666</td>
</tr>
<tr>
<td><strong>TOTAL DISTRIBUTION 2019</strong></td>
<td>2020</td>
<td>31,787</td>
<td>11/10</td>
<td>31,787</td>
<td>59,060</td>
<td>30,000</td>
<td>59,060</td>
<td>30,000</td>
<td>59,060</td>
<td>3,611</td>
<td>3,611</td>
<td>3,611</td>
<td>3,611</td>
<td>3,611</td>
<td>3,611</td>
<td>3,611</td>
<td>3,611</td>
</tr>
<tr>
<td><strong>CUMULATIVE DISTRIBUTION</strong></td>
<td>(a)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>%YTD USERS REACHED 2020</strong></td>
<td>12</td>
<td>3</td>
<td>0%</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td><strong>YTD CYP 2020</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>YTD DALY 2020</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(a) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
## Monthly Distribution by Country

### Period: 2

### Year: 2020

<table>
<thead>
<tr>
<th>Product</th>
<th>YTD Users Reached</th>
<th>Total DALY 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Generic Male Condom</td>
<td>59,672</td>
<td>1,736</td>
</tr>
<tr>
<td>Vibe Condom</td>
<td>6,000</td>
<td>2,604</td>
</tr>
<tr>
<td>HIV Self-Testing Kit</td>
<td>16,605</td>
<td>34,232</td>
</tr>
<tr>
<td>ORAQUICK HIV Self-Testing Kit (Pouch)</td>
<td>16,605</td>
<td>34,232</td>
</tr>
<tr>
<td>HIV Testing Services</td>
<td>6,258</td>
<td>1,521</td>
</tr>
<tr>
<td>VCT Individual (HIV-Negative)</td>
<td>5,797</td>
<td>1,409</td>
</tr>
<tr>
<td>VCT Individual (HIV-Positive)</td>
<td>461</td>
<td>112</td>
</tr>
<tr>
<td>Hypertension Screening</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Implant 3 Insertion</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Non-PSI Implant 3 Inserted</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Implant 5 Insertion</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Non-PSI Implant 5 Inserted</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Injectable 1 Provided</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Non-PSI Injectable 1 Provided</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Injectable 2</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Generic 2-month Injectable</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Injectable 2 Provided</td>
<td>1,331</td>
<td>218</td>
</tr>
<tr>
<td>Non-PSI Injectable 2 Provided</td>
<td>1,331</td>
<td>218</td>
</tr>
<tr>
<td>Injectable 3-IM</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Depo-Provera</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Injectable 3-IM Provided</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Non-PSI Injectable 3 IM Provided</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Lubricant</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Lubricant 25 ml Sachet</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
### Monthly Distribution by Country

#### Period: 2  
#### Year: 2020

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>OCs</td>
<td>-</td>
<td>-</td>
<td>386</td>
<td>-</td>
<td>0%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Oral Contraceptive Pill</td>
<td>-</td>
<td>-</td>
<td>250</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>POPs</td>
<td>-</td>
<td>-</td>
<td>136</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>OCs Provided</td>
<td>1,148</td>
<td>1,130</td>
<td>3,003</td>
<td>15,110</td>
<td>6,513</td>
<td>(54)%</td>
<td>21,974</td>
<td>69,232</td>
<td>200</td>
<td>200</td>
<td>95</td>
<td></td>
</tr>
<tr>
<td>Non-PSI OCs Provided</td>
<td>1,148</td>
<td>1,130</td>
<td>3,003</td>
<td>15,110</td>
<td>6,513</td>
<td>(54)%</td>
<td>21,974</td>
<td>69,232</td>
<td>200</td>
<td>200</td>
<td>95</td>
<td></td>
</tr>
<tr>
<td>PrEP</td>
<td>77</td>
<td>71</td>
<td>150</td>
<td>-</td>
<td>69</td>
<td>117%</td>
<td>688</td>
<td>852</td>
<td>12</td>
<td>-</td>
<td>12</td>
<td></td>
</tr>
<tr>
<td>Referral to HIV Testing Services</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>96</td>
<td>0%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Referral to Linkage to HIV Care</td>
<td>336</td>
<td>352</td>
<td>742</td>
<td>5,625</td>
<td>813</td>
<td>(9)%</td>
<td>4,257</td>
<td>15,747</td>
<td>742</td>
<td>-</td>
<td>446</td>
<td></td>
</tr>
<tr>
<td>TB Diagnosis</td>
<td>1</td>
<td>3</td>
<td>5</td>
<td>36</td>
<td>9</td>
<td>(44)%</td>
<td>33</td>
<td>124</td>
<td>5</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>TB DOTS</td>
<td>2</td>
<td>3</td>
<td>6</td>
<td>36</td>
<td>4</td>
<td>50%</td>
<td>35</td>
<td>88</td>
<td>6</td>
<td>-</td>
<td>49</td>
<td></td>
</tr>
<tr>
<td>Cervical Cancer-VIA/VILI Screening</td>
<td>1,163</td>
<td>1,199</td>
<td>1,694</td>
<td>13,200</td>
<td>1,379</td>
<td>23%</td>
<td>14,788</td>
<td>36,112</td>
<td>1,694</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Voluntary Medical Male Circumcision</td>
<td>5</td>
<td>98</td>
<td>13</td>
<td>1,182</td>
<td>10</td>
<td>30%</td>
<td>767</td>
<td>4,411</td>
<td>13</td>
<td>-</td>
<td>170</td>
<td></td>
</tr>
<tr>
<td>TB Screening</td>
<td>1,641</td>
<td>1,463</td>
<td>3,374</td>
<td>4,761</td>
<td>3,766</td>
<td>(10)%</td>
<td>19,017</td>
<td>50,419</td>
<td>3,374</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Type 2 Diabetes Screening</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>30</td>
<td>3,969</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Voluntary Medical Male Circumcision</td>
<td>5</td>
<td>98</td>
<td>13</td>
<td>1,182</td>
<td>10</td>
<td>30%</td>
<td>767</td>
<td>4,411</td>
<td>13</td>
<td>-</td>
<td>170</td>
<td></td>
</tr>
<tr>
<td>Condom</td>
<td>352,944</td>
<td>521,184</td>
<td>540,864</td>
<td>12,000,000</td>
<td>2,103,004</td>
<td>(74)%</td>
<td>13,907,980</td>
<td>239,913,770</td>
<td>4,056</td>
<td>4,056</td>
<td>11,118</td>
<td></td>
</tr>
</tbody>
</table>

**Note:**

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

---

**3002 - 4/15/2020 10:09:35AM Page 21 of 115**
<table>
<thead>
<tr>
<th>Product</th>
<th>DISTRIBUTION 2/2020</th>
<th>MONTLY AVG PREV 3 MONTHS</th>
<th>YTD DISTRIBUTION 2020</th>
<th>DISTRIBUTION TARGET 2020</th>
<th>LAUNCH DATE</th>
<th>YTD % CHANGE</th>
<th>TOTAL DISTRIBUTION 2019</th>
<th>CUMULATIVE DISTRIBUTION</th>
<th>%YTD USERS REACHED 2020</th>
<th>YTD CYP 2020</th>
<th>YTD DALY 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chishango</td>
<td>352,944</td>
<td>521,184</td>
<td>540,864</td>
<td>12,000,000</td>
<td>2,103,004</td>
<td>(74)%</td>
<td>13,907,980</td>
<td>239,913,770</td>
<td>4,056</td>
<td>4,056</td>
<td>11,118</td>
</tr>
<tr>
<td>Emergency Contraception</td>
<td>1,186</td>
<td>7,397</td>
<td>3,654</td>
<td>35,000</td>
<td>1,066</td>
<td>243%</td>
<td>51,274</td>
<td>163,268</td>
<td>164</td>
<td>164</td>
<td>83</td>
</tr>
<tr>
<td>Levonorgestrel Tablet 0.75 mg x 2's</td>
<td>1,820</td>
<td>8,831</td>
<td>4,968</td>
<td>-</td>
<td>1,410</td>
<td>252%</td>
<td>141,636</td>
<td>148,149</td>
<td>224</td>
<td>224</td>
<td>113</td>
</tr>
<tr>
<td>NORLEVO (Norlevo 1.5mg)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>35,000</td>
<td>2/14</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>(b) PSI Emergency Contraception Distributed</td>
<td>(634)</td>
<td>(1,434)</td>
<td>(1,314)</td>
<td>-</td>
<td>- (344)</td>
<td>-</td>
<td>(90,362)</td>
<td>(96,336)</td>
<td>(59)</td>
<td>(59)</td>
<td>(30)</td>
</tr>
<tr>
<td>Emergency Contraception Provided</td>
<td>634</td>
<td>1,434</td>
<td>1,314</td>
<td>-</td>
<td>344</td>
<td>282%</td>
<td>90,453</td>
<td>96,427</td>
<td>66</td>
<td>66</td>
<td>33</td>
</tr>
<tr>
<td>Non-PSI Emergency Contraception Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>91</td>
<td>91</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PSI Emergency Contraception Provided</td>
<td>634</td>
<td>1,434</td>
<td>1,314</td>
<td>-</td>
<td>344</td>
<td>282%</td>
<td>90,362</td>
<td>96,336</td>
<td>66</td>
<td>66</td>
<td>33</td>
</tr>
<tr>
<td>Female Condom</td>
<td>100</td>
<td>290</td>
<td>100</td>
<td>110,000</td>
<td>27,256</td>
<td>(100)%</td>
<td>78,045</td>
<td>870,628</td>
<td>1</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Care</td>
<td>100</td>
<td>290</td>
<td>100</td>
<td>110,000</td>
<td>27,256</td>
<td>1/08</td>
<td>(100)%</td>
<td>78,045</td>
<td>870,628</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Free Condom</td>
<td>832,336</td>
<td>1,373,115</td>
<td>832,336</td>
<td>11,120,536</td>
<td>2,551,267</td>
<td>(67)%</td>
<td>15,496,066</td>
<td>38,803,896</td>
<td>6,243</td>
<td>6,243</td>
<td>17,109</td>
</tr>
<tr>
<td>Free Male Condoms</td>
<td>-</td>
<td>5,760</td>
<td>-</td>
<td>-</td>
<td>2/14</td>
<td>-</td>
<td>1,000,080</td>
<td>2,659,852</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Generic Male Condom</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>395,000</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Key Population Male Condom</td>
<td>832,336</td>
<td>1,367,355</td>
<td>832,336</td>
<td>10,000,000</td>
<td>2,551,267</td>
<td>7/16</td>
<td>14,495,966</td>
<td>35,597,195</td>
<td>6,243</td>
<td>6,243</td>
<td>17,109</td>
</tr>
<tr>
<td>VMMC Male Condom</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>725,536</td>
<td>1/15</td>
<td>-</td>
<td>-</td>
<td>546,849</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Free Female Condom</td>
<td>3,500</td>
<td>4,871</td>
<td>7,300</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>51,483</td>
<td>366,689</td>
<td>55</td>
<td>55</td>
<td>146</td>
</tr>
<tr>
<td>Free Female Condoms</td>
<td>3,500</td>
<td>4,871</td>
<td>7,300</td>
<td>-</td>
<td>2/14</td>
<td>-</td>
<td>51,483</td>
<td>366,689</td>
<td>55</td>
<td>55</td>
<td>146</td>
</tr>
<tr>
<td>HIV Self-Testing Kit</td>
<td>10,122</td>
<td>1,334</td>
<td>10,622</td>
<td>69,445</td>
<td>35,325</td>
<td>(70)%</td>
<td>178,804</td>
<td>537,291</td>
<td>9,560</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>INSTI HIVST (Blood based)</td>
<td>124</td>
<td>1,333</td>
<td>624</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>9,376</td>
<td>10,000</td>
<td>562</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>ORAQUICK HIV Self-Testing Kit (Pouch)</td>
<td>9,998</td>
<td>1</td>
<td>9,998</td>
<td>69,445</td>
<td>34,975</td>
<td>8/17</td>
<td>169,078</td>
<td>526,941</td>
<td>8,998</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Sure Check HIV Self-Test</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>350</td>
<td>-</td>
<td>-</td>
<td>350</td>
<td>350</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>HIV Testing Services</td>
<td>6,536</td>
<td>5,160</td>
<td>10,362</td>
<td>20,820</td>
<td>7,060</td>
<td>47%</td>
<td>76,528</td>
<td>328,839</td>
<td>10,362</td>
<td>-</td>
<td>441</td>
</tr>
<tr>
<td>VCT Individual (HIV-Negative)</td>
<td>6,348</td>
<td>4,988</td>
<td>10,060</td>
<td>20,036</td>
<td>6,692</td>
<td>12/14</td>
<td>74,351</td>
<td>319,951</td>
<td>10,060</td>
<td>-</td>
<td>428</td>
</tr>
<tr>
<td>VCT Individual (HIV-Positive)</td>
<td>188</td>
<td>172</td>
<td>302</td>
<td>784</td>
<td>368</td>
<td>(18)%</td>
<td>2,177</td>
<td>8,888</td>
<td>302</td>
<td>-</td>
<td>13</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
<table>
<thead>
<tr>
<th>Product</th>
<th>DISTRIBUTION 2/2020</th>
<th>MONTHLY AVG PREV 3 MONTHS</th>
<th>YTD DISTRIBUTION 2020</th>
<th>DISTRIBUTION TARGET 2020</th>
<th>YTD DISTRIBUTION 2019</th>
<th>LAUNCH DATE</th>
<th>YTD % CHANGE</th>
<th>TOTAL DISTRIBUTION 2019</th>
<th>CUMULATIVE DISTRIBUTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Implanon</td>
<td>(742)</td>
<td>(855)</td>
<td>(1,217)</td>
<td>1,200</td>
<td>242</td>
<td>(603)%</td>
<td>-</td>
<td>(2,609)</td>
<td>(2,856)</td>
</tr>
<tr>
<td>Implanon NXT</td>
<td>56</td>
<td>551</td>
<td>251</td>
<td>-</td>
<td>7,089</td>
<td>(96)%</td>
<td>10/12</td>
<td>-84,144</td>
<td>-</td>
</tr>
<tr>
<td>(b)PSI Implant 3 Dism</td>
<td>(798)</td>
<td>(1,406)</td>
<td>(1,468)</td>
<td>-</td>
<td>(6,847)</td>
<td>-</td>
<td>(26,074)</td>
<td>(107,905)</td>
<td>(3,303)</td>
</tr>
<tr>
<td>Implant 3 Inserted</td>
<td>1,688</td>
<td>2,311</td>
<td>3,100</td>
<td>22,578</td>
<td>6,877</td>
<td>(55)%</td>
<td>18,459</td>
<td>17,572</td>
<td>6,269</td>
</tr>
<tr>
<td>Non-PSI Implant 3 Inserted</td>
<td>890</td>
<td>905</td>
<td>1,632</td>
<td>22,578</td>
<td>30</td>
<td>5,340%</td>
<td>7,031</td>
<td>8,719</td>
<td>1,632</td>
</tr>
<tr>
<td>PSI Implant 3 Inserted</td>
<td>798</td>
<td>1,406</td>
<td>1,468</td>
<td>-</td>
<td>6,847</td>
<td>(79)%</td>
<td>26,074</td>
<td>107,905</td>
<td>1,468</td>
</tr>
<tr>
<td>Implant 4</td>
<td>1,070</td>
<td>720</td>
<td>2,996</td>
<td>-</td>
<td>(28)</td>
<td>0%</td>
<td>18,459</td>
<td>17,572</td>
<td>6,269</td>
</tr>
<tr>
<td>Levoplant</td>
<td>2,010</td>
<td>1,351</td>
<td>4,660</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>25,053</td>
<td>60,163</td>
<td>4,194</td>
</tr>
<tr>
<td>(b)PSI Implant 4 Dism</td>
<td>(940)</td>
<td>(631)</td>
<td>(1,664)</td>
<td>-</td>
<td>(28)</td>
<td>-</td>
<td>(7,044)</td>
<td>(42,591)</td>
<td>(4,792)</td>
</tr>
<tr>
<td>Implant 4 Insertion</td>
<td>1,035</td>
<td>882</td>
<td>1,917</td>
<td>-</td>
<td>28</td>
<td>6746%</td>
<td>10,829</td>
<td>46,629</td>
<td>1,917</td>
</tr>
<tr>
<td>Non-PSI Implant 4 Inserted</td>
<td>95</td>
<td>252</td>
<td>253</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>3,785</td>
<td>4,038</td>
<td>253</td>
</tr>
<tr>
<td>PSI Implant 4 Inserted</td>
<td>940</td>
<td>631</td>
<td>1,664</td>
<td>-</td>
<td>28</td>
<td>5,843%</td>
<td>7,044</td>
<td>42,591</td>
<td>1,664</td>
</tr>
<tr>
<td>Implant 5</td>
<td>(664)</td>
<td>(687)</td>
<td>(470)</td>
<td>1,000</td>
<td>(2,711)</td>
<td>0%</td>
<td>1,106</td>
<td>11,207</td>
<td>(423)</td>
</tr>
<tr>
<td>Jadelle</td>
<td>133</td>
<td>954</td>
<td>1,058</td>
<td>1,000</td>
<td>1,801</td>
<td>10/12</td>
<td>(41)%</td>
<td>25,456</td>
<td>147,904</td>
</tr>
<tr>
<td>(b)PSI Implant 5 Dism</td>
<td>(797)</td>
<td>(1,641)</td>
<td>(1,528)</td>
<td>-</td>
<td>(4,512)</td>
<td>3/16</td>
<td>-</td>
<td>(24,350)</td>
<td>(136,697)</td>
</tr>
<tr>
<td>Implant 5 Insertion</td>
<td>2,480</td>
<td>2,347</td>
<td>4,064</td>
<td>28,961</td>
<td>4,712</td>
<td>(14)%</td>
<td>29,893</td>
<td>144,880</td>
<td>4,064</td>
</tr>
<tr>
<td>Non-PSI Implant 5 Inserted</td>
<td>1,683</td>
<td>706</td>
<td>2,536</td>
<td>28,961</td>
<td>200</td>
<td>1,168%</td>
<td>5,543</td>
<td>8,183</td>
<td>2,536</td>
</tr>
<tr>
<td>PSI Implant 5 Inserted</td>
<td>797</td>
<td>1,641</td>
<td>1,528</td>
<td>-</td>
<td>4,512</td>
<td>3/16</td>
<td>(66)%</td>
<td>24,350</td>
<td>136,691</td>
</tr>
<tr>
<td>Injectable 3-IM</td>
<td>861</td>
<td>3,048</td>
<td>7,460</td>
<td>45,000</td>
<td>21,027</td>
<td>(65)%</td>
<td>79,713</td>
<td>1,916,010</td>
<td>1,679</td>
</tr>
<tr>
<td>Depo-Provera</td>
<td>4,700</td>
<td>10,225</td>
<td>16,432</td>
<td>-</td>
<td>34,275</td>
<td>(52)%</td>
<td>165,251</td>
<td>191,404</td>
<td>3,967</td>
</tr>
<tr>
<td>(b)PSI Injectable 3 IM Dism</td>
<td>(3,839)</td>
<td>(7,178)</td>
<td>(8,972)</td>
<td>-</td>
<td>(13,248)</td>
<td>-</td>
<td>(85,538)</td>
<td>(168,290)</td>
<td>(2,019)</td>
</tr>
<tr>
<td>SafePlan Inj3</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>45,000</td>
<td>-</td>
<td>1/08</td>
<td>-</td>
<td>1,892,896</td>
<td>-</td>
</tr>
<tr>
<td>Injectable 3-IM Provided</td>
<td>5,114</td>
<td>8,567</td>
<td>11,245</td>
<td>66,600</td>
<td>13,278</td>
<td>(15)%</td>
<td>96,789</td>
<td>182,839</td>
<td>2,811</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
## Monthly Distribution by Country

### Period: 2
### Year: 2020

<table>
<thead>
<tr>
<th>Product Description</th>
<th>2/2020</th>
<th>AVG PREV 3 MONTHS</th>
<th>DISTRIBUTION TARGET 2020</th>
<th>DISTRIBUTION 2020</th>
<th>LAUNCH DATE</th>
<th>YTD % CHANGE</th>
<th>TOTAL DISTRIBUTION 2019</th>
<th>CUMULATIVE DISTRIBUTION</th>
<th>%YTD USERS REACHED</th>
<th>YTD CYP 2020</th>
<th>YTD DALY 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-PSI Injectable 3 IM Provided</td>
<td>1,275</td>
<td>1,389</td>
<td>2,273</td>
<td>66,600</td>
<td>30</td>
<td>74.77%</td>
<td>11,251</td>
<td>14,549</td>
<td>568</td>
<td>568</td>
<td>378</td>
</tr>
<tr>
<td>PSI Injectable 3 IM Provided</td>
<td>3,839</td>
<td>7,178</td>
<td>8,972</td>
<td>-</td>
<td>13,248</td>
<td>(32)%</td>
<td>85,538</td>
<td>168,290</td>
<td>2,243</td>
<td>2,243</td>
<td>1,494</td>
</tr>
<tr>
<td>Injectable 3-SC</td>
<td>(1,596)</td>
<td>271</td>
<td>(1,552)</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>3,446</td>
<td>1,894</td>
<td>(349)</td>
<td>(349)</td>
<td>(233)</td>
</tr>
<tr>
<td>Sayana Press</td>
<td>922</td>
<td>566</td>
<td>1,183</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>4,221</td>
<td>5,404</td>
<td>266</td>
<td>266</td>
<td>177</td>
</tr>
<tr>
<td>Injectable 3-SC Provided</td>
<td>3,892</td>
<td>721</td>
<td>4,930</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>1,263</td>
<td>6,193</td>
<td>1,233</td>
<td>1,233</td>
<td>821</td>
</tr>
<tr>
<td>Non-PSI Injectable 3 SC Provided</td>
<td>1,374</td>
<td>426</td>
<td>2,195</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>488</td>
<td>2,683</td>
<td>549</td>
<td>549</td>
<td>365</td>
</tr>
<tr>
<td>PSI Injectable 3 SC Provided</td>
<td>2,518</td>
<td>295</td>
<td>2,735</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>775</td>
<td>3,510</td>
<td>684</td>
<td>684</td>
<td>455</td>
</tr>
<tr>
<td>ITN</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>4,808</td>
<td>4,808</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PBO Net</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>4,808</td>
<td>4,808</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>IUD 10</td>
<td>318</td>
<td>179</td>
<td>629</td>
<td>720</td>
<td>46</td>
<td>1267%</td>
<td>1,587</td>
<td>7,468</td>
<td>566</td>
<td>2,604</td>
<td>2,237</td>
</tr>
<tr>
<td>IUD Copper T 380A</td>
<td>448</td>
<td>360</td>
<td>848</td>
<td>720</td>
<td>1,080</td>
<td>10/12 (21)%</td>
<td>5,025</td>
<td>23,022</td>
<td>763</td>
<td>3,511</td>
<td>3,016</td>
</tr>
<tr>
<td>(b)PSI IUD 10 Distributed Inserted</td>
<td>(130)</td>
<td>(181)</td>
<td>(219)</td>
<td>-</td>
<td>(1,034)</td>
<td>3/16 -%</td>
<td>(3,438)</td>
<td>(15,554)</td>
<td>(197)</td>
<td>(907)</td>
<td>(779)</td>
</tr>
<tr>
<td>IUD 10 Insertion</td>
<td>303</td>
<td>335</td>
<td>546</td>
<td>2,780</td>
<td>1,034</td>
<td>(47)%</td>
<td>4,375</td>
<td>16,818</td>
<td>546</td>
<td>2,512</td>
<td>2,158</td>
</tr>
<tr>
<td>Non-PSI IUD 10 Inserted</td>
<td>173</td>
<td>154</td>
<td>327</td>
<td>2,780</td>
<td>-</td>
<td>-%</td>
<td>937</td>
<td>1,264</td>
<td>327</td>
<td>1,504</td>
<td>1,292</td>
</tr>
<tr>
<td>PSI IUD 10 Inserted</td>
<td>130</td>
<td>181</td>
<td>219</td>
<td>-</td>
<td>1,034</td>
<td>3/16 (79)%</td>
<td>3,438</td>
<td>15,554</td>
<td>219</td>
<td>1,007</td>
<td>865</td>
</tr>
<tr>
<td>LLIN</td>
<td>7,824</td>
<td>118</td>
<td>7,829</td>
<td>60,000</td>
<td>5,418</td>
<td>44%</td>
<td>68,507</td>
<td>508,379</td>
<td>12,683</td>
<td>-</td>
<td>490</td>
</tr>
<tr>
<td>Super Chitetezo Net</td>
<td>7,824</td>
<td>118</td>
<td>7,829</td>
<td>60,000</td>
<td>5,418</td>
<td>2/11 44%</td>
<td>68,507</td>
<td>508,379</td>
<td>12,683</td>
<td>-</td>
<td>490</td>
</tr>
<tr>
<td>Lubricant</td>
<td>142,081</td>
<td>207,042</td>
<td>142,081</td>
<td>1,300,000</td>
<td>248,786</td>
<td>(43)%</td>
<td>1,549,435</td>
<td>4,769,864</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Personal Lubricant Water 4.5 g</td>
<td>142,081</td>
<td>207,042</td>
<td>142,081</td>
<td>1,300,000</td>
<td>248,786</td>
<td>12/12 (43)%</td>
<td>1,549,435</td>
<td>4,769,864</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>OCs</td>
<td>11,333</td>
<td>6,934</td>
<td>15,808</td>
<td>75,000</td>
<td>18,714</td>
<td>(16)%</td>
<td>125,327</td>
<td>899,214</td>
<td>948</td>
<td>948</td>
<td>666</td>
</tr>
<tr>
<td>Microgynon</td>
<td>192</td>
<td>901</td>
<td>192</td>
<td>-</td>
<td>6,786</td>
<td>11/11 (97)%</td>
<td>36,996</td>
<td>842,928</td>
<td>12</td>
<td>12</td>
<td>8</td>
</tr>
<tr>
<td>Microgynon combination 3</td>
<td>14,296</td>
<td>8,816</td>
<td>20,468</td>
<td>75,000</td>
<td>19,650</td>
<td>4%</td>
<td>210,866</td>
<td>244,974</td>
<td>1,228</td>
<td>1,228</td>
<td>863</td>
</tr>
<tr>
<td>(b)PSI OCs Distributed Provided</td>
<td>(3,155)</td>
<td>(2,784)</td>
<td>(4,852)</td>
<td>-</td>
<td>(7,722)</td>
<td>-%</td>
<td>(122,535)</td>
<td>(188,688)</td>
<td>(291)</td>
<td>(291)</td>
<td>(204)</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>OCs Provided</td>
<td>4,999</td>
<td>4,002</td>
<td>7,799</td>
<td>15,477</td>
<td>11,220</td>
<td>(30)%</td>
<td>137,790</td>
<td>217,824</td>
<td>520</td>
<td>520</td>
</tr>
<tr>
<td>Non-PSI OCs Provided</td>
<td>1,844</td>
<td>1,218</td>
<td>2,947</td>
<td>15,477</td>
<td>3,498</td>
<td>(16)%</td>
<td>15,255</td>
<td>29,136</td>
<td>196</td>
<td>196</td>
</tr>
<tr>
<td>PSI OCs Provided</td>
<td>3,155</td>
<td>2,784</td>
<td>4,852</td>
<td>-</td>
<td>7,722</td>
<td>(37)%</td>
<td>122,535</td>
<td>188,688</td>
<td>323</td>
<td>323</td>
</tr>
<tr>
<td>PUR</td>
<td>700,000</td>
<td>-</td>
<td>700,000</td>
<td>4,540,800</td>
<td>2,800,000</td>
<td>(75)%</td>
<td>6,811,200</td>
<td>67,619,640</td>
<td>5,753</td>
<td>-</td>
</tr>
<tr>
<td>PuR WaterGuard Waufa</td>
<td>700,000</td>
<td>-</td>
<td>700,000</td>
<td>4,540,800</td>
<td>2,800,000</td>
<td>(75)%</td>
<td>6,811,200</td>
<td>67,619,640</td>
<td>5,753</td>
<td>-</td>
</tr>
<tr>
<td>Referral to Linkage to HIV Care</td>
<td>-</td>
<td>-</td>
<td>745</td>
<td>-</td>
<td>0%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to Linkage to HIV Care</td>
<td>-</td>
<td>-</td>
<td>745</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Safe Water Solution</td>
<td>-</td>
<td>-</td>
<td>432</td>
<td>12/02</td>
<td>(100)%</td>
<td>716</td>
<td>8,496,271</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>WaterGuard</td>
<td>-</td>
<td>-</td>
<td>432</td>
<td>12/02</td>
<td>(100)%</td>
<td>716</td>
<td>8,496,271</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>STI Screening</td>
<td>208</td>
<td>290</td>
<td>355</td>
<td>-</td>
<td>154</td>
<td>131%</td>
<td>3,162</td>
<td>6,137</td>
<td>355</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Cervicitis</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>-</td>
<td>0%</td>
<td>-</td>
<td>34</td>
<td>35</td>
<td>1</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Genital Infections</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>34</td>
<td>35</td>
<td>1</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Genital Herpes</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>-</td>
<td>0%</td>
<td>7</td>
<td>8</td>
<td>1</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Genital Herpes</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>-</td>
<td>-%</td>
<td>7</td>
<td>8</td>
<td>1</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Lower Abdominal Pain</td>
<td>25</td>
<td>41</td>
<td>50</td>
<td>-</td>
<td>0%</td>
<td>368</td>
<td>418</td>
<td>50</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Lower Abdominal Pain</td>
<td>25</td>
<td>41</td>
<td>50</td>
<td>-</td>
<td>-%</td>
<td>368</td>
<td>418</td>
<td>50</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Nonherpetic Genital Ulcer</td>
<td>1</td>
<td>3</td>
<td>1</td>
<td>-</td>
<td>0%</td>
<td>91</td>
<td>92</td>
<td>1</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Nonherpetic Genital Ulcer</td>
<td>1</td>
<td>3</td>
<td>1</td>
<td>-</td>
<td>-%</td>
<td>91</td>
<td>92</td>
<td>1</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Urethral Discharge (Men)</td>
<td>12</td>
<td>13</td>
<td>17</td>
<td>-</td>
<td>0%</td>
<td>119</td>
<td>136</td>
<td>17</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Urethral Discharge (Men)</td>
<td>12</td>
<td>13</td>
<td>17</td>
<td>-</td>
<td>-%</td>
<td>119</td>
<td>136</td>
<td>17</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Urethral Discharge (Women)</td>
<td>27</td>
<td>25</td>
<td>34</td>
<td>-</td>
<td>0%</td>
<td>235</td>
<td>269</td>
<td>34</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Urethral Discharge (Women)</td>
<td>27</td>
<td>25</td>
<td>34</td>
<td>-</td>
<td>-%</td>
<td>235</td>
<td>269</td>
<td>34</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Vaginitis</td>
<td>-</td>
<td>3</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>10</td>
<td>10</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Vaginitis</td>
<td>-</td>
<td>3</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>10</td>
<td>10</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Tubal Ligation</td>
<td>658</td>
<td>706</td>
<td>946</td>
<td>7,138</td>
<td>999</td>
<td>(5)%</td>
<td>10,447</td>
<td>46,559</td>
<td>946</td>
<td>9,460</td>
<td>7,436</td>
<td></td>
</tr>
<tr>
<td>Tubal Ligation</td>
<td>658</td>
<td>706</td>
<td>946</td>
<td>7,138</td>
<td>999</td>
<td>1/15</td>
<td>(5)%</td>
<td>10,447</td>
<td>46,559</td>
<td>946</td>
<td>9,460</td>
<td>7,436</td>
</tr>
<tr>
<td>Voluntary Medical Male Circumcision</td>
<td>3,475</td>
<td>1,843</td>
<td>5,428</td>
<td>56,645</td>
<td>3,748</td>
<td>45%</td>
<td>40,008</td>
<td>138,896</td>
<td>5,428</td>
<td>-</td>
<td>19,566</td>
<td></td>
</tr>
<tr>
<td>Voluntary Medical Male Circumcision</td>
<td>3,475</td>
<td>1,843</td>
<td>5,428</td>
<td>56,645</td>
<td>3,748</td>
<td>45%</td>
<td>40,008</td>
<td>138,896</td>
<td>5,428</td>
<td>-</td>
<td>19,566</td>
<td></td>
</tr>
</tbody>
</table>

### Namibia

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Free Condom</td>
<td>-</td>
<td>16</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>151,681</td>
<td>16,697,726</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Smile</td>
<td>-</td>
<td>16</td>
<td>-</td>
<td>-</td>
<td>-1/08</td>
<td>-%</td>
<td>151,681</td>
<td>16,697,726</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Free Female Condom</td>
<td>-</td>
<td>35</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>3,005</td>
<td>513,071</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Femidom Free</td>
<td>-</td>
<td>35</td>
<td>-</td>
<td>-</td>
<td>-2/07</td>
<td>-%</td>
<td>3,005</td>
<td>513,071</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>HIV Self-Testing Kit</td>
<td>-</td>
<td>49</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>17,384</td>
<td>17,384</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>ORAQUICK HIV Self-Testing Kit (Pouch)</td>
<td>-</td>
<td>49</td>
<td>-</td>
<td>-</td>
<td>-1/18</td>
<td>-%</td>
<td>17,384</td>
<td>17,384</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Lubricant</td>
<td>-</td>
<td>19,400</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>140,982</td>
<td>140,982</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Personal Lubricant 4.5 g</td>
<td>-</td>
<td>19,400</td>
<td>-</td>
<td>-</td>
<td>1/18</td>
<td>-%</td>
<td>140,982</td>
<td>140,982</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
</tbody>
</table>

### PSI Uganda

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Cervical Cancer-VIA and Cryotherapy</td>
<td>-</td>
<td>3</td>
<td>-</td>
<td>-</td>
<td>4</td>
<td>(100)%</td>
<td>74</td>
<td>224</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Cervical Cancer-VIA and Cryotherapy</td>
<td>-</td>
<td>3</td>
<td>-</td>
<td>-</td>
<td>4</td>
<td>(100)%</td>
<td>74</td>
<td>224</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Cervical Cancer-VIA/VILI Screening</td>
<td>-</td>
<td>753</td>
<td>-</td>
<td>3,000</td>
<td>2,445</td>
<td>(100)%</td>
<td>15,275</td>
<td>54,141</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Cervical Cancer-VIA/VILI Screening</td>
<td>-</td>
<td>753</td>
<td>-</td>
<td>3,000</td>
<td>2,445</td>
<td>(100)%</td>
<td>15,275</td>
<td>54,141</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Chlorhexidine</td>
<td>615</td>
<td>379</td>
<td>1,115</td>
<td>11,000</td>
<td>773</td>
<td>44%</td>
<td>6,590</td>
<td>30,916</td>
<td>1,004</td>
<td>-</td>
<td>77</td>
<td></td>
</tr>
<tr>
<td>Chlorhexidine Gel, 5 g tube</td>
<td>615</td>
<td>379</td>
<td>1,115</td>
<td>11,000</td>
<td>773</td>
<td>44%</td>
<td>6,590</td>
<td>30,916</td>
<td>1,004</td>
<td>-</td>
<td>77</td>
<td></td>
</tr>
<tr>
<td>Condom</td>
<td>695,880</td>
<td>293,160</td>
<td>1,076,256</td>
<td>3,870,000</td>
<td>285,696</td>
<td>277%</td>
<td>2,342,808</td>
<td>5,023,800</td>
<td>8,072</td>
<td>8,072</td>
<td>18,792</td>
<td></td>
</tr>
<tr>
<td>Trust</td>
<td>162,720</td>
<td>76,848</td>
<td>264,888</td>
<td>1,035,000</td>
<td>84,384</td>
<td>214%</td>
<td>633,744</td>
<td>1,529,136</td>
<td>1,987</td>
<td>1,987</td>
<td>4,625</td>
<td></td>
</tr>
<tr>
<td>Trust Ribbed</td>
<td>185,760</td>
<td>75,216</td>
<td>282,024</td>
<td>945,000</td>
<td>72,360</td>
<td>290%</td>
<td>592,632</td>
<td>962,064</td>
<td>2,115</td>
<td>2,115</td>
<td>4,924</td>
<td></td>
</tr>
<tr>
<td>Trust Scented</td>
<td>164,376</td>
<td>68,208</td>
<td>253,584</td>
<td>945,000</td>
<td>74,448</td>
<td>241%</td>
<td>566,496</td>
<td>1,169,352</td>
<td>1,902</td>
<td>1,902</td>
<td>4,428</td>
<td></td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
### Monthly Distribution by Country

**Period:** 2  
**Year:** 2020

#### DISTRIBUTION 2/2020  
**MONTHLY AVG PREV 3 MONTHS**  
**YTD DISTRIBUTION 2020**  
**DISTRIBUTION TARGET 2020**  
**YTD DISTRIBUTION 2019**  
**LAUNCH DATE**  
**YTD % CHANGE**  
**TOTAL DISTRIBUTION 2019**  
**CUMULATIVE DISTRIBUTION**  
**%YTD USERS REACHED 2020**  
**YTD CYP 2020**  
**YTD DALY 2020**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Trust Studded</td>
<td>183,024</td>
<td>72,888</td>
<td>275,760</td>
<td>945,000</td>
<td>54,504</td>
<td>406%</td>
<td>549,936</td>
<td>1,363,248</td>
<td>2,068</td>
<td>2,068</td>
<td>4,815</td>
<td></td>
</tr>
<tr>
<td>Emergency Contraception</td>
<td>(188)</td>
<td>(54)</td>
<td>(341)</td>
<td>11,500</td>
<td>(17)</td>
<td>0%</td>
<td>(60)</td>
<td>(508)</td>
<td>(15)</td>
<td>(15)</td>
<td>(9)</td>
<td></td>
</tr>
<tr>
<td>Pronta</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>11,500</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>(b)PSI Emergency Contraception Distributed Provided</td>
<td>(188)</td>
<td>(54)</td>
<td>(341)</td>
<td>-</td>
<td>(17)</td>
<td>-%</td>
<td>(60)</td>
<td>(508)</td>
<td>(15)</td>
<td>(15)</td>
<td>(9)</td>
<td></td>
</tr>
<tr>
<td>Emergency Contraception Provided</td>
<td>188</td>
<td>56</td>
<td>341</td>
<td>-</td>
<td>17</td>
<td>1906%</td>
<td>102</td>
<td>552</td>
<td>17</td>
<td>17</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>Non-PSI Emergency Contraception Provided</td>
<td>-</td>
<td>2</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>42</td>
<td>44</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>PSI Emergency Contraception Provided</td>
<td>188</td>
<td>54</td>
<td>341</td>
<td>-</td>
<td>17</td>
<td>1906%</td>
<td>60</td>
<td>508</td>
<td>17</td>
<td>17</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>Expanded Clean Delivery Kit (+CHX)</td>
<td>457</td>
<td>276</td>
<td>601</td>
<td>18,000</td>
<td>464</td>
<td>30%</td>
<td>11,709</td>
<td>26,147</td>
<td>541</td>
<td>-</td>
<td>88</td>
<td></td>
</tr>
<tr>
<td>Mama Kit with Chlorhexidine</td>
<td>457</td>
<td>276</td>
<td>601</td>
<td>18,000</td>
<td>464</td>
<td>30%</td>
<td>11,709</td>
<td>26,147</td>
<td>541</td>
<td>-</td>
<td>88</td>
<td></td>
</tr>
<tr>
<td>Implant 3</td>
<td>(3,427)</td>
<td>9,120</td>
<td>(3,876)</td>
<td>76,507</td>
<td>7,332</td>
<td>(153)%</td>
<td>77,791</td>
<td>108,183</td>
<td>(3,488)</td>
<td>(8,721)</td>
<td>(8,802)</td>
<td></td>
</tr>
<tr>
<td>Implanon</td>
<td>720</td>
<td>4,843</td>
<td>720</td>
<td>34,400</td>
<td>10,778</td>
<td>(93)%</td>
<td>63,640</td>
<td>119,470</td>
<td>648</td>
<td>1,620</td>
<td>1,635</td>
<td></td>
</tr>
<tr>
<td>Levoplant</td>
<td>1,500</td>
<td>5,316</td>
<td>1,700</td>
<td>51,600</td>
<td>-</td>
<td>-%</td>
<td>34,207</td>
<td>35,907</td>
<td>1,530</td>
<td>3,825</td>
<td>3,860</td>
<td></td>
</tr>
<tr>
<td>(b)PSI Implant 3 Distributed Inserted</td>
<td>(5,647)</td>
<td>(1,038)</td>
<td>(6,296)</td>
<td>(9,493)</td>
<td>(3,446)</td>
<td>-%</td>
<td>(20,056)</td>
<td>(47,194)</td>
<td>(5,666)</td>
<td>(14,166)</td>
<td>(14,297)</td>
<td></td>
</tr>
<tr>
<td>Implant 3 Insertion</td>
<td>5,647</td>
<td>6,585</td>
<td>6,296</td>
<td>29,111</td>
<td>18,108</td>
<td>(65)%</td>
<td>114,111</td>
<td>220,320</td>
<td>6,296</td>
<td>15,740</td>
<td>15,886</td>
<td></td>
</tr>
<tr>
<td>Non-PSI Implant 3 Inserted</td>
<td>-</td>
<td>5,547</td>
<td>-</td>
<td>19,618</td>
<td>14,662</td>
<td>(100)%</td>
<td>94,055</td>
<td>173,126</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>PSI Implant 3 Inserted</td>
<td>5,647</td>
<td>1,038</td>
<td>6,296</td>
<td>9,493</td>
<td>3,446</td>
<td>83%</td>
<td>20,056</td>
<td>47,194</td>
<td>6,296</td>
<td>15,740</td>
<td>15,886</td>
<td></td>
</tr>
<tr>
<td>Implant 4</td>
<td>(25)</td>
<td>(25)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>-</td>
<td>(25)</td>
<td>(23)</td>
<td>(72)</td>
<td>(72)</td>
<td></td>
</tr>
<tr>
<td>(b)PSI Implant 4 Distributed Inserted</td>
<td>(25)</td>
<td>-</td>
<td>(25)</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>(25)</td>
<td>(23)</td>
<td>(72)</td>
<td>(72)</td>
<td></td>
</tr>
<tr>
<td>Implant 4 Insertion</td>
<td>25</td>
<td>-</td>
<td>25</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>-</td>
<td>25</td>
<td>25</td>
<td>80</td>
<td>80</td>
<td></td>
</tr>
<tr>
<td>PSI Implant 4 Inserted</td>
<td>25</td>
<td>-</td>
<td>25</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>25</td>
<td>25</td>
<td>80</td>
<td>80</td>
<td></td>
</tr>
<tr>
<td>Implant 5</td>
<td>(3,445)</td>
<td>1,832</td>
<td>(3,710)</td>
<td>15,628</td>
<td>7,887</td>
<td>(147)%</td>
<td>49,558</td>
<td>87,211</td>
<td>(3,339)</td>
<td>(12,688)</td>
<td>(12,587)</td>
<td></td>
</tr>
<tr>
<td>Jadelle</td>
<td>1,000</td>
<td>2,327</td>
<td>1,000</td>
<td>18,000</td>
<td>9,360</td>
<td>(89)%</td>
<td>59,210</td>
<td>113,370</td>
<td>900</td>
<td>3,420</td>
<td>3,393</td>
<td></td>
</tr>
<tr>
<td>(b)PSI Implant 5 Distributed Inserted</td>
<td>(4,445)</td>
<td>(495)</td>
<td>(4,710)</td>
<td>(2,372)</td>
<td>(1,473)</td>
<td>-%</td>
<td>(9,652)</td>
<td>(26,159)</td>
<td>(4,239)</td>
<td>(16,108)</td>
<td>(15,979)</td>
<td></td>
</tr>
<tr>
<td>Implant 5 Insertion</td>
<td>4,445</td>
<td>2,437</td>
<td>4,710</td>
<td>4,825</td>
<td>11,490</td>
<td>(59)%</td>
<td>57,179</td>
<td>95,224</td>
<td>4,710</td>
<td>17,898</td>
<td>17,755</td>
<td></td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
| Non-PSI Implant 5 Inserted | 1,942 | 2,453 | 10,017 | 100% | 47,527 | 69,065 | - | - | - |
| PSI Implant 5 Inserted | 4,445 | 495 | 4,710 | 2,372 | 1,473 | 220% | 9,652 | 26,159 | 4,710 | 17,898 | 17,755 |
| Injectable 1 | - | - | - | 15,000 | - | 0% | - | - | - | - | - |
| Femi-ject | - | - | - | 15,000 | - | -% | - | - | - | - | - |
| Injectable 3-IM | 1,124 | 6,102 | 2,137 | 69,000 | 9,788 | 122% | 162,766 | 220,278 | 481 | (481) | (357) |
| Depo-Provera | - | 7,358 | - | 80,000 | 13,975 | 100% | 187,350 | 269,525 | - | - | - |
| (b) PSI Injectable 3 IM Distributed Provided | 1,124 | (1,257) | 2,137 | (11,000) | (4,187) | -% | (24,584) | (49,247) | (481) | (481) | (357) |
| Injectable 3-IM Provided | 1,124 | 1,274 | 2,137 | 11,300 | 4,347 | 51% | 25,418 | 51,853 | 534 | 534 | 396 |
| Non-PSI Injectable 3 IM Provided | - | 17 | - | 300 | 160 | 100% | 834 | 2,606 | - | - | - |
| PSI Injectable 3 IM Provided | 1,124 | 1,257 | 2,137 | 11,000 | 4,187 | 49% | 24,584 | 49,247 | 534 | 534 | 396 |
| Injectable 3-SC | 579 | 3,033 | 50,000 | 12,630 | 105% | 87,600 | 142,921 | (130) | (130) | (97) |
| (b) PSI Injectable 3 SC Distributed Provided | 579 | - | 50,000 | 12,630 | 100% | 87,600 | 143,500 | - | - | - |
| Sayana Press | - | 3,033 | - | 50,000 | 12,630 | 100% | 87,600 | 143,500 | - | - | - |
| Injectable 3-SC Provided | 579 | - | 50,000 | 12,630 | 100% | 87,600 | 143,500 | - | - | - |
| PSI Injectable 3 SC Provided | 579 | - | 50,000 | 12,630 | 100% | 87,600 | 143,500 | - | - | - |
| IUD 10 | 57 | 13,380 | (336) | 73,438 | 2,015 | 117% | 117,001 | 229,471 | (302) | (1,391) | (1,320) |
| Copper T 380 | 1,000 | 13,333 | 1,100 | 58,000 | 3,650 | 70% | 107,755 | 219,400 | 990 | 4,554 | 4,320 |
| IUD PACK CU T380A | 550 | 1,725 | 550 | 24,784 | 1,550 | 65% | 30,334 | 74,471 | 495 | 2,277 | 2,160 |
| PPIUD Cu T380A | - | 70 | - | 453 | 350 | 100% | 2,025 | 4,700 | - | - | - |
| (b) PSI IUD 10 Distributed Inserted | 1,493 | (1,298) | 1,986 | (9,799) | (3,535) | -% | (23,113) | (69,100) | (1,787) | (8,222) | (7,799) |
| IUD 10 Insertion | 1,493 | 3,064 | 1,986 | 17,930 | 7,816 | 75% | 57,538 | 149,431 | 1,986 | 9,136 | 8,666 |
| Non-PSI IUD 10 Inserted | - | 1,766 | - | 8,131 | 4,281 | 100% | 34,425 | 80,331 | - | - | - |
| PSI IUD 10 Inserted | 1,493 | 1,298 | 1,986 | 9,799 | 3,535 | 44% | 23,113 | 69,100 | 1,986 | 9,136 | 8,666 |
| IUD 5 | - | - | - | - | - | - | 25% | 100% | 32 | 166 | - |

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
### Monthly Distribution by Country

**Period:** 2  
**Year:** 2020

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>(b)PSI IUD 5 Distributed Inserted</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>(25)</td>
<td>-%</td>
<td>(32)</td>
<td>(166)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>IUD 5 Insertion</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>25</td>
<td>(100)%</td>
<td>34</td>
<td>169</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Non-PSI IUD 5 Inserted</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>2</td>
<td>3</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PSI IUD 5 Inserted</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>25</td>
<td>(100)%</td>
<td>32</td>
<td>166</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Manual Vacuum Aspiration for PAC</td>
<td>81</td>
<td>22</td>
<td>110</td>
<td>1,978</td>
<td>248</td>
<td>(56)%</td>
<td>861</td>
<td>1,440</td>
<td>110</td>
<td>-</td>
<td>31</td>
</tr>
<tr>
<td>MVA for PAC</td>
<td>81</td>
<td>22</td>
<td>110</td>
<td>1,978</td>
<td>248</td>
<td>(56)%</td>
<td>861</td>
<td>1,440</td>
<td>110</td>
<td>-</td>
<td>31</td>
</tr>
<tr>
<td>Manual Vacuum Aspiration for SA</td>
<td>86</td>
<td>73</td>
<td>190</td>
<td>742</td>
<td>143</td>
<td>33%</td>
<td>805</td>
<td>1,256</td>
<td>190</td>
<td>-</td>
<td>69</td>
</tr>
<tr>
<td>Manual Vacuum Aspiration for SA</td>
<td>86</td>
<td>73</td>
<td>190</td>
<td>742</td>
<td>143</td>
<td>33%</td>
<td>805</td>
<td>1,256</td>
<td>190</td>
<td>-</td>
<td>69</td>
</tr>
<tr>
<td>Medical Abortion</td>
<td>675</td>
<td>657</td>
<td>1,431</td>
<td>12,328</td>
<td>854</td>
<td>68%</td>
<td>10,999</td>
<td>28,965</td>
<td>1,288</td>
<td>-</td>
<td>451</td>
</tr>
<tr>
<td>Divabo - Combipack (1+4’s)</td>
<td>746</td>
<td>703</td>
<td>1,545</td>
<td>12,822</td>
<td>994</td>
<td>55%</td>
<td>11,774</td>
<td>30,123</td>
<td>1,391</td>
<td>-</td>
<td>487</td>
</tr>
<tr>
<td>(b)PSI Medical Abortion Distributed Provided</td>
<td>(71)</td>
<td>(47)</td>
<td>(114)</td>
<td>(494)</td>
<td>(140)</td>
<td>-%</td>
<td>(775)</td>
<td>(1,158)</td>
<td>(103)</td>
<td>-</td>
<td>(36)</td>
</tr>
<tr>
<td>Medical Abortion (Misoprostol) Provided</td>
<td>84</td>
<td>49</td>
<td>146</td>
<td>742</td>
<td>225</td>
<td>(35)%</td>
<td>988</td>
<td>1,478</td>
<td>146</td>
<td>-</td>
<td>46</td>
</tr>
<tr>
<td>PSI Medical Abortion (Misoprostol) Provided</td>
<td>84</td>
<td>49</td>
<td>146</td>
<td>742</td>
<td>225</td>
<td>(35)%</td>
<td>988</td>
<td>1,478</td>
<td>146</td>
<td>-</td>
<td>46</td>
</tr>
<tr>
<td>Medical Abortion Provided</td>
<td>71</td>
<td>47</td>
<td>114</td>
<td>494</td>
<td>140</td>
<td>(19)%</td>
<td>775</td>
<td>1,158</td>
<td>114</td>
<td>-</td>
<td>40</td>
</tr>
<tr>
<td>PSI Medical Abortion Provided</td>
<td>71</td>
<td>47</td>
<td>114</td>
<td>494</td>
<td>140</td>
<td>(19)%</td>
<td>775</td>
<td>1,158</td>
<td>114</td>
<td>-</td>
<td>40</td>
</tr>
<tr>
<td>Misoprostol for PAC Provided</td>
<td>55</td>
<td>22</td>
<td>83</td>
<td>989</td>
<td>263</td>
<td>(68)%</td>
<td>858</td>
<td>1,527</td>
<td>83</td>
<td>-</td>
<td>29</td>
</tr>
<tr>
<td>PSI Misoprostol for PAC Provided</td>
<td>55</td>
<td>22</td>
<td>83</td>
<td>989</td>
<td>263</td>
<td>(68)%</td>
<td>858</td>
<td>1,527</td>
<td>83</td>
<td>-</td>
<td>29</td>
</tr>
<tr>
<td>Misoprostol for Safe Abortion</td>
<td>50,873</td>
<td>47,285</td>
<td>84,017</td>
<td>694,896</td>
<td>80,748</td>
<td>4%</td>
<td>668,042</td>
<td>1,204,107</td>
<td>4,411</td>
<td>-</td>
<td>1,381</td>
</tr>
<tr>
<td>Misoprostol 200 mcg Tablet</td>
<td>52,101</td>
<td>47,967</td>
<td>86,101</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>521,230</td>
<td>607,331</td>
<td>4,520</td>
<td>-</td>
<td>1,415</td>
</tr>
<tr>
<td>Misoprostol for Safe Abortion</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>707,756</td>
<td>84,500</td>
<td>(100)%</td>
<td>162,100</td>
<td>620,620</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>(b)PSI Misoprostol for Safe Abortion Dist Provided</td>
<td>(1,228)</td>
<td>(681)</td>
<td>(2,084)</td>
<td>(12,860)</td>
<td>(3,752)</td>
<td>-%</td>
<td>(15,288)</td>
<td>(23,844)</td>
<td>(109)</td>
<td>-</td>
<td>(34)</td>
</tr>
<tr>
<td>OCs</td>
<td>9,122</td>
<td>3,718</td>
<td>9,072</td>
<td>33,800</td>
<td>12,079</td>
<td>(25)%</td>
<td>63,013</td>
<td>87,076</td>
<td>544</td>
<td>544</td>
<td>426</td>
</tr>
<tr>
<td>Combination 3</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1,200</td>
<td>1,360</td>
<td>(100)%</td>
<td>3,100</td>
<td>11,000</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>MEURI</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>11,500</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

---

3002 - 4/15/2020 10:09:35AM Page 29 of 115
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Microlut - Oral Contraceptive</td>
<td>1,440</td>
<td>1,385</td>
<td>1,488</td>
<td>1,200</td>
<td>1,662</td>
<td>(10)%</td>
<td>8,096</td>
<td>10,283</td>
<td>89</td>
<td>89</td>
<td>70</td>
</tr>
<tr>
<td>(b)PSI OCs Distributed Provided</td>
<td>(259)</td>
<td>(166)</td>
<td>(405)</td>
<td>(1,100)</td>
<td>(399)</td>
<td>-</td>
<td>(2,682)</td>
<td>(5,977)</td>
<td>(24)</td>
<td>(24)</td>
<td>(19)</td>
</tr>
<tr>
<td>Zinnia</td>
<td>7,941</td>
<td>2,499</td>
<td>7,989</td>
<td>21,000</td>
<td>9,456</td>
<td>(16)%</td>
<td>54,499</td>
<td>71,770</td>
<td>479</td>
<td>479</td>
<td>375</td>
</tr>
<tr>
<td>OCs Provided</td>
<td>259</td>
<td>168</td>
<td>405</td>
<td>1,180</td>
<td>426</td>
<td>(5)%</td>
<td>2,821</td>
<td>6,292</td>
<td>27</td>
<td>27</td>
<td>21</td>
</tr>
<tr>
<td>Non-PSI OCs Provided</td>
<td>-</td>
<td>2</td>
<td>-</td>
<td>80</td>
<td>27</td>
<td>(100)%</td>
<td>139</td>
<td>315</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PSI OCs Provided</td>
<td>259</td>
<td>166</td>
<td>405</td>
<td>1,100</td>
<td>399</td>
<td>2%</td>
<td>2,682</td>
<td>5,977</td>
<td>27</td>
<td>27</td>
<td>21</td>
</tr>
<tr>
<td>Pregnancy Test</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>10,900</td>
<td>-</td>
<td>0%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Pronta (PTK)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>10,900</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PUR</td>
<td>-</td>
<td>104,000</td>
<td>24,000</td>
<td>4,540,800</td>
<td>1,065,000</td>
<td>(98)%</td>
<td>3,387,421</td>
<td>9,825,166</td>
<td>197</td>
<td>-</td>
<td>1</td>
</tr>
<tr>
<td>PuR</td>
<td>-</td>
<td>104,000</td>
<td>24,000</td>
<td>4,540,800</td>
<td>1,065,000</td>
<td>(98)%</td>
<td>3,387,421</td>
<td>9,825,166</td>
<td>197</td>
<td>-</td>
<td>1</td>
</tr>
<tr>
<td>Tubal Ligation</td>
<td>3</td>
<td>1</td>
<td>5</td>
<td>5</td>
<td>20</td>
<td>18</td>
<td>(72)%</td>
<td>47</td>
<td>98</td>
<td>5</td>
<td>50</td>
</tr>
<tr>
<td>Tubal Ligation</td>
<td>3</td>
<td>1</td>
<td>5</td>
<td>5</td>
<td>20</td>
<td>18</td>
<td>(72)%</td>
<td>47</td>
<td>98</td>
<td>5</td>
<td>50</td>
</tr>
<tr>
<td>Vasectomy</td>
<td>-</td>
<td>2</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>17</td>
<td>17</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Vasectomy</td>
<td>-</td>
<td>2</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>17</td>
<td>17</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Rwanda</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>20,892</td>
<td>39,270</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Condom</td>
<td>1,847,360</td>
<td>978,266</td>
<td>2,289,520</td>
<td>-</td>
<td>3,522,164</td>
<td>(35)%</td>
<td>15,062,917</td>
<td>91,718,837</td>
<td>17,171</td>
<td>17,171</td>
<td>36,800</td>
</tr>
<tr>
<td>Prudence Plus</td>
<td>1,606,160</td>
<td>670,543</td>
<td>1,636,480</td>
<td>-</td>
<td>2,960,684</td>
<td>2/13</td>
<td>(45)%</td>
<td>11,762,728</td>
<td>77,263,654</td>
<td>12,274</td>
<td>12,274</td>
</tr>
<tr>
<td>Free Condom</td>
<td>540</td>
<td>84</td>
<td>660</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>386</td>
<td>2,391,454</td>
<td>5</td>
<td>5</td>
<td>11</td>
</tr>
<tr>
<td>Military Condom</td>
<td>540</td>
<td>84</td>
<td>660</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>386</td>
<td>2,391,454</td>
<td>5</td>
<td>5</td>
<td>11</td>
</tr>
<tr>
<td>Injectable 3-IM</td>
<td>-</td>
<td>4,630</td>
<td>13,440</td>
<td>-</td>
<td>15,082</td>
<td>(11)%</td>
<td>26,582</td>
<td>121,634</td>
<td>3,024</td>
<td>3,024</td>
<td>1,938</td>
</tr>
<tr>
<td>Confiance Depo-Provera</td>
<td>-</td>
<td>4,630</td>
<td>13,440</td>
<td>-</td>
<td>15,082</td>
<td>2/13</td>
<td>(11)%</td>
<td>26,582</td>
<td>121,634</td>
<td>3,024</td>
<td>3,024</td>
</tr>
<tr>
<td>OCs</td>
<td>11,520</td>
<td>7,210</td>
<td>11,520</td>
<td>-</td>
<td>19,027</td>
<td>(39)%</td>
<td>170,539</td>
<td>548,862</td>
<td>691</td>
<td>691</td>
<td>467</td>
</tr>
<tr>
<td>Microgynon</td>
<td>11,520</td>
<td>7,210</td>
<td>11,520</td>
<td>-</td>
<td>19,027</td>
<td>6/15</td>
<td>(39)%</td>
<td>170,539</td>
<td>548,862</td>
<td>691</td>
<td>691</td>
</tr>
<tr>
<td>PUR</td>
<td>-</td>
<td>168</td>
<td>240</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>1,121,565</td>
<td>7,410,982</td>
<td>2</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
## Monthly Distribution by Country

### Period: 2020

<table>
<thead>
<tr>
<th>Product</th>
<th>DISTRIBUTION AVG PREV 3 MONTHS</th>
<th>DISTRIBUTION TARGET 2020</th>
<th>DISTRIBUTION 2019</th>
<th>LAUNCH DATE</th>
<th>YTD % CHANGE</th>
<th>TOTAL DISTRIBUTION 2019</th>
<th>CUMULATIVE DISTRIBUTION</th>
<th>%YTD USERS REACHED 2020</th>
<th>YTD DALY 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>PuR</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>2/13</td>
<td>-</td>
<td>1,121,565</td>
<td>7,410,982</td>
<td>2</td>
<td>-</td>
</tr>
<tr>
<td>Safe Water Solution</td>
<td>5,832</td>
<td>13,549</td>
<td>32,064</td>
<td>-</td>
<td>20%</td>
<td>114,438</td>
<td>1,257,512</td>
<td>26,354</td>
<td>53</td>
</tr>
<tr>
<td>Sur Eau</td>
<td>5,832</td>
<td>13,549</td>
<td>32,064</td>
<td>2/13</td>
<td>20%</td>
<td>114,438</td>
<td>1,257,512</td>
<td>26,354</td>
<td>53</td>
</tr>
</tbody>
</table>

### Tanzania

<table>
<thead>
<tr>
<th>Country</th>
<th>DISTRIBUTION AVG PREV 3 MONTHS</th>
<th>DISTRIBUTION TARGET 2020</th>
<th>DISTRIBUTION 2019</th>
<th>LAUNCH DATE</th>
<th>YTD % CHANGE</th>
<th>TOTAL DISTRIBUTION 2019</th>
<th>CUMULATIVE DISTRIBUTION</th>
<th>%YTD USERS REACHED 2020</th>
<th>YTD DALY 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Condom</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Salama Halisi</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>2/11</td>
<td>-</td>
<td>1,296</td>
<td>345,729,800</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Salama Scented</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>8/06</td>
<td>-</td>
<td>-</td>
<td>136,918,956</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Salama Studded</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>6/04</td>
<td>(100)%</td>
<td>9,072</td>
<td>132,099,624</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Emergency Contraception</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td>(168)</td>
<td>(1,312)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>(b) PSI Emergency Contraception Distributed Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>(168)</td>
<td>-</td>
<td>(484)</td>
<td>(1,312)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Emergency Contraception Provided</td>
<td>2</td>
<td>19</td>
<td>3</td>
<td>220</td>
<td>272</td>
<td>(99)%</td>
<td>1,135</td>
<td>3,536</td>
<td>-</td>
</tr>
<tr>
<td>Non-PSI Emergency Contraception Provided</td>
<td>2</td>
<td>19</td>
<td>3</td>
<td>220</td>
<td>104</td>
<td>(97)%</td>
<td>651</td>
<td>2,224</td>
<td>-</td>
</tr>
<tr>
<td>PSI Emergency Contraception Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>168</td>
<td>(100)%</td>
<td>484</td>
<td>1,312</td>
<td>-</td>
</tr>
<tr>
<td>Implant 3 Insertion</td>
<td>1,525</td>
<td>2,155</td>
<td>2,733</td>
<td>15,976</td>
<td>(69)%</td>
<td>55,755</td>
<td>221,889</td>
<td>2,733</td>
<td>6,833</td>
</tr>
<tr>
<td>Non-PSI Implant 3 Inserted</td>
<td>1,525</td>
<td>2,155</td>
<td>2,733</td>
<td>15,976</td>
<td>(69)%</td>
<td>55,755</td>
<td>221,889</td>
<td>2,733</td>
<td>6,833</td>
</tr>
<tr>
<td>Implant 5</td>
<td>-</td>
<td>87</td>
<td>-</td>
<td></td>
<td>0%</td>
<td>260</td>
<td>84,260</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Jadelle</td>
<td>-</td>
<td>87</td>
<td>-</td>
<td></td>
<td>-</td>
<td>260</td>
<td>84,260</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Implant 5 Insertion</td>
<td>1,570</td>
<td>2,043</td>
<td>2,662</td>
<td>9,777</td>
<td>(44)%</td>
<td>43,609</td>
<td>151,333</td>
<td>2,662</td>
<td>10,116</td>
</tr>
<tr>
<td>Non-PSI Implant 5 Inserted</td>
<td>1,570</td>
<td>2,043</td>
<td>2,662</td>
<td>9,777</td>
<td>(44)%</td>
<td>43,609</td>
<td>151,333</td>
<td>2,662</td>
<td>10,116</td>
</tr>
<tr>
<td>Injectable 3-IM</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td>0%</td>
<td>(650)</td>
<td>(13,763)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>(b) PSI Injectable 3 IM Distributed Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>(248)</td>
<td>-</td>
<td>(650)</td>
<td>(13,763)</td>
<td>-</td>
</tr>
<tr>
<td>Injectable 3-IM Provided</td>
<td>934</td>
<td>1,990</td>
<td>1,679</td>
<td>20,310</td>
<td>(71)%</td>
<td>43,198</td>
<td>151,314</td>
<td>420</td>
<td>420</td>
</tr>
<tr>
<td>Non-PSI Injectable 3 IM Provided</td>
<td>934</td>
<td>1,990</td>
<td>1,679</td>
<td>20,310</td>
<td>5,537</td>
<td>(70)%</td>
<td>42,548</td>
<td>137,551</td>
<td>420</td>
</tr>
<tr>
<td>PSI Injectable 3 IM Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>248</td>
<td>(100)%</td>
<td>650</td>
<td>13,763</td>
<td>-</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

---

(a) ITN

---

The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
# Monthly Distribution by Country

## Period: 2

## Year: 2020

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>PBO Net</td>
<td>-920,232</td>
<td>-</td>
<td>-</td>
<td>-20 1,300</td>
<td>-</td>
<td>1,260,695</td>
<td>1,260,695</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>IUD 10</td>
<td>-1,300,300</td>
<td>-</td>
<td>-</td>
<td>1,100</td>
<td>-</td>
<td>1,100</td>
<td>1,118%</td>
<td>1,313</td>
<td>(22,256)</td>
<td>12,063</td>
</tr>
<tr>
<td>Familia IUD Kit</td>
<td>-1,300,300</td>
<td>-</td>
<td>-</td>
<td>1,100</td>
<td>11/09</td>
<td>1,313</td>
<td>18,650</td>
<td>269,372</td>
<td>12,063</td>
<td>55,488</td>
</tr>
<tr>
<td>Pregna IUD (no safe load)</td>
<td>-1,300,300</td>
<td>-</td>
<td>-</td>
<td>3/17</td>
<td>-</td>
<td>1,313</td>
<td>18,650</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>(b)PSI IUD 10 Distributed Inserted</td>
<td>-1,300,300</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1,313</td>
<td>18,650</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>IUD 10 Insertion</td>
<td>-1,300,300</td>
<td>1,372</td>
<td>294</td>
<td>8,700</td>
<td>6,973</td>
<td>37,319</td>
<td>617,217</td>
<td>294</td>
<td>1,352</td>
<td>1,075</td>
</tr>
<tr>
<td>Non-PSI IUD 10 Inserted</td>
<td>1,372</td>
<td>294</td>
<td>8,700</td>
<td>6,973</td>
<td>(96)%</td>
<td>34,979</td>
<td>306,939</td>
<td>294</td>
<td>1,352</td>
<td>1,075</td>
</tr>
<tr>
<td>PSI IUD 10 Inserted</td>
<td>-1,300,300</td>
<td>-</td>
<td>-</td>
<td>11,494</td>
<td>-</td>
<td>1,300,300</td>
<td>3,579,427</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>LLIN</td>
<td>-1,300,300</td>
<td>-</td>
<td>-</td>
<td>1,120</td>
<td>-</td>
<td>11,494</td>
<td>3,579,427</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Olyset Nets Health Facility</td>
<td>-1,300,300</td>
<td>-</td>
<td>-</td>
<td>374</td>
<td>(100)%</td>
<td>84,496</td>
<td>176,144</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Permanet Health Facility</td>
<td>-1,300,300</td>
<td>-</td>
<td>-</td>
<td>374</td>
<td>(100)%</td>
<td>2,856,843</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Manual Vacuum Aspiration for PAC</td>
<td>-1,300,300</td>
<td>-</td>
<td>-</td>
<td>6,740</td>
<td>856</td>
<td>5,478</td>
<td>13,226</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>MVA for PAC</td>
<td>-1,300,300</td>
<td>-</td>
<td>-</td>
<td>6,740</td>
<td>856</td>
<td>5,478</td>
<td>13,226</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Misoprostol for PAC Provided</td>
<td>-1,300,300</td>
<td>-</td>
<td>-</td>
<td>2,888</td>
<td>-</td>
<td>2,220</td>
<td>4,818</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Non-PSI Misoprostol for PAC Provided</td>
<td>-1,300,300</td>
<td>-</td>
<td>-</td>
<td>2,888</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PSI Misoprostol for PAC Provided</td>
<td>-1,300,300</td>
<td>-</td>
<td>-</td>
<td>438</td>
<td>-</td>
<td>2,220</td>
<td>4,818</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Misoprostol for Safe Abortion</td>
<td>-1,300,300</td>
<td>-</td>
<td>-</td>
<td>32,808</td>
<td>(100)%</td>
<td>885,152</td>
<td>1,651,536</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Misoprostol Cipla 200 mcg</td>
<td>-1,300,300</td>
<td>-</td>
<td>-</td>
<td>34,560</td>
<td>(100)%</td>
<td>894,032</td>
<td>1,670,808</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>(b)PSI Misoprostol for Safe Abortion Dist Provided</td>
<td>-1,300,300</td>
<td>-</td>
<td>-</td>
<td>(1,752)</td>
<td>-</td>
<td>(8,880)</td>
<td>(19,272)</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>OCs</td>
<td>-1,300,300</td>
<td>-</td>
<td>-</td>
<td>(630)</td>
<td>0%</td>
<td>(969)</td>
<td>(21,789)</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>(b)PSI OCs Distributed Provided</td>
<td>-1,300,300</td>
<td>-</td>
<td>-</td>
<td>(630)</td>
<td>-</td>
<td>(969)</td>
<td>(21,789)</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>OCs Provided</td>
<td>4,950</td>
<td>4,941</td>
<td>8,826</td>
<td>7,255</td>
<td>6,975</td>
<td>92,392</td>
<td>221,483</td>
<td>588</td>
<td>588</td>
<td>388</td>
</tr>
<tr>
<td>Non-PSI OCs Provided</td>
<td>4,950</td>
<td>4,941</td>
<td>8,826</td>
<td>7,255</td>
<td>6,345</td>
<td>91,423</td>
<td>199,694</td>
<td>588</td>
<td>588</td>
<td>388</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
<table>
<thead>
<tr>
<th>Product/Service</th>
<th>DISTRIBUTION</th>
<th>MONTHLY AVG PREV 3 MONTHS</th>
<th>YTD DISTRIBUTION</th>
<th>DISTRIBUTION TARGET</th>
<th>LAUNCH DATE</th>
<th>YTD % CHANGE</th>
<th>TOTAL DISTRIBUTION 2019</th>
<th>CUMULATIVE DISTRIBUTION</th>
<th>YTD USERS REACHED 2020</th>
<th>YTD CYP 2020</th>
<th>YTD DALY 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>PSI OCs Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>630</td>
<td>(100)%</td>
<td>969</td>
<td>21,789</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Water Treatment Tablets</td>
<td>300,001</td>
<td>869,433</td>
<td>300,001</td>
<td>20,004,000</td>
<td>819,000</td>
<td>(63)%</td>
<td>5,768,110</td>
<td>125,474,162</td>
<td>4,934</td>
<td>-</td>
<td>20</td>
</tr>
<tr>
<td>Aquatab Tubs 8.68g</td>
<td>1</td>
<td>-</td>
<td>1</td>
<td>-</td>
<td>3/16</td>
<td>-%</td>
<td>-</td>
<td>446,521</td>
<td>2</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>WaterGuard Tablet ENF</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>7/12</td>
<td>(100)%</td>
<td>1,166,640</td>
<td>52,372,322</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>WaterGuard Tablets</td>
<td>300,000</td>
<td>869,433</td>
<td>300,000</td>
<td>-</td>
<td>11/05</td>
<td>-%</td>
<td>4,601,470</td>
<td>72,655,319</td>
<td>4,932</td>
<td>-</td>
<td>20</td>
</tr>
<tr>
<td><strong>Uganda</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3,296</td>
<td>32,193</td>
</tr>
<tr>
<td>Fever Cases Attended</td>
<td>-</td>
<td>22,518</td>
<td>-</td>
<td>340,000</td>
<td>-</td>
<td>0%</td>
<td>238,868</td>
<td>238,868</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Fever Cases Attended</td>
<td>-</td>
<td>22,518</td>
<td>-</td>
<td>340,000</td>
<td>-</td>
<td>0%</td>
<td>227,984</td>
<td>227,984</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Fever Cases Tested with RDTs</td>
<td>-</td>
<td>21,511</td>
<td>-</td>
<td>323,000</td>
<td>-</td>
<td>0%</td>
<td>13,251,432</td>
<td>93,494,111</td>
<td>2,020</td>
<td>2,020</td>
<td>4,702</td>
</tr>
<tr>
<td>Fever Cases Tested with RDTs</td>
<td>-</td>
<td>21,511</td>
<td>-</td>
<td>323,000</td>
<td>-</td>
<td>0%</td>
<td>227,984</td>
<td>227,984</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Free Condom</td>
<td>-</td>
<td>920,501</td>
<td>418,440</td>
<td>18,000,000</td>
<td>10,080</td>
<td>4051%</td>
<td>19,153,992</td>
<td>102,784,365</td>
<td>3,138</td>
<td>3,138</td>
<td>7,306</td>
</tr>
<tr>
<td>Generic</td>
<td>-</td>
<td>793,989</td>
<td>269,304</td>
<td>15,000,000</td>
<td>1/99</td>
<td>-%</td>
<td>13,251,432</td>
<td>93,494,111</td>
<td>2,020</td>
<td>2,020</td>
<td>4,702</td>
</tr>
<tr>
<td>Ulinzi Condoms</td>
<td>-</td>
<td>126,512</td>
<td>149,136</td>
<td>3,000,000</td>
<td>10,080</td>
<td>1,380%</td>
<td>5,902,560</td>
<td>9,290,254</td>
<td>1,119</td>
<td>1,119</td>
<td>2,604</td>
</tr>
<tr>
<td>Free Female Condom</td>
<td>-</td>
<td>15,667</td>
<td>21,000</td>
<td>100,000</td>
<td>-</td>
<td>0%</td>
<td>64,080</td>
<td>2,395,710</td>
<td>157</td>
<td>157</td>
<td>354</td>
</tr>
<tr>
<td>Female Condom Free</td>
<td>-</td>
<td>15,667</td>
<td>21,000</td>
<td>100,000</td>
<td>11/09</td>
<td>-%</td>
<td>64,080</td>
<td>2,395,710</td>
<td>157</td>
<td>157</td>
<td>354</td>
</tr>
<tr>
<td>HIV Testing Services</td>
<td>10,991</td>
<td>-</td>
<td>10,991</td>
<td>-</td>
<td>0%</td>
<td>3,031</td>
<td>141,745</td>
<td>10,991</td>
<td>-</td>
<td>683</td>
<td>-</td>
</tr>
<tr>
<td>VCT Individual (HIV-Negative)</td>
<td>10,819</td>
<td>-</td>
<td>10,819</td>
<td>-</td>
<td>8/13</td>
<td>-%</td>
<td>2,987</td>
<td>137,210</td>
<td>10,819</td>
<td>-</td>
<td>672</td>
</tr>
<tr>
<td>VCT Individual (HIV-Positive)</td>
<td>172</td>
<td>-</td>
<td>172</td>
<td>-</td>
<td>8/13</td>
<td>-%</td>
<td>44</td>
<td>4,535</td>
<td>172</td>
<td>-</td>
<td>11</td>
</tr>
<tr>
<td>Positive RDTs</td>
<td>-</td>
<td>14,222</td>
<td>-</td>
<td>209,952</td>
<td>-</td>
<td>0%</td>
<td>155,419</td>
<td>155,419</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Positive RDTs</td>
<td>-</td>
<td>14,222</td>
<td>-</td>
<td>209,952</td>
<td>-</td>
<td>0%</td>
<td>155,419</td>
<td>155,419</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Positive RDTs Given First Line Treatment</td>
<td>-</td>
<td>13,425</td>
<td>-</td>
<td>188,956</td>
<td>-</td>
<td>0%</td>
<td>144,641</td>
<td>144,641</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Positive RDTs Given First Line Treatment</td>
<td>-</td>
<td>13,425</td>
<td>-</td>
<td>188,956</td>
<td>-</td>
<td>0%</td>
<td>144,641</td>
<td>144,641</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to HIV Testing Services</td>
<td>5,941</td>
<td>1,871</td>
<td>8,998</td>
<td>50,000</td>
<td>5,352</td>
<td>68%</td>
<td>34,434</td>
<td>55,135</td>
<td>8,998</td>
<td>-</td>
<td>279</td>
</tr>
<tr>
<td>Referral to Linkage to HIV Care</td>
<td>14,621</td>
<td>11,045</td>
<td>27,633</td>
<td>148,000</td>
<td>6,168</td>
<td>348%</td>
<td>96,237</td>
<td>128,484</td>
<td>27,633</td>
<td>-</td>
<td>23,571</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
### Monthly Distribution by Country

**Period:** 2  
**Year:** 2020

#### DISTRIBUTION

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Referral to Linkage to HIV Care</td>
<td>14,621</td>
<td>11,045</td>
<td>27,633</td>
<td>148,000</td>
<td>6,168</td>
<td>348%</td>
<td>96,237</td>
<td>128,484</td>
<td>27,633</td>
<td>-</td>
</tr>
</tbody>
</table>

#### Zambia

| Emergency Contraception Provided | - | 7 | 11 | - | - | - | - | - | - | - | - |
| Non-PSI Emergency Contraception Provided | - | 7 | 11 | - | - | - | - | - | - | - | - |
| HIV Self-Testing Kit | - | 167 | - | - | 40,000 | (100)% | 136,450 | 811,250 | - | - | - |
| HIV Self Testing Kits-Blood based | - | 167 | - | - | - | - | 5,000 | 5,000 | - | - | - |
| ORAQUICK HIV Self-Testing Kit (Pouch) | - | - | - | - | 40,000 | 5/16 | (100)% | 131,450 | 806,250 | - | - |
| Implant 3 Insertion | - | 1,188 | 953 | - | 1,024 | (7)% | 11,040 | 17,457 | 953 | 2,383 | 2,401 |
| Non-PSI Implant 3 Inserted | - | 1,188 | 953 | - | 1,024 | (7)% | 11,040 | 17,457 | 953 | 2,383 | 2,401 |
| Implant 5 Insertion | - | 1,887 | 2,108 | - | 4,359 | (52)% | 30,475 | 80,426 | 2,108 | 8,010 | 7,946 |
| Non-PSI Implant 5 Inserted | - | 1,887 | 2,108 | - | 4,359 | (52)% | 30,475 | 80,426 | 2,108 | 8,010 | 7,946 |
| Injectable 2 Provided | - | 1,709 | 2,202 | - | 3,586 | (39)% | 16,958 | 48,581 | 367 | 367 | 271 |
| Non-PSI Injectable 2 Provided | - | 1,709 | 2,202 | - | 3,586 | (39)% | 16,958 | 48,581 | 367 | 367 | 271 |
| Injectable 3-IM Provided | - | 9,534 | 10,740 | - | 33,817 | (68)% | 186,823 | 438,474 | 2,685 | 2,685 | 1,986 |
| Non-PSI Injectable 3 IM Provided | - | 9,534 | 10,740 | - | 33,817 | (68)% | 186,823 | 438,474 | 2,685 | 2,685 | 1,986 |
| Injectable 3-SC Provided | - | 7,941 | 6,130 | - | - | - | 0% | 32,041 | 38,171 | 1,533 | 1,533 | 1,134 |
| Non-PSI Injectable 3 SC Provided | - | 7,941 | 6,130 | - | - | - | 0% | 32,041 | 38,171 | 1,533 | 1,533 | 1,134 |
| IUD 10 Insertion | - | 443 | 502 | - | 359 | 40% | 5,135 | 9,755 | 502 | 2,309 | 2,194 |
| Non-PSI IUD 10 Inserted | - | 443 | 502 | - | 359 | 40% | 5,135 | 9,755 | 502 | 2,309 | 2,194 |
| IUS 3 | - | (80) | (81) | - | - | - | 0% | (379) | (460) | (73) | (182) | (172) |
| (b)PSI IUS 3 Distributed Inserted | - | (80) | (81) | - | - | - | - | (379) | (460) | (73) | (182) | (172) |
| IUS 3 Insertion | - | 80 | 81 | - | - | - | 0% | 379 | 460 | 81 | 203 | 192 |
| PSI IUS 3 Inserted | - | 80 | 81 | - | - | - | 0% | 379 | 460 | 81 | 203 | 192 |
| IUS 5 | - | - | - | - | - | - | 0% | 500 | 1,300 | - | - | - |
| LNG-IUS | - | - | - | - | - | - | 0% | 500 | 1,300 | - | - | - |

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>IUS 5 Insertion</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>112</td>
<td>(100)%</td>
<td>353</td>
<td>1,126</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Non-PSI IUS 5 Inserted</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>112</td>
<td>(100)%</td>
<td>353</td>
<td>1,126</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>OCs Provided</td>
<td>-</td>
<td>11,326</td>
<td>12,126</td>
<td>13,532</td>
<td>(10)%</td>
<td>112,295</td>
<td>222,214</td>
<td>808</td>
<td>808</td>
<td>631</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Non-PSI OCs Provided</td>
<td>-</td>
<td>11,326</td>
<td>12,126</td>
<td>13,532</td>
<td>(10)%</td>
<td>112,295</td>
<td>222,214</td>
<td>808</td>
<td>808</td>
<td>631</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Safe Water Solution</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>138,048</td>
<td>(100)%</td>
<td>277,356</td>
<td>36,072,791</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Clorin</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>138,048</td>
<td>11/98</td>
<td>(100)%</td>
<td>277,356</td>
<td>36,072,791</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Tubal Ligation</td>
<td>-</td>
<td>21</td>
<td>-</td>
<td>1</td>
<td>(100)%</td>
<td>219</td>
<td>698</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Tubal Ligation</td>
<td>-</td>
<td>21</td>
<td>-</td>
<td>1</td>
<td>(100)%</td>
<td>219</td>
<td>698</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Voluntary Medical Male Circumcision</td>
<td>-</td>
<td>3,221</td>
<td>2,799</td>
<td>30,000</td>
<td>7,923</td>
<td>(65)%</td>
<td>36,201</td>
<td>186,399</td>
<td>2,799</td>
<td>-</td>
<td>20,879</td>
<td>-</td>
</tr>
<tr>
<td>Voluntary Medical Male Circumcision</td>
<td>-</td>
<td>3,221</td>
<td>2,799</td>
<td>30,000</td>
<td>7,923</td>
<td>(65)%</td>
<td>36,201</td>
<td>186,399</td>
<td>2,799</td>
<td>-</td>
<td>20,879</td>
<td>-</td>
</tr>
<tr>
<td>Woman Condom</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>480</td>
<td>(100)%</td>
<td>1,920</td>
<td>141,480</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>MAXIMUM DIVA</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>480</td>
<td>4/16</td>
<td>(100)%</td>
<td>1,920</td>
<td>141,480</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Zimbabwe</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>40,221</td>
<td>208,971</td>
</tr>
<tr>
<td>Antiretroviral Treatment (Currently Enrolled)</td>
<td>10,520</td>
<td>10,499</td>
<td>20,643</td>
<td>93,500</td>
<td>18,818</td>
<td>10%</td>
<td>117,988</td>
<td>329,251</td>
<td>1,720</td>
<td>-</td>
<td>3,597</td>
<td>-</td>
</tr>
<tr>
<td>Antiretroviral Treatment (Currently Enrolled)</td>
<td>10,520</td>
<td>10,499</td>
<td>20,643</td>
<td>93,500</td>
<td>18,818</td>
<td>10%</td>
<td>117,988</td>
<td>329,251</td>
<td>1,720</td>
<td>-</td>
<td>3,597</td>
<td>-</td>
</tr>
<tr>
<td>Antiretroviral Treatment (Newly Enrolled)</td>
<td>725</td>
<td>614</td>
<td>1,298</td>
<td>4,730</td>
<td>692</td>
<td>88%</td>
<td>5,909</td>
<td>26,112</td>
<td>1,298</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Antiretroviral Treatment (Newly Enrolled)</td>
<td>725</td>
<td>614</td>
<td>1,298</td>
<td>4,730</td>
<td>692</td>
<td>88%</td>
<td>5,909</td>
<td>26,112</td>
<td>1,298</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Cervical Cancer-HPV DNA and Conization</td>
<td>3</td>
<td>5</td>
<td>11</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>10</td>
<td>21</td>
<td>11</td>
<td>-</td>
<td>5</td>
<td>0</td>
</tr>
<tr>
<td>Cervical Cancer-HPV DNA and Conization</td>
<td>3</td>
<td>5</td>
<td>11</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>10</td>
<td>21</td>
<td>11</td>
<td>-</td>
<td>5</td>
<td>0</td>
</tr>
<tr>
<td>Cervical Cancer-HPV DNA and Cryotherapy</td>
<td>-</td>
<td>4</td>
<td>8</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>8</td>
<td>19</td>
<td>8</td>
<td>-</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Cervical Cancer-HPV DNA and Cryotherapy</td>
<td>-</td>
<td>4</td>
<td>8</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>8</td>
<td>19</td>
<td>8</td>
<td>-</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Cervical Cancer-HPV DNA and Refer to any Treatm</td>
<td>-</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>2</td>
<td>13</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Cervical Cancer-HPV DNA and Refer to any Treatm</td>
<td>-</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>2</td>
<td>13</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Cervical Cancer-HPV DNA and Refer to Cryotherapy</td>
<td>2</td>
<td>-</td>
<td>2</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>-</td>
<td>2</td>
<td>2</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Cervical Cancer-HPV DNA and Refer to Cryotherapy</td>
<td>2</td>
<td>-</td>
<td>2</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>2</td>
<td>2</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
## Monthly Distribution by Country

**Period: 2**  
**Year: 2020**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Cervical Cancer-HPV DNA Screening</td>
<td>162</td>
<td>502</td>
<td>719</td>
<td>17,000</td>
<td>-</td>
<td>0%</td>
<td>-</td>
<td>3,346</td>
<td>4,065</td>
<td>719</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Cervical Cancer-HPV DNA Screening</td>
<td>162</td>
<td>502</td>
<td>719</td>
<td>17,000</td>
<td>-</td>
<td>0%</td>
<td>-</td>
<td>1,753</td>
<td>1,753</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Cervical Cancer-Pap and Conization</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>-</td>
<td>1,753</td>
<td>1,753</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Cervical Cancer-Pap and Conization</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>9</td>
<td>9</td>
<td>10</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Cervical Cancer-Pap and Refer to any Treatment</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>-</td>
<td>9</td>
<td>9</td>
<td>10</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Cervical Cancer-Pap and Refer to any Treatment</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>9</td>
<td>9</td>
<td>10</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Cervical Cancer-VIA and Conization</td>
<td>17</td>
<td>18</td>
<td>41</td>
<td>150</td>
<td>30</td>
<td>37%</td>
<td>245</td>
<td>590</td>
<td>41</td>
<td>41</td>
<td>-</td>
<td>15</td>
</tr>
<tr>
<td>Cervical Cancer-VIA and Conization</td>
<td>17</td>
<td>18</td>
<td>41</td>
<td>150</td>
<td>30</td>
<td>37%</td>
<td>245</td>
<td>590</td>
<td>41</td>
<td>41</td>
<td>-</td>
<td>15</td>
</tr>
<tr>
<td>Cervical Cancer-VIA and Cryotherapy</td>
<td>19</td>
<td>12</td>
<td>38</td>
<td>352</td>
<td>70</td>
<td>(46)%</td>
<td>1,524</td>
<td>5,532</td>
<td>38</td>
<td>-</td>
<td>13</td>
<td></td>
</tr>
<tr>
<td>Cervical Cancer-VIA and Cryotherapy</td>
<td>19</td>
<td>12</td>
<td>38</td>
<td>352</td>
<td>70</td>
<td>(46)%</td>
<td>1,524</td>
<td>5,532</td>
<td>38</td>
<td>-</td>
<td>13</td>
<td></td>
</tr>
<tr>
<td>Cervical Cancer-VIA and Refer to any Treatment</td>
<td>3</td>
<td>3</td>
<td>5</td>
<td>-</td>
<td>9</td>
<td>(44)%</td>
<td>85</td>
<td>401</td>
<td>5</td>
<td>-</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Cervical Cancer-VIA and Refer to any Treatment</td>
<td>3</td>
<td>3</td>
<td>5</td>
<td>-</td>
<td>9</td>
<td>(44)%</td>
<td>85</td>
<td>401</td>
<td>5</td>
<td>-</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Cervical Cancer-VIA and Refer to Conization</td>
<td>2</td>
<td>1</td>
<td>3</td>
<td>-</td>
<td>6</td>
<td>(50)%</td>
<td>23</td>
<td>2,060</td>
<td>3</td>
<td>-</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Cervical Cancer-VIA and Refer to Conization</td>
<td>2</td>
<td>1</td>
<td>3</td>
<td>-</td>
<td>6</td>
<td>(50)%</td>
<td>23</td>
<td>2,060</td>
<td>3</td>
<td>-</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Cervical Cancer-VIA/VILI Screening</td>
<td>864</td>
<td>530</td>
<td>1,513</td>
<td>7,600</td>
<td>2,974</td>
<td>(49)%</td>
<td>15,302</td>
<td>102,634</td>
<td>1,513</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Cervical Cancer-VIA/VILI Screening</td>
<td>864</td>
<td>530</td>
<td>1,513</td>
<td>7,600</td>
<td>2,974</td>
<td>(49)%</td>
<td>15,302</td>
<td>102,634</td>
<td>1,513</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Condom</td>
<td>534,600</td>
<td>801,468</td>
<td>1,357,515</td>
<td>17,000,000</td>
<td>2,888,440</td>
<td>(53)%</td>
<td>15,175,625</td>
<td>343,920,510</td>
<td>10,181</td>
<td>10,181</td>
<td>32,368</td>
<td></td>
</tr>
<tr>
<td>Protector Plus</td>
<td>116,400</td>
<td>160,083</td>
<td>262,650</td>
<td>3,060,000</td>
<td>541,000</td>
<td>1/08</td>
<td>(51)%</td>
<td>2,928,600</td>
<td>279,887,100</td>
<td>1,970</td>
<td>1,970</td>
<td>6,262</td>
</tr>
<tr>
<td>Protector Plus Flavors</td>
<td>418,200</td>
<td>641,385</td>
<td>1,094,865</td>
<td>13,940,000</td>
<td>2,347,440</td>
<td>3/14</td>
<td>(53)%</td>
<td>12,247,025</td>
<td>64,033,410</td>
<td>8,211</td>
<td>8,211</td>
<td>26,105</td>
</tr>
<tr>
<td>Emergency Contraception</td>
<td>15,599</td>
<td>14,440</td>
<td>34,318</td>
<td>-</td>
<td>7,424</td>
<td>362%</td>
<td>72,570</td>
<td>1,062,653</td>
<td>1,544</td>
<td>1,544</td>
<td>466</td>
<td></td>
</tr>
<tr>
<td>Pregnon</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>7,440</td>
<td>9/10</td>
<td>(100)%</td>
<td>37,805</td>
<td>900,767</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>(b) PSI Emergency Contraception Distributed Provided</td>
<td>(1)</td>
<td>(8)</td>
<td>(4)</td>
<td>(16)</td>
<td>-</td>
<td>-%</td>
<td>(92)</td>
<td>(593)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Revoke-72</td>
<td>15,600</td>
<td>14,448</td>
<td>34,322</td>
<td>-</td>
<td>12/15</td>
<td>-%</td>
<td>34,857</td>
<td>162,479</td>
<td>1,544</td>
<td>1,544</td>
<td>466</td>
<td></td>
</tr>
<tr>
<td>Emergency Contraception Provided</td>
<td>1</td>
<td>8</td>
<td>4</td>
<td>-</td>
<td>21</td>
<td>(81)%</td>
<td>98</td>
<td>808</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Non-PSI Emergency Contraception Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>5</td>
<td>(100)%</td>
<td>6</td>
<td>215</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
## Monthly Distribution by Country

**Period:** 2  
**Year:** 2020

<table>
<thead>
<tr>
<th>Product Type</th>
<th>2/2020</th>
<th>AVG PREV 3 MONTHS</th>
<th>MONTHLY DISTRIBUTION 2020</th>
<th>DISTRIBUTION TARGET 2020</th>
<th>DISTRIBUTION DISTRIBUTION 2019</th>
<th>LAUNCH DATE</th>
<th>YTD % CHANGE</th>
<th>TOTAL DISTRIBUTION 2019</th>
<th>CUMULATIVE DISTRIBUTION</th>
<th>%YTD USERS REACHED 2020</th>
<th>YTD DALY 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>PSI Emergency Contraception Provided</td>
<td>1</td>
<td>8</td>
<td>4</td>
<td>-</td>
<td>16</td>
<td>(75)%</td>
<td>92</td>
<td>593</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Female Condom</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>-</td>
<td>1,200</td>
<td>24,049,234</td>
<td>-</td>
<td>213</td>
<td>213</td>
</tr>
<tr>
<td>Care</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>6/97</td>
<td>-%</td>
<td>1,200</td>
<td>24,049,234</td>
<td>-</td>
<td>213</td>
<td>213</td>
</tr>
<tr>
<td>Free Female Condom</td>
<td>23,450</td>
<td>9,650</td>
<td>28,450</td>
<td>16,000</td>
<td>16,160</td>
<td>76%</td>
<td>1,190,533</td>
<td>1,780,983</td>
<td>213</td>
<td>213</td>
<td>669</td>
</tr>
<tr>
<td>Care (Free Distribution)</td>
<td>23,450</td>
<td>9,650</td>
<td>28,450</td>
<td>16,000</td>
<td>16,160</td>
<td>12/11</td>
<td>76%</td>
<td>1,190,533</td>
<td>1,780,983</td>
<td>213</td>
<td>213</td>
</tr>
<tr>
<td>HIV Self-Testing Kit</td>
<td>-</td>
<td>73,081</td>
<td>-</td>
<td>89,200</td>
<td>-</td>
<td>0%</td>
<td>275,739</td>
<td>511,767</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>ORAQUICK HIV Self-Testing Kit (Pouch)</td>
<td>-</td>
<td>73,081</td>
<td>-</td>
<td>89,200</td>
<td>-</td>
<td>-%</td>
<td>275,739</td>
<td>511,767</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>HIV Testing Services</td>
<td>8,285</td>
<td>4,530</td>
<td>12,156</td>
<td>310,300</td>
<td>6,694</td>
<td>82%</td>
<td>48,842</td>
<td>2,600,396</td>
<td>12,156</td>
<td>-</td>
<td>806</td>
</tr>
<tr>
<td>VCT Individual (HIV-Negative)</td>
<td>5,100</td>
<td>3,245</td>
<td>7,641</td>
<td>293,600</td>
<td>4,489</td>
<td>70%</td>
<td>34,401</td>
<td>2,289,212</td>
<td>7,641</td>
<td>-</td>
<td>507</td>
</tr>
<tr>
<td>VCT Individual (HIV-Positive)</td>
<td>3,185</td>
<td>1,285</td>
<td>4,515</td>
<td>16,700</td>
<td>2,205</td>
<td>105%</td>
<td>14,441</td>
<td>311,184</td>
<td>4,515</td>
<td>-</td>
<td>299</td>
</tr>
<tr>
<td>Hypertension Diagnosis</td>
<td>35</td>
<td>26</td>
<td>65</td>
<td>266</td>
<td>56</td>
<td>16%</td>
<td>271</td>
<td>894</td>
<td>65</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Hypertension Diagnosis</td>
<td>35</td>
<td>26</td>
<td>65</td>
<td>266</td>
<td>56</td>
<td>16%</td>
<td>271</td>
<td>894</td>
<td>65</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Hypertension Screening</td>
<td>9,355</td>
<td>7,826</td>
<td>18,107</td>
<td>140,000</td>
<td>25,035</td>
<td>(28)%</td>
<td>127,777</td>
<td>622,137</td>
<td>18,107</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Hypertension Screening</td>
<td>9,355</td>
<td>7,826</td>
<td>18,107</td>
<td>140,000</td>
<td>25,035</td>
<td>(28)%</td>
<td>127,777</td>
<td>622,137</td>
<td>18,107</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Hypertension Controlled Condition</td>
<td>20</td>
<td>6</td>
<td>30</td>
<td>77</td>
<td>12</td>
<td>150%</td>
<td>105</td>
<td>292</td>
<td>12</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Hypertension Controlled Condition</td>
<td>20</td>
<td>6</td>
<td>30</td>
<td>77</td>
<td>12</td>
<td>150%</td>
<td>105</td>
<td>292</td>
<td>12</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Implant 3</td>
<td>-</td>
<td>(1)</td>
<td>-</td>
<td>(227)</td>
<td>0%</td>
<td>(441)</td>
<td>(3,265)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>(b)PSI Implant 3 Distributed Inserted</td>
<td>-</td>
<td>(1)</td>
<td>-</td>
<td>(227)</td>
<td>-</td>
<td>(441)</td>
<td>(3,265)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Non-PSI Implant 3 Inserted</td>
<td>53</td>
<td>82</td>
<td>166</td>
<td>2,280</td>
<td>645</td>
<td>(74)%</td>
<td>3,191</td>
<td>13,564</td>
<td>166</td>
<td>415</td>
<td>224</td>
</tr>
<tr>
<td>PSI Implant 3 Inserted</td>
<td>-</td>
<td>1</td>
<td>-</td>
<td>227</td>
<td>100%</td>
<td>(441)</td>
<td>3,265</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Implant 5</td>
<td>3,161</td>
<td>1,290</td>
<td>2,681</td>
<td>-</td>
<td>(718)</td>
<td>0%</td>
<td>3,975</td>
<td>85,238</td>
<td>2,413</td>
<td>9,169</td>
<td>4,884</td>
</tr>
<tr>
<td>Jadelle</td>
<td>3,500</td>
<td>1,467</td>
<td>3,500</td>
<td>11,832</td>
<td>500</td>
<td>600%</td>
<td>7,400</td>
<td>123,608</td>
<td>3,150</td>
<td>11,970</td>
<td>6,376</td>
</tr>
<tr>
<td>(b)PSI Implant 5 Distributed Inserted</td>
<td>(339)</td>
<td>(177)</td>
<td>(819)</td>
<td>(11,832)</td>
<td>(1,218)</td>
<td>-%</td>
<td>(3,425)</td>
<td>(38,370)</td>
<td>(737)</td>
<td>(2,801)</td>
<td>(1,492)</td>
</tr>
<tr>
<td>Implant 5 Insertion</td>
<td>1,498</td>
<td>1,216</td>
<td>3,254</td>
<td>11,832</td>
<td>2,484</td>
<td>31%</td>
<td>14,604</td>
<td>108,426</td>
<td>3,254</td>
<td>12,365</td>
<td>6,586</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

3002 - 4/15/2020 10:09:35AM  Page 37 of 115
### Monthly Distribution by Country

#### Period: 2, Year: 2020

<table>
<thead>
<tr>
<th>Product Type</th>
<th>2/2020</th>
<th>AVG PREV 3 MONTHS</th>
<th>DISTRIBUTION TARGET 2020</th>
<th>2020</th>
<th>DISTRIBUTION 2019</th>
<th>LAUNCH DATE</th>
<th>YTD % CHANGE</th>
<th>TOTAL DISTRIBUTION 2019</th>
<th>CUMULATIVE DISTRIBUTION</th>
<th>%YTD USERS REACHED</th>
<th>YTD CYP 2020</th>
<th>YTD DALY 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-PSI Implant 5 Inserted</td>
<td>1,159</td>
<td>1,039</td>
<td>2,435</td>
<td>-</td>
<td>1,266</td>
<td>1/14</td>
<td>92%</td>
<td>11,179</td>
<td>70,056</td>
<td>2,435</td>
<td>9,253</td>
<td>4,929</td>
</tr>
<tr>
<td>PSI Implant 5 Inserted</td>
<td>339</td>
<td>177</td>
<td>819</td>
<td>11,832</td>
<td>1,218</td>
<td>(33)%</td>
<td>3,425</td>
<td>38,370</td>
<td>819</td>
<td>3,112</td>
<td>1,658</td>
<td></td>
</tr>
<tr>
<td>Injectable 3-IM</td>
<td>(55)</td>
<td>(153)</td>
<td>(514)</td>
<td>-</td>
<td>(1,493)</td>
<td>-</td>
<td>0%</td>
<td>(2,681)</td>
<td>(56,756)</td>
<td>(116)</td>
<td>(116)</td>
<td>(46)</td>
</tr>
<tr>
<td>(b) PSI Injectable 3 IM Distributed Provided</td>
<td>(55)</td>
<td>(153)</td>
<td>(514)</td>
<td>-</td>
<td>(1,493)</td>
<td>-</td>
<td>-</td>
<td>(2,681)</td>
<td>(56,756)</td>
<td>(116)</td>
<td>(116)</td>
<td>(46)</td>
</tr>
<tr>
<td>Injectable 3-IM Provided</td>
<td>3,785</td>
<td>3,482</td>
<td>8,971</td>
<td>51,216</td>
<td>8,243</td>
<td>9%</td>
<td>45,849</td>
<td>272,650</td>
<td>2,243</td>
<td>2,243</td>
<td>889</td>
<td></td>
</tr>
<tr>
<td>Non-PSI Injectable 3 IM Provided</td>
<td>3,730</td>
<td>3,329</td>
<td>8,457</td>
<td>51,216</td>
<td>6,750</td>
<td>25%</td>
<td>43,168</td>
<td>215,894</td>
<td>2,114</td>
<td>2,114</td>
<td>838</td>
<td></td>
</tr>
<tr>
<td>PSI Injectable 3 IM Provided</td>
<td>55</td>
<td>153</td>
<td>514</td>
<td>-</td>
<td>1,493</td>
<td>(66)%</td>
<td>2,681</td>
<td>56,756</td>
<td>129</td>
<td>129</td>
<td>51</td>
<td></td>
</tr>
<tr>
<td>IUD 10</td>
<td>(39)</td>
<td>(9)</td>
<td>(44)</td>
<td>-</td>
<td>(406)</td>
<td>-</td>
<td>0%</td>
<td>(1,039)</td>
<td>(10,312)</td>
<td>(40)</td>
<td>(182)</td>
<td>(93)</td>
</tr>
<tr>
<td>(b) PSI IUD 10 Distributed Inserted</td>
<td>(39)</td>
<td>(9)</td>
<td>(44)</td>
<td>-</td>
<td>(406)</td>
<td>3/16</td>
<td>-%</td>
<td>(1,039)</td>
<td>(10,312)</td>
<td>(40)</td>
<td>(182)</td>
<td>(93)</td>
</tr>
<tr>
<td>IUD 10 Insertion</td>
<td>202</td>
<td>158</td>
<td>387</td>
<td>2,084</td>
<td>467</td>
<td>(17)%</td>
<td>2,721</td>
<td>12,709</td>
<td>387</td>
<td>1,780</td>
<td>910</td>
<td></td>
</tr>
<tr>
<td>Non-PSI IUD 10 Inserted</td>
<td>163</td>
<td>149</td>
<td>343</td>
<td>2,084</td>
<td>61</td>
<td>462%</td>
<td>1,682</td>
<td>2,397</td>
<td>343</td>
<td>1,578</td>
<td>806</td>
<td></td>
</tr>
<tr>
<td>PSI IUD 10 Inserted</td>
<td>39</td>
<td>9</td>
<td>44</td>
<td>-</td>
<td>406</td>
<td>3/16</td>
<td>(89)%</td>
<td>1,039</td>
<td>10,312</td>
<td>44</td>
<td>202</td>
<td>103</td>
</tr>
<tr>
<td>IUD 5 Insertion</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>55</td>
<td>-</td>
<td>(100)%</td>
<td>128</td>
<td>208</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Non-PSI IUD 5 Inserted</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>55</td>
<td>-</td>
<td>(100)%</td>
<td>128</td>
<td>208</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>IUS 5</td>
<td>109</td>
<td>(12)</td>
<td>91</td>
<td>-</td>
<td>(28)</td>
<td>-</td>
<td>0%</td>
<td>(105)</td>
<td>266</td>
<td>82</td>
<td>270</td>
<td>146</td>
</tr>
<tr>
<td>LNG-IUS</td>
<td>120</td>
<td>-</td>
<td>120</td>
<td>-</td>
<td>20</td>
<td>500%</td>
<td>60</td>
<td>775</td>
<td>108</td>
<td>356</td>
<td>193</td>
<td></td>
</tr>
<tr>
<td>(b) PSI IUS 5 Distributed Inserted</td>
<td>(11)</td>
<td>(12)</td>
<td>(29)</td>
<td>-</td>
<td>(48)</td>
<td>-</td>
<td>-%</td>
<td>(165)</td>
<td>(509)</td>
<td>(26)</td>
<td>(86)</td>
<td>(47)</td>
</tr>
<tr>
<td>IUS 5 Insertion</td>
<td>11</td>
<td>12</td>
<td>29</td>
<td>-</td>
<td>55</td>
<td>-</td>
<td>(47)%</td>
<td>197</td>
<td>558</td>
<td>29</td>
<td>96</td>
<td>52</td>
</tr>
<tr>
<td>Non-PSI IUS 5 Inserted</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>7</td>
<td>-</td>
<td>(100)%</td>
<td>32</td>
<td>49</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PSI IUS 5 Inserted</td>
<td>11</td>
<td>12</td>
<td>29</td>
<td>-</td>
<td>48</td>
<td>-</td>
<td>(40)%</td>
<td>165</td>
<td>509</td>
<td>29</td>
<td>96</td>
<td>52</td>
</tr>
<tr>
<td>Lubricant</td>
<td>42,000</td>
<td>20,833</td>
<td>55,000</td>
<td>420,000</td>
<td>74,800</td>
<td>(26)%</td>
<td>421,000</td>
<td>1,028,300</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Personal lubricants water based 4.5 g</td>
<td>42,000</td>
<td>20,833</td>
<td>55,000</td>
<td>420,000</td>
<td>74,800</td>
<td>2/17</td>
<td>(26)%</td>
<td>421,000</td>
<td>1,028,300</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>OCs</td>
<td>(1,545)</td>
<td>(683)</td>
<td>(3,594)</td>
<td>-</td>
<td>(4,393)</td>
<td>-</td>
<td>0%</td>
<td>(10,150)</td>
<td>(289,417)</td>
<td>(216)</td>
<td>(216)</td>
<td>(90)</td>
</tr>
<tr>
<td>(b) PSI OCs Distributed Provided</td>
<td>(1,545)</td>
<td>(683)</td>
<td>(3,594)</td>
<td>-</td>
<td>(4,393)</td>
<td>-</td>
<td>-%</td>
<td>(10,150)</td>
<td>(289,417)</td>
<td>(216)</td>
<td>(216)</td>
<td>(90)</td>
</tr>
<tr>
<td>OCs Provided</td>
<td>19,088</td>
<td>13,684</td>
<td>36,862</td>
<td>179,844</td>
<td>26,244</td>
<td>40%</td>
<td>167,743</td>
<td>1,208,948</td>
<td>2,457</td>
<td>2,457</td>
<td>1,027</td>
<td></td>
</tr>
</tbody>
</table>

**Notes:**
- The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.
- DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

---

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-PSI OCs Provided</td>
<td>17,543</td>
<td>13,001</td>
<td>33,268</td>
<td>179,844</td>
<td>21,851</td>
<td></td>
<td>52%</td>
<td>157,593</td>
<td>919,531</td>
<td>2,218</td>
<td>2,218</td>
<td>927</td>
</tr>
<tr>
<td>PSI OCs Provided</td>
<td>1,545</td>
<td>683</td>
<td>3,594</td>
<td>-</td>
<td>4,393</td>
<td>(18)%</td>
<td></td>
<td>10,150</td>
<td>289,417</td>
<td>240</td>
<td>240</td>
<td>100</td>
</tr>
<tr>
<td>PrEP</td>
<td>3,384</td>
<td>3,638</td>
<td>7,218</td>
<td>46,300</td>
<td>7,009</td>
<td>3%</td>
<td></td>
<td>43,045</td>
<td>87,724</td>
<td>601</td>
<td>-</td>
<td>235</td>
</tr>
<tr>
<td>PrEP</td>
<td>3,384</td>
<td>3,638</td>
<td>7,218</td>
<td>46,300</td>
<td>7,009</td>
<td>3%</td>
<td></td>
<td>43,045</td>
<td>87,724</td>
<td>601</td>
<td>-</td>
<td>235</td>
</tr>
<tr>
<td>Referral to Advanced Cervical Cancer Treatment</td>
<td>-</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>10</td>
<td>(100)%</td>
<td></td>
<td>62</td>
<td>479</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to Advanced Cervical Cancer Treatment</td>
<td>-</td>
<td>1</td>
<td>-</td>
<td>10</td>
<td>-</td>
<td>(100)%</td>
<td></td>
<td>62</td>
<td>479</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to Hypertension Management</td>
<td>49</td>
<td>30</td>
<td>97</td>
<td>-</td>
<td>42</td>
<td>131%</td>
<td></td>
<td>335</td>
<td>1,517</td>
<td>97</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to Hypertension Management</td>
<td>49</td>
<td>30</td>
<td>97</td>
<td>-</td>
<td>42</td>
<td>131%</td>
<td></td>
<td>335</td>
<td>1,517</td>
<td>97</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to Linkage to HIV Care</td>
<td>816</td>
<td>735</td>
<td>1,540</td>
<td>15,932</td>
<td>1,414</td>
<td>9%</td>
<td></td>
<td>8,103</td>
<td>26,875</td>
<td>1,540</td>
<td>-</td>
<td>852</td>
</tr>
<tr>
<td>Referral to Linkage to HIV Care</td>
<td>816</td>
<td>735</td>
<td>1,540</td>
<td>15,932</td>
<td>1,414</td>
<td>9%</td>
<td></td>
<td>8,103</td>
<td>26,875</td>
<td>1,540</td>
<td>-</td>
<td>852</td>
</tr>
<tr>
<td>Referral to Pre-Exposure Prophylaxis (PrEP)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td></td>
<td>3</td>
<td>253</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to Pre-Exposure Prophylaxis (PrEP)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td></td>
<td>3</td>
<td>253</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to Treatment for Urethral Discharge (Men)</td>
<td>2</td>
<td>2</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td></td>
<td>-</td>
<td>115</td>
<td>2</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to Treatment for Urethral Discharge (Men)</td>
<td>2</td>
<td>2</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td></td>
<td>-</td>
<td>115</td>
<td>2</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to Treatment for Vaginitis</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td></td>
<td>1</td>
<td>9</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to Treatment for Vaginitis</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1/15</td>
<td>-%</td>
<td>1</td>
<td>9</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to Tx for Nonherpetic Genital Ulcer</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>(100)%</td>
<td></td>
<td>1</td>
<td>73</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to Tx for Nonherpetic Genital Ulcer</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>(100)%</td>
<td></td>
<td>1</td>
<td>73</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to Tx for Urethral Discharge (Women)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>4</td>
<td>(100)%</td>
<td></td>
<td>10</td>
<td>557</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to Tx for Urethral Discharge (Women)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>4</td>
<td>(100)%</td>
<td></td>
<td>10</td>
<td>557</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to Voluntary Medical Male Circumcision</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>4</td>
<td>0%</td>
<td></td>
<td>3</td>
<td>10,818</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to Voluntary Medical Male Circumcision</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>4</td>
<td>-%</td>
<td></td>
<td>3</td>
<td>10,818</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>STI Screening</td>
<td>3,975</td>
<td>4,068</td>
<td>8,692</td>
<td>50,000</td>
<td>12,360</td>
<td>(30)%</td>
<td></td>
<td>52,076</td>
<td>71,566</td>
<td>-</td>
<td>8,692</td>
<td>-</td>
</tr>
<tr>
<td>STI Screening</td>
<td>3,975</td>
<td>4,068</td>
<td>8,692</td>
<td>50,000</td>
<td>12,360</td>
<td>(30)%</td>
<td></td>
<td>52,076</td>
<td>71,566</td>
<td>-</td>
<td>8,692</td>
<td>-</td>
</tr>
<tr>
<td>TB Diagnosis</td>
<td>13</td>
<td>21</td>
<td>35</td>
<td>204</td>
<td>26</td>
<td>35%</td>
<td></td>
<td>198</td>
<td>1,624</td>
<td>35</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>TB Diagnosis</td>
<td>13</td>
<td>21</td>
<td>35</td>
<td>204</td>
<td>26</td>
<td></td>
<td>35%</td>
<td>198</td>
<td>1,624</td>
<td>35</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TB Screening</td>
<td>12,739</td>
<td>12,776</td>
<td>25,772</td>
<td>145,000</td>
<td>22,134</td>
<td></td>
<td>16%</td>
<td>155,468</td>
<td>1,085,198</td>
<td>25,772</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TB Screening</td>
<td>12,739</td>
<td>12,776</td>
<td>25,772</td>
<td>145,000</td>
<td>22,134</td>
<td></td>
<td>16%</td>
<td>155,468</td>
<td>1,085,198</td>
<td>25,772</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment for Cervicitis</td>
<td>8</td>
<td>11</td>
<td>19</td>
<td>132</td>
<td>16</td>
<td></td>
<td>19%</td>
<td>159</td>
<td>541</td>
<td>19</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment for Cervicitis</td>
<td>8</td>
<td>11</td>
<td>19</td>
<td>132</td>
<td>16</td>
<td></td>
<td>19%</td>
<td>159</td>
<td>541</td>
<td>19</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment for Genital Herpes</td>
<td>20</td>
<td>18</td>
<td>38</td>
<td>28</td>
<td>-</td>
<td></td>
<td>0%</td>
<td>104</td>
<td>178</td>
<td>38</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment for Genital Herpes</td>
<td>20</td>
<td>18</td>
<td>38</td>
<td>28</td>
<td>-</td>
<td></td>
<td>-%</td>
<td>104</td>
<td>178</td>
<td>38</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment for Inguinal Bubo</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>16</td>
<td>-</td>
<td></td>
<td>0%</td>
<td>17</td>
<td>29</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment for Inguinal Bubo</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>16</td>
<td>-</td>
<td></td>
<td>-%</td>
<td>17</td>
<td>29</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment for Lower Abdominal Pain</td>
<td>4</td>
<td>2</td>
<td>5</td>
<td>20</td>
<td>2</td>
<td></td>
<td>150%</td>
<td>30</td>
<td>72</td>
<td>5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment for Lower Abdominal Pain</td>
<td>4</td>
<td>2</td>
<td>5</td>
<td>20</td>
<td>2</td>
<td></td>
<td>150%</td>
<td>30</td>
<td>72</td>
<td>5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment for Nonherpetic Genital Ulcer</td>
<td>53</td>
<td>36</td>
<td>88</td>
<td>408</td>
<td>69</td>
<td></td>
<td>28%</td>
<td>484</td>
<td>1,408</td>
<td>88</td>
<td></td>
<td>31</td>
</tr>
<tr>
<td>Treatment for Nonherpetic Genital Ulcer</td>
<td>53</td>
<td>36</td>
<td>88</td>
<td>408</td>
<td>69</td>
<td></td>
<td>28%</td>
<td>484</td>
<td>1,408</td>
<td>88</td>
<td></td>
<td>31</td>
</tr>
<tr>
<td>Treatment for Urethral Discharge (Men)</td>
<td>64</td>
<td>46</td>
<td>120</td>
<td>208</td>
<td>17</td>
<td></td>
<td>606%</td>
<td>331</td>
<td>794</td>
<td>120</td>
<td></td>
<td>15</td>
</tr>
<tr>
<td>Treatment for Urethral Discharge (Men)</td>
<td>64</td>
<td>46</td>
<td>120</td>
<td>208</td>
<td>17</td>
<td></td>
<td>606%</td>
<td>331</td>
<td>794</td>
<td>120</td>
<td></td>
<td>15</td>
</tr>
<tr>
<td>Treatment for Urethral Discharge (Women)</td>
<td>111</td>
<td>79</td>
<td>192</td>
<td>676</td>
<td>87</td>
<td></td>
<td>121%</td>
<td>903</td>
<td>2,538</td>
<td>192</td>
<td></td>
<td>35</td>
</tr>
<tr>
<td>Treatment for Urethral Discharge (Women)</td>
<td>111</td>
<td>79</td>
<td>192</td>
<td>676</td>
<td>87</td>
<td></td>
<td>121%</td>
<td>903</td>
<td>2,538</td>
<td>192</td>
<td></td>
<td>35</td>
</tr>
<tr>
<td>Treatment for Vaginitis</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>8</td>
<td>6</td>
<td>(100)%</td>
<td>(100)%</td>
<td>8</td>
<td>19</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment for Vaginitis</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>8</td>
<td>6</td>
<td>(100)%</td>
<td>(100)%</td>
<td>8</td>
<td>19</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Type 2 Diabetes Screening</td>
<td>56</td>
<td>43</td>
<td>104</td>
<td>291</td>
<td>88</td>
<td></td>
<td>18%</td>
<td>342</td>
<td>12,180</td>
<td>104</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Type 2 Diabetes Screening</td>
<td>56</td>
<td>43</td>
<td>104</td>
<td>291</td>
<td>88</td>
<td></td>
<td>18%</td>
<td>342</td>
<td>12,180</td>
<td>104</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Voluntary Medical Male Circumcision</td>
<td>14,791</td>
<td>7,545</td>
<td>22,929</td>
<td>194,306</td>
<td>29,068</td>
<td>(21)%</td>
<td>(21)%</td>
<td>190,647</td>
<td>676,241</td>
<td>22,929</td>
<td>155,364</td>
<td></td>
</tr>
<tr>
<td>Voluntary Medical Male Circumcision</td>
<td>14,791</td>
<td>7,545</td>
<td>22,929</td>
<td>194,306</td>
<td>29,068</td>
<td>(21)%</td>
<td>(21)%</td>
<td>190,647</td>
<td>676,241</td>
<td>22,929</td>
<td>155,364</td>
<td></td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
Franco/Lusophone Africa Market Group
## POPULATION SERVICES INTERNATIONAL
### CYPs, Cases, and Deaths by Country
#### 1/2020 - 2/2020

<table>
<thead>
<tr>
<th>Country</th>
<th>New HIV Infections</th>
<th>STI Deaths</th>
<th>PWID Deaths</th>
<th>TB Deaths</th>
<th>CYP* Deaths</th>
<th>Maternal Deaths</th>
<th>Unintended Pregnancies</th>
<th>Malaria Deaths</th>
<th>Diarrhea Deaths</th>
<th>Pneumonia Deaths</th>
<th>Cervical Cancer Death</th>
<th>Sum of All Deaths</th>
</tr>
</thead>
<tbody>
<tr>
<td>Franco/Lusophone Africa Market Gro</td>
<td>874</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>410,141</td>
<td>666</td>
<td>169,944</td>
<td>86</td>
<td>219</td>
<td>-</td>
<td>-</td>
<td>5,099</td>
</tr>
<tr>
<td>Angola</td>
<td>12</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1,459</td>
<td>7</td>
<td>496</td>
<td>24</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>45</td>
</tr>
<tr>
<td>Benin</td>
<td>40</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>28,272</td>
<td>32</td>
<td>12,098</td>
<td>-</td>
<td>185</td>
<td>-</td>
<td>-</td>
<td>418</td>
</tr>
<tr>
<td>Burundi</td>
<td>19</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>2,323</td>
<td>5</td>
<td>887</td>
<td>56</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>84</td>
</tr>
<tr>
<td>Cameroon</td>
<td>689</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>42,519</td>
<td>265</td>
<td>13,874</td>
<td>3</td>
<td>2</td>
<td>-</td>
<td>-</td>
<td>557</td>
</tr>
<tr>
<td>Cote d'Ivoire</td>
<td>15</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>14,730</td>
<td>27</td>
<td>6,792</td>
<td>-</td>
<td>4</td>
<td>-</td>
<td>-</td>
<td>144</td>
</tr>
<tr>
<td>Mozambique</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>281,833</td>
<td>271</td>
<td>120,446</td>
<td>-</td>
<td>24</td>
<td>-</td>
<td>-</td>
<td>3,483</td>
</tr>
<tr>
<td>Niger</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>17,174</td>
<td>26</td>
<td>7,377</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>217</td>
</tr>
<tr>
<td>PSI Benin</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>4,534</td>
<td>22</td>
<td>2,091</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>56</td>
</tr>
<tr>
<td>Senegal</td>
<td>99</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>17,297</td>
<td>10</td>
<td>5,883</td>
<td>2</td>
<td>2</td>
<td>-</td>
<td>-</td>
<td>96</td>
</tr>
</tbody>
</table>

* Using USAID CYP conversion factors
### Monthly Distribution by Market Group and Product

**Period:** 2  
**Year:** 2020

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Antiretroviral Treatment (Currently Enrolled)</td>
<td>6,359</td>
<td>6,136</td>
<td>12,614</td>
<td>15,223</td>
<td>5,843</td>
<td>116%</td>
<td>62,079</td>
<td>100,339</td>
<td>1,051</td>
<td>-</td>
<td>2,012</td>
</tr>
<tr>
<td>Antiretroviral Treatment (Newly Enrolled)</td>
<td>159</td>
<td>153</td>
<td>322</td>
<td>2,265</td>
<td>68</td>
<td>374%</td>
<td>1,404</td>
<td>3,947</td>
<td>322</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Cervical Cancer-VIA and Cryotherapy</td>
<td>-</td>
<td>2</td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>(100)%</td>
<td>16</td>
<td>390</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Cervical Cancer-VIA/VILI Screening</td>
<td>1,773</td>
<td>2,870</td>
<td>2,741</td>
<td>-</td>
<td>2,528</td>
<td>8%</td>
<td>28,676</td>
<td>182,892</td>
<td>2,741</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Condom</td>
<td>2,886,139</td>
<td>4,134,915</td>
<td>5,461,699</td>
<td>51,814,542</td>
<td>8,416,546</td>
<td>(35)%</td>
<td>41,175,242</td>
<td>361,860,977</td>
<td>40,963</td>
<td>40,963</td>
<td>55,625</td>
</tr>
<tr>
<td>Diarrhea Treatment Kit</td>
<td>16,581</td>
<td>89,123</td>
<td>270,952</td>
<td>413,905</td>
<td>31,297</td>
<td>766%</td>
<td>300,418</td>
<td>4,706,899</td>
<td>243,857</td>
<td>-</td>
<td>14,202</td>
</tr>
<tr>
<td>Emergency Contraception</td>
<td>3,221</td>
<td>6,245</td>
<td>6,425</td>
<td>89,000</td>
<td>14,615</td>
<td>(56)%</td>
<td>51,168</td>
<td>228,536</td>
<td>289</td>
<td>289</td>
<td>167</td>
</tr>
<tr>
<td>Emergency Contraception Provided</td>
<td>207</td>
<td>296</td>
<td>504</td>
<td>3,000</td>
<td>739</td>
<td>(32)%</td>
<td>4,060</td>
<td>7,051</td>
<td>25</td>
<td>25</td>
<td>16</td>
</tr>
<tr>
<td>Fecal Sludge Management (Households)</td>
<td>-</td>
<td>2,723</td>
<td>-</td>
<td>35,464</td>
<td>64</td>
<td>(100)%</td>
<td>24,886</td>
<td>26,260</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Fecal Sludge Management (Liters)</td>
<td>-</td>
<td>4,009,667</td>
<td>-</td>
<td>47,787,489</td>
<td>1,232,000</td>
<td>(100)%</td>
<td>43,412,000</td>
<td>48,522,000</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Female Condom</td>
<td>42,710</td>
<td>113,783</td>
<td>51,750</td>
<td>5,202</td>
<td>594,790</td>
<td>(91)%</td>
<td>1,461,260</td>
<td>5,800,919</td>
<td>388</td>
<td>388</td>
<td>549</td>
</tr>
<tr>
<td>Free Condom</td>
<td>7,500</td>
<td>318,759</td>
<td>10,232</td>
<td>4,956,000</td>
<td>31,100</td>
<td>(67)%</td>
<td>14,956,285</td>
<td>36,595,021</td>
<td>77</td>
<td>77</td>
<td>58</td>
</tr>
<tr>
<td>Free Female Condom</td>
<td>100</td>
<td>3,495</td>
<td>2,400</td>
<td>132,000</td>
<td>-</td>
<td>-%</td>
<td>99,284</td>
<td>362,013</td>
<td>18</td>
<td>18</td>
<td>13</td>
</tr>
<tr>
<td>HIV Self-Testing Kit</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1,849</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>HIV Testing Services</td>
<td>7,133</td>
<td>5,171</td>
<td>10,148</td>
<td>45,316</td>
<td>15,243</td>
<td>(33)%</td>
<td>87,835</td>
<td>1,078,209</td>
<td>10,148</td>
<td>-</td>
<td>61</td>
</tr>
<tr>
<td>Implant 3</td>
<td>8</td>
<td>377</td>
<td>(1,372)</td>
<td>20,373</td>
<td>1,081</td>
<td>(227)%</td>
<td>7,068</td>
<td>32,140</td>
<td>(1,235)</td>
<td>(3,087)</td>
<td>(3,452)</td>
</tr>
<tr>
<td>Implant 3 Insertion</td>
<td>3,963</td>
<td>4,535</td>
<td>7,768</td>
<td>15,870</td>
<td>6,927</td>
<td>12%</td>
<td>69,284</td>
<td>120,835</td>
<td>7,768</td>
<td>19,420</td>
<td>18,934</td>
</tr>
<tr>
<td>Implant 4 Insertion</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>3</td>
<td>(100)%</td>
<td>21</td>
<td>41</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Implant 5</td>
<td>5,035</td>
<td>3,487</td>
<td>4,937</td>
<td>38,273</td>
<td>425</td>
<td>1,062%</td>
<td>33,764</td>
<td>83,958</td>
<td>4,443</td>
<td>16,885</td>
<td>15,394</td>
</tr>
<tr>
<td>Implant 5 Insertion</td>
<td>6,337</td>
<td>17,708</td>
<td>38,842</td>
<td>65,065</td>
<td>9,115</td>
<td>326%</td>
<td>89,663</td>
<td>430,721</td>
<td>38,842</td>
<td>147,600</td>
<td>158,658</td>
</tr>
<tr>
<td>Injectable 2</td>
<td>(827)</td>
<td>(423)</td>
<td>(1,224)</td>
<td>65,016</td>
<td>195</td>
<td>(728)%</td>
<td>21,203</td>
<td>314,323</td>
<td>(184)</td>
<td>(184)</td>
<td>(98)</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.
### Monthly Distribution by Market Group and Product

**Period:** 2  
**Year:** 2020

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Injectable 2 Provided</td>
<td>1,164</td>
<td>977</td>
<td>1,722</td>
<td>-</td>
<td>2,356</td>
<td>(27)%</td>
<td>12,209</td>
<td>52,681</td>
<td>287</td>
<td>287</td>
</tr>
<tr>
<td>Injectable 3-IM</td>
<td>1,095</td>
<td>9,203</td>
<td>1,076</td>
<td>137,085</td>
<td>18,060</td>
<td>(94)%</td>
<td>194,879</td>
<td>755,118</td>
<td>242</td>
<td>242</td>
</tr>
<tr>
<td>Injectable 3-IM Provided</td>
<td>29,752</td>
<td>113,533</td>
<td>309,985</td>
<td>157,287</td>
<td>41,689</td>
<td>644%</td>
<td>317,069</td>
<td>1,246,024</td>
<td>77,496</td>
<td>77,496</td>
</tr>
<tr>
<td>Injectable 3-SC</td>
<td>18,597</td>
<td>12,171</td>
<td>34,729</td>
<td>30,000</td>
<td>12,578</td>
<td>176%</td>
<td>216,555</td>
<td>281,265</td>
<td>7,814</td>
<td>7,814</td>
</tr>
<tr>
<td>Injectable 3-SC Provided</td>
<td>5,068</td>
<td>4,965</td>
<td>9,961</td>
<td>41,377</td>
<td>7,830</td>
<td>27%</td>
<td>63,385</td>
<td>79,075</td>
<td>2,490</td>
<td>2,490</td>
</tr>
<tr>
<td>IUD 10</td>
<td>1,942</td>
<td>1,736</td>
<td>1,658</td>
<td>60,172</td>
<td>3,667</td>
<td>(55)%</td>
<td>38,817</td>
<td>274,389</td>
<td>1,492</td>
<td>6,864</td>
</tr>
<tr>
<td>IUD 10 Insertion</td>
<td>2,418</td>
<td>6,689</td>
<td>12,838</td>
<td>40,730</td>
<td>6,670</td>
<td>92%</td>
<td>75,712</td>
<td>343,132</td>
<td>12,838</td>
<td>-</td>
</tr>
<tr>
<td>LLIN</td>
<td>6,994</td>
<td>204,400</td>
<td>47,388</td>
<td>948,043</td>
<td>248,932</td>
<td>(81)%</td>
<td>1,581,302</td>
<td>31,036,175</td>
<td>76,769</td>
<td>-</td>
</tr>
<tr>
<td>-</td>
<td>745</td>
<td>50</td>
<td>7,200</td>
<td>855</td>
<td>(94)%</td>
<td>11,039</td>
<td>118,098</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Malaria PPT (ACT)</td>
<td>1,912</td>
<td>2,141</td>
<td>7,173</td>
<td>954,610</td>
<td>43,412</td>
<td>(83)%</td>
<td>409,310</td>
<td>798,416</td>
<td>6,456</td>
<td>-</td>
</tr>
<tr>
<td>Malaria RDK</td>
<td>-</td>
<td>37,792</td>
<td>8,100</td>
<td>366,400</td>
<td>24,575</td>
<td>(67)%</td>
<td>147,125</td>
<td>1,031,000</td>
<td>7,290</td>
<td>-</td>
</tr>
<tr>
<td>Manual Vacuum Aspiration for PAC</td>
<td>270</td>
<td>1,031</td>
<td>481</td>
<td>2,479</td>
<td>456</td>
<td>5%</td>
<td>13,991</td>
<td>18,855</td>
<td>481</td>
<td>-</td>
</tr>
<tr>
<td>Manual Vacuum Aspiration for SA</td>
<td>88</td>
<td>208</td>
<td>261</td>
<td>283</td>
<td>86</td>
<td>203%</td>
<td>1,406</td>
<td>2,850</td>
<td>261</td>
<td>-</td>
</tr>
<tr>
<td>Medical Abortion</td>
<td>12,673</td>
<td>6,497</td>
<td>31,612</td>
<td>12,640</td>
<td>675</td>
<td>4,583%</td>
<td>2,359</td>
<td>33,978</td>
<td>28,451</td>
<td>-</td>
</tr>
<tr>
<td>Medical Abortion (Misoprostol) Provided</td>
<td>19</td>
<td>142</td>
<td>44</td>
<td>341</td>
<td>111</td>
<td>(60)%</td>
<td>967</td>
<td>1,320</td>
<td>44</td>
<td>-</td>
</tr>
<tr>
<td>Medical Abortion Provided</td>
<td>37</td>
<td>26</td>
<td>58</td>
<td>990</td>
<td>-</td>
<td>-%</td>
<td>166</td>
<td>329</td>
<td>58</td>
<td>-</td>
</tr>
<tr>
<td>Micronutrient Powder</td>
<td>300</td>
<td>34,143</td>
<td>900</td>
<td>-</td>
<td>78,120</td>
<td>(99)%</td>
<td>326,950</td>
<td>2,664,442</td>
<td>2</td>
<td>-</td>
</tr>
<tr>
<td>Misoprostol for PAC Provided</td>
<td>138</td>
<td>737</td>
<td>264</td>
<td>2,926</td>
<td>316</td>
<td>(16)%</td>
<td>10,819</td>
<td>14,461</td>
<td>264</td>
<td>-</td>
</tr>
<tr>
<td>Misoprostol for Safe Abortion</td>
<td>73,680</td>
<td>64,466</td>
<td>89,826</td>
<td>517,149</td>
<td>76,943</td>
<td>17%</td>
<td>589,221</td>
<td>2,223,341</td>
<td>4,716</td>
<td>-</td>
</tr>
<tr>
<td>OCs</td>
<td>52,897</td>
<td>118,322</td>
<td>111,769</td>
<td>994,174</td>
<td>360,083</td>
<td>(69)%</td>
<td>1,681,290</td>
<td>7,753,026</td>
<td>6,706</td>
<td>6,706</td>
</tr>
<tr>
<td>OCs Provided</td>
<td>44,726</td>
<td>147,214</td>
<td>401,459</td>
<td>288,917</td>
<td>59,499</td>
<td>57%</td>
<td>530,857</td>
<td>1,879,337</td>
<td>26,764</td>
<td>26,764</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.
### Table: Monthly Distribution by Market Group and Product

**Period:** 2  
**Year:** 2020

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>PrEP</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>145</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Safe Water Solution</td>
<td>137,103</td>
<td>145,356</td>
<td>365,967</td>
<td>1,400,000</td>
<td>81,360</td>
<td>350%</td>
<td>1,581,666</td>
<td>8,053,363</td>
<td>300,795</td>
<td>-</td>
<td>1,570</td>
</tr>
<tr>
<td>SDM (Cycle Beads)</td>
<td>6 (4)</td>
<td>6</td>
<td>2,600</td>
<td>9</td>
<td>(33)%</td>
<td>1,449</td>
<td>38,777</td>
<td>5</td>
<td>8</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>SDM (Cycle Beads) Provided</td>
<td>14</td>
<td>4</td>
<td>14</td>
<td>-</td>
<td>11</td>
<td>27%</td>
<td>110</td>
<td>387</td>
<td>14</td>
<td>21</td>
<td>16</td>
</tr>
<tr>
<td>Seasonal Malaria Chemoprevention_children reached</td>
<td>- 926,912</td>
<td>-</td>
<td>2,791,734</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>2,780,737</td>
<td>2,780,737</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Skilled Birth Attendance</td>
<td>183</td>
<td>76</td>
<td>224</td>
<td>-</td>
<td>255</td>
<td>(12)%</td>
<td>1,560</td>
<td>28,119</td>
<td>224</td>
<td>-</td>
<td>284</td>
</tr>
<tr>
<td>STI Screening</td>
<td>843</td>
<td>619</td>
<td>1,459</td>
<td>-</td>
<td>1,726</td>
<td>(15)%</td>
<td>9,457</td>
<td>41,902</td>
<td>1,459</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Toilet Sold</td>
<td>3,553</td>
<td>1,868</td>
<td>4,404</td>
<td>14,075</td>
<td>1,094</td>
<td>302%</td>
<td>15,356</td>
<td>23,777</td>
<td>24,725</td>
<td>-</td>
<td>939</td>
</tr>
<tr>
<td>Toilet Sold - All</td>
<td>4,182</td>
<td>2,236</td>
<td>5,198</td>
<td>-</td>
<td>1,599</td>
<td>225%</td>
<td>22,150</td>
<td>33,074</td>
<td>28,730</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Cervicitis</td>
<td>- 2</td>
<td>-</td>
<td>-</td>
<td>6</td>
<td>(100)%</td>
<td>29</td>
<td>29</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Genital Herpes</td>
<td>62</td>
<td>19</td>
<td>66</td>
<td>-</td>
<td>124</td>
<td>(47)%</td>
<td>476</td>
<td>606</td>
<td>66</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Inguinal Bubo</td>
<td>8</td>
<td>4</td>
<td>12</td>
<td>-</td>
<td>6</td>
<td>100%</td>
<td>55</td>
<td>134</td>
<td>12</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Lower Abdominal Pain</td>
<td>84</td>
<td>56</td>
<td>137</td>
<td>-</td>
<td>174</td>
<td>(21)%</td>
<td>997</td>
<td>2,201</td>
<td>137</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Nonherpetic Genital Ulcer</td>
<td>100</td>
<td>104</td>
<td>220</td>
<td>-</td>
<td>167</td>
<td>32%</td>
<td>1,093</td>
<td>3,102</td>
<td>220</td>
<td>-</td>
<td>32</td>
</tr>
<tr>
<td>Treatment for Urethral Discharge (Men)</td>
<td>182</td>
<td>167</td>
<td>369</td>
<td>-</td>
<td>433</td>
<td>(15)%</td>
<td>2,005</td>
<td>5,330</td>
<td>369</td>
<td>-</td>
<td>4</td>
</tr>
<tr>
<td>Treatment for Urethral Discharge (Women)</td>
<td>400</td>
<td>254</td>
<td>634</td>
<td>-</td>
<td>734</td>
<td>(14)%</td>
<td>3,359</td>
<td>7,518</td>
<td>634</td>
<td>-</td>
<td>17</td>
</tr>
<tr>
<td>Treatment for Vaginitis</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>150</td>
<td>159</td>
<td>2</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Water Treatment Tablets</td>
<td>744,888</td>
<td>2,152,467</td>
<td>4,232,088</td>
<td>18,623,153</td>
<td>4,314,620</td>
<td>(2)%</td>
<td>21,225,440</td>
<td>179,314,608</td>
<td>69,569</td>
<td>-</td>
<td>556</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.
### Franco/Lusophone Africa Market Group

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Condom</td>
<td>47,340</td>
<td>202,896</td>
<td>103,968</td>
<td>(78)%</td>
<td>2,921,076</td>
<td>21,639,198</td>
<td>780</td>
<td>780</td>
<td>939</td>
<td></td>
</tr>
<tr>
<td>Sensual Champagne</td>
<td>5,184</td>
<td>37,788</td>
<td>9,108</td>
<td>(29)%</td>
<td>138,312</td>
<td>832,140</td>
<td>68</td>
<td>68</td>
<td>82</td>
<td></td>
</tr>
<tr>
<td>Sensual Chocolate</td>
<td>8,568</td>
<td>41,292</td>
<td>20,916</td>
<td>(88)%</td>
<td>531,792</td>
<td>4,227,792</td>
<td>157</td>
<td>157</td>
<td>189</td>
<td></td>
</tr>
<tr>
<td>Sensual Maracuja</td>
<td>4,356</td>
<td>15,624</td>
<td>7,992</td>
<td>(89)%</td>
<td>505,044</td>
<td>1,782,756</td>
<td>60</td>
<td>60</td>
<td>72</td>
<td></td>
</tr>
<tr>
<td>Sensual Menta</td>
<td>17,172</td>
<td>46,152</td>
<td>39,204</td>
<td>-</td>
<td>517,176</td>
<td>5,375,448</td>
<td>294</td>
<td>294</td>
<td>354</td>
<td></td>
</tr>
<tr>
<td>Sensual Morango</td>
<td>8,604</td>
<td>36,156</td>
<td>19,152</td>
<td>(91)%</td>
<td>883,728</td>
<td>5,474,799</td>
<td>144</td>
<td>144</td>
<td>173</td>
<td></td>
</tr>
<tr>
<td>Sensual Saliências</td>
<td>3,456</td>
<td>25,884</td>
<td>7,596</td>
<td>-</td>
<td>345,024</td>
<td>3,946,263</td>
<td>57</td>
<td>57</td>
<td>69</td>
<td></td>
</tr>
<tr>
<td>Emergency Contraception</td>
<td>1,878</td>
<td>4,480</td>
<td>3,409</td>
<td>(67)%</td>
<td>41,177</td>
<td>90,100</td>
<td>153</td>
<td>153</td>
<td>95</td>
<td></td>
</tr>
<tr>
<td>Pronta</td>
<td>1,878</td>
<td>4,480</td>
<td>3,409</td>
<td>(67)%</td>
<td>41,177</td>
<td>90,100</td>
<td>153</td>
<td>153</td>
<td>95</td>
<td></td>
</tr>
<tr>
<td>Implant 5</td>
<td>8</td>
<td>7</td>
<td>24</td>
<td>380%</td>
<td>79</td>
<td>1,937</td>
<td>22</td>
<td>82</td>
<td>89</td>
<td></td>
</tr>
<tr>
<td>Jadelle</td>
<td>8</td>
<td>7</td>
<td>24</td>
<td>380%</td>
<td>79</td>
<td>1,937</td>
<td>22</td>
<td>82</td>
<td>89</td>
<td></td>
</tr>
<tr>
<td>Injectable 3-SC</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>123,600</td>
<td>123,600</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Sayana Press</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>123,600</td>
<td>123,600</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>IUD 10</td>
<td>96</td>
<td>(417)</td>
<td>97</td>
<td>(852)%</td>
<td>0%</td>
<td>(8,045)</td>
<td>322</td>
<td>87</td>
<td>402</td>
<td>417</td>
</tr>
<tr>
<td>Copper T 380 A – ENOVA</td>
<td>96</td>
<td>1</td>
<td>97</td>
<td>111%</td>
<td>15,224</td>
<td>45,096</td>
<td>87</td>
<td>402</td>
<td>417</td>
<td></td>
</tr>
<tr>
<td>IUD 10 Distributed Inserted</td>
<td>(417)</td>
<td>-</td>
<td>-</td>
<td>(898)%</td>
<td>- (23,269)</td>
<td>(44,776)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>IUD 10 Insertion</td>
<td>-</td>
<td>417</td>
<td>-</td>
<td>898</td>
<td>(100)%</td>
<td>23,269</td>
<td>44,776</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>PSI IUD 10 Inserted</td>
<td>-</td>
<td>417</td>
<td>-</td>
<td>898</td>
<td>(100)%</td>
<td>23,269</td>
<td>44,776</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>LLIN</td>
<td>328</td>
<td>148</td>
<td>446</td>
<td>145,078</td>
<td>(100)%</td>
<td>251,144</td>
<td>12,756,982</td>
<td>723</td>
<td>- 60</td>
<td></td>
</tr>
<tr>
<td>Generic LLINs</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>143,875</td>
<td>(100)%</td>
<td>143,875</td>
<td>12,303,308</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Joia</td>
<td>328</td>
<td>148</td>
<td>446</td>
<td>1,203</td>
<td>(63)%</td>
<td>107,269</td>
<td>453,674</td>
<td>723</td>
<td>- 60</td>
<td></td>
</tr>
<tr>
<td>Malaria PPT (ACT)</td>
<td>1,912</td>
<td>2,141</td>
<td>7,173</td>
<td>43,412</td>
<td>(83)%</td>
<td>409,310</td>
<td>796,416</td>
<td>6,456</td>
<td>- 1,992</td>
<td></td>
</tr>
<tr>
<td>ALU 20mg/120mg, 12’s, 3-5Yrs (15-24Kg)</td>
<td>358</td>
<td>290</td>
<td>943</td>
<td>240,878</td>
<td>16,135</td>
<td>(94)%</td>
<td>99,134</td>
<td>188,660</td>
<td>849</td>
<td>- 262</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
### Monthly Distribution by Country

**Period:** 2  
**Year:** 2020

<table>
<thead>
<tr>
<th>Product Description</th>
<th>YTD Distribution 2020</th>
<th>YTD Distribution 2019</th>
<th>Launch Date</th>
<th>YTD % Change</th>
<th>Total Distribution 2019</th>
<th>CUMULATIVE Distribution 2020</th>
<th>YTD CYP 2020</th>
<th>YTD DALY 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ALU 20mg/120mg, 18’s, 9-14Yrs (25-34Kg)</strong></td>
<td>1,040</td>
<td>936</td>
<td>6/17</td>
<td>(89)%</td>
<td>85,569</td>
<td>191,114</td>
<td>936</td>
<td>289</td>
</tr>
<tr>
<td><strong>ALU 20mg/120mg, 24’s, &gt;14Yrs (&gt;34Kg)</strong></td>
<td>2,096</td>
<td>1,528</td>
<td>6/17</td>
<td>(72)%</td>
<td>87,744</td>
<td>202,127</td>
<td>1,528</td>
<td>472</td>
</tr>
<tr>
<td><strong>AZAQ 50 mg AS/135 mg AQ, 3 tablets</strong></td>
<td>3,000</td>
<td>2,700</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>833</td>
</tr>
<tr>
<td><strong>Malaria RDK</strong></td>
<td>3,000</td>
<td>2,700</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>833</td>
</tr>
<tr>
<td><strong>Bioline (RDT)</strong></td>
<td>3,000</td>
<td>2,700</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>833</td>
</tr>
<tr>
<td><strong>mRDT Allere</strong></td>
<td>3,000</td>
<td>2,700</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>833</td>
</tr>
<tr>
<td><strong>Manual Vacuum Aspiration for PAC</strong></td>
<td>3,000</td>
<td>2,700</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>833</td>
</tr>
<tr>
<td><strong>MVA for PAC</strong></td>
<td>3,000</td>
<td>2,700</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>833</td>
</tr>
<tr>
<td><strong>Misoprostol for PAC Provided</strong></td>
<td>3,000</td>
<td>2,700</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>833</td>
</tr>
<tr>
<td><strong>PSI Misoprostol for PAC Provided</strong></td>
<td>3,000</td>
<td>2,700</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>833</td>
</tr>
<tr>
<td><strong>Misoprostol for Safe Abortion</strong></td>
<td>3,000</td>
<td>2,700</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>833</td>
</tr>
<tr>
<td><strong>ACE Miso (Misoprostol 200mcg tablet)</strong></td>
<td>3,000</td>
<td>2,700</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>833</td>
</tr>
<tr>
<td><strong>(b)PSI Misoprostol for Safe Abortion Dist Provided</strong></td>
<td>(1,749)</td>
<td>(32,344)</td>
<td></td>
<td></td>
<td>(32,344)</td>
<td></td>
<td></td>
<td>833</td>
</tr>
<tr>
<td><strong>OCs</strong></td>
<td>427</td>
<td>36</td>
<td>11/16</td>
<td>-%</td>
<td>10,495</td>
<td>10,718</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>MEURI</strong></td>
<td>427</td>
<td>36</td>
<td>11/16</td>
<td>-%</td>
<td>10,495</td>
<td>10,718</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Water Treatment Tablets</strong></td>
<td>3,000</td>
<td>2,700</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>833</td>
</tr>
<tr>
<td><strong>Cervical Cancer-VIA and Cryotherapy</strong></td>
<td>2</td>
<td>1</td>
<td>2/13</td>
<td>(100)%</td>
<td>89,176</td>
<td>543,964</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Cervical Cancer-V/A/ILI Screening</strong></td>
<td>2</td>
<td>1</td>
<td>2/13</td>
<td>(100)%</td>
<td>89,176</td>
<td>543,964</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Condom</strong></td>
<td>437</td>
<td>221</td>
<td>6/17</td>
<td>(74)%</td>
<td>8,858,700</td>
<td>77,351,450</td>
<td>6,218</td>
<td>116%</td>
</tr>
<tr>
<td><strong>Benin</strong></td>
<td>28,272</td>
<td>35,657</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
### Monthly Distribution by Country

#### Period: 2
#### Year: 2020

<table>
<thead>
<tr>
<th>Product</th>
<th>DISTRIBUTION 2/2020</th>
<th>MONTHLY AVG PREV 3 MONTHS</th>
<th>YTD DISTRIBUTION 2020</th>
<th>DISTRIBUTION TARGET 2020</th>
<th>YTD DISTRIBUTION 2019</th>
<th>LAUNCH DATE</th>
<th>YTD % CHANGE</th>
<th>TOTAL DISTRIBUTION 2019</th>
<th>CUMULATIVE DISTRIBUTION (a)</th>
<th>YTD USERS REACHED 2020</th>
<th>YTD DALY 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kool</td>
<td>59,730</td>
<td>27,510</td>
<td>64,530</td>
<td>-</td>
<td>-</td>
<td>2/10</td>
<td>-%</td>
<td>144,566</td>
<td>17,012,398</td>
<td>484</td>
<td>484</td>
</tr>
<tr>
<td>Kool Banane</td>
<td>61,959</td>
<td>29,680</td>
<td>70,359</td>
<td>600,000</td>
<td>85,740</td>
<td>4/18</td>
<td>(18)%</td>
<td>517,794</td>
<td>948,897</td>
<td>528</td>
<td>528</td>
</tr>
<tr>
<td>Kool Fraise</td>
<td>62,130</td>
<td>26,980</td>
<td>68,730</td>
<td>750,000</td>
<td>84,900</td>
<td>4/18</td>
<td>(19)%</td>
<td>510,681</td>
<td>931,533</td>
<td>515</td>
<td>515</td>
</tr>
<tr>
<td>Kool Menthe</td>
<td>8,100</td>
<td>4,100</td>
<td>11,400</td>
<td>950,000</td>
<td>96,240</td>
<td>4/18</td>
<td>(88)%</td>
<td>433,113</td>
<td>851,847</td>
<td>85</td>
<td>85</td>
</tr>
<tr>
<td>Prudence Plus</td>
<td>417,312</td>
<td>182,316</td>
<td>448,272</td>
<td>5,000,000</td>
<td>442,008</td>
<td>1/08</td>
<td>1%</td>
<td>3,245,618</td>
<td>62,494,325</td>
<td>3,362</td>
<td>3,362</td>
</tr>
<tr>
<td>Diarrhea Treatment Kit</td>
<td>13,468</td>
<td>85,050</td>
<td>267,599</td>
<td>350,000</td>
<td>17,650</td>
<td>4/08</td>
<td>1,416%</td>
<td>202,350</td>
<td>3,825,424</td>
<td>240,839</td>
<td>-</td>
</tr>
<tr>
<td>Orasel Zinc DTK</td>
<td>13,468</td>
<td>85,050</td>
<td>267,599</td>
<td>350,000</td>
<td>17,650</td>
<td>4/08</td>
<td>1,416%</td>
<td>202,350</td>
<td>3,825,424</td>
<td>240,839</td>
<td>-</td>
</tr>
<tr>
<td>Fecal Sludge Management (Households)</td>
<td>-</td>
<td>2,723</td>
<td>34,794</td>
<td>-</td>
<td>0%</td>
<td>24,484</td>
<td>25,543</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fecal Sludge Management (Households)</td>
<td>-</td>
<td>2,723</td>
<td>34,794</td>
<td>-</td>
<td>-%</td>
<td>24,484</td>
<td>25,543</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fecal Sludge Management (Liters)</td>
<td>-</td>
<td>4,009,667</td>
<td>45,285,489</td>
<td>228,000</td>
<td>(100)%</td>
<td>37,483,000</td>
<td>39,226,000</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fecal Sludge Management (Liters)</td>
<td>-</td>
<td>4,009,667</td>
<td>45,285,489</td>
<td>228,000</td>
<td>(100)%</td>
<td>37,483,000</td>
<td>39,226,000</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female Condom</td>
<td>450</td>
<td>1,857</td>
<td>550</td>
<td>5,202</td>
<td>-</td>
<td>1,857</td>
<td>-%</td>
<td>6,894</td>
<td>41,090</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>Cupid</td>
<td>450</td>
<td>1,857</td>
<td>550</td>
<td>5,202</td>
<td>-</td>
<td>3/14</td>
<td>-%</td>
<td>6,894</td>
<td>41,090</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>Free Condom</td>
<td>7,500</td>
<td>11,952</td>
<td>8,800</td>
<td>3,000,000</td>
<td>27,800</td>
<td>1/12</td>
<td>(68)%</td>
<td>11,852,217</td>
<td>14,798,112</td>
<td>66</td>
<td>66</td>
</tr>
<tr>
<td>No Logo</td>
<td>7,500</td>
<td>11,952</td>
<td>8,800</td>
<td>3,000,000</td>
<td>27,800</td>
<td>1/12</td>
<td>(68)%</td>
<td>11,852,217</td>
<td>14,798,112</td>
<td>66</td>
<td>66</td>
</tr>
<tr>
<td>VCT Individual (HIV-Negative)</td>
<td>4,863</td>
<td>2,346</td>
<td>5,363</td>
<td>-</td>
<td>7,944</td>
<td>1/10</td>
<td>(32)%</td>
<td>43,335</td>
<td>666,337</td>
<td>5,363</td>
<td>-</td>
</tr>
<tr>
<td>VCT Individual (HIV-Positive)</td>
<td>7</td>
<td>2</td>
<td>9</td>
<td>12</td>
<td>1/10</td>
<td>(25)%</td>
<td>119</td>
<td>7,240</td>
<td>4</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Implant 3</td>
<td>594</td>
<td>535</td>
<td>594</td>
<td>-</td>
<td>-</td>
<td>12</td>
<td>(25)%</td>
<td>4,406</td>
<td>5,000</td>
<td>535</td>
<td>1,337</td>
</tr>
<tr>
<td>Implanon</td>
<td>594</td>
<td>535</td>
<td>594</td>
<td>-</td>
<td>-</td>
<td>4/17</td>
<td>-%</td>
<td>4,406</td>
<td>5,000</td>
<td>535</td>
<td>1,337</td>
</tr>
<tr>
<td>Implant 5</td>
<td>1,820</td>
<td>1,295</td>
<td>1,605</td>
<td>31,266</td>
<td>(186)</td>
<td>0%</td>
<td>13,887</td>
<td>12,282</td>
<td>1,445</td>
<td>5,489</td>
<td>3,915</td>
</tr>
<tr>
<td>Implant 5 (insertion)</td>
<td>2,416</td>
<td>1,837</td>
<td>2,566</td>
<td>35,000</td>
<td>940</td>
<td>12/09</td>
<td>173%</td>
<td>21,750</td>
<td>153,953</td>
<td>2,309</td>
<td>8,776</td>
</tr>
<tr>
<td>(b)PSI Implant 5 Distributed Inserted</td>
<td>(596)</td>
<td>(542)</td>
<td>(961)</td>
<td>(3,734)</td>
<td>(1,126)</td>
<td>-%</td>
<td>(7,863)</td>
<td>(141,671)</td>
<td>(865)</td>
<td>(3,287)</td>
<td>(2,344)</td>
</tr>
<tr>
<td>Implant 5 Insertion</td>
<td>1,954</td>
<td>3,539</td>
<td>2,379</td>
<td>3,734</td>
<td>1,504</td>
<td>58%</td>
<td>28,182</td>
<td>223,181</td>
<td>2,379</td>
<td>9,040</td>
<td>6,447</td>
</tr>
</tbody>
</table>

**Notes:**

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

---

3002 - 4/15/2020 10:09:35AM Page 43 of 115
## Monthly Distribution by Country

**Period:** 2  
**Year:** 2020

<table>
<thead>
<tr>
<th>PRODUCT TYPE</th>
<th>DISTRIBUTION 2/2020</th>
<th>MONTHLY AVG PREV 3 MONTHS</th>
<th>YTD DISTRIBUTION 2020</th>
<th>DISTRIBUTION TARGET 2020</th>
<th>YTD DISTRIBUTION 2019</th>
<th>LAUNCH DATE</th>
<th>YTD % CHANGE</th>
<th>TOTAL DISTRIBUTION 2019</th>
<th>CUMULATIVE DISTRIBUTION</th>
<th>%YTD USERS REACHED 2020</th>
<th>YTD CYP</th>
<th>YTD DALY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-PSI Implant 5 Inserted</td>
<td>1,358</td>
<td>2,997</td>
<td>1,418</td>
<td>-</td>
<td>378</td>
<td>275%</td>
<td>20,319</td>
<td>81,510</td>
<td>1,418</td>
<td>5,388</td>
<td>3,843</td>
<td></td>
</tr>
<tr>
<td>PSI Implant 5 Inserted</td>
<td>596</td>
<td>542</td>
<td>961</td>
<td>3,734</td>
<td>1,126</td>
<td>(15)%</td>
<td>7,863</td>
<td>141,671</td>
<td>961</td>
<td>3,652</td>
<td>2,604</td>
<td></td>
</tr>
<tr>
<td>Injectable 2</td>
<td>(827)</td>
<td>(423)</td>
<td>(1,224)</td>
<td>65,016</td>
<td>195</td>
<td>(728)%</td>
<td>21,203</td>
<td>314,323</td>
<td>(184)</td>
<td>(184)</td>
<td>(98)</td>
<td></td>
</tr>
<tr>
<td>Noristerat</td>
<td>-</td>
<td>-</td>
<td>65,016</td>
<td>1,856</td>
<td>1/12</td>
<td>(100)%</td>
<td>27,958</td>
<td>346,739</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>(b)PSI Injectable 2 Distributed Provided</td>
<td>(827)</td>
<td>(423)</td>
<td>(1,224)</td>
<td>-</td>
<td>(1,661)</td>
<td>-%</td>
<td>(6,755)</td>
<td>(32,416)</td>
<td>(184)</td>
<td>(184)</td>
<td>(98)</td>
<td></td>
</tr>
<tr>
<td>Injectable 2 Provided</td>
<td>1,044</td>
<td>823</td>
<td>1,467</td>
<td>-</td>
<td>2,131</td>
<td>(31)%</td>
<td>10,890</td>
<td>49,734</td>
<td>245</td>
<td>245</td>
<td>130</td>
<td></td>
</tr>
<tr>
<td>Non-PSI Injectable 2 Provided</td>
<td>217</td>
<td>400</td>
<td>243</td>
<td>-</td>
<td>470</td>
<td>(48)%</td>
<td>4,135</td>
<td>17,318</td>
<td>41</td>
<td>41</td>
<td>22</td>
<td></td>
</tr>
<tr>
<td>PSI Injectable 2 Provided</td>
<td>827</td>
<td>423</td>
<td>1,224</td>
<td>-</td>
<td>1,661</td>
<td>(26)%</td>
<td>6,755</td>
<td>32,416</td>
<td>204</td>
<td>204</td>
<td>109</td>
<td></td>
</tr>
<tr>
<td>Injectable 3-IM</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>(261)</td>
<td>(7,229)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>(b)PSI Injectable 3 IM Distributed Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>(261)</td>
<td>(7,229)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Injectable 3-IM Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>28%</td>
<td>28</td>
<td>28</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Non-PSI Injectable 3 IM Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>28</td>
<td>28</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>PSI Injectable 3 IM Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>261</td>
<td>7,229</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Injectable 3-SC</td>
<td>2,539</td>
<td>585</td>
<td>4,471</td>
<td>10,000</td>
<td>150</td>
<td>2881%</td>
<td>9,618</td>
<td>14,089</td>
<td>1,006</td>
<td>1,006</td>
<td>536</td>
<td></td>
</tr>
<tr>
<td>(b)PSI Injectable 3 SC Distributed Provided</td>
<td>(279)</td>
<td>(80)</td>
<td>(317)</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>(2,382)</td>
<td>(2,699)</td>
<td>(71)</td>
<td>(71)</td>
<td>(38)</td>
<td></td>
</tr>
<tr>
<td>Sayana Press</td>
<td>2,818</td>
<td>685</td>
<td>4,788</td>
<td>10,000</td>
<td>150</td>
<td>3,092%</td>
<td>12,000</td>
<td>16,788</td>
<td>1,077</td>
<td>1,077</td>
<td>574</td>
<td></td>
</tr>
<tr>
<td>Injectable 3-SC Provided</td>
<td>418</td>
<td>106</td>
<td>458</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>2,730</td>
<td>3,188</td>
<td>115</td>
<td>115</td>
<td>61</td>
<td></td>
</tr>
<tr>
<td>Non-PSI Injectable 3 SC Provided</td>
<td>139</td>
<td>26</td>
<td>141</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>348</td>
<td>489</td>
<td>35</td>
<td>35</td>
<td>19</td>
<td></td>
</tr>
<tr>
<td>PSI Injectable 3 SC Provided</td>
<td>279</td>
<td>80</td>
<td>317</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>2,382</td>
<td>2,699</td>
<td>79</td>
<td>79</td>
<td>42</td>
<td></td>
</tr>
<tr>
<td>IUD 10</td>
<td>410</td>
<td>(405)</td>
<td>(281)</td>
<td>3,189</td>
<td>(1,189)</td>
<td>0%</td>
<td>(6,379)</td>
<td>38,666</td>
<td>(253)</td>
<td>(1,163)</td>
<td>(794)</td>
<td></td>
</tr>
<tr>
<td>IUD (insertion)</td>
<td>800</td>
<td>-</td>
<td>800</td>
<td>-</td>
<td>-</td>
<td>12/09</td>
<td>-%</td>
<td>-</td>
<td>14,220</td>
<td>3,312</td>
<td>2,261</td>
<td></td>
</tr>
<tr>
<td>IUD Copper-T TCU 380A</td>
<td>100</td>
<td>500</td>
<td>200</td>
<td>14,000</td>
<td>120</td>
<td>9/09</td>
<td>67%</td>
<td>5,785</td>
<td>144,993</td>
<td>828</td>
<td>565</td>
<td></td>
</tr>
<tr>
<td>(b)PSI IUD 10 Distributed Inserted</td>
<td>(490)</td>
<td>(905)</td>
<td>(1,281)</td>
<td>(10,811)</td>
<td>(1,309)</td>
<td>-%</td>
<td>(12,164)</td>
<td>(120,547)</td>
<td>(1,153)</td>
<td>(5,303)</td>
<td>(3,621)</td>
<td></td>
</tr>
<tr>
<td>IUD 10 Insertion</td>
<td>775</td>
<td>1,639</td>
<td>1,579</td>
<td>10,811</td>
<td>1,383</td>
<td>14%</td>
<td>18,134</td>
<td>138,048</td>
<td>1,579</td>
<td>7,263</td>
<td>4,959</td>
<td></td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

---

3002 - 4/15/2020 10:09:35AM Page 44 of 115
<table>
<thead>
<tr>
<th>Product Description</th>
<th>2020 YTD Users Reached</th>
<th>2019 YTD DALY</th>
<th>2020 YTD Gala</th>
<th>2019 YTD Gala</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-PSI IUD 10 Inserted</td>
<td>1,371</td>
<td>936</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PSI IUD 10 Inserted</td>
<td>5,893</td>
<td>4,023</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LLIN</td>
<td>74</td>
<td>0</td>
<td>303%</td>
<td>298</td>
</tr>
<tr>
<td>Manual Vacuum Aspiration for PAC</td>
<td>1,021</td>
<td>102</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MVA for PAC</td>
<td>2,073</td>
<td>43</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medical Abortion</td>
<td>559</td>
<td>44</td>
<td>273%</td>
<td>213</td>
</tr>
<tr>
<td>Medical Abortion (Misoprostol) Provided</td>
<td>1,375</td>
<td>44</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Misoprostol for PAC Provided</td>
<td>1,375</td>
<td>44</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Misoprostol for PAC Provided</td>
<td>1,375</td>
<td>44</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Misoprostol for Safe Abortion</td>
<td>1,588,390</td>
<td>(20)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(b)PSI Misoprostol for Safe Abortion Dist Provided</td>
<td>2,073</td>
<td>(15)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OCS</td>
<td>39,346</td>
<td>76</td>
<td>89%</td>
<td>87</td>
</tr>
<tr>
<td>(b)PSI OCS Distributed Provided</td>
<td>6,471</td>
<td>88</td>
<td>73%</td>
<td>71</td>
</tr>
<tr>
<td>SDM (Cycle Beads)</td>
<td>38,777</td>
<td>77</td>
<td>82%</td>
<td>82</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double-count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>CycleBeads</td>
<td>20</td>
<td>-</td>
<td>20</td>
<td>2,600</td>
<td>20</td>
<td>12/04</td>
<td>-%</td>
<td>1,550</td>
<td>39,140</td>
<td>18</td>
<td>27</td>
<td>21</td>
</tr>
<tr>
<td>(b) PSI SDM (Cycle Beads)</td>
<td>(14)</td>
<td>(4)</td>
<td>(14)</td>
<td>-</td>
<td>(11)</td>
<td>-</td>
<td>-%</td>
<td>(101)</td>
<td>(363)</td>
<td>(13)</td>
<td>(19)</td>
<td>(14)</td>
</tr>
<tr>
<td>SDM (Cycle Beads)</td>
<td>14</td>
<td>4</td>
<td>14</td>
<td>-</td>
<td>11</td>
<td>27%</td>
<td>-%</td>
<td>9</td>
<td>24</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Non-PSI SDM (Cycle Beads)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PSI SDM (Cycle Beads)</td>
<td>14</td>
<td>4</td>
<td>14</td>
<td>-</td>
<td>11</td>
<td>27%</td>
<td>-%</td>
<td>9</td>
<td>24</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Skilled Birth Attendance</td>
<td>183</td>
<td>76</td>
<td>224</td>
<td>-</td>
<td>255</td>
<td>(12)%</td>
<td>1,560</td>
<td>28,119</td>
<td>224</td>
<td>-</td>
<td>284</td>
<td>-</td>
</tr>
<tr>
<td>STI Screening</td>
<td>285</td>
<td>111</td>
<td>330</td>
<td>-</td>
<td>618</td>
<td>(47)%</td>
<td>2,404</td>
<td>21,516</td>
<td>330</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Toilets Sold</td>
<td>2,623</td>
<td>2,623</td>
<td>6,255</td>
<td>196</td>
<td>1236%</td>
<td>9,213</td>
<td>14,612</td>
<td>13,115</td>
<td>-</td>
<td>656</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Toilets Sold - All</td>
<td>3,050</td>
<td>3,050</td>
<td>3,050</td>
<td>-</td>
<td>220</td>
<td>1286%</td>
<td>13,043</td>
<td>19,389</td>
<td>15,250</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Cervicitis</td>
<td>-</td>
<td>2</td>
<td>-</td>
<td>6</td>
<td>(100)%</td>
<td>29</td>
<td>29</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Genital Herpes</td>
<td>52</td>
<td>13</td>
<td>52</td>
<td>-</td>
<td>21</td>
<td>148%</td>
<td>187</td>
<td>239</td>
<td>52</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Inguinal Bubo</td>
<td>2</td>
<td>-</td>
<td>2</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>14</td>
<td>16</td>
<td>2</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Lower Abdominal Pain</td>
<td>12</td>
<td>12</td>
<td>20</td>
<td>(40)%</td>
<td>174</td>
<td>186</td>
<td>12</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Lower Abdominal Pain</td>
<td>12</td>
<td>12</td>
<td>20</td>
<td>(40)%</td>
<td>174</td>
<td>186</td>
<td>12</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Nonherpetic Genital Ulcer</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>8</td>
<td>(83)%</td>
<td>136</td>
<td>144</td>
<td>8</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Nonherpetic Genital Ulcer</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>8</td>
<td>(83)%</td>
<td>136</td>
<td>144</td>
<td>8</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Urethral Discharge (Men)</td>
<td>42</td>
<td>16</td>
<td>52</td>
<td>105</td>
<td>(50)%</td>
<td>349</td>
<td>517</td>
<td>52</td>
<td>-</td>
<td>1</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Urethral Discharge (Men)</td>
<td>42</td>
<td>16</td>
<td>52</td>
<td>105</td>
<td>(50)%</td>
<td>349</td>
<td>517</td>
<td>52</td>
<td>-</td>
<td>1</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
## Monthly Distribution by Country

**Period:** 2  
**Year:** 2020

<table>
<thead>
<tr>
<th>Service Category</th>
<th>Average Average</th>
<th>Distribution 2/2020</th>
<th>DISTRIBUTION AVG PREV 3 MONTHS</th>
<th>DISTRIBUTION TARGET 2020</th>
<th>DISTRIBUTION 2019</th>
<th>LAUNCH DATE</th>
<th>YTD % CHANGE</th>
<th>TOTAL DISTRIBUTION 2019</th>
<th>CUMULATIVE DISTRIBUTION</th>
<th>%YTD USERS REACHED 2020</th>
<th>YTD CYP 2020</th>
<th>YTD DALY 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment for Urethral Discharge (Women)</td>
<td>170</td>
<td>60</td>
<td>185</td>
<td>336</td>
<td>(45%)</td>
<td>1,145</td>
<td>1,468</td>
<td>185</td>
<td>-</td>
<td>-</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Treatment for Urethral Discharge (Women)</td>
<td>170</td>
<td>60</td>
<td>185</td>
<td>336</td>
<td>(45%)</td>
<td>1,145</td>
<td>1,468</td>
<td>185</td>
<td>-</td>
<td>-</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Treatment for Vaginitis</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>148</td>
<td>148</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Treatment for Vaginitis</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>148</td>
<td>148</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Water Treatment Tablets</td>
<td>535,300</td>
<td>1,431,200</td>
<td>3,759,700</td>
<td>8,605,083</td>
<td>2,190,300</td>
<td>72%</td>
<td>9,947,200</td>
<td>87,758,430</td>
<td>61,803</td>
<td>-</td>
<td>490</td>
<td></td>
</tr>
<tr>
<td>Aquatab</td>
<td>535,300</td>
<td>1,431,200</td>
<td>3,759,700</td>
<td>8,605,083</td>
<td>2,190,300</td>
<td>72%</td>
<td>9,947,200</td>
<td>87,758,430</td>
<td>61,803</td>
<td>-</td>
<td>490</td>
<td></td>
</tr>
<tr>
<td>Burundi</td>
<td></td>
<td></td>
<td>2,323</td>
<td>7,208</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antiretroviral Treatment (Currently Enrolled)</td>
<td>2,751</td>
<td>2,800</td>
<td>5,459</td>
<td>9,900</td>
<td>3,592</td>
<td>19%</td>
<td>29,611</td>
<td>52,502</td>
<td>455</td>
<td>-</td>
<td>1,025</td>
<td></td>
</tr>
<tr>
<td>Antiretroviral Treatment (Currently Enrolled)</td>
<td>2,751</td>
<td>2,800</td>
<td>5,459</td>
<td>9,900</td>
<td>3,592</td>
<td>19%</td>
<td>29,611</td>
<td>52,502</td>
<td>455</td>
<td>-</td>
<td>1,025</td>
<td></td>
</tr>
<tr>
<td>Antiretroviral Treatment (Newly Enrolled)</td>
<td>59</td>
<td>55</td>
<td>117</td>
<td>66</td>
<td>6</td>
<td>77%</td>
<td>622</td>
<td>2,499</td>
<td>117</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Antiretroviral Treatment (Newly Enrolled)</td>
<td>59</td>
<td>55</td>
<td>117</td>
<td>66</td>
<td>6</td>
<td>77%</td>
<td>622</td>
<td>2,499</td>
<td>117</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Condom</td>
<td>-</td>
<td>120,300</td>
<td>900</td>
<td>5,000,000</td>
<td>1,356,640</td>
<td>(100)%</td>
<td>3,742,920</td>
<td>32,906,533</td>
<td>7</td>
<td>7</td>
<td>11</td>
<td></td>
</tr>
<tr>
<td>Prudence Class</td>
<td>-</td>
<td>120,300</td>
<td>900</td>
<td>5,000,000</td>
<td>1,356,640</td>
<td>12/09</td>
<td>(100)%</td>
<td>3,742,920</td>
<td>32,906,533</td>
<td>7</td>
<td>7</td>
<td>11</td>
</tr>
<tr>
<td>Emergency Contraception</td>
<td>311</td>
<td>380</td>
<td>1,000</td>
<td>88</td>
<td>9/17</td>
<td>28%</td>
<td>4,880</td>
<td>11,898</td>
<td>39</td>
<td>39</td>
<td>24</td>
<td></td>
</tr>
<tr>
<td>Nowill</td>
<td>510</td>
<td>240</td>
<td>860</td>
<td>4,000</td>
<td>671</td>
<td>28%</td>
<td>4,880</td>
<td>11,898</td>
<td>39</td>
<td>39</td>
<td>24</td>
<td></td>
</tr>
<tr>
<td>(b) PSI Emergency Contraception Distributed Provided</td>
<td>(199)</td>
<td>(272)</td>
<td>(480)</td>
<td>(3,000)</td>
<td>(583)</td>
<td>-%</td>
<td>(3,453)</td>
<td>(6,071)</td>
<td>(22)</td>
<td>(22)</td>
<td>(14)</td>
<td></td>
</tr>
<tr>
<td>Emergency Contraception Provided</td>
<td>199</td>
<td>272</td>
<td>480</td>
<td>3,000</td>
<td>583</td>
<td>(18)%</td>
<td>3,453</td>
<td>6,071</td>
<td>24</td>
<td>24</td>
<td>15</td>
<td></td>
</tr>
<tr>
<td>PSI Emergency Contraception Provided</td>
<td>199</td>
<td>272</td>
<td>480</td>
<td>3,000</td>
<td>583</td>
<td>(18)%</td>
<td>3,453</td>
<td>6,071</td>
<td>24</td>
<td>24</td>
<td>15</td>
<td></td>
</tr>
<tr>
<td>Free Condom</td>
<td>-</td>
<td>216,000</td>
<td>1,500,000</td>
<td>-</td>
<td>0%</td>
<td>1,648,800</td>
<td>11,920,016</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Free Male Condomals</td>
<td>-</td>
<td>216,000</td>
<td>1,500,000</td>
<td>-</td>
<td>5/11</td>
<td>-%</td>
<td>1,648,800</td>
<td>11,920,016</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Free Female Condom</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>40,000</td>
<td>0%</td>
<td>-</td>
<td>160,930</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Free Female Condomal</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>40,000</td>
<td>-%</td>
<td>-</td>
<td>160,930</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>HIV Testing Services</td>
<td>1,348</td>
<td>1,469</td>
<td>2,920</td>
<td>22,880</td>
<td>4,406</td>
<td>(34)%</td>
<td>19,655</td>
<td>153,608</td>
<td>2,920</td>
<td>-</td>
<td>19</td>
<td></td>
</tr>
<tr>
<td>VCT Individual (HIV-Negative)</td>
<td>1,283</td>
<td>1,404</td>
<td>2,779</td>
<td>22,400</td>
<td>4,318</td>
<td>(36)%</td>
<td>18,945</td>
<td>150,772</td>
<td>2,797</td>
<td>-</td>
<td>18</td>
<td></td>
</tr>
<tr>
<td>VCT Individual (HIV-Positive)</td>
<td>65</td>
<td>66</td>
<td>141</td>
<td>88</td>
<td>12/09</td>
<td>60%</td>
<td>710</td>
<td>2,836</td>
<td>141</td>
<td>-</td>
<td>1</td>
<td></td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

---

3002 - 4/15/2020 10:09:35AM  
Page 47 of 115
### Population Services International

**Monthly Distribution by Country**

**Period:** 2  
**Year:** 2020

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Implant 5</td>
<td>(14)</td>
<td>(62)</td>
<td>83</td>
<td>500</td>
<td>17</td>
<td>(588)%</td>
<td>(62)</td>
<td>938</td>
<td>(75)</td>
<td>(284)</td>
<td>(312)</td>
<td></td>
</tr>
<tr>
<td>Jadelle</td>
<td>80</td>
<td>45</td>
<td>127</td>
<td>2,000</td>
<td>209</td>
<td>2/14</td>
<td>(39)%</td>
<td>1,285</td>
<td>7,170</td>
<td>114</td>
<td>434</td>
<td>477</td>
</tr>
<tr>
<td>(b) PSI Implant 5 Distributed Inserted</td>
<td>(94)</td>
<td>(107)</td>
<td>(210)</td>
<td>(1,500)</td>
<td>(192)</td>
<td>-%</td>
<td>(1,347)</td>
<td>(6,232)</td>
<td>(189)</td>
<td>(718)</td>
<td>(789)</td>
<td></td>
</tr>
<tr>
<td>Implant 5 Insertion</td>
<td>94</td>
<td>107</td>
<td>210</td>
<td>1,500</td>
<td>192</td>
<td>9%</td>
<td>1,347</td>
<td>6,232</td>
<td>210</td>
<td>798</td>
<td>877</td>
<td></td>
</tr>
<tr>
<td>PSI Implant 5 Inserted</td>
<td>94</td>
<td>107</td>
<td>210</td>
<td>1,500</td>
<td>192</td>
<td>9%</td>
<td>1,347</td>
<td>6,232</td>
<td>210</td>
<td>798</td>
<td>877</td>
<td></td>
</tr>
<tr>
<td>Injectable 3-IM</td>
<td>1,445</td>
<td>(646)</td>
<td>746</td>
<td>3,000</td>
<td>1,012</td>
<td>(26)%</td>
<td>(16)</td>
<td>12,396</td>
<td>168</td>
<td>168</td>
<td>138</td>
<td></td>
</tr>
<tr>
<td>DMPA 3-month Injectable</td>
<td>3,840</td>
<td>1,827</td>
<td>5,780</td>
<td>20,000</td>
<td>4,981</td>
<td>2/14</td>
<td>16%</td>
<td>26,468</td>
<td>98,137</td>
<td>1,301</td>
<td>1,301</td>
<td>1,069</td>
</tr>
<tr>
<td>(b) PSI Injectable 3 IM Distributed Provided</td>
<td>(2,395)</td>
<td>(2,472)</td>
<td>(5,034)</td>
<td>(17,000)</td>
<td>(3,969)</td>
<td>-%</td>
<td>(26,484)</td>
<td>(85,741)</td>
<td>(1,133)</td>
<td>(1,133)</td>
<td>(931)</td>
<td></td>
</tr>
<tr>
<td>Injectable 3-IM Provided</td>
<td>2,395</td>
<td>2,472</td>
<td>5,034</td>
<td>17,000</td>
<td>3,969</td>
<td>27%</td>
<td>26,484</td>
<td>85,741</td>
<td>1,259</td>
<td>1,259</td>
<td>1,034</td>
<td></td>
</tr>
<tr>
<td>PSI Injectable 3 IM Provided</td>
<td>2,395</td>
<td>2,472</td>
<td>5,034</td>
<td>17,000</td>
<td>3,969</td>
<td>27%</td>
<td>26,484</td>
<td>85,741</td>
<td>1,259</td>
<td>1,259</td>
<td>1,034</td>
<td></td>
</tr>
<tr>
<td>IUD 10</td>
<td>(69)</td>
<td>422</td>
<td>(128)</td>
<td>400</td>
<td>28</td>
<td>(557)%</td>
<td>1,660</td>
<td>2,812</td>
<td>(115)</td>
<td>(530)</td>
<td>(557)</td>
<td></td>
</tr>
<tr>
<td>Copper-T 380-A IUD</td>
<td>-</td>
<td>472</td>
<td>13</td>
<td>1,000</td>
<td>112</td>
<td>2/14</td>
<td>(88)%</td>
<td>2,124</td>
<td>5,091</td>
<td>12</td>
<td>54</td>
<td>57</td>
</tr>
<tr>
<td>(b) PSI IUD 10 Distributed Inserted</td>
<td>(69)</td>
<td>(50)</td>
<td>(141)</td>
<td>(600)</td>
<td>(84)</td>
<td>-%</td>
<td>(464)</td>
<td>(2,279)</td>
<td>(127)</td>
<td>(584)</td>
<td>(613)</td>
<td></td>
</tr>
<tr>
<td>IUD 10 Insertion</td>
<td>69</td>
<td>50</td>
<td>141</td>
<td>600</td>
<td>84</td>
<td>68%</td>
<td>464</td>
<td>2,279</td>
<td>141</td>
<td>649</td>
<td>681</td>
<td></td>
</tr>
<tr>
<td>PSI IUD 10 Inserted</td>
<td>69</td>
<td>50</td>
<td>141</td>
<td>600</td>
<td>84</td>
<td>68%</td>
<td>464</td>
<td>2,279</td>
<td>141</td>
<td>649</td>
<td>681</td>
<td></td>
</tr>
<tr>
<td>LLIN</td>
<td>3,171</td>
<td>189,385</td>
<td>39,427</td>
<td>786,400</td>
<td>100,150</td>
<td>(61)%</td>
<td>1,162,677</td>
<td>9,099,291</td>
<td>63,872</td>
<td>-</td>
<td>3,964</td>
<td></td>
</tr>
<tr>
<td>MII Permanet Free</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>786,400</td>
<td>-</td>
<td>4/10</td>
<td>-%</td>
<td>-</td>
<td>6,624,958</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>MIILDA - DAWA PLUS 2.0</td>
<td>-</td>
<td>189,385</td>
<td>36,256</td>
<td>-</td>
<td>100,150</td>
<td>(64)%</td>
<td>1,162,677</td>
<td>2,471,162</td>
<td>58,735</td>
<td>-</td>
<td>3,645</td>
<td></td>
</tr>
<tr>
<td>Standard Brands Bundle</td>
<td>3,171</td>
<td>-</td>
<td>3,171</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>3,171</td>
<td>5,137</td>
<td>-</td>
<td>319</td>
<td></td>
</tr>
<tr>
<td>Manual Vacuum Aspiration for PAC</td>
<td>16</td>
<td>17</td>
<td>42</td>
<td>80</td>
<td>26</td>
<td>62%</td>
<td>128</td>
<td>323</td>
<td>42</td>
<td>-</td>
<td>26</td>
<td></td>
</tr>
<tr>
<td>MVA for PAC</td>
<td>16</td>
<td>17</td>
<td>42</td>
<td>80</td>
<td>26</td>
<td>62%</td>
<td>128</td>
<td>323</td>
<td>42</td>
<td>-</td>
<td>26</td>
<td></td>
</tr>
<tr>
<td>Misoprostol for PAC Provided</td>
<td>18</td>
<td>24</td>
<td>54</td>
<td>500</td>
<td>59</td>
<td>(8)%</td>
<td>325</td>
<td>721</td>
<td>54</td>
<td>-</td>
<td>40</td>
<td></td>
</tr>
<tr>
<td>PSI Misoprostol for PAC Provided</td>
<td>18</td>
<td>24</td>
<td>54</td>
<td>500</td>
<td>59</td>
<td>(8)%</td>
<td>325</td>
<td>721</td>
<td>54</td>
<td>-</td>
<td>40</td>
<td></td>
</tr>
<tr>
<td>Misoprostol for Safe Abortion</td>
<td>(4)</td>
<td>27</td>
<td>(28)</td>
<td>-</td>
<td>(76)</td>
<td>0%</td>
<td>(397)</td>
<td>1,442</td>
<td>(1)</td>
<td>-</td>
<td>(1)</td>
<td></td>
</tr>
<tr>
<td>Misoprostol for Safe Abortion</td>
<td>68</td>
<td>125</td>
<td>188</td>
<td>2,000</td>
<td>160</td>
<td>18%</td>
<td>903</td>
<td>4,326</td>
<td>10</td>
<td>-</td>
<td>-</td>
<td>7</td>
</tr>
</tbody>
</table>

**Notes:**

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
|---------------------|----------------------|---------------------------|------------------------|--------------------------|------------------------|-------------|----------------|------------------------|--------------------------|--------------------------|----------------|----------------|}
| (b)PSI Misoprostol for Safe Abortion Dist Provided | 72 | 97 | 216 | (2,000) | (236) | -% | (1,300) | (2,884) | (11) | - | (8) |
| OCs | 891 | (176) | 834 | 5,000 | 912 | (9)% | 6,837 | 26,662 | 50 | 50 | 43 |
| Confinace OC | 2,058 | 1,106 | 3,318 | 15,000 | 3,081 | 2/14 | 8% | 19,548 | 74,451 | 199 | 199 | 173 |
| (b)PSI OCs Distributed Provided | (1,167) | (1,282) | (2,484) | (10,000) | (2,169) | -% | (12,711) | (47,789) | (149) | (149) | (129) |
| OCs Provided | 1,167 | 1,282 | 2,484 | 10,000 | 2,169 | 15% | 12,711 | 47,789 | 166 | 166 | 144 |
| PSI OCs Provided | 1,167 | 1,282 | 2,484 | 10,000 | 2,169 | 15% | 12,711 | 47,789 | 166 | 166 | 144 |
| STI Screening | 558 | 508 | 1,129 | - | 1,108 | 2% | 7,053 | 20,386 | 1,129 | - | - |
| STI Screening | 558 | 508 | 1,129 | - | 1,108 | 2% | 7,053 | 20,386 | 1,129 | - | - |
| Treatment for Genital Herpes | 10 | 6 | 14 | - | 103 | (86)% | 289 | 367 | 14 | - | - |
| Treatment for Genital Herpes | 10 | 6 | 14 | - | 103 | (86)% | 289 | 367 | 14 | - | - |
| Treatment for Inguinal Bubo | 6 | 4 | 10 | - | 6 | 67% | 41 | 118 | 10 | - | - |
| Treatment for Inguinal Bubo | 6 | 4 | 10 | - | 6 | 67% | 41 | 118 | 10 | - | - |
| Treatment for Lower Abdominal Pain | 72 | 50 | 125 | - | 154 | (19)% | 823 | 2,015 | 125 | - | - |
| Treatment for Lower Abdominal Pain | 72 | 50 | 125 | - | 154 | (19)% | 823 | 2,015 | 125 | - | - |
| Treatment for Nonherpetic Genital Ulcer | 99 | 102 | 212 | - | 119 | 78% | 957 | 2,958 | 212 | - | 32 |
| Treatment for Nonherpetic Genital Ulcer | 99 | 102 | 212 | - | 119 | 78% | 957 | 2,958 | 212 | - | 32 |
| Treatment for Urethral Discharge (Men) | 140 | 151 | 317 | - | 328 | (3)% | 1,656 | 4,813 | 317 | - | 4 |
| Treatment for Urethral Discharge (Men) | 140 | 151 | 317 | - | 328 | (3)% | 1,656 | 4,813 | 317 | - | 4 |
| Treatment for Urethral Discharge (Women) | 230 | 194 | 449 | - | 398 | 13% | 2,214 | 6,050 | 449 | - | 14 |
| Treatment for Urethral Discharge (Women) | 230 | 194 | 449 | - | 398 | 13% | 2,214 | 6,050 | 449 | - | 14 |
| Treatment for Vaginitis | 1 | 1 | 2 | - | - | -% | 2 | 11 | 2 | - | - |
| Treatment for Vaginitis | 1 | 1 | 2 | - | - | -% | 2 | 11 | 2 | - | - |

**Cameroon**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Condom</td>
<td>1,974,960</td>
<td>2,198,278</td>
<td>4,067,508</td>
<td>24,218,673</td>
<td>3,831,422</td>
<td>6%</td>
<td>16,623,328</td>
<td>92,123,543</td>
<td>30,506</td>
<td>30,506</td>
<td>45,555</td>
<td></td>
</tr>
<tr>
<td>Lovers Plus</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1/15</td>
<td>-%</td>
<td>(2,010)</td>
<td>3,213,161</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
<table>
<thead>
<tr>
<th>Product Description</th>
<th>12/15</th>
<th>42,260</th>
<th>51,200</th>
<th>316,082</th>
<th>1,197,701</th>
<th>3,938</th>
<th>6,037</th>
<th>1,350,160</th>
<th>14,543,566</th>
<th>5,759,829</th>
<th>384</th>
<th>384</th>
<th>546</th>
</tr>
</thead>
<tbody>
<tr>
<td>Préservatif Masculin Aromatisé UNFPA</td>
<td>720</td>
<td>9,175</td>
<td>3,720</td>
<td>-</td>
<td>-</td>
<td>12/15</td>
<td>-</td>
<td>-</td>
<td>24,526</td>
<td>37,520</td>
<td>28</td>
<td>28</td>
<td>42</td>
</tr>
<tr>
<td>Préservatif Masculin UNFPA</td>
<td>7,920</td>
<td>38,227</td>
<td>10,944</td>
<td>-</td>
<td>1,014,588</td>
<td>12/15</td>
<td>(99)%</td>
<td>1,595,770</td>
<td>2,659,844</td>
<td>62</td>
<td>62</td>
<td>123</td>
<td></td>
</tr>
<tr>
<td>Prudence Plus Nouveau</td>
<td>1,966,320</td>
<td>2,150,875</td>
<td>4,052,844</td>
<td>24,218,673</td>
<td>2,816,834</td>
<td>1/15</td>
<td>44%</td>
<td>15,005,042</td>
<td>86,213,018</td>
<td>30,396</td>
<td>30,396</td>
<td>45,391</td>
<td></td>
</tr>
<tr>
<td>Diarrhea Treatment Kit</td>
<td>3,113</td>
<td>4,073</td>
<td>3,353</td>
<td>63,905</td>
<td>13,647</td>
<td>(75)%</td>
<td>98,068</td>
<td>881,475</td>
<td>-</td>
<td>134</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Orasel Zinc</td>
<td>3,113</td>
<td>4,073</td>
<td>3,353</td>
<td>63,905</td>
<td>13,647</td>
<td>10/09</td>
<td>(75)%</td>
<td>98,068</td>
<td>881,475</td>
<td>3,018</td>
<td>-</td>
<td>134</td>
<td></td>
</tr>
<tr>
<td>Emergency Contraception</td>
<td>1,032</td>
<td>1,797</td>
<td>2,636</td>
<td>8,000</td>
<td>4,198</td>
<td>(37)%</td>
<td>8,564</td>
<td>132,609</td>
<td>119</td>
<td>119</td>
<td>62</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Norlevo</td>
<td>1,040</td>
<td>1,820</td>
<td>2,660</td>
<td>8,000</td>
<td>4,207</td>
<td>11/15</td>
<td>(37)%</td>
<td>8,785</td>
<td>133,358</td>
<td>120</td>
<td>120</td>
<td>62</td>
<td></td>
</tr>
<tr>
<td>(b)PSI Emergency Contraception Distributed</td>
<td>(8)</td>
<td>(23)</td>
<td>(24)</td>
<td>-</td>
<td>(9)</td>
<td>-</td>
<td>-</td>
<td>(221)</td>
<td>(749)</td>
<td>(1)</td>
<td>(1)</td>
<td>(1)</td>
<td></td>
</tr>
<tr>
<td>Emergency Contraception Provided</td>
<td>8</td>
<td>24</td>
<td>24</td>
<td>-</td>
<td>9</td>
<td>167%</td>
<td>227</td>
<td>773</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-PSI Emergency Contraception Provided</td>
<td>-</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PSI Emergency Contraception Provided</td>
<td>8</td>
<td>23</td>
<td>24</td>
<td>-</td>
<td>9</td>
<td>167%</td>
<td>221</td>
<td>749</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female Condom</td>
<td>42,260</td>
<td>111,927</td>
<td>51,200</td>
<td>-</td>
<td>594,790</td>
<td>(91)%</td>
<td>1,454,366</td>
<td>5,759,829</td>
<td>384</td>
<td>384</td>
<td>546</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Préservatif Féminins UNFPA</td>
<td>42,260</td>
<td>81,060</td>
<td>51,200</td>
<td>-</td>
<td>3,960</td>
<td>3/15</td>
<td>1,193%</td>
<td>316,082</td>
<td>1,197,701</td>
<td>384</td>
<td>384</td>
<td>546</td>
<td></td>
</tr>
<tr>
<td>Protectiv Plus</td>
<td>-</td>
<td>30,867</td>
<td>-</td>
<td>-</td>
<td>129,200</td>
<td>4/14</td>
<td>(100)%</td>
<td>675,800</td>
<td>1,633,957</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Securite Plus Female Condom</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>461,630</td>
<td>11/13</td>
<td>(100)%</td>
<td>462,484</td>
<td>2,928,171</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Free Condom</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>206,000</td>
<td>3,300</td>
<td>(100)%</td>
<td>3,300</td>
<td>1,350,160</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Generic MC</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>206,000</td>
<td>3,300</td>
<td>11/16</td>
<td>(100)%</td>
<td>3,300</td>
<td>1,350,160</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Free Female Condom</td>
<td>100</td>
<td>2,000</td>
<td>100</td>
<td>88,000</td>
<td>-</td>
<td>0%</td>
<td>92,000</td>
<td>118,500</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Generic FC</td>
<td>100</td>
<td>2,000</td>
<td>100</td>
<td>88,000</td>
<td>-</td>
<td>1/08</td>
<td>-</td>
<td>92,000</td>
<td>92,000</td>
<td>118,500</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HIV Testing Services</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>6,249</td>
<td>2,117</td>
<td>(100)%</td>
<td>7,402</td>
<td>74,445</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>VCT Individual (HIV-Negative)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>6,037</td>
<td>2,049</td>
<td>1/10</td>
<td>(100)%</td>
<td>7,247</td>
<td>70,507</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>VCT Individual (HIV-Positive)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>212</td>
<td>68</td>
<td>1/10</td>
<td>(100)%</td>
<td>155</td>
<td>3,938</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Implant 3</td>
<td>(1,306)</td>
<td>(380)</td>
<td>(2,850)</td>
<td>20,373</td>
<td>1,081</td>
<td>(364)%</td>
<td>(22)</td>
<td>23,572</td>
<td>(2,565)</td>
<td>(6,413)</td>
<td>(5,959)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Implanon NXT</td>
<td>95</td>
<td>1,303</td>
<td>150</td>
<td>20,373</td>
<td>4,919</td>
<td>12/15</td>
<td>(97)%</td>
<td>29,545</td>
<td>83,971</td>
<td>135</td>
<td>338</td>
<td>314</td>
<td></td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
### Monthly Distribution by Country

Period: 2  
Year: 2020

<table>
<thead>
<tr>
<th>Product</th>
<th>DISTRIBUTION 2020</th>
<th>MONTHLY AVG PREV 3 MONTHS</th>
<th>YTD DISTRIBUTION 2020</th>
<th>DISTRIBUTION TARGET 2020</th>
<th>LAUNCH DATE</th>
<th>YTD % CHANGE</th>
<th>TOTAL DISTRIBUTION 2019</th>
<th>CUMULATIVE DISTRIBUTION</th>
<th>%YTD USERS REACHED 2020</th>
<th>YTD CYP 2020</th>
<th>YTD DALY 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>PSI Implant 3 Distributed</td>
<td>1,401 (1,683)</td>
<td>(3,000)</td>
<td>-</td>
<td>(3,383)</td>
<td>3/16</td>
<td>-%</td>
<td>(29,567)</td>
<td>(60,399)</td>
<td>(2,700)</td>
<td>(6,750)</td>
<td>(6,273)</td>
</tr>
<tr>
<td>Non-PSI Implant 3 Inserted</td>
<td>-</td>
<td>2</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>71</td>
<td>83</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PSI Implant 3 Inserted</td>
<td>1,401 (1,683)</td>
<td>(3,000)</td>
<td>-</td>
<td>(3,383)</td>
<td>3/16</td>
<td>(22)%</td>
<td>29,638</td>
<td>60,482</td>
<td>3,000</td>
<td>7,500</td>
<td>6,970</td>
</tr>
<tr>
<td>Implant 5</td>
<td>400</td>
<td>302</td>
<td>470</td>
<td>6,449</td>
<td>(160)</td>
<td>0%</td>
<td>3,880</td>
<td>7,335</td>
<td>423</td>
<td>1,607</td>
<td>1,468</td>
</tr>
<tr>
<td>Jadelle UNFPA</td>
<td>400</td>
<td>360</td>
<td>470</td>
<td>6,449</td>
<td>-</td>
<td>3/15</td>
<td>-%</td>
<td>5,080</td>
<td>39,966</td>
<td>423</td>
<td>1,607</td>
</tr>
<tr>
<td>PSI Implant 5 Distributed</td>
<td>-</td>
<td>(58)</td>
<td>-</td>
<td>-</td>
<td>(160)</td>
<td>-%</td>
<td>(1,200)</td>
<td>(32,631)</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Implant 5 Insertion</td>
<td>-</td>
<td>63</td>
<td>-</td>
<td>-</td>
<td>180</td>
<td>(100)%</td>
<td>1,502</td>
<td>35,372</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Non-PSI Implant 5 Inserted</td>
<td>-</td>
<td>5</td>
<td>-</td>
<td>-</td>
<td>20</td>
<td>(100)%</td>
<td>302</td>
<td>2,741</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PSI Implant 5 Inserted</td>
<td>-</td>
<td>58</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>(100)%</td>
<td>1,200</td>
<td>32,631</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Injectable 3-IM</td>
<td>(4,666)</td>
<td>8,349</td>
<td>(4,186)</td>
<td>134,085</td>
<td>16,137</td>
<td>(126)%</td>
<td>180,906</td>
<td>486,024</td>
<td>(942)</td>
<td>(942)</td>
<td>(643)</td>
</tr>
<tr>
<td>Depo-Provera UNFPA</td>
<td>-</td>
<td>5,100</td>
<td>5,300</td>
<td>-</td>
<td>-</td>
<td>3/15</td>
<td>-%</td>
<td>10,000</td>
<td>167,393</td>
<td>1,193</td>
<td>1,193</td>
</tr>
<tr>
<td>Equilibré</td>
<td>650</td>
<td>8,808</td>
<td>650</td>
<td>134,085</td>
<td>26,197</td>
<td>5/16</td>
<td>(98)%</td>
<td>249,166</td>
<td>474,230</td>
<td>146</td>
<td>146</td>
</tr>
<tr>
<td>Injectable 3-IM Distributed</td>
<td>(5,316)</td>
<td>(5,560)</td>
<td>(10,136)</td>
<td>-</td>
<td>(10,060)</td>
<td>-%</td>
<td>(78,260)</td>
<td>(155,599)</td>
<td>(2,281)</td>
<td>(2,281)</td>
<td>(1,558)</td>
</tr>
<tr>
<td>PSI Injectable 3 IM Provided</td>
<td>5,316</td>
<td>5,575</td>
<td>10,136</td>
<td>-</td>
<td>10,105</td>
<td>0%</td>
<td>78,683</td>
<td>157,490</td>
<td>2,534</td>
<td>2,534</td>
<td>1,731</td>
</tr>
<tr>
<td>Non-PSI Injectable 3 IM Provided</td>
<td>-</td>
<td>16</td>
<td>-</td>
<td>-</td>
<td>45</td>
<td>(100)%</td>
<td>423</td>
<td>1,891</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PSI Injectable 3 IM Provided</td>
<td>5,316</td>
<td>5,560</td>
<td>10,136</td>
<td>-</td>
<td>10,060</td>
<td>1%</td>
<td>78,260</td>
<td>155,599</td>
<td>2,534</td>
<td>2,534</td>
<td>1,731</td>
</tr>
<tr>
<td>Injectable 3-SC</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>(100)%</td>
<td>5,524</td>
<td>9,000</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Sayana Press</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1,050</td>
<td>3/18</td>
<td>(100)%</td>
<td>5,524</td>
<td>9,000</td>
</tr>
<tr>
<td>IUD 10</td>
<td>694</td>
<td>1,003</td>
<td>1,159</td>
<td>45,744</td>
<td>3,860</td>
<td>(70)%</td>
<td>14,335</td>
<td>136,609</td>
<td>1,043</td>
<td>4,798</td>
<td>4,191</td>
</tr>
<tr>
<td>DIU UNFPA</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>3,010</td>
<td>-</td>
<td>3/15</td>
<td>-%</td>
<td>-</td>
<td>24,810</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>IUD</td>
<td>1,000</td>
<td>1,350</td>
<td>1,850</td>
<td>11,553</td>
<td>4,450</td>
<td>9/09</td>
<td>(58)%</td>
<td>24,451</td>
<td>179,523</td>
<td>1,665</td>
<td>7,659</td>
</tr>
<tr>
<td>IUD Copper T 380A</td>
<td>-</td>
<td>365</td>
<td>-</td>
<td>31,181</td>
<td>1,785</td>
<td>2/16</td>
<td>(100)%</td>
<td>10,085</td>
<td>40,061</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PSI IUD 10 Distributed</td>
<td>(306)</td>
<td>(713)</td>
<td>(691)</td>
<td>-</td>
<td>(2,375)</td>
<td>-%</td>
<td>(20,201)</td>
<td>(107,785)</td>
<td>(622)</td>
<td>(2,861)</td>
<td>(2,499)</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
### POPULATION SERVICES INTERNATIONAL

#### Monthly Distribution by Country

**Period:** 2  
**Year:** 2020

<table>
<thead>
<tr>
<th>DISTRIBUTION</th>
<th>MONTHLY AVG PREV 3 MONTHS</th>
<th>YTD DISTRIBUTION</th>
<th>DISTRIBUTION TARGET</th>
<th>YTD DISTRIBUTION</th>
<th>YTD % CHANGE</th>
<th>TOTAL DISTRIBUTION</th>
<th>CUMULATIVE DISTRIBUTION</th>
<th>%YTD USERS REACHED</th>
<th>YTD CYP</th>
<th>YTD DALY</th>
</tr>
</thead>
<tbody>
<tr>
<td>IUD 10 Insertion</td>
<td>306</td>
<td>732</td>
<td>691</td>
<td>-</td>
<td>2,448</td>
<td>(72)%</td>
<td>20,878</td>
<td>112,623</td>
<td>691</td>
<td>3,179</td>
</tr>
<tr>
<td>Non-PSI IUD 10 Inserted</td>
<td>-</td>
<td>19</td>
<td>-</td>
<td>-</td>
<td>73</td>
<td>(100)%</td>
<td>677</td>
<td>4,838</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PSI IUD 10 Inserted</td>
<td>306</td>
<td>713</td>
<td>691</td>
<td>-</td>
<td>2,375</td>
<td>(71)%</td>
<td>20,201</td>
<td>107,785</td>
<td>691</td>
<td>3,179</td>
</tr>
<tr>
<td>LLIN</td>
<td>695</td>
<td>485</td>
<td>1,365</td>
<td>15,000</td>
<td>1,679</td>
<td>(19)%</td>
<td>12,087</td>
<td>8,029,379</td>
<td>2,211</td>
<td>-</td>
</tr>
<tr>
<td>Super Moustiquaire</td>
<td>695</td>
<td>462</td>
<td>1,365</td>
<td>15,000</td>
<td>1,679</td>
<td>1/09</td>
<td>(19)%</td>
<td>11,816</td>
<td>8,023,208</td>
<td>2,211</td>
</tr>
<tr>
<td>Super Moustiquaire Interceptor</td>
<td>-</td>
<td>24</td>
<td>-</td>
<td>-</td>
<td>10/15</td>
<td>-%</td>
<td>271</td>
<td>6,171</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Lubricant</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>855</td>
<td>(100)%</td>
<td>855</td>
<td>16,415</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Lubricant 60 mL bottle</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>855</td>
<td>12/15</td>
<td>(100)%</td>
<td>855</td>
<td>16,415</td>
<td>-</td>
</tr>
<tr>
<td>Manual Vacuum Aspiration for PAC</td>
<td>-</td>
<td>218</td>
<td>-</td>
<td>250</td>
<td>145</td>
<td>(100)%</td>
<td>1,105</td>
<td>2,741</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>MVA for PAC</td>
<td>-</td>
<td>218</td>
<td>-</td>
<td>250</td>
<td>145</td>
<td>(100)%</td>
<td>1,105</td>
<td>2,741</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Manual Vacuum Aspiration for SA</td>
<td>-</td>
<td>76</td>
<td>-</td>
<td>-</td>
<td>16</td>
<td>(100)%</td>
<td>426</td>
<td>777</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Manual Vacuum Aspiration for SA</td>
<td>-</td>
<td>76</td>
<td>-</td>
<td>-</td>
<td>16</td>
<td>(100)%</td>
<td>426</td>
<td>777</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Medical Abortion</td>
<td>12,450</td>
<td>6,320</td>
<td>31,410</td>
<td>9,010</td>
<td>585</td>
<td>5269%</td>
<td>785</td>
<td>32,307</td>
<td>28,269</td>
<td>-</td>
</tr>
<tr>
<td>Mifepack</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>10,000</td>
<td>585</td>
<td>(100)%</td>
<td>785</td>
<td>1,000</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Mifeso</td>
<td>12,450</td>
<td>6,320</td>
<td>31,410</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>31,410</td>
<td>28,269</td>
<td>-</td>
<td>11,726</td>
</tr>
<tr>
<td>(b)PSI Medical Abortion Distributed Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>(990)</td>
<td>-</td>
<td>-%</td>
<td>(990)</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Medical Abortion (M Floppin) Provided</td>
<td>-</td>
<td>122</td>
<td>-</td>
<td>-</td>
<td>70</td>
<td>(100)%</td>
<td>773</td>
<td>989</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Non-PSI Medical Abortion (M Floppin) Provided</td>
<td>-</td>
<td>22</td>
<td>-</td>
<td>-</td>
<td>14</td>
<td>(100)%</td>
<td>101</td>
<td>125</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PSI Medical Abortion (M Floppin) Provided</td>
<td>-</td>
<td>100</td>
<td>-</td>
<td>-</td>
<td>56</td>
<td>(100)%</td>
<td>672</td>
<td>864</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Medical Abortion Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>990</td>
<td>0%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PSI Medical Abortion Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>990</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Micronutrient Powder</td>
<td>300</td>
<td>78,120</td>
<td>2,741</td>
<td>-</td>
<td>326,950</td>
<td>(99)%</td>
<td>2,664,442</td>
<td>2</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Super Bebe</td>
<td>300</td>
<td>78,120</td>
<td>2,741</td>
<td>9/16</td>
<td>326,950</td>
<td>(99)%</td>
<td>2,664,442</td>
<td>2</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Misoprostol for PAC Provided</td>
<td>-</td>
<td>184</td>
<td>-</td>
<td>670</td>
<td>70</td>
<td>(100)%</td>
<td>799</td>
<td>2,538</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Non-PSI Misoprostol for PAC Provided</td>
<td>-</td>
<td>31</td>
<td>-</td>
<td>-</td>
<td>7</td>
<td>(100)%</td>
<td>104</td>
<td>287</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
### POPULATION SERVICES INTERNATIONAL

**Monthly Distribution by Country**

**Period:** 2  
**Year:** 2020

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>PSI Misoprostol for PAC Provided</td>
<td>-</td>
<td>153</td>
<td>-</td>
<td>670</td>
<td>63</td>
<td>(100)%</td>
<td>695</td>
<td>2,251</td>
<td>-</td>
</tr>
<tr>
<td>Misoprostol for Safe Abortion</td>
<td>19,560</td>
<td>6,069</td>
<td>26,374</td>
<td>145,979</td>
<td>26,811</td>
<td>(2)%</td>
<td>161,064</td>
<td>929,973</td>
<td>1,385</td>
</tr>
<tr>
<td>Avertiso</td>
<td>19,560</td>
<td>7,800</td>
<td>26,160</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>16,800</td>
<td>42,960</td>
<td>1,373</td>
</tr>
<tr>
<td>(b) PSI Misoprostol for Safe Abortion Dist Provided</td>
<td>-</td>
<td>(1,816)</td>
<td>-</td>
<td>(2,680)</td>
<td>(924)</td>
<td>-</td>
<td>(10,844)</td>
<td>(19,372)</td>
<td>-</td>
</tr>
<tr>
<td>Ocs</td>
<td>(16,879)</td>
<td>(3,483)</td>
<td>(20,015)</td>
<td>123,245</td>
<td>47,992</td>
<td>(142)%</td>
<td>157,872</td>
<td>1,142,776</td>
<td>(1,201)</td>
</tr>
<tr>
<td>Microgynon Ed Fe</td>
<td>(13,334)</td>
<td>16</td>
<td>(13,334)</td>
<td>-</td>
<td>-</td>
<td>7/14</td>
<td>-</td>
<td>105,483</td>
<td>570,322</td>
</tr>
<tr>
<td>Novelle Duo</td>
<td>-</td>
<td>23</td>
<td>-</td>
<td>123,245</td>
<td>49,598</td>
<td>1/08</td>
<td>(100)%</td>
<td>100,000</td>
<td>670,368</td>
</tr>
<tr>
<td>(b) PSI Ocs Distributed Provided</td>
<td>(3,545)</td>
<td>(3,523)</td>
<td>(6,681)</td>
<td>-</td>
<td>(1,606)</td>
<td>-</td>
<td>(47,611)</td>
<td>(97,914)</td>
<td>(401)</td>
</tr>
<tr>
<td>Ocs Provided</td>
<td>3,545</td>
<td>3,526</td>
<td>6,681</td>
<td>-</td>
<td>1,642</td>
<td>307%</td>
<td>47,887</td>
<td>98,715</td>
<td>445</td>
</tr>
<tr>
<td>Non-PSI Ocs Provided</td>
<td>-</td>
<td>3</td>
<td>-</td>
<td>-</td>
<td>36</td>
<td>(100)%</td>
<td>276</td>
<td>801</td>
<td>-</td>
</tr>
<tr>
<td>PSI Ocs Provided</td>
<td>3,545</td>
<td>3,523</td>
<td>6,681</td>
<td>-</td>
<td>1,606</td>
<td>316%</td>
<td>47,611</td>
<td>97,914</td>
<td>445</td>
</tr>
<tr>
<td>Seasonal Malaria Chemoprevention_children reach</td>
<td>-</td>
<td>533,084</td>
<td>-</td>
<td>1,691,734</td>
<td>-</td>
<td>0%</td>
<td>1,599,252</td>
<td>1,599,252</td>
<td>-</td>
</tr>
<tr>
<td>SMC for Children ages 12-59 months</td>
<td>-</td>
<td>449,511</td>
<td>-</td>
<td>1,421,057</td>
<td>-</td>
<td>-</td>
<td>1,348,534</td>
<td>1,348,534</td>
<td>-</td>
</tr>
<tr>
<td>SMC for Infants ages 3-11 months</td>
<td>-</td>
<td>83,573</td>
<td>-</td>
<td>270,677</td>
<td>-</td>
<td>-</td>
<td>250,718</td>
<td>250,718</td>
<td>-</td>
</tr>
<tr>
<td>Water Treatment Tablets</td>
<td>-</td>
<td>4,260</td>
<td>100</td>
<td>191,386</td>
<td>215,220</td>
<td>(100)%</td>
<td>424,100</td>
<td>2,649,622</td>
<td>2</td>
</tr>
<tr>
<td>Aquatabs 67 mg (20 L)</td>
<td>-</td>
<td>4,260</td>
<td>100</td>
<td>191,386</td>
<td>215,220</td>
<td>12/15</td>
<td>(100)%</td>
<td>424,100</td>
<td>2,649,622</td>
</tr>
</tbody>
</table>

**Cote d'Ivoire**

- 14,730 | 12,259 |

| Antiretroviral Treatment (Currently Enrolled) | 3,608 | 3,456 | 7,155 | 5,223 | - | - | 0% | 26,722 | 41,466 | 596 | - | 987 |
| Antiretroviral Treatment (Currently Enrolled) | 3,608 | 3,456 | 7,155 | 5,223 | - | - | 0% | 26,722 | 41,466 | 596 | - | 987 |
| Antiretroviral Treatment (Newly Enrolled) | 100 | 97 | 205 | 1,815 | - | - | 0% | 751 | 1,416 | 205 | - | - |
| Antiretroviral Treatment (Newly Enrolled) | 100 | 97 | 205 | 1,815 | - | - | 0% | 751 | 1,416 | 205 | - | - |
| Fecal Sludge Management (Households) | - | - | - | 670 | 64 | (100)% | 402 | 717 | - | - | - |
| Fecal Sludge Management (Households) | - | - | - | 670 | 64 | (100)% | 402 | 717 | - | - | - |

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
### Monthly Distribution by Country

**Period:** 2  
**Year:** 2020

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Fecal Sludge Management (Liters)</td>
<td>-</td>
<td>-</td>
<td>2,502,000</td>
<td>1,004,000</td>
<td>(100)%</td>
<td>5,929,000</td>
<td>9,296,000</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Fecal Sludge Management (Liters)</td>
<td>-</td>
<td>-</td>
<td>2,502,000</td>
<td>1,004,000</td>
<td>(100)%</td>
<td>5,929,000</td>
<td>9,296,000</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Free Condom</td>
<td>-</td>
<td>90,807</td>
<td>1,432</td>
<td>250,000</td>
<td>-</td>
<td>0%</td>
<td>431,008</td>
<td>6,751,253</td>
<td>11</td>
<td>11</td>
</tr>
<tr>
<td>Free Distribution</td>
<td>-</td>
<td>90,807</td>
<td>1,432</td>
<td>250,000</td>
<td>-</td>
<td>1/08</td>
<td>-%</td>
<td>431,008</td>
<td>6,751,253</td>
<td>11</td>
</tr>
<tr>
<td>Free Female Condom</td>
<td>-</td>
<td>1,495</td>
<td>2,300</td>
<td>4,000</td>
<td>-</td>
<td>0%</td>
<td>7,284</td>
<td>82,583</td>
<td>17</td>
<td>17</td>
</tr>
<tr>
<td>Female Condom Free</td>
<td>-</td>
<td>1,495</td>
<td>2,300</td>
<td>4,000</td>
<td>-</td>
<td>8/12</td>
<td>-%</td>
<td>7,284</td>
<td>82,583</td>
<td>17</td>
</tr>
<tr>
<td>HIV Self-Testing Kit</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1,849</td>
<td>-</td>
<td>0%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>HIV Self-Testing Kit (Oral Fluid)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1,849</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>HIV Testing Services</td>
<td>915</td>
<td>1,354</td>
<td>1,856</td>
<td>16,187</td>
<td>-</td>
<td>0%</td>
<td>9,706</td>
<td>138,047</td>
<td>1,856</td>
<td>-</td>
</tr>
<tr>
<td>VCT Individual (HIV-Negative)</td>
<td>799</td>
<td>1,202</td>
<td>1,619</td>
<td>14,249</td>
<td>-</td>
<td>-%</td>
<td>8,821</td>
<td>130,653</td>
<td>1,619</td>
<td>-</td>
</tr>
<tr>
<td>VCT Individual (HIV-Positive)</td>
<td>116</td>
<td>151</td>
<td>237</td>
<td>1,938</td>
<td>-</td>
<td>1/10</td>
<td>-%</td>
<td>885</td>
<td>7,394</td>
<td>237</td>
</tr>
<tr>
<td>Implant 3</td>
<td>720</td>
<td>223</td>
<td>884</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>2,684</td>
<td>3,568</td>
<td>796</td>
<td>1,989</td>
</tr>
<tr>
<td>Implanon NXT</td>
<td>720</td>
<td>223</td>
<td>884</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>2,684</td>
<td>3,568</td>
<td>796</td>
<td>1,989</td>
</tr>
<tr>
<td>Implant 3 Insertion</td>
<td>967</td>
<td>1,088</td>
<td>1,640</td>
<td>3,870</td>
<td>1,560</td>
<td>5%</td>
<td>18,416</td>
<td>22,126</td>
<td>1,640</td>
<td>4,100</td>
</tr>
<tr>
<td>Non-PSI Implant 3 Inserted</td>
<td>967</td>
<td>1,088</td>
<td>1,640</td>
<td>3,870</td>
<td>1,560</td>
<td>5%</td>
<td>18,416</td>
<td>22,126</td>
<td>1,640</td>
<td>4,100</td>
</tr>
<tr>
<td>Implant 5</td>
<td>-</td>
<td>167</td>
<td>-</td>
<td>2,439</td>
<td>-</td>
<td>0%</td>
<td>2,439</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Jadelle</td>
<td>-</td>
<td>167</td>
<td>-</td>
<td>2,439</td>
<td>-</td>
<td>-%</td>
<td>2,439</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Implant 5 Insertion</td>
<td>815</td>
<td>1,142</td>
<td>1,681</td>
<td>21,009</td>
<td>2,124</td>
<td>(21)%</td>
<td>23,764</td>
<td>28,268</td>
<td>1,681</td>
<td>6,388</td>
</tr>
<tr>
<td>Non-PSI Implant 5 Inserted</td>
<td>815</td>
<td>1,142</td>
<td>1,681</td>
<td>21,009</td>
<td>2,124</td>
<td>(21)%</td>
<td>23,764</td>
<td>28,268</td>
<td>1,681</td>
<td>6,388</td>
</tr>
<tr>
<td>Injectable 2 Provided</td>
<td>120</td>
<td>154</td>
<td>255</td>
<td>-</td>
<td>225</td>
<td>13%</td>
<td>1,319</td>
<td>2,947</td>
<td>43</td>
<td>43</td>
</tr>
<tr>
<td>Non-PSI Injectable 2 Provided</td>
<td>120</td>
<td>154</td>
<td>255</td>
<td>-</td>
<td>225</td>
<td>13%</td>
<td>1,319</td>
<td>2,947</td>
<td>43</td>
<td>43</td>
</tr>
<tr>
<td>Injectable 3-IM</td>
<td>250</td>
<td>333</td>
<td>250</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>2,950</td>
<td>3,200</td>
<td>56</td>
<td>56</td>
</tr>
<tr>
<td>Depo-Provera</td>
<td>250</td>
<td>333</td>
<td>250</td>
<td>-</td>
<td>-</td>
<td>-5/10</td>
<td>-%</td>
<td>2,950</td>
<td>3,200</td>
<td>56</td>
</tr>
<tr>
<td>Injectable 3-IM Provided</td>
<td>1,287</td>
<td>1,835</td>
<td>2,512</td>
<td>8,287</td>
<td>2,570</td>
<td>(2)%</td>
<td>23,223</td>
<td>33,571</td>
<td>628</td>
<td>628</td>
</tr>
<tr>
<td>Non-PSI Injectable 3 IM Provided</td>
<td>1,287</td>
<td>1,835</td>
<td>2,512</td>
<td>8,287</td>
<td>2,570</td>
<td>(2)%</td>
<td>23,223</td>
<td>33,571</td>
<td>628</td>
<td>628</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Injectable 3-SC</td>
<td>600</td>
<td>3</td>
<td>600</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>1,318</td>
<td>1,918</td>
<td>135</td>
<td>135</td>
<td>77</td>
</tr>
<tr>
<td>Sayana Press</td>
<td>600</td>
<td>3</td>
<td>600</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>1,318</td>
<td>1,918</td>
<td>135</td>
<td>135</td>
<td>77</td>
</tr>
<tr>
<td>Injectable 3-SC Provided</td>
<td>684</td>
<td>656</td>
<td>1,471</td>
<td>11,377</td>
<td>428</td>
<td>244%</td>
<td>7,252</td>
<td>9,981</td>
<td>368</td>
<td>368</td>
<td>209</td>
<td></td>
</tr>
<tr>
<td>Non-PSI Injectable 3 SC Provided</td>
<td>684</td>
<td>656</td>
<td>1,471</td>
<td>11,377</td>
<td>428</td>
<td>244%</td>
<td>7,252</td>
<td>9,981</td>
<td>368</td>
<td>368</td>
<td>209</td>
<td></td>
</tr>
<tr>
<td>IUD 10</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>745</td>
<td>745</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Eve’s TCu380A</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>745</td>
<td>745</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>IUD 10 Insertion</td>
<td>146</td>
<td>92</td>
<td>193</td>
<td>5,308</td>
<td>229</td>
<td>(16)%</td>
<td>2,394</td>
<td>2,977</td>
<td>193</td>
<td>888</td>
<td>645</td>
<td></td>
</tr>
<tr>
<td>Non-PSI IUD 10 Inserted</td>
<td>146</td>
<td>92</td>
<td>193</td>
<td>5,308</td>
<td>229</td>
<td>(16)%</td>
<td>2,394</td>
<td>2,977</td>
<td>193</td>
<td>888</td>
<td>645</td>
<td></td>
</tr>
<tr>
<td>Lubricant</td>
<td>-</td>
<td>745</td>
<td>50</td>
<td>7,200</td>
<td>-</td>
<td>9/12</td>
<td>0%</td>
<td>10,184</td>
<td>101,683</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Manual Vacuum Aspiration for PAC</td>
<td>125</td>
<td>18</td>
<td>125</td>
<td>-</td>
<td>46</td>
<td>172%</td>
<td>292</td>
<td>417</td>
<td>125</td>
<td>-</td>
<td>77</td>
<td></td>
</tr>
<tr>
<td>Manual Vacuum Aspiration for PAC</td>
<td>125</td>
<td>18</td>
<td>125</td>
<td>-</td>
<td>46</td>
<td>172%</td>
<td>292</td>
<td>417</td>
<td>125</td>
<td>-</td>
<td>77</td>
<td></td>
</tr>
<tr>
<td>Misoprostol for PAC Provided</td>
<td>2</td>
<td>-</td>
<td>2</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>-</td>
<td>2</td>
<td>2</td>
<td>-</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Non-PSI Misoprostol for PAC Provided</td>
<td>2</td>
<td>-</td>
<td>2</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>2</td>
<td>2</td>
<td>-</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>OCs</td>
<td>-</td>
<td>147</td>
<td>200</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>1,530</td>
<td>1,730</td>
<td>12</td>
<td>12</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>Microgynon</td>
<td>-</td>
<td>40</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>490</td>
<td>490</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Mircolut</td>
<td>-</td>
<td>107</td>
<td>200</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>1,040</td>
<td>1,240</td>
<td>12</td>
<td>12</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>OCs Provided</td>
<td>760</td>
<td>685</td>
<td>1,446</td>
<td>11,117</td>
<td>957</td>
<td>51%</td>
<td>12,397</td>
<td>18,586</td>
<td>96</td>
<td>96</td>
<td>58</td>
<td></td>
</tr>
<tr>
<td>Non-PSI OCs Provided</td>
<td>760</td>
<td>685</td>
<td>1,446</td>
<td>11,117</td>
<td>957</td>
<td>51%</td>
<td>12,397</td>
<td>18,586</td>
<td>96</td>
<td>96</td>
<td>58</td>
<td></td>
</tr>
<tr>
<td>PrEP</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>145</td>
<td>-</td>
<td>0%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PrEP</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>145</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Toilets Sold</td>
<td>472</td>
<td>378</td>
<td>992</td>
<td>4,256</td>
<td>272</td>
<td>265%</td>
<td>3,461</td>
<td>4,736</td>
<td>5,061</td>
<td>-</td>
<td>182</td>
<td></td>
</tr>
<tr>
<td>Toilets Sold</td>
<td>472</td>
<td>378</td>
<td>992</td>
<td>4,256</td>
<td>272</td>
<td>265%</td>
<td>3,461</td>
<td>4,736</td>
<td>5,061</td>
<td>-</td>
<td>182</td>
<td></td>
</tr>
<tr>
<td>Toilets Sold - All</td>
<td>674</td>
<td>563</td>
<td>1,359</td>
<td>-</td>
<td>753</td>
<td>80%</td>
<td>6,289</td>
<td>9,120</td>
<td>6,931</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Toilets Sold - All</td>
<td>674</td>
<td>563</td>
<td>1,359</td>
<td>-</td>
<td>753</td>
<td>80%</td>
<td>6,289</td>
<td>9,120</td>
<td>6,931</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
## Mozambique

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Condom</td>
<td>-</td>
<td>858,792</td>
<td>-</td>
<td>7,776,000</td>
<td>1,668,744</td>
<td>(100)%</td>
<td>10,293,192</td>
<td>101,854,728</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>J0.1</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>864,000</td>
<td>853,920</td>
<td>(100)%</td>
<td>853,920</td>
<td>2,582,064</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>J1</td>
<td>-</td>
<td>718,632</td>
<td>-</td>
<td>3,456,000</td>
<td>814,824</td>
<td>(100)%</td>
<td>5,073,120</td>
<td>52,830,432</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>J18</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>864,000</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>1,728,000</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>J2</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>10/12</td>
<td>-%</td>
<td>1,353,672</td>
<td>18,753,192</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>J3</td>
<td>-</td>
<td>140,160</td>
<td>-</td>
<td>2,592,000</td>
<td>10/12</td>
<td>-%</td>
<td>3,012,480</td>
<td>25,961,040</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Emergency Contraception Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>147</td>
<td>(100)%</td>
<td>380</td>
<td>1,107</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Non-PSI Emergency Contraception Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>147</td>
<td>(100)%</td>
<td>380</td>
<td>1,107</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Implant 3 Insertion</td>
<td>216</td>
<td>158</td>
<td>440</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>886</td>
<td>1,366</td>
<td>440</td>
<td>1,100</td>
</tr>
<tr>
<td>Non-PSI Implant 3 Inserted</td>
<td>216</td>
<td>158</td>
<td>440</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>886</td>
<td>1,366</td>
<td>440</td>
<td>1,100</td>
</tr>
<tr>
<td>Implant 5</td>
<td>2,161</td>
<td>1,570</td>
<td>2,261</td>
<td>-</td>
<td>(4)</td>
<td>0%</td>
<td>9,820</td>
<td>3,692</td>
<td>2,035</td>
<td>7,733</td>
</tr>
<tr>
<td>Jadelle</td>
<td>2,161</td>
<td>1,570</td>
<td>2,261</td>
<td>-</td>
<td>-</td>
<td>589</td>
<td>12/15</td>
<td>284%</td>
<td>10,571</td>
<td>23,966</td>
</tr>
<tr>
<td>(b)PSI Implant 5 Distributed Inserted</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>(593)</td>
<td>-%</td>
<td>(751)</td>
<td>(20,274)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Implant 5 Insertion</td>
<td>3,120</td>
<td>12,393</td>
<td>33,700</td>
<td>33,000</td>
<td>4,723</td>
<td>614%</td>
<td>29,810</td>
<td>128,380</td>
<td>33,700</td>
<td>128,060</td>
</tr>
<tr>
<td>Non-PSI Implant 5 Inserted</td>
<td>3,120</td>
<td>12,393</td>
<td>33,700</td>
<td>33,000</td>
<td>4,130</td>
<td>716%</td>
<td>29,059</td>
<td>108,106</td>
<td>33,700</td>
<td>128,060</td>
</tr>
<tr>
<td>PSI Implant 5 Inserted</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>593</td>
<td>(100)%</td>
<td>751</td>
<td>20,274</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Injectable 3-IM</td>
<td>4,066</td>
<td>1,167</td>
<td>4,266</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>9,587</td>
<td>131,241</td>
<td>960</td>
<td>960</td>
</tr>
<tr>
<td>Enaf Injectable</td>
<td>4,066</td>
<td>1,167</td>
<td>4,266</td>
<td>-</td>
<td>-</td>
<td>911</td>
<td>6/13</td>
<td>368%</td>
<td>11,039</td>
<td>253,498</td>
</tr>
<tr>
<td>(b)PSI Injectable 3 IM Distributed Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>(911)</td>
<td>-%</td>
<td>(1,452)</td>
<td>(122,257)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Injectable 3-IM Provided</td>
<td>12,195</td>
<td>95,153</td>
<td>275,645</td>
<td>100,000</td>
<td>17,138</td>
<td>1508%</td>
<td>87,939</td>
<td>783,494</td>
<td>68,911</td>
<td>68,911</td>
</tr>
<tr>
<td>Non-PSI Injectable 3 IM Provided</td>
<td>12,195</td>
<td>95,153</td>
<td>275,645</td>
<td>100,000</td>
<td>16,227</td>
<td>1,599%</td>
<td>86,487</td>
<td>661,237</td>
<td>68,911</td>
<td>68,911</td>
</tr>
<tr>
<td>PSI Injectable 3 IM Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>911</td>
<td>(100)%</td>
<td>1,452</td>
<td>122,257</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Injectable 3-SC</td>
<td>4,010</td>
<td>4,801</td>
<td>8,210</td>
<td>-</td>
<td>4,103</td>
<td>100%</td>
<td>38,149</td>
<td>54,723</td>
<td>1,847</td>
<td>1,847</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
### POPULATION SERVICES INTERNATIONAL

**Monthly Distribution by Country**

**Period:** 2

**Year:** 2020

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>(b) PSI Injectable 3 SC Distributed Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>(2,523)</td>
<td>-%</td>
<td>(3,829)</td>
<td>(4,867)</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Sayana Press</td>
<td>4,010</td>
<td>4,801</td>
<td>8,210</td>
<td>-</td>
<td>6,626</td>
<td>24%</td>
<td>41,978</td>
<td>59,590</td>
<td>1,847</td>
<td>1,847</td>
<td>1,545</td>
</tr>
<tr>
<td>Injectable 3-SC Provided</td>
<td>3,507</td>
<td>3,950</td>
<td>7,573</td>
<td>30,000</td>
<td>7,402</td>
<td>2%</td>
<td>45,921</td>
<td>57,965</td>
<td>1,893</td>
<td>1,893</td>
<td>1,583</td>
</tr>
<tr>
<td>Non-PSI Injectable 3 SC Provided</td>
<td>3,507</td>
<td>3,950</td>
<td>7,573</td>
<td>30,000</td>
<td>4,879</td>
<td>55%</td>
<td>42,092</td>
<td>53,098</td>
<td>1,893</td>
<td>1,893</td>
<td>1,583</td>
</tr>
<tr>
<td>PSI Injectable 3 SC Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>2,523</td>
<td>(100)%</td>
<td>3,829</td>
<td>4,867</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>IUD 10</td>
<td>261</td>
<td>400</td>
<td>261</td>
<td>-</td>
<td>72</td>
<td>263%</td>
<td>3,462</td>
<td>25,461</td>
<td>235</td>
<td>1,081</td>
<td>1,151</td>
</tr>
<tr>
<td>DIU Copper T 380A</td>
<td>261</td>
<td>400</td>
<td>261</td>
<td>-</td>
<td>72</td>
<td>1/15</td>
<td>263%</td>
<td>3,462</td>
<td>25,461</td>
<td>235</td>
<td>1,081</td>
</tr>
<tr>
<td>IUD 10 Insertion</td>
<td>1,034</td>
<td>3,659</td>
<td>10,090</td>
<td>10,800</td>
<td>1,283</td>
<td>666%</td>
<td>8,255</td>
<td>34,939</td>
<td>10,090</td>
<td>46,414</td>
<td>49,426</td>
</tr>
<tr>
<td>Non-PSI IUD 10 Inserted</td>
<td>1,034</td>
<td>3,659</td>
<td>10,090</td>
<td>10,800</td>
<td>1,283</td>
<td>3/16</td>
<td>666%</td>
<td>8,255</td>
<td>34,939</td>
<td>10,090</td>
<td>46,414</td>
</tr>
<tr>
<td>OCs</td>
<td>1,042</td>
<td>3,662</td>
<td>1,042</td>
<td>-</td>
<td>46,876</td>
<td>(98)%</td>
<td>293,170</td>
<td>284,495</td>
<td>63</td>
<td>63</td>
<td>55</td>
</tr>
<tr>
<td>Microlenyn 30 Combined OC</td>
<td>(385)</td>
<td>2,315</td>
<td>(385)</td>
<td>-</td>
<td>8,210</td>
<td>6/13</td>
<td>(105)%</td>
<td>245,214</td>
<td>447,095</td>
<td>(23)</td>
<td>(23)</td>
</tr>
<tr>
<td>Progestyn OC</td>
<td>1,427</td>
<td>1,347</td>
<td>1,427</td>
<td>-</td>
<td>47,969</td>
<td>6/13</td>
<td>(97)%</td>
<td>59,492</td>
<td>10,090</td>
<td>400</td>
<td>261</td>
</tr>
<tr>
<td>(b) PSI OCs Distributed Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>(9,303)</td>
<td>-%</td>
<td>(11,536)</td>
<td>(313,225)</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>OCs Provided</td>
<td>20,918</td>
<td>124,947</td>
<td>356,575</td>
<td>199,800</td>
<td>32,431</td>
<td>999%</td>
<td>197,476</td>
<td>1,217,751</td>
<td>23,772</td>
<td>23,772</td>
<td>20,971</td>
</tr>
<tr>
<td>Non-PSI OCs Provided</td>
<td>20,918</td>
<td>124,947</td>
<td>356,575</td>
<td>199,800</td>
<td>23,128</td>
<td>1,442%</td>
<td>185,940</td>
<td>904,526</td>
<td>23,772</td>
<td>23,772</td>
<td>20,971</td>
</tr>
<tr>
<td>PSI OCs Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>9,303</td>
<td>(100)%</td>
<td>11,536</td>
<td>313,225</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Safe Water Solution</td>
<td>137,103</td>
<td>145,356</td>
<td>365,967</td>
<td>1,400,000</td>
<td>81,360</td>
<td>350%</td>
<td>1,581,666</td>
<td>8,053,363</td>
<td>300,795</td>
<td>-</td>
<td>1,570</td>
</tr>
<tr>
<td>Certeza Commercial ISM</td>
<td>27,440</td>
<td>93,808</td>
<td>196,304</td>
<td>700,000</td>
<td>15,360</td>
<td>1,178%</td>
<td>447,483</td>
<td>3,631,802</td>
<td>161,346</td>
<td>-</td>
<td>842</td>
</tr>
<tr>
<td>Certeza Free ISM</td>
<td>109,663</td>
<td>51,548</td>
<td>169,663</td>
<td>700,000</td>
<td>66,000</td>
<td>157%</td>
<td>1,134,183</td>
<td>4,421,561</td>
<td>139,449</td>
<td>-</td>
<td>728</td>
</tr>
<tr>
<td>Niger</td>
<td>17,174</td>
<td>17,583</td>
<td>1,251</td>
<td>(100)%</td>
<td>5,746</td>
<td>6,371</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

3002 - 4/15/2020 10:09:35AM
### DISTRIBUTION 2/2020

**MONTHLY AVG PREV 3 MONTHS**
**YTD DISTRIBUTION 2020**
**DISTRIBUTION TARGET 2020**
**YTD DISTRIBUTION 2019**
**LAUNCH DATE**
**YTD % CHANGE**

<table>
<thead>
<tr>
<th>Service</th>
<th>2020</th>
<th>2019</th>
<th>2020</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Free Condom</td>
<td>1,020,960</td>
<td>1,775,480</td>
<td>6/16</td>
<td>-%</td>
</tr>
<tr>
<td>Generic Condom</td>
<td>1,020,960</td>
<td>1,775,480</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>HIV Testing Services</td>
<td>7,618</td>
<td>38,532</td>
<td>(100)%</td>
<td></td>
</tr>
<tr>
<td>VCT Individual (HIV-Negative)</td>
<td>7,567</td>
<td>37,833</td>
<td>(100)%</td>
<td></td>
</tr>
<tr>
<td>VCT Individual (HIV-Positive)</td>
<td>51</td>
<td>699</td>
<td>(100)%</td>
<td></td>
</tr>
<tr>
<td>Implant 3 Insertion</td>
<td>20,175</td>
<td>36,498</td>
<td>2,688</td>
<td>6,720</td>
</tr>
<tr>
<td>Non-PSI Implant 3 Inserted</td>
<td>20,175</td>
<td>36,498</td>
<td>2,688</td>
<td>6,720</td>
</tr>
<tr>
<td>Implant 5 Insertion</td>
<td>4,832</td>
<td>8,826</td>
<td>872</td>
<td>3,314</td>
</tr>
<tr>
<td>Non-PSI Implant 5 Inserted</td>
<td>4,832</td>
<td>8,826</td>
<td>872</td>
<td>3,314</td>
</tr>
<tr>
<td>Injectable 3-IM</td>
<td>0%</td>
<td>(13,046)</td>
<td>(13,046)</td>
<td></td>
</tr>
<tr>
<td>(b)PSI Injectable 3 IM Distributed Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Injectable 3-IM Provided</td>
<td>100,304</td>
<td>178,041</td>
<td>4,165</td>
<td>4,165</td>
</tr>
<tr>
<td>Non-PSI Injectable 3 IM Provided</td>
<td>100,304</td>
<td>178,041</td>
<td>4,165</td>
<td>4,165</td>
</tr>
<tr>
<td>PSI Injectable 3 IM Provided</td>
<td>13,046</td>
<td>13,046</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Injectable 3-SC</td>
<td>0%</td>
<td>(1,463)</td>
<td>(1,463)</td>
<td></td>
</tr>
<tr>
<td>(b)PSI Injectable 3 SC Distributed Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Injectable 3-SC Provided</td>
<td>7,482</td>
<td>7,941</td>
<td>115</td>
<td>115</td>
</tr>
<tr>
<td>Non-PSI Injectable 3 SC Provided</td>
<td>7,482</td>
<td>7,941</td>
<td>115</td>
<td>115</td>
</tr>
<tr>
<td>PSI Injectable 3 SC Provided</td>
<td>1,463</td>
<td>1,463</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>IUD 10 Insertion</td>
<td>2,283</td>
<td>7,409</td>
<td>144</td>
<td>662</td>
</tr>
<tr>
<td>Non-PSI IUD 10 Inserted</td>
<td>2,283</td>
<td>7,409</td>
<td>144</td>
<td>662</td>
</tr>
<tr>
<td>Manual Vacuum Aspiration for PAC</td>
<td>2,283</td>
<td>7,409</td>
<td>144</td>
<td>662</td>
</tr>
<tr>
<td>MVA for PAC</td>
<td>2,283</td>
<td>7,409</td>
<td>144</td>
<td>662</td>
</tr>
<tr>
<td>Misoprostol for PAC Provided</td>
<td>1,050</td>
<td>1,739</td>
<td>128</td>
<td>-</td>
</tr>
<tr>
<td>Non-PSI Misoprostol for PAC Provided</td>
<td>1,050</td>
<td>1,739</td>
<td>128</td>
<td>-</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

---

**Notes:**

- The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

- DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

---

**Population Services International Monthly Distribution by Country**

**Period:** 2

**Year:** 2020

3002 - 4/15/2020 10:09:35AM Page 58 of 115
### Monthly Distribution by Country

#### Year: 2020

<table>
<thead>
<tr>
<th>Product</th>
<th>DISTRIBUTION 2/2020</th>
<th>MONTHLY AVG PREV 3 MONTHS</th>
<th>YTD DISTRIBUTION 2020</th>
<th>DISTRIBUTION TARGET 2020</th>
<th>LAUNCH DATE</th>
<th>YTD % CHANGE</th>
<th>TOTAL DISTRIBUTION 2019</th>
<th>CUMULATIVE DISTRIBUTION</th>
<th>%YTD USERS REACHED 2020</th>
<th>YTD CYP 2020</th>
<th>YTD DALY 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Misoprostol for Safe Abortion</td>
<td>908</td>
<td>795</td>
<td>1,956</td>
<td>-</td>
<td>1,916</td>
<td>2%</td>
<td>24,338</td>
<td>179,130</td>
<td>103</td>
<td>-</td>
<td>60</td>
</tr>
<tr>
<td>Misoprostol for Safe Abortion</td>
<td>908</td>
<td>795</td>
<td>1,956</td>
<td>-</td>
<td>1,916</td>
<td>3/18</td>
<td>2%</td>
<td>24,338</td>
<td>179,130</td>
<td>103</td>
<td>-</td>
</tr>
<tr>
<td>OCs</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>OCs Provided</td>
<td>17,444</td>
<td>15,974</td>
<td>32,974</td>
<td>68,000</td>
<td>21,559</td>
<td>53%</td>
<td>253,911</td>
<td>457,123</td>
<td>2,198</td>
<td>2,198</td>
<td>1,914</td>
</tr>
<tr>
<td>Non-PSI OCs Provided</td>
<td>17,444</td>
<td>15,974</td>
<td>32,974</td>
<td>68,000</td>
<td>21,559</td>
<td>53%</td>
<td>231,158</td>
<td>434,370</td>
<td>2,198</td>
<td>2,198</td>
<td>1,914</td>
</tr>
<tr>
<td>PSI OCs Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>22,753</td>
<td>22,753</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Seasonal Malaria Chemoprevention for Children</td>
<td>-</td>
<td>393,828</td>
<td>-</td>
<td>1,100,000</td>
<td>-</td>
<td>0%</td>
<td>1,181,485</td>
<td>1,181,485</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>SMC for Children ages 12-59 months</td>
<td>-</td>
<td>333,212</td>
<td>-</td>
<td>900,000</td>
<td>-</td>
<td>-%</td>
<td>999,635</td>
<td>999,635</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>SMC for Infants ages 3-11 months</td>
<td>-</td>
<td>60,617</td>
<td>-</td>
<td>200,000</td>
<td>-</td>
<td>-%</td>
<td>181,850</td>
<td>181,850</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>PSI Benin</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Implant 5</td>
<td>660</td>
<td>150</td>
<td>660</td>
<td>58</td>
<td>-</td>
<td>0%</td>
<td>1,770</td>
<td>2,430</td>
<td>594</td>
<td>2,257</td>
<td>1,610</td>
</tr>
<tr>
<td>Jadelle</td>
<td>660</td>
<td>150</td>
<td>660</td>
<td>4,080</td>
<td>1/18</td>
<td>-%</td>
<td>1,770</td>
<td>2,430</td>
<td>594</td>
<td>2,257</td>
<td>1,610</td>
</tr>
<tr>
<td>(b)PSI Implant 5 Distributed Inserted</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>(4,022)</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Implant 5 Insertion</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>4,022</td>
<td>-</td>
<td>0%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>(b)PSI Implant 5 Inserted</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>4,022</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PSI Implant 5 Inserted</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>4,022</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>IUD 10</td>
<td>550</td>
<td>317</td>
<td>550</td>
<td>1,079</td>
<td>850</td>
<td>(35)%</td>
<td>9,770</td>
<td>24,998</td>
<td>495</td>
<td>2,277</td>
<td>1,555</td>
</tr>
<tr>
<td>IUD Copper T 380A</td>
<td>550</td>
<td>317</td>
<td>550</td>
<td>12,690</td>
<td>850</td>
<td>(35)%</td>
<td>9,770</td>
<td>24,998</td>
<td>495</td>
<td>2,277</td>
<td>1,555</td>
</tr>
<tr>
<td>(b)PSI IUD 10 Distributed Inserted</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>(11,611)</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>IUD 10 Insertion</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>11,611</td>
<td>-</td>
<td>0%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PSI IUD 10 Inserted</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>11,611</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Manual Vacuum Aspiration for PAC</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>994</td>
<td>-</td>
<td>0%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>MVA for PAC</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>994</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Manual Vacuum Aspiration for SA</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>128</td>
<td>-</td>
<td>0%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
### Monthly Distribution by Country

**Period:** 2

**Year:** 2020

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Medical Abortion</td>
<td>260</td>
<td>203</td>
<td>260</td>
<td>3,630</td>
<td>90</td>
<td>189%</td>
<td>1,740</td>
<td>2,000</td>
<td>234</td>
<td>-</td>
</tr>
<tr>
<td>Mifeso</td>
<td>260</td>
<td>203</td>
<td>260</td>
<td>3,630</td>
<td>90</td>
<td>189%</td>
<td>1,740</td>
<td>2,000</td>
<td>234</td>
<td>-</td>
</tr>
<tr>
<td>Medical Abortion (Mifegyne)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>301</td>
<td>-</td>
<td>0%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PSI Medical Abortion (Mifegyne)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>301</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Misoprostol for PAC Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>770</td>
<td>-</td>
<td>0%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PSI Misoprostol for PAC Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>770</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Misoprostol for Safe Abortion</td>
<td>49,720</td>
<td>32,613</td>
<td>49,720</td>
<td>254,794</td>
<td>43,440</td>
<td>14%</td>
<td>319,604</td>
<td>578,304</td>
<td>2,610</td>
<td>-</td>
</tr>
<tr>
<td>Misoprostol for Safe Abortion</td>
<td>49,720</td>
<td>32,613</td>
<td>49,720</td>
<td>261,486</td>
<td>43,440</td>
<td>14%</td>
<td>319,604</td>
<td>578,304</td>
<td>2,610</td>
<td>-</td>
</tr>
<tr>
<td>(b) PSI Misoprostol for Safe Abortion Dist Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>(6,692)</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Country</th>
<th>17,297</th>
<th>11,442</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Condom</td>
<td>254,608</td>
<td>483,973</td>
<td>626,032</td>
<td>3,857,469</td>
<td>374,768</td>
<td>67%</td>
<td>2,740,944</td>
<td>34,311,136</td>
<td>4,695</td>
<td>4,695</td>
</tr>
<tr>
<td>Fagaru</td>
<td>29,440</td>
<td>102,752</td>
<td>149,440</td>
<td>1,157,241</td>
<td>79,040</td>
<td>11/12</td>
<td>593,936</td>
<td>12,562,561</td>
<td>1,121</td>
<td>1,121</td>
</tr>
<tr>
<td>Protec Fraise</td>
<td>47,064</td>
<td>76,379</td>
<td>102,504</td>
<td>810,068</td>
<td>88,512</td>
<td>1/13</td>
<td>443,360</td>
<td>4,701,468</td>
<td>769</td>
<td>769</td>
</tr>
<tr>
<td>Protec Naturel</td>
<td>178,104</td>
<td>304,843</td>
<td>374,088</td>
<td>1,890,160</td>
<td>207,216</td>
<td>1/13</td>
<td>1,703,648</td>
<td>17,047,107</td>
<td>2,806</td>
<td>2,806</td>
</tr>
<tr>
<td>Implant 3 Insertion</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>72</td>
<td>(100)%</td>
<td>169</td>
<td>363</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Non-PSI Implant 3 Inserted</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>72</td>
<td>(100)%</td>
<td>169</td>
<td>363</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Implant 4 Insertion</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>3</td>
<td>(100)%</td>
<td>21</td>
<td>41</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Non-PSI Implant 4 Inserted</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>3</td>
<td>(100)%</td>
<td>21</td>
<td>41</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Implant 5 Insertion</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>112</td>
<td>(100)%</td>
<td>226</td>
<td>462</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Non-PSI Implant 5 Inserted</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>112</td>
<td>(100)%</td>
<td>226</td>
<td>462</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Injectable 3-IM Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>32</td>
<td>(100)%</td>
<td>147</td>
<td>430</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Non-PSI Injectable 3 IM Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>32</td>
<td>(100)%</td>
<td>147</td>
<td>430</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Injectable 3-SC</td>
<td>11,448</td>
<td>6,781</td>
<td>21,448</td>
<td>20,000</td>
<td>4,752</td>
<td>351%</td>
<td>34,517</td>
<td>73,068</td>
<td>4,826</td>
<td>4,826</td>
</tr>
<tr>
<td>Securil Press</td>
<td>11,448</td>
<td>6,781</td>
<td>21,448</td>
<td>20,000</td>
<td>4,752</td>
<td>351%</td>
<td>34,517</td>
<td>73,068</td>
<td>4,826</td>
<td>4,826</td>
</tr>
<tr>
<td>IUD 10 Insertion</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>17</td>
<td>(100)%</td>
<td>35</td>
<td>81</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-PSI IUD 10 Inserted</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>17</td>
<td>(100)%</td>
<td>35</td>
<td>81</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>LLIN</td>
<td>2,800</td>
<td>14,372</td>
<td>6,150</td>
<td>142,902</td>
<td>2,025</td>
<td>204%</td>
<td>155,339</td>
<td>1,146,618</td>
<td>9,963</td>
<td>-</td>
<td>172</td>
</tr>
<tr>
<td>MILDA</td>
<td>2,800</td>
<td>14,372</td>
<td>6,150</td>
<td>142,902</td>
<td>2,025</td>
<td>204%</td>
<td>155,339</td>
<td>1,146,618</td>
<td>9,963</td>
<td>-</td>
<td>172</td>
</tr>
<tr>
<td>OCs</td>
<td>67,824</td>
<td>97,345</td>
<td>129,600</td>
<td>525,594</td>
<td>86,400</td>
<td>50%</td>
<td>736,139</td>
<td>4,068,007</td>
<td>7,776</td>
<td>7,776</td>
<td>3,632</td>
</tr>
<tr>
<td>Securil</td>
<td>67,824</td>
<td>97,345</td>
<td>129,600</td>
<td>525,594</td>
<td>86,400</td>
<td>50%</td>
<td>736,139</td>
<td>4,068,007</td>
<td>7,776</td>
<td>7,776</td>
<td>3,632</td>
</tr>
<tr>
<td>OCs Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>(100)%</td>
<td>4</td>
<td>27</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Non-PSI OCs Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>(100)%</td>
<td>4</td>
<td>27</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Toilets Sold</td>
<td>458</td>
<td>272</td>
<td>789</td>
<td>3,564</td>
<td>626</td>
<td>26%</td>
<td>2,683</td>
<td>4,430</td>
<td>6,549</td>
<td>-</td>
<td>101</td>
</tr>
<tr>
<td>Toilets Sold</td>
<td>458</td>
<td>272</td>
<td>789</td>
<td>3,564</td>
<td>626</td>
<td>26%</td>
<td>2,683</td>
<td>4,430</td>
<td>6,549</td>
<td>-</td>
<td>101</td>
</tr>
<tr>
<td>Toilets Sold - All</td>
<td>458</td>
<td>272</td>
<td>789</td>
<td>-</td>
<td>626</td>
<td>26%</td>
<td>2,818</td>
<td>4,565</td>
<td>6,549</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Toilets Sold - All</td>
<td>458</td>
<td>272</td>
<td>789</td>
<td>-</td>
<td>626</td>
<td>26%</td>
<td>2,818</td>
<td>4,565</td>
<td>6,549</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Water Treatment Tablets</td>
<td>40,000</td>
<td>275,573</td>
<td>94,000</td>
<td>1,906,684</td>
<td>476,900</td>
<td>(80)%</td>
<td>1,995,440</td>
<td>11,555,106</td>
<td>1,545</td>
<td>-</td>
<td>4</td>
</tr>
<tr>
<td>Aquatabs 67 mg (20 L)</td>
<td>40,000</td>
<td>275,573</td>
<td>94,000</td>
<td>1,906,684</td>
<td>476,900</td>
<td>(80)%</td>
<td>1,995,440</td>
<td>11,555,106</td>
<td>1,545</td>
<td>-</td>
<td>4</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.
(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
Latin America & Asia Market Group
<table>
<thead>
<tr>
<th>Country</th>
<th>New HIV Infections</th>
<th>STI Deaths</th>
<th>PWID Deaths</th>
<th>TB Deaths</th>
<th>CYP*</th>
<th>Maternal Deaths</th>
<th>Unintended Pregnancies</th>
<th>Malaria Deaths</th>
<th>Diarrhea Deaths</th>
<th>Pneumonia Deaths</th>
<th>Cervical Cancer Death</th>
<th>Sum of All Deaths</th>
</tr>
</thead>
<tbody>
<tr>
<td>Latin America &amp; Asia Market Group</td>
<td>668</td>
<td>-</td>
<td>13</td>
<td>304</td>
<td>541,591</td>
<td>275</td>
<td>201,923</td>
<td>-</td>
<td>8</td>
<td>-</td>
<td>-</td>
<td>1,895</td>
</tr>
<tr>
<td>Cambodia</td>
<td>273</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>98,547</td>
<td>89</td>
<td>36,995</td>
<td>-</td>
<td>8</td>
<td>-</td>
<td>-</td>
<td>301</td>
</tr>
<tr>
<td>Caribbean</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Costa Rica</td>
<td>9</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>2,262</td>
<td>-</td>
<td>637</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1</td>
</tr>
<tr>
<td>Dominican Republic</td>
<td>58</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>9,414</td>
<td>1</td>
<td>2,656</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>9</td>
</tr>
<tr>
<td>El Salvador</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>67</td>
<td>-</td>
<td>29</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>El Salvador SA</td>
<td>31</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>8,453</td>
<td>1</td>
<td>2,824</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>7</td>
</tr>
<tr>
<td>Guatemala</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>23</td>
<td>-</td>
<td>11</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Guatemala SA</td>
<td>47</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>13,520</td>
<td>2</td>
<td>4,123</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>22</td>
</tr>
<tr>
<td>Honduras</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>850</td>
<td>-</td>
<td>391</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1</td>
</tr>
<tr>
<td>Honduras SA</td>
<td>70</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>5,763</td>
<td>1</td>
<td>1,623</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>6</td>
</tr>
<tr>
<td>Kazakhstan</td>
<td>2</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>39</td>
<td>-</td>
<td>11</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Kyrgyzstan</td>
<td>2</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>87</td>
<td>-</td>
<td>25</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Laos</td>
<td>9</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>6</td>
<td>9,058</td>
<td>5</td>
<td>3,654</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>32</td>
</tr>
<tr>
<td>Nepal</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>7,950</td>
<td>22</td>
<td>3,510</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>36</td>
</tr>
<tr>
<td>Nicaragua</td>
<td>27</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>9,500</td>
<td>3</td>
<td>3,255</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>15</td>
</tr>
<tr>
<td>Pakistan</td>
<td>70</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>298</td>
<td>175,006</td>
<td>95</td>
<td>61,998</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>836</td>
</tr>
<tr>
<td>Panama</td>
<td>21</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>4,219</td>
<td>1</td>
<td>1,188</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>3</td>
</tr>
<tr>
<td>Papua New Guinea</td>
<td>4</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>433</td>
<td>-</td>
<td>121</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>2</td>
</tr>
<tr>
<td>PSI Pakistan</td>
<td>31</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>193,835</td>
<td>57</td>
<td>77,863</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>613</td>
</tr>
<tr>
<td>Tajikistan</td>
<td>12</td>
<td>-</td>
<td>13</td>
<td>-</td>
<td>1,005</td>
<td>-</td>
<td>283</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>14</td>
</tr>
<tr>
<td>Viet Nam</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1,561</td>
<td>-</td>
<td>725</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1</td>
</tr>
</tbody>
</table>

* Using USAID CYP conversion factors

3001 - 4/15/2020 10:03:49AM  Page 4 of 6
## Monthly Distribution by Market Group and Product

### Period: 2
### Year: 2020

<table>
<thead>
<tr>
<th>Latin America &amp; Asia Market Group</th>
<th>DISTRIBUTION 2/2020</th>
<th>MONTHLY AVG PREV 3 MONTHS</th>
<th>YTD DISTRIBUTION 2020</th>
<th>DISTRIBUTION TARGET 2020</th>
<th>YTD DISTRIBUTION 2019</th>
<th>YTD % CHANGE</th>
<th>TOTAL DISTRIBUTION 2019</th>
<th>CUMULATIVE SALES</th>
<th>YTD USERS REACHED</th>
<th>YTD CYP</th>
<th>YTD DALY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antiretroviral Treatment (Currently Enrolled)</td>
<td>3,708</td>
<td>1,267</td>
<td>6,742</td>
<td>3,375</td>
<td>-</td>
<td>-</td>
<td>7,541</td>
<td>14,516</td>
<td>562</td>
<td>-</td>
<td>938</td>
</tr>
<tr>
<td>Antiretroviral Treatment (Newly Enrolled)</td>
<td>85</td>
<td>88</td>
<td>262</td>
<td>1,332</td>
<td>-</td>
<td>-</td>
<td>449</td>
<td>803</td>
<td>262</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Cervical Cancer-HPV DNA Screening</td>
<td>-</td>
<td>153</td>
<td>458</td>
<td>800</td>
<td>-</td>
<td>-</td>
<td>777</td>
<td>1,235</td>
<td>458</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Cervical Cancer-Pap Smear Screening</td>
<td>22</td>
<td>31</td>
<td>54</td>
<td>525</td>
<td>106</td>
<td>(49)%</td>
<td>438</td>
<td>820</td>
<td>54</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Condom</td>
<td>13,460,562</td>
<td>13,769,642</td>
<td>24,469,250</td>
<td>222,769,749</td>
<td>26,441,144</td>
<td>(7)%</td>
<td>184,768,465</td>
<td>3,838,202,819</td>
<td>183,519</td>
<td>183,519</td>
<td>55,373</td>
</tr>
<tr>
<td>Diarrhea Treatment Kit</td>
<td>-</td>
<td>1,483</td>
<td>-</td>
<td>-</td>
<td>14,940</td>
<td>(100)%</td>
<td>40,570</td>
<td>971,010</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Emergency Contraception</td>
<td>263,297</td>
<td>205,853</td>
<td>477,551</td>
<td>4,598,351</td>
<td>436,533</td>
<td>9%</td>
<td>2,547,781</td>
<td>12,233,415</td>
<td>21,490</td>
<td>21,490</td>
<td>3,733</td>
</tr>
<tr>
<td>Emergency Contraception Provided</td>
<td>4,203</td>
<td>4,036</td>
<td>8,202</td>
<td>4,373</td>
<td>5,387</td>
<td>52%</td>
<td>30,261</td>
<td>82,204</td>
<td>410</td>
<td>410</td>
<td>70</td>
</tr>
<tr>
<td>Female Condom</td>
<td>20</td>
<td>-</td>
<td>20</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>338,559</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Fever Cases Attended</td>
<td>1,401</td>
<td>7,929</td>
<td>7,853</td>
<td>50,000</td>
<td>10,030</td>
<td>(22)%</td>
<td>88,447</td>
<td>376,225</td>
<td>7,853</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Fever Cases Tested with Microscopy</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>6,737</td>
<td>6,737</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Fever Cases Tested with RDTs</td>
<td>3,089</td>
<td>10,281</td>
<td>10,922</td>
<td>113,372</td>
<td>13,496</td>
<td>(19)%</td>
<td>116,202</td>
<td>422,811</td>
<td>10,922</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Free Condom</td>
<td>23,719</td>
<td>105,242</td>
<td>158,282</td>
<td>677,327</td>
<td>564,000</td>
<td>(72)%</td>
<td>3,741,906</td>
<td>17,595,688</td>
<td>1,187</td>
<td>1,187</td>
<td>627</td>
</tr>
<tr>
<td>Free Female Condom</td>
<td>-</td>
<td>3,103</td>
<td>3,000</td>
<td>10,000</td>
<td>-</td>
<td>-</td>
<td>16,504</td>
<td>19,504</td>
<td>22</td>
<td>22</td>
<td>14</td>
</tr>
<tr>
<td>HIV Self-Testing Kit</td>
<td>1,692</td>
<td>509</td>
<td>2,691</td>
<td>8,062</td>
<td>-</td>
<td>-</td>
<td>1,496</td>
<td>4,187</td>
<td>2,422</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>HIV Testing Services</td>
<td>6,304</td>
<td>5,788</td>
<td>15,304</td>
<td>55,999</td>
<td>10,254</td>
<td>49%</td>
<td>69,479</td>
<td>438,583</td>
<td>15,304</td>
<td>-</td>
<td>36</td>
</tr>
<tr>
<td>Hypertension Diagnosis</td>
<td>-</td>
<td>1</td>
<td>3</td>
<td>-</td>
<td>2,942</td>
<td>(100)%</td>
<td>7,961</td>
<td>60,401</td>
<td>3</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Hypertension Screening</td>
<td>-</td>
<td>1</td>
<td>3</td>
<td>-</td>
<td>64,734</td>
<td>(100)%</td>
<td>191,920</td>
<td>807,617</td>
<td>3</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Hypertension_Controlled Condition</td>
<td>3</td>
<td>1</td>
<td>6</td>
<td>-</td>
<td>4,255</td>
<td>(100)%</td>
<td>12,035</td>
<td>62,594</td>
<td>2</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Implant 3</td>
<td>573</td>
<td>316</td>
<td>1,037</td>
<td>6,506</td>
<td>944</td>
<td>10%</td>
<td>2,894</td>
<td>6,474</td>
<td>933</td>
<td>2,333</td>
<td>334</td>
</tr>
<tr>
<td>Implant 3 Insertion</td>
<td>983</td>
<td>742</td>
<td>1,569</td>
<td>12,428</td>
<td>2,114</td>
<td>(26)%</td>
<td>12,010</td>
<td>40,339</td>
<td>1,569</td>
<td>3,923</td>
<td>836</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.
## Monthly Distribution by Market Group and Product
### Period: 2
### Year: 2020

<table>
<thead>
<tr>
<th>Product Category</th>
<th>DISTRIBUTION 2/2020</th>
<th>MONTHLY AVG PREV 3 MONTHS</th>
<th>YTD DISTRIBUTION 2020</th>
<th>DISTRIBUTION TARGET 2020</th>
<th>YTD DISTRIBUTION 2019</th>
<th>YTD % CHANGE</th>
<th>TOTAL DISTRIBUTION 2019</th>
<th>CUMULATIVE SALES</th>
<th>YTD USERS REACHED (a)</th>
<th>YTD CYP 2020</th>
<th>YTD DALY 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Implant 5</td>
<td>516</td>
<td>1,254</td>
<td>921</td>
<td>27,284</td>
<td>204</td>
<td>351%</td>
<td>19,914</td>
<td>127,423</td>
<td>829</td>
<td>3,150</td>
<td>701</td>
</tr>
<tr>
<td>Implant 5 Insertion</td>
<td>20</td>
<td>537</td>
<td>36</td>
<td>3,886</td>
<td>1,977</td>
<td>(98)%</td>
<td>20,152</td>
<td>73,902</td>
<td>36</td>
<td>137</td>
<td>21</td>
</tr>
<tr>
<td>Injectable 1</td>
<td>(357)</td>
<td>14,480</td>
<td>5,003</td>
<td>137,498</td>
<td>30,583</td>
<td>(84)%</td>
<td>206,175</td>
<td>2,181,414</td>
<td>346</td>
<td>346</td>
<td>74</td>
</tr>
<tr>
<td>Injectable 1 Provided</td>
<td>1,315</td>
<td>6,138</td>
<td>2,035</td>
<td>-</td>
<td>10,321</td>
<td>(80)%</td>
<td>102,997</td>
<td>267,664</td>
<td>157</td>
<td>157</td>
<td>39</td>
</tr>
<tr>
<td>Injectable 2</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>228,471</td>
<td>25,378</td>
<td>(100)%</td>
<td>129,062</td>
<td>7,290,320</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Injectable 2 Provided</td>
<td>-</td>
<td>1,621</td>
<td>-</td>
<td>53,375</td>
<td>3,502</td>
<td>(100)%</td>
<td>39,042</td>
<td>150,644</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Injectable 3-IM</td>
<td>23,624</td>
<td>14,673</td>
<td>43,661</td>
<td>733,115</td>
<td>70,635</td>
<td>(38)%</td>
<td>338,609</td>
<td>8,904,394</td>
<td>9,824</td>
<td>9,824</td>
<td>1,516</td>
</tr>
<tr>
<td>Injectable 3-IM Provided</td>
<td>36,102</td>
<td>54,980</td>
<td>65,701</td>
<td>853,545</td>
<td>78,699</td>
<td>(17)%</td>
<td>517,607</td>
<td>1,471,176</td>
<td>16,425</td>
<td>16,425</td>
<td>3,711</td>
</tr>
<tr>
<td>Injectable 3-SC</td>
<td>(13)</td>
<td>(45)</td>
<td>(47)</td>
<td>200</td>
<td>-</td>
<td>-%</td>
<td>(102)</td>
<td>(149)</td>
<td>(11)</td>
<td>(11)</td>
<td>-</td>
</tr>
<tr>
<td>Injectable 3-SC Provided</td>
<td>13</td>
<td>261</td>
<td>47</td>
<td>800</td>
<td>-</td>
<td>-%</td>
<td>769</td>
<td>816</td>
<td>12</td>
<td>12</td>
<td>-</td>
</tr>
<tr>
<td>IUD 10</td>
<td>3,489</td>
<td>2,677</td>
<td>7,832</td>
<td>76,057</td>
<td>3,938</td>
<td>99%</td>
<td>100,869</td>
<td>394,660</td>
<td>7,049</td>
<td>32,424</td>
<td>6,483</td>
</tr>
<tr>
<td>IUD 10 Insertion</td>
<td>10,633</td>
<td>21,877</td>
<td>22,412</td>
<td>92,904</td>
<td>16,887</td>
<td>33%</td>
<td>141,791</td>
<td>799,978</td>
<td>22,412</td>
<td>103,095</td>
<td>29,842</td>
</tr>
<tr>
<td>IUD 5</td>
<td>4,506</td>
<td>(672)</td>
<td>(1,180)</td>
<td>219,980</td>
<td>25,285</td>
<td>(105)%</td>
<td>40,774</td>
<td>3,058,852</td>
<td>(1,062)</td>
<td>(3,505)</td>
<td>(1,099)</td>
</tr>
<tr>
<td>IUD 5 Insertion</td>
<td>13,130</td>
<td>11,772</td>
<td>24,949</td>
<td>11,229</td>
<td>38,466</td>
<td>(35)%</td>
<td>162,215</td>
<td>1,126,449</td>
<td>24,949</td>
<td>82,332</td>
<td>25,621</td>
</tr>
<tr>
<td>IUS 5 Insertion</td>
<td>-</td>
<td>1</td>
<td>-</td>
<td>3</td>
<td>(100)%</td>
<td>10</td>
<td>13</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>LLIN (Hammock net)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>6,000</td>
<td>400</td>
<td>(100)%</td>
<td>781</td>
<td>2,085</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Lubricant</td>
<td>101,961</td>
<td>99,357</td>
<td>236,700</td>
<td>1,392,857</td>
<td>306,471</td>
<td>(23)%</td>
<td>2,810,451</td>
<td>19,578,951</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Malaria PPT (ACT)</td>
<td>-</td>
<td>(18)</td>
<td>(22)</td>
<td>-</td>
<td>(70)</td>
<td>-%</td>
<td>(227)</td>
<td>(33,442)</td>
<td>(20)</td>
<td>-</td>
<td>(2)</td>
</tr>
<tr>
<td>Malaria RDK</td>
<td>1,010</td>
<td>3,960</td>
<td>2,160</td>
<td>31,500</td>
<td>5,340</td>
<td>(60)%</td>
<td>35,300</td>
<td>61,680</td>
<td>1,944</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Manual Vacuum Aspiration for SA</td>
<td>-</td>
<td>27</td>
<td>-</td>
<td>8</td>
<td>(100)%</td>
<td>696</td>
<td>866</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.
### Monthly Distribution by Market Group and Product

**Period:** 2  
**Year:** 2020

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Medical Abortion</td>
<td>33,955</td>
<td>29,231</td>
<td>59,688</td>
<td>398,484</td>
<td>78,070</td>
<td>(24)%</td>
<td>371,819</td>
<td>2,561,470</td>
<td>53,719</td>
<td>-</td>
<td>5,129</td>
</tr>
<tr>
<td>Medical Abortion Provided</td>
<td>-</td>
<td>1,044</td>
<td>-</td>
<td>3,380</td>
<td>1,224</td>
<td>(100)%</td>
<td>12,874</td>
<td>32,940</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Misoprostol for PAC Provided</td>
<td>8,369</td>
<td>8,451</td>
<td>16,037</td>
<td>-</td>
<td>15,470</td>
<td>4%</td>
<td>87,568</td>
<td>154,685</td>
<td>16,037</td>
<td>-</td>
<td>987</td>
</tr>
<tr>
<td>Misoprostol for Safe Abortion</td>
<td>169,848</td>
<td>163,725</td>
<td>379,360</td>
<td>599,276</td>
<td>417,900</td>
<td>(9)%</td>
<td>1,708,218</td>
<td>4,081,791</td>
<td>19,916</td>
<td>-</td>
<td>1,488</td>
</tr>
<tr>
<td>Multivitamin</td>
<td>1,001</td>
<td>2,467</td>
<td>1,001</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>26,420</td>
<td>27,421</td>
<td>5</td>
<td>-</td>
<td>1</td>
</tr>
<tr>
<td>Naloxone</td>
<td>-</td>
<td>180</td>
<td>540</td>
<td>780</td>
<td>-</td>
<td>-%</td>
<td>1,995</td>
<td>19,248</td>
<td>486</td>
<td>-</td>
<td>737</td>
</tr>
<tr>
<td>Needle &amp; Syringe</td>
<td>-</td>
<td>83,400</td>
<td>207,000</td>
<td>459,300</td>
<td>225,000</td>
<td>(8)%</td>
<td>1,066,900</td>
<td>26,266,968</td>
<td>722</td>
<td>-</td>
<td>2,598</td>
</tr>
<tr>
<td>OCs</td>
<td>606,955</td>
<td>483,615</td>
<td>1,087,525</td>
<td>7,843,988</td>
<td>1,164,127</td>
<td>(7)%</td>
<td>7,186,898</td>
<td>72,838,319</td>
<td>65,252</td>
<td>65,252</td>
<td>12,686</td>
</tr>
<tr>
<td>OCs Provided</td>
<td>175,012</td>
<td>201,074</td>
<td>273,878</td>
<td>1,709,652</td>
<td>208,574</td>
<td>31%</td>
<td>1,359,110</td>
<td>3,168,826</td>
<td>18,259</td>
<td>18,259</td>
<td>4,375</td>
</tr>
<tr>
<td>ORS</td>
<td>47,825</td>
<td>19,924</td>
<td>72,000</td>
<td>356,316</td>
<td>79,477</td>
<td>(9)%</td>
<td>648,134</td>
<td>1,249,368</td>
<td>32,400</td>
<td>-</td>
<td>721</td>
</tr>
<tr>
<td>Positive RDTs</td>
<td>68</td>
<td>122</td>
<td>166</td>
<td>4,000</td>
<td>611</td>
<td>(73)%</td>
<td>1,967</td>
<td>40,706</td>
<td>166</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Positive RDTs Given First Line Treatment</td>
<td>57</td>
<td>97</td>
<td>145</td>
<td>3,815</td>
<td>523</td>
<td>(72)%</td>
<td>1,554</td>
<td>37,247</td>
<td>145</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>QAACTs Provided after Confirmatory Diagnosis</td>
<td>34</td>
<td>82</td>
<td>117</td>
<td>3,514</td>
<td>324</td>
<td>(64)%</td>
<td>1,181</td>
<td>36,538</td>
<td>117</td>
<td>-</td>
<td>21</td>
</tr>
<tr>
<td>Referral to Emergency Contraception</td>
<td>1</td>
<td>-</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>2</td>
<td>110</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to HIV Testing Services</td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>3</td>
<td>(67)%</td>
<td>3</td>
<td>17</td>
<td>20,746</td>
<td>1</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to Implant 3 Insertion</td>
<td>155</td>
<td>127</td>
<td>213</td>
<td>-</td>
<td>311</td>
<td>(32)%</td>
<td>2,064</td>
<td>3,732</td>
<td>213</td>
<td>266</td>
<td>36</td>
</tr>
<tr>
<td>Referral to Implant 5 Insertion</td>
<td>5</td>
<td>26</td>
<td>8</td>
<td>-</td>
<td>77</td>
<td>(90)%</td>
<td>568</td>
<td>1,603</td>
<td>8</td>
<td>15</td>
<td>2</td>
</tr>
<tr>
<td>Referral to Implant Insertion (duration unknown)</td>
<td>4</td>
<td>3</td>
<td>5</td>
<td>25</td>
<td>25</td>
<td>-%</td>
<td>20</td>
<td>25</td>
<td>5</td>
<td>6</td>
<td>1</td>
</tr>
<tr>
<td>Referral to Injectable 1</td>
<td>1</td>
<td>4</td>
<td>1</td>
<td>1</td>
<td>25</td>
<td>-%</td>
<td>25</td>
<td>37</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to Injectable 3</td>
<td>3</td>
<td>60</td>
<td>8</td>
<td>105</td>
<td>(92)%</td>
<td>1,065</td>
<td>2,708</td>
<td>2</td>
<td>1</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to IUD 10 Insertion</td>
<td>180</td>
<td>167</td>
<td>218</td>
<td>-</td>
<td>297</td>
<td>(27)%</td>
<td>2,350</td>
<td>60,812</td>
<td>218</td>
<td>501</td>
<td>64</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.
<table>
<thead>
<tr>
<th>Service</th>
<th>DISTRIBUTION AVG PREV 3 MONTHS</th>
<th>DISTRIBUTION TARGET 2020</th>
<th>DISTRIBUTION 2020</th>
<th>YTD % CHANGE</th>
<th>TOTAL DISTRIBUTION 2019</th>
<th>CUMULATIVE SALES</th>
<th>YTD USERS REACHED (a) 2020</th>
<th>YTD CYP 2020</th>
<th>YTD DALY 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Referral to IUD Insertion (duration unknown)</td>
<td>8</td>
<td>3</td>
<td>12</td>
<td>-</td>
<td>-%</td>
<td>19</td>
<td>31</td>
<td>12</td>
<td>20</td>
</tr>
<tr>
<td>Referral to Linkage to HIV Care</td>
<td>251</td>
<td>272</td>
<td>504</td>
<td>1,660</td>
<td>20%</td>
<td>3,319</td>
<td>9,543</td>
<td>504</td>
<td>-</td>
</tr>
<tr>
<td>Referral to Ovarian Cysts (OCs)</td>
<td>-</td>
<td>44</td>
<td>-</td>
<td>83</td>
<td>(100%)</td>
<td>1,035</td>
<td>1,975</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to Opioid Treatment</td>
<td>2</td>
<td>4</td>
<td>3</td>
<td>10</td>
<td>(70%)</td>
<td>84</td>
<td>559</td>
<td>3</td>
<td>-</td>
</tr>
<tr>
<td>Referral to TB DOTS (completion confirmed)</td>
<td>34</td>
<td>9</td>
<td>34</td>
<td>232</td>
<td>(3%)</td>
<td>81</td>
<td>506</td>
<td>34</td>
<td>-</td>
</tr>
<tr>
<td>Referral to TB DOTS (completion unknown)</td>
<td>27</td>
<td>-</td>
<td>27</td>
<td>-</td>
<td>65%</td>
<td>275</td>
<td>27</td>
<td>-</td>
<td>8</td>
</tr>
<tr>
<td>Referral to Vasectomy</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>(100%)</td>
<td>1</td>
<td>1</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>SDM (Cycle Beads) Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>(100%)</td>
<td>4</td>
<td>10</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>STI Screening</td>
<td>22</td>
<td>22</td>
<td>49</td>
<td>19</td>
<td>158%</td>
<td>265</td>
<td>3,009</td>
<td>49</td>
<td>-</td>
</tr>
<tr>
<td>TB Diagnosis</td>
<td>2,947</td>
<td>2,461</td>
<td>5,448</td>
<td>850</td>
<td>32%</td>
<td>28,670</td>
<td>114,383</td>
<td>5,448</td>
<td>-</td>
</tr>
<tr>
<td>TB DOTS</td>
<td>1,813</td>
<td>1,989</td>
<td>3,521</td>
<td>-</td>
<td>(13%)</td>
<td>25,764</td>
<td>142,760</td>
<td>3,521</td>
<td>16,114</td>
</tr>
<tr>
<td>TB Screening</td>
<td>6,596</td>
<td>7,022</td>
<td>12,232</td>
<td>3,764</td>
<td>31%</td>
<td>65,241</td>
<td>218,089</td>
<td>12,232</td>
<td>-</td>
</tr>
<tr>
<td>Toilets Sold</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>(100%)</td>
<td>1,113</td>
<td>7,416</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Toilets Sold - All</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>(100%)</td>
<td>1,113</td>
<td>5,272</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Cervicitis</td>
<td>4</td>
<td>4</td>
<td>8</td>
<td>20</td>
<td>(60%)</td>
<td>94</td>
<td>145</td>
<td>8</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Genital Herpes</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>(100%)</td>
<td>1</td>
<td>9</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Lower Abdominal Pain</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>(100%)</td>
<td>7</td>
<td>7</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Nonherpetic Genital Ulcer</td>
<td>2</td>
<td>1</td>
<td>5</td>
<td>-</td>
<td>-%</td>
<td>2</td>
<td>9</td>
<td>5</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Urethral Discharge (Women)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>1</td>
<td>9</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Vaginitis</td>
<td>16</td>
<td>17</td>
<td>36</td>
<td>-</td>
<td>(33%)</td>
<td>217</td>
<td>281</td>
<td>36</td>
<td>-</td>
</tr>
<tr>
<td>Tubal Ligation</td>
<td>-</td>
<td>229</td>
<td>-</td>
<td>344</td>
<td>(100%)</td>
<td>8,574</td>
<td>18,703</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.
### Monthly Distribution by Market Group and Product

**Period:** 2  
**Year:** 2020

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Type 2 Diabetes Diagnosis</td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>1</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>Type 2 Diabetes Screening</td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>3</td>
<td>7</td>
<td>1</td>
</tr>
<tr>
<td>Type 2 Diabetes Controlled Condition</td>
<td>1</td>
<td>-</td>
<td>2</td>
<td>-</td>
<td>1</td>
<td>100%</td>
<td>2</td>
<td>4</td>
<td>-</td>
</tr>
<tr>
<td>Vasectomy</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>10</td>
<td>(100)%</td>
<td>290</td>
<td>531</td>
<td>-</td>
</tr>
<tr>
<td>Vivax Treatment after Confirmatory Diagnosis</td>
<td>1</td>
<td>38</td>
<td>38</td>
<td>185</td>
<td>-</td>
<td>-%</td>
<td>293</td>
<td>355</td>
<td>38</td>
</tr>
<tr>
<td>Water Treatment Tablets</td>
<td>5,000</td>
<td>2,583</td>
<td>6,000</td>
<td>15,000</td>
<td>50,500</td>
<td>(88)%</td>
<td>74,110</td>
<td>1,058,893</td>
<td>99</td>
</tr>
<tr>
<td>Zinc</td>
<td>6,910</td>
<td>23</td>
<td>6,910</td>
<td>32,134</td>
<td>-</td>
<td>345,400%</td>
<td>132</td>
<td>39,886</td>
<td>6,219</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.
### Latam + Asia Market Group

<table>
<thead>
<tr>
<th>Country</th>
<th>Condom</th>
<th>Number One</th>
<th>OK Condom</th>
<th>Diarrhea Treatment Kit</th>
<th>Orasel Kit</th>
<th>Emergency Contraception</th>
<th>NEXT 72 EC</th>
<th>Pronta1</th>
<th>(b)PSI Emergency Contraception Distributed Provided</th>
<th>Emergency Contraception Provided</th>
<th>PSI Emergency Contraception Provided</th>
<th>Fever Cases Attended</th>
<th>Fever Cases Attended</th>
<th>Fever Cases Tested with RDTs</th>
<th>Fever Cases Tested with RDTs</th>
<th>Implant 3 Insertion</th>
<th>Non-PSI Implant 3 Inserted</th>
<th>(b)PSI Implant 5 Distributed Inserted</th>
<th>Implant 5 Insertion</th>
<th>PSI Implant 5 Inserted</th>
<th>Injectable 3-IM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cambodia</td>
<td>875,616</td>
<td>436,680</td>
<td>438,936</td>
<td>3,040</td>
<td>-</td>
<td>3,040</td>
<td>1,401</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1,401</td>
<td>1,401</td>
<td>1,403</td>
<td>1,403</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>400</td>
<td>-</td>
<td>30,200</td>
<td></td>
</tr>
<tr>
<td></td>
<td>542,440</td>
<td>184,560</td>
<td>357,880</td>
<td>3,951</td>
<td>1,483</td>
<td>3,953</td>
<td>1,840</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1,840</td>
<td>1,840</td>
<td>1,841</td>
<td>1,841</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>150</td>
<td>-</td>
<td>16,711</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1,707,176</td>
<td>807,912</td>
<td>899,264</td>
<td>5,810</td>
<td>-</td>
<td>5,810</td>
<td>2,802</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>2,802</td>
<td>2,802</td>
<td>2,806</td>
<td>2,806</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>716</td>
<td>-</td>
<td>55,475</td>
<td></td>
</tr>
<tr>
<td></td>
<td>10,788,421</td>
<td>4,759,825</td>
<td>6,028,596</td>
<td>86,133</td>
<td>-</td>
<td>86,133</td>
<td>1,689</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1,689</td>
<td>1,689</td>
<td>1,384</td>
<td>1,384</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>7,715</td>
<td>-</td>
<td>267,076</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2,407,854</td>
<td>336,024</td>
<td>2,071,830</td>
<td>16,283</td>
<td>14,940</td>
<td>16,290</td>
<td>1,523</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1,523</td>
<td>1,523</td>
<td>1,384</td>
<td>1,384</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>267</td>
<td>-</td>
<td>33,781</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(29)%</td>
<td>140%</td>
<td>(57)%</td>
<td>(64)%</td>
<td>(100)%</td>
<td>(64)%</td>
<td>66%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>66%</td>
<td>66%</td>
<td>103%</td>
<td>103%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>-</td>
<td>64%</td>
<td></td>
</tr>
<tr>
<td></td>
<td>9,931,395</td>
<td>2,869,632</td>
<td>7,061,763</td>
<td>65,413</td>
<td>40,570</td>
<td>65,460</td>
<td>15,323</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>15,323</td>
<td>15,323</td>
<td>14,958</td>
<td>14,958</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>8,381</td>
<td>-</td>
<td>56%</td>
<td></td>
</tr>
<tr>
<td></td>
<td>12,804</td>
<td>6,059</td>
<td>6,744</td>
<td>261</td>
<td>47</td>
<td>261</td>
<td>2,802</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>2,802</td>
<td>2,802</td>
<td>2,806</td>
<td>2,806</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>32</td>
<td>-</td>
<td>12,482</td>
<td></td>
</tr>
<tr>
<td></td>
<td>12,804</td>
<td>6,059</td>
<td>971</td>
<td>1,483</td>
<td>-</td>
<td>1,483</td>
<td>1,403</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1,403</td>
<td>1,403</td>
<td>1,401</td>
<td>1,401</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1,401</td>
<td>-</td>
<td>2,160</td>
<td></td>
</tr>
<tr>
<td></td>
<td>33,846</td>
<td>5,984</td>
<td>6,600</td>
<td>34</td>
<td>-</td>
<td>34</td>
<td>174,837</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>174,837</td>
<td>174,837</td>
<td>174,837</td>
<td>174,837</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>12,482</td>
<td></td>
</tr>
<tr>
<td></td>
<td>54,191</td>
<td>12,482</td>
<td>12,644</td>
<td>397</td>
<td>12,804</td>
<td>12,804</td>
<td>5,865,039</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>5,865,039</td>
<td>5,865,039</td>
<td>5,865,039</td>
<td>5,865,039</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>2,802</td>
<td>-</td>
<td>64%</td>
<td></td>
</tr>
</tbody>
</table>

The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
## Monthly Distribution by Country

**Period:** 2  
**Year:** 2020

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>OK Injection-3</td>
<td>30,200</td>
<td>16,983</td>
<td>55,475</td>
<td>267,076</td>
<td>34,350</td>
<td>2/02</td>
<td>61%</td>
<td>259,600</td>
<td>5,883,634</td>
<td>12,482</td>
<td>12,482</td>
<td>2,160</td>
<td></td>
</tr>
<tr>
<td>(b) PSI Injectable 3 IM Distributed Provided</td>
<td>-</td>
<td>(272)</td>
<td>-</td>
<td>-</td>
<td>(569)</td>
<td>-%</td>
<td>-%</td>
<td>(4,265)</td>
<td>(18,595)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Injectable 3-IM Provided</td>
<td>-</td>
<td>272</td>
<td>-</td>
<td>-</td>
<td>569</td>
<td>(100)%</td>
<td>4,265</td>
<td>18,595</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>PSI Injectable 3 IM Provided</td>
<td>-</td>
<td>272</td>
<td>-</td>
<td>-</td>
<td>569</td>
<td>(100)%</td>
<td>4,265</td>
<td>18,595</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>IUD 10</td>
<td>2,730</td>
<td>802</td>
<td>5,130</td>
<td>28,003</td>
<td>(389)</td>
<td>0%</td>
<td>12,455</td>
<td>110,119</td>
<td>4,617</td>
<td>21,238</td>
<td>4,689</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IUD Copper T</td>
<td>2,730</td>
<td>1,623</td>
<td>5,130</td>
<td>28,003</td>
<td>2,005</td>
<td>1/10</td>
<td>156%</td>
<td>28,830</td>
<td>270,285</td>
<td>4,617</td>
<td>21,238</td>
<td>4,689</td>
<td></td>
</tr>
<tr>
<td>(b) PSI IUD 10 Distributed Inserted</td>
<td>-</td>
<td>(822)</td>
<td>-</td>
<td>-</td>
<td>(2,394)</td>
<td>-%</td>
<td>(16,375)</td>
<td>(160,166)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>IUD 10 Insertion</td>
<td>-</td>
<td>822</td>
<td>-</td>
<td>-</td>
<td>2,394</td>
<td>(100)%</td>
<td>16,375</td>
<td>160,166</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>PSI IUD 10 Inserted</td>
<td>-</td>
<td>822</td>
<td>-</td>
<td>-</td>
<td>2,394</td>
<td>(100)%</td>
<td>16,375</td>
<td>160,166</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Lubricant</td>
<td>45,240</td>
<td>38,943</td>
<td>95,528</td>
<td>483,291</td>
<td>133,500</td>
<td>6/09</td>
<td>(28)%</td>
<td>611,460</td>
<td>9,885,088</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>OK Plus Lubricant</td>
<td>45,240</td>
<td>38,943</td>
<td>95,528</td>
<td>483,291</td>
<td>133,500</td>
<td>(28)%</td>
<td>611,460</td>
<td>9,885,088</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Malaria PPT (ACT)</td>
<td>-</td>
<td>(18)</td>
<td>(22)</td>
<td>-</td>
<td>(70)</td>
<td>0%</td>
<td>(227)</td>
<td>(33,442)</td>
<td>(20)</td>
<td>-</td>
<td>(2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(b) PSI QAACTs Distributed Provided after Diagnosis</td>
<td>-</td>
<td>(18)</td>
<td>(22)</td>
<td>-</td>
<td>(70)</td>
<td>-%</td>
<td>(227)</td>
<td>(33,442)</td>
<td>(20)</td>
<td>-</td>
<td>(2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medical Abortion</td>
<td>24,955</td>
<td>18,142</td>
<td>50,688</td>
<td>316,846</td>
<td>64,980</td>
<td>11/09</td>
<td>(23)%</td>
<td>180,127</td>
<td>1,869,250</td>
<td>26,228</td>
<td>-</td>
<td>2,302</td>
<td></td>
</tr>
<tr>
<td>Medabon</td>
<td>12,775</td>
<td>11,852</td>
<td>29,142</td>
<td>200,736</td>
<td>37,738</td>
<td>1/10</td>
<td>(22)%</td>
<td>256,683</td>
<td>2,053,488</td>
<td>45,619</td>
<td>-</td>
<td>4,003</td>
<td></td>
</tr>
<tr>
<td>Mifeiso</td>
<td>12,180</td>
<td>7,130</td>
<td>21,546</td>
<td>116,110</td>
<td>28,354</td>
<td>12/12</td>
<td>(24)%</td>
<td>86,911</td>
<td>213,396</td>
<td>19,391</td>
<td>-</td>
<td>1,702</td>
<td></td>
</tr>
<tr>
<td>(b) PSI Medical Abortion Distributed Provided</td>
<td>-</td>
<td>(840)</td>
<td>-</td>
<td>-</td>
<td>(1,112)</td>
<td>-%</td>
<td>(10,355)</td>
<td>(29,159)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Medical Abortion Provided</td>
<td>-</td>
<td>840</td>
<td>-</td>
<td>-</td>
<td>1,112</td>
<td>(100)%</td>
<td>10,356</td>
<td>29,159</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Non-PSI Medical Abortion Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>1</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>PSI Medical Abortion Provided</td>
<td>-</td>
<td>840</td>
<td>-</td>
<td>-</td>
<td>1,112</td>
<td>(100)%</td>
<td>10,355</td>
<td>29,159</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>OCs</td>
<td>429,139</td>
<td>371,263</td>
<td>821,874</td>
<td>6,328,209</td>
<td>1,054,568</td>
<td>12/12</td>
<td>(22)%</td>
<td>5,954,034</td>
<td>66,966,741</td>
<td>49,312</td>
<td>49,312</td>
<td>9,002</td>
<td></td>
</tr>
<tr>
<td>Marvelon</td>
<td>125,731</td>
<td>91,725</td>
<td>247,134</td>
<td>1,359,879</td>
<td>196,311</td>
<td>12/12</td>
<td>26%</td>
<td>1,169,255</td>
<td>3,780,601</td>
<td>14,828</td>
<td>14,828</td>
<td>2,707</td>
<td></td>
</tr>
<tr>
<td>MEURI</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>142,521</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>OK Pills</td>
<td>303,408</td>
<td>279,948</td>
<td>574,740</td>
<td>4,825,809</td>
<td>858,480</td>
<td>9/07</td>
<td>(33)%</td>
<td>4,789,224</td>
<td>63,203,144</td>
<td>34,484</td>
<td>34,484</td>
<td>6,295</td>
<td></td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
### Monthly Distribution by Country

**Period:** 2  
**Year:** 2020

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>-</td>
<td>(411)</td>
<td>-</td>
<td>-</td>
<td>(223)</td>
<td>-</td>
<td>-%</td>
<td>(4,445)</td>
<td>(17,004)</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>OCs Provided</td>
<td>-</td>
<td>-</td>
<td>223</td>
<td>(100)%</td>
<td>4,445</td>
<td>-</td>
<td>17,004</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PSI OCs Provided</td>
<td>-</td>
<td>-</td>
<td>223</td>
<td>(100)%</td>
<td>4,445</td>
<td>-</td>
<td>17,004</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>ORS</td>
<td>47,825</td>
<td>19,924</td>
<td>72,000</td>
<td>356,316</td>
<td>79,475</td>
<td>(9)%</td>
<td>646,022</td>
<td>1,218,022</td>
<td>32,400</td>
<td>-</td>
<td>721</td>
</tr>
<tr>
<td>Orasel ORS Sachet</td>
<td>47,825</td>
<td>19,924</td>
<td>72,000</td>
<td>356,316</td>
<td>79,475</td>
<td>(9)%</td>
<td>646,022</td>
<td>1,218,022</td>
<td>32,400</td>
<td>-</td>
<td>721</td>
</tr>
<tr>
<td>Positive RDTs</td>
<td>24</td>
<td>30</td>
<td>48</td>
<td>2,700</td>
<td>135</td>
<td>(64)%</td>
<td>390</td>
<td>36,312</td>
<td>48</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Positive RDTs</td>
<td>24</td>
<td>30</td>
<td>48</td>
<td>2,700</td>
<td>135</td>
<td>(64)%</td>
<td>390</td>
<td>36,312</td>
<td>48</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Positive RDTs Given First Line Treatment</td>
<td>22</td>
<td>29</td>
<td>44</td>
<td>2,700</td>
<td>70</td>
<td>(37)%</td>
<td>262</td>
<td>33,499</td>
<td>44</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive RDTs Given First Line Treatment</td>
<td>22</td>
<td>29</td>
<td>44</td>
<td>2,700</td>
<td>70</td>
<td>(37)%</td>
<td>262</td>
<td>33,499</td>
<td>44</td>
<td></td>
<td></td>
</tr>
<tr>
<td>QAACTs Provided after Confirmatory Diagnosis</td>
<td>-</td>
<td>18</td>
<td>22</td>
<td>2,700</td>
<td>70</td>
<td>(69)%</td>
<td>228</td>
<td>33,498</td>
<td>22</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-PSI QAACTs Provided after Confirmed Diagnosis</td>
<td>-</td>
<td>18</td>
<td>22</td>
<td>2,700</td>
<td>70</td>
<td>(69)%</td>
<td>228</td>
<td>33,498</td>
<td>22</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Referral to Emergency Contraception</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>2</td>
<td>109</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Referral to Implant 5 Insertion</td>
<td>-</td>
<td>22</td>
<td>-</td>
<td>64</td>
<td>(100)%</td>
<td>493</td>
<td>1,464</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Referral to Injectable 3</td>
<td>-</td>
<td>58</td>
<td>-</td>
<td>105</td>
<td>(100)%</td>
<td>1,047</td>
<td>2,682</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Referral to IUD 10 Insertion</td>
<td>-</td>
<td>72</td>
<td>-</td>
<td>152</td>
<td>(100)%</td>
<td>1,246</td>
<td>10,725</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Referral to OCs</td>
<td>-</td>
<td>44</td>
<td>-</td>
<td>83</td>
<td>(100)%</td>
<td>1,030</td>
<td>1,970</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zinc</td>
<td>6,910</td>
<td>-</td>
<td>6,910</td>
<td>32,134</td>
<td>-</td>
<td>0%</td>
<td>-</td>
<td>6,910</td>
<td>6,219</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Orasel Zinc</td>
<td>6,910</td>
<td>-</td>
<td>6,910</td>
<td>32,134</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>6,910</td>
<td>6,219</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

---

### Notes

- **Caribbean**
- **Orasel Zinc**

---

3002 - 4/15/2020 10:09:35AM

Page 64 of 115
## Monthly Distribution by Country

**Period:** 2  
**Year:** 2020

### DISTRIBUTION 2/2020  
MONTHLY AVG PREV 3 MONTHS  
DISTRIBUTION TARGET 2020  
DISTRIBUTION 2019  
LAUNCH DATE  
YTD % CHANGE  
TOTAL DISTRIBUTION 2019  
CUMULATIVE DISTRIBUTION  
%YTD USERS REACHED 2020  
YTD CYP 2020  
YTD DALY 2020

<table>
<thead>
<tr>
<th>Product</th>
<th>DISTRIBUTION</th>
<th>MONTHLY AVG PREV 3 MONTHS</th>
<th>DISTRIBUTION TARGET 2020</th>
<th>DISTRIBUTION 2019</th>
<th>LAUNCH DATE</th>
<th>YTD % CHANGE</th>
<th>TOTAL DISTRIBUTION 2019</th>
<th>CUMULATIVE DISTRIBUTION (a)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cervical Cancer-HPV DNA Screening</td>
<td>-</td>
<td>153</td>
<td>458</td>
<td>800</td>
<td>-</td>
<td>0%</td>
<td>777</td>
<td>1,235</td>
</tr>
<tr>
<td>Cervical Cancer-HPV DNA Screening</td>
<td>-</td>
<td>153</td>
<td>458</td>
<td>800</td>
<td>-</td>
<td>-%</td>
<td>777</td>
<td>1,235</td>
</tr>
</tbody>
</table>

### Costa Rica

<table>
<thead>
<tr>
<th>Product</th>
<th>DISTRIBUTION</th>
<th>MONTHLY AVG PREV 3 MONTHS</th>
<th>DISTRIBUTION TARGET 2020</th>
<th>DISTRIBUTION 2019</th>
<th>LAUNCH DATE</th>
<th>YTD % CHANGE</th>
<th>TOTAL DISTRIBUTION 2019</th>
<th>CUMULATIVE DISTRIBUTION (a)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Condom</td>
<td>159,243</td>
<td>159,606</td>
<td>301,566</td>
<td>2,104,788</td>
<td>308,090</td>
<td>(2)%</td>
<td>1,794,252</td>
<td>21,150,157</td>
</tr>
<tr>
<td>Combo-Pack Lub Fresa</td>
<td>-</td>
<td>23</td>
<td>48</td>
<td>31,425</td>
<td>2,528</td>
<td>(98)%</td>
<td>16,308</td>
<td>102,187</td>
</tr>
<tr>
<td>Vive</td>
<td>87,888</td>
<td>97,110</td>
<td>169,320</td>
<td>1,307,466</td>
<td>185,475</td>
<td>(9)%</td>
<td>1,049,394</td>
<td>6,382,222</td>
</tr>
<tr>
<td>Vive Amor</td>
<td>1,632</td>
<td>-</td>
<td>1,632</td>
<td>-</td>
<td>6/04</td>
<td>-%</td>
<td>624</td>
<td>8,045,177</td>
</tr>
<tr>
<td>Vive Colors/Mas Colors</td>
<td>55,746</td>
<td>41,204</td>
<td>98,049</td>
<td>452,125</td>
<td>71,529</td>
<td>37%</td>
<td>405,312</td>
<td>4,179,078</td>
</tr>
<tr>
<td>Vive Mas Fuerte /Retardante</td>
<td>4,434</td>
<td>7,138</td>
<td>10,146</td>
<td>146,060</td>
<td>19,230</td>
<td>(47)%</td>
<td>151,374</td>
<td>939,108</td>
</tr>
<tr>
<td>Vive Mas Natural /Sensitivo</td>
<td>9,645</td>
<td>14,131</td>
<td>22,473</td>
<td>167,712</td>
<td>29,328</td>
<td>(23)%</td>
<td>171,240</td>
<td>1,194,211</td>
</tr>
<tr>
<td>Vive Mas/Texturizado</td>
<td>(102)</td>
<td>-</td>
<td>(102)</td>
<td>-</td>
<td>6/04</td>
<td>-%</td>
<td>-</td>
<td>308,174</td>
</tr>
<tr>
<td>Lubricant</td>
<td>1,459</td>
<td>2,486</td>
<td>3,210</td>
<td>61,813</td>
<td>6,186</td>
<td>(48)%</td>
<td>31,938</td>
<td>196,949</td>
</tr>
<tr>
<td>Vive Lub Natural (sachet)</td>
<td>200</td>
<td>217</td>
<td>350</td>
<td>9,186</td>
<td>1,600</td>
<td>(78)%</td>
<td>7,250</td>
<td>62,114</td>
</tr>
<tr>
<td>Vive Lub Natural (tube)</td>
<td>261</td>
<td>655</td>
<td>1,014</td>
<td>7,499</td>
<td>1,528</td>
<td>(34)%</td>
<td>7,211</td>
<td>31,580</td>
</tr>
<tr>
<td>Vive Lub Sachet Fresa 5 mL</td>
<td>-</td>
<td>725</td>
<td>(25)</td>
<td>7,749</td>
<td>1,350</td>
<td>(102)%</td>
<td>8,200</td>
<td>66,363</td>
</tr>
<tr>
<td>Vive Lub Tubo Fresa 120 mL</td>
<td>998</td>
<td>890</td>
<td>1,871</td>
<td>9,338</td>
<td>1,708</td>
<td>10%</td>
<td>9,277</td>
<td>36,892</td>
</tr>
<tr>
<td>Vive Lub Tubo Fresa 30 mL</td>
<td>-</td>
<td>-</td>
<td>28,041</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

### Dominican Republic

<table>
<thead>
<tr>
<th>Product</th>
<th>DISTRIBUTION</th>
<th>MONTHLY AVG PREV 3 MONTHS</th>
<th>DISTRIBUTION TARGET 2020</th>
<th>DISTRIBUTION 2019</th>
<th>LAUNCH DATE</th>
<th>YTD % CHANGE</th>
<th>TOTAL DISTRIBUTION 2019</th>
<th>CUMULATIVE DISTRIBUTION (a)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antiretroviral Treatment (Currently Enrolled)</td>
<td>3,708</td>
<td>1,267</td>
<td>6,742</td>
<td>3,375</td>
<td>-</td>
<td>0%</td>
<td>7,541</td>
<td>14,516</td>
</tr>
<tr>
<td>Antiretroviral Treatment (Currently Enrolled)</td>
<td>3,708</td>
<td>1,267</td>
<td>6,742</td>
<td>3,375</td>
<td>-</td>
<td>-%</td>
<td>7,541</td>
<td>14,516</td>
</tr>
<tr>
<td>Antiretroviral Treatment (Newly Enrolled)</td>
<td>85</td>
<td>88</td>
<td>262</td>
<td>1,332</td>
<td>-</td>
<td>0%</td>
<td>449</td>
<td>803</td>
</tr>
<tr>
<td>Antiretroviral Treatment (Newly Enrolled)</td>
<td>85</td>
<td>88</td>
<td>262</td>
<td>1,332</td>
<td>-</td>
<td>-%</td>
<td>449</td>
<td>803</td>
</tr>
<tr>
<td>Condom</td>
<td>743,168</td>
<td>393,948</td>
<td>1,251,536</td>
<td>5,500,729</td>
<td>1,693,744</td>
<td>(26)%</td>
<td>10,326,835</td>
<td>200,505,946</td>
</tr>
<tr>
<td>Pante</td>
<td>740,264</td>
<td>378,836</td>
<td>1,246,632</td>
<td>5,344,721</td>
<td>1,647,688</td>
<td>(24)%</td>
<td>10,210,699</td>
<td>200,381,338</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.  
(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

---

3002 - 4/15/2020 10:09:35AM Page 65 of 115
## Monthly Distribution by Country

**Period:** 2nd Quarter of 2020

### Distribution Target 2020

<table>
<thead>
<tr>
<th>Product</th>
<th>AVG PREV 3 MONTHS</th>
<th>DISTRIBUTION 2020</th>
<th>YTD DISTRIBUTION</th>
<th>YTD DISTRIBUTION 2019</th>
<th>LAUNCH DATE</th>
<th>YTD % CHANGE</th>
<th>TOTAL DISTRIBUTION 2019</th>
<th>CUMULATIVE DISTRIBUTION</th>
<th>%YTD USERS REACHED 2020</th>
<th>YTD CYP 2020</th>
<th>YTD DALY 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vive Colors/Mas Colors</td>
<td>1,632</td>
<td>7,344</td>
<td>1,632</td>
<td>141,007</td>
<td>22,464</td>
<td>(93)%</td>
<td>56,688</td>
<td>61,104</td>
<td>12</td>
<td>12</td>
<td>3</td>
</tr>
<tr>
<td>Vive Mas/Sensitivo</td>
<td>1,128</td>
<td>3,200</td>
<td>1,128</td>
<td>15,001</td>
<td>12,408</td>
<td>(91)%</td>
<td>27,720</td>
<td>30,240</td>
<td>8</td>
<td>8</td>
<td>2</td>
</tr>
<tr>
<td>Vive Mas/Texturizado</td>
<td>144</td>
<td>4,568</td>
<td>144</td>
<td>-</td>
<td>11,184</td>
<td>(99)%</td>
<td>31,728</td>
<td>33,264</td>
<td>1</td>
<td>1</td>
<td>-</td>
</tr>
<tr>
<td>Free Condom</td>
<td>-</td>
<td>667</td>
<td>-</td>
<td>18,001</td>
<td>540,000</td>
<td>(100)%</td>
<td>3,233,000</td>
<td>14,765,472</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>No Logo</td>
<td>-</td>
<td>667</td>
<td>-</td>
<td>18,001</td>
<td>540,000</td>
<td>4/10</td>
<td>(100)%</td>
<td>3,233,000</td>
<td>14,765,472</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>HIV Testing Services</td>
<td>4,159</td>
<td>3,524</td>
<td>11,142</td>
<td>22,263</td>
<td>-</td>
<td>0%</td>
<td>19,440</td>
<td>138,447</td>
<td>11,142</td>
<td>-</td>
<td>27</td>
</tr>
<tr>
<td>VCT Individual (HIV-Negative)</td>
<td>4,058</td>
<td>3,431</td>
<td>10,881</td>
<td>20,568</td>
<td>-</td>
<td>-%</td>
<td>18,725</td>
<td>134,820</td>
<td>10,881</td>
<td>-</td>
<td>26</td>
</tr>
<tr>
<td>VCT Individual (HIV-Positive)</td>
<td>101</td>
<td>93</td>
<td>261</td>
<td>1,695</td>
<td>-</td>
<td>9/13</td>
<td>-%</td>
<td>715</td>
<td>3,627</td>
<td>261</td>
<td>-</td>
</tr>
<tr>
<td>Lubricant</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>37,000</td>
<td>-</td>
<td>-</td>
<td>1,037,000</td>
<td>2,825,992</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>No Logo Lubricant (4.5 gram sachet)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>37,000</td>
<td>6/14</td>
<td>100%</td>
<td>1,037,000</td>
<td>2,825,992</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to Implant Insertion (duration unknown)</td>
<td>4</td>
<td>3</td>
<td>5</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>20</td>
<td>25</td>
<td>5</td>
<td>6</td>
<td>1</td>
</tr>
<tr>
<td>Referral to Implant Insertion (duration unknown)</td>
<td>4</td>
<td>3</td>
<td>5</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>20</td>
<td>25</td>
<td>5</td>
<td>6</td>
<td>1</td>
</tr>
<tr>
<td>Referral to Injectable 1</td>
<td>-</td>
<td>4</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>12</td>
<td>12</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to Injectable 1</td>
<td>-</td>
<td>4</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>12</td>
<td>12</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to Injectable 3</td>
<td>3</td>
<td>2</td>
<td>8</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>16</td>
<td>24</td>
<td>2</td>
<td>1</td>
<td>-</td>
</tr>
<tr>
<td>Referral to Injectable 3</td>
<td>3</td>
<td>2</td>
<td>8</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>16</td>
<td>24</td>
<td>2</td>
<td>1</td>
<td>-</td>
</tr>
<tr>
<td>Referral to IUD Insertion (duration unknown)</td>
<td>8</td>
<td>3</td>
<td>12</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>19</td>
<td>31</td>
<td>12</td>
<td>20</td>
<td>3</td>
</tr>
<tr>
<td>Referral to IUD Insertion (duration unknown)</td>
<td>8</td>
<td>3</td>
<td>12</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>19</td>
<td>31</td>
<td>12</td>
<td>20</td>
<td>3</td>
</tr>
<tr>
<td>Referral to OCs</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>3</td>
<td>3</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to OCs</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>3</td>
<td>3</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>El Salvador</td>
<td>67</td>
<td>18</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cervical Cancer-Pap Smear Screening</td>
<td>1,432</td>
<td>7</td>
<td>1,438</td>
<td>3,623,354</td>
<td>470,451</td>
<td>(100)%</td>
<td>4,346,863</td>
<td>43,680,533</td>
<td>11</td>
<td>11</td>
<td>3</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
### Monthly Distribution by Country

**Period:** 2  
**Year:** 2020

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Vive</td>
<td>96</td>
<td>-</td>
<td>96</td>
<td>961,912</td>
<td>133,968</td>
<td>4/98</td>
<td>(100)%</td>
<td>1,110,432</td>
<td>16,315,372</td>
<td>1</td>
<td>1</td>
<td>-</td>
</tr>
<tr>
<td>Vive Amor</td>
<td>48</td>
<td>-</td>
<td>48</td>
<td>1,593,963</td>
<td>141,888</td>
<td>7/04</td>
<td>(100)%</td>
<td>1,631,520</td>
<td>16,089,985</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Vive Colors/Mas Colors</td>
<td>213</td>
<td>3</td>
<td>216</td>
<td>689,936</td>
<td>139,464</td>
<td>10/03</td>
<td>(100)%</td>
<td>1,163,052</td>
<td>8,466,822</td>
<td>2</td>
<td>2</td>
<td>-</td>
</tr>
<tr>
<td>Vive Mas Fuerte /Retardante</td>
<td>36</td>
<td>3</td>
<td>39</td>
<td>265,329</td>
<td>32,139</td>
<td>7/04</td>
<td>(95%)</td>
<td>280,425</td>
<td>1,834,892</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Vive Mas Natural /Sensitivo</td>
<td>1,039</td>
<td>-</td>
<td>1,039</td>
<td>107,077</td>
<td>22,992</td>
<td>7/04</td>
<td>(95%)</td>
<td>132,920</td>
<td>934,664</td>
<td>8</td>
<td>8</td>
<td>2</td>
</tr>
<tr>
<td>HIV Testing Services</td>
<td>-</td>
<td>392</td>
<td>423</td>
<td>4,050</td>
<td>630</td>
<td>(33)%</td>
<td>4,668</td>
<td>49,895</td>
<td>423</td>
<td>-</td>
<td>1</td>
<td>-</td>
</tr>
<tr>
<td>VCT Individual (HIV-Negative)</td>
<td>-</td>
<td>372</td>
<td>401</td>
<td>3,795</td>
<td>604</td>
<td>12/09</td>
<td>(34)%</td>
<td>4,474</td>
<td>49,027</td>
<td>401</td>
<td>-</td>
<td>1</td>
</tr>
<tr>
<td>VCT Individual (HIV-Positive)</td>
<td>-</td>
<td>20</td>
<td>22</td>
<td>255</td>
<td>26</td>
<td>12/09</td>
<td>(15)%</td>
<td>194</td>
<td>868</td>
<td>22</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Hypertension Diagnosis</td>
<td>-</td>
<td>1</td>
<td>3</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>-</td>
<td>5</td>
<td>3</td>
<td>3</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Hypertension Diagnosis</td>
<td>-</td>
<td>1</td>
<td>3</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>5</td>
<td>3</td>
<td>3</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Hypertension Screening</td>
<td>-</td>
<td>1</td>
<td>3</td>
<td>-</td>
<td>1</td>
<td>200%</td>
<td>4</td>
<td>12</td>
<td>3</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Hypertension Screening</td>
<td>-</td>
<td>1</td>
<td>3</td>
<td>-</td>
<td>1</td>
<td>200%</td>
<td>4</td>
<td>12</td>
<td>3</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Hypertension_Controlled Condition</td>
<td>-</td>
<td>1</td>
<td>3</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>-</td>
<td>5</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Hypertension_Controlled Condition</td>
<td>-</td>
<td>1</td>
<td>3</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>5</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Implant 5</td>
<td>3</td>
<td>-</td>
<td>3</td>
<td>(200)</td>
<td>-</td>
<td>0%</td>
<td>(12)</td>
<td>4,354</td>
<td>3</td>
<td>10</td>
<td>1</td>
<td>-</td>
</tr>
<tr>
<td>Jadelle</td>
<td>3</td>
<td>13</td>
<td>11</td>
<td>-</td>
<td>7</td>
<td>12/08</td>
<td>57%</td>
<td>122</td>
<td>5,749</td>
<td>10</td>
<td>38</td>
<td>4</td>
</tr>
<tr>
<td>(b)PSI Implant 5 Distributed Inserted</td>
<td>-</td>
<td>(13)</td>
<td>(8)</td>
<td>(200)</td>
<td>(7)</td>
<td>-%</td>
<td>(134)</td>
<td>(1,395)</td>
<td>(7)</td>
<td>(27)</td>
<td>(3)</td>
<td>-</td>
</tr>
<tr>
<td>Implant 5 Insertion</td>
<td>-</td>
<td>13</td>
<td>8</td>
<td>200</td>
<td>7</td>
<td>14%</td>
<td>134</td>
<td>1,395</td>
<td>8</td>
<td>30</td>
<td>3</td>
<td>-</td>
</tr>
<tr>
<td>PSI Implant 5 Inserted</td>
<td>-</td>
<td>13</td>
<td>8</td>
<td>200</td>
<td>7</td>
<td>14%</td>
<td>134</td>
<td>1,395</td>
<td>8</td>
<td>30</td>
<td>3</td>
<td>-</td>
</tr>
<tr>
<td>Injectable 1</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>4,210</td>
<td>(6)</td>
<td>0%</td>
<td>(6)</td>
<td>(18)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Cyclofem</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>4,210</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>(b)PSI Injectable 1 Distributed Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>(6)</td>
<td>-%</td>
<td>(6)</td>
<td>(18)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Injectable 1 Provided</td>
<td>-</td>
<td>1</td>
<td>4</td>
<td>6</td>
<td>(33)%</td>
<td>9</td>
<td>93</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Non-PSI Injectable 1 Provided</td>
<td>-</td>
<td>1</td>
<td>4</td>
<td>6</td>
<td>(33)%</td>
<td>3</td>
<td>75</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

3002 - 4/15/2020 10:09:35AM
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PSI Injectable 1 Provided</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>6</td>
<td></td>
<td>(100)%</td>
<td>6</td>
<td>18</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>IUD 10</strong></td>
<td>- (12)</td>
<td>(10) (200) (17)</td>
<td>0%</td>
<td>(153) (25,344) (9)</td>
<td>(41) (4)</td>
<td>-</td>
<td>10</td>
<td>46</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>(b)<strong>PSI IUD 10 Distributed Inserted</strong></td>
<td>- (12) (10) (200) (17)</td>
<td>-</td>
<td>-</td>
<td>153 (25,344) (9) (41) (4)</td>
<td>-</td>
<td>(41)%</td>
<td>10</td>
<td>46</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>IUD 10 Insertion</strong></td>
<td>- 12</td>
<td>10</td>
<td>200</td>
<td>17 (41)%</td>
<td>153</td>
<td>25,344</td>
<td>10</td>
<td>46</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>PSI IUD 10 Inserted</strong></td>
<td>- 12</td>
<td>10</td>
<td>200</td>
<td>17 (41)%</td>
<td>153</td>
<td>25,344</td>
<td>10</td>
<td>46</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Lubricant</strong></td>
<td>14</td>
<td>3</td>
<td>19</td>
<td>234,589 (100)%</td>
<td>524,124</td>
<td>1,951,722</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Vive Lub (sachet)</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>103,802 (100)%</td>
<td>236,000</td>
<td>1,038,390</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Vive Lub (tube)</strong></td>
<td>6</td>
<td>1</td>
<td>7</td>
<td>10,265 (100)%</td>
<td>36,790</td>
<td>99,856</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Vive Lub (tube) 30ml</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>21,790 (100)%</td>
<td>10,784</td>
<td>40,074</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Vive Lub Natural (sachet)</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>90,022 (100)%</td>
<td>240,550</td>
<td>773,402</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Vive Lub Natural (tube)</strong></td>
<td>8</td>
<td>2</td>
<td>12</td>
<td>8,710 (99)%</td>
<td>10,764</td>
<td>40,074</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>OCs</strong></td>
<td>-</td>
<td>10</td>
<td>12</td>
<td>47,076 (100)%</td>
<td>82,004</td>
<td>253,957</td>
<td>1</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>(b)<strong>PSI OCs Distributed Provided</strong></td>
<td>-</td>
<td>-</td>
<td>(1)</td>
<td>(1)</td>
<td>(11)</td>
<td>(38)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Segura Plus</strong></td>
<td>-</td>
<td>11</td>
<td>13</td>
<td>47,076 (100)%</td>
<td>82,015</td>
<td>253,995</td>
<td>1</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>OCs Provided</strong></td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>-</td>
<td>0%</td>
<td>11</td>
<td>38</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>PSI OCs Provided</strong></td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>11</td>
<td>38</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Referral to HIV Testing Services</strong></td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>3</td>
<td>473</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Referral to HIV Testing Services</strong></td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>-</td>
<td>12/13</td>
<td>-%</td>
<td>3</td>
<td>473</td>
<td>1</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Referral to Implant 5 Insertion</strong></td>
<td>1</td>
<td>1</td>
<td>3</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>24</td>
<td>33</td>
<td>6</td>
<td>1</td>
<td>-</td>
</tr>
<tr>
<td><strong>Referral to Implant 5 Insertion</strong></td>
<td>1</td>
<td>1</td>
<td>3</td>
<td>-</td>
<td>12/11</td>
<td>-%</td>
<td>24</td>
<td>33</td>
<td>6</td>
<td>1</td>
<td>-</td>
</tr>
<tr>
<td><strong>Referral to Injectable 1</strong></td>
<td>1</td>
<td>-</td>
<td>1</td>
<td>-</td>
<td>0%</td>
<td>7</td>
<td>14</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Referral to Injectable 1</strong></td>
<td>1</td>
<td>-</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>7</td>
<td>14</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Referral to IUD 10 Insertion</strong></td>
<td>1</td>
<td>-</td>
<td>2</td>
<td>-</td>
<td>100%</td>
<td>18</td>
<td>18,958</td>
<td>2</td>
<td>5</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Referral to IUD 10 Insertion</strong></td>
<td>1</td>
<td>-</td>
<td>2</td>
<td>12/11</td>
<td>100%</td>
<td>18</td>
<td>18,958</td>
<td>2</td>
<td>5</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Referral to Linkage to HIV Care</strong></td>
<td>10</td>
<td>11</td>
<td>20</td>
<td>204</td>
<td>100%</td>
<td>141</td>
<td>351</td>
<td>20</td>
<td>-</td>
<td>10</td>
<td>-</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Referral to Linkage to HIV Care</td>
<td>10</td>
<td>215</td>
<td>20</td>
<td>204</td>
<td>10</td>
<td>114</td>
<td>351</td>
<td>351</td>
<td>20</td>
<td>141</td>
</tr>
<tr>
<td>Referral to OCs</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>2</td>
<td>2</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to OCs</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>2</td>
<td>2</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>STI Screening</td>
<td>-</td>
<td>22</td>
<td>27</td>
<td>-</td>
<td>19</td>
<td>42%</td>
<td>265</td>
<td>2,987</td>
<td>27</td>
<td>27</td>
</tr>
<tr>
<td>STI Screening</td>
<td>-</td>
<td>22</td>
<td>27</td>
<td>-</td>
<td>19</td>
<td>42%</td>
<td>265</td>
<td>2,987</td>
<td>27</td>
<td>27</td>
</tr>
<tr>
<td>Treatment for Cervicitis</td>
<td>-</td>
<td>4</td>
<td>4</td>
<td>-</td>
<td>20</td>
<td>(80)%</td>
<td>94</td>
<td>141</td>
<td>4</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Cervicitis</td>
<td>-</td>
<td>4</td>
<td>4</td>
<td>-</td>
<td>20</td>
<td>(80)%</td>
<td>94</td>
<td>141</td>
<td>4</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Genital Herpes</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>(100)%</td>
<td>1</td>
<td>9</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Genital Herpes</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>(100)%</td>
<td>1</td>
<td>9</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Lower Abdominal Pain</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>(100)%</td>
<td>7</td>
<td>7</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Lower Abdominal Pain</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>(100)%</td>
<td>7</td>
<td>7</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Nonherpetic Genital Ulcer</td>
<td>-</td>
<td>1</td>
<td>3</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>2</td>
<td>7</td>
<td>3</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Nonherpetic Genital Ulcer</td>
<td>-</td>
<td>1</td>
<td>3</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>2</td>
<td>7</td>
<td>3</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Urethral Discharge (Women)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>1</td>
<td>9</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Urethral Discharge (Women)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>1</td>
<td>9</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Vaginitis</td>
<td>-</td>
<td>17</td>
<td>20</td>
<td>-</td>
<td>54</td>
<td>(63)%</td>
<td>217</td>
<td>265</td>
<td>20</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Vaginitis</td>
<td>-</td>
<td>17</td>
<td>20</td>
<td>-</td>
<td>54</td>
<td>(63)%</td>
<td>217</td>
<td>265</td>
<td>20</td>
<td>-</td>
</tr>
<tr>
<td>Type 2 Diabetes Diagnosis</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>1</td>
<td>3</td>
<td>1</td>
<td>-</td>
</tr>
<tr>
<td>Type 2 Diabetes Diagnosis</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>1</td>
<td>3</td>
<td>1</td>
<td>-</td>
</tr>
<tr>
<td>Type 2 Diabetes Screening</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>3</td>
<td>7</td>
<td>1</td>
<td>-</td>
</tr>
<tr>
<td>Type 2 Diabetes Screening</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>3</td>
<td>7</td>
<td>1</td>
<td>-</td>
</tr>
<tr>
<td>Type 2 Diabetes_Controlled Condition</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>2</td>
<td>3</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Type 2 Diabetes_Controlled Condition</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>2</td>
<td>3</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Cervical Cancer-Pap Smear Screening</td>
<td>22</td>
<td>22</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>22</td>
<td>22</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
### Monthly Distribution by Country

**Period:** 2020  
**Year:** 2020

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Cervical Cancer-Pap Smear Screening</td>
<td>22</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>22</td>
<td>22</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Condom</td>
<td>347,579</td>
<td>319,507</td>
<td>752,875</td>
<td>5,760</td>
<td>12971%</td>
<td>1,252,992</td>
<td>2,035,915</td>
<td>5,647</td>
<td>5,647</td>
<td>1,424</td>
<td></td>
</tr>
<tr>
<td>Combo-Pack Lub Fresa</td>
<td>512</td>
<td>91</td>
<td>736</td>
<td>-</td>
<td>-%</td>
<td>48</td>
<td>784</td>
<td>6</td>
<td>6</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Vive</td>
<td>121,299</td>
<td>76,784</td>
<td>209,523</td>
<td>-</td>
<td>-%</td>
<td>323,280</td>
<td>532,803</td>
<td>1,571</td>
<td>1,571</td>
<td>396</td>
<td></td>
</tr>
<tr>
<td>Vive Amor</td>
<td>148,464</td>
<td>150,352</td>
<td>319,440</td>
<td>5,760</td>
<td>5,446%</td>
<td>595,008</td>
<td>944,496</td>
<td>2,396</td>
<td>2,396</td>
<td>604</td>
<td></td>
</tr>
<tr>
<td>Vive Colors/Mas Colors</td>
<td>54,936</td>
<td>62,712</td>
<td>151,032</td>
<td>-</td>
<td>-%</td>
<td>221,712</td>
<td>372,744</td>
<td>1,133</td>
<td>1,133</td>
<td>286</td>
<td></td>
</tr>
<tr>
<td>Vive Mas Fuerte /Retardante</td>
<td>17,280</td>
<td>18,920</td>
<td>48,288</td>
<td>-</td>
<td>-%</td>
<td>75,144</td>
<td>123,432</td>
<td>362</td>
<td>362</td>
<td>91</td>
<td></td>
</tr>
<tr>
<td>Vive Mas Natural /Sensitivo</td>
<td>5,088</td>
<td>10,648</td>
<td>23,856</td>
<td>-</td>
<td>-%</td>
<td>37,800</td>
<td>61,656</td>
<td>179</td>
<td>179</td>
<td>45</td>
<td></td>
</tr>
<tr>
<td>Hypertension_Controlled Condition</td>
<td>3</td>
<td>-</td>
<td>3</td>
<td>-</td>
<td>0%</td>
<td>-</td>
<td>3</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Hypertension_Controlled Condition</td>
<td>3</td>
<td>-</td>
<td>3</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>3</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Implant 3 Insertion</td>
<td>-</td>
<td>29</td>
<td>-</td>
<td>72</td>
<td>(100)%</td>
<td>512</td>
<td>512</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Non-PSI Implant 3 Inserted</td>
<td>-</td>
<td>29</td>
<td>-</td>
<td>72</td>
<td>(100)%</td>
<td>512</td>
<td>512</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Implant 5 Insertion</td>
<td>42</td>
<td>165</td>
<td>91</td>
<td>5,000</td>
<td>2%</td>
<td>3,559</td>
<td>4,561</td>
<td>82</td>
<td>311</td>
<td>29</td>
<td></td>
</tr>
<tr>
<td>Jadelle</td>
<td>45</td>
<td>170</td>
<td>94</td>
<td>5,000</td>
<td>100%</td>
<td>3,650</td>
<td>4,720</td>
<td>85</td>
<td>321</td>
<td>30</td>
<td></td>
</tr>
<tr>
<td>(b) PSI Implant 5 Distributed Inserted</td>
<td>(3)</td>
<td>(5)</td>
<td>(3)</td>
<td>(11)</td>
<td>-%</td>
<td>(91)</td>
<td>(159)</td>
<td>(3)</td>
<td>(10)</td>
<td>(1)</td>
<td></td>
</tr>
<tr>
<td>Implant 5 Insertion</td>
<td>3</td>
<td>5</td>
<td>3</td>
<td>11</td>
<td>(73)%</td>
<td>91</td>
<td>159</td>
<td>3</td>
<td>11</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>PSI Implant 5 Inserted</td>
<td>3</td>
<td>5</td>
<td>3</td>
<td>11</td>
<td>(73)%</td>
<td>91</td>
<td>159</td>
<td>3</td>
<td>11</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Injectable 1 Provided</td>
<td>-</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>49</td>
<td>53</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Non-PSI Injectable 1 Provided</td>
<td>-</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>49</td>
<td>53</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>IUD 10</td>
<td>335</td>
<td>193</td>
<td>468</td>
<td>6,000</td>
<td>485%</td>
<td>2,328</td>
<td>5,372</td>
<td>421</td>
<td>1,938</td>
<td>173</td>
<td></td>
</tr>
<tr>
<td>Copper T 380</td>
<td>349</td>
<td>251</td>
<td>482</td>
<td>6,000</td>
<td>12%</td>
<td>3,985</td>
<td>8,488</td>
<td>434</td>
<td>1,995</td>
<td>179</td>
<td></td>
</tr>
<tr>
<td>(b) PSI IUD 10 Distributed Inserted</td>
<td>(14)</td>
<td>(59)</td>
<td>(14)</td>
<td>(349)</td>
<td>-%</td>
<td>(1,657)</td>
<td>(3,116)</td>
<td>(13)</td>
<td>(58)</td>
<td>(5)</td>
<td></td>
</tr>
<tr>
<td>IUD 10 Insertion</td>
<td>14</td>
<td>139</td>
<td>14</td>
<td>507</td>
<td>(97)%</td>
<td>3,326</td>
<td>6,296</td>
<td>14</td>
<td>64</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>Non-PSI IUD 10 Inserted</td>
<td>-</td>
<td>80</td>
<td>-</td>
<td>158</td>
<td>(100)%</td>
<td>1,669</td>
<td>3,180</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

---

3002 - 4/15/2020 10:09:35AM Page 70 of 115
### Monthly Distribution by Country

**Period:** 2  
**Year:** 2020

#### DISTRIBUTION 2/2020

<table>
<thead>
<tr>
<th>Product Description</th>
<th>DISTRIBUTION AVG PREV 3 MONTHS</th>
<th>DISTRIBUTION 2020</th>
<th>YTD DISTRIBUTION 2019</th>
<th>YTD % CHANGE</th>
<th>TOTAL DISTRIBUTION 2019</th>
<th>CUMULATIVE DISTRIBUTION</th>
<th>YTD USERS REACHED 2020</th>
<th>YTD DALY 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>PSI IUD 10 Inserted</td>
<td>14</td>
<td>59</td>
<td>14</td>
<td>(96)%</td>
<td>1,657</td>
<td>3,116</td>
<td>14</td>
<td>64</td>
</tr>
<tr>
<td>Lubricant</td>
<td>22,108</td>
<td>11,398</td>
<td>38,348</td>
<td>-</td>
<td>0%</td>
<td>42,312</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Vive Lub (sachet)</td>
<td>16,200</td>
<td>7,483</td>
<td>24,950</td>
<td>-</td>
<td>-%</td>
<td>28,600</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Vive Lub (tube)</td>
<td>5,062</td>
<td>3,174</td>
<td>10,940</td>
<td>-</td>
<td>-%</td>
<td>11,488</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Vive Lub Natural (tube)</td>
<td>846</td>
<td>741</td>
<td>2,458</td>
<td>-</td>
<td>-%</td>
<td>2,224</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Manual Vacuum Aspiration for PAC</td>
<td>-</td>
<td>22</td>
<td>65</td>
<td>(100)%</td>
<td>498</td>
<td>1,463</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>MVA for PAC</td>
<td>-</td>
<td>22</td>
<td>65</td>
<td>(100)%</td>
<td>498</td>
<td>1,463</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Misoprostol for PAC Provided</td>
<td>-</td>
<td>3</td>
<td>46</td>
<td>(100)%</td>
<td>278</td>
<td>569</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Non-PSI Misoprostol for PAC Provided</td>
<td>-</td>
<td>2</td>
<td>41</td>
<td>(100)%</td>
<td>241</td>
<td>491</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PSI Misoprostol for PAC Provided</td>
<td>-</td>
<td>1</td>
<td>5</td>
<td>(100)%</td>
<td>37</td>
<td>78</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Misoprostol for Safe Abortion</td>
<td>384</td>
<td>1,707</td>
<td>3,028</td>
<td>27,000</td>
<td>80%</td>
<td>30,612</td>
<td>39,568</td>
<td>159</td>
</tr>
<tr>
<td>Misoprostol for Safe Abortion (b)</td>
<td>384</td>
<td>1,707</td>
<td>3,028</td>
<td>27,000</td>
<td>78%</td>
<td>30,760</td>
<td>39,880</td>
<td>159</td>
</tr>
<tr>
<td>Non-PSI Misoprostol for Safe Abortion Dist Provided</td>
<td>-</td>
<td>(5)</td>
<td>(20)</td>
<td>-%</td>
<td>(148)</td>
<td>(312)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>OCs</td>
<td>2,444</td>
<td>1,883</td>
<td>8,024</td>
<td>-</td>
<td>0%</td>
<td>9,514</td>
<td>17,638</td>
<td>481</td>
</tr>
<tr>
<td>Segura Plus</td>
<td>2,444</td>
<td>1,883</td>
<td>8,024</td>
<td>-</td>
<td>0%</td>
<td>9,514</td>
<td>17,638</td>
<td>481</td>
</tr>
<tr>
<td>Non-PSI OCs Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>29</td>
<td>29</td>
<td>-</td>
</tr>
<tr>
<td>STI Screening</td>
<td>22</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>-</td>
<td>22</td>
<td>22</td>
</tr>
<tr>
<td>Treatment for Cervicitis</td>
<td>4</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>-</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>Treatment for Nonherpetic Genital Ulcer</td>
<td>2</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>-</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Treatment for Vaginitis</td>
<td>16</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>-</td>
<td>16</td>
<td>16</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
### Tubal Ligation

- **Tubal Ligation**
  - **2020**: 1
  - **% (2020)**: 100%
  - **2019**: 1
  - **% (2019)**: 100%

### Type 2 Diabetes_Controlled Condition

- **Type 2 Diabetes_Controlled Condition**
  - **2020**: 1
  - **% (2020)**: 0%
  - **2019**: 1
  - **% (2019)**: -

### Guatemala

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Condom</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>100%</td>
<td>1</td>
<td>6,050,778</td>
<td>150,841,319</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Combo Pack</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>100%</td>
<td>1</td>
<td>15,024</td>
<td>462,280</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Vive</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>100%</td>
<td>1</td>
<td>2,082,912</td>
<td>59,787,789</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Vive Amor</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>100%</td>
<td>1</td>
<td>3,237,840</td>
<td>70,365,759</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Vive Colors/Mas Colors</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>100%</td>
<td>1</td>
<td>409,146</td>
<td>14,714,920</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Vive Mas Fuerte /Retardante</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>100%</td>
<td>1</td>
<td>226,608</td>
<td>3,388,784</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Vive Mas Natural /Sensitivo</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>100%</td>
<td>1</td>
<td>67,224</td>
<td>1,150,093</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Vive Mas/Texturizado</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>100%</td>
<td>1</td>
<td>12,024</td>
<td>971,694</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>HIV Testing Services</td>
<td>127</td>
<td>120</td>
<td>230</td>
<td>5,327</td>
<td>586</td>
<td>(61)%</td>
<td>2,714</td>
<td>54,842</td>
<td>230</td>
<td>1</td>
<td>-</td>
</tr>
<tr>
<td>VCT Individual (HIV-Negative)</td>
<td>120</td>
<td>115</td>
<td>214</td>
<td>4,985</td>
<td>574</td>
<td>12/09</td>
<td>(63)%</td>
<td>2,622</td>
<td>53,947</td>
<td>214</td>
<td>1</td>
</tr>
<tr>
<td>VCT Individual (HIV-Positive)</td>
<td>7</td>
<td>5</td>
<td>16</td>
<td>342</td>
<td>12</td>
<td>12/09</td>
<td>33%</td>
<td>92</td>
<td>895</td>
<td>16</td>
<td>-</td>
</tr>
<tr>
<td>Injectable 1</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>45,139</td>
<td>5,945</td>
<td>(100)%</td>
<td>23,566</td>
<td>288,460</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Cyclofem</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>45,139</td>
<td>5,945</td>
<td>(100)%</td>
<td>23,566</td>
<td>288,460</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Lubricant</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>173,201</td>
<td>48,430</td>
<td>(100)%</td>
<td>107,862</td>
<td>1,658,856</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Vive Lub (sachet)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>75,425</td>
<td>32,466</td>
<td>(100)%</td>
<td>52,210</td>
<td>1,051,851</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Vive Lub (tube)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>22,504</td>
<td>4,238</td>
<td>(100)%</td>
<td>15,309</td>
<td>163,075</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Vive Lub (tube) 30ml</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>4,280</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Vive Lub Natural (sachet)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>44,544</td>
<td>7,650</td>
<td>(100)%</td>
<td>23,900</td>
<td>325,677</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Vive Lub Natural (tube)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>26,448</td>
<td>4,076</td>
<td>(100)%</td>
<td>16,443</td>
<td>118,253</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

---

3002 - 4/15/2020 10:09:35AM Page 72 of 115
## Monthly Distribution by Country

**Period:** 2  
**Year:** 2020

### Distribution

<table>
<thead>
<tr>
<th>Product / Intervention</th>
<th>Distribution</th>
<th>YTD Average</th>
<th>Change</th>
<th>YTD Users Reached</th>
<th>Cumulative</th>
</tr>
</thead>
<tbody>
<tr>
<td>OCs</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>86,510</td>
<td>6,020</td>
</tr>
<tr>
<td>Segura Plus</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>86,510</td>
<td>6,020</td>
</tr>
<tr>
<td>Referral to Emergency Contraception</td>
<td>1</td>
<td>1</td>
<td>-</td>
<td>12/11</td>
<td>(62)%</td>
</tr>
<tr>
<td>Referral to Implant 5 Insertion</td>
<td>4</td>
<td>3</td>
<td>5</td>
<td>13</td>
<td>(62)%</td>
</tr>
<tr>
<td>Referral to Implant 5 Insertion</td>
<td>4</td>
<td>3</td>
<td>5</td>
<td>13</td>
<td>(62)%</td>
</tr>
<tr>
<td>Referral to Injectable 1</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to Injectable 1</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to IUD 10 Insertion</td>
<td>3</td>
<td>3</td>
<td>6</td>
<td>9</td>
<td>(33)%</td>
</tr>
<tr>
<td>Referral to IUD 10 Insertion</td>
<td>3</td>
<td>3</td>
<td>6</td>
<td>9</td>
<td>(33)%</td>
</tr>
<tr>
<td>Referral to Linkage to HIV Care</td>
<td>7</td>
<td>5</td>
<td>16</td>
<td>274</td>
<td>12</td>
</tr>
<tr>
<td>Referral to Linkage to HIV Care</td>
<td>7</td>
<td>5</td>
<td>16</td>
<td>274</td>
<td>12</td>
</tr>
<tr>
<td>Referral to Vasectomy</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to Vasectomy</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

### Guatemala SA

<table>
<thead>
<tr>
<th>Product / Intervention</th>
<th>Distribution</th>
<th>YTD Average</th>
<th>Change</th>
<th>YTD Users Reached</th>
<th>Cumulative</th>
</tr>
</thead>
<tbody>
<tr>
<td>Condom</td>
<td>1,222,160</td>
<td>938,597</td>
<td>1,494,760</td>
<td>5,328</td>
<td>27955%</td>
</tr>
<tr>
<td>Combo Pack</td>
<td>1,760</td>
<td>1,973</td>
<td>4,960</td>
<td>-</td>
<td>-%</td>
</tr>
<tr>
<td>Vive</td>
<td>282,192</td>
<td>325,408</td>
<td>443,712</td>
<td>-</td>
<td>-%</td>
</tr>
<tr>
<td>Vive Amor</td>
<td>826,704</td>
<td>489,088</td>
<td>826,704</td>
<td>5,328</td>
<td>15,416%</td>
</tr>
<tr>
<td>Vive Colors/Mas Colors</td>
<td>78,240</td>
<td>72,688</td>
<td>131,520</td>
<td>-</td>
<td>-%</td>
</tr>
<tr>
<td>Vive Mas Fuerte/Retardante</td>
<td>24,600</td>
<td>43,160</td>
<td>67,200</td>
<td>-</td>
<td>-%</td>
</tr>
<tr>
<td>Vive Mas Natural/Sensitivo</td>
<td>8,664</td>
<td>6,280</td>
<td>20,664</td>
<td>-</td>
<td>-%</td>
</tr>
<tr>
<td>Emergency Contraception Provided</td>
<td>-</td>
<td>1</td>
<td>-</td>
<td>3</td>
<td>(100)%</td>
</tr>
<tr>
<td>Non-PSI Emergency Contraception Provided</td>
<td>-</td>
<td>1</td>
<td>-</td>
<td>3</td>
<td>(100)%</td>
</tr>
<tr>
<td>Implant 5</td>
<td>13</td>
<td>(13)</td>
<td>61</td>
<td>9,000</td>
<td>(734)</td>
</tr>
</tbody>
</table>

### Notes

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

---

3002 - 4/15/2020 10:09:35AM  
Page 73 of 115
### Monthly Distribution by Country

**Period:** 2

**Year:** 2020

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Jadelle</strong></td>
<td>13</td>
<td>39</td>
<td>61</td>
<td>9,000</td>
<td>10</td>
<td>7/17</td>
<td>510%</td>
<td>590</td>
<td>4,323</td>
<td>55</td>
<td>209</td>
<td>43</td>
</tr>
<tr>
<td>(b) PSI Implant 5 Distributed Inserted</td>
<td>-</td>
<td>(52)</td>
<td>-</td>
<td>-</td>
<td>(744)</td>
<td>-%</td>
<td>(3,209)</td>
<td>(5,279)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Implant 5 Insertion</td>
<td>-</td>
<td>332</td>
<td>-</td>
<td>-</td>
<td>1,635</td>
<td>(100)%</td>
<td>17,001</td>
<td>32,707</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Non-PSI Implant 5 Inserted</td>
<td>-</td>
<td>280</td>
<td>-</td>
<td>-</td>
<td>891</td>
<td>(100)%</td>
<td>13,792</td>
<td>27,428</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PSI Implant 5 Inserted</td>
<td>-</td>
<td>52</td>
<td>-</td>
<td>-</td>
<td>744</td>
<td>(100)%</td>
<td>3,209</td>
<td>5,279</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Injectable 1</td>
<td>958</td>
<td>2,713</td>
<td>2,134</td>
<td>-</td>
<td>7</td>
<td>30386%</td>
<td>19,027</td>
<td>21,578</td>
<td>148</td>
<td>148</td>
<td>25</td>
<td></td>
</tr>
<tr>
<td>Cyclofem</td>
<td>958</td>
<td>2,743</td>
<td>2,134</td>
<td>-</td>
<td>154</td>
<td>7/17</td>
<td>1,286%</td>
<td>21,521</td>
<td>25,782</td>
<td>148</td>
<td>148</td>
<td>25</td>
</tr>
<tr>
<td>(b) PSI Injectable 1 Distributed Provided</td>
<td>-</td>
<td>(30)</td>
<td>-</td>
<td>-</td>
<td>(147)</td>
<td>-%</td>
<td>(2,494)</td>
<td>(4,204)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Injectable 1 Provided</td>
<td>-</td>
<td>2,827</td>
<td>-</td>
<td>-</td>
<td>3,043</td>
<td>(100)%</td>
<td>58,151</td>
<td>109,003</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Non-PSI Injectable 1 Provided</td>
<td>-</td>
<td>2,797</td>
<td>-</td>
<td>-</td>
<td>2,896</td>
<td>(100)%</td>
<td>55,657</td>
<td>104,799</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PSI Injectable 1 Provided</td>
<td>-</td>
<td>30</td>
<td>-</td>
<td>-</td>
<td>147</td>
<td>(100)%</td>
<td>2,494</td>
<td>4,204</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Injectable 2 Provided</td>
<td>-</td>
<td>1,586</td>
<td>-</td>
<td>-</td>
<td>2,916</td>
<td>(100)%</td>
<td>34,874</td>
<td>69,301</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Non-PSI Injectable 2 Provided</td>
<td>-</td>
<td>1,586</td>
<td>-</td>
<td>-</td>
<td>2,916</td>
<td>(100)%</td>
<td>34,874</td>
<td>69,301</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Injectable 3-IM</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>(41)</td>
<td>(41)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>(b) PSI Injectable 3 IM Distributed Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>(41)</td>
<td>(41)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Injectable 3-IM Provided</td>
<td>-</td>
<td>8,200</td>
<td>-</td>
<td>-</td>
<td>30,329</td>
<td>(100)%</td>
<td>206,567</td>
<td>431,286</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Non-PSI Injectable 3 IM Provided</td>
<td>-</td>
<td>8,200</td>
<td>-</td>
<td>-</td>
<td>30,329</td>
<td>(100)%</td>
<td>206,526</td>
<td>431,245</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PSI Injectable 3 IM Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>41</td>
<td>41</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>IUD 10</td>
<td>183</td>
<td>(53)</td>
<td>264</td>
<td>-</td>
<td>(1,030)</td>
<td>0%</td>
<td>(2,429)</td>
<td>2,223</td>
<td>238</td>
<td>1,093</td>
<td>215</td>
<td></td>
</tr>
<tr>
<td>Copper T 380</td>
<td>183</td>
<td>95</td>
<td>264</td>
<td>-</td>
<td>324</td>
<td>7/17</td>
<td>(19)%</td>
<td>4,020</td>
<td>15,471</td>
<td>238</td>
<td>1,093</td>
<td>215</td>
</tr>
<tr>
<td>Copper T 380 Postpartum</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>6</td>
<td>7/17</td>
<td>(100)%</td>
<td>2,066</td>
<td>3,150</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>(b) PSI IUD 10 Distributed Inserted</td>
<td>-</td>
<td>(147)</td>
<td>-</td>
<td>-</td>
<td>(1,360)</td>
<td>-%</td>
<td>(8,515)</td>
<td>(16,398)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>IUD 10 Insertion</td>
<td>-</td>
<td>1,216</td>
<td>-</td>
<td>-</td>
<td>1,541</td>
<td>(100)%</td>
<td>16,269</td>
<td>28,079</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Non-PSI IUD 10 Inserted</td>
<td>-</td>
<td>1,069</td>
<td>-</td>
<td>-</td>
<td>181</td>
<td>(100)%</td>
<td>7,754</td>
<td>11,681</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
## Monthly Distribution by Country

### POPULATION SERVICES INTERNATIONAL

**Period:** 2  
**Year:** 2020

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>PSI IUD 10 Inserted</td>
<td>-</td>
<td>147</td>
<td>-</td>
<td>1,360</td>
<td>(100)%</td>
<td>8,515</td>
<td>16,398</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>IUD 5</td>
<td>-</td>
<td>138</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>415</td>
<td>1,417</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>IUD Sleek</td>
<td>-</td>
<td>138</td>
<td>-</td>
<td>-</td>
<td>7/17</td>
<td>-%</td>
<td>415</td>
<td>1,417</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Lubricant</td>
<td>12,572</td>
<td>11,181</td>
<td>20,178</td>
<td>8</td>
<td>7/17</td>
<td>-%</td>
<td>53,100</td>
<td>61,200</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Vive Lub (sachet)</td>
<td>5,300</td>
<td>5,050</td>
<td>8,100</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>15,708</td>
<td>23,946</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Vive Lub (tube)</td>
<td>6,362</td>
<td>2,733</td>
<td>8,164</td>
<td>-</td>
<td>7/17</td>
<td>-%</td>
<td>12,946</td>
<td>16,922</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Vive Lub Natural (tube)</td>
<td>910</td>
<td>3,398</td>
<td>3,914</td>
<td>8</td>
<td>7/17</td>
<td>48,825%</td>
<td>12,946</td>
<td>16,922</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Manual Vacuum Aspiration for PAC</td>
<td>-</td>
<td>31</td>
<td>-</td>
<td>-</td>
<td>583</td>
<td>(100)%</td>
<td>7,878</td>
<td>12,779</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>MVA for PAC</td>
<td>-</td>
<td>31</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>(100)%</td>
<td>7,878</td>
<td>12,779</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Misoprostol for PAC Provided</td>
<td>-</td>
<td>3</td>
<td>-</td>
<td>-</td>
<td>899</td>
<td>(100)%</td>
<td>5,536</td>
<td>9,624</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Non-PSI Misoprostol for PAC Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>4</td>
<td>(100)%</td>
<td>1,061</td>
<td>3,301</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PSI Misoprostol for PAC Provided</td>
<td>-</td>
<td>3</td>
<td>-</td>
<td>-</td>
<td>895</td>
<td>(100)%</td>
<td>4,475</td>
<td>6,323</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Misoprostol for Safe Abortion</td>
<td>480</td>
<td>10,575</td>
<td>21,920</td>
<td>110,000</td>
<td>13,188</td>
<td>66%</td>
<td>58,998</td>
<td>137,646</td>
<td>1,151</td>
<td>-</td>
<td>34</td>
</tr>
<tr>
<td>Misoprostol for Safe Abortion</td>
<td>480</td>
<td>10,587</td>
<td>21,920</td>
<td>110,000</td>
<td>16,768</td>
<td>3/18</td>
<td>31%</td>
<td>76,898</td>
<td>162,938</td>
<td>1,151</td>
<td>-</td>
</tr>
<tr>
<td>(b)PSI Misoprostol for Safe Abortion Dist Provided</td>
<td>-</td>
<td>(12)</td>
<td>-</td>
<td>-</td>
<td>(3,580)</td>
<td>-%</td>
<td>(17,900)</td>
<td>(25,292)</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>OCs</td>
<td>5,710</td>
<td>7,539</td>
<td>14,330</td>
<td>-</td>
<td>125</td>
<td>11364%</td>
<td>36,460</td>
<td>49,770</td>
<td>860</td>
<td>860</td>
<td>140</td>
</tr>
<tr>
<td>(b)PSI OCs Distributed Provided</td>
<td>-</td>
<td>(31)</td>
<td>-</td>
<td>-</td>
<td>(29)</td>
<td>-%</td>
<td>(1,403)</td>
<td>(3,723)</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Segura Plus</td>
<td>5,710</td>
<td>7,570</td>
<td>14,330</td>
<td>-</td>
<td>154</td>
<td>7/17</td>
<td>9,205%</td>
<td>37,863</td>
<td>53,493</td>
<td>860</td>
<td>860</td>
</tr>
<tr>
<td>OCs Provided</td>
<td>-</td>
<td>1,236</td>
<td>-</td>
<td>1,675</td>
<td>(100)%</td>
<td>27,226</td>
<td>68,131</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Non-PSI OCs Provided</td>
<td>-</td>
<td>1,205</td>
<td>-</td>
<td>-</td>
<td>1,646</td>
<td>(100)%</td>
<td>25,823</td>
<td>64,408</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PSI OCs Provided</td>
<td>-</td>
<td>31</td>
<td>-</td>
<td>29</td>
<td>(100)%</td>
<td>1,403</td>
<td>3,723</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>SDM (Cycle Beads) Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>(100)%</td>
<td>4</td>
<td>10</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Non-PSI SDM (Cycle Beads) Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>(100)%</td>
<td>4</td>
<td>10</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Tubal Ligation</td>
<td>-</td>
<td>222</td>
<td>-</td>
<td>339</td>
<td>(100)%</td>
<td>8,288</td>
<td>18,280</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

3002 - 4/15/2020 10:09:35AM

Page 75 of 115
### Monthly Distribution by Country

**Period:** 2  
**Year:** 2020

<table>
<thead>
<tr>
<th>DISTRIBUTION 2/2020</th>
<th>MONTHLY AVG PREV 3 MONTHS</th>
<th>DISTRIBUTION TARGET 2020</th>
<th>DISTRIBUTION 2019</th>
<th>YTD % CHANGE</th>
<th>TOTAL DISTRIBUTION 2019</th>
<th>CUMULATIVE DISTRIBUTION (a)</th>
<th>YTD USERS REACHED 2020</th>
<th>YTD DALY 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tubal Ligation</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>(100)%</td>
<td>8,288</td>
<td>18,280</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Vasectomy</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>(100)%</td>
<td>290</td>
<td>531</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Vasectomy</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>(100)%</td>
<td>290</td>
<td>531</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Honduras</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>850</td>
<td>123</td>
<td></td>
</tr>
<tr>
<td>Condom</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>(100)%</td>
<td>4,096</td>
<td>20,144</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Combo-Pack Lub Fresa</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>(100)%</td>
<td>290</td>
<td>531</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Combo-Pack Lub Natural</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>531</td>
<td>290</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Vive</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>10/10</td>
<td>(736)</td>
<td>26,912</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Vive Amor</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>(100)%</td>
<td>1,075,104</td>
<td>25,213,976</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Vive Colors/Mas Colors</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>4/02</td>
<td>308,880</td>
<td>8,922,718</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Vive Mas Fuerte /Retardante</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>8/04</td>
<td>89,136</td>
<td>1,210,392</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Vive Mas Natural /Sensitivo</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>8/04</td>
<td>23,688</td>
<td>513,506</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Vive Mas/Texturizado</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>8/04</td>
<td>720</td>
<td>517,077</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>HIV Testing Services</td>
<td>254</td>
<td>257</td>
<td>512</td>
<td>2,081</td>
<td>3,470</td>
<td>19,099</td>
<td>512</td>
<td>1</td>
</tr>
<tr>
<td>VCT Individual (HIV-Negative)</td>
<td>238</td>
<td>244</td>
<td>481</td>
<td>1,946</td>
<td>3,280</td>
<td>18,604</td>
<td>481</td>
<td>1</td>
</tr>
<tr>
<td>VCT Individual (HIV-Positive)</td>
<td>16</td>
<td>13</td>
<td>31</td>
<td>135</td>
<td>190</td>
<td>495</td>
<td>31</td>
<td>-</td>
</tr>
<tr>
<td>Implant 3 Insertion</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>60</td>
<td>57</td>
<td>121</td>
<td>3</td>
<td>8</td>
</tr>
<tr>
<td>Non-PSI Implant 3 Inserted</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>60</td>
<td>57</td>
<td>121</td>
<td>3</td>
<td>8</td>
</tr>
<tr>
<td>Injectable 1</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>3,337</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Injectable 1 Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>3,337</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Injectable 3-IM Provided</td>
<td>3</td>
<td>2</td>
<td>4</td>
<td>2</td>
<td>100%</td>
<td>28</td>
<td>110</td>
<td>1</td>
</tr>
<tr>
<td>Non-PSI Injectable 3 IM Provided</td>
<td>3</td>
<td>2</td>
<td>4</td>
<td>2</td>
<td>100%</td>
<td>28</td>
<td>110</td>
<td>1</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
<table>
<thead>
<tr>
<th>Product</th>
<th>DISTRIBUTION 2/2020</th>
<th>MONTHLY AVG PREV 3 MONTHS</th>
<th>YTD DISTRIBUTION 2020</th>
<th>DISTRIBUTION TARGET 2020</th>
<th>YTD DISTRIBUTION 2019</th>
<th>LAUNCH DATE</th>
<th>YTD % CHANGE</th>
<th>TOTAL DISTRIBUTION 2019</th>
<th>CUMULATIVE DISTRIBUTION</th>
<th>%YTD USERS REACHED 2020</th>
<th>YTD CYP</th>
<th>YTD DALY</th>
</tr>
</thead>
<tbody>
<tr>
<td>IUD 10</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>(b)PSI IUD 10 Distributed Inserted</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td>-</td>
<td>(91)</td>
<td>(91)</td>
<td>(664)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>IUD 10 Insertion</td>
<td>13</td>
<td>11</td>
<td>20</td>
<td>60</td>
<td>92</td>
<td>(78)%</td>
<td>263</td>
<td>1,291</td>
<td>20</td>
<td>92</td>
<td>12</td>
<td>12</td>
</tr>
<tr>
<td>Non-PSI IUD 10 Inserted</td>
<td>13</td>
<td>11</td>
<td>20</td>
<td>60</td>
<td>1</td>
<td>1,900%</td>
<td>172</td>
<td>627</td>
<td>20</td>
<td>92</td>
<td>12</td>
<td>12</td>
</tr>
<tr>
<td>PSI IUD 10 Inserted</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>91</td>
<td>(100)%</td>
<td>-</td>
<td>12,460</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Lubricant</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>157,781</td>
<td>12,460</td>
<td>(100)%</td>
<td>53,401</td>
<td>960,148</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Vive Lub (sachet)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>68,875</td>
<td>4,650</td>
<td>(100)%</td>
<td>22,600</td>
<td>602,279</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Vive Lub (tube)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>22,451</td>
<td>4,722</td>
<td>(100)%</td>
<td>11,675</td>
<td>106,475</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Vive Lub (tube) 30ml</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>11,280</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Vive Lub Natural (sachet)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>37,377</td>
<td>3,088</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Vive Lub Natural (tube)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>17,798</td>
<td>3,088</td>
<td>(100)%</td>
<td>6,450</td>
<td>64,170</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to Implant 3 Insertion</td>
<td>155</td>
<td>127</td>
<td>213</td>
<td>-</td>
<td>311</td>
<td>(32)%</td>
<td>2,064</td>
<td>3,732</td>
<td>213</td>
<td>266</td>
<td>36</td>
<td>36</td>
</tr>
<tr>
<td>Referral to Injectable 3</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>2</td>
<td>2</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to Injectable 3</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>2</td>
<td>2</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to IUD 10 Insertion</td>
<td>176</td>
<td>92</td>
<td>210</td>
<td>-</td>
<td>135</td>
<td>56%</td>
<td>1,021</td>
<td>1,231</td>
<td>210</td>
<td>483</td>
<td>61</td>
<td>61</td>
</tr>
<tr>
<td>Referral to IUD 10 Insertion</td>
<td>176</td>
<td>92</td>
<td>210</td>
<td>-</td>
<td>135</td>
<td>56%</td>
<td>1,021</td>
<td>1,231</td>
<td>210</td>
<td>483</td>
<td>61</td>
<td>61</td>
</tr>
<tr>
<td>Referral to Linkage to HIV Care</td>
<td>15</td>
<td>6</td>
<td>20</td>
<td>108</td>
<td>8</td>
<td>150%</td>
<td>110</td>
<td>301</td>
<td>20</td>
<td>-</td>
<td>13</td>
<td>13</td>
</tr>
<tr>
<td>Referral to Linkage to HIV Care</td>
<td>15</td>
<td>6</td>
<td>20</td>
<td>108</td>
<td>8</td>
<td>150%</td>
<td>110</td>
<td>301</td>
<td>20</td>
<td>-</td>
<td>13</td>
<td>13</td>
</tr>
<tr>
<td>Honduras SA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5,763</td>
<td>3,423</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Condom</td>
<td>345,984</td>
<td>368,104</td>
<td>768,376</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>1,824,320</td>
<td>2,592,696</td>
<td>5,763</td>
<td>5,763</td>
<td>3,423</td>
<td>3,423</td>
</tr>
<tr>
<td>Combo-Pack Lub Fresa</td>
<td>624</td>
<td>672</td>
<td>784</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>3,200</td>
<td>3,984</td>
<td>6</td>
<td>6</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Vive</td>
<td>105,504</td>
<td>88,320</td>
<td>197,904</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>469,632</td>
<td>667,536</td>
<td>1,484</td>
<td>1,484</td>
<td>882</td>
<td>882</td>
</tr>
<tr>
<td>Vive Amor</td>
<td>181,440</td>
<td>208,176</td>
<td>424,848</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>1,018,464</td>
<td>1,443,312</td>
<td>3,186</td>
<td>3,186</td>
<td>1,893</td>
<td>1,893</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
### Monthly Distribution by Country

**Period:** 2  
**Year:** 2020

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Vive Colors/Mas Colors</td>
<td>43,968</td>
<td>50,960</td>
<td>103,128</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>240,792</td>
<td>343,920</td>
<td>773</td>
<td>773</td>
</tr>
<tr>
<td>Vive Mas Fuerte /Retardante</td>
<td>9,744</td>
<td>16,576</td>
<td>29,304</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>78,144</td>
<td>107,448</td>
<td>220</td>
<td>220</td>
</tr>
<tr>
<td>Vive Mas Natural /Sensitivo</td>
<td>4,704</td>
<td>3,400</td>
<td>12,408</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>14,888</td>
<td>26,496</td>
<td>93</td>
<td>93</td>
</tr>
<tr>
<td>Lubricant</td>
<td>12,424</td>
<td>7,773</td>
<td>17,891</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td></td>
<td>44,462</td>
<td>62,353</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Vive Lub (sachet)</td>
<td>1,950</td>
<td>3,417</td>
<td>4,150</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>23,000</td>
<td>27,150</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Vive Lub (tube)</td>
<td>3,041</td>
<td>2,360</td>
<td>5,032</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>13,594</td>
<td>18,626</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Vive Lub Natural (sachet)</td>
<td>5,800</td>
<td>983</td>
<td>6,150</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>2,650</td>
<td>8,800</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Vive Lub Natural (tube)</td>
<td>1,633</td>
<td>1,013</td>
<td>2,559</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>5,218</td>
<td>7,777</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

| Country: Kazakhstan                   |                     |                           |                        |                          |                        |              |               |                          |                          |                          |                      |
|                                      |                     |                           |                        |                          |                        |              |               |                          |                          |                          |                      |
| Kazakh                               | 39                  | 136                       |                        |                          |                        |              |               |                          |                          |                          |                      |
| Free Condom                          | 5,201               | 2,095                     | 5,201                  | -                        | -                      | 0%           |               | 93,799                   | 772,550                  | 39                       | 39                   |
| Generic Male Condom                  | 5,201               | 2,095                     | 5,201                  | -                        | -                      | 8/16         | -             | 93,799                   | 772,550                  | 39                       | 39                   |
| HIV Self-Testing Kit                 | -                   | 129                       | 387                    | 375                      | -                      | 0%           |               | 113                      | 500                      | 348                      | -                    |
| HIV Self-Testing Kit (Oral Fluid)    | -                   | -                         | -                      | 375                      | -                      | -            | -             | -                        | -                        | -                        | -                    |
| INSTI HIVST (Blood based)           | -                   | 129                       | 387                    | -                        | -                      | -            | -             | 113                      | 500                      | 348                      | -                    |
| HIV Testing Services                 | 106                 | 107                       | 225                    | 1,154                    | 492                    | (54)%        |               | 1,774                    | 7,902                    | 225                      | -                    |
| VCT Individual (HIV-Negative)        | 87                  | 86                        | 191                    | 1,067                    | 468                    | (59)%        |               | 1,555                    | 7,438                    | 191                      | -                    |
| VCT Individual (HIV-Positive)        | 19                  | 21                        | 34                     | 87                       | 24                     | 42%          |               | 219                      | 464                      | 34                       | -                    |
| Referral to HIV Testing Services     | -                   | -                         | -                      | -                        | -                      | 0%           |               | 11                       | 5,163                    | -                        | -                    |
| Referral to HIV Testing Services     | -                   | -                         | -                      | -                        | -                      | -            | -             | 11                       | 5,163                    | -                        | -                    |
| Referral to Linkage to HIV Care      | 72                  | 84                        | 144                    | 204                      | 120                    | 20%          |               | 1,065                    | 2,925                    | 144                      | -                    |
| Referral to Linkage to HIV Care      | 72                  | 84                        | 144                    | 204                      | 120                    | 20%          |               | 1,065                    | 2,925                    | 144                      | -                    |
| Referral to Opioid Treatment         | 1                   | 3                         | 1                      | -                        | 5                      | (80)%        |               | 33                       | 127                      | 1                        | -                    |
| Referral to Opioid Treatment         | 1                   | 3                         | 1                      | -                        | 5                      | (80)%        |               | 33                       | 127                      | 1                        | -                    |
| TB Diagnosis                         | 1                   | 2                         | 1                      | -                        | -                      | 0%           |               | 26                       | 71                       | 1                        | -                    |

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
<table>
<thead>
<tr>
<th>Product</th>
<th>avg prev 3 months</th>
<th>distribution 2020</th>
<th>distribution target 2020</th>
<th>prev 3 months</th>
<th>delivery date</th>
<th>ytd % change</th>
<th>total distribution 2019</th>
<th>cumulative distribution</th>
<th>ytd users reached 2020</th>
<th>ytd DALY 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>TB Diagnosis</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td></td>
<td>-</td>
<td>26</td>
<td>71</td>
<td>1</td>
<td>-</td>
</tr>
<tr>
<td>TB Screening</td>
<td>110</td>
<td>292</td>
<td>268</td>
<td>1,212</td>
<td>374</td>
<td>(28)%</td>
<td>2,149</td>
<td>8,046</td>
<td>268</td>
<td>-</td>
</tr>
<tr>
<td>TB Screening</td>
<td>110</td>
<td>292</td>
<td>268</td>
<td>1,212</td>
<td>374</td>
<td>(28)%</td>
<td>2,149</td>
<td>8,046</td>
<td>268</td>
<td>-</td>
</tr>
<tr>
<td>Kyrgyzstan</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Free Condom</td>
<td>7,024</td>
<td>2,868</td>
<td>11,624</td>
<td>110</td>
<td></td>
<td>0%</td>
<td>36,412</td>
<td>78,180</td>
<td>87</td>
<td>87</td>
</tr>
<tr>
<td>Generic Male Condom</td>
<td>7,024</td>
<td>2,868</td>
<td>11,624</td>
<td>110</td>
<td></td>
<td>0%</td>
<td>36,412</td>
<td>78,180</td>
<td>87</td>
<td>87</td>
</tr>
<tr>
<td>HIV Self-Testing Kit</td>
<td>1,690</td>
<td>134</td>
<td>2,090</td>
<td>2,975</td>
<td>3,750</td>
<td>-</td>
<td>804</td>
<td>2,894</td>
<td>1,881</td>
<td>-</td>
</tr>
<tr>
<td>HIV Self-Testing Kit (Oral Fluid)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ORAQUICK HIV Self-Testing Kit (Saliva based)</td>
<td>1,690</td>
<td>134</td>
<td>2,090</td>
<td>2,975</td>
<td>3,750</td>
<td>-</td>
<td>804</td>
<td>2,894</td>
<td>1,881</td>
<td>-</td>
</tr>
<tr>
<td>HIV Testing Services</td>
<td>309</td>
<td>290</td>
<td>568</td>
<td>3,000</td>
<td>3,161</td>
<td>(82)%</td>
<td>12,569</td>
<td>51,613</td>
<td>568</td>
<td>-</td>
</tr>
<tr>
<td>VCT Individual (HIV-Negative)</td>
<td>282</td>
<td>261</td>
<td>519</td>
<td>2,550</td>
<td>3,087</td>
<td>(83)%</td>
<td>12,148</td>
<td>50,507</td>
<td>519</td>
<td>-</td>
</tr>
<tr>
<td>VCT Individual (HIV-Positive)</td>
<td>27</td>
<td>30</td>
<td>49</td>
<td>450</td>
<td>74</td>
<td>(34)%</td>
<td>421</td>
<td>1,106</td>
<td>49</td>
<td>-</td>
</tr>
<tr>
<td>Lubricant</td>
<td>800</td>
<td>1,335</td>
<td>800</td>
<td>800</td>
<td>1,335</td>
<td>-</td>
<td>6,012</td>
<td>7,812</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Personal lubricants water based 4.5 g</td>
<td>800</td>
<td>1,335</td>
<td>800</td>
<td>800</td>
<td>1,335</td>
<td>-</td>
<td>6,012</td>
<td>7,812</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to Linkage to HIV Care</td>
<td>51</td>
<td>60</td>
<td>103</td>
<td>303</td>
<td>303</td>
<td>27%</td>
<td>610</td>
<td>2,231</td>
<td>103</td>
<td>108</td>
</tr>
<tr>
<td>Referral to Linkage to HIV Care</td>
<td>51</td>
<td>60</td>
<td>103</td>
<td>303</td>
<td>303</td>
<td>27%</td>
<td>610</td>
<td>2,231</td>
<td>103</td>
<td>108</td>
</tr>
<tr>
<td>Referral to Opioid Treatment</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>3</td>
<td></td>
<td>(100)%</td>
<td>3</td>
<td>193</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to Opioid Treatment</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>3</td>
<td></td>
<td>(100)%</td>
<td>3</td>
<td>193</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>TB Diagnosis</td>
<td>1</td>
<td>-</td>
<td>2</td>
<td>2</td>
<td></td>
<td>0%</td>
<td>8</td>
<td>48</td>
<td>2</td>
<td>-</td>
</tr>
<tr>
<td>TB Diagnosis</td>
<td>1</td>
<td>-</td>
<td>2</td>
<td>2</td>
<td></td>
<td>-</td>
<td>8</td>
<td>48</td>
<td>2</td>
<td>-</td>
</tr>
<tr>
<td>TB Screening</td>
<td>84</td>
<td>152</td>
<td>192</td>
<td>902</td>
<td>191</td>
<td>1%</td>
<td>1,701</td>
<td>8,484</td>
<td>192</td>
<td>-</td>
</tr>
<tr>
<td>TB Screening</td>
<td>84</td>
<td>152</td>
<td>192</td>
<td>902</td>
<td>191</td>
<td>1%</td>
<td>1,701</td>
<td>8,484</td>
<td>192</td>
<td>-</td>
</tr>
<tr>
<td>Laos</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Condom</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale. (b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Monthly Distribution by Country

**Period:** 2

**Year:** 2020

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>No 1 Condom Grp</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>122,400</td>
<td>11/10</td>
<td>(100)%</td>
<td>330,624</td>
<td>5,239,492</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>No 1 Condom Orange</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>908,000</td>
<td>-</td>
<td>-%</td>
<td>1,341,792</td>
<td>17,581,704</td>
<td>1,296</td>
<td>1,296</td>
<td>368</td>
</tr>
<tr>
<td>No 1 Condom Strw</td>
<td>-</td>
<td>111,456</td>
<td>172,800</td>
<td>1,200,000</td>
<td>8/08</td>
<td>(50)%</td>
<td>256,176</td>
<td>308,016</td>
<td>389</td>
<td>389</td>
<td>110</td>
</tr>
<tr>
<td>No 1 Condom Super Thin</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>392,000</td>
<td>-</td>
<td>-%</td>
<td>146,664</td>
<td>146,664</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>No.1 Orange</td>
<td>-</td>
<td>21,024</td>
<td>51,840</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>1,200,000</td>
<td>1,200,000</td>
<td>111,456</td>
<td>111,456</td>
<td>-</td>
</tr>
<tr>
<td>No.1 Super Thin</td>
<td>-</td>
<td>9,492</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>392,000</td>
<td>392,000</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Fever Cases Attended</td>
<td>-</td>
<td>6,089</td>
<td>5,051</td>
<td>50,000</td>
<td>8,341</td>
<td>(39)%</td>
<td>73,124</td>
<td>132,327</td>
<td>5,051</td>
<td>5,051</td>
<td>-</td>
</tr>
<tr>
<td>Fever Cases Attended</td>
<td>-</td>
<td>6,089</td>
<td>5,051</td>
<td>50,000</td>
<td>8,341</td>
<td>(39)%</td>
<td>73,124</td>
<td>132,327</td>
<td>5,051</td>
<td>5,051</td>
<td>-</td>
</tr>
<tr>
<td>Fever Cases Tested with Microscopy</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>6,737</td>
<td>6,737</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Fever Cases Tested with Microscopy</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>6,737</td>
<td>6,737</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Fever Cases Tested with RDTs</td>
<td>-</td>
<td>6,089</td>
<td>5,051</td>
<td>50,000</td>
<td>8,341</td>
<td>(39)%</td>
<td>73,124</td>
<td>132,297</td>
<td>5,051</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>HIV Testing Services</td>
<td>554</td>
<td>386</td>
<td>662</td>
<td>6,142</td>
<td>894</td>
<td>(26)%</td>
<td>5,953</td>
<td>26,012</td>
<td>662</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>VCT Individual (HIV-Negative)</td>
<td>551</td>
<td>385</td>
<td>658</td>
<td>6,112</td>
<td>892</td>
<td>(26)%</td>
<td>5,922</td>
<td>25,804</td>
<td>658</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>VCT Individual (HIV-Positive)</td>
<td>3</td>
<td>1</td>
<td>4</td>
<td>30</td>
<td>2</td>
<td>100%</td>
<td>31</td>
<td>208</td>
<td>4</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Implant 3 Insertion</td>
<td>894</td>
<td>499</td>
<td>1,302</td>
<td>11,844</td>
<td>1,919</td>
<td>(32)%</td>
<td>9,352</td>
<td>34,951</td>
<td>1,302</td>
<td>3,255</td>
<td>810</td>
</tr>
<tr>
<td>Non-PSI Implant 3 Inserted</td>
<td>894</td>
<td>499</td>
<td>1,302</td>
<td>11,844</td>
<td>1,919</td>
<td>3/16</td>
<td>(32)%</td>
<td>9,352</td>
<td>34,951</td>
<td>1,302</td>
<td>3,255</td>
</tr>
<tr>
<td>Injectable 3-IM Provided</td>
<td>1,775</td>
<td>869</td>
<td>2,289</td>
<td>18,000</td>
<td>3,575</td>
<td>(36)%</td>
<td>17,268</td>
<td>55,428</td>
<td>572</td>
<td>572</td>
<td>105</td>
</tr>
<tr>
<td>Non-PSI Injectable 3 IM Provided</td>
<td>1,775</td>
<td>869</td>
<td>2,289</td>
<td>18,000</td>
<td>3,575</td>
<td>3/16</td>
<td>(36)%</td>
<td>17,268</td>
<td>55,428</td>
<td>572</td>
<td>572</td>
</tr>
<tr>
<td>IUD 10</td>
<td>-</td>
<td>(19)</td>
<td>-</td>
<td>-</td>
<td>(123)</td>
<td>0%</td>
<td>(614)</td>
<td>3,921</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>(b) PSI IUD 10 Distributed Inserted</td>
<td>-</td>
<td>-</td>
<td>800</td>
<td>-</td>
<td>8/13</td>
<td>-%</td>
<td>-</td>
<td>4,795</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>IUD 10 Insertion</td>
<td>292</td>
<td>281</td>
<td>490</td>
<td>10,340</td>
<td>1,616</td>
<td>(70)%</td>
<td>6,645</td>
<td>52,824</td>
<td>490</td>
<td>2,254</td>
<td>523</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-PSI IUD 10 Inserted</td>
<td>292</td>
<td>262</td>
<td>490</td>
<td>9,540</td>
<td>1,493</td>
<td>(67)%</td>
<td>6,031</td>
<td>51,950</td>
</tr>
<tr>
<td>PSI IUD 10 Inserted</td>
<td>-</td>
<td>19</td>
<td>-</td>
<td>800</td>
<td>123</td>
<td>(100)%</td>
<td>614</td>
<td>874</td>
</tr>
<tr>
<td>IUD 5</td>
<td>30</td>
<td>-</td>
<td>30</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>250</td>
<td>2,890</td>
</tr>
<tr>
<td>IUD Cu375</td>
<td>30</td>
<td>-</td>
<td>30</td>
<td>-</td>
<td>-</td>
<td>7/12</td>
<td>-1%</td>
<td>250</td>
</tr>
<tr>
<td>Misoprostol for Safe Abortion</td>
<td>-</td>
<td>13,333</td>
<td>40,000</td>
<td>200,000</td>
<td>53,000</td>
<td>(25)%</td>
<td>243,100</td>
<td>879,570</td>
</tr>
<tr>
<td>Misoprostol for Safe Abortion</td>
<td>-</td>
<td>13,333</td>
<td>40,000</td>
<td>200,000</td>
<td>53,000</td>
<td>3/18</td>
<td>(25)%</td>
<td>243,100</td>
</tr>
<tr>
<td>OCs Provided</td>
<td>3,435</td>
<td>1,440</td>
<td>4,430</td>
<td>27,200</td>
<td>5,111</td>
<td>(13)%</td>
<td>28,778</td>
<td>84,679</td>
</tr>
<tr>
<td>Non-PSI OCs Provided</td>
<td>3,435</td>
<td>1,440</td>
<td>4,430</td>
<td>27,200</td>
<td>5,111</td>
<td>3/16</td>
<td>(13)%</td>
<td>28,778</td>
</tr>
<tr>
<td>Positive RDTs</td>
<td>-</td>
<td>33</td>
<td>32</td>
<td>400</td>
<td>253</td>
<td>(87)%</td>
<td>723</td>
<td>2,642</td>
</tr>
<tr>
<td>Positive RDTs Given First Line Treatment</td>
<td>-</td>
<td>33</td>
<td>32</td>
<td>400</td>
<td>253</td>
<td>(87)%</td>
<td>723</td>
<td>2,642</td>
</tr>
<tr>
<td>Positive RDTs Given First Line Treatment</td>
<td>-</td>
<td>33</td>
<td>32</td>
<td>400</td>
<td>253</td>
<td>(87)%</td>
<td>723</td>
<td>2,642</td>
</tr>
<tr>
<td>QAACTs Provided after Confirmatory Diagnosis</td>
<td>-</td>
<td>33</td>
<td>32</td>
<td>400</td>
<td>253</td>
<td>(87)%</td>
<td>723</td>
<td>2,642</td>
</tr>
<tr>
<td>Non-PSI QAACTs Provided after Confirmed Diagnosis</td>
<td>-</td>
<td>33</td>
<td>32</td>
<td>400</td>
<td>253</td>
<td>(87)%</td>
<td>723</td>
<td>2,642</td>
</tr>
<tr>
<td>Referral to TB DOTS (completion confirmed)</td>
<td>34</td>
<td>9</td>
<td>34</td>
<td>232</td>
<td>35</td>
<td>(3)%</td>
<td>81</td>
<td>506</td>
</tr>
<tr>
<td>Referral to TB DOTS (completion confirmed)</td>
<td>34</td>
<td>9</td>
<td>34</td>
<td>232</td>
<td>35</td>
<td>3/16</td>
<td>(3)%</td>
<td>81</td>
</tr>
<tr>
<td>Referral to TB DOTS (completion unknown)</td>
<td>27</td>
<td>-</td>
<td>27</td>
<td>-</td>
<td>4</td>
<td>575%</td>
<td>4</td>
<td>275</td>
</tr>
<tr>
<td>Referral to TB DOTS (completion unknown)</td>
<td>27</td>
<td>-</td>
<td>27</td>
<td>-</td>
<td>4</td>
<td>12/13</td>
<td>575%</td>
<td>4</td>
</tr>
<tr>
<td>TB Diagnosis</td>
<td>72</td>
<td>22</td>
<td>72</td>
<td>850</td>
<td>47</td>
<td>53%</td>
<td>228</td>
<td>1,089</td>
</tr>
<tr>
<td>TB Diagnosis</td>
<td>72</td>
<td>22</td>
<td>72</td>
<td>850</td>
<td>47</td>
<td>53%</td>
<td>228</td>
<td>1,089</td>
</tr>
<tr>
<td>TB Screening</td>
<td>254</td>
<td>68</td>
<td>254</td>
<td>-</td>
<td>209</td>
<td>22%</td>
<td>918</td>
<td>4,189</td>
</tr>
<tr>
<td>TB Screening</td>
<td>254</td>
<td>68</td>
<td>254</td>
<td>-</td>
<td>209</td>
<td>22%</td>
<td>918</td>
<td>4,189</td>
</tr>
<tr>
<td>Vivax Treatment after Confirmatory Diagnosis</td>
<td>-</td>
<td>33</td>
<td>32</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>201</td>
<td>233</td>
</tr>
<tr>
<td>Non-PSI Vivax Treatment after Confirmed Diagnosis</td>
<td>-</td>
<td>33</td>
<td>32</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>201</td>
<td>233</td>
</tr>
</tbody>
</table>

Nepal                                                                                                                                                                                                                                                                                                                                
<table>
<thead>
<tr>
<th>Location</th>
<th>Users Reached</th>
<th>DALYs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nepal</td>
<td>7,950</td>
<td>2,479</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Emergency Contraception</td>
<td>543</td>
<td>1,760</td>
<td>423</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>5,400</td>
<td>6,044</td>
<td>19</td>
<td>19</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>i-pill</td>
<td>720</td>
<td>1,800</td>
<td>720</td>
<td>4,373</td>
<td>-</td>
<td>7/17</td>
<td>-%</td>
<td>5,400</td>
<td>6,341</td>
<td>32</td>
<td>32</td>
<td>3</td>
</tr>
<tr>
<td>(b) PSI Emergency Contraception Distributed Provided</td>
<td>(177)</td>
<td>(40)</td>
<td>(297)</td>
<td>(4,373)</td>
<td>-</td>
<td>-</td>
<td>(297)</td>
<td>(13)</td>
<td>(1)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Emergency Contraception Provided</td>
<td>177</td>
<td>40</td>
<td>297</td>
<td>4,373</td>
<td>-</td>
<td>0%</td>
<td>-</td>
<td>297</td>
<td>15</td>
<td>15</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>PSI Emergency Contraception Provided</td>
<td>177</td>
<td>40</td>
<td>297</td>
<td>4,373</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>297</td>
<td>15</td>
<td>15</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Implant 5</td>
<td>(17)</td>
<td>764</td>
<td>25</td>
<td>3,686</td>
<td>8/09</td>
<td>4%</td>
<td>774</td>
<td>2,484</td>
<td>23,314</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Jadelle</td>
<td>-</td>
<td>767</td>
<td>-</td>
<td>3,686</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>1,402</td>
<td>(23)</td>
<td>(85)</td>
<td>(16)</td>
<td></td>
</tr>
<tr>
<td>(b) PSI Implant 5 Distributed Inserted</td>
<td>(17)</td>
<td>(3)</td>
<td>(25)</td>
<td>(3,686)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>(1,402)</td>
<td>(23)</td>
<td>(85)</td>
<td>(16)</td>
<td></td>
</tr>
<tr>
<td>Implant 5 Insertion</td>
<td>17</td>
<td>51</td>
<td>25</td>
<td>3,686</td>
<td>24</td>
<td>(100)%</td>
<td>774</td>
<td>2,484</td>
<td>95</td>
<td>17</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-PSI Implant 5 Inserted</td>
<td>-</td>
<td>48</td>
<td>-</td>
<td>3,686</td>
<td>24</td>
<td>-%</td>
<td>-</td>
<td>1,402</td>
<td>25</td>
<td>95</td>
<td>17</td>
<td></td>
</tr>
<tr>
<td>PSI Implant 5 Inserted</td>
<td>17</td>
<td>3</td>
<td>25</td>
<td>3,686</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>1,402</td>
<td>25</td>
<td>95</td>
<td>17</td>
<td></td>
</tr>
<tr>
<td>Injectable 3-IM</td>
<td>1,624</td>
<td>968</td>
<td>1,727</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>3,000</td>
<td>66,727</td>
<td>389</td>
<td>389</td>
<td>54</td>
<td></td>
</tr>
<tr>
<td>Depo-Provera</td>
<td>2,000</td>
<td>1,000</td>
<td>2,000</td>
<td>6,525</td>
<td>-</td>
<td>6/16</td>
<td>-%</td>
<td>3,000</td>
<td>67,000</td>
<td>450</td>
<td>450</td>
<td>63</td>
</tr>
<tr>
<td>(b) PSI Injectable 3 IM Distributed Provided</td>
<td>(176)</td>
<td>(32)</td>
<td>(273)</td>
<td>(6,525)</td>
<td>-</td>
<td>-</td>
<td>(273)</td>
<td>(61)</td>
<td>(61)</td>
<td>(9)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Injectable 3-IM Provided</td>
<td>176</td>
<td>32</td>
<td>273</td>
<td>6,525</td>
<td>-</td>
<td>0%</td>
<td>-</td>
<td>273</td>
<td>68</td>
<td>68</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>PSI Injectable 3 IM Provided</td>
<td>176</td>
<td>32</td>
<td>273</td>
<td>6,525</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>273</td>
<td>68</td>
<td>68</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>IUD 10</td>
<td>(15)</td>
<td>752</td>
<td>1,699</td>
<td>(1,725)</td>
<td>-</td>
<td>0%</td>
<td>(1,709)</td>
<td>(180,165)</td>
<td>1,529</td>
<td>7,034</td>
<td>1,221</td>
<td></td>
</tr>
<tr>
<td>OK IUD</td>
<td>-</td>
<td>706</td>
<td>1,568</td>
<td>12,106</td>
<td>5/04</td>
<td>-%</td>
<td>12,877</td>
<td>55,755</td>
<td>1,411</td>
<td>6,492</td>
<td>1,127</td>
<td></td>
</tr>
<tr>
<td>Pregna T Cu 380A</td>
<td>-</td>
<td>50</td>
<td>150</td>
<td>1,040</td>
<td>7/17</td>
<td>-%</td>
<td>555</td>
<td>745</td>
<td>135</td>
<td>621</td>
<td>108</td>
<td></td>
</tr>
<tr>
<td>(b) PSI IUD 10 Distributed Inserted</td>
<td>(15)</td>
<td>(837)</td>
<td>(19)</td>
<td>(13,146)</td>
<td>(1,725)</td>
<td>-</td>
<td>(17,641)</td>
<td>(239,165)</td>
<td>(17)</td>
<td>(79)</td>
<td>(14)</td>
<td></td>
</tr>
<tr>
<td>T - CARE IUCD Tcu 380A</td>
<td>-</td>
<td>833</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>2,500</td>
<td>2,500</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IUD 10 Insertion</td>
<td>15</td>
<td>838</td>
<td>19</td>
<td>13,146</td>
<td>1,747</td>
<td>(99)%</td>
<td>17,734</td>
<td>250,678</td>
<td>19</td>
<td>87</td>
<td>15</td>
<td></td>
</tr>
<tr>
<td>Non-PSI IUD 10 Inserted</td>
<td>-</td>
<td>1</td>
<td>-</td>
<td>22</td>
<td>(100)%</td>
<td>-%</td>
<td>93</td>
<td>11,512</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PSI IUD 10 Inserted</td>
<td>15</td>
<td>837</td>
<td>19</td>
<td>13,146</td>
<td>1,725</td>
<td>(99)%</td>
<td>17,641</td>
<td>239,165</td>
<td>19</td>
<td>87</td>
<td>15</td>
<td></td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
## Monthly Distribution by Country

### Period: 2

#### Year: 2020

<table>
<thead>
<tr>
<th></th>
<th>DISTRIBUTION AVG PREV 3 MONTHS</th>
<th>MONTHLY AVG PREV 3 MONTHS</th>
<th>DISTRIBUTION AVG TARGET</th>
<th>DISTRIBUTION 2020</th>
<th>DISTRIBUTION 2019</th>
<th>LAUNCH DATE</th>
<th>YTD DISTRIBUTION CHANGE</th>
<th>TOTAL DISTRIBUTION</th>
<th>CUMULATIVE DISTRIBUTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manual Vacuum Aspiration for PAC</td>
<td>-</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>51</td>
<td>63</td>
</tr>
<tr>
<td>Manual Vacuum Aspiration for PAC</td>
<td>-</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>(100)%</td>
<td>696</td>
<td>866</td>
</tr>
<tr>
<td>Manual Vacuum Aspiration for SA</td>
<td>-</td>
<td>27</td>
<td>-</td>
<td>-</td>
<td>8</td>
<td>12/08</td>
<td>(100)%</td>
<td>696</td>
<td>866</td>
</tr>
<tr>
<td>Medical Abortion</td>
<td>9,000</td>
<td>10,249</td>
<td>9,000</td>
<td>81,638</td>
<td>11,978</td>
<td>(25)%</td>
<td>104,781</td>
<td>478,824</td>
<td>8,100</td>
</tr>
<tr>
<td>Medabon</td>
<td>9,000</td>
<td>10,446</td>
<td>9,000</td>
<td>85,018</td>
<td>12,090</td>
<td>(26)%</td>
<td>107,167</td>
<td>482,433</td>
<td>8,100</td>
</tr>
<tr>
<td>Medical Abortion Provided</td>
<td>-</td>
<td>204</td>
<td>-</td>
<td>3,380</td>
<td>112</td>
<td>(100)%</td>
<td>2,386</td>
<td>3,609</td>
<td>-</td>
</tr>
<tr>
<td>Non-PSI Medical Abortion Provided</td>
<td>-</td>
<td>7</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>132</td>
<td>172</td>
<td>-</td>
</tr>
<tr>
<td>Non-PSI Misoprostol for PAC Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>8</td>
<td>8</td>
<td>-</td>
</tr>
<tr>
<td>OCs</td>
<td>3,282</td>
<td>2,296</td>
<td>2,370</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>2,790</td>
<td>24,750</td>
<td>142</td>
</tr>
<tr>
<td>Zinna - F</td>
<td>5,160</td>
<td>2,600</td>
<td>5,160</td>
<td>9,929</td>
<td>-</td>
<td>/7/17</td>
<td>7,800</td>
<td>27,540</td>
<td>310</td>
</tr>
<tr>
<td>OCs Provided</td>
<td>1,878</td>
<td>304</td>
<td>2,790</td>
<td>9,929</td>
<td>-</td>
<td>0%</td>
<td>2,790</td>
<td>186</td>
<td>186</td>
</tr>
<tr>
<td>PSI OCs Provided</td>
<td>1,878</td>
<td>304</td>
<td>2,790</td>
<td>9,929</td>
<td>-</td>
<td>-</td>
<td>2,790</td>
<td>186</td>
<td>186</td>
</tr>
<tr>
<td>Nicaragua</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Condom</td>
<td>472,320</td>
<td>425,216</td>
<td>851,064</td>
<td>4,725,666</td>
<td>808,872</td>
<td>5%</td>
<td>4,552,683</td>
<td>69,081</td>
<td>6,383</td>
</tr>
<tr>
<td>Combo-Pack Lub Fresa</td>
<td>1,296</td>
<td>288</td>
<td>1,728</td>
<td>21,116</td>
<td>864</td>
<td>5/11</td>
<td>3,456</td>
<td>74,602</td>
<td>13</td>
</tr>
<tr>
<td>Vive</td>
<td>305,184</td>
<td>269,552</td>
<td>521,568</td>
<td>3,331,312</td>
<td>525,456</td>
<td>4/08</td>
<td>(1)%</td>
<td>3,159,504</td>
<td>51,791</td>
</tr>
<tr>
<td>Vive Colors/Mas Colors</td>
<td>120,528</td>
<td>109,480</td>
<td>232,320</td>
<td>915,894</td>
<td>202,104</td>
<td>4/02</td>
<td>920,403</td>
<td>12,757</td>
<td>1,742</td>
</tr>
<tr>
<td>Vive Mas Fuerte /Retardante</td>
<td>37,536</td>
<td>34,808</td>
<td>75,144</td>
<td>357,307</td>
<td>66,840</td>
<td>6/04</td>
<td>368,877</td>
<td>2,596,635</td>
<td>564</td>
</tr>
<tr>
<td>Vive Mas Natural /Sensitivo</td>
<td>7,776</td>
<td>11,088</td>
<td>20,304</td>
<td>100,037</td>
<td>13,608</td>
<td>6/04</td>
<td>100,539</td>
<td>1,109,603</td>
<td>152</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
### Monthly Distribution by Country

**Period:** 2  
**Year:** 2020

<table>
<thead>
<tr>
<th>DISTRIBUTION 2/2020</th>
<th>MONTHLY AVG PREV 3 MONTHS</th>
<th>YTD DISTRIBUTION 2020</th>
<th>DISTRIBUTION TARGET 2020</th>
<th>YTD DISTRIBUTION 2019</th>
<th>LAUNCH DATE</th>
<th>YTD % CHANGE</th>
<th>TOTAL DISTRIBUTION 2019</th>
<th>CUMULATIVE DISTRIBUTION (a)</th>
<th>%YTD USERS REACHED 2020</th>
<th>YTD CYP 2020</th>
<th>YTD DALY 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vive Mas/Texturizado</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>6/04</td>
<td>-%</td>
<td>(96)</td>
<td>749,897</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>HIV Testing Services</td>
<td>50</td>
<td>47</td>
<td>88</td>
<td>616</td>
<td>165</td>
<td>(47)%</td>
<td>864</td>
<td>8,670</td>
<td>88</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>VCT Individual (HIV-Negative)</td>
<td>48</td>
<td>44</td>
<td>84</td>
<td>579</td>
<td>148</td>
<td>(43)%</td>
<td>803</td>
<td>8,474</td>
<td>84</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>VCT Individual (HIV-Positive)</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>37</td>
<td>17</td>
<td>(76)%</td>
<td>61</td>
<td>196</td>
<td>4</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Implant 3</td>
<td>473</td>
<td>226</td>
<td>844</td>
<td>6,476</td>
<td>844</td>
<td>0%</td>
<td>2,188</td>
<td>4,382</td>
<td>760</td>
<td>1,899</td>
<td>317</td>
</tr>
<tr>
<td>Implanon</td>
<td>473</td>
<td>294</td>
<td>844</td>
<td>7,000</td>
<td>880</td>
<td>7/15 (4)%</td>
<td>3,364</td>
<td>7,223</td>
<td>760</td>
<td>1,899</td>
<td>317</td>
</tr>
<tr>
<td>(b)PSI Implant 3 Distributed Inserted</td>
<td>-</td>
<td>(67)</td>
<td>-</td>
<td>(524)</td>
<td>(36)</td>
<td>3/16 -%</td>
<td>(1,176)</td>
<td>(2,841)</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Implant 3 Insertion</td>
<td>-</td>
<td>96</td>
<td>-</td>
<td>524</td>
<td>69</td>
<td>(100)%</td>
<td>1,610</td>
<td>3,553</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Non-PSI Implant 3 Inserted</td>
<td>-</td>
<td>29</td>
<td>-</td>
<td>33</td>
<td>(100)%</td>
<td>434</td>
<td>712</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PSI Implant 3 Inserted</td>
<td>-</td>
<td>67</td>
<td>-</td>
<td>524</td>
<td>36</td>
<td>3/16 (100)%</td>
<td>1,176</td>
<td>2,841</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Implant 5</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>(8)</td>
<td>(3,715)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>(b)PSI Implant 5 Distributed Inserted</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>8</td>
<td>3,715</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Implant 5 Insertion</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>8</td>
<td>3,715</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Non-PSI Implant 5 Inserted</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>(100)%</td>
<td>403</td>
<td>209</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Injectable 1</td>
<td>-</td>
<td>-</td>
<td>13,962</td>
<td>-</td>
<td>0%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Cyclofem</td>
<td>-</td>
<td>-</td>
<td>13,962</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Injectable 1 Provided</td>
<td>-</td>
<td>39</td>
<td>-</td>
<td>54</td>
<td>(100)%</td>
<td>636</td>
<td>1,236</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Non-PSI Injectable 1 Provided</td>
<td>-</td>
<td>39</td>
<td>-</td>
<td>54</td>
<td>(100)%</td>
<td>636</td>
<td>1,236</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Injectable 3-IM Provided</td>
<td>-</td>
<td>18</td>
<td>-</td>
<td>116</td>
<td>15</td>
<td>(100)%</td>
<td>208</td>
<td>319</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Non-PSI Injectable 3 IM Provided</td>
<td>-</td>
<td>18</td>
<td>-</td>
<td>116</td>
<td>15</td>
<td>(100)%</td>
<td>208</td>
<td>319</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>IUD 10</td>
<td>255</td>
<td>19</td>
<td>290</td>
<td>5,856</td>
<td>388</td>
<td>(25)%</td>
<td>3,728</td>
<td>44,228</td>
<td>261</td>
<td>1,201</td>
<td>189</td>
</tr>
<tr>
<td>Copper T 380</td>
<td>225</td>
<td>110</td>
<td>260</td>
<td>6,000</td>
<td>545</td>
<td>12/08 (52)%</td>
<td>5,540</td>
<td>90,675</td>
<td>234</td>
<td>1,076</td>
<td>169</td>
</tr>
<tr>
<td>Copper-T 380-A IUD</td>
<td>30</td>
<td>-</td>
<td>-</td>
<td>30</td>
<td>(30)%</td>
<td>201</td>
<td>427</td>
<td>124</td>
<td>20</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>(b)PSI IUD 10 Distributed Inserted</td>
<td>-</td>
<td>(92)</td>
<td>-</td>
<td>(144)</td>
<td>(177)</td>
<td>-%</td>
<td>(2,063)</td>
<td>(46,874)</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>IUD 10 Insertion</td>
<td>-</td>
<td>92</td>
<td>-</td>
<td>144</td>
<td>177</td>
<td>(100)%</td>
<td>2,063</td>
<td>46,874</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

**Notes:**

- The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.
- DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

---

3002 - 4/15/2020 10:09:35AM  
Page 84 of 115
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>PSI IUD 10 Inserted</td>
<td>-</td>
<td>92</td>
<td>-</td>
<td>144</td>
<td>177</td>
<td>(100)%</td>
<td>-</td>
<td>2,063</td>
<td>46,874</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>IUD 5</td>
<td>6</td>
<td>966</td>
<td>6</td>
<td>43</td>
<td>3,252</td>
<td>(86)%</td>
<td>5</td>
<td>4,245</td>
<td>18</td>
<td>3</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Copper T375 Sleek</td>
<td>6</td>
<td>976</td>
<td>6</td>
<td>47</td>
<td>3,380</td>
<td>(87)%</td>
<td>5</td>
<td>4,458</td>
<td>18</td>
<td>3</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>(b) PSI IUD 5 Distributed Inserted</td>
<td>-</td>
<td>(10)</td>
<td>-</td>
<td>(4)</td>
<td>(128)</td>
<td>-%</td>
<td>(213)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>IUD 5 Insertion</td>
<td>-</td>
<td>10</td>
<td>-</td>
<td>4</td>
<td>128</td>
<td>(100)%</td>
<td>213</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PSI IUD 5 Inserted</td>
<td>-</td>
<td>10</td>
<td>-</td>
<td>4</td>
<td>128</td>
<td>(100)%</td>
<td>213</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>IUS 5 Insertion</td>
<td>-</td>
<td>1</td>
<td>-</td>
<td>3</td>
<td>10</td>
<td>(100)%</td>
<td>13</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Non-PSI IUS 5 Inserted</td>
<td>-</td>
<td>1</td>
<td>-</td>
<td>3</td>
<td>(100)%</td>
<td>10</td>
<td>13</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Lubricant</td>
<td>4,644</td>
<td>21,595</td>
<td>49,522</td>
<td>197,672</td>
<td>32,265</td>
<td>53%</td>
<td>177,084</td>
<td>1,257,874</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Vive Lub (sachet)</td>
<td>1,350</td>
<td>17,333</td>
<td>39,850</td>
<td>75,030</td>
<td>10,800</td>
<td>3/05</td>
<td>269%</td>
<td>77,662</td>
<td>583,905</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Vive Lub (tube)</td>
<td>1,647</td>
<td>2,458</td>
<td>5,158</td>
<td>26,606</td>
<td>4,590</td>
<td>3/05</td>
<td>12%</td>
<td>23,550</td>
<td>155,692</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Vive Lub Natural (sachet)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>73,184</td>
<td>12,150</td>
<td>1/10</td>
<td>(100)%</td>
<td>55,855</td>
<td>408,038</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Vive Lub Natural (tube)</td>
<td>1,647</td>
<td>1,804</td>
<td>4,514</td>
<td>22,852</td>
<td>4,725</td>
<td>1/10</td>
<td>(4)%</td>
<td>20,017</td>
<td>110,239</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Manual Vacuum Aspiration for PAC</td>
<td>-</td>
<td>21</td>
<td>-</td>
<td>121</td>
<td>(100)%</td>
<td>675</td>
<td>2,083</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>MVA for PAC</td>
<td>-</td>
<td>21</td>
<td>-</td>
<td>121</td>
<td>5/16</td>
<td>(100)%</td>
<td>675</td>
<td>2,083</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Misoprostol for PAC Provided</td>
<td>-</td>
<td>10</td>
<td>-</td>
<td>29</td>
<td>(100)%</td>
<td>250</td>
<td>380</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PSI Misoprostol for PAC Provided</td>
<td>-</td>
<td>10</td>
<td>-</td>
<td>29</td>
<td>(100)%</td>
<td>250</td>
<td>380</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Misoprostol for Safe Abortion</td>
<td>4,360</td>
<td>4,098</td>
<td>15,960</td>
<td>55,000</td>
<td>3,996</td>
<td>299%</td>
<td>37,144</td>
<td>98,669</td>
<td>838</td>
<td>-</td>
<td>39</td>
<td>-</td>
</tr>
<tr>
<td>Misoprostol for Safe Abortion</td>
<td>4,360</td>
<td>4,137</td>
<td>15,960</td>
<td>55,000</td>
<td>4,112</td>
<td>3/18</td>
<td>288%</td>
<td>38,144</td>
<td>100,189</td>
<td>838</td>
<td>-</td>
<td>39</td>
</tr>
<tr>
<td>(b) PSI Misoprostol for Safe Abortion Dist Provided</td>
<td>-</td>
<td>(39)</td>
<td>-</td>
<td>(116)</td>
<td>-%</td>
<td>(1,000)</td>
<td>(1,520)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>OCs</td>
<td>-</td>
<td>4</td>
<td>-</td>
<td>121,200</td>
<td>-</td>
<td>0%</td>
<td>12</td>
<td>104,994</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Segura Plus</td>
<td>-</td>
<td>4</td>
<td>-</td>
<td>121,200</td>
<td>-</td>
<td>7/15</td>
<td>-%</td>
<td>12</td>
<td>104,994</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>OCs Provided</td>
<td>-</td>
<td>31</td>
<td>-</td>
<td>42</td>
<td>(100)%</td>
<td>542</td>
<td>1,014</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Non-PSI OCs Provided</td>
<td>-</td>
<td>31</td>
<td>-</td>
<td>42</td>
<td>(100)%</td>
<td>542</td>
<td>1,014</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to Linkage to HIV Care</td>
<td>3</td>
<td>3</td>
<td>5</td>
<td>29</td>
<td>0%</td>
<td>56</td>
<td>100</td>
<td>5</td>
<td>-</td>
<td>3</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
<table>
<thead>
<tr>
<th>Product</th>
<th>2020 Total Users Reached</th>
<th>2019 Total Users Reached</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Condom</td>
<td>8,219,985</td>
<td>6,086,128</td>
<td>14%</td>
</tr>
<tr>
<td>Do</td>
<td>80,280</td>
<td>174,957</td>
<td>(19)%</td>
</tr>
<tr>
<td>Sathi</td>
<td>5,796,285</td>
<td>4,952,606</td>
<td>(1)%</td>
</tr>
<tr>
<td>Sathi Plus</td>
<td>282,240</td>
<td>277,386</td>
<td>2%</td>
</tr>
<tr>
<td>Touch</td>
<td>1,623,780</td>
<td>488,163</td>
<td>74%</td>
</tr>
<tr>
<td>Touch Delay</td>
<td>403,920</td>
<td>172,675</td>
<td>228%</td>
</tr>
<tr>
<td>Touch Strawberry</td>
<td>33,480</td>
<td>20,340</td>
<td>-%</td>
</tr>
<tr>
<td>Emergency Contraception</td>
<td>259,714</td>
<td>102,700</td>
<td>66%</td>
</tr>
<tr>
<td>ECP</td>
<td>254,120</td>
<td>87,402</td>
<td>56%</td>
</tr>
<tr>
<td>Levonorgestrel Tablet 0.75 mg x 2's</td>
<td>9,620</td>
<td>19,240</td>
<td>-%</td>
</tr>
<tr>
<td>(b)PSI Emergency Contraception Distributed Provided</td>
<td>(4,026)</td>
<td>(3,943)</td>
<td>-%</td>
</tr>
<tr>
<td>Emergency Contraception Provided</td>
<td>4,026</td>
<td>3,943</td>
<td>47%</td>
</tr>
<tr>
<td>PSI Emergency Contraception Provided</td>
<td>4,026</td>
<td>3,943</td>
<td>47%</td>
</tr>
<tr>
<td>Implant 5</td>
<td>75</td>
<td>75</td>
<td>47%</td>
</tr>
<tr>
<td>Jadelle</td>
<td>75</td>
<td>75</td>
<td>47%</td>
</tr>
<tr>
<td>Injectable 1</td>
<td>(1,315)</td>
<td>5,088</td>
<td>(113)%</td>
</tr>
<tr>
<td>Femi-ject</td>
<td>-</td>
<td>8,357</td>
<td>(100)%</td>
</tr>
<tr>
<td>(b)PSI Injectable 1 Distributed Provided</td>
<td>(1,315)</td>
<td>(3,270)</td>
<td>-%</td>
</tr>
<tr>
<td>Injectable 1 Provided</td>
<td>1,315</td>
<td>3,270</td>
<td>(72)%</td>
</tr>
<tr>
<td>PSI Injectable 1 Provided</td>
<td>1,315</td>
<td>3,270</td>
<td>(72)%</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.
(b) DALYs credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
### Monthly Distribution by Country

**Period:** 2

**Year:** 2020

<table>
<thead>
<tr>
<th>DISTRIBUTION 2/2020</th>
<th>MONTHLY AVG PREV 3 MONTHS</th>
<th>DISTRIBUTION AVG 2020</th>
<th>DISTRIBUTION AVG 2019</th>
<th>YTD DISTRIBUTION</th>
<th>LAUNCH DATE</th>
<th>YTD % CHANGE</th>
<th>TOTAL DISTRIBUTION 2019</th>
<th>CUMULATIVE DISTRIBUTION</th>
<th>#YTD USERS REACHED 2020</th>
<th>YTD CYP 2020</th>
<th>YTD DALY 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Injectable 2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Novoject</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(b)PSI Injectable 2 Distributed Provided</td>
<td>- (35)</td>
<td>-</td>
<td>-</td>
<td>586</td>
<td>(100)%</td>
<td>4,168</td>
<td>81,343</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Injectable 2 Provided</td>
<td>- 35</td>
<td>-</td>
<td>-</td>
<td>586</td>
<td>(100)%</td>
<td>4,168</td>
<td>81,343</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PSI Injectable 2 Provided</td>
<td>- 35</td>
<td>-</td>
<td>-</td>
<td>586</td>
<td>(100)%</td>
<td>4,168</td>
<td>81,343</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Injectable 3-IM</td>
<td>(8,475)</td>
<td>(13,349)</td>
<td>(25,500)</td>
<td>309,075</td>
<td>2,722</td>
<td>(1037)%</td>
<td>(33,503)</td>
<td>2,831,889</td>
<td>(5,738)</td>
<td>(5,738)</td>
<td>(1,313)</td>
</tr>
<tr>
<td>Depo-Provera</td>
<td>- (10,091)</td>
<td>(11,925)</td>
<td>309,075</td>
<td>13,895</td>
<td>7/11</td>
<td>(186)%</td>
<td>(14,325)</td>
<td>2,969,933</td>
<td>(2,683)</td>
<td>(2,683)</td>
<td>(614)</td>
</tr>
<tr>
<td>(b)PSI Injectable 3 IM Distributed Provided</td>
<td>(8,475)</td>
<td>(3,258)</td>
<td>(13,575)</td>
<td>-</td>
<td>(11,173)</td>
<td>-%</td>
<td>(19,178)</td>
<td>(138,044)</td>
<td>(3,054)</td>
<td>(3,054)</td>
<td>(699)</td>
</tr>
<tr>
<td>Injectable 3-IM Provided</td>
<td>8,475</td>
<td>3,258</td>
<td>13,575</td>
<td>-</td>
<td>11,173</td>
<td>21%</td>
<td>19,178</td>
<td>138,044</td>
<td>3,394</td>
<td>3,394</td>
<td>776</td>
</tr>
<tr>
<td>PSI Injectable 3 IM Provided</td>
<td>8,475</td>
<td>3,258</td>
<td>13,575</td>
<td>-</td>
<td>11,173</td>
<td>21%</td>
<td>19,178</td>
<td>138,044</td>
<td>3,394</td>
<td>3,394</td>
<td>776</td>
</tr>
<tr>
<td>IUD 10</td>
<td>1 (174)</td>
<td>(60)</td>
<td>30,908</td>
<td>1,960</td>
<td>(103)%</td>
<td>57,710</td>
<td>252,909</td>
<td>(54)</td>
<td>(248)</td>
<td>(73)</td>
<td></td>
</tr>
<tr>
<td>Safeload</td>
<td>1 (174)</td>
<td>(60)</td>
<td>30,908</td>
<td>1,960</td>
<td>8/14</td>
<td>(103)%</td>
<td>57,710</td>
<td>252,909</td>
<td>(54)</td>
<td>(248)</td>
<td>(73)</td>
</tr>
<tr>
<td>IUD 5</td>
<td>4,470</td>
<td>(8,256)</td>
<td>(7,504)</td>
<td>159,065</td>
<td>17,188</td>
<td>(144)%</td>
<td>(23,994)</td>
<td>2,983,076</td>
<td>(6,754)</td>
<td>(22,287)</td>
<td>(6,935)</td>
</tr>
<tr>
<td>Multiload</td>
<td>17,600</td>
<td>3,506</td>
<td>17,445</td>
<td>-</td>
<td>55,650</td>
<td>12/95</td>
<td>(69)%</td>
<td>133,774</td>
<td>4,097,745</td>
<td>15,701</td>
<td>51,812</td>
</tr>
<tr>
<td>Protect 5</td>
<td>- -</td>
<td>-</td>
<td>159,065</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>(b)PSI IUD 5 Distributed Inserted</td>
<td>(13,130)</td>
<td>(11,762)</td>
<td>(24,949)</td>
<td>-</td>
<td>(38,462)</td>
<td>-%</td>
<td>(157,768)</td>
<td>(1,114,669)</td>
<td>(22,454)</td>
<td>(74,099)</td>
<td>(23,059)</td>
</tr>
<tr>
<td>IUD 5 Insertion</td>
<td>13,130</td>
<td>11,762</td>
<td>24,949</td>
<td>-</td>
<td>38,462</td>
<td>(35)%</td>
<td>157,768</td>
<td>1,114,669</td>
<td>24,949</td>
<td>82,332</td>
<td>25,621</td>
</tr>
<tr>
<td>PSI IUD 5 Inserted</td>
<td>13,130</td>
<td>11,762</td>
<td>24,949</td>
<td>-</td>
<td>38,462</td>
<td>(35)%</td>
<td>157,768</td>
<td>1,114,669</td>
<td>24,949</td>
<td>82,332</td>
<td>25,621</td>
</tr>
<tr>
<td>Misoprostol for PAC Provided</td>
<td>8,369</td>
<td>8,435</td>
<td>16,037</td>
<td>-</td>
<td>14,496</td>
<td>11%</td>
<td>81,496</td>
<td>144,104</td>
<td>16,037</td>
<td>-</td>
<td>987</td>
</tr>
<tr>
<td>Misoprostol for PAC Provided</td>
<td>8,369</td>
<td>8,435</td>
<td>16,037</td>
<td>-</td>
<td>14,496</td>
<td>11%</td>
<td>81,496</td>
<td>144,104</td>
<td>16,037</td>
<td>-</td>
<td>987</td>
</tr>
<tr>
<td>Misoprostol for Safe Abortion</td>
<td>164,624</td>
<td>133,961</td>
<td>298,452</td>
<td>207,276</td>
<td>342,316</td>
<td>(13)%</td>
<td>1,319,316</td>
<td>2,899,214</td>
<td>15,669</td>
<td>-</td>
<td>1,215</td>
</tr>
<tr>
<td>Misoprostol for Safe Abortion</td>
<td>198,100</td>
<td>167,700</td>
<td>362,600</td>
<td>207,276</td>
<td>400,300</td>
<td>3/18</td>
<td>(9)%</td>
<td>1,645,300</td>
<td>3,475,630</td>
<td>19,036</td>
<td>-</td>
</tr>
<tr>
<td>(b)PSI Misoprostol for Safe Abortion Dist Provided</td>
<td>(33,476)</td>
<td>(33,739)</td>
<td>(64,148)</td>
<td>-</td>
<td>(57,984)</td>
<td>-%</td>
<td>(325,984)</td>
<td>(576,416)</td>
<td>(3,368)</td>
<td>-</td>
<td>(261)</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
<table>
<thead>
<tr>
<th>Product</th>
<th>YTD Users Reached</th>
<th>YTD DALY</th>
<th>YTD % Change</th>
<th>Cumulative Distribution</th>
<th>Total Distribution</th>
<th>YTD Distribution</th>
<th>Launch Date</th>
<th>Average Product Distribution</th>
<th>3 Month Average Distribution</th>
<th>YTD Distribution</th>
<th>YTD Users Reached</th>
<th>YTD % Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Multivitamin</td>
<td>1,001</td>
<td>2,467</td>
<td>1,001</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>26,420</td>
<td>27,421</td>
<td>5</td>
<td>-</td>
<td>1</td>
</tr>
<tr>
<td>Mi-Care</td>
<td>1,001</td>
<td>2,467</td>
<td>1,001</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>26,420</td>
<td>27,421</td>
<td>5</td>
<td>-</td>
<td>1</td>
</tr>
<tr>
<td>OCs</td>
<td>166,380</td>
<td>68,600</td>
<td>205,941</td>
<td>836,467</td>
<td>66,327</td>
<td>210%</td>
<td>763,224</td>
<td>4,842,438</td>
<td>12,356</td>
<td>12,356</td>
<td>2,982</td>
<td></td>
</tr>
<tr>
<td>Novadol</td>
<td>190,080</td>
<td>75,331</td>
<td>240,183</td>
<td>836,467</td>
<td>67,719</td>
<td>1/08</td>
<td>782,280</td>
<td>5,103,843</td>
<td>14,411</td>
<td>14,411</td>
<td>3,478</td>
<td></td>
</tr>
<tr>
<td>(b)PSI OCs Distributed Provided</td>
<td>(23,700)</td>
<td>(6,731)</td>
<td>(34,242)</td>
<td>-</td>
<td>(1,392)</td>
<td>-%</td>
<td>(19,056)</td>
<td>(261,405)</td>
<td>(2,055)</td>
<td></td>
<td>(496)</td>
<td></td>
</tr>
<tr>
<td>OCs Provided</td>
<td>23,700</td>
<td>6,731</td>
<td>34,242</td>
<td>-</td>
<td>1,392</td>
<td>2360%</td>
<td>19,056</td>
<td>261,405</td>
<td>2,283</td>
<td>2,283</td>
<td>551</td>
<td></td>
</tr>
<tr>
<td>PSI OCs Provided</td>
<td>23,700</td>
<td>6,731</td>
<td>34,242</td>
<td>-</td>
<td>1,392</td>
<td>2,360%</td>
<td>19,056</td>
<td>261,405</td>
<td>2,283</td>
<td>2,283</td>
<td>551</td>
<td></td>
</tr>
<tr>
<td>TB Diagnosis</td>
<td>2,873</td>
<td>2,437</td>
<td>5,373</td>
<td>-</td>
<td>4,067</td>
<td>32%</td>
<td>28,405</td>
<td>113,154</td>
<td>5,373</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>TB Diagnosis</td>
<td>2,873</td>
<td>2,437</td>
<td>5,373</td>
<td>-</td>
<td>4,067</td>
<td>32%</td>
<td>28,405</td>
<td>113,154</td>
<td>5,373</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>TB DOTS</td>
<td>1,813</td>
<td>1,989</td>
<td>3,521</td>
<td>-</td>
<td>4,047</td>
<td>(13)%</td>
<td>25,764</td>
<td>142,760</td>
<td>3,521</td>
<td>-</td>
<td>16,114</td>
<td></td>
</tr>
<tr>
<td>TB DOTS</td>
<td>1,813</td>
<td>1,989</td>
<td>3,521</td>
<td>-</td>
<td>4,047</td>
<td>(13)%</td>
<td>25,764</td>
<td>142,760</td>
<td>3,521</td>
<td>-</td>
<td>16,114</td>
<td></td>
</tr>
<tr>
<td>TB Screening</td>
<td>6,054</td>
<td>6,200</td>
<td>11,290</td>
<td>-</td>
<td>8,395</td>
<td>34%</td>
<td>58,687</td>
<td>189,275</td>
<td>11,290</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>TB Screening</td>
<td>6,054</td>
<td>6,200</td>
<td>11,290</td>
<td>-</td>
<td>8,395</td>
<td>34%</td>
<td>58,687</td>
<td>189,275</td>
<td>11,290</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Panama</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>4,219</td>
<td>1,118</td>
<td></td>
</tr>
<tr>
<td>Condom</td>
<td>287,304</td>
<td>188,776</td>
<td>562,512</td>
<td>2,579,619</td>
<td>597,384</td>
<td>(6)%</td>
<td>2,232,960</td>
<td>45,982,830</td>
<td>4,219</td>
<td>4,219</td>
<td>1,104</td>
<td></td>
</tr>
<tr>
<td>Vive</td>
<td>206,400</td>
<td>138,096</td>
<td>402,912</td>
<td>1,856,987</td>
<td>501,120</td>
<td>7/00</td>
<td>(20)%</td>
<td>1,755,648</td>
<td>37,987,889</td>
<td>3,022</td>
<td>791</td>
<td></td>
</tr>
<tr>
<td>Vive Colors/Mas Colors</td>
<td>55,704</td>
<td>22,368</td>
<td>93,912</td>
<td>380,905</td>
<td>46,464</td>
<td>3/05</td>
<td>102%</td>
<td>222,864</td>
<td>4,353,708</td>
<td>704</td>
<td>184</td>
<td></td>
</tr>
<tr>
<td>Vive Mas Fuerte /Retardante</td>
<td>22,800</td>
<td>22,496</td>
<td>48,264</td>
<td>233,866</td>
<td>18,024</td>
<td>3/05</td>
<td>168%</td>
<td>184,872</td>
<td>1,996,423</td>
<td>362</td>
<td>95</td>
<td></td>
</tr>
<tr>
<td>Vive Mas Natural /Sensitivo</td>
<td>2,400</td>
<td>5,816</td>
<td>17,424</td>
<td>107,861</td>
<td>20,160</td>
<td>3/05</td>
<td>(14)%</td>
<td>58,200</td>
<td>935,417</td>
<td>131</td>
<td>34</td>
<td></td>
</tr>
<tr>
<td>Vive Mas/Texturizado</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>11,616</td>
<td>3/05</td>
<td>(100)%</td>
<td>11,376</td>
<td>709,393</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>HIV Testing Services</td>
<td>163</td>
<td>129</td>
<td>338</td>
<td>5,688</td>
<td>272</td>
<td>3/05</td>
<td>24%</td>
<td>2,054</td>
<td>21,169</td>
<td>338</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>VCT Individual (HIV-Negative)</td>
<td>152</td>
<td>115</td>
<td>306</td>
<td>5,323</td>
<td>243</td>
<td>12/11</td>
<td>26%</td>
<td>1,838</td>
<td>20,244</td>
<td>306</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>VCT Individual (HIV-Positive)</td>
<td>11</td>
<td>13</td>
<td>32</td>
<td>365</td>
<td>29</td>
<td>10%</td>
<td>216</td>
<td>925</td>
<td>32</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Lubricant</td>
<td>2,700</td>
<td>4,558</td>
<td>11,204</td>
<td>84,510</td>
<td>(9,903)</td>
<td>0%</td>
<td>92,786</td>
<td>571,176</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Vive Lub (sachet)</td>
<td>-</td>
<td>-</td>
<td>- 20,215 (200)</td>
<td>2/09</td>
<td>-</td>
<td>45,550</td>
<td>313,776</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Vive Lub (tube)</td>
<td>1,200</td>
<td>1,532</td>
<td>3,802 28,348</td>
<td>2/09</td>
<td>-</td>
<td>14,491</td>
<td>94,576</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Vive Lub Natural (sachet)</td>
<td>-</td>
<td>1,000</td>
<td>3,000 6,259 (9,700)</td>
<td>5/11</td>
<td>-</td>
<td>16,350</td>
<td>78,755</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Vive Lub Natural (tube)</td>
<td>1,500</td>
<td>2,026</td>
<td>4,402 29,688</td>
<td>5/11</td>
<td>-</td>
<td>16,395</td>
<td>84,069</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to Linkage to HIV Care</td>
<td>12</td>
<td>12</td>
<td>29 292 23</td>
<td>26%</td>
<td>179</td>
<td>140</td>
<td>14</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Papua New Guinea</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>433</td>
<td>298</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Condom</td>
<td>470</td>
<td>15,587</td>
<td>47,230 500,000</td>
<td>-</td>
<td>0%</td>
<td>-</td>
<td>8,097,389</td>
<td>354</td>
<td>354</td>
<td>244</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Seif Raida</td>
<td>440</td>
<td>8,907</td>
<td>27,160 250,000</td>
<td>-</td>
<td>1/08</td>
<td>-</td>
<td>6,996,165</td>
<td>204</td>
<td>204</td>
<td>140</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Seif Raida Orange Plus</td>
<td>30</td>
<td>6,680</td>
<td>20,070 250,000</td>
<td>-</td>
<td>8/13</td>
<td>-</td>
<td>1,101,224</td>
<td>151</td>
<td>151</td>
<td>104</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female Condom</td>
<td>20</td>
<td>-</td>
<td>20 -</td>
<td>-</td>
<td>0%</td>
<td>-</td>
<td>338,559</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Stap Seif</td>
<td>20</td>
<td>-</td>
<td>20 -</td>
<td>-</td>
<td>2/09</td>
<td>-</td>
<td>338,559</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Free Condom</td>
<td>7,488</td>
<td>47,088</td>
<td>7,488 200,000</td>
<td>-</td>
<td>0%</td>
<td>201,312</td>
<td>208,800</td>
<td>56</td>
<td>56</td>
<td>39</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Generic Male Condom</td>
<td>7,488</td>
<td>47,088</td>
<td>7,488 200,000</td>
<td>-</td>
<td>-</td>
<td>201,312</td>
<td>208,800</td>
<td>56</td>
<td>56</td>
<td>39</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Free Female Condom</td>
<td>-</td>
<td>3,103</td>
<td>3,000 10,000</td>
<td>-</td>
<td>0%</td>
<td>16,504</td>
<td>19,504</td>
<td>22</td>
<td>22</td>
<td>14</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Generic Female Condom</td>
<td>-</td>
<td>3,103</td>
<td>3,000 10,000</td>
<td>-</td>
<td>-</td>
<td>16,504</td>
<td>19,504</td>
<td>22</td>
<td>22</td>
<td>14</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lubricant</td>
<td>-</td>
<td>85</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>256</td>
<td>18,241</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Glide Lubricant</td>
<td>-</td>
<td>85</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>256</td>
<td>18,241</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>ORS</td>
<td>-</td>
<td>-</td>
<td>2</td>
<td>(100)%</td>
<td>2,112</td>
<td>31,346</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>ORS</td>
<td>-</td>
<td>-</td>
<td>2</td>
<td>12/11 (100)%</td>
<td>2,112</td>
<td>31,346</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Water Treatment Tablets</td>
<td>5,000</td>
<td>2,583</td>
<td>6,000 15,000 50,500</td>
<td>(88)%</td>
<td>74,110</td>
<td>1,058,893</td>
<td>99</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Aquatab</td>
<td>5,000</td>
<td>2,583</td>
<td>6,000 15,000 50,500</td>
<td>12/11 (88)%</td>
<td>74,110</td>
<td>1,058,893</td>
<td>99</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Zinc</td>
<td>-</td>
<td>23</td>
<td>-</td>
<td>2</td>
<td>(100)%</td>
<td>132</td>
<td>32,976</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Zinc 20 mg</td>
<td>-</td>
<td>23</td>
<td>-</td>
<td>2</td>
<td>12/11 (100)%</td>
<td>132</td>
<td>32,976</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.
(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
## Monthly Distribution by Country

**Period:** 2  
**Year:** 2020

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PSI Pakistan</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Condom</td>
<td>785,301</td>
<td>4,101,916</td>
<td>4,979,815</td>
<td>42,167,604</td>
<td>6,616,301</td>
<td>(25)%</td>
<td>49,952,410</td>
<td>61,790,687</td>
<td>37,349</td>
<td>37,349</td>
<td>8,480</td>
<td></td>
</tr>
<tr>
<td>Do</td>
<td>-</td>
<td>114,603</td>
<td>114,687</td>
<td>-</td>
<td>151,122</td>
<td>(24)%</td>
<td>1,021,866</td>
<td>1,136,553</td>
<td>860</td>
<td>860</td>
<td>195</td>
<td></td>
</tr>
<tr>
<td>Generic Male Condom</td>
<td>785,301</td>
<td>792,149</td>
<td>1,608,719</td>
<td>42,167,604</td>
<td>818,501</td>
<td>4/16</td>
<td>6,359,600</td>
<td>14,826,781</td>
<td>12,065</td>
<td>12,065</td>
<td>2,739</td>
<td></td>
</tr>
<tr>
<td>Sathi</td>
<td>-</td>
<td>2,266,785</td>
<td>2,484,488</td>
<td>-</td>
<td>4,673,046</td>
<td>(47)%</td>
<td>34,228,862</td>
<td>36,713,350</td>
<td>18,634</td>
<td>18,634</td>
<td>4,231</td>
<td></td>
</tr>
<tr>
<td>Sathi Plus</td>
<td>-</td>
<td>207,734</td>
<td>180,882</td>
<td>-</td>
<td>370,677</td>
<td>(51)%</td>
<td>2,193,555</td>
<td>2,374,437</td>
<td>1,357</td>
<td>1,357</td>
<td>308</td>
<td></td>
</tr>
<tr>
<td>Touch Delay</td>
<td>-</td>
<td>121,752</td>
<td>137,574</td>
<td>-</td>
<td>77,382</td>
<td>78%</td>
<td>1,036,092</td>
<td>1,173,666</td>
<td>1,032</td>
<td>1,032</td>
<td>234</td>
<td></td>
</tr>
<tr>
<td>Emergency Contraception</td>
<td>-</td>
<td>97,440</td>
<td>99,992</td>
<td>1,253,764</td>
<td>196,796</td>
<td>(49)%</td>
<td>1,116,640</td>
<td>1,216,632</td>
<td>4,500</td>
<td>4,500</td>
<td>784</td>
<td></td>
</tr>
<tr>
<td>ECP</td>
<td>-</td>
<td>97,440</td>
<td>99,992</td>
<td>1,253,764</td>
<td>196,796</td>
<td>(49)%</td>
<td>1,116,640</td>
<td>1,216,632</td>
<td>4,500</td>
<td>4,500</td>
<td>784</td>
<td></td>
</tr>
<tr>
<td>Injectable 1</td>
<td>-</td>
<td>6,650</td>
<td>4,934</td>
<td>48,688</td>
<td>8,162</td>
<td>(40)%</td>
<td>64,589</td>
<td>69,523</td>
<td>342</td>
<td>342</td>
<td>85</td>
<td></td>
</tr>
<tr>
<td>Femi-ject</td>
<td>-</td>
<td>6,650</td>
<td>4,934</td>
<td>48,688</td>
<td>8,162</td>
<td>(40)%</td>
<td>64,589</td>
<td>69,523</td>
<td>342</td>
<td>342</td>
<td>85</td>
<td></td>
</tr>
<tr>
<td>Injectable 2</td>
<td>-</td>
<td>66</td>
<td>111,753</td>
<td>39,705</td>
<td>(100)%</td>
<td>143,249</td>
<td>143,249</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Novaject</td>
<td>-</td>
<td>66</td>
<td>111,753</td>
<td>39,705</td>
<td>(100)%</td>
<td>143,249</td>
<td>143,249</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Injectable 2 Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>53,375</td>
<td>-</td>
<td>0%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Non-PSI Injectable 2 Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>53,375</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Injectable 3-IM</td>
<td>-</td>
<td>10,091</td>
<td>11,925</td>
<td>156,964</td>
<td>23,109</td>
<td>(48)%</td>
<td>96,605</td>
<td>99,959</td>
<td>2,683</td>
<td>2,683</td>
<td>614</td>
<td></td>
</tr>
<tr>
<td>Depo-Provera</td>
<td>-</td>
<td>10,091</td>
<td>11,925</td>
<td>156,964</td>
<td>33,546</td>
<td>(64)%</td>
<td>107,042</td>
<td>118,967</td>
<td>2,683</td>
<td>2,683</td>
<td>614</td>
<td></td>
</tr>
<tr>
<td>(b)PSI Injectable 3 IM Distributed Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>(10,437)</td>
<td>-%</td>
<td>(10,437)</td>
<td>(19,008)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Injectable 3-IM Provided</td>
<td>25,570</td>
<td>42,110</td>
<td>49,272</td>
<td>828,904</td>
<td>32,983</td>
<td>49%</td>
<td>268,725</td>
<td>823,908</td>
<td>12,318</td>
<td>12,318</td>
<td>2,818</td>
<td></td>
</tr>
<tr>
<td>Non-PSI Injectable 3 IM Provided</td>
<td>25,570</td>
<td>42,110</td>
<td>49,272</td>
<td>828,904</td>
<td>22,546</td>
<td>119%</td>
<td>258,288</td>
<td>804,900</td>
<td>12,318</td>
<td>12,318</td>
<td>2,818</td>
<td></td>
</tr>
<tr>
<td>PSI Injectable 3 IM Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>10,437</td>
<td>(100)%</td>
<td>10,437</td>
<td>19,008</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>IUD 10</td>
<td>-</td>
<td>204</td>
<td>61</td>
<td>5,491</td>
<td>1,040</td>
<td>(94)%</td>
<td>4,171</td>
<td>4,232</td>
<td>55</td>
<td>253</td>
<td>74</td>
<td></td>
</tr>
<tr>
<td>Safeload</td>
<td>-</td>
<td>204</td>
<td>61</td>
<td>5,491</td>
<td>1,040</td>
<td>(94)%</td>
<td>4,171</td>
<td>4,232</td>
<td>55</td>
<td>253</td>
<td>74</td>
<td></td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
### Monthly Distribution by Country

Period: 2  
Year: 2020

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>IUD 10 Insertion</td>
<td>10,270</td>
<td>17,572</td>
<td>21,766</td>
<td>69,013</td>
<td>8,738</td>
<td>149%</td>
<td>78,634</td>
<td>227,382</td>
<td>21,766</td>
<td>100,124</td>
<td>29,268</td>
</tr>
<tr>
<td>Non-PSI IUD 10 Inserted</td>
<td>10,270</td>
<td>17,572</td>
<td>21,766</td>
<td>69,013</td>
<td>8,738</td>
<td>149%</td>
<td>78,634</td>
<td>227,382</td>
<td>21,766</td>
<td>100,124</td>
<td>29,268</td>
</tr>
<tr>
<td>IUD 5</td>
<td>-</td>
<td>6,470</td>
<td>6,288</td>
<td>60,915</td>
<td>8,050</td>
<td>(22)%</td>
<td>60,723</td>
<td>67,011</td>
<td>5,659</td>
<td>18,675</td>
<td>5,812</td>
</tr>
<tr>
<td>Multiload</td>
<td>-</td>
<td>6,470</td>
<td>6,288</td>
<td>-</td>
<td>8,050</td>
<td>(22)%</td>
<td>60,723</td>
<td>67,011</td>
<td>5,659</td>
<td>18,675</td>
<td>5,812</td>
</tr>
<tr>
<td>Protect 5</td>
<td>-</td>
<td>-</td>
<td>60,915</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>IUD 5 Insertion</td>
<td>-</td>
<td>-</td>
<td>11,229</td>
<td>-</td>
<td>0%</td>
<td>4,319</td>
<td>11,567</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Non-PSI IUD 5 Inserted</td>
<td>-</td>
<td>-</td>
<td>11,229</td>
<td>-</td>
<td>-%</td>
<td>4,319</td>
<td>11,567</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>OCs</td>
<td>-</td>
<td>31,578</td>
<td>34,974</td>
<td>424,525</td>
<td>(29,308)</td>
<td>0%</td>
<td>226,790</td>
<td>228,139</td>
<td>2,098</td>
<td>2,098</td>
<td>506</td>
</tr>
<tr>
<td>Novadol</td>
<td>-</td>
<td>31,578</td>
<td>34,974</td>
<td>424,525</td>
<td>30,921</td>
<td>13%</td>
<td>287,019</td>
<td>321,993</td>
<td>2,098</td>
<td>2,098</td>
<td>506</td>
</tr>
<tr>
<td>OCs Provided</td>
<td>145,999</td>
<td>190,831</td>
<td>232,415</td>
<td>1,672,522</td>
<td>200,130</td>
<td>16%</td>
<td>1,278,755</td>
<td>2,732,137</td>
<td>15,494</td>
<td>15,494</td>
<td>3,739</td>
</tr>
<tr>
<td>Non-PSI OCs Provided</td>
<td>145,999</td>
<td>190,831</td>
<td>232,415</td>
<td>1,672,522</td>
<td>139,901</td>
<td>66%</td>
<td>1,218,526</td>
<td>2,638,283</td>
<td>15,494</td>
<td>15,494</td>
<td>3,739</td>
</tr>
<tr>
<td>PSI OCs Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>60,229</td>
<td>(100)%</td>
<td>60,229</td>
<td>93,854</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

**Tajikistan**

|  |  |  |  |  |  |  |  |  |  |  |  |
|---|---|---|---|---|---|---|---|---|---|---|
| Free Condom         | 4,006 | 52,524 | 133,969 | 459,326 | 24,000 | 458% | 177,383 | 1,770,686 | 1,005 | 1,005 | 562 |
| Generic Male Condom | 4,006 | 52,524 | 133,969 | 459,326 | 24,000 | 8/16 | 458% | 177,383 | 1,770,686 | 1,005 | 1,005 | 562 |
| HIV Self-Testing Kit | 2 | 246 | 214 | 3,937 | - | 0% | 579 | 793 | 193 | - | - |
| HIV Self-Testing Kit (Oral Fluid) | - | - | - | 3,937 | - | -% | - | - | - | - | - |
| ORAQUICK HIV Self-Testing Kit (Saliva based) | 2 | 246 | 214 | - | - | -% | 579 | 793 | 193 | - | - |
| HIV Testing Services | 582 | 537 | 1,116 | 5,678 | 2,938 | (62)% | 15,421 | 48,331 | 1,116 | - | 4 |
| VCT Individual (HIV-Negative) | 509 | 470 | 981 | 4,826 | 2,863 | (66)% | 14,759 | 46,684 | 981 | - | 3 |
| VCT Individual (HIV-Positive) | 73 | 67 | 135 | 852 | 75 | 80% | 662 | 1,647 | 135 | - | - |
| Naloxone            | - | 180 | 540 | 780 | - | 0% | 1,995 | 19,248 | 486 | - | 737 |
| Naloxone            | - | 180 | 540 | 780 | - | 1/11 | 1,995 | 19,248 | 486 | - | 737 |
| Needle & Syringe    | - | 83,400 | 207,000 | 459,300 | - | 0% | 796,800 | 3,861,818 | 722 | - | 2,598 |

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
### Monthly Distribution by Country

**Period:** 2  
**Year:** 2020

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Needle/Syringe</td>
<td>-</td>
<td>83,400</td>
<td>207,000</td>
<td>459,300</td>
<td>-</td>
<td>1/11</td>
<td>-%</td>
<td>796,800</td>
<td>3,861,818</td>
<td>722</td>
<td>-</td>
</tr>
<tr>
<td>Referral to HIV Testing Services</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>3</td>
<td>(100)%</td>
<td>3</td>
<td>15,110</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Referral to HIV Testing Services</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>3</td>
<td>(100)%</td>
<td>3</td>
<td>15,110</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Referral to Linkage to HIV Care</td>
<td>81</td>
<td>91</td>
<td>167</td>
<td>246</td>
<td>167</td>
<td>0%</td>
<td>1,069</td>
<td>2,839</td>
<td>167</td>
<td>-</td>
<td>133</td>
</tr>
<tr>
<td>Referral to Linkage to HIV Care</td>
<td>81</td>
<td>91</td>
<td>167</td>
<td>246</td>
<td>167</td>
<td>-%</td>
<td>1,069</td>
<td>2,839</td>
<td>167</td>
<td>-</td>
<td>133</td>
</tr>
<tr>
<td>Referral to Opioid Treatment</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>-</td>
<td>2</td>
<td>0%</td>
<td>48</td>
<td>239</td>
<td>2</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Referral to Opioid Treatment</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>-</td>
<td>2</td>
<td>-%</td>
<td>48</td>
<td>239</td>
<td>2</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>TB Diagnosis</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>3</td>
<td>21</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>TB Diagnosis</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>3</td>
<td>21</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>TB Screening</td>
<td>94</td>
<td>310</td>
<td>228</td>
<td>1,650</td>
<td>180</td>
<td>27%</td>
<td>1,786</td>
<td>8,995</td>
<td>228</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>TB Screening</td>
<td>94</td>
<td>310</td>
<td>228</td>
<td>1,650</td>
<td>180</td>
<td>27%</td>
<td>1,786</td>
<td>8,995</td>
<td>228</td>
<td>-</td>
<td></td>
</tr>
</tbody>
</table>

**Viet Nam**

<p>| | | | | | | | | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Emergency Contraception Provided</td>
<td>-</td>
<td>50</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>150</td>
<td>932</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-PSI Emergency Contraception Provided</td>
<td>-</td>
<td>50</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>150</td>
<td>932</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fever Cases Tested with RDTs</td>
<td>1,686</td>
<td>2,351</td>
<td>3,065</td>
<td>20,000</td>
<td>3,771</td>
<td>(19)%</td>
<td>28,120</td>
<td>47,083</td>
<td>3,065</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Fever Cases Tested with RDTs</td>
<td>1,686</td>
<td>2,351</td>
<td>3,065</td>
<td>20,000</td>
<td>3,771</td>
<td>(19)%</td>
<td>28,120</td>
<td>47,083</td>
<td>3,065</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>HIV Testing Services</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>514</td>
<td>(100)%</td>
<td>552</td>
<td>12,603</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>VCT Individual (HIV-Negative)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>491</td>
<td>(100)%</td>
<td>527</td>
<td>11,753</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>VCT Individual (HIV-Positive)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>23</td>
<td>(100)%</td>
<td>25</td>
<td>850</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Hypertension Diagnosis</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>2,942</td>
<td>(100)%</td>
<td>7,961</td>
<td>60,396</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension Diagnosis</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>2,942</td>
<td>(100)%</td>
<td>7,961</td>
<td>60,396</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension Screening</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>64,733</td>
<td>(100)%</td>
<td>191,916</td>
<td>807,605</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension Screening</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>64,733</td>
<td>(100)%</td>
<td>191,916</td>
<td>807,605</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension_Controlled Condition</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>4,255</td>
<td>(100)%</td>
<td>12,035</td>
<td>62,586</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension_Controlled Condition</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>4,255</td>
<td>(100)%</td>
<td>12,035</td>
<td>62,586</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

---

3002 - 4/15/2020 10:09:35AM

Page 92 of 115
### Monthly Distribution by Country

**Period:** 2nd Quarter 2020  
**Year:** 2020

#### DISTRIBUTION 2/2020 MONTHLY AVG PREV 3 MONTHS

<table>
<thead>
<tr>
<th>Product</th>
<th>Distribution</th>
<th>Target</th>
<th>Cumulative Distribution</th>
<th>YTD % Change</th>
<th>Launch Date</th>
<th>YTD % Change</th>
<th>Total Distribution 2019</th>
<th>Cumulative Distribution (a)</th>
<th>YTD Users Reached 2020</th>
<th>YTD DALY 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Implant 3</td>
<td>100</td>
<td>89</td>
<td>193</td>
<td>30</td>
<td>100</td>
<td>93%</td>
<td>706</td>
<td>2,092</td>
<td>174</td>
<td>434</td>
</tr>
<tr>
<td>Implanon NXT</td>
<td>100</td>
<td>92</td>
<td>200</td>
<td>30</td>
<td>137</td>
<td>46%</td>
<td>752</td>
<td>2,435</td>
<td>180</td>
<td>450</td>
</tr>
<tr>
<td>(b)PSI Implant 3 Distributed Inserted</td>
<td>-</td>
<td>(2)</td>
<td>(7)</td>
<td>-</td>
<td>(37)</td>
<td>-%</td>
<td>(46)</td>
<td>(343)</td>
<td>(6)</td>
<td>(16)</td>
</tr>
<tr>
<td>Implant 3 Insertion</td>
<td>86</td>
<td>98</td>
<td>264</td>
<td>-</td>
<td>37</td>
<td>614%</td>
<td>192</td>
<td>803</td>
<td>264</td>
<td>660</td>
</tr>
<tr>
<td>Non-PSI Implant 3 Inserted</td>
<td>86</td>
<td>95</td>
<td>257</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>146</td>
<td>460</td>
<td>257</td>
<td>643</td>
</tr>
<tr>
<td>PSI Implant 3 Inserted</td>
<td>-</td>
<td>2</td>
<td>7</td>
<td>-</td>
<td>37</td>
<td>(81)%</td>
<td>46</td>
<td>343</td>
<td>7</td>
<td>18</td>
</tr>
<tr>
<td>Implant 5 Insertion</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>15</td>
<td>15</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Non-PSI Implant 5 Inserted</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>15</td>
<td>15</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Injectable 1 Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>2</td>
<td>42</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Non-PSI Injectable 1 Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>2</td>
<td>42</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Injectable 3-IM</td>
<td>75</td>
<td>(20)</td>
<td>34</td>
<td>-</td>
<td>17</td>
<td>100%</td>
<td>2,470</td>
<td>3,177</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Depoteron</td>
<td>178</td>
<td>197</td>
<td>316</td>
<td>-</td>
<td>50</td>
<td>532%</td>
<td>3,784</td>
<td>5,283</td>
<td>71</td>
<td>71</td>
</tr>
<tr>
<td>(b)PSI Injectable 3 IM Distributed Provided</td>
<td>(103)</td>
<td>(217)</td>
<td>(282)</td>
<td>-</td>
<td>(33)</td>
<td>-%</td>
<td>(1,134)</td>
<td>(2,106)</td>
<td>(63)</td>
<td>(63)</td>
</tr>
<tr>
<td>Injectable 3-IM Provided</td>
<td>103</td>
<td>219</td>
<td>288</td>
<td>-</td>
<td>53</td>
<td>443%</td>
<td>1,368</td>
<td>3,213</td>
<td>72</td>
<td>72</td>
</tr>
<tr>
<td>Non-PSI Injectable 3 IM Provided</td>
<td>-</td>
<td>2</td>
<td>6</td>
<td>-</td>
<td>20</td>
<td>(70)%</td>
<td>54</td>
<td>1,107</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>PSI Injectable 3 IM Provided</td>
<td>103</td>
<td>217</td>
<td>282</td>
<td>-</td>
<td>33</td>
<td>755%</td>
<td>1,314</td>
<td>2,106</td>
<td>71</td>
<td>71</td>
</tr>
<tr>
<td>Injectable 3-SC</td>
<td>(13)</td>
<td>(45)</td>
<td>(47)</td>
<td>200</td>
<td>-</td>
<td>0%</td>
<td>(102)</td>
<td>(149)</td>
<td>(11)</td>
<td>(11)</td>
</tr>
<tr>
<td>(b)PSI Injectable 3 SC Distributed Provided</td>
<td>(13)</td>
<td>(45)</td>
<td>(47)</td>
<td>(800)</td>
<td>-</td>
<td>-%</td>
<td>(102)</td>
<td>(149)</td>
<td>(11)</td>
<td>(11)</td>
</tr>
<tr>
<td>Sayana Press</td>
<td>-</td>
<td>-</td>
<td>1,000</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Injectable 3-SC Provided</td>
<td>13</td>
<td>261</td>
<td>47</td>
<td>800</td>
<td>-</td>
<td>0%</td>
<td>769</td>
<td>816</td>
<td>12</td>
<td>12</td>
</tr>
<tr>
<td>Non-PSI Injectable 3 SC Provided</td>
<td>-</td>
<td>216</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>667</td>
<td>667</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PSI Injectable 3 SC Provided</td>
<td>13</td>
<td>45</td>
<td>47</td>
<td>800</td>
<td>-</td>
<td>-%</td>
<td>102</td>
<td>149</td>
<td>12</td>
<td>12</td>
</tr>
<tr>
<td>IUD 10</td>
<td>-</td>
<td>(3)</td>
<td>(10)</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>492</td>
<td>601</td>
<td>(9)</td>
<td>(41)</td>
</tr>
<tr>
<td>Copper-T 380-A IUD</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>9/16</td>
<td>-</td>
<td>-%</td>
<td>494</td>
<td>644</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>(b)PSI IUD 10 Distributed Inserted</td>
<td>-</td>
<td>(3)</td>
<td>(10)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>IUD 10 Insertion</td>
<td>29</td>
<td>94</td>
<td>93</td>
<td>-</td>
<td>58</td>
<td>60%</td>
<td>329</td>
<td>1,044</td>
<td>93</td>
<td>428</td>
<td>15</td>
<td>-</td>
</tr>
<tr>
<td>Non-PSI IUD 10 Inserted</td>
<td>29</td>
<td>91</td>
<td>83</td>
<td>-</td>
<td>58</td>
<td>43%</td>
<td>327</td>
<td>1,001</td>
<td>83</td>
<td>382</td>
<td>14</td>
<td>-</td>
</tr>
<tr>
<td>PSI IUD 10 Inserted</td>
<td>-</td>
<td>3</td>
<td>10</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>2</td>
<td>43</td>
<td>10</td>
<td>46</td>
<td>2</td>
<td>-</td>
</tr>
<tr>
<td>LLIN (Hammock net)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>6,000</td>
<td>400</td>
<td>(100)%</td>
<td>781</td>
<td>2,085</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Tana Nets</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>6,000</td>
<td>400</td>
<td>(100)%</td>
<td>781</td>
<td>2,085</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Malaria RDK</td>
<td>1,010</td>
<td>3,960</td>
<td>2,160</td>
<td>31,500</td>
<td>5,340</td>
<td>(60)%</td>
<td>35,300</td>
<td>61,680</td>
<td>1,944</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>On-site Malaria Pf/Pv Ag Rapid Test</td>
<td>120</td>
<td>633</td>
<td>120</td>
<td>4,500</td>
<td>90</td>
<td>33%</td>
<td>5,690</td>
<td>30,030</td>
<td>108</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>SD Bioline Malaria Ag Pf/Pv Rapid Test</td>
<td>890</td>
<td>3,327</td>
<td>2,040</td>
<td>27,000</td>
<td>5,250</td>
<td>(61)%</td>
<td>29,610</td>
<td>31,650</td>
<td>1,836</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Needle &amp; Syringe</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>225,000</td>
<td>(100)%</td>
<td>270,100</td>
<td>22,405,150</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>B-braun Omnican 40 (U-40 Insulin/40I.U.)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>225,000</td>
<td>9/13</td>
<td>(100)%</td>
<td>270,100</td>
<td>22,405,150</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>OCs Provided</td>
<td>-</td>
<td>89</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>268</td>
<td>1,599</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Non-PSI OCs Provided</td>
<td>-</td>
<td>89</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>268</td>
<td>1,599</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Positive RDTs</td>
<td>44</td>
<td>59</td>
<td>86</td>
<td>900</td>
<td>223</td>
<td>(61)%</td>
<td>854</td>
<td>1,752</td>
<td>86</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Positive RDTs</td>
<td>44</td>
<td>59</td>
<td>86</td>
<td>900</td>
<td>223</td>
<td>(61)%</td>
<td>854</td>
<td>1,752</td>
<td>86</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Positive RDTs Given First Line Treatment</td>
<td>35</td>
<td>35</td>
<td>69</td>
<td>765</td>
<td>200</td>
<td>(66)%</td>
<td>569</td>
<td>1,106</td>
<td>69</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Positive RDTs Given First Line Treatment</td>
<td>35</td>
<td>35</td>
<td>69</td>
<td>765</td>
<td>200</td>
<td>(66)%</td>
<td>569</td>
<td>1,106</td>
<td>69</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>QAACTs Provided after Confirmatory Diagnosis</td>
<td>34</td>
<td>32</td>
<td>63</td>
<td>464</td>
<td>1</td>
<td>6200%</td>
<td>230</td>
<td>398</td>
<td>63</td>
<td>-</td>
<td>12</td>
<td>-</td>
</tr>
<tr>
<td>Non-PSI QAACTs Provided after Confirmed Diagnosis</td>
<td>34</td>
<td>32</td>
<td>63</td>
<td>464</td>
<td>1</td>
<td>6200%</td>
<td>230</td>
<td>398</td>
<td>63</td>
<td>-</td>
<td>12</td>
<td>-</td>
</tr>
<tr>
<td>Referral to Linkage to HIV Care</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>-</td>
<td>19</td>
<td>19</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral to Linkage to HIV Care</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>19</td>
<td>19</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Toilets Sold</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>410</td>
<td>-</td>
<td>(100)%</td>
<td>1,113</td>
<td>7,416</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Toilet Type 1, Direct Sales</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>410</td>
<td>-</td>
<td>(100)%</td>
<td>1,113</td>
<td>7,416</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Toilets Sold - All</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>410</td>
<td>-</td>
<td>(100)%</td>
<td>1,113</td>
<td>5,272</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Toilets Sold - All</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>410</td>
<td>-</td>
<td>(100)%</td>
<td>1,113</td>
<td>5,272</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
<table>
<thead>
<tr>
<th>Treatment</th>
<th>DISTRIBUTION 2/2020</th>
<th>MONTHLY AVG PREV 3 MONTHS</th>
<th>YTD DISTRIBUTION 2020</th>
<th>DISTRIBUTION TARGET 2020</th>
<th>YTD DISTRIBUTION 2019</th>
<th>LAUNCH DATE</th>
<th>YTD % CHANGE</th>
<th>TOTAL DISTRIBUTION 2019</th>
<th>CUMULATIVE DISTRIBUTION (a)</th>
<th>YTD USERS REACHED 2020</th>
<th>YTD CYP 2020</th>
<th>YTD DALY 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vivax Treatment after Confirmatory Diagnosis</td>
<td>1</td>
<td>5</td>
<td>6</td>
<td>185</td>
<td>-</td>
<td>0%</td>
<td>92</td>
<td>122</td>
<td>6</td>
<td>-</td>
<td>-</td>
<td>1</td>
</tr>
<tr>
<td>Non-PSI Vivax Treatment after Confirmed Diagnosis</td>
<td>1</td>
<td>5</td>
<td>6</td>
<td>185</td>
<td>-</td>
<td>-%</td>
<td>92</td>
<td>122</td>
<td>6</td>
<td>-</td>
<td>-</td>
<td>1</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.
(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
Foundation Market Group
<table>
<thead>
<tr>
<th>Country</th>
<th>New HIV Infections</th>
<th>STI Deaths</th>
<th>PWID Deaths</th>
<th>TB Deaths</th>
<th>CYP*</th>
<th>Maternal Deaths</th>
<th>Unintended Pregnancies</th>
<th>Malaria Deaths</th>
<th>Diarrhea Deaths</th>
<th>Pneumonia Deaths</th>
<th>Cervical Cancer Death</th>
<th>Sum of All Deaths</th>
</tr>
</thead>
<tbody>
<tr>
<td>Foundation Market Group</td>
<td>415</td>
<td>-</td>
<td>-</td>
<td>156</td>
<td>264,083</td>
<td>299</td>
<td>103,822</td>
<td>7,143</td>
<td>10</td>
<td>105</td>
<td>-</td>
<td>9,866</td>
</tr>
<tr>
<td>Haiti</td>
<td>220</td>
<td>-</td>
<td>-</td>
<td>156</td>
<td>2,004</td>
<td>1</td>
<td>603</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>164</td>
</tr>
<tr>
<td>Madagascar</td>
<td>191</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>173,922</td>
<td>130</td>
<td>62,455</td>
<td>344</td>
<td>7</td>
<td>79</td>
<td>-</td>
<td>1,415</td>
</tr>
<tr>
<td>Mali</td>
<td>4</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>87,755</td>
<td>160</td>
<td>40,579</td>
<td>6,778</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>7,995</td>
</tr>
<tr>
<td>Somaliland</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>401</td>
<td>8</td>
<td>186</td>
<td>2</td>
<td>2</td>
<td>26</td>
<td>-</td>
<td>273</td>
</tr>
<tr>
<td>South Sudan</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>19</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>19</td>
</tr>
</tbody>
</table>

* Using USAID CYP conversion factors
## Monthly Distribution by Market Group and Product

### Period: 2
### Year: 2020

<table>
<thead>
<tr>
<th>Foundation Market Group</th>
<th>DISTRIBUTION</th>
<th>MONTHLY AVG PREV 3 MONTHS</th>
<th>YTD DISTRIBUTION 2020</th>
<th>DISTRIBUTION TARGET 2020</th>
<th>YTD DISTRIBUTION 2019</th>
<th>YTD % CHANGE</th>
<th>TOTAL DISTRIBUTION 2019</th>
<th>CUMULATIVE SALES</th>
<th>YTD USERS REACHED (a)</th>
<th>YTD CYP 2020</th>
<th>YTD DALY 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute Malnutrition Screening_CU5</td>
<td>-</td>
<td>7</td>
<td>-</td>
<td>-</td>
<td>389</td>
<td>(100)%</td>
<td>410</td>
<td>410</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Antiretroviral Treatment (Currently Enrolled)</td>
<td>35,784</td>
<td>34,005</td>
<td>68,402</td>
<td>153,740</td>
<td>-</td>
<td>-%</td>
<td>139,035</td>
<td>694,012</td>
<td>5,700</td>
<td>-</td>
<td>11,610</td>
</tr>
<tr>
<td>Antiretroviral Treatment (Newly Enrolled)</td>
<td>397</td>
<td>483</td>
<td>692</td>
<td>2,275</td>
<td>-</td>
<td>-%</td>
<td>6,702</td>
<td>15,593</td>
<td>692</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Cervical Cancer-VIA and Cryotherapy</td>
<td>34</td>
<td>9</td>
<td>34</td>
<td>160</td>
<td>6</td>
<td>467%</td>
<td>156</td>
<td>1,532</td>
<td>34</td>
<td>-</td>
<td>10</td>
</tr>
<tr>
<td>Cervical Cancer-VIA and Thermal Ablation</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>250</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Cervical Cancer-VIA/VILI Screening</td>
<td>4,955</td>
<td>3,006</td>
<td>5,843</td>
<td>6,000</td>
<td>103</td>
<td>5,573%</td>
<td>25,479</td>
<td>105,022</td>
<td>5,843</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Chlorhexidine</td>
<td>440</td>
<td>979</td>
<td>1,040</td>
<td>30,604</td>
<td>-</td>
<td>-%</td>
<td>31,731</td>
<td>465,615</td>
<td>936</td>
<td>-</td>
<td>61</td>
</tr>
<tr>
<td>Condom</td>
<td>163,632</td>
<td>91,856</td>
<td>204,768</td>
<td>2,495,736</td>
<td>263,016</td>
<td>(22)%</td>
<td>1,828,764</td>
<td>71,331,544</td>
<td>1,536</td>
<td>1,536</td>
<td>1,858</td>
</tr>
<tr>
<td>Counseling &amp; Tx for Moderate Acute Malnutrition</td>
<td>2,858</td>
<td>1,297</td>
<td>2,858</td>
<td>18,059</td>
<td>1,962</td>
<td>46%</td>
<td>19,252</td>
<td>42,442</td>
<td>2,858</td>
<td>-</td>
<td>9,524</td>
</tr>
<tr>
<td>Diarrhea Treatment Kit</td>
<td>15,586</td>
<td>4,587</td>
<td>20,286</td>
<td>169,554</td>
<td>41,240</td>
<td>(51)%</td>
<td>91,713</td>
<td>1,673,884</td>
<td>18,257</td>
<td>-</td>
<td>595</td>
</tr>
<tr>
<td>Diarrhea Treatment Kit Provided</td>
<td>-</td>
<td>212</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>635</td>
<td>635</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Emergency Contraception</td>
<td>(9)</td>
<td>(5)</td>
<td>(13)</td>
<td>-</td>
<td>44,847</td>
<td>(100)%</td>
<td>44,760</td>
<td>83,708</td>
<td>(1)</td>
<td>(1)</td>
<td>-</td>
</tr>
<tr>
<td>Emergency Contraception Provided</td>
<td>12</td>
<td>5</td>
<td>16</td>
<td>-</td>
<td>33</td>
<td>(52)%</td>
<td>123</td>
<td>1,479</td>
<td>1</td>
<td>1</td>
<td>-</td>
</tr>
<tr>
<td>Fever Cases Attended</td>
<td>31,565</td>
<td>26,267</td>
<td>62,498</td>
<td>3,934,351</td>
<td>23,449</td>
<td>167%</td>
<td>204,513</td>
<td>733,170</td>
<td>62,498</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Fever Cases Tested with Microscopy</td>
<td>5,049</td>
<td>4,026</td>
<td>9,823</td>
<td>47,274</td>
<td>4,381</td>
<td>124%</td>
<td>37,419</td>
<td>231,484</td>
<td>9,823</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Fever Cases Tested with RDTs</td>
<td>47,203</td>
<td>34,943</td>
<td>92,009</td>
<td>3,895,899</td>
<td>42,060</td>
<td>119%</td>
<td>297,762</td>
<td>1,526,610</td>
<td>92,009</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Free Condom</td>
<td>405,336</td>
<td>2,035,363</td>
<td>1,602,816</td>
<td>19,218,164</td>
<td>956,862</td>
<td>68%</td>
<td>23,328,462</td>
<td>53,406,898</td>
<td>12,021</td>
<td>12,021</td>
<td>13,744</td>
</tr>
<tr>
<td>HIV Testing Services</td>
<td>19,145</td>
<td>55,275</td>
<td>56,870</td>
<td>221,964</td>
<td>19,807</td>
<td>187%</td>
<td>583,801</td>
<td>2,056,357</td>
<td>56,870</td>
<td>-</td>
<td>352</td>
</tr>
<tr>
<td>Hypertension Diagnosis</td>
<td>-</td>
<td>20</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>59</td>
<td>59</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Implant 3</td>
<td>178</td>
<td>2,002</td>
<td>502</td>
<td>1,360</td>
<td>5,501</td>
<td>(91)%</td>
<td>15,508</td>
<td>(12,158)</td>
<td>452</td>
<td>1,130</td>
<td>681</td>
</tr>
<tr>
<td>Implant 3 Insertion</td>
<td>3,338</td>
<td>4,302</td>
<td>5,920</td>
<td>6,497</td>
<td>5,133</td>
<td>15%</td>
<td>58,002</td>
<td>163,260</td>
<td>5,920</td>
<td>14,800</td>
<td>11,394</td>
</tr>
</tbody>
</table>

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Implant 4</td>
<td>-</td>
<td>(1)</td>
<td>(1)</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>(12)</td>
<td>(2,541)</td>
<td>(1)</td>
<td>(3)</td>
<td>(2)</td>
</tr>
<tr>
<td>Implant 4 Insertion</td>
<td>-</td>
<td>1</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>182</td>
<td>2,711</td>
<td>1</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>Implant 5</td>
<td>4,191</td>
<td>914</td>
<td>6,940</td>
<td>1,500</td>
<td>4,492</td>
<td>54%</td>
<td>20,434</td>
<td>137,930</td>
<td>6,246</td>
<td>23,735</td>
<td>26,917</td>
</tr>
<tr>
<td>Implant 5 Insertion</td>
<td>5,088</td>
<td>5,980</td>
<td>9,949</td>
<td>7,500</td>
<td>1,687</td>
<td>490%</td>
<td>45,724</td>
<td>162,359</td>
<td>9,949</td>
<td>37,806</td>
<td>42,824</td>
</tr>
<tr>
<td>Injectable 1 Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>270</td>
<td>270</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Injectable 3-IM</td>
<td>318,445</td>
<td>187,396</td>
<td>509,229</td>
<td>1,868,316</td>
<td>194,568</td>
<td>162%</td>
<td>2,150,139</td>
<td>22,535,624</td>
<td>114,577</td>
<td>114,577</td>
<td>50,988</td>
</tr>
<tr>
<td>Injectable 3-IM Provided</td>
<td>7,529</td>
<td>8,381</td>
<td>13,038</td>
<td>5,589</td>
<td>6,666</td>
<td>96%</td>
<td>80,561</td>
<td>337,744</td>
<td>3,260</td>
<td>3,260</td>
<td>2,499</td>
</tr>
<tr>
<td>Injectable 3-SC</td>
<td>-</td>
<td>465</td>
<td>-</td>
<td>480,284</td>
<td>21,291</td>
<td>(100)%</td>
<td>509,958</td>
<td>1,914,252</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Injectable 3-SC Provided</td>
<td>506</td>
<td>242</td>
<td>737</td>
<td>2,000</td>
<td>63</td>
<td>1,070%</td>
<td>1,774</td>
<td>2,686</td>
<td>184</td>
<td>184</td>
<td>130</td>
</tr>
<tr>
<td>IPTp2</td>
<td>1,091</td>
<td>382</td>
<td>1,091</td>
<td>275,251</td>
<td>753</td>
<td>45%</td>
<td>5,919</td>
<td>10,768</td>
<td>1,091</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Iron Folic Acid Tablet</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>13,755</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>IUD 10</td>
<td>328</td>
<td>2,190</td>
<td>1,634</td>
<td>3,000</td>
<td>943</td>
<td>73%</td>
<td>12,638</td>
<td>54,088</td>
<td>1,471</td>
<td>6,765</td>
<td>7,649</td>
</tr>
<tr>
<td>IUD 10 Insertion</td>
<td>1,420</td>
<td>2,852</td>
<td>3,174</td>
<td>7,000</td>
<td>2,763</td>
<td>15%</td>
<td>37,004</td>
<td>308,222</td>
<td>3,174</td>
<td>14,600</td>
<td>14,103</td>
</tr>
<tr>
<td>IUD 5 Insertion</td>
<td>45</td>
<td>21</td>
<td>46</td>
<td>304</td>
<td>56</td>
<td>(18)%</td>
<td>265</td>
<td>610</td>
<td>46</td>
<td>152</td>
<td>142</td>
</tr>
<tr>
<td>IUS 3</td>
<td>(16)</td>
<td>9</td>
<td>(80)</td>
<td>-</td>
<td>24</td>
<td>(433)%</td>
<td>51</td>
<td>69</td>
<td>(72)</td>
<td>(180)</td>
<td>(102)</td>
</tr>
<tr>
<td>IUS 3 Insertion</td>
<td>86</td>
<td>103</td>
<td>182</td>
<td>1,500</td>
<td>58</td>
<td>214%</td>
<td>1,131</td>
<td>1,448</td>
<td>182</td>
<td>455</td>
<td>258</td>
</tr>
<tr>
<td>IUS 5</td>
<td>-</td>
<td>3</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>30</td>
<td>30</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>IUS 5 Insertion</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>82</td>
<td>82</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>LLIN</td>
<td>3,020</td>
<td>1,163,093</td>
<td>82,570</td>
<td>16,809,477</td>
<td>1,274,895</td>
<td>(94)%</td>
<td>6,377,414</td>
<td>69,286,112</td>
<td>133,763</td>
<td>-</td>
<td>3,266</td>
</tr>
<tr>
<td>Lubricant</td>
<td>23,900</td>
<td>259,183</td>
<td>580,400</td>
<td>3,312,000</td>
<td>1,110,864</td>
<td>(48)%</td>
<td>3,676,834</td>
<td>6,199,888</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Malaria PPT (ACT)</td>
<td>-</td>
<td>1,682,262</td>
<td>1,288,567</td>
<td>12,248,518</td>
<td>430,578</td>
<td>199%</td>
<td>5,930,040</td>
<td>24,545,513</td>
<td>1,159,710</td>
<td>-</td>
<td>607,275</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.
## Monthly Distribution by Market Group and Product

**Period:** 2  
**Year:** 2020

<table>
<thead>
<tr>
<th>Product</th>
<th>DISTRIBUTION 2/2020</th>
<th>MONTHLY AVG PREV 3 MONTHS</th>
<th>YTD DISTRIBUTION 2020</th>
<th>DISTRIBUTION TARGET 2020</th>
<th>YTD DISTRIBUTION 2019</th>
<th>YTD % CHANGE</th>
<th>TOTAL DISTRIBUTION 2019</th>
<th>CUMULATIVE SALES</th>
<th>YTD USERS REACHED</th>
<th>YTD DALY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Malaria PPT (Non-ACT)</td>
<td>900</td>
<td>15,000</td>
<td>-%</td>
<td>22,080</td>
<td>338,320</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Malaria RDK</td>
<td>202,525</td>
<td>361,975</td>
<td>122,250</td>
<td>196%</td>
<td>3,675,250</td>
<td>29,628,983</td>
<td>325,778</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Manual Vacuum Aspiration for PAC</td>
<td>457</td>
<td>855</td>
<td>603</td>
<td>107%</td>
<td>7,505</td>
<td>22,246</td>
<td>855</td>
<td>-</td>
<td>381</td>
<td></td>
</tr>
<tr>
<td>Misoprostol for PAC Provided</td>
<td>1,143</td>
<td>924</td>
<td>1,210</td>
<td>(6)%</td>
<td>16,306</td>
<td>43,008</td>
<td>1,142</td>
<td>-</td>
<td>551</td>
<td></td>
</tr>
<tr>
<td>Misoprostol for PPH</td>
<td>167</td>
<td>4,500</td>
<td>2,500</td>
<td>(100)%</td>
<td>15,500</td>
<td>210,208</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Misoprostol for Safe Abortion</td>
<td>5,477</td>
<td>29,191</td>
<td>485,300</td>
<td>80%</td>
<td>106,820</td>
<td>199,818</td>
<td>1,533</td>
<td>-</td>
<td>652</td>
<td></td>
</tr>
<tr>
<td>Multivitamin</td>
<td>-</td>
<td>-</td>
<td>14,171</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>OCs</td>
<td>376,273</td>
<td>550,207</td>
<td>1,789,552</td>
<td>651%</td>
<td>2,317,388</td>
<td>43,858,757</td>
<td>33,012</td>
<td>33,012</td>
<td>15,479</td>
<td></td>
</tr>
<tr>
<td>OCs Provided</td>
<td>1,454</td>
<td>7,187</td>
<td>1,435</td>
<td>70%</td>
<td>12,988</td>
<td>114,008</td>
<td>163</td>
<td>163</td>
<td>119</td>
<td></td>
</tr>
<tr>
<td>ORS</td>
<td>27,448</td>
<td>-</td>
<td>570</td>
<td>(100)%</td>
<td>299,226</td>
<td>10,385,932</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>ORS Provided</td>
<td>3,342</td>
<td>2,613</td>
<td>4,445</td>
<td>(25)%</td>
<td>29,095</td>
<td>45,946</td>
<td>3,342</td>
<td>-</td>
<td>134</td>
<td></td>
</tr>
<tr>
<td>Pneumonia PPT</td>
<td>10,246</td>
<td>18,352</td>
<td>221,280</td>
<td>-%</td>
<td>152,525</td>
<td>170,877</td>
<td>16,517</td>
<td>-</td>
<td>6,735</td>
<td></td>
</tr>
<tr>
<td>Pneumonia PPT Provided</td>
<td>1,842</td>
<td>13,959</td>
<td>2,689</td>
<td>(29)%</td>
<td>16,712</td>
<td>30,186</td>
<td>1,899</td>
<td>-</td>
<td>2,194</td>
<td></td>
</tr>
<tr>
<td>Positive RDTs</td>
<td>5,576</td>
<td>375,409</td>
<td>3,254</td>
<td>471%</td>
<td>28,743</td>
<td>200,526</td>
<td>18,590</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Pregnancy Test</td>
<td>-</td>
<td>-</td>
<td>100,752</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>QAACTs Provided after Confirmatory Diagnosis</td>
<td>354</td>
<td>2,057</td>
<td>295</td>
<td>20%</td>
<td>1,748</td>
<td>3,974</td>
<td>354</td>
<td>-</td>
<td>80</td>
<td></td>
</tr>
<tr>
<td>Safe Water Solution</td>
<td>8</td>
<td>993,368</td>
<td>(100)%</td>
<td>370,393</td>
<td>23,928,568</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SDM (Cycle Beads)</td>
<td>(3)</td>
<td>-</td>
<td>39</td>
<td>(39)</td>
<td>(185)</td>
<td>143,324</td>
<td>(7)</td>
<td>(7)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SDM (Cycle Beads) Provided</td>
<td>52</td>
<td>152</td>
<td>41</td>
<td>27%</td>
<td>247</td>
<td>5,456</td>
<td>52</td>
<td>78</td>
<td>88</td>
<td></td>
</tr>
<tr>
<td>Seasonal Malaria Chemoprevention_children reached</td>
<td>664,026</td>
<td>2,497,230</td>
<td>-%</td>
<td>1,992,077</td>
<td>1,992,077</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Skilled Birth Attendance</td>
<td>1,727</td>
<td>15,731</td>
<td>2,239</td>
<td>8%</td>
<td>18,979</td>
<td>38,094</td>
<td>2,420</td>
<td>-</td>
<td>3,448</td>
<td></td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>STI Screening</td>
<td>812</td>
<td>710</td>
<td>1,120</td>
<td>990</td>
<td>1,361</td>
<td>(18)%</td>
<td>9,330</td>
<td>88,698</td>
<td>1,120</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>TB Diagnosis</td>
<td>2,905</td>
<td>-</td>
<td>2,905</td>
<td>17,836</td>
<td>3,172</td>
<td>(8)%</td>
<td>10,115</td>
<td>52,150</td>
<td>2,905</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>TB DOTS</td>
<td>2,568</td>
<td>-</td>
<td>2,568</td>
<td>17,836</td>
<td>3,901</td>
<td>(34)%</td>
<td>11,108</td>
<td>56,710</td>
<td>2,568</td>
<td>8,790</td>
<td></td>
</tr>
<tr>
<td>TB Screening</td>
<td>10,572</td>
<td>-</td>
<td>10,572</td>
<td>76,668</td>
<td>14,933</td>
<td>(29)%</td>
<td>38,860</td>
<td>149,633</td>
<td>10,572</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Toilets Sold</td>
<td>10</td>
<td>6</td>
<td>18</td>
<td>-</td>
<td>6</td>
<td>199%</td>
<td>93</td>
<td>6,408</td>
<td>101</td>
<td>-</td>
<td>4</td>
</tr>
<tr>
<td>Toilets Sold - All</td>
<td>202</td>
<td>127</td>
<td>353</td>
<td>-</td>
<td>118</td>
<td>199%</td>
<td>1,908</td>
<td>3,776</td>
<td>2,012</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Inguinal Bubo</td>
<td>3</td>
<td>2</td>
<td>6</td>
<td>-</td>
<td>6</td>
<td>-%</td>
<td>26</td>
<td>168</td>
<td>6</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Lower Abdominal Pain</td>
<td>37</td>
<td>32</td>
<td>59</td>
<td>-</td>
<td>66</td>
<td>(11)%</td>
<td>494</td>
<td>2,602</td>
<td>59</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Nonherpetic Genital Ulcer</td>
<td>47</td>
<td>41</td>
<td>69</td>
<td>-</td>
<td>112</td>
<td>(38)%</td>
<td>686</td>
<td>3,621</td>
<td>69</td>
<td>-</td>
<td>8</td>
</tr>
<tr>
<td>Treatment for Pre-Eclampsia (with MgSO4)</td>
<td>79</td>
<td>50</td>
<td>79</td>
<td>313</td>
<td>38</td>
<td>108%</td>
<td>410</td>
<td>832</td>
<td>79</td>
<td>-</td>
<td>274</td>
</tr>
<tr>
<td>Treatment for Severe Acute Malnutrition</td>
<td>1,294</td>
<td>548</td>
<td>1,294</td>
<td>6,773</td>
<td>389</td>
<td>233%</td>
<td>6,999</td>
<td>17,893</td>
<td>1,294</td>
<td>6,811</td>
<td></td>
</tr>
<tr>
<td>Treatment for Urethral Discharge (Men)</td>
<td>293</td>
<td>279</td>
<td>439</td>
<td>-</td>
<td>563</td>
<td>(22)%</td>
<td>3,705</td>
<td>17,361</td>
<td>439</td>
<td>-</td>
<td>3</td>
</tr>
<tr>
<td>Treatment for Urethral Discharge (Women)</td>
<td>-</td>
<td>94</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>282</td>
<td>282</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Vaginitis</td>
<td>219</td>
<td>201</td>
<td>333</td>
<td>-</td>
<td>468</td>
<td>(29)%</td>
<td>3,213</td>
<td>15,579</td>
<td>333</td>
<td>-</td>
<td>3</td>
</tr>
<tr>
<td>Tubal Ligation</td>
<td>-</td>
<td>1</td>
<td>-</td>
<td>23</td>
<td>1</td>
<td>(100)%</td>
<td>31</td>
<td>147</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Type 2 Diabetes Diagnosis</td>
<td>-</td>
<td>9</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>26</td>
<td>26</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Water Treatment Tablets</td>
<td>172,000</td>
<td>232,267</td>
<td>252,000</td>
<td>6,079,936</td>
<td>1,123,360</td>
<td>(78)%</td>
<td>4,854,942</td>
<td>151,631,984</td>
<td>4,142</td>
<td>-</td>
<td>18</td>
</tr>
<tr>
<td>Zinc</td>
<td>1,112</td>
<td>850</td>
<td>1,112</td>
<td>-</td>
<td>40</td>
<td>2,680%</td>
<td>2,690</td>
<td>16,934</td>
<td>1,001</td>
<td>-</td>
<td>5</td>
</tr>
<tr>
<td>Zinc Provided</td>
<td>3,333</td>
<td>2,408</td>
<td>3,333</td>
<td>26,010</td>
<td>4,376</td>
<td>(24)%</td>
<td>28,688</td>
<td>43,855</td>
<td>3,333</td>
<td>-</td>
<td>67</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.
<table>
<thead>
<tr>
<th>Foundation Market Group</th>
<th>TOTAL DISTRIBUTION 2019</th>
<th>CUMULATIVE DISTRIBUTION</th>
<th>%YTD USERS REACHED 2020</th>
<th>YTD CYP 2020</th>
<th>YTD DALY 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Haiti</td>
<td>2,004</td>
<td>22,039</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Antiretroviral Treatment (Currently Enrolled) | 35,784 | 33,941 | 68,402 | 153,740 | - | 0% | 138,841 | 693,818 | 5,700 | - | 11,610 |
| Antiretroviral Treatment (Currently Enrolled) | 35,784 | 33,941 | 68,402 | 153,740 | - | -% | 138,841 | 693,818 | 5,700 | - | 11,610 |
| Antiretroviral Treatment (Newly Enrolled) | 397 | 298 | 692 | 1,582 | - | 0% | 6,054 | 14,608 | 692 | - | - |
| Antiretroviral Treatment (Newly Enrolled) | 397 | 298 | 692 | 1,582 | - | -% | 6,054 | 14,608 | 692 | - | - |
| Cervical Cancer-VIA and Cryotherapy | - | - | - | - | - | 0% | 1 | 124 | - | - | - |
| Cervical Cancer-VIA and Cryotherapy | - | - | - | - | - | -% | 1 | 124 | - | - | - |
| Cervical Cancer-VIA/VILI Screening | - | - | - | - | - | 1 (100)% | 7 | 820 | - | - | - |
| Cervical Cancer-VIA/VILI Screening | - | - | - | - | - | 1 (100)% | 7 | 820 | - | - | - |
| Emergency Contraception | - | - | - | 44,880 | 9/17 | (100)% | 44,880 | 85,180 | - | - | - |
| Levonorgestrel 1.5 mg Tablet | - | - | - | 44,880 | 9/17 | (100)% | 44,880 | 85,180 | - | - | - |
| Emergency Contraception Provided | 3 | - | 3 | - | - | 0% | 3 | 6 | - | - | - |
| Non-PSI Emergency Contraception Provided | 3 | - | 3 | - | - | -% | 3 | 6 | - | - | - |
| Fever Cases Attended | - | 1,164 | 1,918 | - | 795 | 141% | 5,003 | 53,490 | 1,918 | - | - |
| Fever Cases Attended | - | 1,164 | 1,918 | - | 795 | 141% | 5,003 | 53,490 | 1,918 | - | - |
| Fever Cases Tested with Microscopy | 3,561 | 2,816 | 6,903 | 47,274 | 4,252 | 62% | 29,938 | 212,076 | 6,903 | - | - |
| Fever Cases Tested with Microscopy | 3,561 | 2,816 | 6,903 | 47,274 | 4,252 | 62% | 29,938 | 212,076 | 6,903 | - | - |
| Fever Cases Tested with RDTs | 19,650 | 14,478 | 40,305 | 158,266 | 25,901 | 56% | 144,954 | 953,099 | 40,305 | - | - |
| Fever Cases Tested with RDTs | 19,650 | 14,478 | 40,305 | 158,266 | 25,901 | 56% | 144,954 | 953,099 | 40,305 | - | - |
| Free Condom | 14,400 | 132,752 | 232,656 | - | 781,902 | (70)% | 3,054,510 | 11,543,704 | 1,745 | 1,745 | 1,279 |
| Generic Condom | 14,400 | 132,752 | 232,656 | - | 781,902 | (70)% | 3,054,510 | 11,543,704 | 1,745 | 1,745 | 1,279 |
| HIV Testing Services | 14,162 | 14,611 | 30,661 | 173,595 | - | 0% | 264,946 | 962,565 | 30,661 | - | 247 |
| VCT Individual (HIV-Negative) | 13,838 | 14,310 | 30,005 | 170,191 | - | -% | 259,040 | 922,686 | 30,005 | - | 242 |
| VCT Individual (HIV-Positive) | 324 | 301 | 656 | 3,404 | - | -% | 5,906 | 39,879 | 656 | - | 5 |

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Implant 3 Insertion</td>
<td>4</td>
<td>11</td>
<td>18</td>
<td>-</td>
<td>21</td>
<td>(14)%</td>
<td>120</td>
<td>825</td>
<td>18</td>
<td>45</td>
<td>22</td>
<td></td>
</tr>
<tr>
<td>Non-PSI Implant 3 Inserted</td>
<td>4</td>
<td>11</td>
<td>18</td>
<td>-</td>
<td>21</td>
<td>(14)%</td>
<td>120</td>
<td>825</td>
<td>18</td>
<td>45</td>
<td>22</td>
<td></td>
</tr>
<tr>
<td>Injectable 3-SC Provided</td>
<td>99</td>
<td>89</td>
<td>214</td>
<td>-</td>
<td>63</td>
<td>240%</td>
<td>804</td>
<td>1,193</td>
<td>54</td>
<td>54</td>
<td>19</td>
<td></td>
</tr>
<tr>
<td>Non-PSI Injectable 3 SC Provided</td>
<td>99</td>
<td>89</td>
<td>214</td>
<td>-</td>
<td>63</td>
<td>240%</td>
<td>804</td>
<td>1,193</td>
<td>54</td>
<td>54</td>
<td>19</td>
<td></td>
</tr>
<tr>
<td>IUD 10</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>450</td>
<td>2,747</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Confi ance Plus IUD</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>450</td>
<td>2,747</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>IUD 10 Insertion</td>
<td>7</td>
<td>9</td>
<td>24</td>
<td>-</td>
<td>13</td>
<td>85%</td>
<td>72</td>
<td>420</td>
<td>24</td>
<td>110</td>
<td>51</td>
<td></td>
</tr>
<tr>
<td>Non-PSI IUD 10 Inserted</td>
<td>7</td>
<td>9</td>
<td>24</td>
<td>-</td>
<td>13</td>
<td>85%</td>
<td>72</td>
<td>420</td>
<td>24</td>
<td>110</td>
<td>51</td>
<td></td>
</tr>
<tr>
<td>IUD 5 Insertion</td>
<td>6</td>
<td>3</td>
<td>7</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>9</td>
<td>16</td>
<td>7</td>
<td>23</td>
<td>11</td>
<td></td>
</tr>
<tr>
<td>Non-PSI IUD 5 Inserted</td>
<td>6</td>
<td>3</td>
<td>7</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>9</td>
<td>16</td>
<td>7</td>
<td>23</td>
<td>11</td>
<td></td>
</tr>
<tr>
<td>IUS 5</td>
<td>-</td>
<td>3</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>30</td>
<td>30</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>LNG IUS - Bayer</td>
<td>-</td>
<td>3</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>30</td>
<td>30</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>LLIN</td>
<td>-</td>
<td>-</td>
<td>887,009</td>
<td>50</td>
<td>(100)%</td>
<td>226,310</td>
<td>3,931,636</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>LLIN Free</td>
<td>-</td>
<td>-</td>
<td>887,009</td>
<td>50</td>
<td>1/08</td>
<td>(100)%</td>
<td>226,310</td>
<td>3,931,636</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Lubricant</td>
<td>15,000</td>
<td>198,333</td>
<td>550,000</td>
<td>-</td>
<td>1,077,000</td>
<td>(49)%</td>
<td>2,230,072</td>
<td>3,003,072</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Lube Sachet Free</td>
<td>15,000</td>
<td>198,333</td>
<td>550,000</td>
<td>-</td>
<td>1,077,000</td>
<td>3/17</td>
<td>(49)%</td>
<td>2,230,072</td>
<td>3,003,072</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Malaria PPT (Non-ACT)</td>
<td>-</td>
<td>900</td>
<td>-</td>
<td>15,000</td>
<td>-</td>
<td>0%</td>
<td>22,080</td>
<td>338,320</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Chloroquine</td>
<td>-</td>
<td>900</td>
<td>-</td>
<td>15,000</td>
<td>-</td>
<td>0%</td>
<td>22,080</td>
<td>338,320</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>MEURI</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>25,532</td>
<td>101,854</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>OCs Provided</td>
<td>195</td>
<td>176</td>
<td>408</td>
<td>-</td>
<td>189</td>
<td>116%</td>
<td>1,053</td>
<td>3,216</td>
<td>27</td>
<td>27</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>Non-PSI OCs Provided</td>
<td>195</td>
<td>176</td>
<td>408</td>
<td>-</td>
<td>189</td>
<td>116%</td>
<td>1,053</td>
<td>3,216</td>
<td>27</td>
<td>27</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>ORS</td>
<td>-</td>
<td>26,448</td>
<td>-</td>
<td>490</td>
<td>189</td>
<td>116%</td>
<td>1,053</td>
<td>3,216</td>
<td>27</td>
<td>27</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>Sel Lavi</td>
<td>-</td>
<td>26,448</td>
<td>-</td>
<td>490</td>
<td>10/99</td>
<td>(100)%</td>
<td>296,146</td>
<td>10,343,484</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Positive RDTs</td>
<td>2,687</td>
<td>1,342</td>
<td>4,975</td>
<td>15,000</td>
<td>1,099</td>
<td>353%</td>
<td>5,620</td>
<td>50,279</td>
<td>4,975</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
### Monthly Distribution by Country

**Period:** 2  
**Year:** 2020

| Product Type                                      | DISTRIBUTION 2/2020 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION TARGET 2020 | DISTRIBUTION 2020 | YTD DISTRIBUTION 2019 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2019 | CUMULATIVE DISTRIBUTION (a) | (%)YTD USERS REACHED 2020 | YTD CYP 2020 | YTD DALY 2020 |
|--------------------------------------------------|---------------------|---------------------------|-------------------------------|-------------------|------------------------|-------------|--------------|-------------------------|-----------------------------|-----------------------------|----------------|----------------|----------------|
| Positive RDTs                                    | 2,687               | 1,342                     | 4,975                         | 15,000            | 1,099                  |             | 353%         | 5,620                   | 50,279                      | 4,975                       | -              | -              |
| TB Diagnosis                                     | 2,905               | -                         | 2,905                         | 17,836            | 3,172                  | (8)%        |             | 10,115                  | 52,150                      | 2,905                       | -              | -              |
| TB Diagnosis                                     | 2,905               | -                         | 2,905                         | 17,836            | 3,172                  | (8)%        |             | 10,115                  | 52,150                      | 2,905                       | -              | -              |
| TB DOTS                                          | 2,568               | -                         | 2,568                         | 17,836            | 3,901                  | (34)%       |             | 11,108                  | 56,710                      | 2,568                       | -              | 8,790          |
| TB DOTS                                          | 2,568               | -                         | 2,568                         | 17,836            | 3,901                  | (34)%       |             | 11,108                  | 56,710                      | 2,568                       | -              | 8,790          |
| TB Screening                                     | 10,572              | -                         | 10,572                        | 76,668            | 14,933                 | (29)%       |             | 38,860                  | 149,633                     | 10,572                      | -              | -              |
| TB Screening                                     | 10,572              | -                         | 10,572                        | 76,668            | 14,933                 | (29)%       |             | 38,860                  | 149,633                     | 10,572                      | -              | -              |

#### Liberia

| Product Type                                      | DISTRIBUTION 2/2020 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION TARGET 2020 | DISTRIBUTION 2020 | YTD DISTRIBUTION 2019 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2019 | CUMULATIVE DISTRIBUTION (a) | (%)YTD USERS REACHED 2020 | YTD CYP 2020 | YTD DALY 2020 |
|--------------------------------------------------|---------------------|---------------------------|-------------------------------|-------------------|------------------------|-------------|--------------|-------------------------|-----------------------------|-----------------------------|----------------|----------------|----------------|
| Condom                                           | -                   | 65                        | -                             | -                 | -                      | 0%          | -            | 194                     | 194                          | -                           | -              | -              |
| STAR                                             | -                   | -                         | -                             | -                 | -                      | -%          | -            | 194                     | 194                          | -                           | -              | -              |
| Antiretroviral Treatment (Newly Enrolled)         | -                   | 185                       | -                             | 693               | -                      | 0%          | -            | 648                     | 985                          | -                           | -              | -              |
| Antiretroviral Treatment (Newly Enrolled)         | -                   | 185                       | -                             | 693               | -                      | -%          | -            | 648                     | 985                          | -                           | -              | -              |
| Condom                                           | -                   | -                         | -                             | -                 | 129,024                | (100)%      | -            | 132,672                 | 6,628,730                     | -                           | -              | -              |
| Free Condom                                      | -                   | 9,600                     | -                             | 3,312,000         | 18,000                 | (100)%      | 925,200      | 1,680,581               | -                            | -                           | -              | -              |
| Generic Condom                                   | -                   | 9,600                     | -                             | 3,312,000         | 18,000                 | (100)%      | 925,200      | 1,680,581               | -                            | -                           | -              | -              |
| HIV Testing Services                             | -                   | 1,505                     | -                             | 23,077            | 159                    | (100)%      | 16,543       | 30,848                  | -                            | -                           | -              | -              |
| VCT Individual (HIV-Negative)                    | -                   | 1,470                     | -                             | 21,922            | 154                    | (100)%      | 15,863       | 29,521                  | -                            | -                           | -              | -              |
| VCT Individual (HIV-Positive)                    | -                   | 35                        | -                             | 1,155             | 5                      | (100)%      | 680          | 1,327                   | -                            | -                           | -              | -              |
| Lubricant                                        | -                   | 2,667                     | -                             | 3,312,000         | 33,000                 | (100)%      | 1,259,000    | 1,860,891               | -                            | -                           | -              | -              |
| Lube Sachet Free                                 | -                   | 2,667                     | -                             | 3,312,000         | 33,000                 | (100)%      | 1,259,000    | 1,860,891               | -                            | -                           | -              | -              |
| Safe Water Solution                              | -                   | 8                         | -                             | 4,000             | 7,608                  | (100)%      | 25,798       | 798,487                 | -                            | -                           | -              | -              |
| WaterGuard                                       | -                   | 8                         | -                             | 4,000             | 7,608                  | (100)%      | 25,798       | 798,487                 | -                            | -                           | -              | -              |

#### Madagascar

| Product Type                                      | DISTRIBUTION 2/2020 | MONTHLY AVG PREV 3 MONTHS | YTD DISTRIBUTION TARGET 2020 | DISTRIBUTION 2020 | YTD DISTRIBUTION 2019 | LAUNCH DATE | YTD % CHANGE | TOTAL DISTRIBUTION 2019 | CUMULATIVE DISTRIBUTION (a) | (%)YTD USERS REACHED 2020 | YTD CYP 2020 | YTD DALY 2020 |
|--------------------------------------------------|---------------------|---------------------------|-------------------------------|-------------------|------------------------|-------------|--------------|-------------------------|-----------------------------|-----------------------------|----------------|----------------|----------------|
| Cervical Cancer-VIA and Cryotherapy              | -                   | 1                         | -                             | -                 | 6                      | (100)%      | 26           | 206                     | -                            | -                           | -              | -              |

---

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
## Monthly Distribution by Country

**Period:** 2  
**Year:** 2020

<table>
<thead>
<tr>
<th>DISTRIBUTION 2/2020</th>
<th>MONTHLY AVG PREV 3 MONTHS</th>
<th>YTD DISTRIBUTION 2020</th>
<th>DISTRIBUTION TARGET 2020</th>
<th>YTD DISTRIBUTION 2019</th>
<th>LAUNCH DATE</th>
<th>YTD % CHANGE</th>
<th>TOTAL DISTRIBUTION 2019</th>
<th>CUMULATIVE DISTRIBUTION (a)</th>
<th>%YTD USERS REACHED 2020</th>
<th>YTD CYP 2020</th>
<th>YTD DALY 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cervical Cancer-VIA and Cryotherapy</td>
<td>-</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>6</td>
<td>(100)%</td>
<td>26</td>
<td>206</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Cervical Cancer-VIA/VILI Screening</td>
<td>53</td>
<td>44</td>
<td>88</td>
<td>-</td>
<td>85</td>
<td>4%</td>
<td>631</td>
<td>3,151</td>
<td>88</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Cervical Cancer-VIA/VILI Screening</td>
<td>53</td>
<td>44</td>
<td>88</td>
<td>-</td>
<td>85</td>
<td>4%</td>
<td>631</td>
<td>3,151</td>
<td>88</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Chlorhexidine</td>
<td>440</td>
<td>979</td>
<td>1,040</td>
<td>30,604</td>
<td>-</td>
<td>0%</td>
<td>31,731</td>
<td>465,615</td>
<td>936</td>
<td>-</td>
<td>61</td>
</tr>
<tr>
<td>Arofoitra</td>
<td>440</td>
<td>979</td>
<td>1,040</td>
<td>30,604</td>
<td>-</td>
<td>9/15</td>
<td>-%</td>
<td>31,731</td>
<td>465,615</td>
<td>936</td>
<td>-</td>
</tr>
<tr>
<td>Condom</td>
<td>163,632</td>
<td>91,856</td>
<td>204,768</td>
<td>2,495,736</td>
<td>133,992</td>
<td>53%</td>
<td>1,696,092</td>
<td>64,702,814</td>
<td>1,536</td>
<td>1,536</td>
<td>1,858</td>
</tr>
<tr>
<td>Protector Plus</td>
<td>163,632</td>
<td>91,856</td>
<td>204,768</td>
<td>1,646,048</td>
<td>63,792</td>
<td>221%</td>
<td>1,426,992</td>
<td>59,998,994</td>
<td>1,536</td>
<td>1,536</td>
<td>1,858</td>
</tr>
<tr>
<td>YES</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>849,688</td>
<td>70,200</td>
<td>(100)%</td>
<td>269,100</td>
<td>4,703,820</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Diarrhea Treatment Kit</td>
<td>15,586</td>
<td>4,587</td>
<td>20,286</td>
<td>59,346</td>
<td>1,240</td>
<td>1536%</td>
<td>11,713</td>
<td>497,928</td>
<td>18,257</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>ORS-Zinc</td>
<td>15,586</td>
<td>4,587</td>
<td>20,286</td>
<td>59,346</td>
<td>1,240</td>
<td>8/14</td>
<td>1,536%</td>
<td>11,713</td>
<td>497,928</td>
<td>18,257</td>
<td>-</td>
</tr>
<tr>
<td>Emergency Contraception</td>
<td>(9)</td>
<td>(5)</td>
<td>(13)</td>
<td>-</td>
<td>(33)</td>
<td>0%</td>
<td>(120)</td>
<td>(1,472)</td>
<td>(1)</td>
<td>(1)</td>
<td>-</td>
</tr>
<tr>
<td>(b) PSI Emergency Contraception Distributed Provided</td>
<td>(9)</td>
<td>(5)</td>
<td>(13)</td>
<td>-</td>
<td>(33)</td>
<td>-%</td>
<td>(120)</td>
<td>(1,472)</td>
<td>(1)</td>
<td>(1)</td>
<td>-</td>
</tr>
<tr>
<td>Emergency Contraception Provided</td>
<td>9</td>
<td>5</td>
<td>13</td>
<td>-</td>
<td>33</td>
<td>(61)%</td>
<td>120</td>
<td>1,472</td>
<td>1</td>
<td>1</td>
<td>-</td>
</tr>
<tr>
<td>PSI Emergency Contraception Provided</td>
<td>9</td>
<td>5</td>
<td>13</td>
<td>-</td>
<td>33</td>
<td>(61)%</td>
<td>120</td>
<td>1,472</td>
<td>1</td>
<td>1</td>
<td>-</td>
</tr>
<tr>
<td>Fever Cases Attended</td>
<td>31,565</td>
<td>25,085</td>
<td>60,580</td>
<td>3,934,351</td>
<td>22,654</td>
<td>167%</td>
<td>199,455</td>
<td>679,625</td>
<td>60,580</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Fever Cases Attended</td>
<td>31,565</td>
<td>25,085</td>
<td>60,580</td>
<td>3,934,351</td>
<td>22,654</td>
<td>167%</td>
<td>199,455</td>
<td>679,625</td>
<td>60,580</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Fever Cases Tested with Microscopy</td>
<td>1,488</td>
<td>1,211</td>
<td>2,920</td>
<td>-</td>
<td>129</td>
<td>2164%</td>
<td>7,481</td>
<td>19,408</td>
<td>2,920</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Fever Cases Tested with Microscopy</td>
<td>1,488</td>
<td>1,211</td>
<td>2,920</td>
<td>-</td>
<td>129</td>
<td>2,164%</td>
<td>7,481</td>
<td>19,408</td>
<td>2,920</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Fever Cases Tested with RDTs</td>
<td>27,553</td>
<td>20,465</td>
<td>51,704</td>
<td>3,737,633</td>
<td>16,159</td>
<td>220%</td>
<td>152,808</td>
<td>573,511</td>
<td>51,704</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Fever Cases Tested with RDTs</td>
<td>27,553</td>
<td>20,465</td>
<td>51,704</td>
<td>3,737,633</td>
<td>16,159</td>
<td>220%</td>
<td>152,808</td>
<td>573,511</td>
<td>51,704</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Free Condom</td>
<td>384,336</td>
<td>1,885,611</td>
<td>1,341,360</td>
<td>15,906,164</td>
<td>156,960</td>
<td>755%</td>
<td>19,237,152</td>
<td>40,042,013</td>
<td>10,060</td>
<td>10,060</td>
<td>12,169</td>
</tr>
<tr>
<td>KPOTY</td>
<td>384,336</td>
<td>1,885,611</td>
<td>1,341,360</td>
<td>15,906,164</td>
<td>156,960</td>
<td>1/18</td>
<td>755%</td>
<td>19,237,152</td>
<td>40,042,013</td>
<td>10,060</td>
<td>10,060</td>
</tr>
<tr>
<td>HIV Testing Services</td>
<td>2,397</td>
<td>37,198</td>
<td>23,623</td>
<td>8,278</td>
<td>17,025</td>
<td>39%</td>
<td>282,199</td>
<td>1,027,650</td>
<td>23,623</td>
<td>-</td>
<td>80</td>
</tr>
<tr>
<td>VCT Individual (HIV-Negative)</td>
<td>2,390</td>
<td>37,193</td>
<td>23,549</td>
<td>7,450</td>
<td>16,912</td>
<td>39%</td>
<td>281,299</td>
<td>1,025,061</td>
<td>23,549</td>
<td>-</td>
<td>79</td>
</tr>
<tr>
<td>VCT Individual (HIV-Positive)</td>
<td>7</td>
<td>95</td>
<td>74</td>
<td>828</td>
<td>113</td>
<td>12/09</td>
<td>(35)%</td>
<td>811</td>
<td>2,589</td>
<td>74</td>
<td>-</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Implant 3</td>
<td>178</td>
<td>1,726</td>
<td>502</td>
<td>-</td>
<td>3,480</td>
<td>(86)%</td>
<td></td>
<td>8,423</td>
<td>(21,596)</td>
<td>452</td>
<td>1,130</td>
<td>681</td>
</tr>
<tr>
<td>Implanon NXT</td>
<td>2,760</td>
<td>4,627</td>
<td>4,578</td>
<td>-</td>
<td>7,678</td>
<td>5/17</td>
<td>(40)%</td>
<td>51,579</td>
<td>95,862</td>
<td>4,120</td>
<td>10,301</td>
<td>6,215</td>
</tr>
<tr>
<td>(b)PSI Implant 3 Distributed Inserted</td>
<td>(2,582)</td>
<td>(2,901)</td>
<td>(4,076)</td>
<td>-</td>
<td>(4,198)</td>
<td>-</td>
<td>(3)%</td>
<td>(43,156)</td>
<td>(117,460)</td>
<td>(3,668)</td>
<td>(9,171)</td>
<td>(5,533)</td>
</tr>
<tr>
<td>Implant 3 Insertion</td>
<td>2,582</td>
<td>2,901</td>
<td>4,076</td>
<td>-</td>
<td>4,198</td>
<td>(3)%</td>
<td></td>
<td>43,156</td>
<td>117,460</td>
<td>4,076</td>
<td>10,190</td>
<td>6,148</td>
</tr>
<tr>
<td>PSI Implant 3 Inserted</td>
<td>2,582</td>
<td>2,901</td>
<td>4,076</td>
<td>-</td>
<td>4,198</td>
<td>(3)%</td>
<td>(43,156)</td>
<td>117,460</td>
<td>4,076</td>
<td>10,190</td>
<td>6,148</td>
<td></td>
</tr>
<tr>
<td>Implant 4</td>
<td>-</td>
<td>(1)</td>
<td>(1)</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>(12)</td>
<td>(2,541)</td>
<td>(1)</td>
<td>(3)</td>
<td>(2)</td>
<td>(2)</td>
</tr>
<tr>
<td>(b)PSI Implant 4 Distributed Inserted</td>
<td>-</td>
<td>(1)</td>
<td>(1)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>(12)</td>
<td>(2,541)</td>
<td>(1)</td>
<td>(3)</td>
<td>(2)</td>
<td></td>
</tr>
<tr>
<td>Implant 4 Insertion</td>
<td>-</td>
<td>1</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>12</td>
<td>2,541</td>
<td>1</td>
<td>3</td>
<td>2</td>
<td>(2)</td>
</tr>
<tr>
<td>PSI Implant 4 Inserted</td>
<td>-</td>
<td>1</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>12</td>
<td>2,541</td>
<td>1</td>
<td>3</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Implant 5</td>
<td>(9)</td>
<td>(2)</td>
<td>(10)</td>
<td>-</td>
<td>(8)</td>
<td>0%</td>
<td>(67)</td>
<td>(2,274)</td>
<td>(9)</td>
<td>(34)</td>
<td>(20)</td>
<td>(20)</td>
</tr>
<tr>
<td>(b)PSI Implant 5 Distributed Inserted</td>
<td>(9)</td>
<td>(2)</td>
<td>(10)</td>
<td>-</td>
<td>(8)</td>
<td>-</td>
<td>(67)</td>
<td>(2,274)</td>
<td>(9)</td>
<td>(34)</td>
<td>(20)</td>
<td></td>
</tr>
<tr>
<td>Implant 5 Insertion</td>
<td>9</td>
<td>2</td>
<td>10</td>
<td>-</td>
<td>8</td>
<td>25%</td>
<td>67</td>
<td>2,274</td>
<td>10</td>
<td>38</td>
<td>22</td>
<td>22</td>
</tr>
<tr>
<td>PSI Implant 5 Inserted</td>
<td>9</td>
<td>2</td>
<td>10</td>
<td>-</td>
<td>8</td>
<td>25%</td>
<td>67</td>
<td>2,274</td>
<td>10</td>
<td>38</td>
<td>22</td>
<td></td>
</tr>
<tr>
<td>Injectable 3-IM</td>
<td>318,345</td>
<td>187,029</td>
<td>508,529</td>
<td>1,864,716</td>
<td>193,223</td>
<td>163%</td>
<td></td>
<td>2,147,544</td>
<td>22,504,076</td>
<td>114,419</td>
<td>114,419</td>
<td>50,855</td>
</tr>
<tr>
<td>Contraceptive Injectable</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>198,150</td>
<td>10/98</td>
<td>(100)%</td>
<td>384,066</td>
<td>20,435,562</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>(b)PSI Injectable 3 IM Distributed Provided</td>
<td>(1,570)</td>
<td>(1,744)</td>
<td>(2,516)</td>
<td>-</td>
<td>(4,927)</td>
<td>-</td>
<td>(29,673)</td>
<td>(235,682)</td>
<td>(566)</td>
<td>(252)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Triclofen Injection 150 mg/mL</td>
<td>319,915</td>
<td>188,773</td>
<td>511,045</td>
<td>1,864,716</td>
<td>-</td>
<td>-</td>
<td>(1,793,151)</td>
<td>2,304,196</td>
<td>114,985</td>
<td>114,985</td>
<td>51,107</td>
<td></td>
</tr>
<tr>
<td>Injectable 3-IM Provided</td>
<td>1,570</td>
<td>1,744</td>
<td>2,516</td>
<td>-</td>
<td>4,927</td>
<td>(49)%</td>
<td>29,673</td>
<td>235,682</td>
<td>629</td>
<td>629</td>
<td>280</td>
<td></td>
</tr>
<tr>
<td>Triclofen Injection 150 mg/mL Provided</td>
<td>1,570</td>
<td>1,744</td>
<td>2,516</td>
<td>-</td>
<td>4,927</td>
<td>(49)%</td>
<td>29,673</td>
<td>235,682</td>
<td>629</td>
<td>629</td>
<td>280</td>
<td></td>
</tr>
<tr>
<td>Injectable 3-SC</td>
<td>-</td>
<td>465</td>
<td>-</td>
<td>480,284</td>
<td>21,291</td>
<td>(100)%</td>
<td></td>
<td>509,958</td>
<td>1,914,252</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Sayana Press</td>
<td>-</td>
<td>465</td>
<td>-</td>
<td>480,284</td>
<td>21,291</td>
<td>9/15</td>
<td>(100)%</td>
<td>509,958</td>
<td>1,914,252</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>IPTp2</td>
<td>-</td>
<td>-</td>
<td>269,681</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>IPTp2</td>
<td>-</td>
<td>-</td>
<td>269,681</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>IUD 10</td>
<td>(197)</td>
<td>928</td>
<td>(141)</td>
<td>-</td>
<td>(345)</td>
<td>0%</td>
<td>(1,865)</td>
<td>11,052</td>
<td>(127)</td>
<td>(584)</td>
<td>(330)</td>
<td>(330)</td>
</tr>
<tr>
<td>Copper T</td>
<td>-</td>
<td>176</td>
<td>300</td>
<td>-</td>
<td>361</td>
<td>5/06</td>
<td>(17)%</td>
<td>2,340</td>
<td>200,392</td>
<td>270</td>
<td>1,242</td>
<td>701</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pregna T Cu 380A</strong></td>
<td>260</td>
<td>1,757</td>
<td>260</td>
<td>-</td>
<td>975</td>
<td>7/17</td>
<td>(73)%</td>
<td>14,332</td>
<td>34,892</td>
<td>234</td>
<td>1,076</td>
<td>608</td>
</tr>
<tr>
<td>(b) <strong>PSI IUD 10 Distributed Inserted</strong></td>
<td>(457)</td>
<td>(1,004)</td>
<td>(701)</td>
<td>-</td>
<td>(1,681)</td>
<td>-</td>
<td>-</td>
<td>(18,537)</td>
<td>(224,232)</td>
<td>(631)</td>
<td>(2,902)</td>
<td>(1,639)</td>
</tr>
<tr>
<td><strong>IUD 10 Insertion</strong></td>
<td>457</td>
<td>1,004</td>
<td>701</td>
<td>-</td>
<td>1,681</td>
<td>(58)%</td>
<td>(224,232)</td>
<td>701</td>
<td>3,225</td>
<td>1,821</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>PSI IUD 10 Inserted</strong></td>
<td>457</td>
<td>1,004</td>
<td>701</td>
<td>-</td>
<td>1,681</td>
<td>(58)%</td>
<td>(224,232)</td>
<td>701</td>
<td>3,225</td>
<td>1,821</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>IUS 3</strong></td>
<td>(16)</td>
<td>9</td>
<td>(80)</td>
<td>-</td>
<td>24</td>
<td>(433)%</td>
<td>111</td>
<td>916</td>
<td>230</td>
<td>130</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Avibela (52 mg levonorgestrel)</strong></td>
<td>70</td>
<td>112</td>
<td>102</td>
<td>1,500</td>
<td>82</td>
<td>2/18</td>
<td>24%</td>
<td>1,182</td>
<td>1,517</td>
<td>92</td>
<td>230</td>
<td>130</td>
</tr>
<tr>
<td>(b) <strong>PSI IUS 3 Distributed Inserted</strong></td>
<td>(86)</td>
<td>(103)</td>
<td>(182)</td>
<td>(1,500)</td>
<td>(58)</td>
<td>-</td>
<td>-</td>
<td>(1,131)</td>
<td>(1,448)</td>
<td>(164)</td>
<td>(410)</td>
<td>(222)</td>
</tr>
<tr>
<td><strong>IUS 3 Insertion</strong></td>
<td>86</td>
<td>103</td>
<td>182</td>
<td>1,500</td>
<td>58</td>
<td>214%</td>
<td>1,131</td>
<td>(1,448)</td>
<td>182</td>
<td>455</td>
<td>258</td>
<td></td>
</tr>
<tr>
<td><strong>PSI IUS 3 Inserted</strong></td>
<td>86</td>
<td>103</td>
<td>182</td>
<td>1,500</td>
<td>58</td>
<td>214%</td>
<td>1,131</td>
<td>(1,448)</td>
<td>182</td>
<td>455</td>
<td>258</td>
<td></td>
</tr>
<tr>
<td><strong>LLIN</strong></td>
<td>3,020</td>
<td>182,917</td>
<td>82,570</td>
<td>1,521,563</td>
<td>575,250</td>
<td>(86)%</td>
<td>(1,060,856)</td>
<td>32,155,264</td>
<td>133,763</td>
<td>-</td>
<td>3,266</td>
<td></td>
</tr>
<tr>
<td><strong>Dawa Plus White</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>131,050</td>
<td>4/18</td>
<td>(100)%</td>
<td>131,050</td>
<td>7,022,800</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Generic net ‘PERMANET WHITE’</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>PermaNet</strong></td>
<td>420</td>
<td>583</td>
<td>2,070</td>
<td>-</td>
<td>38,000</td>
<td>3/07</td>
<td>(95)%</td>
<td>39,150</td>
<td>4,707,851</td>
<td>3,353</td>
<td>82</td>
<td></td>
</tr>
<tr>
<td><strong>Royal Sentry White</strong></td>
<td>-</td>
<td>34,667</td>
<td>77,900</td>
<td>824,167</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>26,100</td>
<td>104,000</td>
<td>126,198</td>
<td>-</td>
<td>3,081</td>
</tr>
<tr>
<td><strong>Safe Net Blue</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>8,650</td>
<td>(100)%</td>
<td>8,650</td>
<td>1,741,250</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Safe Net White</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>363,400</td>
<td>(100)%</td>
<td>363,400</td>
<td>859,050</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Super Moustiquaire</strong></td>
<td>2,600</td>
<td>147,667</td>
<td>2,600</td>
<td>450,000</td>
<td>2,500</td>
<td>9/01</td>
<td>4%</td>
<td>460,726</td>
<td>4,123,930</td>
<td>4,212</td>
<td>-</td>
<td>103</td>
</tr>
<tr>
<td><strong>Yorkool Blue (Generic Net)</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>247,396</td>
<td>-</td>
<td>7/15</td>
<td>-</td>
<td>1,378,824</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Yorkool White (Generic Net)</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>31,650</td>
<td>9/13</td>
<td>(100)%</td>
<td>31,650</td>
<td>3,001,393</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Lubricant</strong></td>
<td>8,900</td>
<td>58,183</td>
<td>30,400</td>
<td>-</td>
<td>864</td>
<td>3419%</td>
<td>187,762</td>
<td>1,335,925</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Gel Lubricant 5 mL</strong></td>
<td>8,900</td>
<td>58,183</td>
<td>30,400</td>
<td>-</td>
<td>864</td>
<td>12/16</td>
<td>3,419%</td>
<td>187,762</td>
<td>1,335,925</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Malaria PPT (ACT)</strong></td>
<td>-</td>
<td>182,541</td>
<td>100,619</td>
<td>4,355,313</td>
<td>328,094</td>
<td>(69)%</td>
<td>1,325,195</td>
<td>4,685,239</td>
<td>90,557</td>
<td>-</td>
<td>25,545</td>
<td></td>
</tr>
<tr>
<td><strong>ASAQ for Adolescent, 100/270mg, 3’s</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>336,276</td>
<td>109,995</td>
<td>7/16</td>
<td>(100)%</td>
<td>146,247</td>
<td>1,034,823</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td><strong>ASAQ for Adult, 100/270mg, 6’s</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>160,200</td>
<td>153,475</td>
<td>7/16</td>
<td>(100)%</td>
<td>196,332</td>
<td>1,196,686</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
### Monthly Distribution by Country

**Period:** 2  
**Year:** 2020

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>ASAQ for Infant, 25/67.5mg, 3’s</td>
<td>-</td>
<td>33,548</td>
<td>100,619</td>
<td>139,924</td>
<td>9,859</td>
<td>7/16</td>
<td>921%</td>
<td>125,758</td>
<td>472,406</td>
<td>90,557</td>
<td>-</td>
</tr>
<tr>
<td>ASAQ for Toddler, 50/135mg, 3’s</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>442,824</td>
<td>54,765</td>
<td>7/16</td>
<td>(100)%</td>
<td>263,628</td>
<td>1,388,094</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PRIVATE - AS/AQ 100mg+270mg (base) - 3 - Blister-3</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>2,631</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PRIVATE - AS/AQ 100mg+270mg (base) - 3 - Blister-6</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>17,239</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PRIVATE - AS/AQ 25mg+67.5mg (base) - 3 - Blister-3</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>18,044</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PRIVATE - AS/AQ 50mg+135mg (base) - 3 - Blister-3</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>17,222</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PRIVATE A/L(20/120mg,FDC,24's,Indiv)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>4,306</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PRIVATE A/L(20/120mg,FDC,6x1,Indiv)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>657</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PRIVATE A/L(20/120mg,FDC,6x3,Indiv)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>4,511</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PUBLIC - AS/AQ 100mg+270mg (base) - 3 - Blister-3</td>
<td>-</td>
<td>9,445</td>
<td>-</td>
<td>191,192</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>28,335</td>
<td>28,335</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PUBLIC - AS/AQ 100mg+270mg (base) - 3 - Blister-6</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1,033,843</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PUBLIC - AS/AQ 25mg+67.5mg (base) - 3 - Blister-3</td>
<td>-</td>
<td>45,892</td>
<td>-</td>
<td>611,092</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>157,925</td>
<td>157,925</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PUBLIC - AS/AQ 50mg+135mg (base) - 3 - Blister-3</td>
<td>-</td>
<td>93,657</td>
<td>-</td>
<td>1,266,156</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>406,970</td>
<td>406,970</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PUBLIC A/L(20/120mg,FDC,6x1,Indiv)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>5,003</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PUBLIC A/L(20/120mg,FDC,6x2,Indiv)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>32,795</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PUBLIC A/L(20/120mg,FDC,6x3,Indiv)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>34,326</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PUBLIC A/L(20/120mg,FDC,6x4,Indiv)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>32,763</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Malaria RDK</td>
<td>159,025</td>
<td>491,125</td>
<td>236,575</td>
<td>11,625,003</td>
<td>70,950</td>
<td>233%</td>
<td>2,113,625</td>
<td>19,450,063</td>
<td>212,918</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>RDT Malaria</td>
<td>159,025</td>
<td>491,125</td>
<td>236,575</td>
<td>11,625,003</td>
<td>70,950</td>
<td>8/11</td>
<td>233%</td>
<td>2,113,625</td>
<td>19,450,063</td>
<td>212,918</td>
<td>-</td>
</tr>
<tr>
<td>Manual Vacuum Aspiration for PAC</td>
<td>302</td>
<td>276</td>
<td>412</td>
<td>3,103</td>
<td>269</td>
<td>53%</td>
<td>3,055</td>
<td>9,643</td>
<td>412</td>
<td>-</td>
<td>128</td>
</tr>
<tr>
<td>MVA for PAC</td>
<td>302</td>
<td>276</td>
<td>412</td>
<td>3,103</td>
<td>269</td>
<td>53%</td>
<td>3,055</td>
<td>9,643</td>
<td>412</td>
<td>-</td>
<td>128</td>
</tr>
<tr>
<td>Misoprostol for PAC Provided</td>
<td>541</td>
<td>636</td>
<td>737</td>
<td>6,247</td>
<td>825</td>
<td>(11)%</td>
<td>9,055</td>
<td>21,140</td>
<td>737</td>
<td>92%</td>
<td>-</td>
</tr>
<tr>
<td>Non-PSI Misoprostol for PAC Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>6,247</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
<table>
<thead>
<tr>
<th>Product Description</th>
<th>DISTRIBUTION 2/2020</th>
<th>MONTHLY AVG PREV 3 MONTHS</th>
<th>YTD DISTRIBUTION 2020</th>
<th>DISTRIBUTION TARGET 2020</th>
<th>LAUNCH DATE</th>
<th>YTD % CHANGE</th>
<th>TOTAL DISTRIBUTION 2019</th>
<th>CUMULATIVE DISTRIBUTION</th>
<th>(b)YTD USERS REACHED 2020</th>
<th>YTD CYP 2020</th>
<th>YTD DALY 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>PSI Misoprostol for PAC Provided</td>
<td>541</td>
<td>636</td>
<td>737</td>
<td>-</td>
<td>825</td>
<td>(11)%</td>
<td>9,055</td>
<td>21,140</td>
<td>737</td>
<td>-</td>
<td>273</td>
</tr>
<tr>
<td>Misoprostol for Safe Abortion</td>
<td>20,455</td>
<td>5,477</td>
<td>19,671</td>
<td>435,300</td>
<td>16,200</td>
<td>21%</td>
<td>106,820</td>
<td>187,898</td>
<td>1,033</td>
<td>-</td>
<td>349</td>
</tr>
<tr>
<td>Misoprostol 200 mcg Tablet</td>
<td>22,619</td>
<td>8,020</td>
<td>22,619</td>
<td>435,300</td>
<td>19,500</td>
<td>16%</td>
<td>143,040</td>
<td>272,458</td>
<td>1,187</td>
<td>-</td>
<td>401</td>
</tr>
<tr>
<td>(b)PSI Misoprostol for Safe Abortion Dist Provided</td>
<td>(2,164)</td>
<td>(2,543)</td>
<td>(2,948)</td>
<td>(3,300)</td>
<td>-</td>
<td>-%</td>
<td>(36,220)</td>
<td>(84,560)</td>
<td>(155)</td>
<td>-</td>
<td>(52)</td>
</tr>
<tr>
<td>OCs</td>
<td>376,273</td>
<td>190,280</td>
<td>550,207</td>
<td>1,766,152</td>
<td>73,238</td>
<td>651%</td>
<td>2,291,856</td>
<td>43,606,684</td>
<td>33,012</td>
<td>33,012</td>
<td>15,479</td>
</tr>
<tr>
<td>Combination 3</td>
<td>365,350</td>
<td>40,567</td>
<td>485,550</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>742,940</td>
<td>1,228,490</td>
<td>29,133</td>
<td>29,133</td>
<td>13,660</td>
</tr>
<tr>
<td>Microgynon</td>
<td>11,160</td>
<td>149,991</td>
<td>65,031</td>
<td>1,766,400</td>
<td>27,960</td>
<td>133%</td>
<td>1,343,466</td>
<td>2,879,852</td>
<td>3,902</td>
<td>3,902</td>
<td>1,830</td>
</tr>
<tr>
<td>Pilplan</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>45,995</td>
<td>10/98</td>
<td>(100)%</td>
<td>209,745</td>
<td>39,591,072</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>(b)PSI OCs Distributed Provided</td>
<td>(237)</td>
<td>(278)</td>
<td>(374)</td>
<td>(3,248)</td>
<td>(717)</td>
<td>-%</td>
<td>(4,295)</td>
<td>(92,730)</td>
<td>(22)</td>
<td>(22)</td>
<td>(11)</td>
</tr>
<tr>
<td>OCs Provided</td>
<td>237</td>
<td>278</td>
<td>374</td>
<td>3,248</td>
<td>717</td>
<td>(48)%</td>
<td>4,295</td>
<td>92,730</td>
<td>25</td>
<td>25</td>
<td>12</td>
</tr>
<tr>
<td>PSI OCs Provided</td>
<td>237</td>
<td>278</td>
<td>374</td>
<td>3,248</td>
<td>717</td>
<td>(48)%</td>
<td>4,295</td>
<td>92,730</td>
<td>25</td>
<td>25</td>
<td>12</td>
</tr>
<tr>
<td>ORS</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>80</td>
<td>-</td>
<td>(100)%</td>
<td>80</td>
<td>39,448</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>SRO Generique</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>80</td>
<td>4/18</td>
<td>(100)%</td>
<td>80</td>
<td>39,448</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Pneumonia PPT</td>
<td>10,246</td>
<td>9,755</td>
<td>18,352</td>
<td>221,280</td>
<td>-</td>
<td>0%</td>
<td>152,525</td>
<td>170,877</td>
<td>16,517</td>
<td>-</td>
<td>6,735</td>
</tr>
<tr>
<td>Pneumox 250 (10's)</td>
<td>10,246</td>
<td>9,755</td>
<td>18,352</td>
<td>221,280</td>
<td>-</td>
<td>-%</td>
<td>152,525</td>
<td>170,877</td>
<td>16,517</td>
<td>-</td>
<td>6,735</td>
</tr>
<tr>
<td>Positive RDTs</td>
<td>8,153</td>
<td>4,234</td>
<td>13,615</td>
<td>360,409</td>
<td>2,155</td>
<td>532%</td>
<td>23,123</td>
<td>150,247</td>
<td>13,615</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Positive RDTs</td>
<td>8,153</td>
<td>4,234</td>
<td>13,615</td>
<td>360,409</td>
<td>2,155</td>
<td>532%</td>
<td>23,123</td>
<td>150,247</td>
<td>13,615</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Pregnancy Test</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>100,752</td>
<td>-</td>
<td>0%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Pregnancy Test</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>100,752</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Safe Water Solution</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>989,368</td>
<td>91,640</td>
<td>(100)%</td>
<td>344,595</td>
<td>23,130,081</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Sur Eau Vaovao</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>989,368</td>
<td>91,640</td>
<td>9/04</td>
<td>(100)%</td>
<td>344,595</td>
<td>23,130,081</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>SDM (Cycle Beads)</td>
<td>(3)</td>
<td>(8)</td>
<td>(8)</td>
<td>(39)</td>
<td>(39)</td>
<td>0%</td>
<td>(187)</td>
<td>(5,306)</td>
<td>(7)</td>
<td>(11)</td>
<td>(7)</td>
</tr>
<tr>
<td>(b)PSI SDM (Cycle Beads) Distributed Provided</td>
<td>(3)</td>
<td>(8)</td>
<td>(8)</td>
<td>(39)</td>
<td>(39)</td>
<td>-%</td>
<td>(187)</td>
<td>(5,306)</td>
<td>(7)</td>
<td>(11)</td>
<td>(7)</td>
</tr>
<tr>
<td>Rojo</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>3/12</td>
<td>-%</td>
<td>2</td>
<td>148,630</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>SDM (Cycle Beads) Provided</td>
<td>3</td>
<td>8</td>
<td>8</td>
<td>152</td>
<td>39</td>
<td>(79)%</td>
<td>187</td>
<td>5,306</td>
<td>8</td>
<td>12</td>
<td>8</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
### Monthly Distribution by Country

**Period:** 2  
**Year:** 2020

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-PSI SDM (Cycle Beads) Provided</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>152</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PSI SDM (Cycle Beads) Provided</td>
<td>3</td>
<td>8</td>
<td>8</td>
<td>-</td>
<td>39</td>
<td>(79)%</td>
<td>187</td>
<td>5,306</td>
<td>8</td>
<td>12</td>
<td>8</td>
</tr>
<tr>
<td>STI Screening</td>
<td>606</td>
<td>514</td>
<td>914</td>
<td>-</td>
<td>1,239</td>
<td>(26)%</td>
<td>8,085</td>
<td>84,945</td>
<td>914</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>STI Screening</td>
<td>606</td>
<td>514</td>
<td>914</td>
<td>-</td>
<td>1,239</td>
<td>(26)%</td>
<td>8,085</td>
<td>84,945</td>
<td>914</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Inguinal Bubo</td>
<td>3</td>
<td>2</td>
<td>6</td>
<td>-</td>
<td>6</td>
<td>0%</td>
<td>0</td>
<td>26</td>
<td>168</td>
<td>6</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Lower Abdominal Pain</td>
<td>37</td>
<td>32</td>
<td>59</td>
<td>-</td>
<td>66</td>
<td>(11)%</td>
<td>494</td>
<td>2,602</td>
<td>59</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Lower Abdominal Pain</td>
<td>37</td>
<td>32</td>
<td>59</td>
<td>-</td>
<td>66</td>
<td>(11)%</td>
<td>494</td>
<td>2,602</td>
<td>59</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Nonherpetic Genital Ulcer</td>
<td>47</td>
<td>41</td>
<td>69</td>
<td>-</td>
<td>112</td>
<td>(38)%</td>
<td>686</td>
<td>3,621</td>
<td>69</td>
<td>-</td>
<td>8</td>
</tr>
<tr>
<td>Treatment for Nonherpetic Genital Ulcer</td>
<td>47</td>
<td>41</td>
<td>69</td>
<td>-</td>
<td>112</td>
<td>(38)%</td>
<td>686</td>
<td>3,621</td>
<td>69</td>
<td>-</td>
<td>8</td>
</tr>
<tr>
<td>Treatment for Urethral Discharge (Men)</td>
<td>293</td>
<td>232</td>
<td>439</td>
<td>-</td>
<td>563</td>
<td>(22)%</td>
<td>3,565</td>
<td>17,221</td>
<td>439</td>
<td>-</td>
<td>3</td>
</tr>
<tr>
<td>Treatment for Urethral Discharge (Men)</td>
<td>293</td>
<td>232</td>
<td>439</td>
<td>-</td>
<td>563</td>
<td>(22)%</td>
<td>3,565</td>
<td>17,221</td>
<td>439</td>
<td>-</td>
<td>3</td>
</tr>
<tr>
<td>Treatment for Vaginitis</td>
<td>219</td>
<td>201</td>
<td>333</td>
<td>-</td>
<td>468</td>
<td>(29)%</td>
<td>3,213</td>
<td>15,579</td>
<td>333</td>
<td>-</td>
<td>3</td>
</tr>
<tr>
<td>Treatment for Vaginitis</td>
<td>219</td>
<td>201</td>
<td>333</td>
<td>-</td>
<td>468</td>
<td>(29)%</td>
<td>3,213</td>
<td>15,579</td>
<td>333</td>
<td>-</td>
<td>3</td>
</tr>
<tr>
<td>Tubal Ligation</td>
<td>-</td>
<td>1</td>
<td>-</td>
<td>23</td>
<td>1</td>
<td>(100)%</td>
<td>31</td>
<td>147</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Tubal Ligation</td>
<td>-</td>
<td>1</td>
<td>-</td>
<td>23</td>
<td>1</td>
<td>(100)%</td>
<td>31</td>
<td>147</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Water Treatment Tablets</td>
<td>124,000</td>
<td>68,867</td>
<td>204,000</td>
<td>3,647,936</td>
<td>475,200</td>
<td>(57)%</td>
<td>3,002,980</td>
<td>31,496,610</td>
<td>3,353</td>
<td>-</td>
<td>11</td>
</tr>
<tr>
<td>SUR'EAU PILINA (67mg tablet)</td>
<td>124,000</td>
<td>68,867</td>
<td>204,000</td>
<td>3,647,936</td>
<td>475,200</td>
<td>10/14</td>
<td>(57)%</td>
<td>3,002,980</td>
<td>31,496,610</td>
<td>3,353</td>
<td>-</td>
</tr>
<tr>
<td>Zinc</td>
<td>1,112</td>
<td>-</td>
<td>1,112</td>
<td>-</td>
<td>40</td>
<td>2680%</td>
<td>140</td>
<td>14,384</td>
<td>1,001</td>
<td>-</td>
<td>5</td>
</tr>
<tr>
<td>Zinc</td>
<td>1,112</td>
<td>-</td>
<td>1,112</td>
<td>-</td>
<td>40</td>
<td>1/08</td>
<td>2,680%</td>
<td>140</td>
<td>14,384</td>
<td>1,001</td>
<td>-</td>
</tr>
</tbody>
</table>

### Mali

<table>
<thead>
<tr>
<th>Product</th>
<th>DISTRIBUTION CUMULATIVE</th>
<th>YTD CYP</th>
<th>YTD DALY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cervical Cancer-VIA and Cryotherapy</td>
<td>34</td>
<td>7</td>
<td>34</td>
</tr>
<tr>
<td>Cervical Cancer-VIA and Cryotherapy</td>
<td>34</td>
<td>7</td>
<td>34</td>
</tr>
<tr>
<td>Cervical Cancer-VIA and Thermal Ablation</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Cervical Cancer-VIA and Thermal Ablation</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
## Monthly Distribution by Country
### Period: 2
### Year: 2020

<table>
<thead>
<tr>
<th></th>
<th>DISTRIBUTION 2/2020</th>
<th>MONTHLY AVG PREV 3 MONTHS</th>
<th>YTD DISTRIBUTION</th>
<th>DISTRIBUTION TARGET</th>
<th>YTD DISTRIBUTION 2019</th>
<th>LAUNCH DATE</th>
<th>YTD % CHANGE</th>
<th>TOTAL DISTRIBUTION 2019</th>
<th>CUMULATIVE DISTRIBUTION</th>
<th>%YTD USERS REACHED 2020</th>
<th>YTD CYP 2020</th>
<th>YTD DALY 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cervical Cancer-VIA/VILI Screening</strong></td>
<td>4,902</td>
<td>2,962</td>
<td>5,755</td>
<td>6,000</td>
<td>17</td>
<td>33753%</td>
<td>24,841</td>
<td>101,051</td>
<td>5,755</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Cervical Cancer-VIA/VILI Screening</strong></td>
<td>4,902</td>
<td>2,962</td>
<td>5,755</td>
<td>6,000</td>
<td>17</td>
<td>33753%</td>
<td>24,841</td>
<td>101,051</td>
<td>5,755</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Free Condom</strong></td>
<td>6,600</td>
<td>7,400</td>
<td>28,800</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>111,600</td>
<td>140,600</td>
<td>216</td>
<td>216</td>
<td>296</td>
</tr>
<tr>
<td><strong>Generic Condom</strong></td>
<td>6,600</td>
<td>7,400</td>
<td>28,800</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>111,600</td>
<td>140,600</td>
<td>216</td>
<td>216</td>
<td>296</td>
</tr>
<tr>
<td><strong>Implant 3</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1.000</td>
<td>2,016</td>
<td>(100)%</td>
<td>5,936</td>
<td>7,472</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Implanon NXT</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1.000</td>
<td>2,016</td>
<td>(100)%</td>
<td>5,936</td>
<td>7,472</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Implant 3 Insertion</strong></td>
<td>661</td>
<td>1,322</td>
<td>1,735</td>
<td>6,000</td>
<td>816</td>
<td>113%</td>
<td>14,195</td>
<td>43,457</td>
<td>1,735</td>
<td>4,338</td>
<td>4,993</td>
<td></td>
</tr>
<tr>
<td><strong>Non-PSI Implant 3 Inserted</strong></td>
<td>661</td>
<td>1,322</td>
<td>1,735</td>
<td>6,000</td>
<td>816</td>
<td>113%</td>
<td>14,195</td>
<td>43,457</td>
<td>1,735</td>
<td>4,338</td>
<td>4,993</td>
<td></td>
</tr>
<tr>
<td><strong>Implant 5</strong></td>
<td>4,200</td>
<td>917</td>
<td>6,950</td>
<td>1,500</td>
<td>4,500</td>
<td>54%</td>
<td>20,501</td>
<td>140,204</td>
<td>6,255</td>
<td>23,769</td>
<td>26,937</td>
<td></td>
</tr>
<tr>
<td><strong>Jadelle</strong></td>
<td>4,200</td>
<td>917</td>
<td>6,950</td>
<td>1,500</td>
<td>4,500</td>
<td>7/09</td>
<td>54%</td>
<td>20,501</td>
<td>140,204</td>
<td>6,255</td>
<td>23,769</td>
<td></td>
</tr>
<tr>
<td><strong>Implant 5 Insertion</strong></td>
<td>5,079</td>
<td>5,977</td>
<td>9,939</td>
<td>7,500</td>
<td>1,679</td>
<td>492%</td>
<td>45,657</td>
<td>160,085</td>
<td>9,939</td>
<td>37,768</td>
<td>42,802</td>
<td></td>
</tr>
<tr>
<td><strong>Non-PSI Implant 5 Inserted</strong></td>
<td>5,079</td>
<td>5,977</td>
<td>9,939</td>
<td>7,500</td>
<td>1,679</td>
<td>492%</td>
<td>45,657</td>
<td>160,085</td>
<td>9,939</td>
<td>37,768</td>
<td>42,802</td>
<td></td>
</tr>
<tr>
<td><strong>Injectable 3-IM</strong></td>
<td>100</td>
<td>367</td>
<td>700</td>
<td>-</td>
<td>1,025</td>
<td>(32)%</td>
<td>2,275</td>
<td>3,902</td>
<td>158</td>
<td>158</td>
<td>133</td>
<td></td>
</tr>
<tr>
<td><strong>Depo-Provera</strong></td>
<td>100</td>
<td>367</td>
<td>700</td>
<td>-</td>
<td>1,025</td>
<td>1/08</td>
<td>32%</td>
<td>2,275</td>
<td>3,902</td>
<td>158</td>
<td>158</td>
<td></td>
</tr>
<tr>
<td><strong>Injectable 3-IM Provided</strong></td>
<td>5,844</td>
<td>6,533</td>
<td>10,407</td>
<td>4,500</td>
<td>1,616</td>
<td>544%</td>
<td>49,970</td>
<td>100,093</td>
<td>2,602</td>
<td>2,602</td>
<td>2,198</td>
<td></td>
</tr>
<tr>
<td><strong>Non-PSI Injectable 3 IM Provided</strong></td>
<td>5,844</td>
<td>6,533</td>
<td>10,407</td>
<td>4,500</td>
<td>1,616</td>
<td>544%</td>
<td>49,970</td>
<td>100,093</td>
<td>2,602</td>
<td>2,602</td>
<td>2,198</td>
<td></td>
</tr>
<tr>
<td><strong>Injectable 3-SC Provided</strong></td>
<td>407</td>
<td>153</td>
<td>523</td>
<td>2,000</td>
<td>-</td>
<td>0%</td>
<td>970</td>
<td>1,493</td>
<td>131</td>
<td>131</td>
<td>110</td>
<td></td>
</tr>
<tr>
<td><strong>Non-PSI Injectable 3 SC Provided</strong></td>
<td>407</td>
<td>153</td>
<td>523</td>
<td>2,000</td>
<td>-</td>
<td>-</td>
<td>970</td>
<td>1,493</td>
<td>131</td>
<td>131</td>
<td>110</td>
<td></td>
</tr>
<tr>
<td><strong>IUD 10</strong></td>
<td>525</td>
<td>1,262</td>
<td>1,775</td>
<td>3,000</td>
<td>1,288</td>
<td>38%</td>
<td>14,053</td>
<td>40,289</td>
<td>1,598</td>
<td>7,348</td>
<td>7,979</td>
<td></td>
</tr>
<tr>
<td><strong>IUD Copper T 380A</strong></td>
<td>450</td>
<td>845</td>
<td>1,200</td>
<td>3,000</td>
<td>1,088</td>
<td>10%</td>
<td>11,803</td>
<td>37,339</td>
<td>1,080</td>
<td>4,968</td>
<td>5,394</td>
<td></td>
</tr>
<tr>
<td><strong>PPIUD Cu T380A</strong></td>
<td>75</td>
<td>417</td>
<td>575</td>
<td>-</td>
<td>200</td>
<td>188%</td>
<td>2,250</td>
<td>2,950</td>
<td>518</td>
<td>2,380</td>
<td>2,585</td>
<td></td>
</tr>
<tr>
<td><strong>IUD 10 Insertion</strong></td>
<td>956</td>
<td>1,839</td>
<td>2,449</td>
<td>7,000</td>
<td>1,069</td>
<td>129%</td>
<td>18,395</td>
<td>83,570</td>
<td>2,449</td>
<td>11,265</td>
<td>12,232</td>
<td></td>
</tr>
<tr>
<td><strong>Non-PSI IUD 10 Inserted</strong></td>
<td>956</td>
<td>1,839</td>
<td>2,449</td>
<td>7,000</td>
<td>1,069</td>
<td>129%</td>
<td>18,395</td>
<td>83,570</td>
<td>2,449</td>
<td>11,265</td>
<td>12,232</td>
<td></td>
</tr>
<tr>
<td><strong>LLIN</strong></td>
<td>-</td>
<td>884,980</td>
<td>-</td>
<td>9,156,691</td>
<td>657,095</td>
<td>(100)%</td>
<td>4,258,834</td>
<td>23,797,071</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td><strong>MILD - (G)</strong></td>
<td>-</td>
<td>409,513</td>
<td>-</td>
<td>7,856,691</td>
<td>-</td>
<td>10/14</td>
<td>2,108,334</td>
<td>13,306,486</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
### Monthly Distribution by Country

**Period:** 2  
**Year:** 2020

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>MILD - (O)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>9/16</td>
<td>-%</td>
<td>36</td>
<td>1,125,719</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>MILD - (U)</td>
<td>- 159,668</td>
<td>- 1,300,000</td>
<td>657,095</td>
<td>- 1,203,064</td>
<td>12/14</td>
<td>(100)%</td>
<td>8,417,466</td>
<td>947,400</td>
<td>947,400</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Yorkool White (Generic Net)</td>
<td>- 315,800</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td>-%</td>
<td>947,400</td>
<td>947,400</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Malaria PPT (ACT)</td>
<td>- 394,283</td>
<td>1,182,848</td>
<td>2,569,344</td>
<td>- 1,182,848</td>
<td>-</td>
<td>0%</td>
<td>1,064,563</td>
<td>580,122</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Artemether (Lumefantrine;20-120) 12's</td>
<td>-</td>
<td>836,845</td>
<td>-</td>
<td>-</td>
<td></td>
<td>-%</td>
<td>657,095</td>
<td>346,707</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Artemether/Lumefantrine 20/120mg Tab, 1x12's</td>
<td>- 128,410</td>
<td>385,230</td>
<td>-</td>
<td>-</td>
<td></td>
<td>-%</td>
<td>346,707</td>
<td>188,934</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Artemether/Lumefantrine 20/120mg Tab, 1x6's</td>
<td>- 265,873</td>
<td>797,618</td>
<td>1,732,499</td>
<td>-</td>
<td></td>
<td>-%</td>
<td>717,856</td>
<td>391,188</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Manual Vacuum Aspiration for PAC</td>
<td>155</td>
<td>399</td>
<td>443</td>
<td>2,900</td>
<td>145</td>
<td>206%</td>
<td>12,603</td>
<td>443</td>
<td>-</td>
<td>-</td>
<td>254</td>
</tr>
<tr>
<td>Misoprostol for PAC Provided</td>
<td>181</td>
<td>507</td>
<td>405</td>
<td>3,000</td>
<td>385</td>
<td>5%</td>
<td>21,868</td>
<td>405</td>
<td>-</td>
<td>-</td>
<td>278</td>
</tr>
<tr>
<td>Non-PSI Misoprostol for PAC Provided</td>
<td>181</td>
<td>507</td>
<td>405</td>
<td>3,000</td>
<td>385</td>
<td>5%</td>
<td>21,868</td>
<td>405</td>
<td>-</td>
<td>-</td>
<td>278</td>
</tr>
<tr>
<td>Misoprostol for Safe Abortion</td>
<td>9,520</td>
<td>- 9,520</td>
<td>50,000</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>500</td>
<td>304</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Misoprostol for Safe Abortion</td>
<td>-</td>
<td>-</td>
<td>50,000</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>2,400</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>OCs Provided</td>
<td>688</td>
<td>847</td>
<td>1,411</td>
<td>2,000</td>
<td>204</td>
<td>592%</td>
<td>13,947</td>
<td>94</td>
<td>94</td>
<td>84</td>
<td></td>
</tr>
<tr>
<td>Non-PSI OCs Provided</td>
<td>688</td>
<td>847</td>
<td>1,411</td>
<td>2,000</td>
<td>204</td>
<td>592%</td>
<td>13,947</td>
<td>94</td>
<td>94</td>
<td>84</td>
<td></td>
</tr>
<tr>
<td>SDM (Cycle Beads) Provided</td>
<td>36</td>
<td>11</td>
<td>44</td>
<td>-</td>
<td>2</td>
<td>2100%</td>
<td>60</td>
<td>44</td>
<td>66</td>
<td>80</td>
<td></td>
</tr>
<tr>
<td>Non-PSI SDM (Cycle Beads) Provided</td>
<td>36</td>
<td>11</td>
<td>44</td>
<td>-</td>
<td>2</td>
<td>2,100%</td>
<td>60</td>
<td>44</td>
<td>66</td>
<td>80</td>
<td></td>
</tr>
<tr>
<td>Seasonal Malaria Chemoprevention_children reach</td>
<td>- 664,026</td>
<td>- 2,497,230</td>
<td>-</td>
<td>0%</td>
<td>1,992,077</td>
<td>1,992,077</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>SMC for Children ages 12-59 months</td>
<td>- 554,228</td>
<td>- 2,497,230</td>
<td>-</td>
<td>-%</td>
<td>1,662,685</td>
<td>1,662,685</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>SMC for Infants ages 3-11 months</td>
<td>- 109,797</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>329,392</td>
<td>329,392</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Toilets Sold</td>
<td>10</td>
<td>6</td>
<td>18</td>
<td>-</td>
<td>6</td>
<td>199%</td>
<td>93</td>
<td>6,408</td>
<td>101</td>
<td>-</td>
<td>4</td>
</tr>
<tr>
<td>Toilet Type 1, Direct Sales</td>
<td>10</td>
<td>6</td>
<td>18</td>
<td>-</td>
<td>6</td>
<td>199%</td>
<td>93</td>
<td>6,408</td>
<td>101</td>
<td>-</td>
<td>4</td>
</tr>
<tr>
<td>Toilets Sold - All</td>
<td>202</td>
<td>127</td>
<td>353</td>
<td>- 118</td>
<td>-</td>
<td>199%</td>
<td>1,908</td>
<td>3,776</td>
<td>2,012</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

### Notes:

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
Toilets Sold - All

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>202</td>
<td>127</td>
<td>353</td>
<td>-</td>
<td>118</td>
<td>199%</td>
<td>1,908</td>
<td>3,776</td>
<td>2,012</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

Water Treatment Tablets

| Toilets Sold - All | 48,000 | 118,400 | 48,000 | 1,500,000 | - | 0% | 787,200 | 44,359,670 | 789 | - | 7 |

Aquatab

| Aquatab            | 48,000 | 118,400 | 48,000 | 1,500,000 | - | 2/09 | -% | 787,200 | 44,359,670 | 789 | - | 7 |

Somaliland

Acute Malnutrition Screening_CU5

| Acute Malnutrition Screening_CU5 | - | 7 | - | - | 389 | (100)% | 410 | 410 | - | - | - |

Acute Malnutrition Screening_CU5

| Acute Malnutrition Screening_CU5 | - | 7 | - | - | 389 | (100)% | 410 | 410 | - | - | - |

Counseling & Tx for Moderate Acute MalnutritionCU5

| Counseling & Tx for Moderate Acute MalnutritionCU5 | 2,858 | 1,297 | 2,858 | 18,059 | 1,962 | 46% | 19,252 | 42,442 | 2,858 | - | 9,524 |

Counseling & Tx for Moderate Acute MalnutritionCU5

| Counseling & Tx for Moderate Acute MalnutritionCU5 | 2,858 | 1,297 | 2,858 | 18,059 | 1,962 | 46% | 19,252 | 42,442 | 2,858 | - | 9,524 |

SD OFLV-DTK

| SD OFLV-DTK | - | - | - | - | 40,000 | (100)% | 80,000 | 1,175,956 | - | - | - |

Shuban Daweeye_DTK

| Shuban Daweeye_DTK | - | 212 | - | - | - | - | 635 | 635 | - | - | - |

Diarrhea Treatment Kit Provided

| Diarrhea Treatment Kit Provided | - | - | - | - | 110,208 | 40,000 | (100)% | 80,000 | 1,030,435 | - | - | - |

Non-PSI Diarrhea Treatment Kit Provided

| Non-PSI Diarrhea Treatment Kit Provided | - | 212 | - | - | - | - | 635 | 635 | - | - | - |

HIV Testing Services

| HIV Testing Services | 2,586 | 1,962 | 2,586 | 17,015 | 2,623 | (1)% | 20,202 | 35,294 | 2,586 | - | 25 |

VCT Individual (HIV-Negative)

| VCT Individual (HIV-Negative) | 2,586 | 1,962 | 2,586 | 17,015 | 2,623 | (1)% | 20,202 | 35,294 | 2,586 | - | 25 |

Hypertension Diagnosis

| Hypertension Diagnosis | - | 20 | - | - | - | - | 0% | 59 | 59 | - | - |

Hypertension Diagnosis

| Hypertension Diagnosis | - | 20 | - | - | - | - | 0% | 59 | 59 | - | - |

Implant 3

| Implant 3 | - | 276 | - | 360 | (41) | 0% | 1,095 | 1,404 | - | - | - |

Nasiye Implant (Implanon)

| Nasiye Implant (Implanon) | - | 276 | - | 360 | 5 | 12/15 | (100)% | 1,149 | 1,968 | - | - |

(b)PSI Implant 3 Distributed Inserted

| (b)PSI Implant 3 Distributed Inserted | - | - | - | - | (46) | -% | (54) | (564) | - | - | - |

Implant 3 Insertion

| Implant 3 Insertion | 91 | 68 | 91 | 497 | 98 | (7)% | 531 | 1,518 | 91 | 228 | 231 |

Non-PSI Implant 3 Inserted

| Non-PSI Implant 3 Inserted | 91 | 68 | 91 | 497 | 52 | 75% | 477 | 954 | 91 | 228 | 231 |

PSI Implant 3 Inserted

| PSI Implant 3 Inserted | - | - | - | - | 46 | (100)% | 54 | 564 | - | - | - |

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
## Monthly Distribution by Country

### Period: 2

#### Year: 2020

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Implant 4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0%</td>
<td>(85) (85)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(b) PSI Implant 4 Distributed Inserted</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>-%</td>
<td>(85) (85)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Implant 4 Insertion</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0%</td>
<td>170 170</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-PSI Implant 4 Inserted</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>-%</td>
<td>85 85</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PSI Implant 4 Inserted</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>-%</td>
<td>85 85</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Injectable 1 Provided</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0%</td>
<td>270 270</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-PSI Injectable 1 Provided</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>-%</td>
<td>270 270</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Injectable 3-IM</td>
<td></td>
<td></td>
<td>-</td>
<td>3,600 320</td>
<td>(100)%</td>
<td>320 27,646</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nasiye - Inj 3</td>
<td></td>
<td></td>
<td>-</td>
<td>3,600 320</td>
<td>6/11 (100)%</td>
<td>320 27,646</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Injectable 3-IM Provided</td>
<td></td>
<td></td>
<td>115 105 115</td>
<td>1,089 123</td>
<td>(7)%</td>
<td>918 1,969</td>
<td>29 29</td>
<td>21</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-PSI Injectable 3 IM Provided</td>
<td></td>
<td></td>
<td>115 105 115</td>
<td>1,089 123</td>
<td>(7)%</td>
<td>918 1,969</td>
<td>29 29</td>
<td>21</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IPTp2</td>
<td></td>
<td>1,091 382</td>
<td>1,091 5,570</td>
<td>753</td>
<td>45%</td>
<td>5,919 10,768</td>
<td>1,091 1,091</td>
<td>122</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IPTp2</td>
<td></td>
<td>1,091 382</td>
<td>1,091 5,570</td>
<td>753</td>
<td>45%</td>
<td>5,919 10,768</td>
<td>1,091 1,091</td>
<td>122</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Iron Folic Acid Tablet</td>
<td></td>
<td></td>
<td>-</td>
<td>-</td>
<td>13,755</td>
<td>0%</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Iron Folic Acid Tablet</td>
<td></td>
<td></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IUD 5 Insertion</td>
<td></td>
<td>39 18</td>
<td>39 304 56</td>
<td>(30)%</td>
<td>256 594</td>
<td>39 129</td>
<td>131</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-PSI IUD 5 Inserted</td>
<td></td>
<td>39 18</td>
<td>39 304 56</td>
<td>(30)%</td>
<td>256 594</td>
<td>39 129</td>
<td>131</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IUS 5</td>
<td></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>(41) (41)</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(b) PSI IUS 5 Distributed Inserted</td>
<td></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>(41) (41)</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IUS 5 Insertion</td>
<td></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>82 82</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-PSI IUS 5 Inserted</td>
<td></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>41 41</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PSI IUS 5 Inserted</td>
<td></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>41 41</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Misoprostol for PPH</td>
<td></td>
<td>- 167</td>
<td>- 4,500 2,500</td>
<td>(100)%</td>
<td>15,500 210,208</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ummul-gargaar</td>
<td></td>
<td>- 167</td>
<td>- 4,500 2,500</td>
<td>3/10 (100)%</td>
<td>15,500 210,208</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Multivitamin</td>
<td></td>
<td>-</td>
<td>-</td>
<td>14,171</td>
<td>0%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
## Monthly Distribution by Country

### Period: 2
### Year: 2020

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Multivitamin</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>OCs</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Nasiye - OC</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>OCs Provided</td>
<td>248</td>
<td>153</td>
<td>248</td>
<td>1,939</td>
<td>325</td>
<td>(24)%</td>
<td>1,987</td>
<td>4,115</td>
<td>17</td>
<td>17</td>
<td>13</td>
</tr>
<tr>
<td>Non-PSI OCs Provided</td>
<td>248</td>
<td>153</td>
<td>248</td>
<td>1,939</td>
<td>325</td>
<td>(24)%</td>
<td>1,987</td>
<td>4,115</td>
<td>17</td>
<td>17</td>
<td>13</td>
</tr>
<tr>
<td>ORS</td>
<td>-</td>
<td>1,000</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>3,000</td>
<td>3,000</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Orasel ORS Sachet</td>
<td>-</td>
<td>1,000</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>3,000</td>
<td>3,000</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>ORS Provided</td>
<td>3,342</td>
<td>2,369</td>
<td>3,342</td>
<td>26,613</td>
<td>4,445</td>
<td>(25)%</td>
<td>29,095</td>
<td>45,946</td>
<td>3,342</td>
<td>-</td>
<td>134</td>
</tr>
<tr>
<td>Non-PSI ORS Provided</td>
<td>3,342</td>
<td>2,369</td>
<td>3,342</td>
<td>26,613</td>
<td>4,445</td>
<td>(25)%</td>
<td>29,095</td>
<td>45,946</td>
<td>3,342</td>
<td>-</td>
<td>134</td>
</tr>
<tr>
<td>Pneumonia PPT Provided</td>
<td>1,899</td>
<td>1,842</td>
<td>1,899</td>
<td>13,959</td>
<td>2,689</td>
<td>(29)%</td>
<td>16,712</td>
<td>30,186</td>
<td>1,899</td>
<td>-</td>
<td>2,194</td>
</tr>
<tr>
<td>Non-PSI Pneumonia PPT Provided</td>
<td>1,899</td>
<td>1,842</td>
<td>1,899</td>
<td>13,959</td>
<td>2,689</td>
<td>(29)%</td>
<td>16,712</td>
<td>30,186</td>
<td>1,899</td>
<td>-</td>
<td>2,194</td>
</tr>
<tr>
<td>QAACTs Provided after Confirmatory Diagnosis</td>
<td>354</td>
<td>129</td>
<td>354</td>
<td>2,057</td>
<td>295</td>
<td>20%</td>
<td>1,748</td>
<td>3,974</td>
<td>354</td>
<td>-</td>
<td>80</td>
</tr>
<tr>
<td>Non-PSI QAACTs Provided after Confirmed Diagnosis</td>
<td>354</td>
<td>129</td>
<td>354</td>
<td>2,057</td>
<td>295</td>
<td>20%</td>
<td>1,748</td>
<td>3,974</td>
<td>354</td>
<td>-</td>
<td>80</td>
</tr>
<tr>
<td>Skilled Birth Attendance</td>
<td>2,420</td>
<td>1,727</td>
<td>2,420</td>
<td>15,731</td>
<td>2,239</td>
<td>8%</td>
<td>18,979</td>
<td>38,094</td>
<td>2,420</td>
<td>-</td>
<td>3,448</td>
</tr>
<tr>
<td>Skilled Birth Attendance</td>
<td>2,420</td>
<td>1,727</td>
<td>2,420</td>
<td>15,731</td>
<td>2,239</td>
<td>8%</td>
<td>18,979</td>
<td>38,094</td>
<td>2,420</td>
<td>-</td>
<td>3,448</td>
</tr>
<tr>
<td>STI Screening</td>
<td>206</td>
<td>196</td>
<td>206</td>
<td>990</td>
<td>122</td>
<td>69%</td>
<td>1,245</td>
<td>3,753</td>
<td>206</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>STI Screening</td>
<td>206</td>
<td>196</td>
<td>206</td>
<td>990</td>
<td>122</td>
<td>69%</td>
<td>1,245</td>
<td>3,753</td>
<td>206</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Treatment for Pre-Eclampsia (with MgSO4)</td>
<td>79</td>
<td>50</td>
<td>79</td>
<td>313</td>
<td>38</td>
<td>108%</td>
<td>410</td>
<td>832</td>
<td>79</td>
<td>-</td>
<td>274</td>
</tr>
<tr>
<td>Treatment for Pre-Eclampsia (with MgSO4)</td>
<td>79</td>
<td>50</td>
<td>79</td>
<td>313</td>
<td>38</td>
<td>108%</td>
<td>410</td>
<td>832</td>
<td>79</td>
<td>-</td>
<td>274</td>
</tr>
<tr>
<td>Treatment for Severe Acute Malnutrition</td>
<td>1,294</td>
<td>548</td>
<td>1,294</td>
<td>6,773</td>
<td>389</td>
<td>233%</td>
<td>6,999</td>
<td>17,893</td>
<td>1,294</td>
<td>-</td>
<td>6,811</td>
</tr>
<tr>
<td>Treatment for Severe Acute Malnutrition</td>
<td>1,294</td>
<td>548</td>
<td>1,294</td>
<td>6,773</td>
<td>389</td>
<td>233%</td>
<td>6,999</td>
<td>17,893</td>
<td>1,294</td>
<td>-</td>
<td>6,811</td>
</tr>
<tr>
<td>Treatment for Pre-Eclampsia (with MgSO4)</td>
<td>79</td>
<td>50</td>
<td>79</td>
<td>313</td>
<td>38</td>
<td>108%</td>
<td>410</td>
<td>832</td>
<td>79</td>
<td>-</td>
<td>274</td>
</tr>
<tr>
<td>Treatment for Pre-Eclampsia (with MgSO4)</td>
<td>79</td>
<td>50</td>
<td>79</td>
<td>313</td>
<td>38</td>
<td>108%</td>
<td>410</td>
<td>832</td>
<td>79</td>
<td>-</td>
<td>274</td>
</tr>
<tr>
<td>Treatment for Severe Acute Malnutrition</td>
<td>1,294</td>
<td>548</td>
<td>1,294</td>
<td>6,773</td>
<td>389</td>
<td>233%</td>
<td>6,999</td>
<td>17,893</td>
<td>1,294</td>
<td>-</td>
<td>6,811</td>
</tr>
<tr>
<td>Treatment for Severe Acute Malnutrition</td>
<td>1,294</td>
<td>548</td>
<td>1,294</td>
<td>6,773</td>
<td>389</td>
<td>233%</td>
<td>6,999</td>
<td>17,893</td>
<td>1,294</td>
<td>-</td>
<td>6,811</td>
</tr>
<tr>
<td>Treatment for Urethral Discharge (Men)</td>
<td>-</td>
<td>47</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>140</td>
<td>140</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Treatment for Urethral Discharge (Men)</td>
<td>-</td>
<td>47</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>140</td>
<td>140</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Treatment for Urethral Discharge (Women)</td>
<td>-</td>
<td>94</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>282</td>
<td>282</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Treatment for Urethral Discharge (Women)</td>
<td>-</td>
<td>94</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>282</td>
<td>282</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Type 2 Diabetes Diagnosis</td>
<td>- 9</td>
<td>-</td>
<td>699</td>
<td>648,160</td>
<td>9/10</td>
<td>(100)%</td>
<td>1,064,762</td>
<td>75,775,704</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Water Treatment Tablets</td>
<td>- 45,000</td>
<td>-</td>
<td>932,000</td>
<td>648,160</td>
<td>9/10</td>
<td>(100)%</td>
<td>627,602</td>
<td>36,581,392</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Aquatab</td>
<td>- 45,000</td>
<td>-</td>
<td>432,000</td>
<td>256,000</td>
<td>7/08</td>
<td>(100)%</td>
<td>392,160</td>
<td>39,194,312</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Biyosifeeye</td>
<td>850</td>
<td>-</td>
<td>500,000</td>
<td>392,160</td>
<td>7/08</td>
<td>(100)%</td>
<td>392,160</td>
<td>39,194,312</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Zinc</td>
<td>850</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>6/11</td>
<td>-</td>
<td>2,550</td>
<td>2,550</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Shuban Daweeye_Zinc</td>
<td>850</td>
<td>-</td>
<td>-</td>
<td>0%</td>
<td>6/11</td>
<td>-</td>
<td>2,550</td>
<td>2,550</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Zinc Provided</td>
<td>3,333</td>
<td>2,408</td>
<td>3,333</td>
<td>26,010</td>
<td>4,376</td>
<td>(24)%</td>
<td>28,688</td>
<td>43,855</td>
<td>3,333</td>
<td>67</td>
</tr>
<tr>
<td>Non-PSI Zinc Provided</td>
<td>3,333</td>
<td>2,408</td>
<td>3,333</td>
<td>26,010</td>
<td>4,376</td>
<td>(24)%</td>
<td>28,688</td>
<td>43,855</td>
<td>3,333</td>
<td>67</td>
</tr>
<tr>
<td>South Sudan</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1,608</td>
</tr>
<tr>
<td>LLIN</td>
<td>95,196</td>
<td>5,244,214</td>
<td>42,500</td>
<td>2,523,861</td>
<td>102,484</td>
<td>(95)%</td>
<td>4,604,845</td>
<td>18,677,426</td>
<td>9,402,141</td>
<td>-</td>
</tr>
<tr>
<td>Free Permatent Mesh</td>
<td>95,196</td>
<td>5,244,214</td>
<td>42,500</td>
<td>2,523,861</td>
<td>102,484</td>
<td>(95)%</td>
<td>4,604,845</td>
<td>18,677,426</td>
<td>9,402,141</td>
<td>-</td>
</tr>
<tr>
<td>Malaria PPT (ACT)</td>
<td>1,105,438</td>
<td>5,100</td>
<td>5,323,861</td>
<td>102,484</td>
<td>2,523,861</td>
<td>(95)%</td>
<td>4,604,845</td>
<td>18,677,426</td>
<td>9,402,141</td>
<td>-</td>
</tr>
<tr>
<td>ACTs for Adult (14+ years)</td>
<td>289,972</td>
<td>1,461,050</td>
<td>45,700</td>
<td>1,008,537</td>
<td>2,785,207</td>
<td>(100)%</td>
<td>1,364,000</td>
<td>4,415,095</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>ACTs for Child (6-14 years)</td>
<td>218,361</td>
<td>1,066,905</td>
<td>34,200</td>
<td>1,066,905</td>
<td>2,785,207</td>
<td>(100)%</td>
<td>1,008,537</td>
<td>2,785,207</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>ACTs for Infant (2-12 months)</td>
<td>170,687</td>
<td>1,024,876</td>
<td>3,510</td>
<td>2,550</td>
<td>2,785,207</td>
<td>(23)%</td>
<td>589,069</td>
<td>4,079,153</td>
<td>2,430</td>
<td>-</td>
</tr>
<tr>
<td>ACTs for Toddler (1-5 years)</td>
<td>360,329</td>
<td>1,431,406</td>
<td>11,400</td>
<td>2,160</td>
<td>2,785,207</td>
<td>(79)%</td>
<td>1,335,575</td>
<td>7,019,783</td>
<td>2,160</td>
<td>-</td>
</tr>
<tr>
<td>Artemether Tabs – Adult</td>
<td>24,330</td>
<td>162,339</td>
<td>4,050</td>
<td>2,160</td>
<td>2,785,207</td>
<td>(100)%</td>
<td>142,200</td>
<td>178,550</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Artemether Tabs - Child</td>
<td>25,292</td>
<td>118,545</td>
<td>2,700</td>
<td>2,160</td>
<td>2,785,207</td>
<td>(100)%</td>
<td>107,100</td>
<td>133,376</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Artemether Tabs - Infant</td>
<td>2,933</td>
<td>18,979</td>
<td>264</td>
<td>2,160</td>
<td>2,785,207</td>
<td>(100)%</td>
<td>11,764</td>
<td>13,786</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Artemether Tabs - Toddler</td>
<td>13,533</td>
<td>39,761</td>
<td>660</td>
<td>2,160</td>
<td>2,785,207</td>
<td>(100)%</td>
<td>46,600</td>
<td>52,476</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Malaria RDK</td>
<td>43,500</td>
<td>368,233</td>
<td>125,400</td>
<td>1,452,641</td>
<td>51,300</td>
<td>144%</td>
<td>1,561,625</td>
<td>10,178,920</td>
<td>112,860</td>
<td>-</td>
</tr>
<tr>
<td>Malaria Rapid Diagnostic Kit</td>
<td>43,500</td>
<td>368,233</td>
<td>125,400</td>
<td>1,452,641</td>
<td>51,300</td>
<td>144%</td>
<td>1,561,625</td>
<td>10,178,920</td>
<td>112,860</td>
<td>-</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
Social Enterprise Market Group
<table>
<thead>
<tr>
<th></th>
<th>New HIV Infections</th>
<th>STI Deaths</th>
<th>PWID Deaths</th>
<th>TB Deaths</th>
<th>CYP*</th>
<th>Maternal Deaths</th>
<th>Unintended Pregnancies</th>
<th>Malaria Deaths</th>
<th>Diarrhea Deaths</th>
<th>Pneumonia Deaths</th>
<th>Cervical Cancer Death</th>
<th>Sum of All Deaths</th>
</tr>
</thead>
<tbody>
<tr>
<td>Social Enterprise</td>
<td>4,449</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>110,354</td>
<td>144</td>
<td>34,049</td>
<td>-</td>
<td>85</td>
<td>-</td>
<td>-</td>
<td>419</td>
</tr>
<tr>
<td>India LLC</td>
<td>50</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>30,131</td>
<td>127</td>
<td>10,970</td>
<td>-</td>
<td>85</td>
<td>-</td>
<td>-</td>
<td>265</td>
</tr>
<tr>
<td>Paraguay</td>
<td>78</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>14,946</td>
<td>3</td>
<td>4,760</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>16</td>
</tr>
<tr>
<td>PSI South Africa</td>
<td>4,321</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>65,278</td>
<td>14</td>
<td>18,319</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>135</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>24,010</strong></td>
<td><strong>5</strong></td>
<td><strong>13</strong></td>
<td><strong>808</strong></td>
<td><strong>2,193,464</strong></td>
<td><strong>2,392</strong></td>
<td><strong>898,028</strong></td>
<td><strong>7,278</strong></td>
<td><strong>384</strong></td>
<td><strong>128</strong></td>
<td><strong>2</strong></td>
<td><strong>23,386</strong></td>
</tr>
</tbody>
</table>

* Using USAID CYP conversion factors
<table>
<thead>
<tr>
<th>Product Type</th>
<th>DISTRIBUTION 2/2020</th>
<th>MONTHLY AVG PREV 3 MONTHS</th>
<th>YTD DISTRIBUTION 2020</th>
<th>DISTRIBUTION TARGET 2020</th>
<th>YTD DISTRIBUTION 2019</th>
<th>YTD % CHANGE</th>
<th>TOTAL DISTRIBUTION 2019</th>
<th>CUMULATIVE SALES</th>
<th>YTD USERS REACHED (a)</th>
<th>YTD CYP 2020</th>
<th>YTD DALY 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Social Enterprise</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Condom</td>
<td>5,217,475</td>
<td>8,504,010</td>
<td>9,881,990</td>
<td>91,116,126</td>
<td>12,232,054</td>
<td>(19)%</td>
<td>98,181,497</td>
<td>769,365,087</td>
<td>74,115</td>
<td>74,115</td>
<td>181,224</td>
</tr>
<tr>
<td>Emergency Contraception</td>
<td>95,355</td>
<td>45,571</td>
<td>164,653</td>
<td>484,873</td>
<td>61,001</td>
<td>170%</td>
<td>425,634</td>
<td>3,456,421</td>
<td>7,409</td>
<td>7,409</td>
<td>919</td>
</tr>
<tr>
<td>Injectable 3-iM</td>
<td>3,408</td>
<td>1,284</td>
<td>1,937</td>
<td>169,372</td>
<td>7,285</td>
<td>(73)%</td>
<td>39,544</td>
<td>240,291</td>
<td>436</td>
<td>436</td>
<td>72</td>
</tr>
<tr>
<td>IUD 10</td>
<td>-</td>
<td>(8)</td>
<td>-</td>
<td>1,715</td>
<td>35</td>
<td>(100)%</td>
<td>10</td>
<td>65,520</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>IUD 3</td>
<td>(45)</td>
<td>(28)</td>
<td>(5)</td>
<td>165,715</td>
<td>(250)</td>
<td>-%</td>
<td>(57)</td>
<td>6,891</td>
<td>(5)</td>
<td>(11)</td>
<td>(2)</td>
</tr>
<tr>
<td>IUD 5</td>
<td>670</td>
<td>368</td>
<td>1,660</td>
<td>735</td>
<td>16,112</td>
<td>(90)%</td>
<td>130,659</td>
<td>312,654</td>
<td>1,494</td>
<td>4,930</td>
<td>1,111</td>
</tr>
<tr>
<td>IUS 5</td>
<td>55</td>
<td>7</td>
<td>75</td>
<td>863</td>
<td>264</td>
<td>(72)%</td>
<td>419</td>
<td>494</td>
<td>68</td>
<td>223</td>
<td>50</td>
</tr>
<tr>
<td>Lubricant</td>
<td>23,726</td>
<td>13,427</td>
<td>40,766</td>
<td>163,987</td>
<td>3,588</td>
<td>1,036%</td>
<td>49,209</td>
<td>214,343</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Male Vasodilator</td>
<td>106,960</td>
<td>48,000</td>
<td>150,960</td>
<td>786,000</td>
<td>174,900</td>
<td>(14)%</td>
<td>1,766,180</td>
<td>1,917,140</td>
<td>1,132</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Medical Abortion</td>
<td>60,000</td>
<td>25,188</td>
<td>74,592</td>
<td>1,403,555</td>
<td>88,281</td>
<td>(16)%</td>
<td>571,512</td>
<td>2,300,174</td>
<td>67,133</td>
<td>-</td>
<td>6,931</td>
</tr>
<tr>
<td>Multivitamin</td>
<td>162,570</td>
<td>128,670</td>
<td>308,010</td>
<td>2,106,000</td>
<td>215,610</td>
<td>43%</td>
<td>1,410,030</td>
<td>38,272,600</td>
<td>1,540</td>
<td>-</td>
<td>53</td>
</tr>
<tr>
<td>OCs</td>
<td>233,413</td>
<td>138,593</td>
<td>387,541</td>
<td>4,037,620</td>
<td>136,716</td>
<td>183%</td>
<td>1,342,940</td>
<td>17,813,881</td>
<td>23,252</td>
<td>23,252</td>
<td>3,549</td>
</tr>
<tr>
<td>ORS</td>
<td>337,707</td>
<td>15,300</td>
<td>388,107</td>
<td>4,107,157</td>
<td>398,019</td>
<td>(2)%</td>
<td>1,349,277</td>
<td>3,208,318</td>
<td>174,648</td>
<td>-</td>
<td>7,324</td>
</tr>
<tr>
<td>Pregnancy Test</td>
<td>66,750</td>
<td>22,013</td>
<td>92,090</td>
<td>1,015,720</td>
<td>58,716</td>
<td>57%</td>
<td>313,592</td>
<td>981,357</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Vaginal Wash</td>
<td>-</td>
<td>(6)</td>
<td>20</td>
<td>1,920</td>
<td>(99)%</td>
<td></td>
<td>18,625</td>
<td>18,645</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.
### Social Enterprise

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Masti 10's - Banana &amp; Chocolate</td>
<td>5,580,489</td>
<td>57,118,460</td>
<td>5838,078</td>
<td>(82)%</td>
<td>817,440</td>
<td>831,840</td>
<td>292,206,612</td>
<td>8,076</td>
<td>108</td>
<td>108</td>
</tr>
<tr>
<td>Masti 10's - Strawberry &amp; Banana</td>
<td>-</td>
<td>57,118,460</td>
<td>-</td>
<td>-</td>
<td>1,011,120</td>
<td>1,011,120</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Masti Banana Dotted 3's</td>
<td>7,200</td>
<td>46,800</td>
<td>-</td>
<td>-</td>
<td>680,520</td>
<td>727,320</td>
<td>351</td>
<td>351</td>
<td>138</td>
<td></td>
</tr>
<tr>
<td>Masti Banana Dotted 4's</td>
<td>(10,296)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1,998,600</td>
<td>1,988,304</td>
<td>(77)</td>
<td>(77)</td>
<td>(30)</td>
<td></td>
</tr>
<tr>
<td>Masti Cherry 2's</td>
<td>-</td>
<td>183,600</td>
<td>(100)%</td>
<td>-</td>
<td>5,019,300</td>
<td>5,019,300</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Masti Chocolate 4's</td>
<td>76,840</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>3,954,360</td>
<td>3,954,360</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Masti Chocolate Dotted 3's</td>
<td>-</td>
<td>574,800</td>
<td>-</td>
<td>-</td>
<td>741,720</td>
<td>1,316,520</td>
<td>4,311</td>
<td>4,311</td>
<td>1,691</td>
<td></td>
</tr>
<tr>
<td>Masti Classic 10's</td>
<td>(63,000)</td>
<td>94,569</td>
<td>(63,000)</td>
<td>10/17</td>
<td>5,054,907</td>
<td>22,066,437</td>
<td>(472)</td>
<td>(472)</td>
<td>(185)</td>
<td></td>
</tr>
<tr>
<td>Masti Classic 10's (Flavoured)</td>
<td>(6,948)</td>
<td>115,667</td>
<td>(6,948)</td>
<td>-</td>
<td>8,252,860</td>
<td>30,093,952</td>
<td>(52)</td>
<td>(52)</td>
<td>(20)</td>
<td></td>
</tr>
<tr>
<td>Masti Classic 2's Orange</td>
<td>(540)</td>
<td>(65)</td>
<td>(540)</td>
<td>4/18</td>
<td>1,666,597</td>
<td>9,000,367</td>
<td>(4)</td>
<td>(4)</td>
<td>(2)</td>
<td></td>
</tr>
<tr>
<td>Masti Classic 3's Cool Mint</td>
<td>(4,320)</td>
<td>(5,937)</td>
<td>(6,240)</td>
<td>-</td>
<td>48,760</td>
<td>945,080</td>
<td>(47)</td>
<td>(47)</td>
<td>(18)</td>
<td></td>
</tr>
<tr>
<td>Masti Classic 3's</td>
<td>10,908</td>
<td>216,108</td>
<td>3,793,617</td>
<td>12/16</td>
<td>16,260,216</td>
<td>125,589,745</td>
<td>1,621</td>
<td>1,621</td>
<td>636</td>
<td></td>
</tr>
<tr>
<td>Masti Classic 3's (Flavoured)</td>
<td>(8,589)</td>
<td>325,383</td>
<td>(8,589)</td>
<td>-</td>
<td>5,545,468</td>
<td>42,276,282</td>
<td>(64)</td>
<td>(64)</td>
<td>(25)</td>
<td></td>
</tr>
<tr>
<td>Masti Green Apple 2's</td>
<td>(2,333)</td>
<td>36,000</td>
<td>(2,333)</td>
<td>-</td>
<td>39,780</td>
<td>3,976,867</td>
<td>(17)</td>
<td>(17)</td>
<td>(7)</td>
<td></td>
</tr>
<tr>
<td>Masti Lemon 2's</td>
<td>-</td>
<td>1,582,350</td>
<td>-</td>
<td>-</td>
<td>5,001,990</td>
<td>5,001,990</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Masti Long Innings 2's</td>
<td>677,990</td>
<td>-</td>
<td>120</td>
<td>(100)%</td>
<td>2,502,870</td>
<td>2,502,870</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Masti Mix 10's Chocolate &amp; Strawberry</td>
<td>-</td>
<td>15,640</td>
<td>-</td>
<td>-</td>
<td>1,886,280</td>
<td>1,886,280</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Masti Night Queen (Raat Ki Rani) 2's</td>
<td>(3,240)</td>
<td>284,870</td>
<td>(3,240)</td>
<td>-</td>
<td>3,007,110</td>
<td>3,003,870</td>
<td>(24)</td>
<td>(24)</td>
<td>(10)</td>
<td></td>
</tr>
<tr>
<td>Masti Premium 10's (Flavoured)</td>
<td>(3,360)</td>
<td>135,549</td>
<td>(3,360)</td>
<td>-</td>
<td>(1,452)</td>
<td>10,777,068</td>
<td>(25)</td>
<td>(25)</td>
<td>(10)</td>
<td></td>
</tr>
<tr>
<td>Masti Premium 3's Cool Mint</td>
<td>(602)</td>
<td>(720)</td>
<td>-</td>
<td>4/18</td>
<td>(1,327)</td>
<td>911,153</td>
<td>(5)</td>
<td>(5)</td>
<td>(2)</td>
<td></td>
</tr>
<tr>
<td>Masti Premium 3's (Flavoured)</td>
<td>(8,496)</td>
<td>2,263</td>
<td>(8,496)</td>
<td>-</td>
<td>9,253</td>
<td>16,127,287</td>
<td>(64)</td>
<td>(64)</td>
<td>(25)</td>
<td></td>
</tr>
</tbody>
</table>

**Notes:**

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
### Monthly Distribution by Country

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Masti Strawberry Dotted 3’s</td>
<td>61,200</td>
<td>374,440</td>
<td>338,400</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>846,120</td>
<td>1,184,520</td>
<td>2,538</td>
<td>2,538</td>
<td>995</td>
</tr>
<tr>
<td>Masti Strawberry Dotted 4’s</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>2,014,080</td>
<td>2,014,080</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Emergency Contraception</td>
<td>292</td>
<td>(1,060)</td>
<td>652</td>
<td>-</td>
<td>13,660</td>
<td>4/18</td>
<td>(95)%</td>
<td>35,412</td>
<td>229,791</td>
<td>29</td>
<td>29</td>
<td>4</td>
</tr>
<tr>
<td>Pronta1</td>
<td>-</td>
<td>(1,780)</td>
<td>-</td>
<td>2,797</td>
<td>4/18</td>
<td>(100)%</td>
<td>(6,742)</td>
<td>171,727</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Pronta-72</td>
<td>292</td>
<td>720</td>
<td>652</td>
<td>-</td>
<td>10,863</td>
<td>12/16</td>
<td>(94)%</td>
<td>42,154</td>
<td>58,064</td>
<td>29</td>
<td>29</td>
<td>4</td>
</tr>
<tr>
<td>Injectable 3-IM</td>
<td>3,408</td>
<td>1,284</td>
<td>1,937</td>
<td>169,372</td>
<td>7,285</td>
<td>12/16</td>
<td>(73)%</td>
<td>39,544</td>
<td>240,291</td>
<td>436</td>
<td>436</td>
<td>72</td>
</tr>
<tr>
<td>Freedom Inject (3-month)</td>
<td>3,408</td>
<td>1,284</td>
<td>1,937</td>
<td>169,372</td>
<td>7,285</td>
<td>12/16</td>
<td>(73)%</td>
<td>39,544</td>
<td>240,291</td>
<td>436</td>
<td>436</td>
<td>72</td>
</tr>
<tr>
<td>IUD 10</td>
<td>-</td>
<td>(8)</td>
<td>-</td>
<td>35</td>
<td>-</td>
<td>10</td>
<td>(100)%</td>
<td>65,520</td>
<td>65,520</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Freedom 10</td>
<td>-</td>
<td>(8)</td>
<td>-</td>
<td>35</td>
<td>12/16</td>
<td>(100)%</td>
<td>65,520</td>
<td>65,520</td>
<td>65,520</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>IUD 3</td>
<td>(45)</td>
<td>(28)</td>
<td>(5)</td>
<td>165,715</td>
<td>(250)</td>
<td>1/18</td>
<td>0%</td>
<td>6,891</td>
<td>5 (5)</td>
<td>(11)</td>
<td>(2)</td>
<td>(2)</td>
</tr>
<tr>
<td>Freedom 3</td>
<td>(45)</td>
<td>(28)</td>
<td>(5)</td>
<td>165,715</td>
<td>(250)</td>
<td>1/18</td>
<td>-</td>
<td>6,891</td>
<td>5 (5)</td>
<td>(11)</td>
<td>(2)</td>
<td>(2)</td>
</tr>
<tr>
<td>IUD 5</td>
<td>670</td>
<td>368</td>
<td>1,660</td>
<td>-</td>
<td>16,112</td>
<td>(90)%</td>
<td>10</td>
<td>312,654</td>
<td>1,494</td>
<td>4,930</td>
<td>1,111</td>
<td>-</td>
</tr>
<tr>
<td>Freedom 5</td>
<td>55</td>
<td>85</td>
<td>695</td>
<td>-</td>
<td>16,220</td>
<td>12/16</td>
<td>(96)%</td>
<td>297,000</td>
<td>626</td>
<td>2,064</td>
<td>465</td>
<td>-</td>
</tr>
<tr>
<td>Freedom 5 – Sleek</td>
<td>605</td>
<td>263</td>
<td>895</td>
<td>-</td>
<td>(50)</td>
<td>1/18</td>
<td>-</td>
<td>12,228</td>
<td>806</td>
<td>2,658</td>
<td>599</td>
<td>-</td>
</tr>
<tr>
<td>Freedom 5 (PPIUCD) Cu 375</td>
<td>10</td>
<td>20</td>
<td>70</td>
<td>-</td>
<td>(58)</td>
<td>-</td>
<td>-</td>
<td>2,426</td>
<td>63</td>
<td>208</td>
<td>47</td>
<td>-</td>
</tr>
<tr>
<td>IUS 5</td>
<td>55</td>
<td>17</td>
<td>75</td>
<td>863</td>
<td>264</td>
<td>(72)%</td>
<td>419</td>
<td>494</td>
<td>68</td>
<td>223</td>
<td>50</td>
<td>-</td>
</tr>
<tr>
<td>Sabatica – LNG IUS</td>
<td>55</td>
<td>7</td>
<td>75</td>
<td>863</td>
<td>264</td>
<td>(72)%</td>
<td>419</td>
<td>494</td>
<td>68</td>
<td>223</td>
<td>50</td>
<td>-</td>
</tr>
<tr>
<td>Male Vasodilator</td>
<td>106,960</td>
<td>48,000</td>
<td>150,960</td>
<td>786,000</td>
<td>174,900</td>
<td>(14)%</td>
<td>1,766,180</td>
<td>1,917,140</td>
<td>1,132</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Masti Super 100 - 100 mg Tab</td>
<td>106,960</td>
<td>48,000</td>
<td>150,960</td>
<td>786,000</td>
<td>174,900</td>
<td>(14)%</td>
<td>1,766,180</td>
<td>1,917,140</td>
<td>1,132</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Medical Abortion</td>
<td>60,000</td>
<td>25,188</td>
<td>74,592</td>
<td>1,403,555</td>
<td>88,281</td>
<td>(16)%</td>
<td>571,512</td>
<td>2,300,174</td>
<td>67,133</td>
<td>-</td>
<td>6,931</td>
<td>-</td>
</tr>
<tr>
<td>Mifeos</td>
<td>950</td>
<td>67</td>
<td>1,150</td>
<td>23,425</td>
<td>-</td>
<td>-</td>
<td>9,000</td>
<td>10,150</td>
<td>1,035</td>
<td>-</td>
<td>-</td>
<td>107</td>
</tr>
<tr>
<td>Safe Abort kit</td>
<td>59,050</td>
<td>25,121</td>
<td>73,442</td>
<td>1,380,130</td>
<td>88,281</td>
<td>12/16</td>
<td>(17)%</td>
<td>562,512</td>
<td>66,098</td>
<td>-</td>
<td>6,824</td>
<td>-</td>
</tr>
<tr>
<td>OCSs</td>
<td>165,455</td>
<td>81,324</td>
<td>274,135</td>
<td>3,306,322</td>
<td>7,448</td>
<td>3581%</td>
<td>667,680</td>
<td>8,664,394</td>
<td>16,448</td>
<td>16,448</td>
<td>2,886</td>
<td>-</td>
</tr>
<tr>
<td>Freedom 28</td>
<td>60</td>
<td>33</td>
<td>360</td>
<td>-</td>
<td>(1,380)</td>
<td>-</td>
<td>(656)</td>
<td>41,850</td>
<td>22</td>
<td>22</td>
<td>4</td>
<td>-</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
### Monthly Distribution by Country

**Period:** 2

**Year:** 2020

<table>
<thead>
<tr>
<th>DISTRIBUTION</th>
<th>MONTHLY AVG PREV 3 MONTHS</th>
<th>YTD DISTRIBUTION</th>
<th>DISTRIBUTION TARGET</th>
<th>YTD DISTRIBUTION</th>
<th>LAUNCH DATE</th>
<th>YTD % CHANGE</th>
<th>TOTAL DISTRIBUTION</th>
<th>CUMULATIVE DISTRIBUTION</th>
<th>% YTD USERS REACHED</th>
<th>YTD DALY</th>
</tr>
</thead>
<tbody>
<tr>
<td>MEURI</td>
<td>1,880</td>
<td>2,815</td>
<td>2,260</td>
<td>72,305</td>
<td>1,718</td>
<td>32%</td>
<td>34,414</td>
<td>74,319</td>
<td>136</td>
<td>136</td>
</tr>
<tr>
<td>Pearl</td>
<td>163,515</td>
<td>78,476</td>
<td>271,515</td>
<td>3,234,017</td>
<td>7,110</td>
<td>12/16</td>
<td>3,719%</td>
<td>633,922</td>
<td>8,548,225</td>
<td>16,291</td>
</tr>
<tr>
<td>ORS</td>
<td>337,707</td>
<td>15,300</td>
<td>388,107</td>
<td>4,107,157</td>
<td>398,019</td>
<td>(2)%</td>
<td>1,349,277</td>
<td>3,208,318</td>
<td>174,648</td>
<td>-</td>
</tr>
<tr>
<td>Neotal Orange 1000ml</td>
<td>337,707</td>
<td>15,300</td>
<td>388,107</td>
<td>4,107,157</td>
<td>398,019</td>
<td>(2)%</td>
<td>1,349,277</td>
<td>3,208,318</td>
<td>174,648</td>
<td>-</td>
</tr>
<tr>
<td>Pregnancy Test</td>
<td>66,750</td>
<td>22,013</td>
<td>92,090</td>
<td>1,015,720</td>
<td>58,716</td>
<td>57%</td>
<td>313,592</td>
<td>981,357</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Pronta (PTK)</td>
<td>66,750</td>
<td>22,013</td>
<td>92,090</td>
<td>1,015,720</td>
<td>58,716</td>
<td>4/18</td>
<td>57%</td>
<td>313,592</td>
<td>981,357</td>
<td>-</td>
</tr>
<tr>
<td>Vaginal Wash</td>
<td>-</td>
<td>(6)</td>
<td>20</td>
<td>-</td>
<td>1,920</td>
<td>(99)%</td>
<td>18,625</td>
<td>18,645</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Pronta Intimate Wash – 100 ml bottle</td>
<td>-</td>
<td>(6)</td>
<td>20</td>
<td>-</td>
<td>1,920</td>
<td>(99)%</td>
<td>18,625</td>
<td>18,645</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Paraguay</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Condom</td>
<td>293,457</td>
<td>404,529</td>
<td>681,700</td>
<td>3,323,268</td>
<td>475,000</td>
<td>44%</td>
<td>3,409,365</td>
<td>47,479,092</td>
<td>5,113</td>
<td>5,113</td>
</tr>
<tr>
<td>Pantera</td>
<td>94,358</td>
<td>185,350</td>
<td>235,883</td>
<td>1,604,736</td>
<td>249,848</td>
<td>8/08</td>
<td>(6)%</td>
<td>1,651,691</td>
<td>38,668,729</td>
<td>1,769</td>
</tr>
<tr>
<td>Pantera Banana</td>
<td>14,449</td>
<td>19,438</td>
<td>31,954</td>
<td>158,004</td>
<td>21,101</td>
<td>9/16</td>
<td>51%</td>
<td>163,747</td>
<td>597,501</td>
<td>240</td>
</tr>
<tr>
<td>Pantera Chocolate</td>
<td>13,762</td>
<td>23,801</td>
<td>38,257</td>
<td>186,048</td>
<td>23,435</td>
<td>2/14</td>
<td>63%</td>
<td>204,079</td>
<td>1,266,258</td>
<td>287</td>
</tr>
<tr>
<td>Pantera Neon</td>
<td>31,920</td>
<td>7,260</td>
<td>51,062</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>2,637</td>
<td>53,699</td>
<td>383</td>
<td>383</td>
</tr>
<tr>
<td>Pantera Retardant</td>
<td>39,599</td>
<td>65,742</td>
<td>108,257</td>
<td>600,192</td>
<td>62,013</td>
<td>2/14</td>
<td>75%</td>
<td>577,683</td>
<td>2,947,609</td>
<td>812</td>
</tr>
<tr>
<td>Pantera Ribbed</td>
<td>9,358</td>
<td>15,241</td>
<td>25,789</td>
<td>128,880</td>
<td>22,224</td>
<td>2/14</td>
<td>16%</td>
<td>127,327</td>
<td>949,822</td>
<td>193</td>
</tr>
<tr>
<td>Pantera Strawberry</td>
<td>28,171</td>
<td>40,467</td>
<td>68,671</td>
<td>316,008</td>
<td>42,954</td>
<td>2/14</td>
<td>60%</td>
<td>336,707</td>
<td>1,685,899</td>
<td>515</td>
</tr>
<tr>
<td>Pantera Tachas</td>
<td>10,655</td>
<td>15,817</td>
<td>27,026</td>
<td>128,880</td>
<td>22,005</td>
<td>9/16</td>
<td>23%</td>
<td>127,324</td>
<td>510,990</td>
<td>203</td>
</tr>
<tr>
<td>Pantera Tutti Frutti</td>
<td>18,051</td>
<td>25,139</td>
<td>44,994</td>
<td>200,520</td>
<td>31,420</td>
<td>9/16</td>
<td>43%</td>
<td>216,013</td>
<td>746,621</td>
<td>337</td>
</tr>
<tr>
<td>Pantera XL</td>
<td>33,134</td>
<td>6,277</td>
<td>49,807</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>2,157</td>
<td>51,964</td>
<td>374</td>
<td>374</td>
</tr>
<tr>
<td>Pronta</td>
<td>25,454</td>
<td>27,408</td>
<td>58,041</td>
<td>300,000</td>
<td>48,764</td>
<td>2/04</td>
<td>19%</td>
<td>304,584</td>
<td>3,213,411</td>
<td>2,612</td>
</tr>
<tr>
<td>Pronta1</td>
<td>3,315</td>
<td>4,200</td>
<td>9,325</td>
<td>79,200</td>
<td>1,374</td>
<td>57%</td>
<td>33,267</td>
<td>42,682</td>
<td>420</td>
<td>420</td>
</tr>
<tr>
<td>Lubricant</td>
<td>20,330</td>
<td>8,039</td>
<td>34,790</td>
<td>120,480</td>
<td>-</td>
<td>0%</td>
<td>9,657</td>
<td>44,447</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
### Monthly Distribution by Country

**Period:** 2nd Quarter 2020

**Year:** 2020

<table>
<thead>
<tr>
<th>Product</th>
<th>DISTRIBUTION 2020</th>
<th>MONTHLY AVG PREV 3 MONTHS</th>
<th>DISTRIBUTION TARGET 2020</th>
<th>YTD DISTRIBUTION 2019</th>
<th>LAUNCH DATE</th>
<th>YTD % CHANGE</th>
<th>TOTAL DISTRIBUTION 2019</th>
<th>CUMULATIVE DISTRIBUTION (a)</th>
<th>YTD USERS REACHED 2020</th>
<th>YTD % CHANGE</th>
<th>YTD CYP 2020</th>
<th>YTD DALY 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pantera sachet classic</td>
<td>11,115</td>
<td>5,852</td>
<td>20,186</td>
<td>70,200</td>
<td>-</td>
<td>-%</td>
<td>8,485</td>
<td>28,671</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Pantera sachet strawberry</td>
<td>7,775</td>
<td>1,860</td>
<td>12,185</td>
<td>40,200</td>
<td>-</td>
<td>-%</td>
<td>1,170</td>
<td>13,355</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Pantera tube classic</td>
<td>745</td>
<td>177</td>
<td>1,275</td>
<td>5,040</td>
<td>-</td>
<td>-%</td>
<td>1</td>
<td>1,276</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Pantera tube strawberry</td>
<td>695</td>
<td>150</td>
<td>1,144</td>
<td>5,040</td>
<td>-</td>
<td>-%</td>
<td>1</td>
<td>1,145</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Multivitamin</td>
<td>162,570</td>
<td>128,670</td>
<td>308,010</td>
<td>2,106,000</td>
<td>215,610</td>
<td>43%</td>
<td>1,410,030</td>
<td>38,727,600</td>
<td>1,540</td>
<td>-%</td>
<td>53</td>
<td></td>
</tr>
<tr>
<td>VitalDia</td>
<td>162,570</td>
<td>128,670</td>
<td>308,010</td>
<td>2,106,000</td>
<td>215,610</td>
<td>43%</td>
<td>1,410,030</td>
<td>38,727,600</td>
<td>1,540</td>
<td>-%</td>
<td>53</td>
<td></td>
</tr>
<tr>
<td>OCs</td>
<td>67,923</td>
<td>57,234</td>
<td>113,365</td>
<td>682,800</td>
<td>129,268</td>
<td>(12)%</td>
<td>675,161</td>
<td>9,149,347</td>
<td>6,802</td>
<td>-%</td>
<td>662</td>
<td></td>
</tr>
<tr>
<td>Segura</td>
<td>62,458</td>
<td>53,229</td>
<td>103,459</td>
<td>636,000</td>
<td>122,333</td>
<td>(15)%</td>
<td>627,692</td>
<td>8,848,523</td>
<td>6,208</td>
<td>-%</td>
<td>605</td>
<td></td>
</tr>
<tr>
<td>Segura Plus</td>
<td>5,465</td>
<td>4,006</td>
<td>9,906</td>
<td>46,800</td>
<td>6,935</td>
<td>43%</td>
<td>47,469</td>
<td>300,824</td>
<td>594</td>
<td>-%</td>
<td>58</td>
<td></td>
</tr>
<tr>
<td><strong>PSI South Africa</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>65,278</td>
</tr>
<tr>
<td>Condom</td>
<td>4,955,832</td>
<td>2,518,992</td>
<td>8,123,544</td>
<td>30,674,399</td>
<td>5,918,976</td>
<td>37%</td>
<td>28,592,640</td>
<td>429,679,383</td>
<td>60,927</td>
<td>-</td>
<td>14,288</td>
<td></td>
</tr>
<tr>
<td>Lovers Plus</td>
<td>321,768</td>
<td>242,664</td>
<td>666,504</td>
<td>2,661,025</td>
<td>759,024</td>
<td>10/92</td>
<td>1,702,160</td>
<td>51,102,424</td>
<td>4,999</td>
<td>-%</td>
<td>4,999</td>
<td></td>
</tr>
<tr>
<td>Lovers Plus C&amp;F</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>137,016</td>
<td>1/08</td>
<td>137,016</td>
<td>36,451,690</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Lovers Plus C&amp;S</td>
<td>228,456</td>
<td>222,576</td>
<td>355,464</td>
<td>2,063,652</td>
<td>316,656</td>
<td>12%</td>
<td>2,099,736</td>
<td>2,455,200</td>
<td>2,666</td>
<td>-%</td>
<td>7,620</td>
<td></td>
</tr>
<tr>
<td>Lovers Plus Climax Delay</td>
<td>48,096</td>
<td>57,264</td>
<td>101,880</td>
<td>335,254</td>
<td>82,368</td>
<td>24%</td>
<td>304,776</td>
<td>406,656</td>
<td>764</td>
<td>-%</td>
<td>2,184</td>
<td></td>
</tr>
<tr>
<td>Lovers Plus Extra Play</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>63,072</td>
<td>9/13</td>
<td>63,072</td>
<td>3,148,622</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Lovers Plus R&amp;S</td>
<td>179,352</td>
<td>214,896</td>
<td>437,832</td>
<td>1,979,921</td>
<td>338,040</td>
<td>5/10</td>
<td>1,799,928</td>
<td>24,832,613</td>
<td>3,284</td>
<td>-%</td>
<td>3,284</td>
<td>9,386</td>
</tr>
<tr>
<td>Lovers Plus UltraThin</td>
<td>73,512</td>
<td>79,080</td>
<td>145,872</td>
<td>350,222</td>
<td>95,760</td>
<td>52%</td>
<td>318,384</td>
<td>1,036,440</td>
<td>1,094</td>
<td>-%</td>
<td>1,094</td>
<td>3,127</td>
</tr>
<tr>
<td>Trust</td>
<td>1,305,792</td>
<td>458,952</td>
<td>1,989,792</td>
<td>9,106,178</td>
<td>1,635,768</td>
<td>5/01</td>
<td>8,278,344</td>
<td>150,136,032</td>
<td>14,923</td>
<td>22%</td>
<td>14,923</td>
<td>42,655</td>
</tr>
<tr>
<td>Trust Extra C&amp;S</td>
<td>176,184</td>
<td>96,216</td>
<td>269,712</td>
<td>792,713</td>
<td>113,256</td>
<td>138%</td>
<td>720,648</td>
<td>1,695,888</td>
<td>2,023</td>
<td>-%</td>
<td>2,023</td>
<td>5,782</td>
</tr>
<tr>
<td>Trust Extra Thin</td>
<td>155,376</td>
<td>132,048</td>
<td>277,920</td>
<td>1,199,246</td>
<td>141,552</td>
<td>96%</td>
<td>1,090,224</td>
<td>2,060,640</td>
<td>2,084</td>
<td>-%</td>
<td>2,084</td>
<td>5,958</td>
</tr>
<tr>
<td>Trust Studded</td>
<td>2,467,296</td>
<td>1,015,296</td>
<td>3,878,568</td>
<td>12,186,187</td>
<td>2,236,464</td>
<td>1/05</td>
<td>11,078,352</td>
<td>156,353,178</td>
<td>29,089</td>
<td>73%</td>
<td>29,089</td>
<td>83,144</td>
</tr>
<tr>
<td>Emergency Contraception</td>
<td>66,294</td>
<td>13,243</td>
<td>96,635</td>
<td>105,673</td>
<td>-</td>
<td>-%</td>
<td>45,629</td>
<td>142,264</td>
<td>4,349</td>
<td>-%</td>
<td>4,349</td>
<td>703</td>
</tr>
<tr>
<td>Escapelle</td>
<td>3,894</td>
<td>13,243</td>
<td>34,235</td>
<td>35,373</td>
<td>-</td>
<td>-%</td>
<td>9,389</td>
<td>43,624</td>
<td>1,541</td>
<td>-%</td>
<td>1,541</td>
<td>249</td>
</tr>
</tbody>
</table>

---

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.
## Monthly Distribution by Country

### Period: 2
### Year: 2020

<table>
<thead>
<tr>
<th>Product</th>
<th>DISTRIBUTION 2/2020</th>
<th>MONTHLY AVG PREV 3 MONTHS</th>
<th>YTD DISTRIBUTION TARGET 2020</th>
<th>YTD DISTRIBUTION 2019</th>
<th>LAUNCH DATE</th>
<th>YTD % CHANGE</th>
<th>TOTAL DISTRIBUTION 2019</th>
<th>CUMULATIVE DISTRIBUTION (a)</th>
<th>YTD USERS REACHED 2020</th>
<th>YTD CYP 2020</th>
<th>YTD DALY 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pronta1</td>
<td>62,400</td>
<td>62,400</td>
<td>70,300</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>36,240</td>
<td>98,640</td>
<td>2,808</td>
<td>2,808</td>
<td>454</td>
</tr>
<tr>
<td>IUD 10</td>
<td>-</td>
<td>-</td>
<td>1,715</td>
<td>-</td>
<td>0%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PP T380 Pregna</td>
<td>-</td>
<td>-</td>
<td>1,715</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>IUD 5</td>
<td>-</td>
<td>-</td>
<td>735</td>
<td>-</td>
<td>0%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>CU T375 Pregna</td>
<td>-</td>
<td>-</td>
<td>735</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Lubricant</td>
<td>3,396</td>
<td>5,388</td>
<td>5,976</td>
<td>43,507</td>
<td>3,588</td>
<td>67%</td>
<td>39,552</td>
<td>169,896</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Lovers Plus Lube Natural (100mL)</td>
<td>2,856</td>
<td>4,536</td>
<td>3,456</td>
<td>38,570</td>
<td>3,588</td>
<td>- (4)%</td>
<td>35,064</td>
<td>162,888</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Lovers Plus Lubricant 2-in-1, 100 ml tube</td>
<td>-</td>
<td>48</td>
<td>48</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>1,068</td>
<td>1,116</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Lovers Plus Lubricant Strawberry, 100 ml tube</td>
<td>468</td>
<td>704</td>
<td>2,340</td>
<td>-</td>
<td>-</td>
<td>-%</td>
<td>2,220</td>
<td>4,560</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Lovers Plus Lubricant Warming, 100 ml tube</td>
<td>72</td>
<td>100</td>
<td>132</td>
<td>4,937</td>
<td>-</td>
<td>-%</td>
<td>1,200</td>
<td>1,332</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>OCs</td>
<td>35</td>
<td>35</td>
<td>41</td>
<td>48,498</td>
<td>-</td>
<td>0%</td>
<td>99</td>
<td>140</td>
<td>2</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>MEURI</td>
<td>-</td>
<td>-</td>
<td>48,000</td>
<td>-</td>
<td>-%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Novynette</td>
<td>35</td>
<td>35</td>
<td>41</td>
<td>498</td>
<td>-</td>
<td>-%</td>
<td>99</td>
<td>140</td>
<td>2</td>
<td>2</td>
<td>1</td>
</tr>
</tbody>
</table>

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.